<SEC-DOCUMENT>0000950170-24-021253.txt : 20240227
<SEC-HEADER>0000950170-24-021253.hdr.sgml : 20240227
<ACCEPTANCE-DATETIME>20240227163319
ACCESSION NUMBER:		0000950170-24-021253
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240227
DATE AS OF CHANGE:		20240227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Syndax Pharmaceuticals Inc
		CENTRAL INDEX KEY:			0001395937
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				320162505
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37708
		FILM NUMBER:		24687479

	BUSINESS ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		STREET 2:		BUILDING D, FLOOR 3
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-419-1400

	MAIL ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		STREET 2:		BUILDING D, FLOOR 3
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sndx-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sndx="http://www.syndax.com/20231231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_026657be-4472-43be-b934-35ed42b29885" name="dei:AmendmentFlag" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_6e6cbe80-054b-43e0-8d6f-dba3d9ad3d9f" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_91017a34-0c67-4d46-b4ae-37fe8f976968" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonNumeric id="F_cf5e2c01-f3bc-4a4a-aee2-65795177679e" name="dei:DocumentFiscalPeriodFocus" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef">FY</ix:nonNumeric><ix:nonNumeric id="F_5615f5e0-c1bf-4350-9f87-98c7130e89d5" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonNumeric id="F_49217c6b-d1c6-4a8c-980b-beb8c95d7595" name="dei:EntityCentralIndexKey" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef">0001395937</ix:nonNumeric><ix:nonNumeric id="F_6f2174af-1087-4534-a1d4-8c84dd8719fd" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonNumeric id="F_d12f5813-8d4e-42e6-a1b5-dd3b99859a2c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_91017a34-0c67-4d46-b4ae-37fe8f976968" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonNumeric id="F_bdf0f075-bc1e-404e-af00-b70e479f0d98" name="dei:CurrentFiscalYearEndDate" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef">--12-31</ix:nonNumeric><ix:nonFraction id="F_debbfc9d-6778-4f47-b928-17023ff29f09" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5c24cdeb-9f74-4eee-842e-e218a265196d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_bfa9a871-0b75-4568-9859-df85dcd68379" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_6061cd85-0c54-4a24-9e24-640882b2bfe9" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_0835679e-b7bf-456b-81ca-3e9b85f608a3" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_0e6f7b74-b212-412d-a290-cfa9eb6e858f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_a6fd8f00-bdcc-47d9-a213-80afd3cac541">P3Y</ix:nonNumeric><ix:nonNumeric id="F_91e0244e-9f65-4985-ba1b-f7857d8ad080" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_297b9be3-9752-4119-bccd-c1340527438c" format="ixt-sec:duryear">3</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sndx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_9f8d8621-1769-4079-8f0b-99e55c437b8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:AtTheMarketStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_baf118b0-3cb5-42c6-83f0-5fe1ec439d64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">sndx:SeriesB1PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e282358-b6f3-4650-be0c-94030a98bc79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddd4ae65-26c4-4c11-8b88-b2c7bac6eacb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4373a863-e88a-4778-ad8a-e38be55f38f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sndx:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af3f7b3f-463f-4a43-9924-f3224ae76c2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0733728d-ca28-4bce-89bd-0ce117dade3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fde2bde-fcd6-4136-938c-690acb7faf69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">sndx:HerculesCapitalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sndx:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-23</xbrli:startDate><xbrli:endDate>2022-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9760b9c-06c7-4dcd-b0bf-ccb9fd1298a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd52ffb1-9775-4773-a4a5-24f8f2743b17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_626a678f-9c61-4d24-8cc1-62a2dcd3abf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5804989-e5d4-4066-86ae-9576d589c5cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_707b5fb4-b3b3-44e7-845a-f9f779873732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_220ba3e8-b19e-4dfb-b2aa-b75c2caad42b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29366536-a819-434b-97a9-ff39b709d103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2007-12-01</xbrli:startDate><xbrli:endDate>2007-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38a4d3d9-61d6-470e-85bb-48eeea883916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:EquityPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43d48b69-d64f-4673-aae8-70b5559a6dd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2cdaf15-a3dd-4128-b806-5785e9adeb08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sndx:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8419044-984d-4ea5-bd39-f4268be140ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75ddf898-7154-4fbc-bbc2-0484c10d01f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc34cf4d-0ad9-4ca8-abcc-8a189f682e20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76ed7aa3-1ed8-4f3a-a48f-60eaa77cb270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-17</xbrli:startDate><xbrli:endDate>2021-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02ca18d5-fa6f-4bfb-a876-c093b9ca6330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c35cea5-4932-446f-bd97-79a9161a45c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66e29f85-4ac7-49ec-9bd3-2f763f1d6dfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c1506a9-4d8e-4770-b740-d3e5f9ee156e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07dde341-6b8e-4d35-a0a4-24bc46311598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a26f97c-58f3-47db-91e7-cf5136111b06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sndx:FederalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bd80ba5-9483-4290-bd6b-8b3b7622307a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sndx:GlobalAndUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d380c115-0599-4d7d-9e27-c31a2dc98460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6644a9fe-b908-416a-b736-f657bd63cd2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_610a039f-ddb5-49bf-b2aa-26efc9285ba9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9f5b310-329a-4434-9537-4ce7c13c5b4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbef3127-bb0c-4874-825e-07108d441436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa3bed87-c1df-42e6-8758-39e220363797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88e95505-429a-46a9-b560-ae0bf5e61908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85e6672e-416a-4bb1-ba66-37049365978f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_192455fe-8853-44c4-a2af-b22ba6210f6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89ee900b-0daa-4278-b35c-28e5ea1dacc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50387594-1a28-42ed-ac94-8000e7132fac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cef59505-ba7f-4bd7-ba0f-7111fc336f1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndTwentyTwoPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae0f6773-2219-4d93-912b-9c9e98f6fd82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7005891b-8702-43ec-a77e-2e47fc88621f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7214ed50-0829-4c9b-97ed-3efc7a00a846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e51750f9-2ca2-48a3-9d96-269b2ec8e4b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f09442a-717e-4f09-b5dc-359eda68d688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e02600c-bd29-4c11-ab55-d1e0405d802e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84340f1a-f771-4068-83fa-b64ee4e714f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_665c9384-a612-4a95-ba6a-78cf2d4a9797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndTwentyTwoPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff8445ca-ff4b-4f13-8184-af4837d5724f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_758bdea3-3881-4991-b7bf-ed3b171e2195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bda1e555-b0cf-4f5d-88a3-0159c9f3b0d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e0f6494-687d-4fd7-836a-90f591faf296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d906a55-0f18-4eb6-ae44-5a99a86227fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d113b0b-ab5a-4247-a874-32521d39ece2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sndx:NonRefundableCashPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0422204c-ea29-458e-977a-fbc28c65fb5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6fd8f00-bdcc-47d9-a213-80afd3cac541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb680055-68ee-453c-b640-6693cd2778c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c711bf57-6128-4aae-b770-abe66d25ee43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2f341e1-b250-4994-9c50-93dfdd23e649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5197e4c4-abe0-4b59-8b72-08d7ab8fd593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faebc9a2-2fb9-4f9c-a490-ab75ff58a5e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7ff0eef-d6fb-487a-ac3a-bd8883e7c5ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteCollaborationAgreementAndSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12411cb5-5f6c-4911-b870-4a0f20b18078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c271aab5-a01e-42fd-86b6-0377aa3b4a22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ef30512-4d6b-4796-82fc-67c194464ce1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d4310ad-0736-4012-b9ce-4a0f9454edae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac9227a8-0a7a-4171-9671-16e3b7033e1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24de1833-922d-42e7-b50e-b99703d2a57a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_361a189b-bde2-4ebc-a732-bb3aba4d7e9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b6fd47e-9446-44a8-8162-95fdb9778785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbf91643-4660-41e0-b476-3872edbb72d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sndx:MichaelMetzgerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d63904f7-84ba-4976-8198-140293f5c68a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_012a6df5-8424-40f8-96a5-5e06d8ae24bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26c0fc6f-728e-49e8-824f-78d32eaa25c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bfce7e8-ef98-48b8-86a7-775779587ee8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6950da94-09bf-4054-a1fa-0feb68fcf8c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aff4aaae-ac9e-419d-8194-f5b7a5c562dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5a2c5e6-ee95-4e95-ac72-df05f5b19d1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7704e7f4-6094-4899-941c-17cce4c1ad53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9897c974-eaaf-4ce1-84bb-983cacae668c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98367a91-be3e-42b9-a2a7-0457ff239e69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8268fa6-6e38-4789-b18f-986f4e625037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f419700-e28e-40c1-b23d-a0b900e72318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4d0fa56-19c4-4e1e-be2c-7d22cb6fdd00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65978307-b055-4116-8a9e-5b4d03aedbd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8240772c-7e9d-4f0c-9469-d94e57373408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_113325fa-4d36-4203-99b1-36c13868211f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_916862c9-8345-48c9-8135-c267e4176f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-26</xbrli:startDate><xbrli:endDate>2023-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5bfe040-8225-40e0-ac2c-1d2335fa468e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e76b045-86c3-442e-89f0-3831e63a85a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10d30f98-e352-4e95-8d0c-6ec352eb4220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1bbc6b4-e3a0-44a7-bf52-605ed66340b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandTwentyThreeInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29309db1-308b-4019-86e8-51c14a636d14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sndx:BriggsWMorrisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41f595f4-58d1-4879-8f5e-6bf3c89f425e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aea89429-70c4-454c-97d0-6401610eb508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">sndx:HerculesCapitalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sndx:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9415a8d6-3456-4c2f-b211-310686e40961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:AtTheMarketStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72227cf4-0a6a-4050-89fc-fc52e7d77a79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sndx:GlobalAndUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1245cc97-cdcd-478a-a01f-e41febf804e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65848bf9-3945-493c-98fa-73d365aadae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe987b96-157e-484d-ab17-c2d98a5f8ce5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49c6449d-685a-4b8d-9ad2-69b9cf9fce2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f94caae1-f892-4d89-8e4b-773c52c2f2b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_074a6418-7106-47c6-9070-807b4c2674f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a02bc65a-614e-4743-902b-962e339de54c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99c2e544-076a-4909-9149-b0b33903b58f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2da8d5ee-6ea1-4242-a4dc-afb090386702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7c24763-4fb0-48dc-a5f9-391a27f7a6e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2007-03-01</xbrli:startDate><xbrli:endDate>2007-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22fc27d0-840a-44e9-bbda-98d42fe3a807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02ad79b9-c653-4f87-a48e-92ebf9946d11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b797780-f333-41ad-9804-9f77932b06b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-24</xbrli:startDate><xbrli:endDate>2023-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_382491e5-93f3-4c43-b99a-07ae7ae81dd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87ff6aa9-d940-48eb-b1df-219774898bb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abcfbe51-431c-4e69-83e7-98632aac4ec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_007add38-cb78-4807-8ceb-0a17db3708dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5fddb73-bec6-44ab-935b-04ba4ac070ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fb90d48-7668-4c0f-a774-c90206135131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f06b4d49-9703-446a-ba86-02d5b5a8111b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13c0b160-1a0f-43dd-81e7-cca1d5370eb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3636803-aef2-421b-a81e-02758a0838f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1753470-c399-4d8b-ad2e-484c414ecc39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6da63ab9-2ebc-46a8-b7da-7c40838fae15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sndx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9e7a5e0-1ec9-492f-858b-bc50f9566629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6b0a3dc-0d13-4e49-af3e-9c0ec95c0551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sndx:BeginToExpireInTwoThousandAndTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14164814-000e-4a3d-8ee4-dd58a37f263b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22b82249-a476-47d0-8dbf-74f15062836e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sndx:FederalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e5821c0-1935-43a7-b0ba-c858e0c7d907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7394970-59e6-4cd6-89a6-54b79f895f1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a968746-243d-4b7c-af53-3e25f8258536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9cd7896-122a-468d-9a8b-9879b929f973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d513726-c3ac-4260-a084-166bd284aeba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteCollaborationAgreementAndSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cacdbd9-72ea-4585-80a2-d53f1908716b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97645584-c333-40ca-801b-2613f368a789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c652789-8302-4cea-ba90-91fe2cce9a9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29ad8473-2e34-453e-8357-0aecf445558f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdda42ce-b5f5-4335-9c1e-37c83c1c9673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_784acd93-e389-42e6-b562-fe5fa32789cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a664e17-cf9e-4ee2-bfdc-d015d6af8887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ac62b3c-c563-4a8e-956a-51511134c433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe65bbb1-0d57-4bdf-9127-31463d2d09a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03d34840-d717-4c96-9735-0033d3f99ef2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_078b50de-5b41-4db5-9cf7-84fdb243368a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03aeaecd-5be7-490b-86d3-d29870f2e796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ac7d980-2b3e-46ff-96cc-410f348499f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3afde7f0-2827-4e68-8635-4702b62c6d21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sndx:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndNineteenPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96174531-bfea-4e9f-8dc3-133a02db014e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f9cd118-679a-40a6-847e-91450d6633ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d97a76a-d900-4c17-babb-1f3067aebaca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_444b653e-7ff0-4aea-832b-063c09c055b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteCollaborationAgreementAndSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5b70f38-d948-41d2-b18c-a03562f8c1ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4711878e-a968-48f8-9c3d-730171fe4f23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandAndSevenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7641cc13-8c39-40ae-b57f-0758cc213d32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b7db385-57f7-42af-835a-310ebe8bfb57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91017a34-0c67-4d46-b4ae-37fe8f976968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c738d44a-3667-401f-876a-5549892bf0b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndTwentyTwoPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f48e2289-7c74-4e8f-bb83-8c460905d6be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a61dd5c-53ff-496f-8daa-f66e8960c075"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a678240-3c1b-4c9f-88f3-1d437a7bd663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sndx:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandTwentyThreePerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_722e2254-0e1d-493b-95a1-3d802704cc35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndNineteenPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0134674c-550a-4425-b294-4c3c79a415b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fee34826-8d9f-4166-a555-2a64fedf432a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a064fef4-51ed-42ca-be0f-f995b8a0ed8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:AtTheMarketStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b85eec17-a5e7-48d2-bfca-2ef6ffdae4ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sndx:BeginToExpireInTwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4be5e2a-ca86-4e3c-b7a9-c1323e17fe48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d5d3e07-b0b8-4bc6-b16b-19628d2c4e5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_160ba5f0-0235-4944-95c1-f31751bf8c30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cbcc0e4-7e7b-486d-b6a3-470613e2d7a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sndx:IndefiniteCarryforwardPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b24797a-527f-4f5d-beb7-f6e788fb41fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e4ddcb8-8500-42e0-9874-81661d600b3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sndx:NonRefundableCashPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92922bd5-099d-4ec5-8e83-d7fd9dbf0f21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fc4e017-06d9-47f7-8d2d-9de747aea836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b690c391-1b7b-4548-a001-dbef6009526c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sndx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f35290a2-0231-4805-aa9a-709a7b059991"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ea6052a-2eb2-4c2d-8093-dc9a96bc2333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ef8960c-7219-442c-81b3-4e10b484489f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3fb6f51-13eb-4e43-9466-09f4818f1386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a245d0cf-1677-4b8f-a3f8-dfbf1b2276ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a5e0f58-65f4-485e-beb0-bd6d07cb0472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_868dfba4-86a0-4c35-b789-a2dee2096244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4e199a4-716e-4324-8f4d-ea865c2c0770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e8b74ff-4a3e-4c5e-9f04-3c68740d89c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56f021a8-a8b1-4814-8e60-e30e3153a6ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandTwentyThreeInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c5c1097-e2eb-4741-8da2-1908684c710b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51f40d68-fa17-4b98-aa7c-a40331129e97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ed50075-e059-4c68-a550-a38411e61645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sndx:MichaelMetzgerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61e6f7c1-9801-49e0-ac76-fee878967704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40e59aaf-8789-463b-945c-25dc7a6c94bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b2fc26e-e3b0-4306-aa00-2175018e0133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_844de8bc-e6f9-4600-bf14-e5765bd7475d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d925cfd-9465-4602-88c6-bc4641cd2271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9a02a8b-944c-450f-9447-629ff2beb166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_297b9be3-9752-4119-bccd-c1340527438c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fdbce86-90d7-42aa-9453-ad5900bc17d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34717b5e-c295-4ed1-ac0e-58d0e54bae5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a9ae94c-95c4-4bc4-9ea1-a708c250d19f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2aa831f-6fca-40f4-af27-257fe1eaf973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf403011-6a3c-4874-b13f-c83dceca4aaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sndx:BriggsWMorrisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92736a1f-42c0-4d1d-a622-0b95ffb0a33b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6963fa61-8ec6-4bd0-aa49-52db5ff91e9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56286884-2fcc-4f47-8d67-14db89877f0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d930a60-dcb4-4913-bea6-46745efcd9fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00ddaa2a-3337-45b1-b374-1c84e826418c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d21a99f4-ccca-4ef1-962f-a9239148a2f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1cf4bfa-5db9-4119-8b19-8336fe8db925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_beb1fbb6-8eaa-4bd9-a278-f0c3ba62c037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ff18d23-59d3-47d1-9c4b-5af2583db483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fa3ac50-99f5-4a54-9d47-385cab5f80e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f584b500-1b67-48fb-b034-847318b00b67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d702b7c-2eb0-4b1b-9fdd-4c94f41fbc74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Employee"><xbrli:measure>sndx:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>sndx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Claim"><xbrli:measure>sndx:Claim</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_aaa0a647-4c49-431e-a394-238030f55c8b" fromRefs="F_37e11f1a-0751-4158-b47f-05f24953c364 F_019950da-7c9e-4648-93df-baef4c55a740"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_82b8419b-1637-433c-bec5-9d6f6e1629e5" fromRefs="F_571d65c8-f8f1-445f-8ee1-7e17ce2ffbfc F_4c71cf37-0a72-4642-a37b-7ae4969c410b"></ix:relationship></ix:resources></ix:header></div>
  <div style="min-height:1in;"></div>
  <p style="border-top:0.75pt solid #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">84,826,632</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="border-top:0.75pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8b3a0436-44d2-4836-b16d-ee6d78894c69" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d934129f-b075-48f8-a595-48228ba9323d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the Fiscal Year Ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3c2867e-5630-4c6d-b01d-22f6e542fd3d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e90f3a73-aacf-4d72-8432-4b6bbd06c4f8" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bad62e7-9f35-4f89-8bdf-a4323fddad98" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the Transition Period from</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">                        </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">                        </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01e10b44-e28a-4b25-a3e2-d3ab6ccfe346" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">001-37708</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64f710e4-ea15-46a3-a652-37398051e76e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_86cc9d3d-6932-4421-bad5-a5c01331f2e6" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2834</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_43baf5a9-bec8-4f14-b407-047b272a8d67" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">32-0162505</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporation or Organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Primary Standard Industrial</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classification Code Number)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification Number)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbf571bb-09a3-4eeb-a23d-3f35895f8a7a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">35 Gatehouse Drive</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8f17822-6481-476b-a69f-b86ebec6e3f2" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Building D</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba3798ca-9140-4e45-a96c-b4dc1a8420ff" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityAddressAddressLine3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Floor 3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59378add-33ef-4d96-a589-0c79b8b61f31" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Waltham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3cdca37-3d20-4a53-b22e-041abc28efd3" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ecaff22-906c-4a9d-a4b2-d5963127bdba" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">02451</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e56ec8b3-967d-4c40-b017-cb0668df2a1b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">781</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b588813-2009-4241-9040-a18f35669865" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">419-1400</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.48%;"/>
    <td style="width:18.16%;"/>
    <td style="width:48.36%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0a523d5d-2dcd-4e85-9401-4066bfa0a852" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b57e0524-82a0-4bba-89dd-9a387945343a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SNDX</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_8906f365-c385-4844-b80b-18f36251bbfb" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market, LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_225bf403-4485-4e49-a23e-24b850d278bc" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Act.    Yes  &#9744;    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_000237c4-e982-44a0-b3d9-6e01986c0aca" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days.    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85de03f4-be89-49d9-8855-f132bc635185" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76729c6e-93e5-4827-9514-9d231251cb0f" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.16%;"/>
    <td style="width:56.78%;"/>
    <td style="width:19.02%;"/>
    <td style="width:3.04%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_29f7ccdd-7c89-4fe0-a67b-5b7a9eae63a5" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large Accelerated Filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated Filer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated Filer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller Reporting Company</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_0d4e2d7a-b1ff-435b-96f9-c6f3710cd06a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_bc0e2e9c-ae8c-4f4e-af0c-ac86f6b2eeb7" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb52c361-2496-4fbc-85fa-4a18b9a1bf9c" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79d98125-a15e-402f-bfa8-e2b53eefbe96" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)    Yes  &#9744;    No  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e37841e8-820f-4593-bc57-3a7b2c49cdb7" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:1in;"></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the voting and non-voting of common equity held by non-affiliates of the registrant was $</span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9246c324-cb77-428c-a7b2-fb9ce75fbce0" contextRef="C_9a61dd5c-53ff-496f-8daa-f66e8960c075" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,452,441,662</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> as of June 30, 2023 based on the closing price of $20.93 as reported on the Nasdaq Global Select Market on such date. Shares of the registrant's common stock held by executive officers, directors, and their affiliates have been excluded from this calculation. The determination of affiliate status is not necessarily a conclusive determination for other purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">As of February 19, 2024, there were </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3468b80-b0d1-4a2c-a080-ad7dfa7d3574" contextRef="C_9f09442a-717e-4f09-b5dc-359eda68d688" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,965,486</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_522906f3-a228-49d7-a8be-6dfce787cb24" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.283%;"/>
    <td style="width:14.103%;"/>
    <td style="width:12.723%;"/>
    <td style="width:20.004%;"/>
    <td style="width:16.143%;"/>
    <td style="width:22.745%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Firm Id:</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">#</span><span style="font-size:8.5pt;"><ix:nonNumeric id="F_20788387-7aca-4d03-a09a-a73898705d0e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Name:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_2d22defd-29e4-48f8-babb-36dd7f47bbcc" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Location:</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_68b57250-91e1-4882-af6a-5f043de27a37" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New York, New York</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.4%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="border-top:0.75pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.44%;"/>
    <td style="width:87%;"/>
    <td style="width:4.56%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#special_note_regarding_forwardlooking_st"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ii</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statements_sc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="special_note_regarding_forwardlooking_st"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Annual Report. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative or plural of those terms, and similar expressions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forward-looking statements include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding our expenses, future revenues, anticipated capital requirements and our needs for additional financing; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, cost, timing, progress and results of our research and development activities, clinical trials and preclinical studies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to replicate results in future clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the potential safety, efficacy or clinical utility of our product candidates as well as the potential use of our product candidates to treat various cancer indications and fibrotic diseases; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain regulatory approval for our product candidates and the timing or likelihood of regulatory filings and approvals for such candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain our licenses with UCB Biopharma Sprl, and Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc, which was acquired by AbbVie Inc.; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of our collaboration with Incyte Corporation, or Incyte, to further develop and commercialize axatilimab;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential milestone and royalty payments under certain of our license agreements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the implementation of our strategic plans for our business and development of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection we establish and maintain for intellectual property rights covering our product candidates and our technology; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the market adoption of our product candidates by physicians and patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments relating to our competitors and our industry; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of geo-political actions, including war or the perception that hostilities may be imminent (such as the ongoing war between Russia and Ukraine and the war in Israel), adverse global economic conditions, terrorism, public health crises or natural disasters on our operations, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, or CROs, other service providers, and collaborators with whom we conduct business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part I, Item 1A, &#8220;Risk Factors,&#8221; below and for the reasons described elsewhere in this Annual Report. Any forward-looking statement in this Annual Report reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, our information may be incomplete or limited and we cannot guarantee future results. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs and consumer products, including data regarding the estimated size of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources and we have not independently verified the data from third party sources. In some cases, we do not expressly refer to the sources from which these data are derived.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In this Annual Report, unless otherwise stated or as the context otherwise requires, references to &#8220;Syndax,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries. This Annual Report also contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">USINESS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Company</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our two lead product candidates are revumenib, and axatilimab. We are developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, or KMT2Ar, also known as mixed lineage leukemia rearranged or MLLr, acute leukemias including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, and necleophosmin 1, also known as NPM1, mutant AML. We are also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. We are developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor, or CSF-1R, in chronic graft-versus-host disease, or cGVHD, as well as idiopathic pulmonary fibrosis, or IPF. We plan to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional therapeutics to expand our pipeline.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing revumenib for the treatment of acute leukemias and as a treatment for solid tumors, and axatilimab for use in cGVHD and other fibrotic-macrophage driven diseases, such as IPF, as single agents and in combination with approved drugs. Key elements of our strategy include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Develop and commercialize revumenib for the treatment of genetically defined leukemias. We believe that revumenib has the potential to treat at least two genetically defined acute leukemias: (i) KMT2Ar and (ii) mutations in NPM1, or mNPM1, AML. Our Phase 1/2 open-label AUGMENT-101 trial is nearing completion. The pivotal Phase 2 portion of the trial enrolled relapsed/refractory, or R/R, patients in three indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib in KMT2Ar ALL, KMT2Ar AML and mNPM1 AML. We have submitted a New Drug Application, or NDA, for revumenib for the treatment of R/R KMT2Ar acute leukemia under the U.S. Food and Drug Administration&#8217;s, or FDA, Real-Time Oncology Review, or RTOR, program and we continue to enroll patients in the mNPM1 AML cohort. We are also concurrently expanding into the frontline and maintenance settings in AML with new clinical trials as well as in solid tumors.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Develop and commercialize axatilimab for the treatment of cGVHD. We completed enrollment in the pivotal AGAVE-201 trial for the treatment of patients with cGVHD and, together with Incyte, have submitted a Biologics License Application, or BLA to the FDA. Also, our partner Incyte plans to initiate two combination trials with axatilimab in cGVHD in mid-2024, including a Phase 2 combination trial with ruxolitinib and a Phase 3 combination trial with steroids. We are further exploring the use of axatilimab to treat other fibrotic diseases where monocyte-derived macrophages have been shown to play a role, and have initiated a Phase 2 trial to assess the efficacy, safety and tolerability of axatilimab in patients with IPF.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leverage the technical, clinical, regulatory and business expertise of our management team and scientific collaborators to license, acquire and develop additional cancer therapies to expand our pipeline. We licensed the global rights to axatilimab and revumenib and are working closely with our collaboration partner, Incyte, on the development and commercialization of axatilimab. We are continuing to leverage the collective talent within our organization and network of advisors to guide our pipeline expansion and development plans.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Pipeline</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img207175068_0.jpg" alt="img207175068_0.jpg" style="width:624px;height:777px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revumenib</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first clinical-stage product candidate, revumenib, is a potent, orally active inhibitor of the high affinity interaction site on menin with the protein MLL1. This specific interaction is a key driver for two genetically defined acute leukemias: (i) KMT2Ar and (ii) mNPM1 AML. The R/R settings of both diseases have a poor prognosis. In preclinical testing, revumenib has demonstrated benefit in leukemic models of disease. Clinical evidence with revumenib also supports the hypothesis that disruption of the menin-MLL interaction can lead to responses in acute leukemias.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img207175068_1.jpg" alt="img207175068_1.jpg" style="width:624px;height:286px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, we commenced AUGMENT-101, a global clinical trial consisting initially of a Phase 1 dose escalation portion to determine the maximum tolerated dose, or MTD, and recommended Phase 2 dose of revumenib in patients with R/R KMT2Ar or mNPM1 acute leukemia. As discussed below, we completed the Phase 1 portion of the trial. The three cohorts of the pivotal Phase 2 portion of the trial, enrolled R/R patients across each of three distinct trial populations: patients with NPM1 mutant AML, patients with KMT2Ar AML, and patients with KMT2Ar ALL to determine the efficacy, safety, and tolerability of revumenib. We completed enrollment of the KMT2Ar cohorts and the NPM1 cohort continues to accrue patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, we announced data that the trial met its primary endpoint at the protocol-defined interim analysis stage with a complete remission, or a CR, with partial hematological recovery, or a CRh rate of 23% (13/57; 95% confidence interval [CI]: [12.7, 35.8, one-sided p-value = 0.0036]) in the pooled KMT2Ar acute leukemia cohort. The CR/CRh rate in patients with KMT2Ar AML was 24.5% (12/49). 39% (14/36) of patients who achieved a CR/CRh underwent hematopoietic stem cell transplant, or HSCT; with eight of fourteen proceeding to transplant prior to achieving CR/CRh and could not be included in the reported CR/CRh rate. The CR/CRh responses in both the overall population and the AML subset were durable with a 6.4-month (95% CI: 3.4, NR) median duration of response and 46% (6/13) remaining in response, as of July 2023 data cut-off. Minimal residual disease, or MRD, status was assessed in 10 of the 13 patients who achieved a CR/CRh, 70% (7/10) of whom were MRD negative. Revumenib was well tolerated, and the overall safety profile was consistent with our previously reported data. Treatment-related adverse events, or TREAs, leading to dose reductions and treatment discontinuation were low. Grade 3 differentiation syndrome, DS, was observed in 15% (14/94) of patients while one patient (1%) experienced Grade 4 DS and no patients experienced a Grade 5. Grade 3 QTc prolongation was observed in 14% (13/94) of patients, with no Grade 4 or 5 events. There were no discontinuations related to DS or QTc prolongation on the trial. Further accrual in the KMT2Ar cohorts was halted based on the Independent Data Monitoring Committee recommendation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We submitted an NDA to the FDA for revumenib for the treatment of adult and pediatric R/R KMT2Ar acute leukemia. The NDA submission is being reviewed under the FDA's RTOR program, and expects to receive a PDUFA action date from the FDA in the first quarter of 2024. RTOR allows for close engagement between the sponsor and the FDA throughout the submission process and enables the FDA to review individual modules of a drug application rather than requiring a complete application prior to initiating its review. We expect to complete</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enrollment in the AUGMENT-101 pivotal trial cohort of patients with R/R mNPM1 AML late in the first quarter or early in the second quarter of 2024. We expect to report topline data for this cohort in the fourth quarter of 2024, which could support a supplemental NDA regulatory filing for revumenib in an additional indication of treatment of R/R mNPM1 AML.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, we announced updated results from the R/R mNPM1 AML patients enrolled in the Phase 1 portion of the AUGMENT-101 trial, who met the RP2D criteria. The final dataset includes three additional patients, for a total of 14, that were enrolled in the Phase 1 trial to complete the pharmacokinetic characterization of revumenib. In this analysis, the overall response rate, or ORR, was 50% (7/14) with a CR/CRh rate of 36% (5/14); 100% (5/5) of CR/CRh patients were MRD negative. 43% (3/7) of responders proceeded to transplant, all after achieving a CR or CRh.  60% (3/5) of CR/CRh patients maintained a response beyond six months. At the time of the analysis, four patients remained in response, with two patients in response over 22 months, at the time of data cut-off. Revumenib was well tolerated, and the safety profile was consistent with what was previously reported in the AUGMENT-101 trial. There were no Grade 4 or 5 QTc prolongation or differentiation syndrome events, greater than Grade 2, and no patients discontinued due to TREAs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also announced data from patients in the AUGMENT-101 Phase 1 trial who received revumenib maintenance therapy, including some ongoing for more than one year after HSCT, that demonstrated revumenib duration of treatment in the maintenance setting at the time of this analysis ranged from 1 to 701 days, with treatment ongoing for nine of the 16 patients. CRc (CR + CRh + CRp + CRi + MLFS) was maintained in 12 patients after HSCT and maintenance revumenib. MRD negative remissions were maintained in 6 patients as of the data cutoff with one patient converting from an MRD+ to MRD- response. Three patients remain on revumenib maintenance therapy for more than one-year post-transplant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the 65th American Society of Hematology (ASH) Annual Meeting in December 2023 and during the our accompanying investor event, investigators presented compelling data from multiple Phase 1 combination trials of revumenib in mNPM1 and KMT2Ar acute leukemia across the treatment landscape. The trials are expanding to validate recommended Phase 2 doses, with additional data expected in the second half of 2024. These trials include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BEAT-AML: Evaluating the combination of revumenib with venetoclax and azacitidine in front-line AML patients. This trial is being conducted as part of the Leukemia &amp; Lymphoma Society's Beat AML&#174; Master Clinical Trial. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SAVE: Evaluating the all-oral combination of revumenib with venetoclax and decitabine/cedazuridine in R/R AML or mixed phenotype acute leukemias. The trial is being conducted by investigators from the MD Anderson Cancer Center and continues to add patients.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AUGMENT-102: Evaluating the combination of revumenib with fludarabine and cytarabine in patients with R/R acute leukemias.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have initiated a Phase 1 trial of revumenib in combination with 7+3 chemotherapy followed by maintenance treatment in newly diagnosed patients with mNPM1 or KMT2Ar acute leukemias. We also plan to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unable to tolerate intensive induction chemotherapy by year-end 2024. Additionally, enrollment is ongoing in a Phase 1 proof-of-concept clinical trial of revumenib in patients with unresectable metastatic microsatellite stable colorectal cancer. We expect to provide an update on the trial in the second quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rationale for Targeting MLLr</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MLLr leukemias arise by rare, spontaneous translocations at the MLL1 locus (11q23). It is estimated that approximately 10% of AML and ALL harbor this MLL-re-arrangement with a worldwide incidence of approximately 5,000 to 7,000 cases per year. These translocations generate oncogenic fusion proteins with more than 90 different MLL fusions currently known. All MLL fusion proteins bind with high affinity to the chromatin associated protein menin through a conserved N-terminal sequence. This specific interaction with menin enables an aberrant transcription program that drives leukemic transformation. In pre-clinical animal models, small molecule inhibitors of the menin-MLL interaction have demonstrated deep and durable single agent treatment effects in multiple leukemic xenografts harboring MLL fusions. Inhibiting the menin-MLL1 interaction represents a novel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">targeted strategy for the treatment of MLLr leukemias. Today, the first choice therapy for both MLLr AML and MLLr ALL still relies heavily on intensive chemotherapy, if a patient can tolerate such treatment. Despite these patients being routinely diagnosed, there are currently no targeted therapies approved to treat patients with MLLr acute leukemias. Currently there are several other clinical-stage menin-inhibitors in development for the treatment of MLLr AML and MLLr ALL.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img207175068_2.jpg" alt="img207175068_2.jpg" style="width:496px;height:169px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rationale for Targeting Nucleophosmin 1 Mutant AML</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NPM1 is among the most frequently mutated genes in AML, found in approximately 30% of AML cases for an incidence of approximately 20,000 cases per year. Recent preclinical research has demonstrated that mNPM1 works directly with the menin-MLL complex to induce a leukemic transcription program</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, mNPM1 harboring cells are sensitive to menin-MLL interaction inhibitors. In mNPM1 cells, inhibition of the menin-MLL interaction suppresses the leukemic transcription program, causing growth arrest, terminal differentiation and cell death. In animal models, small molecule inhibitors of the menin-MLL interaction have demonstrated deep and durable single agent treatment effects in multiple mNPM1 xenografts. Based on these findings, blocking the menin-MLL1 interaction represents a novel targeted strategy for the treatment of mNPM1 AML.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Like MLLr, NPM1 is readily diagnosed as part of the standard AML patient work-up today, and yet there are no targeted therapies specifically approved to treat patients with mNPM1 AML. There are several additional clinical stage agents currently advancing as potential treatments for mNPM1 AML.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rational for Targeting CRC</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRC is the second most lethal cancer, the third most prevalent malignant tumor worldwide, and the fourth most common cancer diagnosed in the United States each year. In 2023, over 153,000 new CRC estimated cases arose, resulting in 52,500 estimated deaths, accounting for nearly 8% of new cancer cases and 9% of cancer deaths in the U.S. Meanwhile, the five-year survival rate for CRC is approximately 65% and drops to 15% for metastatic CRC. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Today, physicians can choose from a number of approved chemotherapies (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stivarga</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lonsurf&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), immunotherapies (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Yervoy&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Keytruda&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opdivo&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and targeted agents (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Avastin&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cyramza&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zaltrap&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Erbitux&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vectibix&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Braftovi&#174;, </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FRUZAQLA</span><span style="color:#333333;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;font-style:italic;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)) to treat CRC. Despite these advancements, there remains a critical need for more effective therapies to address metastatic CRC.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nearly all colorectal tumors, harbor genetic mutations that lead to the hyperactivation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin signaling, which in turn initiate the expression of various downstream targets that promote proliferation and maintain a stem cell state, highlighting the potential value of developing treatments that target </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin signaling in cancer. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin itself, however, is an intractable drug target and the mechanisms underlying </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin&#8211;driven transcription remains largely elusive, underscoring the need to identify therapeutically tractable components of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin transcriptional output. Recently, several researchers have utilized functional genomic screens to uncover new targets of high relevance to the oncogenic property of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin. Through this process they have validated the selective dependence of KMT2A for growth of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin&#8211;active CRC cells and showed KMT2A expression to be associated with malignant CRC growth in vivo and shortened survival in patients with CRC. Targeting KMT2A using menin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inhibitors has been shown to selectively reduce the viability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin&#8211;active cells and CRC organoids, but not </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-catenin&#8211;inactive cells and normal organoids. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Axatilimab</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also developing axatilimab a monoclonal antibody targeting the colony stimulating factor-1 receptor, or CSF-1R, a cell surface protein thought to control the survival and function of monocytes and macrophages. Axatilimab binds with high affinity to CSF-1R and blocks the binding of the two known CSF-1R ligands CSF-1 and IL-34. CSF-1R is expressed on the surface of specific immune cells known as macrophages and their precursor cells known as monocytes. CSF-1R signaling on these cells has been demonstrated in preclinical studies conducted in animal models of skin and lung cGVHD to be the key regulatory pathway involved in the expansion and infiltration of the macrophages that mediate fibrosis and the cGVHD disease process. Blocking CSF-1R activity with an experimental CSF-1R antibody in these studies was shown to prevent and treat the symptoms of cGVHD. We believe that by inhibiting CSF-1R activation on monocytes and macrophages, axatilimab has the potential to be used to treat cGVHD as well as other fibrotic diseases where monocyte-derived macrophages have been shown to play a significant role.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img207175068_3.jpg" alt="img207175068_3.jpg" style="width:364px;height:239px;"/>&#160;</p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our near-term focus is to rapidly establish that axatilimab can provide meaningful clinical benefit in patients with advanced cGVHD where prior therapies are no longer effective and to establish proof-of-concept of using axatilimab to treat other fibrotic diseases where monocyte-derived macrophages have been shown to play a role.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, we and our partner, Incyte, announced positive topline data from the pivotal AGAVE-201 trial of axatilimab in patients with cGVHD following two or more prior lines of therapy.&#8239;All three dose cohorts, 0.3 mg/kg every two weeks, 1.0 mg/kg every two weeks and 3.0 mg/kg every four weeks, met the primary endpoint. The ORR within the first six months of treatment at the 0.3 mg/kg dose was 74%, and 60% of these patients were still responding at one year. Furthermore, axatilimab was generally well tolerated, and the most common adverse events were consistent with on-target effects and prior trials.&#8239;Results from the trial were featured in the Plenary Scientific Session at the 65th ASH Annual Meeting in December 2023. The FDA has accepted the BLA filing for axatilimab in adult and pediatric patients six years or older with cGVHD after failure of at least two prior lines of systemic therapy. The application has been granted Priority Review and assigned a PDUFA action date of August 28, 2024.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we announced that we exercised our option under the collaboration agreement and license agreement with Incyte described below under the heading "Collaborations - Incyte Collaboration and License Agreement" to co-commercialize axatilimab in the United States. We also announced the randomized, double-blind and placebo-controlled Phase 2 trial to assess the efficacy, safety and tolerability of axatilimab in patients with idiopathic pulmonary fibrosis, or IPF, is open for enrollment. Additionally, Incyte plans to initiate two combination trials with axatilimab in cGVHD in mid-2024, including both a Phase 2 combination trial with ruxolitinib and a Phase 3 combination trial with steroids.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Axatilimab in GVHD</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cGVHD, an immune response of the donor-derived hematopoietic cells against recipient tissues, is a serious, potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation, or HSCT, that can last for years. cGVHD is estimated to develop in approximately 40% of transplant recipients and affects approximately 14,000 patients in the United States. cGVHD typically manifests across multiple organ systems, with the skin and mucosa being commonly involved, and is characterized by the development of fibrotic tissue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first line of therapy for cGVHD is typically corticosteroids, though approximately 50% of patients may require treatment with additional systemic therapies, such as extracorporeal photopheresis, cytostatic agents such as mycophenolate moftetil, methotrexate, and immunomodulators such as rituximab, IL-2. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Imbruvica</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#174; (ibrutinib), a BTK inhibitor, was the first FDA-approved therapy for cGVHD and is indicated for use after one or more lines of therapy. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Imbruvica</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> received approval based on Phase 1/2 clinical trial data that showed a 68% overall response rate, with 48% of responses lasting 20 weeks or longer and reduced dependence on steroids for most patients. The FDA has approved two additional drugs, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rezurock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#174; (belomosidil) and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Jakafi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#174; (ruxolitinib), for use in patients with cGVHD after failure of one or more lines of systemic therapy. While approved agents have shown a benefit in improving symptoms of this disease, none have demonstrated an improvement in long-term outcomes and a significant unmet medical need still remains for this patient population. Additionally, all currently approved agents are believed to exert their effect through T- and B-cells, with minimal impact on macrophages. By inhibiting the work of monocyte-derived macrophages, axatilimab, provides a differentiated way to treat cGVHD, which we expect is ultimately expected to have a more pronounced impact on the fibrotic process. We also believe that shifting CSF-1R inhibition earlier in the treatment phase of cGVHD, to minimize formation of fibrotic tissue, could have a meaningful long-term impact on the disease process itself.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Axatilimab in IPF</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IPF is a specific form of chronic, fibrosing, interstitial pneumonia limited to the lungs with a median survival of approximately three to five years after diagnosis. IPF is a rare disease, with an estimated prevalence of 281,000 people among the seven major market countries. IPF incidence and prevalence increase with age and are higher among males. Although rare, the incidence of IPF is increasing, likely due to an increasing understanding of the disease and the recent development of uniform diagnostic criteria.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently two approved therapies for IPF, nintedanib and pirfenidone. Despite these recent advances, the unmet medical need in IPF remains high, with a five-year mortality rate of 50% to 70% with deaths occurring mainly due to respiratory failure. Lung transplantation remains the only curative treatment option, but less than five percent of IPF patients undergo lung transplantation. There is an urgent need for new and more effective treatments for IPF that can address the limitations of current treatment options, improve mortality, and quality of life.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>Growing evidence suggests macrophages are critical regulators of lung fibrosis. Recent work has established a role for monocyte-derived macrophages as the pathogenic population of cells required for the development of fibrosis and that drive the fibrotic process. Reducing the circulating levels of pathogenic monocyte-derived macrophage precursors or inhibiting their activation in tissues provides an opportunity to therapeutically intervene and directly inhibit fibrosis. Recent experiments have demonstrated that the monocyte-derived, pro-fibrotic macrophages are CSF-1-dependent and CSF-1R inhibition through anti-CSF-1R antibody can block fibrosis in fibrotic disease models. We believe that using axatilimab to inhibit the work of monocyte-derived macrophages may provide a differentiated way to treat IPF, and could result in a more pronounced impact on the fibrotic process. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entinostat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entinostat is our oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body&#8217;s immune response to tumors. We have deprioritized the development of entinostat, but maintain a license, development and commercialization agreement with Eddingpharm International Company Limited, or Eddingpharm, under which we granted Eddingpharm an exclusive license under our intellectual property rights to develop and commercialize entinostat in China and certain other Asian countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incyte Collaboration and License Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we entered into a collaboration and license agreement, or the Incyte Collaboration Agreement, with Incyte for the development and commercialization of axatilimab. Additionally, in September 2021 we entered into a share purchase agreement with Incyte, or the Incyte Share Purchase Agreement. Under the terms of the Incyte Collaboration Agreement, Incyte received exclusive commercialization rights outside of the United States, and we and Incyte will, subject to the exercise of our co-promotion option, have co-commercialization rights in the United States, with respect to axatilimab. Incyte is responsible for leading commercialization strategy and booking all revenue from worldwide sales of axatilimab, subject to its royalty payment obligations set forth below. The parties will share equally the profits and losses from the co-commercialization efforts. We and Incyte are co-developing axatilimab and sharing development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and we are responsible for 45% of such costs. Each company is responsible for funding any independent development activities. All development costs related to the collaboration are subject to a joint development plan. A joint development committee between us and Incyte will govern future development of axatilimab.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are eligible to receive up to $220 million in future contingent development and regulatory milestones and up to $230 million in commercialization milestones under the Incyte Collaboration Agreement. In addition, we are eligible to receive tiered royalties on potential net sales of the licensed product comprising axatilimab ranging from the low to mid double-digit percentages. In December 2021, we received an upfront cash payment of $117 million and we issued 1,421,523 shares of common stock for an aggregate purchase price of $35 million, or $24.62 per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License Agreements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vitae Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of AbbVie plc, or the AbbVie License Agreement, under which Vitae granted us an exclusive, sublicensable, worldwide license to, preclinical, orally-available, small molecule inhibitors of the interaction of menin with the MLL protein, or the Menin Assets. We are solely responsible for the development and commercialization of the Menin Assets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the achievement of certain milestone events, we may be required to pay Vitae up to an aggregate of $99.0 million in one-time development and regulatory milestone payments over the term of the AbbVie License Agreement. In the event that we or any of its affiliates or sublicensees commercializes the Menin Assets, we will also be obligated to pay Vitae low single to low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $70.0 million in potential one-time, sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, we may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with Vitae. Since the inception of the agreement, we achieved certain development and regulatory milestones resulting in $8.0 million in milestone payments to Vitae, which includes $2.0 million paid in the first quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each party may terminate the AbbVie License Agreement for the other party&#8217;s uncured material breach or insolvency; and we may terminate the AbbVie License Agreement at will at any time upon advance written notice to Vitae. Vitae may terminate the AbbVie License Agreement if we or any of its affiliates or sublicensees institutes a legal challenge to the validity, enforceability, or patentability of the licensed patent rights. Unless terminated earlier in accordance with its terms, the AbbVie License Agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) 10 years from the date of the first commercial sale of the product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">UCB</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a license agreement with UCB, or the UCB license agreement, under which UCB granted us a worldwide, sublicensable, exclusive license to UCB6352, which we refer to as axatilimab. The UCB license agreement permits us to use axatilimab or other licensed products for all human uses, including treatment,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevention and diagnostic uses, in all indications, diseases, conditions or disorders, and we are obligated to use commercially reasonable efforts to develop, obtain regulatory approval and commercialize a certain licensed product. We are solely responsible for the development and commercialization of axatilimab, subject to our collaboration with Incyte.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the achievement of certain milestone events, we may be required to pay UCB up to $119.5 million in one-time development and regulatory milestone payments over the term of the UCB license agreement. In the event that we or any of our affiliates or sublicensees commercializes axatilimab, we will also be obligated to pay UCB low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $250.0 million in potential one-time, sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, we may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with UCB. During the year ended December 31, 2020 and 2021, we were required to pay $2.0 million and $4.0 million, respectively, due to the achievement of certain development and regulatory milestones. Additionally, in connection with its most recent amendment of the UCB license agreement, in the second quarter of 2022 we paid UCB $5.8 million, which was recognized as a milestone expense. In the fourth quarter of 2023, we achieved certain development and regulatory milestones, resulting in a $10.0 million expense, which has been recorded in accrued expenses as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each party may terminate the UCB license agreement for the other party&#8217;s uncured material breach or insolvency; and we may terminate the UCB license agreement at will at any time upon advance written notice to UCB. UCB may terminate the UCB license agreement if we or any of our affiliates or sublicensees institutes a legal challenge to the validity, enforceability, or patentability of the licensed patent rights. Unless terminated earlier in accordance with its terms, the UCB license agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) 10 years from the date of the first commercial sale of the product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bayer Pharma AG</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a license agreement with Bayer Pharma AG, or Bayer, pursuant to which we obtained a worldwide, exclusive license to develop and commercialize entinostat and any other products containing the same active ingredient. The Bayer license agreement, as amended, permits us to use entinostat or other licensed products for the treatment of any human disease, and we are obligated to use commercially reasonable efforts to develop, manufacture and commercialize licensed products for all commercially reasonable indications. Initially, Bayer manufactured and supplied our requirements of entinostat, but effective May 2012, manufacturing rights and responsibility for entinostat was transferred to us, by mutual agreement of the parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are obligated to pay up to approximately $50.0 million in the aggregate upon obtaining certain milestones in the development and marketing approval of entinostat, assuming that we pursue at least two different indications for entinostat or any other licensed product. We are also obligated to pay Bayer up to $100.0 million in aggregate sales milestones, and a tiered single-digit royalty on net sales by us, our affiliates and sublicensees of entinostat and any other licensed products under the Bayer license agreement. We are obligated to pay Bayer these royalties on a country-by-country basis for the life of the relevant licensed patents covering such product or 15 years after the first commercial sale of such product in such country, whichever is longer. We cannot determine the date on which our royalty payment obligations to Bayer would expire because no commercial sales of entinostat have occurred and the last-to-expire relevant patent covering entinostat in a given country may change in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Bayer license agreement will remain in effect until the expiration of our royalty obligations under the agreement in all countries. Upon expiration of the agreement our licenses become fully paid-up and irrevocable. Either party may terminate the Bayer license agreement in its entirety or with respect to certain countries in the event of an uncured material breach by the other party. Either party may terminate the Bayer license agreement if voluntary or involuntary bankruptcy proceedings are instituted against the other party, if the other party makes an assignment for the benefit of creditors, or upon the occurrence of other specific events relating to the insolvency or dissolution of the other party. Bayer may terminate the Bayer license agreement if we seek to revoke or challenge the validity of any patent licensed to us by Bayer under the Bayer license agreement or if we procure or assist a third party to take any such action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and Marketing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given our stage of development, we have recently started building a commercial infrastructure to support sales of our product candidates in the United States. We expect that our targeted sales force will focus on a well-defined group of medical oncologists, and transplant physicians, primarily in the non-hospital and academic settings, who are responsible for the care and treatment of cancer patients. For revumenib, we expect to manage sales, marketing and distribution through internal resources and third-party relationships. In accordance with our agreement, Incyte will lead the commercialization of axatilimab globally and we have elected to co-promote axatilimab in the United States. While we may commit significant financial and management resources to commercial activities, we would also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities. Outside the United States, we plan to rely on our current partners and may seek additional pharmaceutical partners for development as well as sales and marketing activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate manufacturing facilities for the production of axatilimab, revumenib or entinostat, and we do not have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers as well as Incyte for all of our required raw materials, active pharmaceutical ingredients and finished product for our preclinical research, clinical trials, and anticipated commercial supply. Development and commercial quantities of any products that we develop will need to be manufactured in facilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patents and Property Rights</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through licensed intellectual property and our owned intellectual property, we seek patent protection in the United States and internationally for our product candidates, their methods of use and processes for their manufacture, as well as for other technologies, where appropriate. Our policy is to actively seek to protect our proprietary position by, among other things, filing patent applications in the United States and abroad claiming our proprietary technologies that are important to the development of our business. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be sure that patents will be granted with respect to any of our owned or licensed pending patent applications or with respect to any patent applications filed by us or our licensors in the future, nor can we be sure that any of our existing owned or licensed patents or any patents that may be granted to us or to our licensors in the future will protect our technology. Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for the technologies that we consider important to our business, defend our patents, preserve the confidentiality of our trade secrets, operate our business without infringing the patents and proprietary rights of third parties, and prevent third parties from infringing our proprietary rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Axatilimab Patent Portfolio</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We in-licensed from UCB a patent portfolio directed to axatilimab. As of December 31, 2023, the in-licensed axatilimab composition-of-matter patent portfolio included two granted U.S. patents, 27 granted non-U.S. patents, including a granted Eurasian patent which has been validated in 3 countries and two granted EP patent which have been validated in 37 countries each, and 22 non-U.S. pending patent applications. The in-licensed granted patents covering axatilimab, and any non-U.S. pending applications should they issue, will expire in August 2034 or later should patent term extension be granted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our in-licensed patent portfolio also includes patents and patent applications directed to methods for the treatment and/or prophylaxis of fibrotic disease by administration of an inhibitor of CSF-1R activity, methods for the treatment and/or prophylaxis of inflammatory bowel disease, or IBD, by administration of an inhibitor of CSF-1R activity, and liquid pharmaceutical compositions of anti-CSF-1R antibodies. As of December 31, 2023, the in-licensed method of use patent family included 11 granted non-U.S. patents, including a granted EP patent which has been validated in 7 countries, and another granted EP patent which has been validated in 8 countries, and 3 non-U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pending patent applications. The in-licensed granted patents covering axatilimab, and any non-U.S. pending applications should they issue, will expire in August 2034 or later should patent term extension be granted. As of December 31, 2023, the in-licensed liquid pharmaceutical compositions of anti-CSF-1R antibodies patent family included 1 granted U.S. patent, 13 granted non-U.S. patents including a granted EP patent which has been validated in 33 countries, and 5 non-U.S. pending patent applications. These in-licensed granted patents covering axatilimab, and any non-U.S. pending applications should they issue, will expire between November 2024 and February 2036 or later should patent term extension be granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our owned axatilimab patent portfolio includes one pending U.S. patent application and six non-U.S. patent applications directed to combinations of entinostat and axatilimab. If any one of these applications were to issue as one or more patents, these patents would expire in May 2038 or later should patent term extension be granted. Our owned axatilimab patent portfolio also consists of patent applications directed to the treatment regimens and methods of using axatilimab includes one pending U.S. patent application and 18 non-U.S. patent applications. If any one of these applications were to issue as one or more patents, these patents would expire in December 2040 or later should patent term extension be granted.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Menin Asset Patent Portfolio</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We in-licensed from Vitae Pharmaceuticals, LLC (formerly Vitae Pharmaceuticals, Inc., "Vitae") a subsidiary of AbbVie Inc., a patent portfolio directed to a series of selective preclinical inhibitors targeting the binding interaction of menin with MLL-r. As of December 31, 2023, the in-licensed portfolio includes four granted U.S. patents, U.S. Patent Nos. 11,479,557, 10,683,302, 11,739,085 and 10,899,758, 20 granted non-U.S patents, including a granted European patent, which was validated in 30 member states and another granted European patent which was validated in 15 member states, two pending U.S. applications and 25 non-U.S. pending patent applications covering composition of matter and methods of treating, e.g., MLL. The in-licensed granted patents, and any pending application should they issue, are expected to expire between June 2037 and September 2037 or later should patent term extension be granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our owned menin patent portfolio consists of twelve pending non-U.S. patent applications and one pending U.S. patent application, directed to combinations of a menin inhibitor and a CYP3A inhibitor for the treatment of various cancers. Our owned menin patent portfolio also consists of one U.S. provisional applications directed to the salts and polymorphic forms of menin inhibitors and pharmaceutical combinations thereof and one pending PCT patent application directed to methods of treating colorectal cancer in a subject in need thereof with a menin-MLL inhibitor. If any of these pending applications were to issue as one or more patents, these patents would expire between April 2041 and November 20244 or later should patent term extension be granted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We co-own with Vitae and/or Syngene International Limited seventeen pending non-U.S. patent applications, two pending U.S. patent application, and two pending U.S. provisional applications, covering composition of matter and methods of treating cancer and other diseases mediated by the menin-MLL interaction. Syngene International Limited is obligated to assign their rights to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also co-own with Board of Regents, The University of Texas System six pending non-U.S. patent applications, one pending U.S. patent application, covering methods of treating cancer with combinations, including menin inhibitors and Bcl-2 inhibitors.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Entinostat Patent Portfolio</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to protect entinostat with multiple layers of patents. As of December 31, 2023, our portfolio included four owned pending U.S. non-provisional patent applications, three owned granted U.S. patents, U.S. Patent Nos. 10,226,472, 11,324,822, and 11,397,184 which expire in August 2032, March 2036 and October 2036, respectively, or later should patent term extension be granted, directed to methods of treating a patient with combinations of entinostat and pembrolizumab or other therapeutic agents, 19 granted non-U.S. patents (including one European patent validated in countries), and 39 owned non-U.S. pending patent applications. Our owned entinostat patent portfolio includes pending U.S. and non-U.S. patent applications directed to methods of treating cancer patients by administration of entinostat and exemestane, methods of treating cancer patients by administration of entinostat in combination with an HER2 inhibitor, treatments with entinostat combined with anti PD-1 or anti PD-L1 antibodies, entinostat and CSF-1 or CSF-1R combination therapies (also discussed above in the Axatilimab Patent Portfolio) and patient selection for combination therapy comprising entinostat and a second therapeutic agent. The granted patents, and any pending applications should they issue as one or more patents, these patents would expire between August 2032 and May 2039 or later should patent term extension be granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent portfolio we licensed from Bayer contains a number of issued U.S. and foreign patents as well as patent applications pending outside the United States. A number of the patents and patent applications we licensed from Bayer are directed to entinostat while other patents and patent applications are directed to compounds other than entinostat. As of December 31, 2023, the portfolio we licensed from Bayer included seven issued U.S. patents, 62 granted non-U.S. patents and 17 patent applications pending in non-U.S. patent offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The portfolio we licensed from Bayer also includes U.S. Patent 7,973,166, or the &#8217;166- patent, which covers a crystalline polymorph of entinostat which is referred to as crystalline polymorph- B, the crystalline polymorph used in the clinical development of entinostat. Many compounds can exist in different crystalline forms. A compound which in the solid state may exhibit multiple different crystalline forms is called polymorphic, and each crystalline form of the same chemical compound is termed a polymorph. A new crystalline form of a compound may arise, for example, due to a change in the chemical process or the introduction of an impurity. Such new crystalline forms may be patented. By comparison, the U.S. Patent RE39,754, which expired in September 2017, covers the chemical entity of entinostat and any crystalline or non-crystalline form of entinostat. On March 7, 2014, our licensor Bayer applied for reissue of the &#8216;166 patent. The reissue application sought to add three additional inventors to the &#8216;166 patent. The reissue was granted as RE45,499 on April 28, 2015, at which time the original &#8216;166 patent was surrendered. The reissue patent has the same force and effect as the original &#8216;166 patent and the same August 2029 expiration date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Of the unexpired foreign-granted patents we licensed from Bayer, there are 33 granted foreign counterparts of the &#8216;166 patent (now RE45,499) that cover crystalline polymorph B, including the European patent and Eurasian patent. The granted European patent comprises 37 national countries that have all been validated, and the granted Eurasian patent comprises nine countries that have all been validated. Likewise, there are 3 pending foreign counterparts of the &#8216;166 crystalline polymorph B patent. Other patents and patent applications in the licensed Bayer portfolio are expired and covered methods of treatment by administration of entinostat.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing the earliest non-provisional application or PCT application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. The term of a patent that covers an approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the development and regulatory review process. To obtain a patent extension in the United States, the term of the relevant patent must not have expired before the extension application, the patent cannot have been extended previously under this law, an application for extension must be submitted, the product must be subject to regulatory review prior to its commercialization, and the permission for the commercial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing or use of the product after such regulatory review period is the first permitted commercial marketing or use of the product. If our future products contain active ingredients which have not been previously approved, we may be eligible for a patent term extension in the United States. In the United States, we expect to seek extension of patent terms under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of the patent for patent claims covering a new chemical entity. If patent extensions are available to us outside of the United States, we would expect to file for a patent term extension in applicable jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Confidential Information and Inventions Assignment Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment, consulting or collaborative relationships with us. These agreements provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not disclosed to third parties except in specific circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the case of employees, the agreements provide that all inventions resulting from work performed for us, utilizing our property or relating to our business and conceived or completed by the individual during employment shall be our exclusive property to the extent permitted by applicable law. Our consulting and service agreements also provide for assignment to us of any intellectual property resulting from services performed for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation and Product Approval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">United States Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the FDA regulates drugs and biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, and related regulations. Drugs and biologics are also subject to other federal, state and local statutes and regulations. The FDA and comparable regulatory agencies in state and local jurisdictions impose substantial requirements upon, among other things, the testing, development, manufacture, quality control, safety, purity, potency, labeling, storage, distribution, record keeping and reporting, approval, import and export, advertising and promotion, and postmarket surveillance of drugs and biologics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biopharmaceutical Product Development Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process required by the FDA before biopharmaceutical products may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of extensive preclinical laboratory tests and animal studies in accordance with applicable regulations, including the FDA&#8217;s good laboratory practice, or GLP regulations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission of an Investigational New Drug, or IND, application which must become effective before clinical trials may begin; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable regulations, including the FDA&#8217;s current good clinical practice, or GCP, regulations to establish the safety and efficacy of the proposed drug for its intended use or uses; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an NDA for a new drug product or a Biologics License Application, or BLA, for biologics; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the application for filing and review; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is produced to assess compliance with the FDA&#8217;s current Good Manufacturing Practices, or cGMP, regulations to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of an NDA or BLA; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the biopharmaceutical product in the United States. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any compounds with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry and formulation, as well as animal studies to assess the potential safety, toxicity profile and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to commencing the first clinical trial in humans, an IND must be submitted to the FDA, and the IND must become effective. A sponsor must submit preclinical testing results to the FDA as part of the IND and the FDA must evaluate whether there is an adequate basis for testing the drug in humans. The IND automatically becomes effective 30 days after receipt by the FDA unless the FDA within the 30-day time period raises concerns or questions about the submitted data or the conduct of the proposed clinical trial and places the IND on clinical hold. In such case, the IND application sponsor must resolve any outstanding concerns with the FDA before the clinical trial may begin. A separate submission to the existing IND application must be made for each successive clinical trial to be conducted during product development. Further, an independent Institutional Review Board, or IRB, for each site proposing to conduct the clinical trial must review and approve the protocol and informed consent for any clinical trial before it commences at that site. Informed consent must also be obtained from each study subject. Regulatory authorities, an IRB, a data safety monitoring board or the trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the participants are being exposed to an unacceptable health risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1&#8212;The drug is initially given to healthy human subjects or patients and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2&#8212;The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to determine dosage tolerance, optimal dosage and dosing schedule. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3&#8212;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall benefit-risk ratio of the product and to provide an adequate basis for product approval by the FDA. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval studies, or Phase 4 clinical trials, may be conducted after initial marketing approval. These studies may be required by the FDA as a condition of approval and are used to gain additional experience from the treatment of patients in the intended therapeutic indication. The FDA also has express statutory authority to require post-market clinical studies to address safety issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data monitoring board or committee. This group provides recommendations for whether or not a trial may move forward at designated checkpoints based on access to certain data from the study. A sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must include developed methods for testing the identity, strength, quality and purity of the finished product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA Review and Approval Processes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to obtain approval to market a biopharmaceutical product in the United States, a marketing application must be submitted to the FDA that provides data establishing to the FDA&#8217;s satisfaction the safety and effectiveness of the investigational drug for the proposed indication. Each NDA or BLA submission requires a substantial user fee payment unless a waiver or exemption applies. The application includes all relevant data available from pertinent nonclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA will initially review an NDA or BLA for completeness before it accepts it for filing. The FDA has 60 days from its receipt of an application to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. If it is not, the FDA may refuse to file the application and request additional information, in which case the application must be resubmitted with the supplemental information, and review of the application is delayed. After an NDA or BLA submission is accepted for filing, the FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the filing of an NDA or BLA, the FDA may grant a priority review designation to a product, which sets the target date for FDA action on the application at 6 months, rather than the standard 10 months. Priority review is given for drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. Priority review designation does not change the scientific or medical standard for approval or the quality of evidence necessary to support approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA or BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical sites to assure compliance with GCP.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the FDA completes its initial review of an NDA or BLA, it will communicate to the sponsor that the product is approved, or it will issue a complete response letter to communicate that the application will not be approved in its current form and inform the sponsor of changes that must be made or additional clinical, nonclinical or manufacturing data that must be received before the application can be approved.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution, or post-marketing study requirements. For example, the FDA may require Phase 4 testing, which involves clinical trials designed to further assess a drug&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also determine that a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of an NDA must submit a proposed REMS, and the FDA will not approve an NDA without an approved REMS, if required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Among other programs, the FDA may expedite the review of a product candidate designated as a breakthrough therapy, which is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A sponsor may request the FDA to designate a drug as a breakthrough therapy at the time of, or any time after, the submission of an IND application for the drug. If the FDA designates a drug as a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the drug; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment. The FDA may rescind a breakthrough therapy designation in the future if further clinical development later shows that the criteria for designation are no longer met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Breakthrough therapy designation does not change the standards for approval but may expedite the development or review process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If and when approved, any products manufactured or distributed by us or on our behalf will be subject to continuing regulation by the FDA, including requirements for record-keeping, reporting of adverse experiences and submitting annual reports.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharmaceutical manufacturers are required to register their facilities with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain quality processes, manufacturing controls and documentation requirements upon us and our third-party manufacturers in order to ensure that the product is safe, has the identity and strength, and meets the quality and purity characteristics that it purports to have. The FDA and certain states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including technology capable of tracking and tracing product as it moves through the distribution chain. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP and other FDA regulatory requirements. If our present or future suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, fail to approve any application, shut down manufacturing operations or withdraw approval of an application, or we may recall the product from distribution. Noncompliance with cGMP or other requirements can result in issuance of warning letters, civil and criminal penalties, seizures and injunctive action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA closely regulates the labeling, marketing and promotion of drugs and biologics. While doctors are free to prescribe any drug approved by the FDA for any use based on the doctor&#8217;s independent medical judgment, a company can only make claims relating to safety and efficacy of a drug that are consistent with FDA approval, and a company is allowed to actively market a drug only for the particular use and treatment approved by the FDA. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addition, any claims we make for our products in advertising or promotion must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties. Government regulators recently have increased their scrutiny of the promotion and marketing of drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In both domestic and foreign markets, sales of any products for which we may receive regulatory approval will depend in part upon the availability of coverage and adequate reimbursement to healthcare providers from third-party payors. Such third-party payors include government health programs, such as Medicare and Medicaid, as well as managed care organizations, private health insurers and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are available. Assuming coverage is granted, the reimbursement rates paid for covered products might not be adequate. Even if favorable coverage status and adequate reimbursement rates are attained, less favorable coverage policies and reimbursement rates may be implemented in the future. The marketability of any products for which we may receive regulatory approval for commercial sale may suffer if the government and other third-party payors fail to provide coverage and adequate reimbursement to allow us to sell such products on a competitive and profitable basis. For example, under these circumstances, physicians may limit how much or under what circumstances they will prescribe or administer such products, and patients may decline to purchase them. This, in turn, could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition, and future success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the European Union and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies. Such pressure, along with the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union, will likely put additional downward pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions, governmental laws and regulations related to government healthcare programs, healthcare reform, and pharmaceutical coverage and reimbursement policies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market for any product candidates for which we may receive regulatory approval will depend significantly on the degree to which these products are listed on third-party payors&#8217; drug formularies or lists of medications for which third-party payors provide coverage and reimbursement to the extent products for which we may receive regulatory approval are covered under a pharmacy benefit or are otherwise subject to a formulary. The industry competition to be included on such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. In addition, because each third-party payor individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming and costly process. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval would be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. We cannot be certain that our product candidates will be considered cost-effective. This process could delay the market acceptance of any product candidates for which we may receive approval and could have a negative effect on our future revenues and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Federal and State Fraud and Abuse and Data Privacy and Security Laws and Regulations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state laws restrict business practices in the pharmaceutical industry. These laws include anti-kickback and false claims laws and regulations as well as data privacy and security laws and regulations. The laws that will affect our operations include, but are not limited to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the Affordable Care Act, amended the intent requirement of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.803127325319387%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal civil and criminal false claims laws, including, without limitation, the False Claims Act, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The Affordable Care Act provides, and recent government cases against pharmaceutical manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act;</span></div></div>
  <div style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.803127325319387%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private);</span></div></div>
  <div style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.803127325319387%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform certain services on behalf of a covered entity that involves the use or disclosure of individually identifiable health information, and their covered subcontractors;</span></div></div>
  <div style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.803127325319387%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to: (i) payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals; and (ii) ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.803127325319387%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers, state laws that require manufactures to report pricing information regarding certain drugs, state and local laws that require the registration of pharmaceutical sales representatives, and state laws that govern the privacy and security of health information, which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to federal and state laws that govern the privacy and security of other personal information, including federal and state consumer protection laws, state data security laws, and data breach notification laws. A data breach affecting sensitive personal information, including health information, could result in significant legal and financial exposure and reputational damages.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge, investigation or legal action under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, imprisonment, disgorgement, exclusion from participation in government healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any of our product candidates receive approval and are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, international data protection laws (including the General Data Protection Directive ((EU) 2016/679) on the protection of individuals with regard to the processing of personal data and on the free movement of such data as well as EU member state implementing legislation), and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, then President Obama signed into law the Affordable Care Act, which substantially changed the way healthcare will be financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. Among the provisions of the Affordable Care Act of importance to our business, including, without limitation, our ability to commercialize, and the prices we may obtain for, any of our product candidates that are approved for sale, are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an annual, nondeductible fee payable by any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of- sale discounts off negotiated prices;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extension of manufacturers&#8217; Medicaid rebate liability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">new requirements to report financial arrangements with physicians and teaching hospitals;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable Care Act&#8217;s mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries, Presidential executive orders, and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Further, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program, or SIP, proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The full impact on our business of the Affordable Care Act and other new laws is uncertain but may result in additional reductions in Medicare and other healthcare funding. Nor is it clear whether other legislative changes will be adopted, if any, or how such changes would affect the demand for our products once commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulations Outside of the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates to the extent we choose to sell any products outside of the United States. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. As in the United States, post-approval regulatory requirements, such as those regarding product manufacture, marketing, or distribution would apply to any product that is approved outside the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Regulations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 19, 2024, we had 184 full-time employees. Of the full-time employees, 112 were primarily engaged in research and development activities and 44 have an M.D., Ph.D., or PharmD degree. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. To allow us flexibility in meeting varying workflow demands, we also engage consultants and temporary workers when needed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through the granting of equity-based compensation awards and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation and Benefits</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider a number of measures and objectives in managing our human capital assets, including, among others, employee engagement, development, and training, talent acquisition and retention, employee safety and wellness, diversity and inclusion, and compensation and pay equity. We provide our employees with salaries and bonuses intended to be competitive for our industry, opportunities for equity ownership, development programs that enable continued learning and growth and a robust benefits package to promote well-being across all aspects of their lives, including health care, retirement planning and paid time off. In addition, we have conducted employee surveys to gauge employee engagement and identify areas of future focus for our human capital practices and benefits offerings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diversity, Equity and Inclusion (DEI)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that a diverse workforce is critical to our success and we are fundamentally committed to creating and maintaining a work environment in which employees are treated fairly, with dignity, decency, respect and in accordance with all applicable laws. We understand that varied perspectives lead to the best ideas and outcomes. We believe that by creating a workplace where every individual can feel welcome and valued, we will be better able to achieve our corporate objectives. All employees must adhere to a code of business conduct and ethics and our employee handbook, which combined, define standards for appropriate behavior and are annually trained to help</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent, identify, report, and stop any type of discrimination and harassment. Our recruitment, hiring, development, training, compensation, and advancement is based on qualifications, performance, skills, and experience without regard to gender, race or ethnicity.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Environmental, Social and Governance Commitment</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly committed to policies and practices focused on environmental, social and governance, or ESG, positively impacting our social community and maintaining and cultivating good corporate governance. By focusing on ESG policies and practices, we believe that we can affect a meaningful and positive change in our communities and continue to cultivate our open and inclusive collaborative culture. Some of the initiatives that we were most proud of in 2023 included continuing support for the scientific, medical, patient and local communities in which we operate, including disease awareness and supporting community needs through participation in events within the community at large. We are committed to reducing our environmental footprint. Electric car charging stations are available to employees at our Massachusetts office location. We have been methodically minimizing our use of paper records in favor of electronic records and have a robust recycling program in each office for paper, batteries and electronic equipment. We enable our employees to participate in various charity events, including walks, races and other events that impact change in the communities of the patients that we serve. This allows our employees to support causes that are meaningful to them and their families and aligns with our mission, goals and vision.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate and Other Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in Delaware in 2005. In 2011, we established a wholly owned subsidiary in the United Kingdom, in 2014 we established a wholly owned U.S. subsidiary, and in 2021, we established a wholly owned subsidiary in the Netherlands. There have been no material activities for these entities to date. We currently operate in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal office is located in Waltham, Massachusetts, where we lease approximately 12,000 square feet of office space pursuant to a lease that expires in February 2025. We also lease approximately 16,000 square feet of office space in New York, New York pursuant to leases that expires in August 2025. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space will be readily available on commercially reasonable terms.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We file electronically with the SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available on our website at </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">www.syndax.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, under &#8220;Investors,&#8221; free of charge, copies of these reports as soon as reasonably practicable after filing or furnishing these reports with the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ri</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This Annual Report contains forward-looking information based on our current expectations. Because our business is subject to many risks and our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our business, operating results, financial condition and the trading price of our common stock. You should carefully consider these risk factors, together with all of the other information included in this Annual Report as well as our other publicly available filings with the Securities and Exchange Commission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Selected Risks</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, of which you should be aware before making a decision to invest in our securities. These risks and uncertainties include, among others, the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently developing several product candidates. If we are unable to successfully complete clinical development of, obtain regulatory approval for and commercialize our product candidates, our business prospects will be significantly harmed. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revumenib and axatilimab has undergone limited clinical testing and we may fail to show that it is well tolerated and provides sufficient clinical benefit for patients. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes to the final data.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any of our product candidates.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incyte may fail to perform its obligations as expected under the collaboration or may deprioritize its investment to further develop and commercialize axatilimab. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are or our collaborators are unable to enroll patients in clinical trials, these clinical trials may not be completed on a timely basis or at all.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory approval processes of the FDA and foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. Our inability to obtain regulatory approval for our product candidates would harm our business.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community to be commercially successful.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-party suppliers as well as Incyte to manufacture and distribute our clinical drug supplies for our product candidates, we intend to rely on third parties for commercial manufacturing and distribution of our product candidates and we expect to rely on third parties for manufacturing and distribution of preclinical, clinical and commercial supplies of any future product candidates.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial scope of their approved use, or result in significant negative consequences following any marketing approval.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred net losses since our inception, except 2021, and anticipate that we will continue to incur net losses for the foreseeable future.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no source of product revenue and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require additional capital to finance our planned operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of, or obtain regulatory approval for our existing product candidates or develop new product candidates.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our stock may be volatile and you could lose all or part of your investment.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business and Industry</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are currently developing several product candidates. If we are unable to successfully complete clinical development of, obtain regulatory approval for and commercialize our product candidates, our business prospects will be significantly harmed.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial success will depend substantially on our ability to effectively and profitably commercialize our product candidates. In order to commercialize our product candidates, we will be required to obtain regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approvals by establishing that each of them is sufficiently safe and effective. The clinical and commercial success of our product candidates will depend on a number of factors, including the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, cost, timing, progress and results of our research and development activities, clinical trials and preclinical studies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timely completion of any future clinical trials of revumenib and axatilimab;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interruption of key clinical trial activities, in connection with public health threats or any future geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in Israel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we are required by the FDA or foreign regulatory authorities to conduct additional clinical trials prior to receiving marketing approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of adverse drug reactions in any of our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to demonstrate safety and efficacy of our product candidates for their proposed indications and the timely receipt of necessary marketing approvals from the FDA and foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully meeting the endpoints in the clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieving and maintaining compliance with all applicable regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential use of our product candidates to treat various cancer indications and fibrotic diseases;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our own or our potential strategic collaborators&#8217; marketing, sales and distribution strategy and operations in the United States and abroad;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our collaboration partner and of third-party contract manufacturers to produce trial supplies and to develop, validate and maintain a commercially viable manufacturing process that is compliant with cGMP;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully commercialize our product candidates in the United States and abroad, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to prevent any significant disruptions of our information technology systems and protect the security of our data; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enforce our intellectual property rights in and to our product candidates.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to obtain regulatory approval for our product candidates, we will not be able to generate product sales, which will have a material adverse effect on our business and our prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revumenib has undergone limited clinical testing and we may fail to show that it is well tolerated and provides sufficient clinical benefit for patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research suggests that certain acute leukemias, such as lysine methyltransferase 2A rearranged, or KMT2Ar, acute myeloid or lymphoid leukemia, AML or ALL, and nucleophosmin 1, or NPM1, mutant AML, are driven by the interaction of menin, a nuclear protein involved in transcription, with the N-terminus of KMT2A protein. In NPM1 mutant AML the interaction with menin occurs via the wild type KMT2A protein, and in KMT2Ar acute leukemia, the interaction occurs via a mutant form of KMT2A, a fusion protein known as KMT2Ar. KMT2Ar results from a rare, spontaneous fusion between the N-terminus of the KMT2A gene and a host of signaling molecules and nuclear transcription factors. This fusion produces an aberrant transcription program that drives leukemic transformation. In pre-clinical animal models, small molecule inhibitors of the menin-KMT2Ar interaction, such as revumenib, which bind to, and block the interaction of menin with either KMT2A rearranged or wildtype, have demonstrated deep and durable single agent treatment effects in multiple leukemic xenograft models harboring KMT2A fusions or NPM1 mutations. Our strategy for developing revumenib is to conduct a Phase 1/2 clinical trial in r/r patients with KMT2Ar and NPM1 mutant acute leukemias and determine if the observed clinical efficacy supports further development. The Phase 1 portion of the trial is assessing the safety, tolerability and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pharmacokinetics of revumenib, and seeks to establish a recommended Phase 2 dose. It is open label, and we have released and may in the future release results from time to time that reflect small numbers of patients which may not be accurately predictive of safety or efficacy results later in the trial or in subsequent trials. The Phase 2 portion is evaluating the efficacy of revumenib across three expansion cohorts enrolling pediatric and adult R/R patients with KMT2Ar ALL, KMT2Ar AML, and NPM1 mutant AML. In October 2023, we announced positive topline data in patients with R/R KMT2Ar acute leukemia and that we have submitted an NDA under the FDA&#8217;s RTOR program. Neither breakthrough therapy designation nor RTOR review change the standards for approval and may not ultimately expedite the approval process or lead to approval. While we believe that we have established sufficient efficacy to warrant an NDA submission and continued development in these indications, we may not yet have sufficiently demonstrated a favorable risk-benefit of revumenib in patients.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Axatilimab has undergone limited clinical testing and we may fail to show that it is well tolerated and provides sufficient clinical benefit for patients.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies suggest that CSF-1/CSF-1R signaling may be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD and other fibrotic or inflammatory diseases. Nonclinical studies and analysis of patient samples indicates that the cGVHD inflammatory disease process is a result of a complex interaction between host and donor immune cells including B cells, and regulatory T cells with M2 differentiated macrophages in target tissue appearing to represent the common distal mediator of fibrosis. Therefore, we hypothesize that a CSF-1R signal inhibitor such as axatilimab may play a meaningful role as a monotherapy agent in the treatment of cGVHD. In 2018, we commenced a Phase 1/2 clinical trial with axatilimab in subjects with active cGVHD who had failed at least two prior lines of therapy. Following our end of Phase 1 meeting with the FDA, we aligned on a regulatory path for axatilimab for the treatment of cGVHD and commenced a pivotal Phase 2 clinical trial, AGAVE-201, to assess the safety and efficacy of different doses and schedules of axatilimab for the treatment of patients with cGVHD. In July 2023, we announced that AGAVE-201 met its primary endpoint across all three doses in the trial. In January 2024, we announced that, along with Incyte, we have submitted a BLA, the previous December. While we believe that we have established sufficient efficacy to warrant a BLA submission and continued development in this indication, we may not yet have sufficiently demonstrated a favorable risk-benefit of axatilimab in patients.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes to the final data.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publish interim top-line or preliminary data from our clinical trials. For example, in each of November 2022 and 2023, we announced interim data from our Phase 1/2 clinical trial of revumenib. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Preliminary or top-line data may include, for example, data regarding a small percentage of the patients enrolled in a clinical trial, and such preliminary data should not be viewed as an indication, belief or guarantee that other patients enrolled in such clinical trial will achieve similar results or that the preliminary results from such patients will be maintained. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any of our product candidates.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of any of our product candidates, we or our collaborators must conduct extensive trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive and difficult to design and implement, can take many years to complete and is inherently uncertain as to the outcome. A failure of one or more trials can occur at any stage of testing. The outcome of preclinical studies and early clinical trials may not accurately predict the success of later trials, and interim results of a trial do not necessarily predict final results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent upon our collaboration with Incyte to further develop and commercialize axatilimab. If we or Incyte fail to perform as expected the potential for us to generate future revenues under the collaboration could be significantly reduced, the development and/or commercialization of axatilimab may be terminated or substantially delayed, and our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to numerous risks related to the Incyte Collaboration Agreement to collaborate on the development and commercialization of axatilimab.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, there is no assurance that the parties will achieve any of the regulatory development or sales milestones, that we will receive any future milestone or royalty payments under the collaboration agreement. Incyte&#8217;s activities may be influenced by, among other things, the efforts and allocation of resources by Incyte, which we cannot control. If Incyte does not perform in the manner we expect or fulfill its responsibilities in a timely manner, or at all, the clinical development, manufacturing, regulatory approval, and commercialization efforts related to axatilimab could be delayed or terminated. In addition, our license with Incyte may be unsuccessful due to other factors, including, without limitation, the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <div style="margin-left:5.833%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.539456497499124%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incyte may terminate the agreement for convenience upon 90 or 180 days&#8217; notice depending on whether or not the parties have commercialized axatilimab in an indication in the respective territory;</span></div></div>
  <div style="margin-left:5.833%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.539456497499124%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incyte may change the focus of its development and commercialization efforts or prioritize other programs more highly and, accordingly, reduce the efforts and resources allocated to axatilimab</span></div></div>
  <div style="margin-left:5.833%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.539456497499124%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incyte may, within its commercially reasonable discretion, choose not to develop and commercialize axatilimab in all relevant markets or for one or more indications, if at all; and</span></div></div>
  <div style="margin-left:5.833%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.539456497499124%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if Incyte is acquired during the term of our collaboration, the acquirer may have competing programs or different strategic priorities that could cause it to reduce its commitment to our collaboration or to terminate the collaboration.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot ensure that the potential strategic benefits and opportunities expected from this collaboration with be realized on our anticipated timeline or at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our collaborators are unable to enroll patients in clinical trials, these clinical trials may not be completed on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The timely completion of clinical trials largely depends on patient enrollment. Many factors affect patient enrollment, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of public health crises, or geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in Israel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perception about the relative efficacy of our product candidates versus other compounds in clinical development or commercially available;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evolving standard of care in treating cancer patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and nature of the patient population, especially in the case of an orphan indication, we are pursuing;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and location of clinical trial sites enrolled;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competition with other organizations or our own clinical trials for clinical trial sites or patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility and exclusion criteria for the trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ability to obtain and maintain patient consent; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risk that enrolled subjects will drop out before completion.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the above factors, there is a risk that our or our collaborators&#8217; clinical trials may not be completed on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be required to relinquish important rights to and control over the development and commercialization of our product candidates to our current or future collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our collaborations, including any future strategic collaborations we enter into, could subject us to a number of risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to undertake the expenditure of substantial operational, financial and management resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to issue equity securities that would dilute our existing stockholders&#8217; percentage of ownership;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to assume substantial actual or contingent liabilities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic collaborators may not commit adequate resources to the marketing, sales and distribution of our product candidates, limiting our potential revenues from these products;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic collaborators may experience financial difficulties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business combinations or significant changes in a strategic collaborator&#8217;s business strategy may also adversely affect a strategic collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic collaborators could decide to move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing, our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may explore strategic collaborations that may never materialize or may fail.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We periodically explore a variety of possible strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may enter into strategic collaborations that we subsequently no longer wish to pursue, and we may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. Our inability to obtain regulatory approval for our product candidates would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and comparable foreign regulatory authorities extensively and rigorously regulate and evaluate the manufacture, testing, distribution, advertising and marketing of drug products prior to granting marketing approvals with respect to such products. This approval process generally requires, at minimum, testing of any product candidate in preclinical studies and clinical trials to establish its safety and effectiveness, and confirmation by the FDA and comparable foreign regulatory authorities that any such product candidate, and any parties involved in its manufacturing, testing and development, complied with current Good Manufacturing Practices, or cGMP, current Good Laboratory Practices and current Good Clinical Practices, regulations, standards and guidelines during such manufacturing, testing and development. The time required to obtain approval by the FDA and foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any of our product candidates and it is possible that we will never obtain regulatory approval for our existing product candidates or any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In addition, our product candidates could fail to receive regulatory approval from the FDA or foreign regulatory authorities for other reasons, including but not limited to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to demonstrate that our product candidates are effective for their proposed indication and have an acceptable safety profile;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of clinical trials to meet the primary endpoints or level of statistical significance required for approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to demonstrate that the clinical and other benefits of a product candidate outweigh any of its safety risks;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreement with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreement with the design, size, conduct or implementation of our or our collaborators&#8217; trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the insufficiency of data collected from trials of our product candidates to support the submission and filing of an NDA, BLA or other submission or to obtain regulatory approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to obtain approval of the manufacturing and testing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of a negative opinion from an advisory committee due to a change in the standard of care regardless of the outcome of the clinical trials; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or foreign regulatory authorities may require more information, including additional preclinical or clinical data, to support approval, which may delay or prevent approval and our commercialization plans, or may cause us to decide to abandon our development program. Even if we were to obtain approval, regulatory authorities may approve one or more of our product candidates for a more limited patient population than we request, may grant approval contingent on the performance of costly post-marketing trials, may impose a risk evaluation and mitigation strategy, or REMS, or foreign regulatory authorities may require the establishment or modification of a similar strategy that may, for instance, restrict distribution of one or more of our product candidates and impose burdensome implementation requirements on us, or may approve it with a label that does not include the labeling claims necessary or desirable for the successful commercialization of one or more of our product candidates, all of which could limit our ability to successfully commercialize our product candidates. Moreover, if adopted in the form proposed, the recent European Commission proposals to revise the existing European Union, or EU, laws governing authorization of medicinal products may result in a decrease in data and market exclusivity for our product candidates in the EU.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community to be commercially successful</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may not gain sufficient market acceptance among physicians, patients, healthcare payors and others in the medical community. Our commercial success also depends on coverage and adequate reimbursement by third-party payors, including government payors, which may be difficult or time-consuming to obtain, may be limited in scope and may not be obtained in all jurisdictions in which we may seek to market our product candidates. The degree of market acceptance will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile as demonstrated in trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction as well as competitive products;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product candidate is approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of the product candidate as a safe and effective treatment by physicians, clinics and patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pricing and the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the frequency and severity of adverse events;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of sales and marketing; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable publicity relating to our product candidates.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue to become or remain profitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third-party suppliers as well as Incyte to manufacture and distribute our clinical drug supplies for our product candidates, we intend to rely on third parties for commercial manufacturing and distribution of our product candidates and we expect to rely on third parties for manufacturing and distribution of preclinical, clinical and commercial supplies of any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have, nor do we plan to acquire, the infrastructure or capability to manufacture or distribute preclinical, clinical or commercial quantities of drug substance or drug product, including our existing product candidates. While we expect to continue to depend on third-party manufacturers and Incyte for the foreseeable future, we do not have direct control over the ability of these parties to maintain adequate manufacturing capacity and capabilities to serve our needs, including quality control, quality assurance and qualified personnel. In addition, public health crises, may impact the ability of our existing or future manufacturers to perform their obligations to us.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on our third-party manufacturers and Incyte for compliance with cGMPs and for manufacture of both active drug substances and finished drug products. Facilities used by our third-party manufacturers and Incyte to manufacture drug substance and drug product for commercial sale must be approved by the FDA or other relevant foreign regulatory agencies pursuant to inspections that will be conducted after we submit our NDA or relevant foreign regulatory submission to the applicable regulatory agency. If our third-party manufacturers or Incyte cannot successfully manufacture materials that conform to our specifications and/or the strict regulatory requirements of the FDA or foreign regulatory agencies, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. Furthermore, these third-party manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which also exposes our third-party manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a third-party manufacturers&#8217; facility. If the FDA or a foreign regulatory agency does not approve these facilities for the manufacture of our product candidates, or if it withdraws its approval in the future,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may need to find alternative manufacturing facilities, which would impede or delay our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain regulatory approval for our product candidates, they would be subject to ongoing requirements by the FDA and foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The FDA and foreign regulatory authorities will continue to monitor closely the safety profile of any product even after approval. If the FDA or foreign regulatory authorities become aware of new safety information after approval of a product candidate, they may require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on its indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including withdrawal of the product from the market or suspension of manufacturing, or we may recall the product from distribution. If we, or our third-party manufacturers, fail to comply with applicable regulatory requirements, a regulatory agency may:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue warning letters or untitled letters;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or withdraw regulatory approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend any ongoing clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to approve pending applications or supplements to applications filed by us;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seize or detain products, or refuse to permit the import or export of products.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize and generate revenue from the sale of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advertising and promotion of any product candidate that obtains approval in the United States is heavily scrutinized by the FDA&#8217;s Office of Prescription Drug Promotion, the Department of Justice, the Department of Health and Human Services&#8217; Office of Inspector General, state attorneys general, members of Congress, other government agencies and the public. While physicians may prescribe products for off-label uses as the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. Violations, including promotion of our products for unapproved (or off-label) uses, may be subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the government. Additionally, foreign regulatory authorities will heavily scrutinize advertising and promotion of any product candidate that obtains approval in their respective jurisdictions.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, engaging in the impermissible promotion of our products for off-label uses can also subject us to false claims litigation under federal and state statutes, which can lead to administrative, civil and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">criminal penalties, damages, monetary fines, disgorgement, individual imprisonment, exclusion from participation in Medicare, Medicaid and other federal healthcare programs, curtailment or restructuring of our operations and agreements that materially restrict the manner in which a company promotes or distributes drug products. These false claims statutes include, but are not limited to, the federal civil False Claims Act, which allows any individual to bring a lawsuit against an individual or entity, including a pharmaceutical or biopharmaceutical company on behalf of the federal government alleging the knowing submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment or approval by a federal program such as Medicare or Medicaid. These False Claims Act lawsuits against pharmaceutical or biopharmaceutical companies have increased significantly in number and breadth, leading to several substantial civil and criminal settlements regarding certain sales practices, including promoting off-label drug uses involving fines in excess of $1.0 billion. This growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations, and be excluded from participation in Medicare, Medicaid and other federal and state healthcare programs. If we, or any partner that we may engage, do not lawfully promote our approved products, we may become subject to such litigation, which may have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial scope of their approved use, or result in significant negative consequences following any marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Undesirable side effects caused by our product candidates could cause the interruption, delay or halting of the trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other foreign regulatory authorities. Results of the clinical trials may reveal a high and unacceptable severity and prevalence of side effects or other unexpected characteristics. In such event, the trials could be suspended or terminated, or the FDA or foreign regulatory authorities could deny approval of our product candidates for any or all targeted indications. Drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if our product candidates receive marketing approval, and we or others later identify undesirable side effects, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may suspend marketing of, or withdraw or recall, the product;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw approvals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the product labels;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or other regulatory authorities may issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about the product;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA may require the establishment or modification of a REMS or foreign regulatory authorities may require the establishment or modification of a similar strategy that may, for instance, restrict distribution of the product and impose burdensome implementation requirements on us;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require that we conduct post-marketing studies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to subjects or patients; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates for use in targeted indications or otherwise materially harm its commercial prospects, if approved, and could harm our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market and sell our product candidates in other jurisdictions, we must obtain separate marketing approvals for those jurisdictions and comply with their numerous and varying regulatory requirements. We may not obtain foreign regulatory approvals on a timely basis, or at all. The approval procedure varies among countries and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, product reimbursement approvals must be secured before regulatory authorities will approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. Our failure to obtain approval of our product candidates by foreign regulatory authorities may negatively impact the commercial prospects of such product candidates and our business prospects could decline. Also, if regulatory approval for our product candidates is granted, it may be later withdrawn. If we fail to comply with the regulatory requirements in international jurisdictions and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential for our product candidates will be harmed and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if any of our product candidates received regulatory approval, such product candidates would face competition from other therapies in the relevant indication. For example, chronic graft versus host disease has historically been managed by off-label treatments. However, in the past several years, the FDA has approved three drugs, ibrutinib (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Imbruvica</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), belomosidil (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rezurock</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and ruxolitinib (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Jakafi</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), for use in patients with cGVHD after failure of one or more lines of systemic therapy. All three of these drugs may compete with axatilimab in patients diagnosed with cGVHD.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revumenib is being developed for the treatment of R/R adult and pediatric patients with KMT2Ar ALL, KMT2Ar AML and NPM1 mutant AML. At this time, there are no drugs approved for these defined populations and patients are managed using the standard of care treatment regimens developed for general AML and ALL populations. While there are other agents in early development for similar populations, revumenib has the potential to be the first defined therapy for patients with KMT2Ar ALL, KMT2Ar AML and/or NPM1 mutant AML.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products. Our competitors may be more successful than us in obtaining FDA approval for drugs and achieving widespread market acceptance. Our competitors&#8217; drugs may be more effective or more effectively marketed and sold than any drug we may commercialize and may render our product candidates obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our product candidates. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our ability to successfully compete will depend on, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile of our product candidates relative to marketed products and product candidates in development by third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the time it takes for our product candidates to complete clinical development and receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to commercialize our product candidates if they receive regulatory approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the price of our product candidates, including in comparison to branded or generic competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether coverage and adequate levels of reimbursement are available under private and governmental health insurance plans, including Medicare;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to manufacture commercial quantities of our product candidates if they receive regulatory approval; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to negotiate preferential formulary status for our product candidates.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain regulatory approval of our product candidates, the availability, commercial formulary placement, and price of our competitors&#8217; products could limit the demand and the price we are able to charge. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment, or if physicians switch to other new drug or biologic products or choose to reserve our drugs for use in limited circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain of our investigational products may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization. Certain of our revumenib clinical trials include the use of an investigational or laboratory developed diagnostic test to help identify eligible patients. We currently do not have any plans to develop diagnostic tests internally. We are therefore dependent on the sustained cooperation and effort of third-party collaborators in developing and, if our investigational products are approved for use only with an approved companion diagnostic test, obtaining approval and commercializing these tests. If these parties are unable to successfully develop companion diagnostics for our investigational products, or experience delays in doing so, the development of our investigational products may be adversely affected and we may not be able to obtain marketing authorization for these investigational products. Furthermore, our ability to market and sell, as well as the commercial success, of any of our investigational products that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies. Any failure to develop, validate, obtain and maintain marketing authorization and supply for a companion diagnostic we need may harm our business prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent on UCB Biopharma Sprl, or UCB, to comply with the terms of our license agreement for axatilimab.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success also depends upon our ability to develop, manufacture, market and sell axatilimab. We have a worldwide, sublicensable, exclusive license to axatilimab pursuant to a license agreement with UCB. Certain of the rights licensed to us under the UCB license agreement are in-licensed by UCB from third parties. We are dependent on UCB maintaining the applicable third-party license agreements in full force and effect, which may include activities and performance obligations that are not within our control. If any of these third-party license agreements terminate, certain of our rights to develop, manufacture, commercialize or sell axatilimab may be terminated as well. The occurrence of any of these events could adversely affect the development and commercialization of axatilimab, and materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, consultants and collaborators may engage in misconduct or other improper activities, including insider trading and non-compliance with regulatory standards and requirements.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees, consultants, distributors, and collaborators may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates the regulations of the FDA and non-U.S. regulators, including those laws requiring the reporting of true, complete and accurate information to such regulators, manufacturing standards, healthcare fraud and abuse laws and regulations in the United States and abroad or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry, including the sale of pharmaceuticals, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We must attract and retain additional highly skilled employees in order to succeed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical, commercial and management personnel and we face significant competition for experienced personnel. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the pharmaceutical and biopharmaceutical industries is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we commercialize our product candidates, they or any other product candidates that we develop, may become subject to unfavorable pricing regulations or third-party coverage or reimbursement practices, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to successfully commercialize our existing product candidates, or any other product candidates that we develop, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government healthcare programs, private health insurers, pharmacy benefit managers, managed care plans and other organizations. Third-party payors determine which medications they will cover and establish reimbursement levels. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined rebates and discounts from list prices and are challenging the prices charged for medical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Limitation on coverage and reimbursement may impact the demand for, or the price of, and our ability to successfully commercialize any product candidates that we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining adequate coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, marketing, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private payors often follow decisions by Center for Medicare &amp; Medicaid Services, or CMS, regarding coverage and reimbursement to a substantial degree. However, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. As a result, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulations that govern marketing approvals, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for our product candidates in a particular country, but be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment even if our product candidates obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that our product candidates, if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication, that it will be considered cost effective by third-party payors, that coverage and an adequate level of reimbursement will be available, or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably. Even if favorable coverage status and adequate reimbursement rates are attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us to commercialize our product candidates and affect the prices we may obtain.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidate for which we obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, then President Obama signed into law the Affordable Care Act. Among other cost containment measures, the Affordable Care Act established an annual, nondeductible fee on any entity that manufactures or imports branded prescription drugs and biologic agents, a Medicare Part D coverage gap discount program, and a formula that increased the rebates a manufacturer must pay under the Medicaid Drug Rebate Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket costs through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which began in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2013, and due to subsequent legislative amendments to the statute, will remain in effect through 2032 unless additional Congressional action is taken.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which ended the use of the statutory formula and established a quality payment program, also referred to as the Quality Payment Program. Under both APMs and MIPS, performance data collected each performance year will affect Medicare payments in later years, including potentially reducing payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several, Presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to President Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (i) directs the Secretary of HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare Part B and Medicare Part D, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program, or SIP, proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. For example, based on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are in the process of building our sales, marketing and distribution infrastructure.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market any approved product candidate in the future, we must build our sales, marketing, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, as we do not presently have all of these capabilities. To develop our internal sales, distribution and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing capabilities, we must invest significant amounts of financial and management resources in the future. For drugs where we decide to perform sales, marketing and distribution functions ourselves, we could face a number of challenges, including that:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to attract and build an effective marketing or sales organization;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of establishing, training and providing regulatory oversight for a marketing or sales force may not be justifiable in light of the revenues generated by any particular product;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our direct or indirect sales and marketing efforts may not be successful; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there are significant legal and regulatory risks in drug marketing and sales that we have never faced, and any failure to comply with all legal and regulatory requirements for sales, marketing and distribution could result in enforcement action by the FDA or other authorities that could jeopardize our ability to market the product or could subject us to substantial liabilities.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alternatively, we may rely on third parties to launch and market our product candidates, if approved. We may have limited or no control over the sales, marketing and distribution activities of these third parties and our future revenue may depend on the success of these third parties. Additionally, if these third parties fail to comply with all applicable legal or regulatory requirements, the FDA or another governmental agency could take enforcement action that could jeopardize their ability and our ability to market our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or other products that we may develop caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">termination of clinical trial sites or entire trial programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of trial participants;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial subjects or patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of management and scientific resources from our business operations; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any products that we may develop.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we currently hold trial liability insurance coverage consistent with industry standards, this may not adequately cover all liabilities that we may incur. We also may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise in the future. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for our product candidates, but we may be unable to obtain commercially reasonable product liability insurance. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with healthcare providers, customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations as well as privacy and data security laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">reputational harm, fines, exclusion from participation in government healthcare programs, curtailments or restrictions of our operations, administrative burdens and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, including physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct clinical research and market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute prohibits persons from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for the furnishing or arranging for the furnishing, or the purchase, lease or order, or arranging for or recommending purchase, lease or order, or any good or service for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other.;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Affordable Care Act amended the intent requirement of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal false claims, including the federal civil False Claims Act, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, and civil monetary penalties laws, which prohibit knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, also imposes obligations on covered entities, including certain health care providers, health plans and health care clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information for or on behalf of such covered entities, and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to CMS information related to &#8220;payments or other transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians (as defined above) and their immediate family members; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require manufacturers to report pricing information regarding certain drugs; state and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and federal, state, and foreign laws that govern the privacy and security of other personal information, including federal and state consumer protection laws, state data security laws, and data breach notification laws (a data breach affecting sensitive personal information, including health information, could result in significant legal and financial exposure and reputational damages).</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any physician or other healthcare provider or entity with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share, or collectively, process, personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, clinical trial data and financial information or collectively, sensitive data.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information. For more information regarding risks associated with HIPAA, please refer to the section above that discusses risks associated with healthcare laws and regulations.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or CPRA and collectively, CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws may impact (possibly significantly) our business activities depending on how it is interpreted, should we become subject to the CCPA in the future. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts and increase legal risk and compliance costs for us and the third parties upon whom we rely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom&#8217;s GDPR, or UK GDPR, impose strict requirements for processing personal data. For example, under GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to new laws governing the privacy of consumer health data, including reproductive, sexual orientation, and gender identity privacy rights. For example, Washington&#8217;s My Health My Data Act, or MHMD, broadly defines consumer health data, places restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. Other states are considering and may adopt similar laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our employees and personnel may occasionally use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area, or EEA, and the United Kingdom, or UK, have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to data privacy and security laws, we are bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We also publish privacy policies, marketing materials, and other statements regarding data privacy and security and if these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data (including clinical trial data); and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our information technology systems, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; fines and penalties; disruptions of our business operations; reputational harm;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">loss of revenue or profits; and other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats that could cause security incidents. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks and our sensitive data. In addition, those third-party vendors may in turn subcontract or outsource some of their responsibilities to other parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the accessibility and distributed nature of our information technology systems, and the sensitive data stored on those systems, make such systems vulnerable to unintentional or malicious, internal and external attacks on our technology environment. Furthermore, our ability to monitor the aforementioned third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we currently offer a hybrid-work environment, which may make us more vulnerable to cyberattacks as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or by malicious third parties. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely); however, we may not detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities are increasing in their frequency, levels of persistence, sophistication and intensity, and are also being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. Such attacks could include the deployment of harmful malware (including as a result of advanced persistent threat intrusions), ransomware attacks, denial-of-service attacks, credential stuffing and/or harvesting, social engineering (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of sensitive data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fires, floods and other means to affect service reliability and threaten the confidentiality, integrity and availability of our information systems and sensitive data. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant disruptions of our, our third-party vendors&#8217; and/or business partners&#8217; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive data, which could result in financial, legal, regulatory, business and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may expend significant resources or modify our business activities to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, including but not limited to a security incident involving personal information regarding employees or clinical trial patients, we may experience adverse consequences, such as disruptions to our business, harm to our reputation, government enforcement actions (for example, investigations, fines, penalties, audits, and inspections), additional reporting requirements and/or oversight, or we may otherwise be subject to liability under laws, regulations, and contractual obligations, including those that protect the privacy and security of personal information. This could result in increased costs to us and result in significant legal and financial exposure and/or reputational harm. Any failure or perceived failure by us or our vendors or business partners to comply with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our privacy, confidentiality or data security-related legal or other obligations to third parties, or any further security incidents or other inappropriate access events resulting in the unauthorized access, release or transfer of sensitive data, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including clinical sites, regulators or current and potential partners, to lose trust in us or we could be subject to claims by third parties that we have breached our privacy or confidentiality-related obligations, which could materially and adversely affect our business and prospects. Moreover, data security incidents and other inappropriate access can be difficult to detect and any delay in identifying them may lead to increased harm of the type described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have implemented security measures to protect our information technology systems and infrastructure, there can be no assurance that such measures will be effective. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company or our customers could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; potential use of generative AI technologies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Social media platforms and AI-based platforms present new risks and challenges to our business.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As social media continues to expand, it also presents us with new risks and challenges. Social media is increasingly being used to communicate information about us, our programs and the diseases our product candidates are being developed to treat. Social media practices in the biopharmaceutical industry are evolving, creating uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product or a product candidate, which could result in reporting obligations or other consequences. Further, the accidental or intentional disclosure of non-public information by our workforce or others through media channels could lead to information loss. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us, our products, or our product candidates on any social media platform. The nature of social media prevents us from having real-time control over postings about us on social media. We may not be able to reverse damage to our reputation from negative publicity or adverse information posted on social media platforms or similar mediums. If any of these events were to occur or we otherwise fail to comply with application regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business including quick and irreversible damage to our reputation, brand image and goodwill. Additionally, AI-based platforms are increasingly being used in the biopharmaceutical industry. The use of AI platforms by people, including our vendors, suppliers and contractors, with access to our proprietary and confidential information, including trade secrets, may continue to increase and may lead to the release of such information, which may negatively impact our company, including our ability to realize the benefit of our intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Financial Position and Capital Needs</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred net losses since our inception, except 2021, and anticipate that we will continue to incur net losses for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval or be commercially viable. We are a clinical-stage biopharmaceutical company with limited operating history. We have no products approved for commercial sale and have not generated any product revenues to date, and we continue to incur significant research and development and other expenses related to our ongoing operations and clinical development of our product candidates. As a result, we are not and have never been profitable and have incurred losses in each period since our inception in 2005, except in 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, we reported a net loss of $209.4 million. As of December 31, 2023, we had an accumulated deficit of $902.4 million, which included non-cash charges for stock-based compensation, preferred stock accretion and historical extinguishment charges. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our pre-commercialization activities for, and our research and development of, and seek regulatory approvals for, our product candidates. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of growth of our expenses and our ability to generate revenues, if any. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have no source of product revenue and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate product revenue and become profitable depends upon our ability to successfully commercialize our product candidates. We do not anticipate generating revenue from the sale of our product candidates for the foreseeable future. Our ability to generate future product revenue also depends on a number of additional factors, including, but not limited to, our ability to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully complete the research and clinical development of, and receive regulatory approval for, our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">launch, commercialize and achieve market acceptance of our product candidates, and if launched independently, successfully establish a sales, marketing and distribution infrastructure;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to build a portfolio of product candidates through the acquisition or in-license of products, product candidates or technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiate preclinical and clinical trials for any additional product candidates that we may pursue in the future;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish and maintain supplier and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of bulk drug substances and drug products to maintain that supply;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain coverage and adequate product reimbursement from third-party payors, including government payors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish, maintain, expand and protect our intellectual property rights; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attract, hire and retain additional qualified personnel.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of increased expenses, and if or when we will achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we decide to or are required by the FDA or foreign regulatory authorities to perform studies or trials in addition to those that we currently anticipate. Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with launching and commercializing our current product candidates and any other product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we generate revenues from the sale of our product candidates, we may not become profitable and may need to obtain additional funding to continue operations or acquire additional products that will require additional funding to develop them. If we fail to become profitable or do not sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations or even shut down.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require additional capital to finance our planned operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of, or obtain regulatory approval for our existing product candidates or develop new product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations have consumed substantial amounts of cash since our inception, primarily due to our research and development efforts. We expect our research and development expenses to increase substantially in connection with our ongoing and planned activities. We believe that our existing cash, cash equivalents and short-term investments will fund our projected operating expenses and capital expenditure requirements for at least the next 12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">months. Unexpected circumstances may cause us to consume capital more rapidly than we currently anticipate, including as a result of the global economic slowdown, including any recessions that have occurred or may occur in the future. In addition, we may discover that we need to conduct additional activities that exceed our current budget to achieve appropriate rates of patient enrollment, which would increase our development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In any event, we will require additional capital to continue the development of, obtain regulatory approval for, and to commercialize our existing product candidates and any future product candidates. Any efforts to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the long-term economic impacts associated with public health crises and global geopolitical tensions, like the ongoing war between Russia and Ukraine and the war in Israel, are difficult to assess or predict, each of these events has caused significant disruptions to the global financial markets and contributed to a general global economic slowdown. Furthermore, inflation rates have increased recently to levels not seen in decades. Increased inflation may result in increased operating costs (including labor costs) and may affect our operating budgets. In addition, the U.S. Federal Reserve has raised and is expected to further raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. If the disruptions and slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could in the future negatively affect our financial condition and our ability to pursue our business strategy. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we do not raise additional capital when required or on acceptable terms, we may need to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay, scale back or discontinue the development or commercialization of our product candidates or cease operations altogether;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek strategic alliances for our existing product candidates on terms less favorable than might otherwise be available; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relinquish, or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we need to conduct additional fundraising activities and we do not raise additional capital in sufficient amounts or on terms acceptable to us, we may be unable to pursue development and commercialization efforts, which will harm our business, operating results and prospects.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future funding requirements, both short- and long-term, will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, progress, timing, costs and results of clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more trials than we currently expect;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost to establish, maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents or other intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market acceptance of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of selecting, auditing and developing manufacturing capabilities, and potentially validating manufacturing sites for commercial-scale manufacturing;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing for obtaining pricing, and coverage and reimbursement by third-party payors, which may require additional trials to address pharmacoeconomic benefit;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for our product candidates if any candidate receives regulatory approval and we determine to commercialize it ourselves;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our need to implement additional internal systems and infrastructure, including financial and reporting systems, as we grow our company; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geo-political actions, including war or the perception that hostilities may be imminent (such as the ongoing war between Russia and Ukraine and the war in Israel), terrorism, natural disasters, including earthquakes, typhoons, floods and fires, or public health crises.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we cannot expand our operations or otherwise capitalize on our business opportunities because we cannot secure sufficient capital, our business, financial condition and results of operations could be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or regulations could materially adversely affect our company.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us, which could adversely affect our business and financial condition. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws, including changes in corporate tax rates, which collectively may impact the utilization of our NOLs and other deferred tax assets, the deductibility of expenses, and the taxation of foreign earnings. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. Most recently, the IRA included a number of significant drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require pharmaceutical manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers under Medicare Parts B and D to penalize price increases that outpace inflation, and a redesign of the Part D benefit, as part of which manufacturers are required to provide discounts on Part D drugs and Part D beneficiaries&#8217; annual out-of-pocket spending will be capped at $2,000 beginning in 2025. The impact of changes under the Tax Act, the CARES Act, the IRA, or future reform legislation could increase our future U.S. tax expense and could have a material adverse impact on our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred substantial losses during our history. We do not expect to become profitable in the near future, and we may never achieve profitability. Unused losses generally are available to be carried forward to offset future taxable income, if any. Under Sections 382 and 383 of the Code if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income or taxes may be limited. We last completed an analysis from January 1, 2021 through December 31, 2022 and determined that no ownership changes had occurred in that period. Prior analyses determined that on March 30, 2007, August 21, 2015, and May 4, 2020, ownership changes had occurred. We may also experience ownership changes in the future as a result of shifts in our stock ownership, some of which may be outside of our control. As a result, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights in and to our product candidates, we may not be able to compete effectively in our market.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in significant part on our and our licensors&#8217; and licensees&#8217; ability to establish, maintain and protect patents and other intellectual property rights and operate without infringing the intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rights of others. We have filed patent applications both in the United States and in foreign jurisdictions to obtain patent rights to inventions we have discovered. We have also licensed from third parties rights to patent portfolios. Some of these licenses give us the right to prepare, file and prosecute patent applications and maintain and enforce patents we have licensed, and other licenses may not give us such rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors or licensees will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current or future licensors or licensees fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217; or licensees&#8217; patent rights are highly uncertain. Our and our licensors&#8217; or licensees&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors or licensees to narrow the scope of the claims of our or our licensors&#8217; or licensees&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. It is possible that third parties with products that are very similar to ours will circumvent our or our licensors&#8217; or licensees&#8217; patents by means of alternate designs or processes. We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidate, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidate or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our products. Our and our licensors&#8217; or licensees&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The portfolio that we licensed from UCB includes granted patents and applications with pending claims directed to the composition of matter of axatilimab (a humanized, full-length IgG4 (kappa light chain) antibody with high affinity for the CSF-1R) as well as claims directed to methods of use of axatilimab. There is no guarantee that any further patents will be granted based on the pending applications we licensed from UCB or even if one or more patents are granted that the claims issued in those patents would cover axatilimab, methods of using axatilimab, or formulations of axatilimab. Based on the priority date and filing date of the applications in the portfolio we licensed from UCB, we expect that additional patents, if any, granted based on the currently pending applications would</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expire in 2036. The actual term of any patents granted based on the pending applications we licensed from UCB can only be determined after such patents are granted.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The portfolio that we licensed from Vitae Pharmaceuticals, which is now a subsidiary of AbbVie Inc., or AbbVie, includes granted patents and applications with pending claims directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction. There is no guarantee that any additional patents will be granted based on the pending applications that we licensed from AbbVie or even if one or more patents are granted that the claims issued in those patents would cover the desired lead compounds, compositions, and methods of use thereof. Based on the priority date and filing date of the applications in the portfolio that we licensed from AbbVie, we expect that a patent, if any, granted based on the currently pending applications would expire in 2037. The actual term of any patents granted based on the pending applications that we licensed from AbbVie can only be determined after such patents are granted.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world is prohibitively expensive, and our or our licensors&#8217; intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors may not be able to prevent third parties from practicing our and our licensors&#8217; inventions in countries outside the United States, or from selling or importing products made using our and our licensors&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our licensors to stop the infringement of our and our licensors&#8217; patents or marketing of competing products in violation of our and our licensors&#8217; proprietary rights generally. Proceedings to enforce our and our licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our attention from other aspects of our business, could put our and our licensors&#8217; patents at risk of being invalidated or interpreted narrowly and our and our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuits that we or our licensors initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval of a drug and its patent status. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. In addition to India, certain countries in Europe and developing countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our and our licensors&#8217; efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we breach the UCB license agreement related to axatilimab or if the UCB license agreement is otherwise terminated, we could lose the ability to continue the development and commercialization of axatilimab.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends upon our ability to develop, manufacture, market and sell axatilimab. Subject to the achievement of certain milestone events, we may be required to pay UCB up to $119.5 million in one-time development and regulatory milestone payments over the term of the UCB license agreement. If we or any of our affiliates or sublicensees commercializes axatilimab, we will also be obligated to pay UCB low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $250.0 million in potential one-time sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, we may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with UCB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Either party may terminate the UCB license agreement in its entirety or with respect to certain countries in the event of an uncured material breach by the other party. Either party may terminate the UCB license agreement if voluntary or involuntary bankruptcy proceedings are instituted against the other party, if the other party makes an assignment for the benefit of creditors, or upon the occurrence of other specific events relating to the insolvency or dissolution of the other party. UCB may terminate the UCB license agreement if we seek to revoke or challenge the validity of any patent licensed to us by UCB under the UCB license agreement or if we procure or assist a third party to take any such action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless terminated earlier in accordance with its terms, the UCB license agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) 10 years from the date of the first commercial sale of the product in such country. We cannot determine the date on which our royalty payment obligations to UCB would expire because no commercial sales of axatilimab have occurred and the last-to-expire relevant patent covering axatilimab in a given country may change in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the UCB license agreement is terminated, we would not be able to develop, manufacture, market or sell axatilimab and would need to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all. In addition, our collaboration with Incyte to further develop and commercialize axatilimab is dependent upon the effectiveness of the UCB license agreement. If the UCB license agreement is terminated, Incyte may terminate our collaboration and our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we breach the license agreement related to revumenib or if the license agreement is otherwise terminated, we could lose the ability to continue the development and commercialization of revumenib.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends upon our ability to develop, manufacture, market and sell revumenib. Subject to the achievement of certain milestone events, we may be required to pay Vitae, which is now a subsidiary of AbbVie, up to $99.0 million in one-time development and regulatory milestone payments over the term of the AbbVie license agreement. In the event that we or any of our affiliates or sublicensees commercializes revumenib, we will also be obligated to pay AbbVie low single to low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $70.0 million in potential one-time sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, we may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with AbbVie.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Either party may terminate the license agreement in its entirety or with respect to certain countries in the event of an uncured material breach by the other party. Either party may terminate the license agreement if voluntary or involuntary bankruptcy proceedings are instituted against the other party, if the other party makes an assignment for the benefit of creditors, or upon the occurrence of other specific events relating to the insolvency or dissolution of the other party. AbbVie may terminate the license agreement if we seek to revoke or challenge the validity of any patent licensed to us by AbbVie under the license agreement or if we procure or assist a third party to take any such action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless terminated earlier in accordance with its terms, the license agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) 10 years from the date of the first commercial sale of the product in such country. We cannot determine the date on which our royalty payment obligations to AbbVie would expire because no commercial sales of revumenib have occurred and the last-to-expire relevant patent covering revumenib in a given country may change in the future.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the license agreement is terminated, we would not be able to develop, manufacture, market or sell revumenib and would need to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may weaken our and our licensors&#8217; ability to obtain new patents or to enforce existing patents and patents we and our licensors or collaborators may obtain in the future. In view of recent developments in U.S. patent laws, in spite of our efforts and the efforts of our licensors, we may face difficulties in obtaining allowance of our biomarker based patient selection patent claims or if we are successful in obtaining allowance of our biomarker based patient selection claims, we or our licensor may be unsuccessful in defending the validity of such claims if challenged before a competent court.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the America Invents Act, was signed into law. The America Invents Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO recently developed new regulations and procedures to govern administration of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the America Invents Act will have on the operation of our business. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents, all of which could harm our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business and on our stock price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may infringe our or our licensors&#8217; patents or misappropriate or otherwise violate our or our licensors&#8217; intellectual property rights. In the future, we or our licensors may initiate legal proceedings to enforce or defend our or our licensors&#8217; intellectual property rights, to protect our or our licensors&#8217; trade secrets or to determine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the validity or scope of intellectual property rights we own or control. Also, third parties may initiate legal proceedings against us or our licensors to challenge the validity or scope of intellectual property rights we own or control. The proceedings can be expensive and time-consuming and many of our or our licensors&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors can. Accordingly, despite our or our licensors&#8217; efforts, we or our licensors may not be able to prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect our rights as fully as in the United States. Litigation could result in substantial costs and diversion of management resources, which could harm our business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#8217; patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our or our licensors&#8217; patents at risk of being invalidated, held unenforceable or interpreted narrowly.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party pre-issuance submission of prior art to the USPTO, or opposition, derivation, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review or interference proceedings, or other pre-issuance or post-grant proceedings in the United States or other jurisdictions provoked by third parties or brought by us or our licensors or collaborators may be necessary to determine the priority of inventions with respect to our or our licensors&#8217; patents or patent applications. An unfavorable outcome could require us or our licensors to cease using the related technology and commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors a license on commercially reasonable terms or at all. Even if we or our licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors. In addition, if the breadth or strength of protection provided by our or our licensors&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial costs and it may distract our management and other employees. We could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this process. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a downward effect on the price of shares of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may initiate legal proceedings against us or our licensors or collaborators alleging that we or our licensors or collaborators infringe their intellectual property rights or we or our licensors or collaborators may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, reexaminations, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reviews or derivation proceedings before the United States or other jurisdictions. These proceedings can be expensive and time-consuming and many of our or our licensors&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators can.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An unfavorable outcome could require us or our licensors or collaborators to cease using the related technology or developing or commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors or collaborators a license on commercially reasonable terms or at all. Even if we or our licensors or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or collaborators. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, for some of our in-licensed patents and patent applications, we do not have access to every patent assignments or employee agreements demonstrating that all inventors have assigned their rights to the inventions or related patents. As a result, we may be subject to claims of ownership by such inventors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our inability to protect our confidential information and trade secrets would harm our business and competitive position.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, third-party manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. If a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Ownership of Our Common Stock and Other General Matters</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our stock may be volatile and you could lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock is highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report, these factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory actions with respect to our products or our competitors&#8217; products;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in our growth rate relative to our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of trials of our product candidates or those of our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of expenses related to our product candidates or clinical development programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us, our insiders or our other stockholders;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry, political and market conditions, including, but not limited to new or ongoing public health crises and the war between Russia and Ukraine and the war in Israel.</span></div></div>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock market in general, and the Nasdaq Global Select Market, or Nasdaq, and biopharmaceutical companies in particular, frequently experiences extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of such companies. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and negative impact on the market price of our common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, bank failures, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the global capital markets. Similarly, the current Russia-Ukraine war exacerbated volatility in the global capital markets and continues to disrupt the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Inflation can adversely affect us by increasing our costs, including personnel costs (wages). Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until we can generate a sufficient amount of profit from our products, if ever, we expect to finance future cash needs through public or private equity or debt offerings. If we raise additional funds through the issuance of additional equity or debt securities, it may result in dilution to our existing stockholders and/or increased fixed payment obligations. For example, in December 2023, we sold a total of 12,432,431 shares of our common stock in a public offering. The issuance of these shares of our common stock resulted, and any future issuance pursuant to sales under the 2023 ATM Program will result, in dilution to our stockholders.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The shares of common stock into which the warrants may be exercised are considered outstanding for the purposes of computing earnings per share. Additionally, in November 2023, we sold 2,719,744 common shares under the 2023 ATM Program, with net proceeds of approximately $42.1 million. The issuance of these shares of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our common stock resulted, and any future issuance pursuant to the exercise of the outstanding pre-funded warrants or sales under the 2023 ATM Program will result, in dilution to our stockholders.</span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also seek additional funding through government or other third-party funding and other collaborations, strategic alliances and licensing arrangements. These financing activities may have an adverse impact on our stockholders&#8217; rights as well as on our operations, and such additional funding may not be available on reasonable terms, if at all. Furthermore, these securities may have rights senior to those of our common stock and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if we seek funds through arrangements with collaborative partners, these arrangements may require us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us. Any of these events could significantly harm our business, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts continue coverage of us, the trading price for our stock could be negatively impacted. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our trials or operating results fail to meet the expectations of analysts, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence control over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our executive officers, directors, and holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 37.3% of our outstanding voting stock and options. As a result, these stockholders will continue to have a significant influence over all matters requiring stockholder approval. For example, these stockholders may be able to influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert management attention.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock may be volatile, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. Commencing after the filing of our initial annual report on Form 10-K, we have been required, under Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section 404 of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sarbanes-Oxley Act also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to get an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. Our compliance with Section 404 requires that we incur substantial expense and expend significant management efforts. We currently do not have an internal audit group, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Global Select Market, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would benefit our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue preferred stock without stockholder approval. These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under the DGCL, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change of control could limit the opportunity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed Staff Comments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cyber Security</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Management and Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and our clinical trial and related data, or Information Systems and Data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our information security function, which is led by our Vice President of Information Technology, or VP of IT, helps identify, assess and manage our cybersecurity threats and risks. The information security function identifies and assesses cybersecurity threats and risks by monitoring and evaluating our threat environment and the our risk profile using various methods including, for example manual and automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats, evaluating threats reported to us, internal and external audits, leveraging third party threat assessments, conducting vulnerability identification assessments, and leveraging external threat intelligence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending on the environment or system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident detection and response, disaster recovery and business continuity plans, encryption of certain data, network security controls, data segregation for certain data, access controls, physical controls, systems monitoring, penetration testing, and cybersecurity insurance. Certain information about our assessment and management of material risks from cybersecurity threats is included in risk management reports as applicable to senior leadership and the audit committee.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example cybersecurity consultants, managed cybersecurity service providers, professional service firms, including legal counsel, forensic investigators, and penetration testing service providers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers to perform a variety of functions throughout our business, such as software-as-a-service providers, hosting companies, supply chain resources, contract research organizations, and contract manufacturing organizations. Depending on the nature of the services provided, the sensitivity of the critical systems, information and assets at issue, and the identity of the provider, we may conduct a review of security assessments provided by the vendor.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. &#8220;Risk Factors&#8221; in this Annual Report, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;If our information technology systems, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. Our board of directors&#8217; audit committee is responsible for overseeing the Company&#8217;s cybersecurity risk management processes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our VP of IT, who has 25 years of experience in information technology including IT leadership in Department of Defense Research, who reports to our Chief Financial Officer, or CFO, who has over 20 years of experience as a CFO, including supervisory responsibility over IT and cybersecurity functions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our VP of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Our VP of IT is also responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity incident processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our CFO, General Counsel, or GC, and Chief Executive Officer, or CEO. Our GC, CFO, and other leadership personnel work with our incident response team to help assess impact and mitigate and remediate cybersecurity incidents of which they are notified, in addition to notifying the audit committee of our board of directors, as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors&#8217; audit committee receives annual reports from our CFO, concerning our significant cybersecurity threats and risk and the processes the Company has implemented to address them. Our audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headquarters is located in Waltham, Massachusetts, and consists of 12,000 square feet of leased office space under a lease that expires on February 28, 2025. We also have 16,000 square feet of leased office space in New York, New York, under a lease that expires on August 31, 2025. We believe that our existing facilities are sufficient for our needs for the foreseeable future. If we determine that additional or new facilities are needed in the future, we believe that appropriate alternative space would be available to us on commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently a party to any material legal proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ty Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> II</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock began trading on the Nasdaq Global Select Market on March 2, 2016, under the symbol &#8220;SNDX.&#8221; Prior to that time, there was no public market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Record</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 19, 2024, we had approximately 20 holders of record of our common stock. Certain shares are held in &#8220;street&#8221; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings to fund the development and growth of our business. We do not expect to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our financial conditions, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance Graph</span></p>
  <p style="text-indent:6.933%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The performance graph shown below compares the annual change in cumulative total stockholder return on our common shares with the Nasdaq Composite Index and the Nasdaq Biotechnology Index from December 31, 2018, through the year ended December 31, 2023. The graph assumes an investment of $100 on December 31, 2018 in our common shares, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes that any dividends are reinvested. All index values are weighted by the capitalization of the companies included in the index. The comparisons shown in the graph below are based upon historical data. The stock price performance included in this graph is not necessarily indicative of future stock price performance. The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></p>
  <p style="text-indent:6.933%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img207175068_4.jpg" alt="img207175068_4.jpg" style="width:608px;height:500px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">m 6. [Reserved]</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion and analysis and other parts of this Annual Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. You should carefully read the &#8220;Risk Factors&#8221; section of this Annual Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">For the discussion of the financial condition and results of operations for the year ended December 31, 2022 compared to the year ended December 31, 2021, refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations" and "&#8212;Liquidity and Capital Resources" included in the Annual Report on Form 10-K filed with the SEC on February 28, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our two lead product candidates are revumenib, and axatilimab. We are developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, or KMT2Ar, also known as mixed lineage leukemia rearranged or MLLr, acute leukemias including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, and necleophosmin 1, also known as NPM1, mutant AML. We are also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. We are developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor, or CSF-1, in chronic graft-versus-host disease, or cGVHD, as well as idiopathic pulmonary fibrosis, or IPF. We plan to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional therapeutics to expand our pipeline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no products approved for commercial sale and have not generated any product revenues from product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. Except for 2021, we have not been profitable and have incurred losses in each period since our inception in 2005. For the years ended December 31, 2023 and 2022, we reported a net loss of $209.4 million and $149.3 million, respectively. For the year ended December 31, 2021, we reported a net profit of $24.9 million. As of December 31, 2023, we had an accumulated deficit of $902.4 million, which included non-cash charges for stock-based compensation, preferred stock accretion and extinguishment charges. As of December 31, 2023, we had cash, cash equivalents and short-term and long-term investments of $600.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Risks and Uncertainties</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current inflationary environment may materially affect our business and operating results by increasing the cost of our clinical trial materials and supplies, driving the U.S. Federal Reserve system to increase interest rates, which in turn increased our overhead costs. Rising interest rates could make it more difficult for us to obtain traditional financing on acceptable terms, if at all. Additionally, the ongoing recession risk together with the foregoing, could result in further economic uncertainty and volatility in the capital markets in the near term and, as a result could negatively affect our operations. Furthermore, such economic conditions have produced downward pressure on share prices. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, additional high inflation could increase our operating costs, including our labor costs and research and development costs. These costs may also be negatively impacted due to supply chain constraints, global geopolitical tensions as a result of the ongoing war between Russia and Ukraine and the war in Israel, worsening macroeconomic conditions and employee availability and wage increases, which may result in additional stress on our working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we are subject to other challenges and risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of our late-stage product candidate; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; and complying with applicable regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not generated any product revenues. Our ability to generate revenue and become profitable depends upon our ability to obtain marketing approval of and successfully commercialize our product candidates. Our revenues for the year ended December 31, 2021, have been solely derived from our license, development and commercialization agreements with Kyowa Kirin Co., Ltd., or KKC, and with Incyte Corporation, or Incyte. We generated no revenue during the years ended December 31, 2023 and 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we entered into a collaboration and license agreement with Incyte or the Incyte Collaboration Agreement, with Incyte for the worldwide development and commercialization of axatilimab. Additionally, in September 2021, we entered into a share purchase agreement with Incyte, or the Incyte Share Purchase Agreement. Under the terms of the Incyte Collaboration Agreement, Incyte received exclusive commercialization rights outside of the United States, and we and Incyte will, subject to the exercise of our co-promotion option, have co-commercialization rights in the United States, with respect to axatilimab. Incyte is responsible for leading commercialization strategy and booking all revenue from worldwide sales of axatilimab, subject to its royalty payment obligations set forth below. The parties will share equally the profits and losses from the co-commercialization efforts. We and Incyte are co-developing axatilimab and sharing development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and we are responsible for 45% of such costs. Each company is responsible for funding any independent development activities. All development costs related to the collaboration are subject to a joint development plan. A joint development committee between us and Incyte will govern future development of axatilimab. Incyte is responsible for 100% of future development costs for trials that are specific to ex-U.S. countries. All development costs related to the collaboration will be subject to a joint development plan. In December 2021, we received an upfront cash payment of $117 million and issued 1,421,523 shares of common stock for an aggregate purchase price of $35 million. We allocated $126.6 million of the total consideration received to the license, and such amount was recognized as license revenue upon transfer of license to Incyte.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We granted KKC an exclusive license to develop and commercialize entinostat in Japan and Korea, or the KKC license agreement. In 2015, we received a $25.0 million upfront payment from KKC, inclusive of an equity investment. We allocated $17.3 million of the upfront payment to the license fee, and such fee is being recognized as revenue ratably over our expected performance period (expected to be through 2029). The balance of the upfront payment of $7.7 million was allocated to KKC&#8217;s purchase of shares of our convertible preferred stock. In September 2021, KKC informed us that they discontinued the entinostat program and cancelled the license to develop and commercialize entinostat. As a result, we recognized $12.4 million in revenue which was previously deferred in the third quarter of 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have primarily focused on our clinical development programs. Research and development expenses consist primarily of costs incurred for the development of our product candidates and include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements related to our clinical trials, including the costs for investigative sites and contract research organizations, or CROs, that conduct our clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employee-related expenses associated with our research and development activities, including salaries, benefits, travel and non-cash stock-based compensation expenses; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing process-development, clinical supplies and technology-transfer expenses; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">license fees and milestone payments under our license agreements; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consulting fees paid to third parties; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocated facilities and overhead expenses; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs associated with regulatory operations and regulatory compliance requirements. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Internal and external research and development costs are expensed as they are incurred. Cost-sharing amounts received by us are recorded as reductions to research and development expense. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development activities are central to our business model. Drug candidates in late stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of late-stage clinical trials. We plan to continue to spend a significant amount of our resources on research and development activities for the foreseeable future as we continue to advance the development of our drug candidates. The amount of research and development expenses allocated to external spending will continue to grow, while we expect our internal spending to grow at a slower and more controlled pace.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is difficult to determine, with certainty, the duration and completion costs of our current or future preclinical programs, research studies and clinical trials of our product candidates. The duration, costs and timing of research studies and clinical trials of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per patient costs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients that participate; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of clinical trial sites; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the countries in which the trials are conducted; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the length of time required to enroll eligible patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential additional safety monitoring or other studies requested by regulatory agencies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration of patient monitoring; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile of the product candidates; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timing and receipt of any regulatory approvals. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the probability of success for each drug product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of our product candidates for the period, if any, in which material net cash inflows from these potential product candidates may commence. Clinical development timelines, the probability of success and development costs can differ materially from expectations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling, General and Administrative</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative expenses consist primarily of employee-related expenses, including salaries, benefits, non-cash stock-based compensation and travel expenses, for our employees in executive, finance, human resources, business development and support functions. Other selling, general and administrative expenses include facility-related costs not otherwise allocated to research and development expenses and accounting, tax, legal, information technology and consulting services. We anticipate that our selling, general and administrative expenses will further increase in the future as we continue to increase our headcount to support our continued research and development and anticipated commercialization of our product candidates. Additionally, in anticipation of expected regulatory approvals of the our drug candidates, we expect an increase in employee-related expenses and other commercial expenses in 2024 as a result of our preparation for the commercial launch, especially as it relates to the sales and marketing of our drug product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense consists primarily of interest expense on our operational and capital leases and in prior years consisted of our term loan, which was paid off in 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income consists of income earned on our cash, cash equivalents and short and long-term investment balances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other (Expense) Income, net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other (expense) income net includes income (expense), net consisting of revaluation of foreign currency related to trade payables.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed in "Summary of Significant Accounting Policies" (Note 3) to our audited consolidated financial statements included in this Annual Report, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Accounting Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies. Other significant accounting policies are outlined in "Summary of Significant Accounting Policies" (Note 3) to our consolidated financial statements included in this Annual Report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have listed below our critical accounting estimates that we believe to have the greatest potential impact on our consolidated financial statements. Historically, our assumptions, judgments and estimates relative to our critical accounting estimates have not differed materially from actual results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into license agreements for the development and commercialization of our product candidates. License agreements may include non-refundable upfront payments, contingent payments based on the occurrence of specified events under our license arrangements, partial or complete reimbursement of research and development expenses, license fees and royalties on sales of entinostat if they are successfully approved and commercialized. Our performance obligations under the license agreements may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and related materials and participation on certain development and/or commercialization committees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized when, or as, performance obligations are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer, or the transaction price. To the extent that the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We assessed the promises to determine if they are distinct performance obligations. Once the performance obligations are determined, the transaction price is allocated based on a relative standalone selling price basis. Milestone payments and royalties are typically considered variable consideration at the outset of the contract and are recognized in the transaction price either upon occurrence or when the constraint of a probable reversal is no longer applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021, we recorded revenue of $126.6 million relating to the Incyte Collaboration Agreement and $13.3 million relating to the KKC Agreement. For the years ended December 31, 2023 and 2022, no revenue has been recognized relating to either agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We applied significant judgment to our Incyte Collaboration Agreement. We evaluated whether our contractual obligations represented distinct performance obligations. Such evaluation required judgment since it was made from the customer&#8217;s perspective. We determined that the transfer of the license to Incyte was a distinct performance obligation, separate from the ongoing collaboration activities. As such, we estimated the standalone selling price to be $126.6 million which we recognized as $126.6 million of license revenue for the year ended December 31, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We applied significant judgment to our KKC Agreement. We evaluated whether our contractual obligations represented distinct performance obligations. Such evaluation required judgment since it was made from the customer&#8217;s perspective. We determined that our performance obligations under the collaboration at contract inception were not distinct and represented a single performance obligation. In September 2021, KKC informed us, that they have discontinued the entinostat program and have cancelled the license to develop and commercialize entinostat. As a result, we recognized $12.4 million in revenue, which was previously deferred in the third quarter of 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing contracts and vendor agreements, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. We make estimates of our accrued and prepaid clinical expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to contract research organizations, or CROs, and investigative sites in connection with clinical studies and to vendors related to product manufacturing and development of clinical supplies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We base our expenses related to clinical study and trial costs on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows and expense recognition. Payments under some of these contracts depend on factors out of our control, such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the years ended December 31, 2023, 2022 and 2021:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.893%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.2620000000000005%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.8629999999999995%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.2620000000000005%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.8629999999999995%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023 - 2022 Increase<br/>(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 - 2021 Increase<br/>(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">139,709</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(139,709</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">139,709</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(139,709</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163,032</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,248</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,533</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,251</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,922</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,258</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,241</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,664</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,017</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">229,954</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,757</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,489</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,197</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,268</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(229,954</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(151,757</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,220</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(78,197</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(177,977</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(679</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(208</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,137</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,899</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,929</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(93</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,238</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,163</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,872</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">403</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,291</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">260</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,469</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1357</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other (expense) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(361</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(316</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(45</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(518</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(256</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,594</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,419</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,294</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,175</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">751</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,713</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(287</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(209,360</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(149,338</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,926</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(60,022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(174,264</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(699</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the research and development expenses for the full years ended December 31, 2023, 2022 and 2021:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.893%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.2620000000000005%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.8629999999999995%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.2620000000000005%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.8629999999999995%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023 - 2022 Increase<br/>(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 - 2021 Increase<br/>(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revumenib-related costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,122</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,315</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,054</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,807</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,261</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Axatilimab-related  costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,114</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,318</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,925</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,204</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,393</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other R&amp;D programs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,441</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,328</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,873</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(887</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,545</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(29</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel cost and other expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,208</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,522</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,998</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,686</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,524</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,147</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,016</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,398</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,131</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,618</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163,032</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,248</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,533</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,251</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, our total research and development expenses increased by $44.5 million or 38 % from the prior year. The increase is primarily due to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An increase in $16.8 million in revumenib related costs due to increases in expenses associated with registrational trials, the initiation of frontline/combination trials, clinical diagnostic test development costs, and regulatory expenses associated with New Drug Applications, or NDA, submission. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A decrease of $1.2 million in axatilimab-related costs is due to lower registrational trial costs, lower costs for the IPF trial that were driven by start-up costs in 2022, and lower CMC-related expenses, net of expense reimbursement from Incyte, our co-development partner, of  $12.3 million in 2023 and $25.9 million in 2022.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An increase of $29.8 million in personnel costs, including non-cash stock-based compensation, and other expenses related to increases in headcount to support of on-going clinical trials and regulatory expenses, NDA activities and related expenses and overhead expenses (e.g. information technology and facilities). </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the internal and external research and development expenses for the full years ended December 31, 2023 and 2022:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.081%;"/>
    <td style="width:1.501%;"/>
    <td style="width:1%;"/>
    <td style="width:9.104000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.501%;"/>
    <td style="width:1%;"/>
    <td style="width:9.104000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.501%;"/>
    <td style="width:1%;"/>
    <td style="width:9.104000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:6.083%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase<br/>(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,978</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,788</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,190</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Internal research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,054</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,711</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,343</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163,032</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,533</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect research and development expenses to fluctuate from quarter to quarter depending on the timing of clinical trial activities, clinical manufacturing, and other development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling, General and Administrative</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the selling, general and administrative expenses for the full years ended December 31, 2023, 2022 and 2021:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.893%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.383000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.2620000000000005%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.863%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:6.2620000000000005%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.863%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023 - 2022 Increase<br/>(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 - 2021 Increase<br/>(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,115</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,116</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">356</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,999</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">520</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,760</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">494</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other SG&amp;A expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,105</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,838</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,697</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,267</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel cost and other expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,898</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,301</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,269</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,597</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,032</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,804</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,003</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,919</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,801</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,084</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total selling, general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,922</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,258</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,241</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,664</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,017</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#160;%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2e2e2e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, our total selling, general and administrative expenses increased by $33.7 million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or 101%, from the prior year. The increase primarily is due to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An increase of  $11.0 million in commercialization activities for the revumenib and axatilimab programs.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An increase of  $4.3 million related to increases in rent, information technology, human resources and legal related expenses. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An increase of  $18.4 million in personnel costs, including non-cash stock-based compensation, and related costs related to increases in headcount to support a growing research and development organization and preparation for commercial launch. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense and Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year end December 31, 2023, interest expense decreased by $2.9 million, or 93%, from the prior year. The decrease is primarily due to the elimination of interest expense related to the amended loan agreement by and between the Company and Hercules, which was terminated in September 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, interest income increased by $15.3 million, or 260%, from the prior year. This increase was primarily due to higher interest rates and increased average balance on cash equivalents and short and long-term investments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other (Expense) Income, net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, the total other (expense) income, net increased from the comparable period in the prior year primarily due to an increase in revaluation of foreign currency related to trade payables.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="results_of_operations_for_2018_vs_2017"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents and short-term and long-term investments totaling $600.5 million. Since our inception, our operations have been primarily financed by net proceeds from our public stock offerings, and revenue from our license agreements. We believe that our cash, cash equivalents and short and long-term investments as of December 31, 2023, will fund our projected operating expenses and capital expenditure requirements for at least the next 12 months. In addition to our existing cash, cash equivalents, short and long-term investments, we are eligible to receive research and development funding and to earn milestone and other contingent payments for the achievement of defined collaboration objectives and certain development, regulatory and commercial milestones, and royalty payments under our collaboration agreements. Our ability to earn these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators&#8217; research and development activities and is uncertain at this time.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loan and Security Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2020, we entered into a loan and security agreement, with Hercules, as amended in December 2021, which we refer to as the Amended Loan Agreement. We terminated the Amended Loan Agreement in September 2022. On September 23, 2022, we made a prepayment of $21.5 million to satisfy in full all of our principal and interest obligations and related fees under the Amended Loan Agreement. The payoff amount paid by us in connection with the termination of the Amended Loan Agreement was pursuant to a payoff letter with Hercules and included payment of (a) $1.0 million as an end-of term fee and (b) $0.4 million as a pre-payment fee. Hercules released all security interests held on our assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional details on our Amended Loan Agreement, see "Loan Payable" (Note 14) to our consolidated financial statements in this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our available cash, cash equivalents, short-term and long-term investments are sufficient to fund existing and planned cash requirements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, clinical costs, legal and other regulatory expenses and general overhead costs. We have based our estimates on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. We cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, progress, timing, costs and results of clinical trials of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more trials than we currently expect; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost to establish, maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents or other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market acceptance of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of selecting, auditing and developing manufacturing capabilities, and potentially validating manufacturing sites for commercial-scale manufacturing; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing for obtaining pricing and reimbursement, which may require additional trials to address pharmacoeconomic benefit; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for our product candidates if either candidate receives regulatory approval and we determine, in the case of revumenib to commercialize it ourselves, or in the case of axatilimab to co-commercialize it with Incyte; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the interruption of key clinical trial activities, such as clinical trial site monitoring;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of disruption to our supply chain and operations, and associated delays in the manufacturing and supply of our products, which would adversely impact our ability to continue our clinical trial operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our need to implement additional internal systems and infrastructure, including financial and reporting systems, as we grow our company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no products approved for commercial sale and have not generated any product revenues from product sales to date. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings and additional funding from license and collaboration arrangements. Except for any obligations of our collaborators to reimburse us for research and development expenses or to make milestone or royalty payments under our agreements with them, we will not have any committed external source of liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our material cash requirements include the following contractual obligations as of December 31, 2023, and the effects that such obligations are expected to have on our liquidity and cash flows in future periods. For additional information, see our consolidated financial statements.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.887%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:9.222000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:9.222000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:9.222000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:9.222000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:9.222000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less than<br/>1 Year</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1 to 3<br/>Years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3 to 5<br/>Years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">More than<br/>5 Years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases for office space</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,802</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,196</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">606</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capital lease for office equipment </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,828</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,210</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">618</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2021, we signed a 36-month extension of the lease for the office space in Waltham, MA. In August 2022, we signed a 36-month extension of the lease for the office space in New York, NY. In May 2023, we </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">signed a 27-month lease for an additional space in New York, NY. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes.</span></div></div>
  <div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2022, we entered into two four-year non-cancelable leases for office equipment. In June 2023, we entered into one two-year non-cancelable lease for office equipment. All three leases are accounted for as a capital lease. The leased assets are included in property, plant and equipment, at cost.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses and cumulative negative cash flows from operations since our inception, excluding year ending December 31, 2021. As of December 31, 2023, we had an accumulated deficit of $902.4 million. We anticipate that we will continue to incur significant losses for at least the next several years. We expect that our research and development and selling, general and administrative expenses will continue to increase. As a result, we will need additional capital to fund our operations, which we may raise through a combination of the sale of equity, debt financings, or other sources, including potential collaborations. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through collaboration arrangements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At-the-Market Offering Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we entered into a sales agreement with Cowen and Company, LLC, or TD Cowen, under which we could, from time to time, issue and sell shares of our common stock having aggregate sales proceeds of up to $75.0 million, in a series of one or more at-the-market, or ATM, equity offerings, or the 2021 ATM Program. On May 26, 2023, we terminated the 2021 ATM Program. Prior to termination, we sold shares under the 2021 ATM Program for aggregate net proceeds of approximately $25.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we entered into a new sales agreement with TD Cowen under which we could, from time to time, issue and sell shares of our common stock having aggregate sales proceeds of up to $200.0 million, in a series of one or more ATM equity offerings, or the 2023 ATM Program. TD Cowen is not required to sell any specific share amounts but acts as the Company&#8217;s sales agent, using commercially reasonable efforts consistent with its normal trading and sales practices. Pursuant to the sales agreement, shares will be sold under the shelf registration statement on Form S-3ASR (Registration No. 333-254661), which became automatically effective upon the filing on March 24, 2021. Our common stock will be sold at prevailing market prices at the time of the sale, and as a result, prices may vary. As of December 31, 2023, we sold 2,719,744 shares of common stock under the 2023 ATM Program for net proceeds of approximately $42.1 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of cash flows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.013%;"/>
    <td style="width:1.111%;"/>
    <td style="width:1%;"/>
    <td style="width:10.647%;"/>
    <td style="width:1%;"/>
    <td style="width:1.111%;"/>
    <td style="width:1%;"/>
    <td style="width:10.647%;"/>
    <td style="width:1%;"/>
    <td style="width:1.111%;"/>
    <td style="width:1%;"/>
    <td style="width:9.357999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(160,601</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(133,675</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,131</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,609</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(186,188</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(40,873</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,132</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,254</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,464</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">221,140</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(147,609</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,722</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash (Used in) Provided by Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2023, was $160.6 million and primarily consisted of our net loss of $209.4 million adjusted for non-cash items including stock-based compensation of $31.0 million, an investment increase of $14.8 million, a net increase in operating assets and liabilities of $32.0 million and non-cash operating lease expense of $0.7 million. The significant items in the increase in operating assets and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">liabilities include an increase in accrued expenses and other liabilities of $14.9 million, an increase in collaboration payable of $10.7 million, an increase in accounts payable of $5.7 million, and an increase in prepaid expenses and other assets of $0.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2022 was $133.7 million and primarily consisted of our net loss of $149.3 million adjusted for non-cash items including stock-based compensation of $16.0 million, an investment increase of $3.4 million, a net increase in operating assets and liabilities of $1.7 million, an increase in interest expense associated with the term loan of $1.1 million, and non-cash operating lease expense of $0.4 million. The significant items in the increase in operating assets and liabilities include an increase in accrued expenses and other liabilities of $9.4 million, an increase in collaboration receivable of $3.5 million, partially offset by a decrease in prepaid expenses and other assets of $3.0 million, and a decrease in accounts payable of $1.3 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Provided by (Used in) Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by in investing activities for the year ended December 31, 2023 was $117.6 million and was due to $472.2 million in proceeds from the maturities of available-for-sale marketable securities, partially offset by the purchase of $354.6 million of available-for-sale marketable securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2022, was $186.2 million and was primarily due to the purchase of $495.3 million of available-for-sale marketable securities partially offset by $308.9 million in proceeds from the maturities of available-for-sale marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2023, was $264.1 million and was primarily due to proceeds of $215.9 million from the issuance of common stock in a follow-up offering, $42.1 million from the issuance of common in at-the-market offering, and $6.0 million of proceeds from the stock option exercises and ESPP purchases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2022, was $172.3 million and was primarily due proceeds of $162.0 million from the issuance of common stock in a public offering, $19.4 million of proceeds from at-the-market offerings, and $11.9 million of proceeds from the stock option exercises and ESPP purchases, partially offset by payment on the term loan of $21.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Operating Loss and Research and Development Tax Credit Carryforwards</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, we had federal and state tax net operating loss carryforwards, or NOLs, of approximately $136.4 million and $63.5 million, respectively. We have generated federal NOLs of $114.3 million and state NOLs of $0.9 million which have an indefinite carryforward period. The remaining $22.1 million of federal NOLs and the $62.6 million of state NOLs will begin to expire at various dates starting in 2026. At December 31, 2023, we had available income tax credits of approximately $12.7 million, with $8.9 million attributable to Federal R&amp;D Credits and $3.8 million attributable to state R&amp;D Credits, which are available to reduce future income taxes, if any. These income tax credits began to expire in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating losses and credits may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended. The annual limitation may result in the expiration of our net operating losses and credits before we can use them. We have recorded a valuation allowance on all of our deferred tax assets, including our deferred tax assets related to our net operating loss and research and development tax credit carryforwards.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ive Disclosures about Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of December 31, 2023, we had cash, cash equivalents and short-term and long-term investments of $600.5 million, consisting of overnight investments, interest-bearing money market funds and highly rated federal bonds and short and long-term investments including commercial paper, highly rated corporate bonds and treasuries. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objectives of our investment activities are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to ensure liquidity and to preserve principal while at the same time maximizing the interest income, we receive from our marketable securities without significantly increasing risk. We have established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity. Due to the relative short-term maturities of our cash equivalents and the low risk profile of our short and long-term investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and short and long-term investments. We have the ability to hold our investments until maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investment portfolio.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ts and Supplementary Data</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements, together with the report of our independent registered public accounting firm, appear in this Annual Report on Form 10-K beginning on page F-1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntants on Accounting and Financial Disclosure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of our Disclosure Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on an evaluation of our disclosure controls and procedures as of December 31, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Based on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that assessment, our management concluded that, as of December 31, 2023, our internal control over financial reporting was effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deloitte &amp; Touche LLP, the independent registered public accounting firm that audited the consolidated financial statements included in this Annual Report on Form 10-K, has issued an attestation report on the effectiveness of internal control over financial reporting as of December 31, 2023, included herein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the stockholders and the Board of Directors of Syndax Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the internal control over financial reporting of Syndax Pharmaceuticals, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> issued by COSO.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2023, of the Company and our report dated February 27, 2024, expressed an unqualified opinion on those financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts<br/>February 27, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_otherinformation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e07c93a4-3386-43c9-ad5b-bb785d13f31f" contextRef="C_bbef3127-bb0c-4874-825e-07108d441436" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 27, 2024, several of our named executive officers entered into amendments to their employment agreements providing, in part, for increases in their change in control benefits. For Mr. Metzger, in the event of an involuntary termination without cause or resignation for good reason within three (3) months prior to, or within twelve (12) months following, a change in control, he will receive (i) an amount equal to 24 months of base salary, payable in a lump sum, (ii) an amount equal to 24 months of the target annual incentive award, payable in a lump sum, and (iii) continuation of health benefits for 24 months. For Drs. Gallagher and Madigan and Messrs. Albrecht and Goldan, in the event of an involuntary termination without cause or resignation for good reason within three (3) months prior to, or within twelve (12) months following, a change in control, each will receive (i) an amount equal to 18 months of base salary, payable in a lump sum, (ii) an amount equal to 18 months of the target annual incentive award, payable in a lump sum, and (iii) continuation of health benefits for 18 months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During our last fiscal quarter, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c00081c-deb4-4401-9876-0a78674e9af7" contextRef="C_bbef3127-bb0c-4874-825e-07108d441436" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_3f715556-20d6-4b67-beec-e15a39e06583" contextRef="C_bbef3127-bb0c-4874-825e-07108d441436" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24c0f399-bfba-46be-a421-080dfeed1540" contextRef="C_bbef3127-bb0c-4874-825e-07108d441436" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_e804158a-a5f6-48a8-8906-69634e2818bf" contextRef="C_bbef3127-bb0c-4874-825e-07108d441436" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408 for the purchase or sale of our securities, except as set forth below:</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:16.76%;"/>
      <td style="width:14.88%;"/>
      <td style="width:14.76%;"/>
      <td style="width:13.58%;"/>
      <td style="width:1%;"/>
      <td style="width:15.58%;"/>
      <td style="width:1%;"/>
      <td style="width:22.44%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and Title</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Type of Plan</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Adoption Date</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Duration or End Date</span></p></td>
      <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Number of Securities to be Sold</span></p></td>
      <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description of Trading Arrangement</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_019950da-7c9e-4648-93df-baef4c55a740" contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Metzger</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_be72bccc-3c4e-47b0-b1b1-834994aefc81" contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b8284168-3f13-4768-8d1a-4f6d9ed68283" contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rule 10b5-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;trading arrangement</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_42f41713-7dec-4dd8-8d64-6791652a1511" contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/05/2023</span></ix:nonNumeric></span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c3360dfa-27fe-4447-a74c-63e3d28f0078" contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/22/2023</span></ix:nonNumeric></span></p></td>
      <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f2f9700-4e1d-4c92-9424-0beb6649895a" contextRef="C_6ed50075-e059-4c68-a550-a38411e61645" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales of shares intended to satisfy the affirmative defense of Rule 10b5&#8211;1(c)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_37e11f1a-0751-4158-b47f-05f24953c364" contextRef="C_29309db1-308b-4019-86e8-51c14a636d14" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Briggs W. Morrison</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_2066d97d-612e-430c-95c1-8f92d450ae3a" contextRef="C_29309db1-308b-4019-86e8-51c14a636d14" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">M.D. - Director</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6937d70a-a198-4693-b219-f050ccd3a68f" contextRef="C_29309db1-308b-4019-86e8-51c14a636d14" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rule 10b5-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;trading arrangement</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_61ce5d82-2fc2-471d-8f25-dc0d1c95d9fe" contextRef="C_29309db1-308b-4019-86e8-51c14a636d14" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/09/2023</span></ix:nonNumeric></span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_78d37cf1-d9ac-4057-a403-c5a56376cccc" contextRef="C_29309db1-308b-4019-86e8-51c14a636d14" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/06/2023</span></ix:nonNumeric></span></p></td>
      <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55a6884f-7ae3-4155-95c6-5e9d88608453" contextRef="C_bf403011-6a3c-4874-b13f-c83dceca4aaf" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">466,167</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales of shares intended to satisfy the affirmative</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     </tr>
    </table><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:16.76%;"/>
      <td style="width:14.88%;"/>
      <td style="width:14.76%;"/>
      <td style="width:13.58%;"/>
      <td style="width:1%;"/>
      <td style="width:15.58%;"/>
      <td style="width:1%;"/>
      <td style="width:22.44%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">defense of Rule 10b5&#8211;1(c)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) </span><ix:footnote id="FNT_aaa0a647-4c49-431e-a394-238030f55c8b" xml:lang="en-US"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5af59a3-600d-4bce-b90a-3156d43b6359" contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_98b6abb6-35d3-4cdb-9c67-b01ba925a536" contextRef="C_29309db1-308b-4019-86e8-51c14a636d14" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of Rule 10b5-1 trading arrangement, each of which the reporting person terminated prior to the sale of all plan securities.</span></ix:footnote></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain information required by Part III is omitted from this Annual Report because we will file with the SEC a definitive proxy statement pursuant to Regulation 14A, or the 2024 Proxy Statement, no later than 120 days after the end of our fiscal year ended December 31, 2023, and certain information included therein is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers, and Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#8220;Information About Our Board of Directors,&#8221; &#8220;Executive Officers&#8221; and &#8220;The Board of Directors and Its Committees&#8221; and &#8220;Delinquent Section 16(a) Reports,&#8221; if applicable, in our 2024 Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled "Compensation Discussion and Analysis", &#8220;Executive Officer&#8221; and &#8220;Director Compensation&#8221;, "Pay Versus Performance" and "The Board of Directors and its Committees-Compensation Committee Interlocks and Insider Participation" in our 2024 Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information regarding our Code of Business Conduct and Ethics, or the Code of Conduct, required by this item will be contained in our 2024 Proxy Statement under the caption &#8220;The Board of Directors and Its Committees &#8211; Code of Business Conduct and Ethics,&#8221; and is hereby incorporated by reference. If we make any substantive amendments to the Code of Conduct or grants any waiver from a provision of the Code of Conduct to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on its website. The full text of our Code of Conduct is available at the investors section of our website at www.syndax.com. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ers and Management and Related Stockholder Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; and "Securities Authorized for Issuance Under Equity Compensation Plans" in our 2024 Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Relate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d Transactions and Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#8220;The Board of Directors and Its Committees &#8211; Board Independence&#8221; and &#8220;Certain Relationships and Related Party Transactions&#8221; in our 2024 Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accountant_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tant Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#8220;Independent Registered Public Accounting Firm Fees&#8221; and &#8220;Pre-Approval Policies and Procedures&#8221; contained in Proposal 3 in our 2024 Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statements_sc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits and Financial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)(1) Financial Statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pages</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID 34)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations for the Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_comprehensive_lo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive (Loss) Income for the Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)(2) Financial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All schedules have been omitted because they are not required or because the required information is given in the Consolidated Financial Statements or Notes thereto.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)(3) Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>No.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516496764/d119516dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on March 8, 2016).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/sndx-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on May 18, 2023).</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516496764/d119516dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on March 8, 2016).</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516457615/d117131dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen Common Stock Certificate of the Company (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1/A (File No. 333-208861), as filed with the SEC on February 20, 2016).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312521361105/d274870dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant issued pursuant to the securities purchase agreement between the Company and Certain Purchasers, dated December 16, 2021 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on December 17, 2021).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Capital Stock.</span></a></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2007 Stock Plan (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2007 Stock Plan Amendment, dated as of March 8, 2013 (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2007 Stock Plan Amendment, dated as of July 10, 2013 (incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>No.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2007 Stock Plan Amendment, dated as of January 23, 2014 (incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2007 Stock Plan Amendment, dated as of December 17, 2014 (incorporated herein by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2007 Stock Plan Amendment, dated as of May 28, 2015 (incorporated herein by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2007 Stock Plan Amendment, dated as of August 20, 2015 (incorporated herein by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Incentive Stock Option Agreement under 2007 Stock Plan (incorporated herein by reference to Exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Statutory Stock Option Agreement under 2007 Stock Plan (incorporated herein by reference to Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-210412), as filed with the SEC on March 25, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516518181/d166957dex413.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Incentive Stock Option Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 4.13 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-210412), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Qualified Option Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on March 25, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459020037777/sndx-ex101_313.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Unit Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on August 6, 2020).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459021012607/sndx-ex1014_191.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Deferred Settlement Stock Unit Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.14 to the Company&#8217;s Annual Report on Form 10-K (file No. 001-37708), as filed with the SEC on March 12, 2021).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516518181/d166957dex416.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2015 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 4.16 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-210412), as filed with the SEC on March 25, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex10_16.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Syndax Pharmaceuticals, Inc. 2023 Inducement Plan.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000095017023002172/sndx-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Option Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on February 8, 2023).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000095017023018806/sndx-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on May 8, 2023).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459022008112/sndx-ex1017_443.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Executive Employment Agreement by and between the Company and Michael A. Metzger, dated as of February 2, 2022 (incorporated herein by reference to Exhibit 10.17 to the</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>No.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459022008112/sndx-ex1017_443.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Company's Annual Report on Form 10-K (File No. 001-37708), as filed with the SEC on March 1, 2022).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex10_20.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Amended and Restated Executive Employment by and between the Company and Michael A. Metzger, dated as of February 26, 2024.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459022008112/sndx-ex1016_444.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Executive Employment Agreement by and between the Company and Briggs W. Morrison, M.D., dated as of February 2, 2022 (incorporated herein by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K (File No. 001-37708), as filed with the SEC on March 1, 2022).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex10_22.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Executive Employment Agreement by and between the Company and Luke J. Albrecht, dated as of April 27, 2020.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Amended and Restated Executive Employment by and between the Company and Luke J. Albrecht, dated as of February 26, 2024.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.24*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459022018873/sndx-ex101_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Employment Agreement by and between the Company and Catherine Madigan, M.D., dated as of March 1, 2022 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on May 9, 2022).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.25*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex10_25.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Executive Employment by and between the Company and Catherine Madigan, M.D., dated as of February 26, 2024.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459022023045/sndx-ex101_16.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Employment Agreement by and between the Company and Keith A. Goldan, dated as of June 8, 2022 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on June 13, 2022).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Executive Employment by and between the Company and Keith A. Goldan, dated as of February 26, 2024.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.28*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/sndx-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Employment Agreement by and between the Company and Steve M. Sabus, dated as of December 1, 2022 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on December 5, 2022).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.29*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000095017023010756/sndx-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Employment Agreement by and between the Company and Neil Gallagher, M.D., Ph.D., dated as of March 30, 2023 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on March 30, 2023).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.30*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex10_30.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Executive Employment by and between the Company and Neil Gallagher, M.D., Ph.D., dated as of February 26, 2024.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.31*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex10_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-employee Director Compensation Policy, as amended, dated as of February 7, 2024.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.32*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement by and between the company and each of its directors and officers (incorporated herein by reference to Exhibit 10.21 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License, Development and Commercialization Agreement by and between the company and Bayer Schering Pharma AG, dated as of March 26, 2007 (incorporated herein by reference to Exhibit 10.22 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.34&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1023.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to the License, Development and Commercialization Agreement by and between the company and Bayer Pharma AG, dated as of October 13, 2012 (incorporated herein by reference to Exhibit 10.23 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.35</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1024.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to the License, Development and Commercialization Agreement by and between the company and Bayer Pharma AG, dated as of February 1, 2013 (incorporated herein by reference to</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>No.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1024.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit 10.24 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.36&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1025.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to the License, Development and Commercialization Agreement by and between the company and Bayer Pharma AG, dated as of October 9, 2013 (incorporated herein by reference to Exhibit 10.25 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.37&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516420122/d39288dex1026.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter Agreement by and between the company and Bayer Pharma AG, dated as of September 18, 2014 (incorporated herein by reference to Exhibit 10.26 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.38&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000119312516733845/d250701dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement by and between the Company and UCB Biopharma Sprl, dated as of July 1, 2016 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001- 37708), as filed with the SEC on October 7, 2016).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.39&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001395937/000119312517163872/d380147dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Side Agreement by and between the Company and UCB Biopharma Sprl, dated March 8, 2017 (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on May 9, 2017).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.40&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459019041719/sndx-ex102_185.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to License Agreement by and between the Company and UCB Biopharma Sprl, dated as of July 9, 2019 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on November 7, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.41&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000095017022015523/sndx-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mutual Release and Settlement Agreement by and between the Company and UCB Biopharma SRL, dated as of June 6, 2022 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on August 8, 2022).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.42&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/sndx-ex1047_509.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of October 13, 2017 (incorporated herein by reference to Exhibit 10.47 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-37708), as filed with the SEC on March 8, 2018).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.43&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459019017318/sndx-ex101_122.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of January 25, 2019 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on May 8, 2019).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.44&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459021057004/sndx-ex101_182.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Collaboration and License Agreement by and between the Company and Incyte Corporation, dated as of September 24, 2021 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on November 15, 2021).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.45</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000156459021057004/sndx-ex102_181.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Purchase Agreement by and between the Company and Incyte Corporation, dated as of September 24, 2021 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on November 15, 2021).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1395937/000095017023005079/sndx-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiaries of the Registrant (incorporated herein by reference to Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-37708), as filed with the SEC on February 28, 2023).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (included on the signature page to this report).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Principal Financial Officer</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:8pt;min-width:fit-content;"> </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">and Principal Accounting Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>No.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Incentive Compensation Recoupment Policy.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td>
   </tr>
   <tr style="height:6.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.074%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Indicates a management contract or compensatory plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; Confidential treatment has been granted for certain portions of this exhibit. These portions have been omitted and filed separately with the SEC.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-K Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 of 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.62%;"/>
    <td style="width:1%;"/>
    <td style="width:4%;"/>
    <td style="width:40.38%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</span></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/    Michael A. Metzger</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael A. Metzger</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TTORNEY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each person whose individual signature appears below hereby authorizes and appoints Michael A. Metzger and Luke J. Albrecht, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:43%;"/>
    <td style="width:1%;"/>
    <td style="width:35%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:43%;"/>
    <td style="width:1%;"/>
    <td style="width:35%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:0.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael A. Metzger</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael A. Metzger</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Keith Goldan</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Keith Goldan</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Dennis G. Podlesak</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dennis G. Podlesak</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Martin H. Huber, M.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Martin H. Huber, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jennifer Jarrett</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jennifer Jarrett</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Keith A. Katkin</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Keith A. Katkin</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Pierre Legault</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pierre Legault</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ William Meury</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">William Meury</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Briggs W. Morrison, MD.</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:2.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Briggs W. Morrison, MD.</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Index to Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pages</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID 34)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations for the Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_comprehensive_lo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive (Loss) Income for the Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="report_of_public_accounting_firm"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the stockholders and Board of Directors of Syndax Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Syndax Pharmaceuticals, Inc. and subsidiaries (the "Company") as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive (loss) income, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 27, 2024, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prepaid and Accrued Clinical Costs&#8212; Refer to Notes 3 and 11 to the financial statements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes research and development expenses as incurred, which include costs relating to clinical trial and clinical study activities performed by the CROs. Expenses related to clinical trials and studies are based on estimates of the services received and efforts expended pursuant to contracts with each of the contract research organizations (&#8220;CROs&#8221;). Tracking the progress of the clinical study and trial activities, including payments made by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company and by the CROs, allows the Company to record the appropriate expense, prepayments, and accruals under the terms of the agreements with the CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We identified the estimates for research and development accrued and prepaid CRO expenses, including costs incurred by CROs as a critical audit matter due to the judgments necessary for management to estimate the level of services provided and the costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. Prepaid CRO expenses are recorded within the balance of short-term deposits on the consolidated balance sheet, while accrued CRO expenses are recorded within the balance of accrued expenses and other current liabilities on the consolidated balance sheet. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to audit management's estimates of such accrued and prepaid CRO expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit procedures related to prepaid and accrued clinical costs included the following, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We tested the effectiveness of internal controls over the estimation of accrued CRO and prepaid CRO expense calculations, including management&#8217;s controls over the assessment and estimation of the costs incurred for significant research and development activities performed by CROs.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a sample of contracts, we read the related contracts, purchase orders, statements of work and other contractual documentation. We tested the completeness and accuracy of the information used to develop the estimates and evaluated the significant assumptions used by management to estimate the recorded amounts by performing the following:</span></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performed corroborating inquiries with the Company&#8217;s research and development personnel to understand the nature and progress of the studies conducted by the CROs.</span></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inspected information from third-party service provider CRO.</span></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtained corresponding invoices and evidence of payment to third-party service provider CROs.</span></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compared the estimated accrual balance as of December 31, 2023, to the invoices received after year-end to evaluate the Company&#8217;s ability to estimate the accrual. </span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts  <br/>February 27, 2024</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2008.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.58%;"/>
    <td style="width:1.76%;"/>
    <td style="width:1%;"/>
    <td style="width:10.9%;"/>
    <td style="width:1%;"/>
    <td style="width:1.76%;"/>
    <td style="width:1%;"/>
    <td style="width:9%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ASSETS</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28069441-a21f-47a9-bb5f-76345a557778" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,394</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00b90065-47af-43ab-92d5-24a07e592e03" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25fb03fa-4a68-463d-9275-57cf57cb7ba7" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24f8c146-e80b-4071-90a1-1a5ebd6d4a5d" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401,446</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term deposits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e158c0d-af49-4988-aad9-0107e41a8402" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DepositsAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,885</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5963c0c0-985b-41a1-a2f2-5ee13b28ab78" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DepositsAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration receivable, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9f36e7e-6164-46b5-b8d8-b92483db6b1d" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f79ba228-febe-4c0e-a3d0-a377f785d5b5" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,474</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58304fce-9d75-4078-b066-ee2a4c887bb5" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,293</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e23ef2c-e16a-4779-9481-10a4fb7b90d4" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e98d4c6b-17c4-46e2-a393-8fe4af39f394" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">580,876</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54c4345c-4b90-49ae-8059-7bfe983f4135" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489,786</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbcbb235-3696-4cf3-a5dc-96f40a4e6e6f" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e67c0fb6-2cc9-4e4f-9c31-52bc63b0e519" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54b09fbb-c307-4700-a8ef-57327bf1f600" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6341836-36de-4eee-8888-0bacd7c155e6" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ddb6acb-9264-4407-838c-a604648d5422" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,487</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb84bb9b-c38e-449d-8157-e9cb34d3c70b" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,039</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2e8de88-8f0c-42ea-ab18-81035cfbf702" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f77c1ca1-9f4e-4116-a7ec-6daa2a11e7e4" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea6e48c9-ccd4-4d6b-b333-d34e268be24c" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">463</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cf35cf6-1d4d-49e5-842e-6d77d0c208cb" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">807</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_949ba060-d037-4b6c-941d-33e3f45720bf" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">612,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6387abc6-ba4b-4fa5-a8c0-2962f6fc2f84" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">497,236</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d2093c5-80bb-4c64-b426-7dc0274165a7" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,961</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a8d7282-b27b-40ff-b42f-ceb9bec12c50" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,350</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration payable, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d489e1ad-2881-460b-ad55-01aac1772bb1" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:CollaborationPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f002822b-fa73-4797-a1c7-6f2a3a506d28" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:CollaborationPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_094616d2-7215-4586-aed6-0eb6097819b1" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,856</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ef4c229-9109-4c9a-aa75-f19243f1819a" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,276</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of right-of-use liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f129e4d9-21b5-4981-85f2-983b7733b2bd" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c17e5a0-f4e1-4230-a98b-d2981c88fd8e" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of capital lease</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e2d15e9-4a9b-478a-b3a5-94a62853f4f5" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:CurrentPortionOfCapitalLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13ad18d8-bdaf-4a7d-8ecb-4dc9a1d41526" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:CurrentPortionOfCapitalLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81e457d8-6045-4c9b-837f-28af16d516d0" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,096</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c40141bf-ce4a-474a-b358-2f3948dd4aaf" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,065</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term liabilities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability, less current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8597cfc6-1fef-463a-9e17-de8d30e69975" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">578</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1abfc018-5c11-42f2-b4dc-65809f57294d" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capital lease, less current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ae47a8a-a0e8-4e8b-9d96-9b37dd434d91" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:CapitalLeaseLessCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5e2e04e-9138-4fef-8a48-7c8a541375a3" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:CapitalLeaseLessCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_030d3f1d-d307-4333-a7cc-7f2446767b79" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2b80493-32f0-48dc-be45-2f7f70388085" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb10c907-fe0e-4b8f-a9d6-149d088e3b15" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6feb2ef3-751f-446b-b41e-03915485891f" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,787</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_debbfc9d-6778-4f47-b928-17023ff29f09;"><span style="-sec-ix-hidden:F_5c24cdeb-9f74-4eee-842e-e218a265196d;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 16)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71476097-3bf2-4524-9c11-563203f8021b" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2e95891d-6df1-4bba-bd4e-2ec333547a80" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1ea90a0-4ce4-47d7-8177-e8d061b93c8f" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ac04c682-7bec-4f1e-9c65-e0641a707c57" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized;<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9548f1e5-19a5-4b88-96f6-1c483f3d84c0" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c66715ed-cf64-4378-9652-53f62fa44e38" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares outstanding at December 31, 2023 and December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d03be623-bef1-4080-a140-4f801cb977fe" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58c3ff3b-07b7-4796-a85e-fca42f80424c" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0702abbf-b28a-4d6d-b818-b71b7a45f915" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e447e163-1331-4efa-a1d6-9bfb2623ffcf" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_795b1daf-e38a-45c3-a14e-30a56444c9ba" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b72a559-cbdc-4f84-9f22-37652a0a9087" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and December 31, 2022, respectively; <br/></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d23002fa-2f3d-4336-977c-54044fe19591" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,826,632</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c3df322-03f9-4390-984b-2931cea6a7f1" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,111,385</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares outstanding at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1ea7712-e063-4e01-84c5-ec71836a1a87" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e704bbc4-fa74-4a5a-a60c-8cbba7d009c0" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be718fcc-15d9-4337-b9ce-b951142d8be2" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,456,370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f6addff-7b68-4a59-8053-2cf6a2406f2e" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88c4955c-5313-4a94-95b7-b7c24ba55500" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_741ce834-a449-4294-acd0-56e3b7c50514" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">806</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cbd17c5-a54d-4664-ba16-f9d7845b009b" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">902,400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79ac0ec5-14f4-4aed-a2b8-6bb9d857a871" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">693,040</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf5bb96b-b0c0-4c90-b7c3-283138c66af6" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">554,196</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0520343-b26c-4699-be81-a4be00e95c32" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">467,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db1e2032-f3bb-48c1-8068-4b72a874c1c7" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">612,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_506c1302-954f-4fe5-b3fc-2131c27dc349" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">497,236</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.473%;"/>
    <td style="width:1.56%;"/>
    <td style="width:1%;"/>
    <td style="width:8.282%;"/>
    <td style="width:1%;"/>
    <td style="width:1.56%;"/>
    <td style="width:1%;"/>
    <td style="width:8.282%;"/>
    <td style="width:1%;"/>
    <td style="width:1.56%;"/>
    <td style="width:1%;"/>
    <td style="width:8.282%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_bfa9a871-0b75-4568-9859-df85dcd68379;"><span style="-sec-ix-hidden:F_6061cd85-0c54-4a24-9e24-640882b2bfe9;"><span style="-sec-ix-hidden:F_0835679e-b7bf-456b-81ca-3e9b85f608a3;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License fees</span></span></span></span></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acce096e-c2e4-43ba-a75f-5d7bfdad8376" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4e764d0-8228-45a7-a091-fce3ae4c94ef" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a4306d7-646b-4cc9-bb87-d09127ee0141" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,709</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f330f219-0e47-4bbe-8271-1c4e2906bcf9" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f4ec015-f60a-494a-a33b-76f17adbdbf2" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de7f2d15-3dbe-4fa0-b2b9-72bc83c3727d" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,709</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42ea97a5-4c7c-464b-b9c9-d1a7a52da32b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d6f1777-d7f6-46a0-a7e1-7e8208902161" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66638b3c-ddc2-48a9-9419-fa04005a2424" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,248</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7de400a5-25c2-420e-8bd4-c82b58bc8d24" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,922</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f7ba0c9-f86f-42a6-afd4-d52c04bf7454" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1ed76ef-3ac9-45d5-a64a-1497ec990c50" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,241</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75a89285-c568-4094-85e5-98cf67a42de3" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,954</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_155514d0-da62-4249-ae5c-d060dcd53daa" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,757</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e702e52f-b7f8-4d25-9cc1-17a6ad4f21f6" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,489</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ecf43ec-5579-4073-940e-c03e17a4c510" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">229,954</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9807462-de57-4567-9164-93df866f32c8" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151,757</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaaffe3f-1a57-4a7c-890d-1d3653d6b834" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,220</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bf9b137-2b30-4f1f-9ae3-804c469e108b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68f155df-8951-4d08-862a-ff6dd6dd6a32" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,137</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f18396a2-b3bc-4a35-849d-d9e2410d7db8" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,899</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aded91ae-870d-4aca-8b4f-1d2b344ac1cb" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,163</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e777cf11-7ac1-4f64-89c9-d30500a66709" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,872</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eb2d92a-6f19-4414-ae8c-ec4aa4250a7b" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other (expense) income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbfcf8f8-02de-43a2-8c9a-18dd49684db7" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">361</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e0e47bf-89ff-4330-95b2-f6cfa64ff251" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">316</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f945d485-f726-4f22-9272-c96370e565bd" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70dcff03-2280-4065-ba94-1f53cd5cc47d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,594</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1c0dda5-af55-4af7-be64-14bd6e077abb" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,419</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9464f28-b9c2-4591-9249-94b720788d91" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,294</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80159323-cc32-4889-b57f-6da82ef4faff" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12c56e80-f629-4aa0-8196-1b425b568dd4" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a86d3ef6-6f15-43da-89c5-81a602e281a7" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f41cf94-7051-4697-a1e6-10ccb4d9f31b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6446bcfc-ce2f-4d5f-bf2e-6ea331850722" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c83899d9-5066-4677-82e0-b907f78bf2a1" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income Per Share:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic (loss) earnings per share attributable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49afbd28-6957-4879-98cc-0800b0cfdde6" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.98</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08b7c7b2-a7fa-4c84-b06f-92719a047d14" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.46</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f7640a1-e33a-42fb-bef8-ce366d3d363e" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.48</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted (loss) earnings per share attributable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0fe79a5-ea67-4996-9915-15617795302e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.98</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bc82022-de7c-4ada-8657-849522875fda" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.46</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccfdbe41-2014-42d7-953b-a0f0e351ec6f" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.46</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares used in calculating:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic (loss) earnings per share attributable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db7e8ef8-48b6-498f-98c4-19cae260d793" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">70,370,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3660de7a-d97b-47f1-8db2-12ddd76e8221" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,760,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbd56fb3-37d9-4ab3-a061-5ddbb3572c43" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">52,064,809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted (loss) earnings per share attributable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c89380e-81ea-4e5e-b81a-21695811fae0" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">70,370,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0c94f22-1662-4619-b3da-006eece70f33" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,760,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9c61176-1167-42c2-8f31-d02547441ba2" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,622,904</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_comprehensive_lo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OF COMPREHENSIVE (LOSS) INCOME</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.493%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:7.922000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:7.922000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:7.922000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06ca38fa-0de2-4afd-90cb-2cc86e44501e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ee261cf-4a0c-4eb7-8909-3e7cee2d3256" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38ea2548-1e2b-4ed2-befb-74ac1a09d8a7" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive gain (loss):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on marketable securities, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b5b456d-64a5-46a7-8e17-5a8708da2e88" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eaf4923-8991-4510-b4f0-9124b64d3a80" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">851</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f565952-a6e4-423d-8f14-2d539d2600fd" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_219bf695-df22-453d-9b02-1dbdbbe2b882" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">208,336</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b69e8f8c-9a97-4ff2-ab9b-3cb1eb334761" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">150,189</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2b613e8-ad22-4668-974f-e6ed4193fc31" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,975</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_convertible_pref"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.564%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.997%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.737%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.397%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.737%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.737%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.837%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock<br/>$0.0001<br/>Par Value</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders'<br/>Equity</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Loss) Income</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Deficit)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance&#8212;January 1, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc2e6ca0-6125-4254-a1ad-a4068ac89f06" contextRef="C_02ad79b9-c653-4f87-a48e-92ebf9946d11" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">47,881,223</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0af9143e-6f27-4bb7-b315-e1f7994db98f" contextRef="C_02ad79b9-c653-4f87-a48e-92ebf9946d11" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02d5bfd3-ffa9-49ae-b1eb-8808304462f4" contextRef="C_5ac62b3c-c563-4a8e-956a-51511134c433" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">820,815</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8633ffd1-43eb-4ec5-a0a2-db33e428efd4" contextRef="C_99c2e544-076a-4909-9149-b0b33903b58f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64bec66b-28c6-492c-ae03-c861f7187353" contextRef="C_29ad8473-2e34-453e-8357-0aecf445558f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">568,628</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b922e013-fb82-4ea8-9f38-298323cbb1c4" contextRef="C_07dde341-6b8e-4d35-a0a4-24bc46311598" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">Proceeds from at-the-market offering, net of $</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8da1f2a-7d2f-4985-b770-774b3acc473a" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;"><br/>&#160;&#160;&#160;offering expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_272736e9-fb1a-45e9-a2f6-8165253dbb59" contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc" name="sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">277,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbcc8fdf-2ea2-4235-ba4e-510fac671895" contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9e6d35e-5119-4896-8fdc-3c1d9ea55e78" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">Proceeds from direct offering, net of $</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f54c011b-9426-477e-8c93-b0b28f63766d" contextRef="C_844de8bc-e6f9-4600-bf14-e5765bd7475d" name="sndx:StockIssuedDuringPeriodValueOfferingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,332</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">&#160;offering expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d58a3f2-ade9-4f41-ade3-eab841e1f095" contextRef="C_50387594-1a28-42ed-ac94-8000e7132fac" name="sndx:StockIssuedDuringPeriodSharesDirectOffering" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,802,144</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07e0490b-37d1-4d4c-9b85-b4c5d2efbde2" contextRef="C_50387594-1a28-42ed-ac94-8000e7132fac" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80000b97-acd8-4e39-ba3c-ee4b97474d72" contextRef="C_2b24797a-527f-4f5d-beb7-f6e788fb41fa" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,205</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1345371e-8728-4140-8d78-99176fb45e5e" contextRef="C_844de8bc-e6f9-4600-bf14-e5765bd7475d" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock purchase under ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8d39fb5-f112-44e0-aeff-9bc0e904edfe" contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">26,878</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-funded warrant cashless exercise</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b99582b-eaef-40a0-a336-0a13c3bfd59f" contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc" name="sndx:PreFundedWarrantExerciseShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">725,784</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from Incyte Share Purchase Agreement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9913a288-63e2-440c-8d3f-db7a195323ec" contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,421,523</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bb4776f-b42c-4909-8018-dc8fdfdf8597" contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e78d8118-010f-4b9a-8ef7-5a43905806c9" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d550b12d-c3ca-45b6-b5c8-ccff206468f5" contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,317</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_512d34d6-570c-4b60-897c-f0b99e3c4ceb" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,317</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc1af6ec-a45e-4a3d-a6c3-ab2a557e1e32" contextRef="C_e4e199a4-716e-4324-8f4d-ea865c2c0770" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_807dead0-858e-4bba-b5fb-48d2e9d96d0d" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of RSU</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d24bbb9-c376-4f62-9ef4-8daf1ac0850f" contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee withholdings ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86d1814b-fc0e-4a43-8966-15801b6a0734" contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244" name="sndx:EmployeeWithholdingsEspp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_023b757c-8b0f-4c93-a017-4bba380b4727" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="sndx:EmployeeWithholdingsEspp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa40bc6c-75b6-4bb8-b948-1ee22613cfcc" contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">842,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_654541f4-a773-4e76-bde0-8652cb69cc1f" contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,336</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_642d9f58-ec8f-47fe-b386-2a3a9a6bcdf6" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,336</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13d9d170-a67d-4613-9811-f8855234fd99" contextRef="C_ddd4ae65-26c4-4c11-8b88-b2c7bac6eacb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2d47245-f3e2-4f5f-8205-a18009e28259" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance&#8212;December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e211daba-ce1b-4841-8358-2cebe2c075a2" contextRef="C_4f9cd118-679a-40a6-847e-91450d6633ea" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">54,983,105</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95d5e218-46f7-4c15-8e96-4fff29fd078d" contextRef="C_4f9cd118-679a-40a6-847e-91450d6633ea" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f03740fa-a11b-4356-a886-ea3ded60e721" contextRef="C_5e8b74ff-4a3e-4c5e-9f04-3c68740d89c7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">952,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_882656ce-8d52-411a-bd90-4932af13ba12" contextRef="C_8d925cfd-9465-4602-88c6-bc4641cd2271" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be29b2bf-821f-4455-98e1-d749ebc4d5cd" contextRef="C_43d48b69-d64f-4673-aae8-70b5559a6dd7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">543,702</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1065d4b9-1ab2-4f9f-a5bf-1369a0784d81" contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">408,368</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">Proceeds from at-the-market offering, net of $</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ebe7847-6e63-4586-8bd8-e9eb6b9484a1" contextRef="C_d21a99f4-ccca-4ef1-962f-a9239148a2f8" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;"><br/>&#160;&#160;&#160;offering expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_976a7ada-ef58-405e-abf4-b5a5dba8fe76" contextRef="C_97645584-c333-40ca-801b-2613f368a789" name="sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,111,111</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbfd4efa-c2d3-4815-8db9-8e4d4e77bcf2" contextRef="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,425</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1daefd5d-b94c-41c4-be33-139b172f0b6b" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,425</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">Proceeds from direct offering, net of $</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac99ea7f-5dae-423a-9857-705b3c010c26" contextRef="C_a5804989-e5d4-4066-86ae-9576d589c5cb" name="sndx:StockIssuedDuringPeriodValueOfferingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,535</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">&#160;offering expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc13e855-d5c8-4ea0-86f5-c3203ea625b4" contextRef="C_0422204c-ea29-458e-977a-fbc28c65fb5d" name="sndx:StockIssuedDuringPeriodSharesDirectOffering" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,840,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47e8c531-8364-4ba1-be2c-c90ef9c5e786" contextRef="C_0422204c-ea29-458e-977a-fbc28c65fb5d" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79e2fc2f-83d7-46cb-aca8-2dfdbf39bfb9" contextRef="C_88e95505-429a-46a9-b560-ae0bf5e61908" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7046870-353c-4222-9f65-c587de891c62" contextRef="C_a5804989-e5d4-4066-86ae-9576d589c5cb" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,966</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock purchase under ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41d869ef-2fee-4915-b379-1bf2e08800b2" contextRef="C_97645584-c333-40ca-801b-2613f368a789" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,999</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-funded warrant cashless exercise</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4707e89a-7680-40cd-a69c-0aa0638f0b85" contextRef="C_97645584-c333-40ca-801b-2613f368a789" name="sndx:PreFundedWarrantExerciseShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,832,151</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c67a02ed-f97d-446d-b3a0-aa543e25fe36" contextRef="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d94dad8-c42b-45ad-b6b3-aa6d2d100527" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of RSU</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a43e8318-7271-441f-b87b-d03ce5e78a5b" contextRef="C_97645584-c333-40ca-801b-2613f368a789" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">38,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5dfa556d-5a63-4ad9-a7a7-abed1815978f" contextRef="C_b1cf4bfa-5db9-4119-8b19-8336fe8db925" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">851</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0040670-0216-4848-84d5-3c1bdbb2404b" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">851</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee withholdings ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd6de439-63c3-4a49-a27c-d1fd795f48e2" contextRef="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf" name="sndx:EmployeeWithholdingsEspp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f74e9d4a-e8ec-4d3d-bd4c-28c7ec3e33ad" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="sndx:EmployeeWithholdingsEspp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6459eb36-43b7-4f53-95e2-82b2879ba6af" contextRef="C_97645584-c333-40ca-801b-2613f368a789" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,276,361</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbb4effe-a639-4ac5-af42-3b70b537fb61" contextRef="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,459</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdb9f1dc-18ed-4b30-a795-6fc08e4c844e" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,459</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa0e3be-61b9-41d3-95e7-75edd49a728e" contextRef="C_5197e4c4-abe0-4b59-8b72-08d7ab8fd593" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_595b3a03-2c07-4f56-9809-64597ab7361a" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance&#8212;December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e86f800-afea-4c93-a1ea-78c2eafea1d9" contextRef="C_7ef30512-4d6b-4796-82fc-67c194464ce1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">68,111,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22916c90-c6c8-485f-8852-112cd5c9186b" contextRef="C_7ef30512-4d6b-4796-82fc-67c194464ce1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b81c0ed1-d544-4e98-a3b3-b311de031ae8" contextRef="C_a9e7a5e0-1ec9-492f-858b-bc50f9566629" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8310fe3c-f3e1-4189-98a8-a22037b76248" contextRef="C_d63904f7-84ba-4976-8198-140293f5c68a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">806</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11814988-1db4-4750-b1e4-2a90f4720f8a" contextRef="C_87ff6aa9-d940-48eb-b1df-219774898bb5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">693,040</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf7957ac-ffeb-4787-a37d-48bdbe9e2082" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">467,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">Proceeds from direct offering, net of $</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85d49dfa-8d36-4af6-9ded-48e7d700d3e3" contextRef="C_012a6df5-8424-40f8-96a5-5e06d8ae24bd" name="sndx:StockIssuedDuringPeriodValueOfferingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,044</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">&#160;offering expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cf7d606-70a8-4596-8099-25126d962bac" contextRef="C_ac9227a8-0a7a-4171-9671-16e3b7033e1c" name="sndx:StockIssuedDuringPeriodSharesDirectOffering" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,432,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8230072a-e6b1-4595-a0aa-ea7373f451ec" contextRef="C_ac9227a8-0a7a-4171-9671-16e3b7033e1c" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec125ead-fbe8-41d8-85e7-6d6d8aff7be9" contextRef="C_078b50de-5b41-4db5-9cf7-84fdb243368a" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,954</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_801f6749-45b7-4a47-9465-43a64e62c5f2" contextRef="C_012a6df5-8424-40f8-96a5-5e06d8ae24bd" name="sndx:StockIssuedDuringPeriodValueDirectOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,955</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">Proceeds from at-the-market offerings, net of $</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0e85229-18d4-44ab-8571-f9551ef88bf8" contextRef="C_3fdbce86-90d7-42aa-9453-ad5900bc17d9" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,086</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">&#160;offering expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5115654-d80f-46d8-abc3-fd96e3fe5ac4" contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6" name="sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,719,744</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32f58e82-7189-445b-a7c3-724776d040ec" contextRef="C_758bdea3-3881-4991-b7bf-ed3b171e2195" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45824ede-63cd-4ed5-9f8d-e36943ba45e6" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17742bb7-96cb-4b84-8f81-3a432e3dfcdd" contextRef="C_758bdea3-3881-4991-b7bf-ed3b171e2195" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,951</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c34eb4f-a1e1-4a99-9ed3-301618933c9a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,951</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f8bb2b8-e0f6-4ca3-92f4-55704d02d0ed" contextRef="C_1245cc97-cdcd-478a-a01f-e41febf804e7" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba14bf5b-58c9-4109-8410-527ba2918a88" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock purchase under ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72dbb3e3-1b20-461e-afbf-843beaf66af1" contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">34,797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee withholdings ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb00e116-1be7-4836-ba5e-cb56c4cd2dfb" contextRef="C_758bdea3-3881-4991-b7bf-ed3b171e2195" name="sndx:EmployeeWithholdingsEspp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_537a5269-7bfa-4890-92b3-d4ede2c897a4" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:EmployeeWithholdingsEspp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-funded warrant cashless exercise</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28dd2605-718b-4f82-b4f3-54733a0654de" contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6" name="sndx:PreFundedWarrantExerciseShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">857,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of RSU</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e96a29b7-9f85-4e7e-86bd-65add1a6ce8f" contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec05c259-a33a-4347-a545-ff492591ce90" contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">662,042</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_245c42bd-cf5c-4723-834c-1a3a80ec85df" contextRef="C_758bdea3-3881-4991-b7bf-ed3b171e2195" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d724320-edb8-4b4c-949d-a766de1de375" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd26e8b5-309a-4f7a-80eb-e430793143bb" contextRef="C_f06b4d49-9703-446a-ba86-02d5b5a8111b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb4417db-f4d7-4a87-bd7d-76431083fa8e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance&#8212;December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1021a8b5-a33a-4885-9859-6499a416b262" contextRef="C_c3fb6f51-13eb-4e43-9466-09f4818f1386" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,826,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb847ca2-f8ea-4ac4-81ac-d67711fef482" contextRef="C_c3fb6f51-13eb-4e43-9466-09f4818f1386" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7348a80-3193-4716-b4f7-ad097b391963" contextRef="C_aff4aaae-ac9e-419d-8194-f5b7a5c562dd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,456,370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bac8760-5fc4-47c2-926e-1d6a3bc90bf3" contextRef="C_cdda42ce-b5f5-4335-9c1e-37c83c1c9673" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9834359-aae0-4353-8284-361544189b77" contextRef="C_220ba3e8-b19e-4dfb-b2aa-b75c2caad42b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">902,400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f122f12-2143-4fb5-8ebe-975072f3f814" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">554,196</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEME</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.076%;"/>
    <td style="width:1.699%;"/>
    <td style="width:1%;"/>
    <td style="width:9.276%;"/>
    <td style="width:1%;"/>
    <td style="width:1.699%;"/>
    <td style="width:1%;"/>
    <td style="width:9.276%;"/>
    <td style="width:1%;"/>
    <td style="width:1.699%;"/>
    <td style="width:1%;"/>
    <td style="width:9.276%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CASH FLOWS FROM OPERATING ACTIVITIES:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da17f7ce-17ba-4015-a51c-fcba70563911" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b3f07db-17b8-466a-accc-56cdedc54f69" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc835bc1-3169-40ca-a569-fcc966a85128" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash provided (used in) provided by<br/>&#160;&#160;&#160;operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3473d2c1-44dd-478f-8431-9eaeecb371b7" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:DepreciationAndRelatedAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_482508ef-6d48-41a5-ace9-70236e8b9595" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="sndx:DepreciationAndRelatedAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b794359b-2d1a-4efa-8061-81c1ee114432" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="sndx:DepreciationAndRelatedAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Accretion) amortization of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3e956e6-771b-4d62-a05d-8a16f4a8f0b4" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd298bb1-0e59-4d7f-8f79-be41791e1101" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,382</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef7d12b8-2828-43a3-900b-b4957efc9a6b" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">644</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22fa09ff-2b33-4e39-859a-234d35bf8767" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_297ce599-3f61-4e6d-b6ea-3dcc451d70d8" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="sndx:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7e22223-cf8d-450c-9717-a7c4de48d73f" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="sndx:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">413</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash interest income (expense)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8946d4b3-6d98-41b6-8bed-19f80d5416b2" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:PaidInKindInterestAndInterestReversal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cb3fd70-6c87-40d5-ae22-13be4e48cd84" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="sndx:PaidInKindInterestAndInterestReversal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b67bd33-3b64-426b-9e4e-aed3498bb3a0" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="sndx:PaidInKindInterestAndInterestReversal" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value of derivative liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b8f8383-0446-4cf3-a456-c4f51ea619de" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a8e920c-5676-4e7c-80d2-913abd664bb0" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e390267-7eac-4878-9448-dd1c5c365c7c" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_436e45a8-8296-45cc-ac9a-1d51d10561b9" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,951</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91bac2fe-c3b4-4ae7-821a-5a1b3773ed4e" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adce9bc8-bf02-46c4-a030-df32efdee25d" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,317</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20904291-06b9-4b92-be28-cb7663454a12" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19fbfaf7-7c42-4f06-9235-563c76a6a52c" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01852103-576f-48a0-8ea8-dfecece031d7" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0e99ae4-f51e-4374-98c6-691d158ad10d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">676</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dca52fc5-2cd0-4b83-840a-ca592baf1c8f" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,972</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ec14558-236f-43b8-bc7b-ef9a07174008" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,394</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration payable/receivable, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be10877d-248c-4184-a688-fe64debf0a71" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,706</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56caa256-1f8e-4247-934b-7229af1c5e93" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="sndx:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,474</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78d20166-ff49-44dd-b3ca-a5fae27733be" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="sndx:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64f912b6-3c62-494d-b6a5-baadcffd6c1a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cff389dd-8dac-454b-9bff-d28ce87a0c70" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,319</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_972bab35-399a-4817-abf4-35f5e5ce618d" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42b5ee6b-4d17-4887-a84b-cd2466dbf0b8" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0d41e4d-82db-4b04-bf1a-aa86b9e75558" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4c2f388-c4ee-4591-9207-e2df9d4692fb" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6974827-c0ed-4aac-8384-940d5c1e5412" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,867</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_115452e7-41f2-4fad-8f8c-f77a7939ac92" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,421</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_109f0da2-fdb4-4fa1-98d6-76b79e4f4100" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fff8f0e-736c-4201-b72d-43a415aece75" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,601</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef89b3e4-a35c-4c32-82a5-1693ab447430" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">133,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fc2bf7f-9ccd-47e3-afbe-28e485d482df" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CASH FLOWS FROM INVESTING ACTIVITIES:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed6253ab-da9b-4c4b-aea9-d9cc5e72bbb9" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7fd64c4-3d5f-4bbf-9d58-10a1067db88f" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbba43a3-e44b-4159-ab9a-2f8d1d84286d" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sales of equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1af755e-7b51-45b2-8e07-ee48940e305d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9661fd49-809a-46ee-b682-6c493d12633a" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30c05656-6337-4001-8da0-c077467e378c" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of short and long-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52c7d085-f2ec-4a39-be64-5391408a7279" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28976beb-5b45-4c93-97cd-6f681d8df264" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">495,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a94bea8-8f22-41fa-9c85-88369df72102" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294,719</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sales and maturities of short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa46e81e-9445-45b0-89b6-65805f0fc36f" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472,215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c06b9bf7-3754-4566-b8ff-c0faa2831522" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9084e02-c6f2-4294-8a6c-10119280b5da" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253,975</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f66432a7-9b95-4f13-bd18-35c7f498d763" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,609</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7521972a-2ffa-4d79-959a-8dd936ec8eb2" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">186,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bb79f62-b332-4715-be27-35b5a432f1af" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CASH FLOWS FROM FINANCING ACTIVITIES:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock in follow on public <br/>&#160;&#160;&#160;&#160;offerings, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd6bd8b0-3031-4d60-b569-aa7a7f7703bb" contextRef="C_192455fe-8853-44c4-a2af-b22ba6210f6a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,955</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53d3c7ae-fb98-4ce4-aafb-c204de7ce533" contextRef="C_7704e7f4-6094-4899-941c-17cce4c1ad53" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66871f2b-4b4f-4b57-b2f3-83fbb1af1761" contextRef="C_c9f5b310-329a-4434-9537-4ce7c13c5b4b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock in at-the-market <br/>&#160;&#160;&#160;&#160;offering, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d21c4ff-02d4-4e69-b48c-94fbdc6040d9" contextRef="C_9415a8d6-3456-4c2f-b211-310686e40961" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d7ec539-d1f4-46cd-b96c-b1bbac988114" contextRef="C_a064fef4-51ed-42ca-be0f-f995b8a0ed8a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,425</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de9a80d2-f6d3-489b-a3ca-4ccb00adca7c" contextRef="C_9f8d8621-1769-4079-8f0b-99e55c437b8e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allocation of proceeds to common stock issued under the Incyte Share Purchase Agreement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dec6b41f-3d19-4bbb-acf8-d8210404bb3c" contextRef="C_1d4310ad-0736-4012-b9ce-4a0f9454edae" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c85eb0f-39e0-47e4-bd52-08bbfb452c51" contextRef="C_fe65bbb1-0d57-4bdf-9127-31463d2d09a8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4269630a-dd42-482a-8c14-83c86d70205e" contextRef="C_e7394970-59e6-4cd6-89a6-54b79f895f1d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allocation of proceeds to derivative liability recorded under the Incyte Share Purchase Agreement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e01afd99-4e44-4e28-b97e-31cdf57768b2" contextRef="C_ff8445ca-ff4b-4f13-8184-af4837d5724f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e1b5dbb-0e38-4bd8-aa80-a5f4c20241c4" contextRef="C_13c0b160-1a0f-43dd-81e7-cca1d5370eb4" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1e2ee21-c53a-4bd9-b812-c6f0d5812758" contextRef="C_9d930a60-dcb4-4913-bea6-46745efcd9fc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">576</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment on term loan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff43858a-c307-437c-bf1d-d3c0b2d6a67b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:PaymentsForProceedsFromDepositOnLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dff7fd26-dc8f-488c-9d0f-55f29d00e939" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:PaymentsForProceedsFromDepositOnLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,996</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e4ad878-55a0-4208-9a71-1ad8b28938be" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:PaymentsForProceedsFromDepositOnLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0900e17d-c283-4ea5-81a2-916515cc827c" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_972230b3-d7df-4c16-a68e-eda2446b5974" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e85e71c-9ddb-41cf-bab2-b475492b4527" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from stock option exercises</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c88c490f-e673-4285-9d27-e5b76bd5932c" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_100c5d75-c85c-48f2-916b-8e561f17f14c" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,459</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4edad0d8-f0c2-47e3-91ef-ab9f1d34fa08" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,336</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ab157d9-a722-4f94-8bb5-4f9f473afb1b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,132</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a85c2143-28d2-4565-a631-d24cd9c45046" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a38a25eb-163c-4612-81a8-659fcf9345aa" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS<br/>&#160;&#160;&#160;AND RESTRICTED CASH</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c3334a8-68a0-4eea-8ef1-7afe8a225312" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_152382fd-bafb-4e5d-a793-94e8afbbc55d" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">147,609</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c15c371f-c617-4b23-8f1c-c7f8128d3511" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;beginning of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08e1667c-80d6-4206-b534-fe06c8b7625e" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0887133-caff-4385-a62d-01e2d022ff62" contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e47f811-449b-4f63-a766-359d3dee193a" contextRef="C_07dde341-6b8e-4d35-a0a4-24bc46311598" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,358</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;end of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3fb8f1c-c8d5-4202-8d98-9e59fbc6d981" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b034d1b9-26a1-4ade-b810-b406adea315b" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d66fe369-db97-409a-a6c8-e6fa8565e9c6" contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash equivalents reported within the consolidated balance sheets that sum to the total of the amounts shown in the consolidated statements of cash flows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.412%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:9.422%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:9.442%;"/>
    <td style="width:1%;"/>
    <td style="width:1.76%;"/>
    <td style="width:1%;"/>
    <td style="width:9.482%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cae6e758-3b5e-4a83-8de9-bb32d8d0c5ce" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,394</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33b0495b-bae9-42ba-822c-af257edce7e1" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7791ab0-4b69-4fa7-a701-aeebd815194c" contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16577908-adb9-478a-a981-b4fc55340bb0" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f23c04d-3ca9-4d25-a06e-7175381ad3e1" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86417aea-9f37-4814-a3e6-a6a78149fa80" contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7703d346-60df-435f-99c6-b55aa6197a4e" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f688a25-49b7-4e7e-8e47-8feff69844ed" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6be7a242-e00f-4b93-a61a-1d3ee994037c" contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental disclosures of cash flow information (Note 17).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c22bc0b-6b50-4e24-b305-90456bc49bbf" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc. (&#8220;the Company&#8221; or &#8220;Syndax&#8221;) is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's two lead product candidates are revumenib and axatilimab. The Company is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, (&#8220;KMT2Ar&#8221;), also known as mixed lineage leukemia rearranged, (&#8220;MLLr&#8221;), acute leukemias including acute lymphoblastic leukemia, (&#8220;ALL&#8221;), and acute myeloid leukemia, or AML, and nucleophosmin 1, also known as NPM1, mutant AML. The Company is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The Company is developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor, (&#8220;CSF-1R&#8221;), in chronic graft-versus-host disease, (&#8220;cGVHD&#8221;), as well as idiopathic pulmonary fibrosis, (&#8220;IPF&#8221;). The Company plans to continue to leverage the technical and business expertise of its management team and scientific collaborators to license, acquire and develop additional therapeutics to expand its pipeline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company&#8217;s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it will be several years before any of its product candidates is approved, if ever, and the Company begins to generate revenue from sales of such product candidates. Accordingly, management expects to incur substantial losses on the ongoing development of its product candidates and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management believes that the cash, cash equivalents and short-term investments balances as of December 31, 2023, should enable the Company to maintain its planned operations for at least 12 months from the issuance date of these financial statements. The Company&#8217;s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds were not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and selling, general and administrative activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to challenges and risks specific to its business and ability to execute on the strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of the Company&#8217;s late-stage product candidate; delays or problems in the supply of the Company&#8217;s products, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing the Company&#8217;s intellectual property rights; complying with applicable regulatory requirements.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a48757d7-732f-475a-93d5-69226bf88e03" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" continuedAt="F_a48757d7-732f-475a-93d5-69226bf88e03_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_a48757d7-732f-475a-93d5-69226bf88e03_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has prepared the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </span></ix:continuation></span><span style=""></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0eeaa7a6-0ff7-4d63-81cb-50312f315a10" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_099713ed-c4b2-4dad-ac78-ec8ab6eb21d1" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:UseOfEstimates" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s consolidated financial statements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f716aeee-3947-4697-a207-9bf5a52e651b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents include all highly liquid investments maturing within 90 days or less from the date of purchase. Cash equivalents include money market funds, corporate debt securities, U.S. government agency notes, and overnight deposits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a898836d-b42e-4d91-8073-991a37725d49" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_492cec17-f51e-474d-88ab-f62816a189f2" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> All investments in marketable securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses excluded from earnings and reported net of tax in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. Unrealized losses that are determined to be other-than-temporary, based on current and expected market conditions, are recognized in earnings. Declines in fair value determined to be credit related are charged to earnings. The cost of marketable securities sold is determined by the specific identification method.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc676cd9-783e-4446-b93f-18c31f610309" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ffafec2-4da9-47fb-abf5-fb783d0ead24" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d10f854-076b-4993-842f-82a61ae35d2e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents, restricted cash, and short and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company&#8217;s cash, cash equivalents, and short and long-term investments were deposited in accounts at two financial institutions, and at times, such deposits may exceed federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#8217;s available-for-sale investments primarily consist of government money market funds, corporate debt securities, commercial paper, credit card asset-backed securities and overnight deposits and potentially subject the Company to concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d24d114-6e8c-451d-92e6-d04e99469eff" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0e6f7b74-b212-412d-a290-cfa9eb6e858f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb1798ad-d15a-477b-ae87-aa1ecd110033" contextRef="C_d5b70f38-d948-41d2-b18c-a03562f8c1ad" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). Assets under capital leases are amortized over the shorter of their useful lives or lease term using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_310c46c4-060c-4985-9921-39a09c1c3c97" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value. To date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73573a35-28e0-4f93-bff3-8fe7490389bd" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:TangibleAssetImpairmentCharges" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such impairments have been recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c1a82fc-d310-46bd-89db-4290893229b2" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true" continuedAt="F_4c1a82fc-d310-46bd-89db-4290893229b2_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. The Company recognize revenue following the five &#8211; step model prescribed under FASB Accounting Standards Codification (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASC 606), Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: (i) identify contract(s) with customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Revenue from non-refundable, up-front fees allocated to the licenses related to the Company's intellectual property, are recognized as the license is transferred to the customer and the customer is able to use and benefit from the license. This generally takes place over the related know-how transfer period, or if applicable, over the term of transfer of future updates to the intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Development Milestone Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company evaluates whether milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license fees and earnings in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commercial Milestone Payments and Royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: For arrangements that include sales-based royalties, including milestone payments based on the level of commercial sales, and the license is deemed to be the predominant item to which the royalties or commercial milestones relate, the Company will recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date no commercial milestone payments or royalties have been achieved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When no performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability. Upfront payment contract liabilities resulting from the Company&#8217;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4c1a82fc-d310-46bd-89db-4290893229b2_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information on our collaboration and license arrangements, please read </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 4, Collaborative Research and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to these consolidated financial statements. </span></ix:continuation></span><span style="font-size:10pt;font-family:Times New Roman;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28ca995c-a577-45f7-ab1c-114bf8993e9b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include payroll and personnel expenses, consulting costs, external contract research and development expenses, and allocated overhead, including rent, equipment depreciation, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. The Company expenses upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In instances where the Company enters into cost-sharing arrangements, all research and development costs reimbursed by the collaborators are accounted for as reductions to research and development expense. During the years ended December 31, 2023 and 2022, the Company has incurred external costs related to Incyte cost-sharing collaboration. During the year ended December 31, 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company incurred </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_baa6705c-7f69-4984-ae0c-ac2c0325ad39" contextRef="C_8240772c-7e9d-4f0c-9469-d94e57373408" name="sndx:CostsRelatedToCostSharingCollaborations" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> external costs related to cost-sharing collaborations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49f211de-582d-489f-aa17-2616fde6a8bd" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:ClinicalTrialCostPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical study and trial costs are a component of research and development expenses. The Company expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific contract tasks using data such as patient enrollment, clinical site activations, or other information provided to us by our vendors. Depending on the progression of the contract and timing of invoicing and payment the research and development expense can be an accrued expense or a prepaid expense. Prepaid clinical study and trial costs are included in short-term deposits on the accompanying consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58eb5c03-abc7-4493-9c35-c3ef4b36d732" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax bases of assets and liabilities and for loss and credit carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is provided to reduce the net deferred tax assets to the amount that will more likely than not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfed8db2-112b-4230-b708-91b95d86b382" contextRef="C_297b9be3-9752-4119-bccd-c1340527438c" name="sndx:PercentageOfIncomeTaxContingencyRealized" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d803ae9-7cf7-49de-839f-a97ecaca6159" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Guarantees and Indemnifications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. The Company has standard indemnification arrangements under office leases (as described in Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to these consolidated financial statements) that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the Company&#8217;s lease. Through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had not experienced any losses related to these indemnification obligations and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7991757-719c-4155-b524-efd38d5cd55e" contextRef="C_6644a9fe-b908-416a-b736-f657bd63cd2b" name="us-gaap:LossContingencyPendingClaimsNumber" unitRef="U_Claim" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0942e069-07e3-4965-bc5e-6e30311ff2e6" contextRef="C_22fc27d0-840a-44e9-bbda-98d42fe3a807" name="sndx:IndemnificationObligationsClaimsReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related reserves were established.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b66291a-6448-4951-8d60-fe1e92cf8829" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for all stock option awards granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value of the stock option grants and is recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved. The Company accounts for forfeitures as they occur.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77736f33-020f-4a6f-aeda-5567e788ea55" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_77736f33-020f-4a6f-aeda-5567e788ea55_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Loss) Earnings Per Share</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_77736f33-020f-4a6f-aeda-5567e788ea55_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic earnings per share is computed by dividing undistributed net income attributable to Syndax by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cb2372d-40bb-4d80-948c-ab3b914f1151" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ed644b8-ad26-4414-a34f-64b482bd9308" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:CollaborativeResearchAndLicenseAgreementsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Collaborative Research and License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incyte Collaboration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, the Company entered into license and collaboration agreement (the "Incyte License and Collaboration Agreement") with Incyte Corporation ("Incyte") covering the worldwide development and commercialization of axatilimab. Also, in September 2021 the Company entered into a share purchase agreement with Incyte, ("Incyte Share Purchase Agreement" and together with Incyte License and Collaboration Agreement, the Incyte Agreements"). Under the terms of the Incyte Agreements, Incyte will receive exclusive commercialization rights outside of the United States, subject to its royalty payment obligations set forth below. In the United States, Incyte and the Company will co-commercialize axatilimab, with the Company having the right to co-promote axatilimab with Incyte, subject to the Company&#8217;s exercise of its co-promotion option. Incyte will be responsible for leading all aspects of commercialization of axatilimab in the United States. The Company and Incyte will share equally the profits and losses from co-commercialization efforts in the United States. The Company and Incyte have agreed to co-develop axatilimab and to share development costs associated with global and U.S. &#8211; specific clinical trials, with Incyte responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5967dca2-fb0a-4527-8938-4e053d2ec6ac" contextRef="C_72227cf4-0a6a-4050-89fc-fc52e7d77a79" name="sndx:DevelopmentCostsAssociatedWithClinicalTrials" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of such costs and the Company responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd92d8fb-35fa-4fc0-b914-191fb82bd9b3" contextRef="C_4bd80ba5-9483-4290-bd6b-8b3b7622307a" name="sndx:DevelopmentCostsAssociatedWithClinicalTrials" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of such costs. Each company will be responsible for funding any of its own independent development activities. Incyte is responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b69bf6b-75ca-42f1-825d-901cb8614408" contextRef="C_784acd93-e389-42e6-b562-fe5fa32789cf" name="sndx:DevelopmentCostsAssociatedWithClinicalTrials" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of future development costs for trials that are specific to ex-U.S. countries. All development costs related to the collaboration with Incyte will be subject to a joint development plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Incyte Agreements, in December 2021, Incyte paid the Company a non-refundable cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e8c5491-18b9-4976-95f8-e209b901ab00" contextRef="C_8e4ddcb8-8500-42e0-9874-81661d600b3a" name="sndx:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">117.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5827f76-17e7-4c07-9a36-e0db1a0e1bba" contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,421,523</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with an aggregate purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfc91ade-8af5-4d40-ba91-d57da8c64c1b" contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42cc179d-c6d3-4dd4-a40d-125fc85e28c4" contextRef="C_0ac7d980-2b3e-46ff-96cc-410f348499f9" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.62</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Additionally, under the terms of the Incyte Agreements, the Company is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e7051a2-0b8b-43b4-9a85-a7cceb3e3e4f" contextRef="C_abcfbe51-431c-4e69-83e7-98632aac4ec0" name="sndx:PotentialMilestonePaymentsUponAchievementOfMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">220.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in future contingent development and regulatory milestones and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1172761-e452-4a49-ae64-f3c930e46c92" contextRef="C_abcfbe51-431c-4e69-83e7-98632aac4ec0" name="sndx:CommercializationMilestonesAndTieredRoyalties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">230.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commercialization milestones as well as tiered royalties ranging in the mid-teens percentage on net sales of the licensed product comprising axatilimab in Europe and Japan and low double digit percentage in the rest of the world outside of the United States. The Company's right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of licensed patent rights covering the licensed product in that particular country, (b) a specified period of time after the first post - marketing authorization sale of a licensed product in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Incyte Agreement and the Incyte Share Purchase Agreement were executed on the same date and negotiated simultaneously. Management therefore concluded that the Incyte Agreements are to be combined for accounting purposes and therefore allocated the total consideration to the units of account identified. The common stock issued to Incyte was recorded at fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64754950-a238-4c0d-b217-2cbbd8e55773" contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Pursuant to the Letter Agreement, Incyte is permitted to terminate the Incyte Agreement, under circumstances under which the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ae48f44-e627-46b1-8932-48526fb9caaa" contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b" name="sndx:UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">117</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million would be returned to Incyte and a cash settlement on the sale of the Company's common stock would be made to make the parties whole (the &#8220;Letter Agreement&#8221;). In connection with the closing of this transaction in December 2021, the Company determined that the cash settlement feature of the Letter Agreement represented an embedded derivative requiring bifurcation and separate accounting recognition at fair value. The Letter Agreement terminated in March 2022. Accordingly, the Company initially allocated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95299003-9e3a-4f71-a6a7-08ade6e120bb" contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b" name="sndx:CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the total consideration received to the derivative liability. As of December 31, 2022, the fair value of the derivative is zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluated the terms of the Incyte Agreement and determined it is within the scope of Accounting Standard Update </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018-18, Collaborative Arrangements (Topic 808)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and has elements that are within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 808</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company identified the following promises in the Incyte Agreements that were evaluated under the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: (i) delivery of a license for axatilimab to develop, commercialize, and conduct medical affairs and (ii) services to be performed in accordance with the development plan. The Company also evaluated whether certain options outlined within the Incyte Agreements represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Incyte and therefore are not considered separate performance obligations within the Incyte Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the above promises and determined that the license for axatilimab represents the only performance obligation within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The license for axatilimab is considered functional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intellectual property and distinct from other promises under the contract as Incyte can benefit from the license on its own or together with other readily available resources. The services performed by the Company to obtain regulatory approval of axatilimab are not complex or specialized, could be performed by another qualified third party, are not expected to significantly modify or customize the license given that axatilimab is late-stage intellectual property that has completed its Phase 1/2 trial and is currently enrolling in a global pivotal Phase 2 trial, and the services are expected to be performed over a short period of time. Therefore, the license represents a separate performance obligation within a contract with a customer under the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at contract inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers the collaborative research and development activities and manufacturing activities to be separate units of account within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 808</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and are not deliverables under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company and Incyte are both active participants in the activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities in the arrangement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company identified contract promises for the license of intellectual property and know-how rights for axatilimab. The Company determined that the license was capable of being distinct from the ongoing collaboration activities. After the allocation to the common stock and derivative liability, the total transaction price to be allocated to the Incyte Agreement is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47ca9c3b-cda2-498a-af6b-7e29a288aee8" contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b" name="sndx:CollaborationAndLicenseAgreementConsiderationTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">126.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company estimated the standalone selling price of the license to be the entire $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81bbf944-2b61-4322-b65b-49b42ee321d7" contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b" name="sndx:EstimatedStandaloneSellingPriceOfLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">126.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, based on an application of the income approach by measuring the fair value of the discounted cash flows from commercialization. Significant assumptions included in the valuation included judgments relating to the probability of achieving both regulatory and commercial milestones, forecasted future cash flows and the election of the discount rate. As the Company concluded the license was distinct, revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e61f006b-f9c0-4153-9dd7-98bb6885ba41" contextRef="C_007add38-cb78-4807-8ceb-0a17db3708dd" name="sndx:RevenueRecognizedUponTransferOfLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">126.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized upon transfer of the license to Incyte in the year ended December 31, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential preclinical, development, and regulatory variable consideration milestone payment under this agreement is zero, as achievement of those milestones is uncertain and highly susceptible to factors outside the Company&#8217;s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based royalties, including milestones based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate. The company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Company considers the collaborative research and development activities and manufacturing activities to be separate units of account within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 808</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and are not deliverables under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company and Incyte are both active participants in the activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities in the arrangement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e586a21-aa17-4261-b6e5-248b8c686992" contextRef="C_6fa3ac50-99f5-4a54-9d47-385cab5f80e9" name="sndx:CollaborationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a collaboration receivable due from Incyte related to the Company's development and pre-commercialization costs under the Incyte Agreements and has recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8163d2c-7611-453f-9bc6-36edd30ab4ad" contextRef="C_6fa3ac50-99f5-4a54-9d47-385cab5f80e9" name="sndx:CollaborationExpenseDueToCounterparty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a collaboration payable due to Incyte for development and pre-commercialization costs incurred by Incyte as of December 31, 2023. Both expenses and cost offset are recorded as part of research and development and selling, general and administrative expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a52eaa7-bd0f-4682-83dd-9110a77d9e33" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for leases in accordance with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASC 842, Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and determines whether an arrangement is a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. For leases that do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The ROU asset also includes any lease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company identified three existing long-term building leases under ASC 842 that are classified as operating leases. In September 2016, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f706b3a-8041-4adb-af97-d82a8154496a" contextRef="C_f35290a2-0231-4805-aa9a-709a7b059991" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0cd7ae3-0289-4543-8e4b-e1607e2911aa" contextRef="C_f35290a2-0231-4805-aa9a-709a7b059991" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">12,207</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in Waltham, MA, with a lease commencement date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_058311a0-2f9f-4fe4-8b84-c8f2cabbe0ac" contextRef="C_02ca18d5-fa6f-4bfb-a876-c093b9ca6330" name="sndx:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2017</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bba6e7b7-7b09-4e14-bb43-4ba494122d66" contextRef="C_0d97a76a-d900-4c17-babb-1f3067aebaca" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 17, 2021, the Company signed a 36-month extension to the lease for the Waltham, MA office with aggregate payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4550e691-4cca-4d79-be1b-06a3aaef2b21" contextRef="C_76ed7aa3-1ed8-4f3a-a48f-60eaa77cb270" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with a lease commencement date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db83ca62-25c9-4943-bc25-af017dcb7cd1" contextRef="C_76ed7aa3-1ed8-4f3a-a48f-60eaa77cb270" name="sndx:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2015, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_169339ce-0987-456f-af6d-b0b42b0f45aa" contextRef="C_1fc4e017-06d9-47f7-8d2d-9de747aea836" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1fb3016-8ce2-4a92-a6b5-c89ef72c4be3" contextRef="C_1fc4e017-06d9-47f7-8d2d-9de747aea836" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">4,039</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of space in New York, NY, which commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fe6a37d-f975-4f4c-b7b8-ef28d5a6ca0b" contextRef="C_66e29f85-4ac7-49ec-9bd3-2f763f1d6dfa" name="sndx:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2016</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In February 2021, the Company signed an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_973e6232-a3ce-4a72-a59a-935f0f8d9ada" contextRef="C_12411cb5-5f6c-4911-b870-4a0f20b18078" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month extension to the lease for the New York office, which commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8c03bf9-9516-4040-9649-c258224ebf45" contextRef="C_00ddaa2a-3337-45b1-b374-1c84e826418c" name="sndx:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In August 2022, the Company signed a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04baecb4-11a2-4bce-bda7-209045294230" contextRef="C_51f40d68-fa17-4b98-aa7c-a40331129e97" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month extension to the lease for the New York office, with aggregate payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08357b12-e32f-456c-8872-7805133f1204" contextRef="C_84340f1a-f771-4068-83fa-b64ee4e714f5" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">689,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with a lease commencement date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b51ad27d-8e6d-472a-a6b6-a163e60b0e4a" contextRef="C_84340f1a-f771-4068-83fa-b64ee4e714f5" name="sndx:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5be2adda-67b0-45dd-a04d-944b011f3725" contextRef="C_03aeaecd-5be7-490b-86d3-d29870f2e796" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month operating lease f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66ec374b-74b7-45fa-a83a-9adafb4ae3dd" contextRef="C_03aeaecd-5be7-490b-86d3-d29870f2e796" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">12,217</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sq</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uare feet of space in New York, NY, with aggregate payments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c63786c-0f17-4c45-b7be-89111541a91c" contextRef="C_0733728d-ca28-4bce-89bd-0ce117dade3e" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with a lease commencement date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ba0fc96-6566-4ee2-b437-508c00e14702" contextRef="C_0733728d-ca28-4bce-89bd-0ce117dade3e" name="sndx:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remaining lease terms as of December 31, 2023, for the facility in Waltham, MA and the two facilities in New York, NY, were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d85560df-1301-4730-89be-3923efd503fc" contextRef="C_fd52ffb1-9775-4773-a4a5-24f8f2743b17" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b900ea8d-f559-4e66-948a-ce24a2c098c5" contextRef="C_2e5821c0-1935-43a7-b0ba-c858e0c7d907" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the consolidated balance sheet includes a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_163d61d0-f806-4774-a86f-4196f486f93e" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating lease ROU asset and a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0a51645-da5c-4f64-90d7-153cf0ef963b" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ROU liability. The Company used a weighted average discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34c63128-4911-41d0-bb99-b8437cebc1b9" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to calculate its lease obligations, and an increase or decrease in the rate does not have a significant impact on the ROU asset or ROU liability. The ROU asset is amortized on a straight-line basis over the remainder of the lease term. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b28d3a06-84e9-4926-a7c5-4c9dc8849faa" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">743,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in operating lease expense and made approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bde2f449-ee41-469f-adc7-0b992784fe4e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">924,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in lease payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db40cab2-8f0f-4307-8d36-f7754aecaf51" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the Company&#8217;s operating leases, were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;"/>
        <td style="width:3.401%;"/>
        <td style="width:1%;"/>
        <td style="width:39.208000000000006%;"/>
        <td style="width:1%;"/>
        <td style="width:3.401%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa2564fe-2590-4e7d-ad55-fc2a8e41f3e6" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,196</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e65ebc7-2092-4905-a7e8-1c8a635d34ba" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67f90d6d-b5d4-4d3c-a8de-d2973660f59c" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c740c0a-e152-4ec0-9099-8cfe40bf9107" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,802</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d66d4e9-f706-4ace-b609-0e18e06fa730" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb519ed3-d7ef-41d2-b896-35a7ab9c6480" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the Company&#8217;s capital leases as of December 31, 2023 and 2022, were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f80c76a-baa8-43c1-b6e7-850cacb9bcc3" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,864</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f6330d5-cf8b-47bf-8a2d-4be174e66858" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,441</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8aa2d22f-8f38-4164-902f-55b2d0bf1461" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. (Loss) Earnings per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54982a5c-8abb-44c5-a912-edc372c4f540" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted (loss) earnings per share are calculated as follows (in 000s):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.352%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:9.902000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:9.022%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62f8e7f0-3245-42ef-88d0-f60346e9d7a0" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,360</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bd5eecf-812a-4fff-b5fc-169bc0c64781" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,338</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_428161a0-9c6f-4278-8e75-5780a019275c" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,926</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b7a9da7-6e80-43a8-9f1f-c663d11d0ecb" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,360</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c02cc855-a6c2-46e0-bc86-e372e648c98d" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,338</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5da5e785-974f-4d6f-b21c-c79075818870" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,926</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88bf2ad6-4eeb-4b96-be88-0da49eddcee0" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,371</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd8eff4a-c3ae-4509-88c5-d2c33080e195" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,761</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf675e7c-8326-4d94-9cbb-cba7f7a7214b" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,065</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective of Dilutive Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e37a5ab-205c-499a-98d2-822a9236ea38" contextRef="C_6ff18d23-59d3-47d1-9c4b-5af2583db483" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,429</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non - vested restricted stock units (RSUs)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d53564f-d952-44d0-b2cb-0ebc9e0f7b57" contextRef="C_6963fa61-8ec6-4bd0-aa49-52db5ff91e9b" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF">118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6a47c1c-5d45-499a-bb82-b49a0f901d32" contextRef="C_26c0fc6f-728e-49e8-824f-78d32eaa25c6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive potential common shares</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c1d644c-864c-4c16-8dad-fbca8bd58374" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Shares used in calculating diluted (loss) earnings per share</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f94308c-e7cb-45d0-a143-abab2043ca23" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,371</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1a00ea0-510d-4579-9b07-6727eecdc346" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,761</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e3914fb-841a-414f-8062-b3fdd1c9f4fb" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,623</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_389f4f48-50ab-4774-a918-d7a245fde56a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in 000s):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.34%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:10.36%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:9.5%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:9.74%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c34434f-23e2-497e-a496-859d8630983b" contextRef="C_5b6fd47e-9446-44a8-8162-95fdb9778785" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,685</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bea7473-c4d0-41ef-be1e-06412cb2033f" contextRef="C_382491e5-93f3-4c43-b99a-07ae7ae81dd4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f85de70b-d673-4dad-92bb-f9daada57d54" contextRef="C_2e0f6494-687d-4fd7-836a-90f591faf296" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested RSUs</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2862681f-9304-4f9f-aa67-cee39c2f602a" contextRef="C_a02bc65a-614e-4743-902b-962e339de54c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">309</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d84f05c2-b07b-4110-9920-7d5b0eb92b27" contextRef="C_f4d0fa56-19c4-4e1e-be2c-7d22cb6fdd00" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_558a13d4-054c-471d-96cd-526e8c3961b7" contextRef="C_8a5e0f58-65f4-485e-beb0-bd6d07cb0472" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bba4765-724c-47ff-a617-6098aef5dc0c" contextRef="C_e4be5e2a-ca86-4e3c-b7a9-c1323e17fe48" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5edfe43b-c2a5-4cab-a52a-dc18cb96f4d8" contextRef="C_7b7db385-57f7-42af-835a-310ebe8bfb57" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58251fda-0823-42a7-8e64-f307effe1954" contextRef="C_113325fa-4d36-4203-99b1-36c13868211f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information related to the Company's common stock see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 12, Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f37d0864-f2d6-4fcf-86c9-e774e463cf1d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:SignificantAgreementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Significant Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vitae Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2017, the Company entered into a license agreement (the &#8220;Allergan License Agreement&#8221;) with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan (&#8220;Allergan&#8221;), under which Allergan granted the Company an exclusive, sublicensable, worldwide license to a portfolio of preclinical, orally available, small molecule inhibitors of the interaction of menin with Mixed Lineage Leukemia (&#8220;MLL&#8221;) protein (the &#8220;Menin Assets&#8221;). The Company made a nonrefundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_678fc3cb-f58a-4b32-9373-6e0a9028bbfd" contextRef="C_65848bf9-3945-493c-98fa-73d365aadae6" name="sndx:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Allergan in the fourth quarter of 2017. Additionally, subject to the achievement of certain milestone events, the Company may be required to pay Allergan up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaf7c472-0872-41d2-967a-beebba1e86da" contextRef="C_40e59aaf-8789-463b-945c-25dc7a6c94bd" name="sndx:PotentialMilestonePaymentsUponAchievementOfMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">99.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in one-time development and regulatory milestone payments over the term of the Allergan License Agreement. In the event that the Company or any of its affiliates or sublicensees commercializes the Menin Assets, the Company will also be obligated to pay Allergan low single to low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ddbe3b4-dbbc-411b-ae81-62e2549e7ecf" contextRef="C_40e59aaf-8789-463b-945c-25dc7a6c94bd" name="sndx:AggregatePotentialMilestonePayable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">70.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in potential one-time, sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, the Company may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with Allergan. The Company is solely responsible for the development and commercialization of the Menin Assets. Each party may terminate the Allergan License Agreement for the other party&#8217;s uncured material breach or insolvency; and the Company may terminate the Allergan License Agreement at will at any time upon advance written notice to Allergan. Allergan may terminate the Allergan License Agreement if the Company or any of its affiliates or sublicensees institutes a legal challenge to the validity, enforceability, or patentability of the licensed patent rights. Unless terminated earlier in accordance with its terms, the Allergan License Agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ea2e841-0852-41fc-b5dc-a382993c7410" contextRef="C_65978307-b055-4116-8a9e-5b4d03aedbd6" name="sndx:LicenseAgreementsExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the date of the first commercial sale of the product in such country.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of the Allergan License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility. As the processes or activities that were acquired along with the license do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset acquisition. As a result, in 2017, the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2144a0cc-d997-4b82-883d-40ad7361f4ca" contextRef="C_bda1e555-b0cf-4f5d-88a3-0159c9f3b0d3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as research and development expense in the consolidated statements of operations. Since the inception of the agreement, the Company achieved certain development and regulatory milestones resulting in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29e2afe3-8ee6-43a1-9f25-daeac85f5ff4" contextRef="C_b2f341e1-b250-4994-9c50-93dfdd23e649" name="sndx:DevelopmentAndRegulaotryMilestonesExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in expense, which included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ad94e4b-0365-42bf-addc-01da3c351ce2" contextRef="C_b2f341e1-b250-4994-9c50-93dfdd23e649" name="sndx:MilestoneExpensesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million paid in the first quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">UCB Biopharma Sprl</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2016, the Company entered into a license agreement (the &#8220;UCB License Agreement&#8221;) with UCB Biopharma Sprl (&#8220;UCB&#8221;), under which UCB granted to the Company a worldwide, sublicensable, exclusive license to UCB6352, which the Company refers to as axatilimab, an Investigational New Drug Application-ready anti-CSF-1R monoclonal antibody. The Company made a nonrefundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1012e9c0-b8b2-49b8-ade0-3f99c2be30d8" contextRef="C_9897c974-eaaf-4ce1-84bb-983cacae668c" name="sndx:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to UCB in the third quarter of 2016. Additionally, subject to the achievement of certain milestone events, the Company may be required to pay UCB up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62f6cc45-26de-4d7e-842d-d85cdaa50337" contextRef="C_24de1833-922d-42e7-b50e-b99703d2a57a" name="sndx:PotentialMilestonePaymentsUponAchievementOfMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">119.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in one-time development and regulatory milestone payments over the term of the UCB License Agreement. In the event that the Company or any of its affiliates or sublicensees commercializes axatilimab, the Company will also be obligated to pay UCB low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f1a063b-704f-4ab5-8af1-b0b5e9b47369" contextRef="C_24de1833-922d-42e7-b50e-b99703d2a57a" name="sndx:AggregatePotentialMilestonePayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in potential one-time, sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, the Company may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with UCB. The Company will be solely responsible for the development and commercialization of axatilimab, except that UCB is performing a limited set of transitional chemistry, manufacturing and control tasks related to axatilimab. Each party may terminate the UCB License Agreement for the other party&#8217;s uncured material breach or insolvency; and the Company may terminate the UCB License Agreement at will at any time upon advance written notice to UCB. UCB may terminate the UCB License Agreement if the Company or any of its affiliates or sublicensees institutes a legal challenge to the validity, enforceability, or patentability of the licensed patent rights. Unless terminated earlier in accordance with its terms, the UCB License Agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_440ed2b1-1cb4-4643-83de-94c6966f29b5" contextRef="C_0d5d3e07-b0b8-4bc6-b16b-19628d2c4e5d" name="sndx:LicenseAgreementsExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the date of the first commercial sale of the product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of the UCB License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility. As the processes or activities that were acquired along with the license do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset acquisition. As a result, in 2016, the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17a78484-5643-4ffc-aeb5-253bec967052" contextRef="C_4d702b7c-2eb0-4b1b-9fdd-4c94f41fbc74" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as research and development expense in the consolidated statements of operations. Since the start of the license agreement, the Company achieved certain development and regulatory milestones and has recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e53fad42-cc96-4229-89db-30d950e0df18" contextRef="C_f48e2289-7c74-4e8f-bb83-8c460905d6be" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as research and development expense. Additionally, in connection with its most recent amendment of the UCB License Agreement, in the second quarter of 2022 the Company paid UCB $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1703637-19c4-44ed-aa6d-462a67911da3" contextRef="C_f5a2c5e6-ee95-4e95-ac72-df05f5b19d1a" name="sndx:MilestonePaymentDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is recognized as a milestone expense. In the fourth quarter of 2023, UCB achieved a development and regulatory milestone resulting in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c69c5671-c4d9-466d-8d20-84098e8a9c25" contextRef="C_fe987b96-157e-484d-ab17-c2d98a5f8ce5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expense, which has been recorded in accrued expenses as of December 31, 2023. The Company paid the amount to UCB in the first quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bayer Pharma AG (formerly known as Bayer Schering Pharma AG)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2007, the Company entered into a license agreement (the &#8220;Bayer Agreement&#8221;) with Bayer Schering Pharma AG (&#8220;Bayer&#8221;) for a worldwide, exclusive license to develop and commercialize entinostat and any other products containing the same active ingredient. Under the terms of the Bayer Agreement, the Company paid a nonrefundable up-front license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_115b0353-100f-43fc-90c5-1e268658a504" contextRef="C_c7c24763-4fb0-48dc-a5f9-391a27f7a6e7" name="sndx:UpfrontLicenseFeesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is responsible for the development and marketing of entinostat. The Company recorded the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6581a953-6309-4d95-9b70-9892313064e4" contextRef="C_29366536-a819-434b-97a9-ff39b709d103" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million license fee as research and development expense during the year ended December 31, 2007, as it had no alternative future use. The Company will pay Bayer royalties on a sliding scale based on net sales, if any, and make future milestone payments to Bayer of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7d5aa38-95ce-4d14-b3be-01817a334453" contextRef="C_bc34cf4d-0ad9-4ca8-abcc-8a189f682e20" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the event that certain specified development and regulatory goals and sales levels are achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa27265f-dc3e-41c6-854b-fcf4b3c1693a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Property and Equipment, net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ed08bed-99b0-4eb4-a6d7-b56d3028c929" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:9.200000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:9.200000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_599b71b6-432b-48c6-8a14-babba9caef17" contextRef="C_34717b5e-c295-4ed1-ac0e-58d0e54bae5b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0e22e03-2506-47e0-b16c-bd4bcb09a5c5" contextRef="C_03d34840-d717-4c96-9735-0033d3f99ef2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9bcda3b-bfd4-4a41-9001-738f2bbeb710" contextRef="C_faebc9a2-2fb9-4f9c-a490-ab75ff58a5e6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a072e33-48fa-4de2-ba95-85abf67ffd22" contextRef="C_e51750f9-2ca2-48a3-9d96-269b2ec8e4b2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7bad042-6d59-4aa4-9f01-dad4531c0502" contextRef="C_e1753470-c399-4d8b-ad2e-484c414ecc39" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac5f6cc0-f42d-4e5a-89b0-260e51f1a086" contextRef="C_c271aab5-a01e-42fd-86b6-0377aa3b4a22" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b554c07-a9b4-4635-b77d-02f92ea8c5c7" contextRef="C_6da63ab9-2ebc-46a8-b7da-7c40838fae15" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6f1a65a-983d-4a7f-9c25-8049cac7abef" contextRef="C_b690c391-1b7b-4548-a001-dbef6009526c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bc3ff39-355b-445b-b01b-4f57656b2b38" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4c26f3f-43d6-475a-8905-6ef452918c46" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64720435-e68a-4fa7-bebb-358c96132ac2" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1256aea-e07d-4b37-a1a5-646d2a6458fd" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">399</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0804304a-9d45-4235-83cb-3777ac9e3263" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2e26346-f9e7-4243-a5ef-d31a60bf09ee" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bde99d8-6c54-4f9a-a76a-7812d2d14ffc" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc18e627-7231-4512-a8b1-5c806f779151" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_243192c7-4902-4cbd-8f9a-917903fe1b6d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash and cash equivalents, restricted cash, accounts payable, and accrued expenses approximated their estimated fair values due to the short-term nature of these financial instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quoted prices (unadjusted) in active markets that are accessible at the market date for identical unrestricted assets or liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4989e8d-0cc5-4ac3-850b-1716ec22094b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques the Company utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.411%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:9.798%;"/>
        <td style="width:1%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:9.798%;"/>
        <td style="width:1%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:9.798%;"/>
        <td style="width:1%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:9.798%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Carrying<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b9ffb74-7af5-4361-be13-ae91be703765" contextRef="C_6cacdbd9-72ea-4585-80a2-d53f1908716b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,394</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6894b061-8af8-46cc-8cca-df53433348c0" contextRef="C_e9760b9c-06c7-4dcd-b0bf-ccb9fd1298a2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,394</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bfa1b97-d63b-4baf-afb2-dbfb0e32ef99" contextRef="C_6cacdbd9-72ea-4585-80a2-d53f1908716b" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275,304</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b766162-2e18-4db7-8bcd-962bd54ca3ab" contextRef="C_41f595f4-58d1-4879-8f5e-6bf3c89f425e" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275,304</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fb874ea-e5fc-4076-bf3d-f7b01677a7ff" contextRef="C_6cacdbd9-72ea-4585-80a2-d53f1908716b" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0415f48-1d3f-4f0f-a384-b60ff96d9c90" contextRef="C_41f595f4-58d1-4879-8f5e-6bf3c89f425e" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_849322c9-e7ba-4aa0-bf71-85c97623843b" contextRef="C_6cacdbd9-72ea-4585-80a2-d53f1908716b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0a4674e-e6ef-4576-b711-9edeb3d5c3b4" contextRef="C_e9760b9c-06c7-4dcd-b0bf-ccb9fd1298a2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,394</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ad5879e-e383-4aff-a79a-2177d4617bf5" contextRef="C_41f595f4-58d1-4879-8f5e-6bf3c89f425e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,133</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_371a226b-88f7-4305-94ef-e3fa64390e7b" contextRef="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,356</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cea8f4a-0956-44c5-96c0-dfcc44b71780" contextRef="C_7c5c1097-e2eb-4741-8da2-1908684c710b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,496</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4cbda32-9d39-4575-b7a6-e5f867147e4c" contextRef="C_7b2fc26e-e3b0-4306-aa00-2175018e0133" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1c8db72-2ccf-49c7-81dc-e382e4d544e9" contextRef="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401,446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca48a024-2cbe-4bb0-8cff-2cf8dd0722cc" contextRef="C_7b2fc26e-e3b0-4306-aa00-2175018e0133" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401,446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9391da86-5e39-4e20-8ca0-005903cbc3cd" contextRef="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e201247-f78d-40b1-97f3-9ea710c6a0e8" contextRef="C_7b2fc26e-e3b0-4306-aa00-2175018e0133" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4283c7a1-e700-4c56-a217-94f19f6c8ecb" contextRef="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481,271</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bec41c78-0091-495e-9fae-a4e2b02c0b62" contextRef="C_7c5c1097-e2eb-4741-8da2-1908684c710b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,496</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e8f6dbd-596f-4a47-84fb-4aa7b71b9756" contextRef="C_7b2fc26e-e3b0-4306-aa00-2175018e0133" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421,775</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no material impairments of our assets measured and carried at fair value during the years ended December 31, 2023, and 2022. In addition, there have been no changes in valuation techniques during the years ended December 31, 2023, and 2022. The fair value of Level 1 instruments classified as cash equivalents are valued using quoted market prices in active markets. The fair value of Level 2 instruments classified as cash equivalents and short and long-term investments was determined other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and fair value is determined using models or other valuation methodologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The short-term and long-term investments are classified as available-for-sale securities. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the remaining contractual maturities of the available-for-sale securities were 1 to 15 months, and the balance in the Company&#8217;s accumulated other comprehensive income was comprised solely of activity related to the Company&#8217;s available-for-sale securities. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d1a97b6-76e2-4148-99f0-9e6a414aa118" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains or losses recognized on the sale or maturity of available-for-sale securities during the three years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. As a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the same periods. The Company has a limited number of available-for-sale securities in insignificant loss positions as of December 31, 2023, which the Company does not intend to sell and has concluded will not be required to sell before recovery of the amortized cost for the investment at maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bde4e4f-258d-4613-bf2d-aa7b22169c10" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The following table summarizes the available-for-sale securities (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.235%;"/>
        <td style="width:1.879%;"/>
        <td style="width:1%;"/>
        <td style="width:10.812%;"/>
        <td style="width:1%;"/>
        <td style="width:1.879%;"/>
        <td style="width:1%;"/>
        <td style="width:10.812%;"/>
        <td style="width:1%;"/>
        <td style="width:1.879%;"/>
        <td style="width:1%;"/>
        <td style="width:10.812%;"/>
        <td style="width:1%;"/>
        <td style="width:1.879%;"/>
        <td style="width:1%;"/>
        <td style="width:10.812%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>(Losses)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38d5993c-8b3a-4c8d-abf7-9a5b49bef417" contextRef="C_89ee900b-0daa-4278-b35c-28e5ea1dacc8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,657</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fa1e6b7-deff-47e6-834c-f824969cebb9" contextRef="C_89ee900b-0daa-4278-b35c-28e5ea1dacc8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_453c7743-6a35-448c-8750-749f75a3b6c3" contextRef="C_89ee900b-0daa-4278-b35c-28e5ea1dacc8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,806</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4238851-bb87-461a-930c-c54dad16b504" contextRef="C_ae0f6773-2219-4d93-912b-9c9e98f6fd82" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d9b1420-5dbd-473a-98b6-0118181f4ba4" contextRef="C_ae0f6773-2219-4d93-912b-9c9e98f6fd82" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58b0a119-1a75-4dfc-be6a-5728043792cf" contextRef="C_ae0f6773-2219-4d93-912b-9c9e98f6fd82" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,212</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">US Treasury</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c6d4414-1ce0-438b-ae21-08dcb45fdcde" contextRef="C_6a664e17-cf9e-4ee2-bfdc-d015d6af8887" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,111</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ded489b1-6273-45fb-ba32-e8458db90bfa" contextRef="C_6a664e17-cf9e-4ee2-bfdc-d015d6af8887" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b72378d1-faaa-418f-8413-ae3fdbf8c02b" contextRef="C_6a664e17-cf9e-4ee2-bfdc-d015d6af8887" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9e0448b-2cc3-4021-877c-09ed7675c1a4" contextRef="C_7a26f97c-58f3-47db-91e7-cf5136111b06" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4be363d9-a3a1-4921-bb03-4a10944b7209" contextRef="C_7a26f97c-58f3-47db-91e7-cf5136111b06" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fe57c68-b473-4ec6-a18a-da7f099e1b47" contextRef="C_7a26f97c-58f3-47db-91e7-cf5136111b06" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,958</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcb23742-94fd-42ab-845b-a87bf8e3c2f0" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304,916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14e211ec-5486-4c82-a549-3fbf71b8f8d6" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a9f03ac-b19c-4bc4-a39d-bc82e4ecc608" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8400a493-29f3-4d1a-a0c4-d3e1f559fca6" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,133</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2649570e-b602-4868-8f5b-1e3df22085cd" contextRef="C_7641cc13-8c39-40ae-b57f-0758cc213d32" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">321,630</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_444ded94-a177-43f3-9bda-b4f1b06d6537" contextRef="C_7641cc13-8c39-40ae-b57f-0758cc213d32" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6d1aba6-50b9-4fb4-847a-d90b6fed8948" contextRef="C_7641cc13-8c39-40ae-b57f-0758cc213d32" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">321,425</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">US Treasury</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56facb17-8bca-4518-a3ca-8a1141209389" contextRef="C_6fb90d48-7668-4c0f-a774-c90206135131" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,759</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc0739aa-bc05-4639-b51c-de3061872c4d" contextRef="C_6fb90d48-7668-4c0f-a774-c90206135131" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">566</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfe0a75f-d8f6-4d34-9d8d-0384db45f793" contextRef="C_6fb90d48-7668-4c0f-a774-c90206135131" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,193</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_458f8b33-6fe9-4c43-9f8f-19a4745fb2b3" contextRef="C_22b82249-a476-47d0-8dbf-74f15062836e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab72566a-45db-4549-87f3-adf8e770c206" contextRef="C_22b82249-a476-47d0-8dbf-74f15062836e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aff022a2-0d7b-4365-84c8-d5c6484a4f58" contextRef="C_22b82249-a476-47d0-8dbf-74f15062836e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfb3a611-03ea-4a22-8583-2c88fbaf9981" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">422,581</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4cfb426-d219-44bb-a585-330a74671e8f" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">806</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86b124e7-ac8d-4873-93d6-0adada4391a9" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421,775</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92a4b7df-b2c2-4643-bb39-71b777ec5754" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:OtherCurrentAssetsTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1ce3233-e15a-4a1d-b22a-bdaf7567acc5" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.482000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:13.283000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e64fef7c-d6e8-4402-bbb2-e6a1fe63255a" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">807</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbacad30-7882-4fd8-8101-f30c89a5c8f4" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable on investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e07234e-b13f-49c5-aa02-ec58436aedae" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,227</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c71cc3ea-3f0b-448a-9f5c-734f74baeb6c" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">583</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid subscriptions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7645569d-5f84-4b4a-b453-900fdf0f795a" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:PrepaidSubscriptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">769</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f09227d-b22e-4184-82ed-9bf7c38af2c3" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:PrepaidSubscriptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid state and local taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f175158c-d7f2-465f-a597-529212941606" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:PrepaidStateAndLocalTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60a3500f-1381-4bf2-855d-2faf320f8ae7" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:PrepaidStateAndLocalTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec843635-2607-480f-acfb-a40eb4c11658" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f6ba834-7ad8-4086-8733-19ebe1e2fedd" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a1557bf-4cf7-46af-aa96-899ef49166d7" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8ab0b1c-296c-4f1f-a1eb-c1e6e65f1a2f" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd7c2d0d-7fa4-4bef-a965-27f3bc1adbb7" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,293</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef7e62e5-3500-49e7-8f32-d5b2571692ad" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,915</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dfb36a51-7667-4d5e-9b31-1c044ccdc02f" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_202b47f6-7d85-438c-960b-c390b7c6310d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.652%;"/>
        <td style="width:1.96%;"/>
        <td style="width:1%;"/>
        <td style="width:14.823%;"/>
        <td style="width:1%;"/>
        <td style="width:1.96%;"/>
        <td style="width:1%;"/>
        <td style="width:17.604%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical study and trial costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15abcaf1-045b-42c2-87cb-8abc96385753" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:AccruedClinicalCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,346</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_574a35a8-38de-4651-b1ce-49d8f52d5531" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:AccruedClinicalCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,375</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1723b45f-c166-4eb7-808e-d6da8a22b31c" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,172</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15af3325-8c92-4302-8055-3ebcb5f11404" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,945</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9104a2af-43b0-4619-bea1-bc6d4593fcd8" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00df1335-e115-49f1-a818-1e65f66133f8" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,352</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued milestone costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6ba9af4-8b0f-44b3-bdcc-267e2e9dd273" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:AccruedMilestoneCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eb8bab5-2294-4cea-bc8b-ae5920c641a5" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:AccruedMilestoneCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2274133c-cb61-42df-99aa-8f581ded7cfe" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">888</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f45afcab-357a-4f55-9cd5-8460912801cb" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expense and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_905ae9fb-7c65-48b4-96b0-4cd877945c5a" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,856</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c139be2a-67f6-4cbe-b09b-a1b1826ee0fa" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,276</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3282fc02-7897-4496-b92b-3f5b10534ec6" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:CommonStockDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb550c53-acbb-46af-b41d-0db65025dffe" contextRef="C_4e02600c-bd29-4c11-ab55-d1e0405d802e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The holders of each share of common stock are entitled to one vote per share held and are entitled to receive dividends, if and when declared by the Board, and to share ratably in the Company&#8217;s assets available for distribution to stockholders, in the event of liquidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the Company entered into a sales agreement with Cowen and Company, LLC, or TD Cowen, under which the Company could, from time to time, issue and sell shares of its common stock having aggregate sales proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f61aa55-7dbd-4101-89e0-a4336304d57e" contextRef="C_b2cdaf15-a3dd-4128-b806-5785e9adeb08" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in a series of one or more at-the-market, or ATM, equity offerings, or the 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Program. On May 26, 2023, the Company terminated the 2021 ATM Program. Prior to termination the Company sold shares under the 2021 ATM Program for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb4dc982-e9c7-416b-85e3-4acd98e7b49d" contextRef="C_916862c9-8345-48c9-8135-c267e4176f68" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company entered into a new sales agreement with TD Cowen under which the Company could, from time to time, issue and sell shares of its common stock having aggregate sales proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68162a2e-a73c-4648-a68c-eecf88131af1" contextRef="C_4373a863-e88a-4778-ad8a-e38be55f38f0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, in a series of one or more ATM equity offerings, or the 2023 ATM Program. TD Cowen is not required to sell any specific share amounts but acts as the Company&#8217;s sales agent, using commercially reasonable efforts consistent with its normal trading and sales practices. Pursuant to the new sales agreement, shares will be sold pursuant to the previous shelf registration statement on Form S-3ASR (Registration No. 333-254661), which became automatically effective upon filing on March 24, 2021. The Company&#8217;s common stock will be sold at prevailing market prices at the time of the sale, and as a result, prices may vary. In the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_be04d0db-109f-444d-90d0-6ae03b9c07ce" contextRef="C_6f419700-e28e-40c1-b23d-a0b900e72318" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,719,744</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares of common stock under the 2023 ATM Program, with net proceeds of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82664c87-c71c-4736-83f4-48bc8047498e" contextRef="C_6f419700-e28e-40c1-b23d-a0b900e72318" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_800fead2-989a-413d-b153-3c17ff6e3931" contextRef="C_af3f7b3f-463f-4a43-9924-f3224ae76c2a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,802,144</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32dcaf15-d97c-449e-a6ae-a267cf938e1b" contextRef="C_10d30f98-e352-4e95-8d0c-6ec352eb4220" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,142,856</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The offering price for the securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9286ee5b-8951-453e-80e9-b63f50f7cebe" contextRef="C_c5bfe040-8225-40e0-ac2c-1d2335fa468e" name="sndx:OfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">17.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39884d9d-c9a4-4897-9b42-37bb15426965" contextRef="C_92922bd5-099d-4ec5-8e83-d7fd9dbf0f21" name="sndx:OfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">17.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each Pre-Funded Warrant,</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eba0d67c-cdc1-483f-bcdc-3ba9c02ea630" contextRef="C_af3f7b3f-463f-4a43-9924-f3224ae76c2a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">81.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On January 24, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e712cec0-15f3-4abf-b5da-9cdcb947a6cb" contextRef="C_2b797780-f333-41ad-9804-9f77932b06b7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fcc14b8-8470-47a9-9297-9180a21bd785" contextRef="C_f8419044-984d-4ea5-bd39-f4268be140ef" name="sndx:NumberOfPreFundedWarrantsExercisedForCommonStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,998</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, under a cashless exercise. On April 12, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7b57cde-11bf-409e-8052-c877521d4cfe" contextRef="C_626a678f-9c61-4d24-8cc1-62a2dcd3abf0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">273,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4e154bc-a8a1-4a71-a7b0-48c249546f2b" contextRef="C_75ddf898-7154-4fbc-bbc2-0484c10d01f1" name="sndx:NumberOfPreFundedWarrantsExercisedForCommonStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">272,996</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, under a cashless exercise. On May 9, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83f88cf5-09aa-42f1-9f3e-c310928e9ce4" contextRef="C_3a9ae94c-95c4-4bc4-9ea1-a708c250d19f" name="sndx:NumberOfPreFundedWarrantsExercisedForCommonStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">498,142</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5869c23b-604b-4e8f-8c83-e83b7a96dbaa" contextRef="C_fee34826-8d9f-4166-a555-2a64fedf432a" name="sndx:NumberOfPreFundedWarrantsExercisedForCommonStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">498,137</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, under a cashless exercise. As of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b02a6b8-b4ed-4ea5-b14d-6297e7ccff9b" contextRef="C_96174531-bfea-4e9f-8dc3-133a02db014e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">285,714</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were considered issued and outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, in connection with the Incyte License and Collaboration Agreement and Share Purchase Agreement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1930ba17-47a6-4869-acad-62ff49f7c17f" contextRef="C_444b653e-7ff0-4aea-832b-063c09c055b5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,421,523</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, with net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_200c7844-aeca-4804-91ba-c6eae57ded4c" contextRef="C_444b653e-7ff0-4aea-832b-063c09c055b5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company recorded the equity issuance at a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b902eb2c-b566-4260-9ca2-f6bb645fc24a" contextRef="C_444b653e-7ff0-4aea-832b-063c09c055b5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on the market price of the stock on the date of issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_152bd809-0f43-4a4b-b630-962ea5b04d09" contextRef="C_14164814-000e-4a3d-8ee4-dd58a37f263b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,840,909</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The offering price for the securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_973df9f6-b5a1-4180-ace8-94e0370a61d0" contextRef="C_14164814-000e-4a3d-8ee4-dd58a37f263b" name="sndx:OfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, with gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_439f4643-466b-4668-aabe-f2bfa3fb6626" contextRef="C_14164814-000e-4a3d-8ee4-dd58a37f263b" name="sndx:GrossProceedsFromOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">172.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, offset by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0acc4633-799c-4da8-b5e8-90b419ea8673" contextRef="C_4d513726-c3ac-4260-a084-166bd284aeba" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of issuance cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf74b330-d600-4425-a146-75227b029689" contextRef="C_6a968746-243d-4b7c-af53-3e25f8258536" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,432,431</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The offering price for the securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_347a47d6-6b6f-4de8-93dc-c67b014e4c9b" contextRef="C_6a968746-243d-4b7c-af53-3e25f8258536" name="sndx:OfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, with gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c43d0af2-c4fb-4ff7-8431-43e71ea2648d" contextRef="C_6a968746-243d-4b7c-af53-3e25f8258536" name="sndx:GrossProceedsFromOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">230.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, offset by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17643c59-5f48-44fa-b4c1-e3a7c407d9e0" contextRef="C_a7ff0eef-d6fb-487a-ac3a-bd8883e7c5ec" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of issuance cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_537a0c8c-87ac-4881-940a-540f411b0f07" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has reserved for future issuance the following shares of common stock pursuant to the following outstanding securities or equity plans:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.72%;"/>
        <td style="width:1%;"/>
        <td style="width:26.28%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issuable under pre-funded warrants</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9674502d-7f2f-4571-93ab-1f5a326fa2aa" contextRef="C_96174531-bfea-4e9f-8dc3-133a02db014e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">285,714</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At-the-market program</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a1a0950-9677-4c54-b568-4ab44a25f97e" contextRef="C_8c652789-8302-4cea-ba90-91fe2cce9a9e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,280,256</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs and Options to purchase common stock</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1e0f3a6-90f1-452d-9189-73b8224c8eb5" contextRef="C_c711bf57-6128-4aae-b770-abe66d25ee43" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,204,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity plans</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36bca15f-bdea-4c6f-94f6-b87915abe583" contextRef="C_38a4d3d9-61d6-470e-85bb-48eeea883916" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,403,382</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2015 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_986f8575-e054-4c5b-abb3-4d3db7b75701" contextRef="C_7ea6052a-2eb2-4c2d-8093-dc9a96bc2333" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,732,614</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e9c94f7-2d34-4ee3-ae86-105029dbc4c8" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,906,260</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_0850ad17-12b2-45fb-9e63-a6dcb8d1945d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2015, the Company&#8217;s board of directors adopted its 2015 Omnibus Incentive Plan (&#8220;2015 Plan&#8221;), which was subsequently approved by its stockholders and became effective upon the closing of the IPO on March 8, 2016. The 2015 Plan replaced the 2007 Stock Plan (&#8220;2007 Plan&#8221;) and allows for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, dividend equivalent rights, performance awards, annual incentive awards, and other equity-based awards to the Company&#8217;s executives and other employees, non-employee members of the board of directors, and consultants of the Company. Any options or awards outstanding under the Company&#8217;s 2007 Plan remain outstanding and continue to govern the terms of any equity grants that remain outstanding under the 2007 Plan. Any shares of common stock related to awards outstanding under the 2007 Plan that thereafter terminate by expiration, forfeiture, cancellation or otherwise without the issuance of such shares will be added to, and included in, the 2015 Plan reserve amount. The Company initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf8c2842-5526-472a-9efe-cf58674f01be" contextRef="C_2da8d5ee-6ea1-4242-a4dc-afb090386702" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock for the issuance of awards under the 2015 Plan. The 2015 Plan provides that the number of shares reserved and available for issuance under the 2015 Plan will automatically increase each January 1, beginning on January 1, 2017, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_464be5cf-0936-4748-94a9-bd363bbb20c2" contextRef="C_6e76b045-86c3-442e-89f0-3831e63a85a7" name="sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company&#8217;s board of directors. On January 1, 2024, the shares available for issuance under the 2015 was increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_928cd6b1-6e39-4960-b8e7-a49198fa67d5" contextRef="C_f2aa831f-6fca-40f4-af27-257fe1eaf973" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,393,065</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, the Company's board of directors adopted its 2023 Inducement Plan (the &#8220;2023 Inducement Plan&#8221;), which became effective March 1, 2023. The 2023 Inducement Plan allows for the granting of nonqualified stock options, restricted stock units, and other awards under the 2023 Inducement Plan to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, an inducement material to such persons entering into employment with the Company. The Company initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3362ddd-9497-4610-b411-5246ac336f0d" contextRef="C_56f021a8-a8b1-4814-8e60-e30e3153a6ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,900,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock for the issuance of awards under the 2023 Inducement Plan. On December 6, 2023, the Company's board of directors increased the reserve by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e50e54b6-be8a-47d7-a307-de5c2302a947" contextRef="C_c1bbc6b4-e3a0-44a7-bf52-605ed66340b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f56874f4-d65b-4eef-b5fb-5555690800b0" contextRef="C_2da8d5ee-6ea1-4242-a4dc-afb090386702" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,191,732</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for issuance under the 2015 Plan and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db9a5996-686b-4b25-8d4f-1392aff1c194" contextRef="C_56f021a8-a8b1-4814-8e60-e30e3153a6ee" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,211,650</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for issuance under the 2023 Inducement Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1217fca-2358-4577-bc4e-900fb455b16b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees and related to the Employee Stock Purchase Plan in the consolidated statements of operations as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.42%;"/>
        <td style="width:2.32%;"/>
        <td style="width:1%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.32%;"/>
        <td style="width:1%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.32%;"/>
        <td style="width:1%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a859b2fd-3a82-48cd-92d8-db9ae121d888" contextRef="C_85e6672e-416a-4bb1-ba66-37049365978f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,147</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7574b0d5-6fef-4ba5-bd23-a4d94b16fdec" contextRef="C_a245d0cf-1677-4b8f-a3f8-dfbf1b2276ba" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,016</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4027ec0c-5a2f-485e-ad5d-1e7b12227028" contextRef="C_610a039f-ddb5-49bf-b2aa-26efc9285ba9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bda3627-10fc-4c0b-a76d-974251d0c281" contextRef="C_61e6f7c1-9801-49e0-ac76-fee878967704" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,804</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_033630bc-3748-425b-93be-5d8f39f08472" contextRef="C_49c6449d-685a-4b8d-9ad2-69b9cf9fce2a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,003</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daa4349d-a50a-46a8-b074-d9116910c82b" contextRef="C_fa3bed87-c1df-42e6-8758-39e220363797" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,919</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1da9cb34-1be2-4247-9ba2-8c8016ccf013" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,951</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f7080ab-0720-4bb6-9c7a-df79056534c3" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,019</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30877b7e-8fe9-428b-9ce5-4522e9732af7" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,317</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options and Restricted Stock Units</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9dfc764-40e8-4a4a-80fc-4a7ec35c4299" contextRef="C_361a189b-bde2-4ebc-a732-bb3aba4d7e9c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">74.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of unrecognized compensation cost related to employee and non-employee unvested stock options and RSUs granted under the 2015 Plan and the 2023 Inducement Plan, which is expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_625d4d64-098e-4ebf-a621-e26e1d05e266" contextRef="C_3c1506a9-4d8e-4770-b740-d3e5f9ee156e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. Stock compensation costs have not been capitalized by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the straight-line method to the extent achievement of the performance condition is probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, the Company granted to certain employees </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dec1abcf-5069-4830-b6dc-0da17f83f4dd" contextRef="C_3afde7f0-2827-4e68-8635-4702b62c6d21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">583,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options that contain performance-based vesting criteria (&#8220;2019 Performance Awards&#8221;), primarily related to the achievement of certain clinical and regulatory development milestones related to product candidates. In the fourth quarter of 2020, one performance milestone, for the 2019 Performance Awards, was achieved. The Company recorded approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_576b6f8e-8620-44a8-9cf2-8b6614b4d615" contextRef="C_722e2254-0e1d-493b-95a1-3d802704cc35" name="sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">128,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of stock compensation related to the achievement of the performance milestone for years ended December 31, 2022. As of December 31, 2022, all other performance milestones were not achieved, and the associated awards have been cancelled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the Company granted to certain employees </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f74cf854-acd0-43ce-9e79-595e256cf67c" contextRef="C_665c9384-a612-4a95-ba6a-78cf2d4a9797" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">140,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance-based stock options (&#8220;2022 Performance Awards&#8221;), primarily related to the achievement of certain regulatory development milestones related to product candidates. Recognition of stock-based compensation expense associated with these performance-based stock options commences when the performance condition is considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the first quarter of 2022, management estimated one of the milestones, for the 2022 Performance Awards, was probable of achievement. The Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_406498ca-04fa-4e2e-ac10-c1c416dfd057" contextRef="C_c738d44a-3667-401f-876a-5549892bf0b8" name="sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">258,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f45dcb3c-bc4b-4930-aa3d-c4e55ab3e08b" contextRef="C_665c9384-a612-4a95-ba6a-78cf2d4a9797" name="sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">479,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of stock compensation expense for these awards for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03fd3fa4-606e-4165-a987-f4b48971d567" contextRef="C_cef59505-ba7f-4bd7-ba0f-7111fc336f1d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">140,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options outstanding were unvested, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0050d25e-0ecf-4b7d-a7df-2cb5a0c16668" contextRef="C_c738d44a-3667-401f-876a-5549892bf0b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options had been cancelled.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the first quarter of 2023, the Company granted to certain employees </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44e2c4bf-5a75-469a-8219-4409e6ed68c8" contextRef="C_4a678240-3c1b-4c9f-88f3-1d437a7bd663" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">129,550</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance-based RSUs, primarily related to the achievement of certain regulatory development milestones related to product candidates. Recognition of stock-based compensation expense associated with these performance-based RSUs commences when the performance condition is considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, in connection with the retirement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d5a3625-581b-469d-8265-ff547faee518" contextRef="C_4711878e-a968-48f8-9c3d-730171fe4f23" name="sndx:NumberOfEmployeesRetirement" unitRef="U_Employee" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> employees, the Company entered into severance and consulting agreements. Under these agreements the Company extended the vesting term for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcc628b6-874b-4dbd-96d9-d2f657d83838" contextRef="C_4711878e-a968-48f8-9c3d-730171fe4f23" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,728</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unvested options, which would not have otherwise vested and extended the exercise period of the vested options post termination of the consulting agreement. The Company accounted for the change as a modification of an equity award under ASC 718. As a result of the modifications, the Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04f871e6-f84c-4e44-a3f7-52fbf830426d" contextRef="C_4711878e-a968-48f8-9c3d-730171fe4f23" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of incremental stock compensation expense in 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model with the weighted-average assumptions noted in the table below. Expected volatility for the Company&#8217;s common stock was determined based on an average of the historical volatility of the Company's public stock price. The Company estimated the expected term of its employee stock options using the &#8220;simplified&#8221; method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The contractual life of the option was used for the estimated life of the non-employee grants. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free interest rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. The Company accounts for forfeitures when they occur. </span><span><ix:nonNumeric id="F_a3be5e38-5bfa-4601-9b74-424b0d6918ad" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_a3be5e38-5bfa-4601-9b74-424b0d6918ad_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The grant date fair values of options issued to employees and non-employees were estimated using the Black-Scholes option-pricing model with the following assumptions: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_a3be5e38-5bfa-4601-9b74-424b0d6918ad_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.75%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:12.618%;"/>
        <td style="width:1%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:12.618%;"/>
        <td style="width:1%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:12.618%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fe8216da-ec01-40f4-8a62-ab8b7771b7c1" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.03</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1542e676-0ae8-4ef1-ab32-df29fa0cea60" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.04</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7887c418-db09-4e03-89fd-6b10b501074f" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.02</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b6a9ba2-4ec9-4de4-a1b3-3500bfd5e1ba" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">75.13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c4a2212-3582-43d4-92fe-5b8931b8f5e3" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">77.87</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_795b483b-f74d-4884-82b4-7f4572f92631" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">85.84</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43d0943c-3d2b-4241-a3a4-54b00fb21f5a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.65</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27e00844-0614-4ef3-9c1d-e66a6ff5d99d" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_879cdf7f-6940-4dc4-bc6c-9bac924e77c5" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aadeb771-1047-47f5-b696-6cf4d79ee087" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3bb8ecb-f8ce-49ed-bc0a-59ace066086c" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b3e904a-6e7b-439a-a1bb-5372c85014cf" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c3ccd8a-7bf5-40b6-b7d7-081e8c9a9fb1" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of employee and non-employee option activity under the Company&#8217;s equity award plans is presented below (in thousands, except share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.96%;"/>
        <td style="width:1.36%;"/>
        <td style="width:1%;"/>
        <td style="width:9.94%;"/>
        <td style="width:1%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1%;"/>
        <td style="width:9.46%;"/>
        <td style="width:1%;"/>
        <td style="width:1.36%;"/>
        <td style="width:1%;"/>
        <td style="width:9.94%;"/>
        <td style="width:1%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1%;"/>
        <td style="width:11.3%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_215e0556-3761-49d8-b1a8-4bfa3b07fbb0" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,981,677</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a9500c5-1c6a-4e96-9a4d-3e37f19eca98" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.42</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c17eb7eb-deec-44b8-959b-185bdf169792" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15f2208b-4e94-44a5-884e-98d0505a4eaa" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,016</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd2eb33b-51ce-4f46-96f4-283044f6fc5b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,800,691</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_607923be-60fd-4e52-b34e-647a7bef80c9" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cad8591-5a45-4844-8e79-447831136c82" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">662,042</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba000a6b-c793-49cc-b878-f061a2554e05" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.08</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled, forfeited or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_889be445-c19d-48bc-8d80-c738f335d2de" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">435,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0da951bd-2f6f-4408-beeb-f02e39ffe601" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ec8e33a-4ea6-4be6-8d39-1e191108efbe" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,684,858</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c700937-9e48-4fcb-931c-e21f81ce0d13" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_549862ca-e9c2-4e58-a65c-5044fffb922b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c29b0e7e-9b60-4625-a0b9-5f997bf61ad8" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,091</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56881dbb-601f-4d12-9d32-612a47fc74cb" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,468,638</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3701ce03-ed7a-41ac-b435-f89090256522" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.32</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_51a9ca4a-bde9-4d4b-81c7-1ddafe54f08e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cfbed41-3ac9-4998-97d5-da96efbb24ab" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,160</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested, or expected to<br/>&#160;&#160;&#160;vest</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a86d813-b7d9-46d5-978a-90c62c89b5ad" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,684,858</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_812714d5-5279-46fb-ba5d-6c23014db586" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5d1573ab-b8ee-442e-90d8-9388674e5052" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_496328d1-af00-47e8-9270-514636b722b8" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,091</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of options granted during the years ended December 31, 2023, 2022 and 2021, was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8182edeb-964d-4968-b7f9-bf4d01cefa33" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a805712-fe20-4cf9-a363-7e9fff7edbbf" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2902b789-e522-49ee-ac40-062fe82e528c" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The fair value is being expensed over the vesting period of the options (usually </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_91e0244e-9f65-4985-ba1b-f7857d8ad080;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40ca8732-8745-499f-b2bf-5563c1a2bb88" contextRef="C_0134674c-550a-4425-b294-4c3c79a415b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) on a straight-line basis as the services are being provided.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62acfa11-7f3b-43b0-9fdc-fcfb25bf8675" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">662,042</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options exercised for the year ended December 31, 2023, resulting in total proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc316470-a16f-48cd-b7ea-81012e028993" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aafce0d-8b11-41c0-a451-b39d3c55f1d6" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million options exercised for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, resulting in total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7220bf1-d4ed-447e-8398-3e011172dc3b" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million; and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9420b50-8e78-4819-bee6-d737480a4c84" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">842,424</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options exercised for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, resulting in total proceeds of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_013fdedf-1d0d-444f-99e3-0bcf7ee55918" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The intrinsic value of options exercised during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bcf71c7-6602-43ff-9f17-b6f6c098fba1" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58e5cfed-a2af-4833-8cd8-f7d5118aeb50" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0b3ea74-44ed-4a3f-8e01-310bd650785c" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. In accordance with the Company&#8217;s policy, the shares were issued from a pool of shares reserved for issuance under the 2015 Plan and 2023 Inducement Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs awarded to Board of Directors or employees vest on either i) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fc2d0f0-6d97-4cad-aacb-9682cf12a0fc" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one &#8211; year anniversary date of the related grant or ii) 25% on each anniversary for 4 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_484aa305-e0f9-4afa-a816-d5feded3e458" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true" continuedAt="F_484aa305-e0f9-4afa-a816-d5feded3e458_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our RSU activity:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_484aa305-e0f9-4afa-a816-d5feded3e458_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.609%;"/>
        <td style="width:2.519%;"/>
        <td style="width:1%;"/>
        <td style="width:17.177%;"/>
        <td style="width:1%;"/>
        <td style="width:2.999%;"/>
        <td style="width:1%;"/>
        <td style="width:16.697%;"/>
        <td style="width:1%;"/>
        <td style="width:2.999%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a685c568-babc-4bd0-9a03-2c6cf9d362d0" contextRef="C_707b5fb4-b3b3-44e7-845a-f9f779873732" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">224,788</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae125faf-4fb8-402f-a60c-db4b03632ec3" contextRef="C_707b5fb4-b3b3-44e7-845a-f9f779873732" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.02</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_571d65c8-f8f1-445f-8ee1-7e17ce2ffbfc" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">308,550</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c71cf37-0a72-4642-a37b-7ae4969c410b" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4aa78e38-7d83-4c38-8111-fe67192c14c5" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,102</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0daec735-3730-404d-a4e0-7a8c46416b64" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.87</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10183d18-7e70-4b1d-8782-131bb0f9518b" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,800</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30c173cc-940e-48e8-99f7-ec54d9417b58" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested&#8212;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bc01169-8804-4032-b5d5-edf27b956a1e" contextRef="C_f94caae1-f892-4d89-8e4b-773c52c2f2b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">519,436</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a89518c1-4d5c-4283-b726-c437ab30898e" contextRef="C_f94caae1-f892-4d89-8e4b-773c52c2f2b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.17</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><ix:footnote id="FNT_82b8419b-1637-433c-bec5-9d6f6e1629e5" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 had a weighted average grant date fair value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b906284-6131-41ce-ac8a-d18db056ec52" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.94</ix:nonFraction></span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e604f75-0071-4eaa-9ed0-aed1558f07a7" contextRef="C_f9cd7896-122a-468d-9a8b-9879b929f973" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair values of RSUs vested in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a0f3cd6-ee77-4cb9-8bf2-4c25bd4d5474" contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">126,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c965d754-a51a-4ed6-a582-e6ba23fa21a2" contextRef="C_f9cd7896-122a-468d-9a8b-9879b929f973" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">705,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></ix:footnote></p></ix:continuation></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2015, the Company&#8217;s Board adopted the ESPP, which was subsequently approved by the Company&#8217;s stockholders and became effective in 2016. The ESPP authorized the initial issuance of up to a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fb2add6-8e08-40f0-aebe-ee7f46d65ceb" contextRef="C_7ef8960c-7219-442c-81b3-4e10b484489f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the Company&#8217;s employees. The number of shares of common stock available under the ESPP will automatically increase on January 1st of each year, continuing until the expiration of the ESPP, in an amount equal to the lesser of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdf07de0-487c-49a1-8bb4-cc538f73c4b5" contextRef="C_5d906a55-0f18-4eb6-ae44-5a99a86227fd" name="sndx:ExpirationOfTheEspp" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, or (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1238dbb-f24f-4834-bbd6-837380bb5311" contextRef="C_92736a1f-42c0-4d1d-a622-0b95ffb0a33b" name="sndx:ExpirationOfTheEsppShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. On January 1, 2024, the shares of common stock reserved for issuance under the ESPP was increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1c89e27-d7b8-4eaf-aed4-7b807c907ccd" contextRef="C_f584b500-1b67-48fb-b034-847318b00b67" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,982,614</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under the terms of the ESPP, eligible employees can elect to acquire shares of the Company&#8217;s common stock through periodic payroll deductions during a series of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32460169-8e76-4a4c-9c51-7a444ba5446b" contextRef="C_fb680055-68ee-453c-b640-6693cd2778c7" name="sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> offering periods. Purchases under the ESPP are affected on the last business day of each offering period at a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5a1ee02-04bc-45f4-8772-671114bbdc5e" contextRef="C_7214ed50-0829-4c9b-97ed-3efc7a00a846" name="sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" unitRef="U_pure" scale="-2" decimals="2">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% discount to the lower of closing price on that day or the closing price on the first day of the offering period. The Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16c59131-b7fe-4478-9604-18a6b4f20a65" contextRef="C_a8268fa6-6e38-4789-b18f-986f4e625037" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">34,797</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed3c4347-2e3e-4262-926c-d34043949b4c" contextRef="C_160ba5f0-0235-4944-95c1-f31751bf8c30" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares during </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ESPP is considered a compensatory plan with the related compensation cost expensed over the six-month offering period. For the years ended December 31, 2023, 2022 and 2021 the Company recorded stock-based compensation expense related to the ESPP of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d45ad10c-3d83-4733-84ab-0390103d1be0" contextRef="C_a8268fa6-6e38-4789-b18f-986f4e625037" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">308,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eda64f49-ddfb-4296-a573-f9dd43cc16d1" contextRef="C_160ba5f0-0235-4944-95c1-f31751bf8c30" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">166,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_865bace4-83f4-4e4b-8eb9-97c325e73255" contextRef="C_98367a91-be3e-42b9-a2a7-0457ff239e69" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">175,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> respectively.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Benefit Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a Section 401(k) defined contribution savings plan for its employees. The plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis, subject to legal limitations. Company contributions to the plan may be made at the discretion of the Board. For the years ended December 31, 2023, 2022 and 2021, the Company made </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3c97055-fe34-48a0-83e9-0f2fed5417c8" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a21dd4e-95e2-42e1-a4fd-611ecb57cc8d" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">712,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb9fdafa-385e-4e8f-baa8-cc51284d1e72" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">444,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contributions to the plan, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a2c13fc-6647-4001-a38d-ab8c04ca9013" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Loan Payable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2020, the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;). In December 2021, the Company entered into Amendment No. 1 to the Company&#8217;s Loan Agreement (the &#8220;First Amendment&#8221; and the Loan Agreement, as amended, the &#8220;Amended Loan Agreement&#8221;) with several banks and financial institutions or entities from time-to-time party thereto (collectively, the &#8220;Lender&#8221;) and Hercules, in its capacity as administrative agent for itself and the Lender.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 23, 2022, the Company made a prepayment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_feea0dbb-4e10-4f0e-a0aa-dffdd41b73b1" contextRef="C_2fde2bde-fcd6-4136-938c-690acb7faf69" name="us-gaap:PaymentsForProceedsFromDepositOnLoan" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to satisfy in full all of the Company's principal and interest obligations and related fees under the Amended Loan Agreement. The payoff amount paid by the Company in connection with the termination of the Amended Loan Agreement was pursuant to a payoff letter with Hercules and included payment of (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d89bea67-8fe8-4db0-9225-288739f95335" contextRef="C_2fde2bde-fcd6-4136-938c-690acb7faf69" name="sndx:PaymentForEndOfTermFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as an end-of term fee and (b) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af33855c-0dc5-4ca4-adaa-515f0cf64842" contextRef="C_2fde2bde-fcd6-4136-938c-690acb7faf69" name="us-gaap:PaymentsForFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a pre-payment fee. Hercules released all security interests held on the assets of the Company and its subsidiaries. The Amended Loan Agreement was fully terminated as of September 23, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f57fe242-db14-4f47-af67-f0e821296db5" contextRef="C_aea89429-70c4-454c-97d0-6401610eb508" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e05b7fae-9b6a-4ab9-9c23-aacfbc5351a0" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="sndx:PrepaymentFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of pre-payment fee, of interest expense related to the initial advance pursuant to the Amended Loan Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8691bee3-033d-4062-bad0-0cd6e6edb43c" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized current state income expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff4619b1-29f6-4e4c-8975-65c5b65d917b" contextRef="C_7005891b-8702-43ec-a77e-2e47fc88621f" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the year ending December 31, 2023 as a result of investment income earned in Syndax Securities Corporation. The Company recognized no income taxes in the years ended December 31, 2022 and 2021, due to the utilization of tax attributes to offset current year federal and state taxable income, immaterial investment income earned at Syndax Securities Corporation, the historical losses incurred and the need for a full valuation allowance on deferred tax assets. The Company&#8217;s current year profit and historical losses before income tax for the periods presented was generated entirely in the United States.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2a0db1f-d380-4b79-88d5-a0a03f0106ca" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes computed at the statutory federal income tax rate to the provision for income taxes as reflected in the financial statements is as follows:</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.493%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:8.382%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:8.382%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:8.382%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71c08e5b-7643-4a82-8cbe-292f9a860075" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f04bc3fe-08a5-470d-a184-47ba4480eec4" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c88f626e-8e28-46f1-b270-d5aa7ec09e4a" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a94af9c9-46c2-4fb5-b2da-13a8aee4ec86" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1750047-2b3e-4a47-9858-67bbf486a557" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2705a8af-366e-4f31-82af-7376f0d04f1f" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General business credit carryovers</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b20c533-e8c8-4a4c-a7bd-a4e22b624ec5" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e929cebe-9e03-4be9-8027-4ade0e26acdd" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9de9888e-6f2b-486a-9d1a-9c9799ec56ff" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_276e0edd-28c3-4100-8084-12e64f8e81ad" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1cb7768-2955-4e96-9caa-5e9427063451" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fe32d91-f20f-4f58-8a0b-ab14742e2a9b" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c9498ff-90c4-4b8d-8b0a-38112f4f6971" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">34.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_182c4ec4-16e3-41c9-81be-371d453c06c7" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e8438c7-11c0-4e1a-b67f-583e71fff821" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">19.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Return to provision true up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6dc73a8-127b-47c8-8237-8299a4f22931" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="sndx:ReturnToProvisionTrueUp" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebb0a301-548f-4bef-b6c2-a06fe3efd9bb" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="sndx:ReturnToProvisionTrueUp" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a7af693-8575-4ee6-8def-f3549630bf56" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="sndx:ReturnToProvisionTrueUp" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_941369b3-e419-4cb8-9dae-949460544bfc" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d23be24b-9c4b-4a3c-9b2f-494d74a26509" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbda3bac-ef9e-47d0-ab31-8207d8fe1b76" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0de6057e-68cc-4cd0-811c-f2399016e86a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be46b5df-835c-44e1-b181-5ed56e5a982a" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37ff3ce0-7c58-41a6-9d0b-94880eb9c277" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64bdb8b0-ad73-4e85-86ed-67a344f798c8" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s deferred tax are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:9.200000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:9.200000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets (liabilities):</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_641f97bf-04c3-4870-ae14-059549032d66" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7533a460-356e-41a5-b13e-9ca87dc4ff18" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,650</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45d1e50c-1733-4da7-a2e9-e0b29d1e4dea" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,765</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7321e03c-9ed7-4957-8a5b-cf77b01ebf3f" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,124</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized start-up and other costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a561eb8-cf2e-4f42-ad65-6b8d537f9e4a" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,859</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_434110e4-2db9-4665-8411-f2a539f0a139" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,374</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aed8fb07-a5d3-4688-8d58-8b6260eedd60" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="sndx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,562</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef6395c8-9175-4125-ac80-7864d844d452" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="sndx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,917</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f6e8528-bb0d-4dc5-bc5f-07e8f78aabfe" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,276</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43490b31-f355-4e92-96ed-5fd0a975e5c8" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6555631c-e06d-4923-b05d-395006578f89" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,795</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af708051-b5ed-4a03-98cb-2bbb8e0f1862" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,985</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dcb2e0b-7457-4789-b6c7-fc593f52b4fa" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4267aa8-e0d5-4418-a0cf-753156f37988" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets before valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_003ec259-6cfe-4fb5-891b-d157173e8979" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205,957</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79e370c4-9240-4aa2-9267-14f794d06e27" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,081</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowances</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78401e72-9298-462d-bc6f-b1b757e01ce2" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205,957</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39ffbaae-6fc0-401e-a311-2f81ffda37e3" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,081</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee605dbd-56d3-46ea-9078-f2ac3766ab1c" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b82de64d-fe55-4f6a-97fa-bcb0da06ee37" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_205edd71-4c80-4b4c-b189-bdb5d0fae92b" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ValuationAllowanceMethodologiesAndAssumptions"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_218aa801-0d92-4a01-be2a-b519fb3956a6" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">72.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized research expenses, and capitalized start-up costs. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0603aea5-cb40-437e-a9e1-0771dca2de58" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized start-up costs, partially offset by a decrease to other deferred tax assets.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfb03fc6-f485-4732-853e-6796c33bbdf0" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">136.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83dc8c75-65d1-4368-85cc-e45c79d2c92f" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in federal and state Net Operating Losses (&#8220;NOLs&#8221;), respectively, which may be available to offset future taxable income. The Company has generated federal NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_716f9b8f-d9a9-4577-a890-d3d01f8840c1" contextRef="C_3cbcc0e4-7e7b-486d-b6a3-470613e2d7a2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">114.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and state NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6576f5c5-8cc8-4d45-8de8-b4740f7940c8" contextRef="C_3cbcc0e4-7e7b-486d-b6a3-470613e2d7a2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which have indefinite carryforward period. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f8692fb-6d0d-47d0-b538-3f995bb80ba8" contextRef="C_b85eec17-a5e7-48d2-bfca-2ef6ffdae4ef" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal NOLs and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce63756e-94b3-4071-8dff-9cfce8d88556" contextRef="C_a6b0a3dc-0d13-4e49-af3e-9c0ec95c0551" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million the Company&#8217;s state NOLs will begin to expire at various dates starting in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ffe6952-c04c-4d20-9c9b-257e955a971c" contextRef="C_074a6418-7106-47c6-9070-807b4c2674f4" name="sndx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod"><ix:nonNumeric id="F_94aa6462-4c13-4a90-88d0-bf668b3e9d6d" contextRef="C_7005891b-8702-43ec-a77e-2e47fc88621f" name="sndx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2026</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had federal and state research credits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1274320f-b56e-432b-a917-3ecb47181d6d" contextRef="C_6950da94-09bf-4054-a1fa-0feb68fcf8c9" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53ce5fe7-7085-4036-85d6-59469d951106" contextRef="C_beb1fbb6-8eaa-4bd9-a278-f0c3ba62c037" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, which began to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce79edc1-78a6-483d-912c-8cdd31b52a0d" contextRef="C_074a6418-7106-47c6-9070-807b4c2674f4" name="sndx:DeferredTaxAssetsResearchCreditsExpirationPeriod"><ix:nonNumeric id="F_8b250376-83d5-42ea-9d0e-b67d8e3438b4" contextRef="C_7005891b-8702-43ec-a77e-2e47fc88621f" name="sndx:DeferredTaxAssetsResearchCreditsExpirationPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Under the Internal Revenue Code provisions, certain substantial changes in the Company&#8217;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards which could be used annually to offset future taxable income. The Company last completed an analysis from January 1, 2021 through December 31, 2022 and determined that no ownership changes had occurred in that period. Prior analyses determined that on March 30, 2007, August 21, 2015 and May 4, 2020, ownership changes had occurred. The Company may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, its ability to use its pre- change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted in the United States on March 27, 2020. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides extensive tax changes in response to the COVID-19 pandemic, the provisions did not have a significant impact on the Company&#8217;s financial results. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminates the option to deduct research and development expenditures currently and requires taxpayers to amortize them, over five years for domestically incurred expenditures and over fifteen years for foreign incurred expenditures, pursuant to IRC Section 174. As of December 31, 2023, the Company has recorded a deferred tax asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_841b91d5-f7d7-41e0-802f-0d3670842c82" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">79.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the Capitalized IRC Section 174 expenditures, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84241a0b-f50c-4cf5-875d-a846a2e61ed7" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">53.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million relate to expenses required to be capitalized under the TCJA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, and 2022, the Company had uncertain tax positions of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd7ff8c3-c7f4-4c68-add0-6aca99c7ca30" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to research and development credits, which reduce the deferred tax assets with a corresponding decrease to the valuation allowance. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_422f9681-d186-4fc7-9305-6d92026d6481" contextRef="C_9bfce7e8-ef98-48b8-86a7-775779587ee8" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_adb9fcf9-fb9c-4515-a88e-d37418b90ccc" contextRef="C_9c35cea5-4932-446f-bd97-79a9161a45c0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest or penalties were recorded for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company expects none of the unrecognized tax benefits to decrease within the next 12 months related to expired statutes or settlement with the taxing authorities. Due to the Company&#8217;s valuation allowance as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8da92fdc-1912-4726-8309-a871f4675c10" contextRef="C_d380c115-0599-4d7d-9e27-c31a2dc98460" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company&#8217;s unrecognized tax benefits, if recognized, would affect the effective tax rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4fb1705-53bf-469d-bf86-3504aa18a5d8" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.493%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:7.922000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:7.922000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:7.922000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefit--beginning of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51cf7587-dec9-4001-b888-7ef4b8102128" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_549fad41-aa81-4685-9426-bd2390f612ee" contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e712020-7c48-405f-ae92-b363f28b2203" contextRef="C_07dde341-6b8e-4d35-a0a4-24bc46311598" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases related to prior period positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18e71f7a-0462-4ba0-9b5b-c81c2e378313" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dda32b9e-ee9e-47b8-8161-009c2c9441b2" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43f2687a-ddbc-4523-a2c1-6afe8ea7a8ba" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefit--end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eeec11d2-7d4a-4ff6-ba5c-05a6fef35b40" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffbefd9a-5f49-400f-98b2-e0895202a729" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_128fe104-2281-48be-9f4e-fda9e65493c2" contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files tax returns in the U.S. and various states. All tax years since inception (October 11, 2005) remain open to examination by major tax jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service or state tax authorities if they have or will be used in a future period. The Company is currently not under examination by the Internal Revenue Service or any other jurisdictions for any tax years.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6dbd4d83-49ed-4ea9-b41b-67718f967b4d" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Commitments and Contingencies</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incyte &#8211; In September 2021, the Company entered into the Incyte Agreement and Incyte Stock Purchase Agreement. Under the terms of the Incyte Agreement, Incyte will receive exclusive commercialization rights of axatilimab outside of the United States.  In the United States, Incyte and the Company will co-commercialize axatilimab, with the Company having the right to co-promote the product with Incyte. In exchange for these rights, Incyte agreed to pay a non-refundable cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8063095-08e6-43c8-8407-70ca1ff9adda" contextRef="C_6d113b0b-ab5a-4247-a874-32521d39ece2" name="sndx:UpfrontPayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">117</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and in addition a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b9158d4-36af-4fb4-808b-0257ecb64ed8" contextRef="C_a5fddb73-bec6-44ab-935b-04ba4ac070ab" name="sndx:UpfrontPayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million equity investment. In certain cases, the Company is required to assist Incyte and is responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa61cf58-4aa3-4869-a1b2-8d278048da4f" contextRef="C_4bd80ba5-9483-4290-bd6b-8b3b7622307a" name="sndx:DevelopmentCostsAssociatedWithClinicalTrials" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of development costs associated with global and U.S. specific clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eddingpharm&#8212;In April 2013, the Company entered into a License and Development Agreement (the &#8220;Eddingpharm License Agreement&#8221;) and a Series B-1 purchase agreement (the &#8220;Eddingpharm Purchase Agreement&#8221;) with Eddingpharm International Company Limited (&#8220;Eddingpharm&#8221;). Under the terms of the Eddingpharm License Agreement, Eddingpharm, in exchange for rights to develop and commercialize entinostat in China and certain other Asian countries, purchased $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c74f5586-a7c2-4088-8888-670861285aa7" contextRef="C_baf118b0-3cb5-42c6-83f0-5fe1ec439d64" name="us-gaap:PurchaseObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Series B-1 and agreed to make certain contingent milestone and royalty payments based on revenue targets. In certain cases, the Company is required to assist Eddingpharm, and Eddingpharm is required to reimburse the Company for any out-of-pocket expenses incurred in providing this assistance, including reimbursement for person-hours above a certain cap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may be subject to various claims and proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_473230ea-372c-422d-8892-e2efcd8045cf" contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_064abf4c-015d-4ff9-96c6-3aa1f0af30b8" contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contingent liabilities recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, or 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22aa7756-f492-4244-b911-00d62f65616e" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17. Supplemental Cash Flow Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98428a58-509a-4ac0-a9dd-40721560f322" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.913%;"/>
        <td style="width:1.479%;"/>
        <td style="width:1%;"/>
        <td style="width:7.2170000000000005%;"/>
        <td style="width:1%;"/>
        <td style="width:1.479%;"/>
        <td style="width:1%;"/>
        <td style="width:7.2170000000000005%;"/>
        <td style="width:1%;"/>
        <td style="width:1.479%;"/>
        <td style="width:1%;"/>
        <td style="width:7.2170000000000005%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosures of Cash Flow Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_256eb23f-2755-42dc-9d52-978c2f8a3513" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da34bf4b-2d84-4281-ae5d-483dced76aa2" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_affe8a4e-638a-4397-b0be-fbeadd623876" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosures of Non-Cash Investing and Financing<br/>&#160;&#160;&#160;Activities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance costs included in accounts payable and accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58f09d77-4026-4035-8a9b-03e4e3efbe8a" contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ddbd58a-fd68-465d-ba04-f2a519a4b4ec" contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ee4e662-988a-4be0-aef4-100286726594" contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>sndx-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.3</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF CAPITAL STOCK</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are included as an exhibit to our Annual Report on Form 10-K.  All references to the &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us&#x201d; refer to Syndax Pharmaceuticals, Inc.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under our amended and restated certificate of incorporation we are authorized to issue up to 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock are undesignated. Our board of directors may establish the rights and preferences of the preferred stock from time to time.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders. The affirmative vote of holders of at least 66</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2044;</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to preferences that may apply to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose on a non-cumulative basis.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidation</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any outstanding preferred stock.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rights and Preferences</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to our amended and restated certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the number, rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, and the number of shares constituting any series or the designation of such</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control or other corporate action, or make the removal of management more difficult.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-Takeover Provisions</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws include a number of provisions that may deter or impede hostile takeovers or changes of control or management. These provisions include:</font></p>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuance of Undesignated Preferred Stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to make it more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Classified Board.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our amended and restated certificate of incorporation provides for a classified board of directors consisting of three classes of directors, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. This provision may have the effect of delaying a change in control of our board.</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board of Directors Vacancies.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our amended and restated certificate of incorporation and amended and restated bylaws authorize only our board of directors to fill vacant directorships. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominee.</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stockholder Action; Special Meetings of Stockholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our amended and restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. Stockholders will not be permitted to cumulate their votes for the election of directors. Our amended and restated certificate of incorporation further provides that only the chairman of our board of directors or a majority of our board of directors may call special meetings of our stockholders.</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advance Notice Requirements for Stockholder Proposals and Director Nominations.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our amended and restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders. Our amended and restated bylaws also specify certain requirements as to the form and content of a stockholder&#x2019;s notice. These provisions may make it more difficult for our stockholders to bring matters before our annual meeting of stockholders or to nominate directors at annual meetings of stockholders.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We designed these provisions to enhance the likelihood of continued stability in the composition of our board of directors and its policies, to discourage certain types of transactions that may involve an actual or threatened acquisition of us, and to reduce our vulnerability to an unsolicited acquisition proposal. We also designed these provisions to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they may also reduce fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 203 of the Delaware General Corporation Law</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</font></p>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2044;</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding voting stock that is not owned by the interested stockholder.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, Section 203 defines a &#x201c;business combination&#x201d; to include the following:</font></p>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></div>
  <div style="margin-left:3.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.457540612875786%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.64%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, Section 203 defines an &#x201c;interested stockholder&#x201d; as an entity or person who, together with the entity or person&#x2019;s affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A Delaware corporation may &#x201c;opt out&#x201d; of these provisions with an express provision in its certificate of incorporation. We have not opted out of these provisions, which may as a result, discourage or prevent mergers or other takeover or change of control attempts of us.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Choice of Forum</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation will provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware), the Court of Chancery of the State of Delaware will be the exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action or proceeding commenced by any of our stockholders (including any class action) asserting a breach of fiduciary duty owed, or other wrongdoing, by any director, officer, employee or agent to us or our stockholders, (3) any action or proceeding commenced by any of our stockholders (including any class action) asserting a claim against us arising pursuant to the DGCL or our amended and restated certificate of incorporation or our amended and restated bylaws, (4) any action or proceeding commenced by any of our stockholders (including any class action) to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws, or (5) any action or proceeding commenced by any of our stockholders (including any class action) asserting a claim against us that is governed by the internal affairs doctrine.</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>3
<FILENAME>sndx-ex10_16.htm
<DESCRIPTION>EX-10.16
<TEXT>
<html>
 <head>
  <title>EX-10.16</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.16</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 INDUCEMENT PLAN</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As Amended: December 6, 2023</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), sets forth herein the terms of its 2023 Inducement Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), as follows:</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GENERAL</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purpose.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Plan is intended to provide (a) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Marketplace Rules, and (b) incentives to Eligible Employees to stimulate their efforts towards the success of the Company and to operate and manage its business in a manner that will provide for the long-term growth and profitability of the Company. To that end, the Plan provides for the grant of Awards of Options, Stock Appreciation Rights, Restricted Stock, Unrestricted Stock, Stock Units, Dividend Equivalent Rights, Performance Awards, and Other Equity-Based Awards.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eligible Award Recipients. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under NASDAQ Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under NASDAQ IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bona fide </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period of non-employment. Persons eligible to receive grants of Awards under this Plan are referred to in this Plan as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eligible Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; These Awards must be approved by either a majority of the Company&#x2019;s &#x201c;Independent Directors&#x201d; (as such term is defined in NASDAQ Marketplace Rule 5605(a)(2)) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Independent Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or the Company&#x2019;s compensation committee, provided such committee is comprised solely of Independent Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Independent Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in order to comply with the exemption from the stockholder approval requirement for &#x201c;inducement grants&#x201d; provided under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. NASDAQ Marketplace Rule 5635(c)(4) and the related guidance under NASDAQ IM 5635-1 (together with any analogous rules or guidance effective after the date hereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inducement Award Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.87%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DEFINITIONS</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For purposes of interpreting the Plan and related documents (including Award Agreements), the following definitions shall apply:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.388%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to the Company, any company or other trade or business that controls, is controlled by, or is under common control with, the Company within the meaning of Rule 405 of Regulation C under the Securities Act, including, without limitation, any Subsidiary. For purposes of grants of Options or Stock Appreciation Rights, an entity may not be considered an Affiliate of the Company unless the Company holds a &#x201c;controlling interest&#x201d; in such entity, where the term &#x201c;controlling interest&#x201d; has the same meaning as provided in Treasury Regulation Section 1.414(c)-2(b)(2)(i), provided that the language &#x201c;at least 50 percent&#x201d; is used instead of &#x201c;at least 80 percent&#x201d; and, provided further, that where granting of Options or Stock Appreciation Rights is based upon a legitimate business criteria, the language &#x201c;at least 20 percent&#x201d; is used instead of &#x201c;at least 80 percent&#x201d; each place it appears in Treasury Regulation Section 1.414(c)-2(b)(2)(i).</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.415%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.398%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the legal requirements relating to the Plan and the Awards under (a) applicable provisions of the Code, the Securities Act, the Exchange Act, any rules or regulations thereunder, and any other laws, rules, regulations, and government orders of any jurisdiction applicable to the Company or its Affiliates, (b) applicable provisions of the corporate, securities, tax and other laws, rules, regulations and government orders of any jurisdiction applicable to Awards granted to residents thereof, and (c) the rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.657%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.458%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:3.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a grant of an Option, Stock Appreciation Right, Restricted Stock, Unrestricted Stock, Stock Units, Dividend Equivalent Right, Performance Award, or Other Equity-Based Award under the Plan.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.278%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.411%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the written agreement, in such written, electronic, or other form as </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:3.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determined by the Committee, between the Company and a Grantee that evidences and sets forth the terms and conditions of an Award.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Benefit Arrangement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 15</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.593%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.492%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:4.537%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capital Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, with respect to any Person, any and all shares, interests, participations, or other equivalents (however designated, whether voting or non-voting) in equity of such Person, whether outstanding on the Effective Date or issued thereafter, including, without limitation, all shares of Stock.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.102%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.439%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:3.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in an applicable agreement between a Grantee and the Company or an Affiliate, and in the absence of such agreement, shall mean, with respect to any Grantee and as determined by the Board, (i) gross negligence or willful misconduct in connection with the performance of duties&#x37e; (ii) conviction of, or pleading guilty or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">nolo contendere </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to, a criminal offense (other than minor traffic offenses)&#x37e; (iii) a material violation of a Company policy&#x37e; or (iv) a material breach of any term of any employment, consulting, or other services, confidentiality, intellectual property, or non-competition agreements, if any, between such Grantee and the Company or an Affiliate. Any determination by the Committee regarding whether an event constituting Cause shall have occurred shall be final, binding, and conclusive.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 18.9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the occurrence of any of the following:</font></div></div>
  <div style="text-indent:3.401%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A transaction or a series of related transactions whereby any person (as defined in Sections 13(d) and 14(d)(2) of the Exchange Act) or Group (other than the Company or any Affiliate) becomes the Beneficial Owner of more than fifty percent (50%) of the total voting power of the Voting Stock of the Company, on a Fully Diluted Basis&#x37e;</font></div></div>
  <div style="text-indent:3.392%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individuals who, as of the Effective Date, constitute the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incumbent Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (together with any new directors whose election by such Incumbent Board or whose nomination by such Incumbent Board for election by the stockholders of the Company was approved by a vote of at least a majority of the members of such Incumbent Board then in office who either were members of such Incumbent Board or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the members of such Board then in office&#x37e;</font></div></div>
  <div style="text-indent:3.401%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company consolidates with, or merges with or into, any Person, or any Person consolidates with, or merges with or into, the Company (regardless of whether the Company is the surviving Person), other than any such transaction in which the Prior Stockholders own directly or indirectly at least a majority of the voting power of the Voting Stock of the surviving Person in such reorganization, merger, or consolidation transaction immediately after such transaction&#x37e;</font></div></div>
  <div style="text-indent:3.463%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:3.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consummation of any direct or indirect sale, lease, transfer, conveyance, or other disposition (other than by way of reorganization, merger, or consolidation), in one transaction or a series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, to any person (as defined in Sections 13(d) and 14(d)(2) of the Exchange Act) or Group (other than the Company or any Affiliate)&#x37e; or</font></div></div>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stockholders of the Company adopt a plan or proposal for the liquidation, winding up, or dissolution of the Company.</font></div></div>
  <p style="text-indent:3.377%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board shall have full and final authority, in its sole discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control, and any incidental matters relating thereto.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.815%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.397%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, as now in effect or as hereafter amended, and any successor thereto. References in the Plan to any Code Section shall be deemed to include, as applicable, regulations and guidance promulgated under such Code Section.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.815%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.397%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a committee of, and designated from time to time by resolution of, the Board, which shall be constituted as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (or, if no Committee has been designated, the Board itself).</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Syndax Pharmaceuticals, Inc., a Delaware corporation, and any successor thereto.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:3.472%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:4%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Determination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Grant Date or such other date as of which the Fair Market Value of a share of Stock is required to be established for purposes of the Plan.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.388%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a member of the Board. Directors are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.388%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.15</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the inability of the Grantee to perform each of the essential duties of such Grantee&#x2019;s position by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected to last for a continuous period of not less than 12 months.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.63%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.388%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.16</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Equivalent Right</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a right, granted to a Grantee under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to receive, or to receive credits for the future payment of, cash, Stock, other Awards or other property equal in value to dividend payments or distributions or other periodic payments, declared or paid with respect to a specified number of shares of Stock, as if such shares of Stock had been issued to and held by the Grantee of such Dividend Equivalent Right as of the record date.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.17</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means February 2, 2023.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.18</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eligible Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.19</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#x201c;Employee&#x201d; for purposes of the Plan.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.20</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as now in effect or as hereafter amended.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:5.972%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.546%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:6%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.21</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the fair market value of a share of Stock for purposes of the Plan, which shall be determined as of any Determination Date as follows:</font></div></div>
  <div style="text-indent:3.425%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.667%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If on such Determination Date the shares of Stock are listed on a Stock Exchange, or are publicly traded on another Securities Market, the Fair Market Value of a share of Stock shall be the closing price of the Stock as reported on such Stock Exchange or such Securities Market (provided that, if there is more than one such Stock Exchange or Securities Market, the Committee shall designate the appropriate Stock Exchange or Securities Market for purposes of the Fair Market Value determination). If there is no such reported closing price on such Determination Date, the Fair Market Value of a share of Stock shall be the closing price of the Stock on the next preceding day on which any sale of Stock shall have been reported on such Stock Exchange or such Securities Market.</font></div></div>
  <div style="text-indent:3.425%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.667%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If on such Determination Date the shares of Stock are not listed on a Stock Exchange or publicly traded on a Securities Market, the Fair Market Value of a share of Stock shall be the value of the Stock as determined by the Committee by the reasonable application of a reasonable valuation method, in a manner consistent with Code Section 409A.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 2.21 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 18.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for purposes of determining taxable income and the amount of the related tax withholding obligation pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 18.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Fair Market Value will be determined by the Committee in good faith using any reasonable method as it deems appropriate, to be applied consistently with respect to Grantees&#x37e; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provided, further</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that the Committee shall determine the Fair Market Value of shares of Stock for tax withholding obligations due in connection with sales, by or on behalf of a Grantee, of such shares of Stock subject to an Award to pay the Option Price, SAR Exercise Price, and/or any tax withholding obligation on the same date on which such shares may first be sold pursuant to the terms of the applicable Award Agreement (including broker-assisted cashless exercises of Options and Stock Appreciation Rights, as described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 12.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and sell-to-cover transactions) in any manner consistent with applicable provisions of the Code, including but not limited to using the sale price of such shares on such date (or if sales of such shares are effectuated at more than one sale price, the weighted average sale price of such shares on such date) as the Fair Market Value of such shares, so long as such Grantee has provided to the Company, or its designee or agent, with advance written notice of such sale.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.741%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.392%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.22</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family Member</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, with respect to any Grantee as of any date of determination, (a) a person who is a spouse, former spouse, child, stepchild, grandchild, parent, stepparent, grandparent, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother, sister, brother-in-law, or sister-in-law, including adoptive relationships, of the Grantee, (b) any person sharing the Grantee&#x2019;s household (other </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">than a tenant or employee), (c) a trust in which any one or more of the persons specified in clauses (a) and (b) above (and such Grantee) own more than fifty percent (50%) of the beneficial interest, (d) a foundation in which any one or more of the persons specified in clauses (a) and (b) above and (and such Grantee) control the management of assets, and (e) any other entity in which one or more of the persons specified in clauses (a) and (b) above and (and such Grantee) own more than fifty percent (50%) of the voting interests.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.411%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.23</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fully Diluted Basis</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, as of any date of determination, the sum of (x) the number of shares of Voting Stock outstanding as of such date of determination plus (y) the number of shares of Voting Stock issuable upon the exercise, conversion, or exchange of all then- outstanding warrants, options, convertible Capital Stock or indebtedness, exchangeable Capital Stock or indebtedness, or other rights exercisable for or convertible or exchangeable into, directly or indirectly, shares of Voting Stock, whether at the time of issue or upon the passage of time or upon the occurrence of some future event, and whether or not in-the-money as of such date of determination.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.935%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.472%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:4%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.24</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Grant Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as determined by the Board, the latest to occur of (i) the date as of which the Board approves the Award, (ii) the date on which the recipient of an Award first becomes eligible to receive an Award under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or (iii) such subsequent date as may be specified by the Board in a corporate action approving the Award.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.25</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Grantee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a person who receives or holds an Award under the Plan.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.26</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Group</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in Sections 13(d) and 14(d)(2) of the Exchange Act.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.27</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Independent Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.28</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Independent Director</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.29</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inducement Award Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.30</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-Employee Director</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in Rule 16b-3 under the Exchange Act.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.31</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an option to purchase one or more shares of Stock at a specified Option Price awarded to a Grantee pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that does not qualify as an &#x201c;incentive stock option&#x201d; within the meaning of Section 422 of the Code.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.32</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option Price</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the per share exercise price for shares of Stock subject to an Option.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.33</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 15</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.34</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside Director</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a member of the Board who is not an officer or Employee of the Company.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.35</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Equity-Based Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award representing a right or other interest that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Stock, other than an Option, Stock Appreciation Right, Restricted Stock, a Stock Unit, Unrestricted Stock, a Dividend Equivalent Right, or a Performance Award.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.36</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parachute Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 15.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.009%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.587%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:7.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.37</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award made subject to the attainment of performance goals (as determined by the Board) over a Performance Period of up to ten (10) years.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.398%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.415%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.398%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.38</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means measures as specified in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 14.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.333%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.561%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:6.398%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.39</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of time, up to ten (10) years, during which the performance goals must be met in order to determine the degree of payout and/or vesting with respect to a Performance Award.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.40</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Syndax Pharmaceuticals, Inc. 2023 Inducement Plan, as amended from time to time.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.415%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.398%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.41</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchase Price</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the purchase price for each share of Stock pursuant to a grant of Restricted Stock, Stock Units or Unrestricted Stock.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.42</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means shares of Stock awarded to a Grantee pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.43</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SAR Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the per share exercise price of a SAR.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.44</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as now in effect or as hereafter amended.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.45</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Market</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean an established securities market.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.46</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in Code Section 409A.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.397%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.47</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Service</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means service qualifying a Grantee as a Service Provider to the Company or any Affiliate. Unless otherwise provided in the applicable Award Agreement, a Grantee&#x2019;s change in position or duties shall not result in interrupted or terminated Service, so long as such Grantee continues to be a Service Provider to the Company or any Affiliate. Subject to the preceding sentence, any determination by the Board whether a termination of Service shall have occurred for purposes of the Plan shall be final, binding, and conclusive. If a Service Provider&#x2019;s employment or other Service relationship is with an Affiliate of the Company and the applicable entity ceases to be an Affiliate of the Company, a termination of Service shall be deemed to have occurred when such entity ceases to be an Affiliate unless the Service Provider transfers his or her employment or other Service relationship to the Company or any of its other Affiliates.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.417%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.415%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.398%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.48</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean (a) an Employee or Director of the Company or an Affiliate, or (b) a consultant or adviser to the Company or an Affiliate (i) who is a natural person, (ii) who is currently providing bona fide services to the Company or an Affiliate, and (iii) whose services are not in connection with the Company&#x2019;s sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company&#x2019;s Capital Stock; provided, that consultants and advisers are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.49</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Service Recipient Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in Code Section 409A.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:5.778%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.50</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:5.778%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.536%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:5.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.51</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the common stock, par value $0.0001 per share, of the Company, or any security into which shares of Stock may be changed or for which shares of Stock may be exchanged as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.52</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SAR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a right awarded to a Grantee under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.843%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.501%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:4.796%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.53</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the NASDAQ Stock Market LLC, any successor thereto, or another established national or regional stock exchange.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.54</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Unit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a bookkeeping entry representing the equivalent of one share of Stock awarded to a Grantee pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 10 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that may be settled, subject to the terms and conditions of the applicable Award Agreement, in shares of Stock, cash, or a combination thereof.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.935%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.401%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.55</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any corporation (other than the Company) or non-corporate entity with respect to which the Company owns, directly or indirectly, fifty percent (50%) or more of the total combined voting power of all classes of Voting Stock. In addition, any other entity may be designated by the Committee as a Subsidiary, provided that (a) such entity could be considered as a subsidiary according to generally accepted accounting principles in the United States of America and (b) in the case of an Award of Options or Stock Appreciation Rights, such Award would be considered to be granted in respect of Service Recipient Stock under Code Section 409A.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.889%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.468%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:3.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.56</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substitute Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award granted upon assumption of, or in substitution for, outstanding awards previously granted by a company or other entity acquired by the Company or an Affiliate or with which the Company or an Affiliate combines.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.57</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrestricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean Stock that is free of any restrictions.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.481%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.492%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:4.537%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.58</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Voting Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, with respect to any Person, Capital Stock of any class or kind ordinarily having the power to vote for the election of directors, managers, or other voting members of the governing body of such Person.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADMINISTRATION</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.5776271746766395%;display:inline-flex;justify-content:flex-start;">3.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Board.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board shall have such powers and authorities related to the administration of the Plan as are consistent with the Company&#x2019;s certificate of incorporation and by-laws, Applicable Laws, and the Inducement Award Rules. The Board shall have full power and authority to take all actions and to make all determinations required or provided for under the Plan, any Award, or any Award Agreement and shall have full power and authority to take all such other actions and to make all such other determinations not inconsistent with the specific terms and provisions of the Plan that the Board deems to be necessary or appropriate to the administration of the Plan, any Award, or any Award Agreement; provided, however, that Awards may only be granted by either (a) a majority of the Company&#x2019;s Independent Directors or (b) the Independent Compensation Committee. Subject to those constraints and the other constraints of the Inducement Award Rules, the Board may delegate some of its powers of administration of the Plan to a Committee or Committees, as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. All such actions and determinations shall be made by the affirmative vote of a majority of the members of the Board present at a meeting at which a quorum is present or by unanimous consent of the members of the Board executed in writing or evidenced by electronic transmission in accordance with the Company&#x2019;s certificate of incorporation and by-laws and Applicable Laws. The Board shall have the authority to interpret and construe all provisions of the Plan, any Award, and any Award Agreement, and any such interpretation and construction, and any other determination contemplated to be made under the Plan, any Award, or any Award Agreement, by the Board shall be final, binding, and conclusive on all persons, whether or not expressly provided for in any provision of the Plan, such Award, or such Award Agreement.</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Committee.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board from time to time may delegate to the Committee such powers and authorities related to the administration and implementation of the Plan, as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.1 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">above and other applicable provisions, as the Board shall determine, consistent with the Company&#x2019;s certificate of incorporation and by-laws, Applicable Laws, and the Inducement Award Rules.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as provided in Subsection (ii) and except as the Board may otherwise determine, the Committee, if any, appointed by the Board to administer the Plan shall consist of two or more Outside Directors of the Company who: (a) meet such requirements as may be established from time to time by the Securities and Exchange Commission for plans intended to qualify for exemption under Rule 16b-3 (or its successor) under the Exchange Act, and (b) comply with the independence requirements of the Stock Exchange or Securities Market on which the shares of Stock are listed or publicly traded.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board may also appoint one or more separate committees of the Board, each composed of one or more directors of the Company who need not be Outside Directors, who may administer the Plan with respect to Employees or other Service Providers who are not executive officers (as defined under Rule 3b-7 or the Exchange Act) or Directors of the Company, may grant Awards under the Plan to Eligible Employees (provided that Awards may only be granted by either (x) a majority of the Company&#x2019;s Independent Directors or (y) the Independent Compensation Committee), and may determine all terms of such Awards, subject to the requirements of the Inducement Award Rules, Rule 16b-3 and the rules of the Stock Exchange or Securities Market on which the shares of Stock are listed or publicly traded.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Plan, any Award, or any Award Agreement entered into hereunder provides for any action to be taken by or determination to be made by the Board, such action may be taken or such determination may be made by a Committee if the power and authority to do so has been delegated (and such delegated authority has not been revoked) to such Committee by the Board as provided for in this Section. Unless otherwise expressly determined by the Board, any such action or determination by the Committee shall be final, binding, and conclusive. To the extent permitted by Applicable Laws, the Committee may delegate its authority under the Plan to a member of the Board, provided, that such member of the Board to whom the Committee delegates authority under the Plan must be an Outside Director who satisfies the requirements of Subsection (i) (a)-(b) of this Section 3.2.</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Terms of Awards.</font></div></div>
  <p style="text-indent:6.519%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the other terms and conditions of the Plan and the Inducement Award Rules, the Board shall have full and final authority to:</font></p>
  <div style="text-indent:6.542%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designate Grantees (provided that Awards may only be granted by either (x) a majority of the Company&#x2019;s Independent Directors or (y) the Independent Compensation Committee)&#x37e;</font></div></div>
  <div style="text-indent:6.542%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determine the type or types of Awards to be made to a Grantee&#x37e;</font></div></div>
  <div style="text-indent:6.542%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determine the number of shares of Stock to be subject to an Award or to which an Award relates;</font></div></div>
  <div style="text-indent:6.542%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish the terms and conditions of each Award (including, but not limited to, the Option Price, SAR Exercise Price, the Purchase Price, the nature and duration of any restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer, or forfeiture of an Award or the shares of Stock subject thereto, the treatment of an Award in the event of a Change in Control (subject to applicable agreements)&#x37e;</font></div></div>
  <div style="text-indent:6.542%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prescribe the form of each Award Agreement evidencing an Award&#x37e;</font></div></div>
  <div style="text-indent:6.542%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to the limitations on repricing in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, amend, modify or supplement the terms of any outstanding Award. Such authority specifically includes the authority, in order to effectuate the purposes of the Plan but without amending the Plan, to make or modify outstanding Awards made to Eligible Employees who are foreign nationals or are individuals who are employed outside the United States to recognize differences in local law, tax policy, or custom. Notwithstanding the foregoing, no amendment, modification, or supplement of the terms of any outstanding Award shall, without the consent of the Grantee thereof, impair the Grantee&#x2019;s rights under such Award&#x37e; and</font></div></div>
  <div style="text-indent:6.542%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make Substitute Awards.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effect of Board&#x2019;s Decision.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forfeiture&#x37e; Recoupment.</font></div></div>
  <p style="text-indent:3.338%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board may reserve the right in an Award Agreement to cause a forfeiture of the gain realized by a Grantee with respect to an Award thereunder on account of actions taken by, or failed to be taken by, such Grantee in violation or breach of, or in conflict with, any (a) employment agreement, (b) non-competition agreement, (c) agreement prohibiting solicitation of employees or clients of the Company or any Affiliate, (d) confidentiality obligation with respect to the Company or any Affiliate, or (e) Company or Affiliate policy or procedure, (f) other agreement, or (g) other obligation of such Grantee to the Company or an Affiliate, as and to the extent specified in such Award Agreement. If the Grantee of an outstanding Award is an employee of the Company or any Affiliate and such Grantee&#x2019;s Service is terminated for Cause, the Committee may annul such Grantee&#x2019;s outstanding Award as of the date of the Grantee&#x2019;s termination of Service for Cause.</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any Award granted pursuant to the Plan shall be subject to mandatory repayment by the Grantee to the Company (x) to the extent set forth in this Plan or an Award Agreement or (y) to the extent the Grantee is, or in the future becomes, subject to (i) any Company &#x201c;clawback&#x201d; or recoupment policy that is adopted to comply with the requirements of any Applicable Laws or (ii) any Applicable Laws which impose mandatory recoupment, under circumstances set forth in such Applicable Laws.</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, if the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the federal securities laws, and any Award Agreement so provides, any Grantee of an Award under such Award Agreement who knowingly engaged in such misconduct, was grossly negligent in engaging in such misconduct, knowingly failed to prevent such misconduct, or was grossly negligent in failing to prevent such misconduct, shall reimburse the Company the amount of any payment in settlement of an Award earned or accrued during the 12-month period following the first public issuance or filing with the United States Securities and Exchange Commission (whichever first occurred) of the financial document that contained information affected by such material noncompliance.</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any other provision of the Plan or any provision of any Award Agreement, if the Company is required to prepare an accounting restatement, then a Grantee shall forfeit any cash or shares of Stock received</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in connection with an Award (or an amount equal to the Fair Market Value of such shares of Stock on the date of delivery if the Grantee no longer holds the shares of Stock) if pursuant to the terms of the Award Agreement for such Award, the amount of the Award earned or the vesting in the Award was explicitly based on the achievement of pre- established performance goals set forth in the Award Agreement (including earnings, gains, or other performance goals) that are later determined, as a result of the accounting restatement, not to have been achieved.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">3.6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No Repricing Without Stockholder Approval.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, distribution (whether in the form of cash, shares of Stock, other securities, or other property), stock split, extraordinary dividend, recapitalization, Change in Control, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of shares of Stock, or other securities or similar transaction), the Company may not: (a) amend the terms of outstanding Options or SARs to reduce the Option Price or SAR Exercise Price, as applicable, of such outstanding Options or SARs&#x37e; (b) cancel outstanding Options or SARs in exchange for or substitution of Options or SARs with an Option Price or SAR Exercise Price, as applicable, that is less than the Option Price or SAR Exercise Price of the original Options or SARs&#x37e; or (c) cancel outstanding Options or SARs with an Option Price or SAR Exercise Price, as applicable, above the current per share Fair Market Value in exchange for cash or other securities, in each case unless such action (i) is subject to and approved by the Company&#x2019;s stockholders or (ii) would not be deemed to be a repricing under the rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">3.7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferral Arrangement.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board may permit or require the deferral of any payment pursuant to an Award into a deferred compensation arrangement, subject to such rules and procedures as it may establish, which may include provisions for the payment or crediting of interest or Dividend Equivalent Rights and, in connection therewith, provisions for converting such credits into deferred Stock Units and for restricting deferrals to comply with hardship distribution rules affecting tax-qualified retirement plans subject to Code Section 401(k)(2)(B)(IV)&#x37e; provided that no Dividend Equivalent Rights may be granted in connection with, or related to, an Award of Options or SARs. Any such deferrals shall be made in a manner that complies with Code Section 409A, including, if applicable, with respect to when a Separation from Service occurs.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">3.8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limitation on Liability.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No member of the Board or the Committee shall be liable for any action or determination made in good faith with respect to the Plan, any Award, or any Award Agreement. Notwithstanding any provision of the Plan to the contrary, neither the Company, any of its Affiliates, the Board, the Committee, nor any person acting on behalf of the Company, any of its Affiliates, the Board, or the Committee will be liable to any Grantee or to the estate or beneficiary of any Grantee or to any other holder of an Award under the Plan by reason of any acceleration of income, or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements of Code Section 409A or by reason of Code Section 4999, or otherwise asserted with respect to the Award&#x37e; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.8 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shall not affect any of the rights or obligations set forth in an applicable agreement between the Grantee and the Company or any of its Affiliates.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">3.9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Issuance/Book-Entry.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any provision of this Plan to the contrary, the issuance of the shares of Stock under the Plan may be evidenced in such a manner as the Board, in its discretion, deems appropriate, including by book-entry or direct registration (including transaction advices) or the issuance of one or more share certificates.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.073267088467979%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STOCK SUBJECT TO THE PLAN</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">4.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares of Stock Available for Awards.</font></div></div>
  <p style="text-indent:3.633%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.633%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the other provisions of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 4 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and subject to adjustment as provided under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 3,000,000 shares of Stock shall be authorized for issuance pursuant to Awards under the Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:1.241375029741277%;display:inline-flex;justify-content:flex-start;">4.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjustments in Authorized Shares of Stock.</font></div></div>
  <p style="text-indent:3.631%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.631%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board shall have the right to substitute or assume awards in connection with mergers, reorganizations, separations, or other transactions. The Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shall be increased by the corresponding number of awards assumed and, in the case of a substitution, by the net increase in the number of shares of Stock subject to awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">before and after the substitution. Shares available for issuance under a stockholder-approved plan of a business entity that is party to such transaction (as appropriately adjusted, if necessary, to reflect the transaction) may be used for Awards under the Plan and shall not reduce the number of shares of Stock otherwise available for issuance under the Plan, subject to applicable rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:1.241375029741277%;display:inline-flex;justify-content:flex-start;">4.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share Usage.</font></div></div>
  <p style="text-indent:3.633%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.633%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of Stock covered by an Award shall be counted as used as of the Grant Date for purposes of calculating the number of shares of Stock available for issuance under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Any shares of Stock that are subject to Awards, including shares of Stock acquired through dividend reinvestment pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, will be counted against the limit set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as one (1) share of Stock for every one (1) share of Stock subject to an Award. With respect to SARs, the number of shares of Stock subject to an award of SARs will be counted against the aggregate number of shares of Stock available for issuance under the Plan regardless of the number of shares of Stock actually issued to settle the SAR upon exercise. The target number of shares issuable under a Performance Award grant shall be counted against the limit set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as of the Grant Date, but such number shall be adjusted to equal the actual number of shares issued upon settlement of the Performance Award to the extent different from such target number of shares. If any shares of Stock covered by an Award granted under the Plan are not purchased or are forfeited or expire, or if an Award otherwise terminates without delivery of any shares of Stock subject thereto or is settled in cash in lieu of shares of Stock, then the number of shares of Stock counted against the aggregate number of shares of Stock available under the Plan with respect to such Award shall, to the extent of any such forfeiture, termination, expiration, or settlement, again be available for making Awards under the Plan in the same amount as such shares of Stock were counted against the limit set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of Stock available for issuance under the Plan will not be increased by the number of shares of Stock (i) tendered, withheld, or subject to an Award granted under the Plan surrendered in connection with the purchase of shares of Stock upon exercise of an Option, (ii) that were not issued upon the net settlement or net exercise of a Stock-settled SAR granted under the Plan, (iii) deducted or delivered from payment of an Award granted under the Plan in connection with the Company&#x2019;s tax withholding obligations as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 18.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or (iv) purchased by the Company with proceeds from Option exercises.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EFFECTIVE DATE, DURATION AND AMENDMENTS</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">5.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective Date.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Plan shall be effective as of the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">5.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Term.</font></div></div>
  <p style="text-indent:3.377%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.377%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Plan shall terminate on the first to occur of (a) the tenth (10th) anniversary of the Effective Date, (b) the date determined in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 5.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and (c) the date determined in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Upon such termination of the Plan, all outstanding Awards shall continue to have full force and effect in accordance with the provisions of the terminated Plan and the applicable Award Agreement (or other documents evidencing such Awards).</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">5.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendment, Suspension and Termination of the Plan.</font></div></div>
  <p style="text-indent:3.394%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.778%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.394%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.778%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board may, at any time and from time to time, amend, suspend, or terminate the Plan&#x37e; provided that, with respect to Awards theretofore granted under the Plan, no amendment, suspension, or termination of the Plan shall, without the consent of the Grantee, impair rights or obligations under any such Award theretofore awarded under the Plan. The effectiveness of any amendment to the Plan shall be contingent on approval of such amendment by the Company&#x2019;s stockholders to the extent stated by the Board, required by Applicable Laws, or required by the Stock Exchange or Securities Market on which the shares of Stock are listed or publicly traded.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AWARD ELIGIBILITY AND LIMITATIONS</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">6.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eligibility for Awards.</font></div></div>
  <p style="text-indent:3.478%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.157%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.478%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Awards may only be granted to persons who are Eligible Employees described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Plan, where the Award is an inducement material to the individual&#x2019;s entering into</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the NASDAQ Marketplace Rules, provided however, that Awards may not be granted to Employees who are providing Service only to any &#x201c;parent&#x201d; of the Company, as such term is defined in Rule 405 of the Securities Act, unless (i) the stock underlying such Awards is treated as &#x201c;service recipient stock&#x201d; under Section 409A of the Code (for example, because the Awards are granted pursuant to a corporate transaction such as a spin off transaction), or (ii) the Company, in consultation with its legal counsel, has determined that such Awards are otherwise exempt from or comply with the distribution requirements of Section 409A of the Code.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">6.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stand-Alone, Additional, Tandem, and Substitute Awards.</font></div></div>
  <p style="text-indent:3.405%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.102%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.405%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Awards granted under the Plan may, in the discretion of the Board, be granted either alone or in addition to, in tandem with, or in substitution or exchange for, any other Award or any award granted under another plan of the Company, any Affiliate, or any business entity to be acquired by the Company or an Affiliate, or any other right of a Grantee to receive payment from the Company or any Affiliate. Such additional, tandem, exchange, or Substitute Awards may be granted at any time. If an Award is granted in substitution or exchange for another Award, or for an award granted under another plan of the Company, an Affiliate, or any business entity that has been a party to a transaction with the Company or an Affiliate, the Board shall require the surrender of such other Award or award under such other plan in consideration for such exchange or grant of the Substitute Award. In addition, Awards may be granted in lieu of cash compensation, including in lieu of cash amounts payable under other plans of the Company or any Affiliate. Notwithstanding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8.1 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 9.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, but subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Option Price of an Option or the SAR Exercise Price of an SAR that is a Substitute Award may be less than one hundred percent (100%) of the Fair Market Value of a share of Stock on the original Grant Date&#x37e; provided, that, the Option Price or SAR Exercise Price is consistent with Code Section 409A for any Option or SAR.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AWARD AGREEMENT</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Award granted pursuant to the Plan shall be evidenced by an Award Agreement, in such form or forms as the Board shall from time to time determine. Award Agreements utilized under the Plan from time to time or at the same time need not contain similar provisions but shall be consistent with the terms of the Plan. Each Award Agreement evidencing an Award of Options shall specify that such Options are intended to be nonqualified, and, in the absence of such specification, such Options shall be deemed to be nonqualified. In the event of any inconsistency between the Plan and an Award Agreement, the provisions of the Plan shall control.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF OPTIONS</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option Price.</font></div></div>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Option Price of each Option shall be fixed by the Board and stated in the Award Agreement evidencing such Option. Except in the case of Substitute Awards, the Option Price of each Option shall be at least the Fair Market Value of one (1) share of Stock on the Grant Date. In no case shall the Option Price of any Option be less than the par value of one (1) share of Stock.</font></p>
  <p style="text-indent:5.113%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:34.806%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting and Exercisability.</font></div></div>
  <p style="text-indent:3.386%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.546%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.386%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.546%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sections 8.3 and 17.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, each Option granted under the Plan shall become vested and/or exercisable at such times and under such conditions as shall be determined by the Board and stated in the Award Agreement, in another agreement with the Grantee, or otherwise in writing&#x37e; provided that no Option shall be granted to Grantees who are entitled to overtime under Applicable Laws that will vest or be exercisable within a six (6)-month period starting on the Grant Date.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Term.</font></div></div>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Option granted under the Plan shall terminate, and all rights to purchase shares of Stock thereunder shall cease, upon the expiration of ten (10) years from the Grant Date of such Option, or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the Board and stated in the Award Agreement relating to such Option&#x37e; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that to the extent deemed necessary or appropriate by the Board to reflect differences in local law, tax policy, or custom with respect to any Option granted to a Grantee who is a foreign national or is a natural Person who is employed outside the United States, such Option may terminate, and all rights to purchase shares of Stock thereunder may cease, upon the expiration of a period longer than ten (10) years from the Grant Date of such Option as the Board shall determine.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Termination of Service.</font></div></div>
  <p style="text-indent:3.452%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.435%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.452%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.435%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Award Agreement with respect to the grant of an Option shall set forth the extent to which the Grantee thereof, if at all, shall have the right to exercise such Option following termination of such Grantee&#x2019;s Service. Such provisions shall be determined in the sole discretion of the Board, need not be uniform among all Options issued pursuant to the Plan, and may reflect distinctions based on the reasons for termination of Service.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limitations on Exercise of Option.</font></div></div>
  <p style="text-indent:3.419%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.5%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.419%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.5%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any other provision of the Plan, in no event may any Option be exercised, in whole or in part, after the occurrence of an event referred to in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which results in the termination of the Option.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Method of Exercise.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 12 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 18.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, an Option that is exercisable may be exercised by the Grantee&#x2019;s delivery to the Company or its designee or agent of notice of exercise on any business day, at the Company&#x2019;s principal office, or the office of such designee or agent, on the form specified by the Company and in accordance with any additional procedures specified by the Board. Such notice shall specify the number of shares of Stock with respect to which the Option is being exercised and shall be accompanied by payment in full of the Option Price of the shares of Stock for which the Option is being exercised plus the amount (if any) of federal and/or other taxes which the Company may, in its judgment, be required to withhold with respect to the exercise of such Option.</font></p>
  <p style="text-indent:5.113%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:34.806%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rights of Holders of Options.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise stated in the applicable Award Agreement, a Grantee or other person holding or exercising an Option shall have none of the rights of a stockholder of the Company (for example, the right to receive cash or dividend payments or distributions attributable to the subject shares of Stock or to direct the voting of the subject shares of Stock subject to such Option, or to receive notice of any meeting of the Company&#x2019;s stockholders) until the shares of Stock subject thereto are fully paid and issued to such Grantee or other person. Except as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, no adjustment shall be made for dividends, distributions or other rights with respect to any shares of Stock subject to an Option for which the record date is prior to the date of issuance of such shares of Stock.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delivery of Stock Certificates.</font></div></div>
  <p style="text-indent:3.419%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.5%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.419%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.5%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Promptly after the exercise of an Option by a Grantee and the payment in full of the Option Price, such Grantee shall be entitled to the issuance of a stock certificate or certificates evidencing his or her ownership of the shares of Stock subject to the Option, as shall be consistent with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transferability of Options.</font></div></div>
  <p style="text-indent:3.478%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.157%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.478%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8.10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, during the lifetime of a Grantee of an Option, only the Grantee (or, in the event of such Grantee&#x2019;s legal incapacity or incompetency, the Grantee&#x2019;s guardian or legal representative) may exercise such Option. Except as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8.10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, no Option shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">8.10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family Transfers.</font></div></div>
  <p style="text-indent:3.381%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.407%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.381%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.407%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If authorized in the applicable Award Agreement and by the Board, in its sole discretion, a Grantee may transfer, not for value, all or part of an Option to any Family Member. For the purpose of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8.10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a &#x201c;not for value&#x201d; transfer is a transfer which is (i) a gift, (ii) a transfer under a domestic relations order in settlement of marital property rights&#x37e; or (iii) unless Applicable Laws do not permit such transfer, a transfer to an entity in which more than fifty percent (50%) of the voting interests are owned by Family Members (or the Grantee) in exchange for an interest in that entity. Following a transfer under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8.10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, any such Option shall continue to be subject to the same terms and conditions as were applicable immediately prior to such transfer. Subsequent transfers of transferred Options are prohibited except to Family Members of the original Grantee in accordance with this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8.10 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or by will or the laws of descent and distribution. The events of termination of Service of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8.4 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shall continue to be applied with respect to the original Grantee, following which such Option shall be exercisable by the transferee only to the extent, and for the periods specified, in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.073267088467979%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">9.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right to Payment and SAR Exercise Price.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.389%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.63%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A SAR shall confer on the Grantee to whom it is granted a right to receive, upon exercise thereof, the excess of (A) the Fair Market Value of one (1) share of Stock on the date of exercise over (B) the SAR Exercise Price as determined by the Board. The Award Agreement for a SAR shall specify the SAR Exercise Price, which shall be no less than the Fair Market Value of one (1) share of Stock on the Grant Date. SARs may be granted in conjunction with all or part of an Option granted under the Plan or at any subsequent time during the term of such Option, in conjunction with all or any part of any other Award or without regard to any Option or other Award&#x37e; provided that a SAR that is granted in tandem with all or part of an Option will have the same term, and expire at the same time, as the related Option&#x37e; provided, further, that a SAR that is granted subsequent to the Grant Date of a related Option must have a SAR Exercise Price that is no less than the Fair Market Value of one share of Stock on the SAR Grant Date.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">9.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Terms.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board shall determine on the Grant Date or thereafter, the time or times at which and the circumstances under which a SAR may be exercised in whole or in part (including based on achievement of performance goals and/or future service requirements), the time or times at which SARs shall cease to be or become exercisable following termination of Service or upon other conditions, the method of exercise, method of settlement, form of consideration payable in settlement, method by or forms in which shares of Stock will be delivered or deemed to be delivered to Grantees, whether or not a SAR shall be granted in tandem or in combination with any other Award&#x37e; and any and all other terms and conditions of any SAR&#x37e; provided that no SARs shall be granted to Grantees who are entitled to overtime under Applicable Laws that will vest or be exercisable within a six (6)-month period starting on the Grant Date.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">9.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Term.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each SAR granted under the Plan shall terminate, and all rights thereunder shall cease, upon the expiration of ten (10) years from the Grant Date of such SAR, or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the Board and stated in the Award Agreement relating to such SAR.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">9.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rights of Holders of SARs.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise stated in the applicable Award Agreement, a Grantee or other Person holding or exercising a SAR shall have none of the rights of a stockholder of the Company (for example, the right to receive cash or dividend payments or distributions attributable to the shares of Stock underlying such SAR, to direct the voting of the shares of Stock underlying such SAR, or to receive notice of any meeting of the Company&#x2019;s stockholders) until the shares of Stock underlying such SAR, if any, are issued to such Grantee or other Person. Except as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, no adjustment shall be made for dividends, distributions, or other rights with respect to any shares of Stock underlying a SAR for which the record date is prior to the date of issuance of such shares of Stock, if any.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">9.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transferability of SARs.</font></div></div>
  <p style="text-indent:3.478%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.157%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.478%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 9.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, during the lifetime of a Grantee of a SAR, only the Grantee (or, in the event of such Grantee&#x2019;s legal incapacity or incompetency, such Grantee&#x2019;s guardian or legal representative) may exercise such SAR. Except as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 9.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, no SAR shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">9.6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Family Transfers.</font></div></div>
  <p style="text-indent:3.389%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.63%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.389%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.63%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If authorized in the applicable Award Agreement and by the Board, in its sole discretion, a Grantee may transfer, not for value, all or part of a SAR to any Family Member. For the purpose of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 9.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a &#x201c;not for value&#x201d; transfer is a transfer which is (i) a gift, (ii) a transfer under a domestic relations order in settlement of marital property rights&#x37e; or (iii) unless Applicable Laws do not permit such transfers, a transfer to an entity in which more than fifty percent (50%) of the voting interests are owned by Family Members (and/or the Grantee) in exchange for an interest in that entity. Following a transfer under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 9.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, any such SAR shall continue to be subject to the same terms and conditions as were applicable immediately prior to such transfer. Subsequent transfers of transferred SARs are prohibited except to Family Members of the original Grantee in accordance with this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 9.6 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or by will or the laws of descent and distribution.</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF RESTRICTED STOCK AND STOCK UNITS</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">10.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Grant of Restricted Stock or Stock Units.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Awards of Restricted Stock or Stock Units may be made in consideration for the promise to perform future Service to the Company or an Affiliate.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">10.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions.</font></div></div>
  <p style="text-indent:3.419%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.5%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.419%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.5%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the time a grant of Restricted Stock or Stock Units is made, the Board may, in its sole discretion, establish a period of time (a &#x201c;restricted period&#x201d;) applicable to such Restricted Stock or Stock Units. Each Award of Restricted Stock or Stock Units may be subject to a different restricted period. The Board may in its sole discretion, at the time a grant of Restricted Stock or Stock Units is made, prescribe restrictions in addition to or other than the expiration of the restricted period, including the achievement of corporate or individual performance objectives, which may be applicable to all or any portion of the Restricted Stock or Stock Units as described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Neither Restricted Stock nor Stock Units may be sold, transferred, assigned, pledged or otherwise encumbered or disposed of during the restricted period or prior to the satisfaction of any other restrictions prescribed by the Board with respect to such Restricted Stock or Stock Units.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">10.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Certificates.</font></div></div>
  <p style="text-indent:3.386%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.546%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.386%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.546%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to the extent that ownership of Restricted Stock is evidenced by a book-entry registration or direct registration (including transaction advices), such registration shall be notated to evidence the restrictions imposed on such Award of Restricted Stock under the Plan and the applicable Award Agreement. Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the immediately following sentence, the Company may issue, in the name of each Grantee to whom Restricted Stock has been granted, certificates representing the total number of shares of Restricted Stock granted to the Grantee, as soon as reasonably practicable after the Grant Date of such Restricted Stock. The Board may provide in an Award Agreement with respect to an Award of Restricted Stock that either (i) the Secretary of the Company shall hold such certificates for the Grantee&#x2019;s benefit until such time as the shares of Restricted Stock are forfeited to the Company or the restrictions applicable thereto lapse and such Grantee shall deliver a stock power to the Company with respect to each certificate, or (ii) such certificates shall be delivered to such Grantee, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that such certificates shall bear a legend or legends that comply with the applicable securities laws and regulations and makes appropriate reference to the restrictions imposed on such Award of Restricted Stock under the Plan and such Award Agreement.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">10.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rights of Holders of Restricted Stock.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless the Board otherwise provides in an Award Agreement, holders of Restricted Stock shall have the right to vote such shares of Stock and the right to receive any dividend payments or distributions declared or paid with respect to such shares of Restricted Stock. The Board may provide in an Award Agreement evidencing a grant of Restricted Stock that that (a) any cash dividend payments or distributions paid on Restricted Stock must be reinvested in shares of Stock, which may or may not be subject to the same vesting conditions and restrictions as applicable to such underlying shares of Restricted Stock or (b) any dividend payments or distributions declared or paid on shares of Restricted Stock shall only be made or paid upon satisfaction of the vesting conditions and restrictions applicable to such shares of Restricted Stock. Dividend payments or distributions declared or paid on shares of Restricted Stock which vest or are earned based upon the achievement of performance goals shall not vest unless such performance goals for such shares of Restricted Stock are achieved, and if such performance goals are not achieved, the Grantee of such shares of Restricted Stock shall promptly forfeit and, to the extent already paid or distributed, repay to the Company such dividend payments or distributions. All stock dividend payments or distributions, if any received by a Grantee with respect to shares of Restricted Stock as a result of any stock split, stock dividend, combination of stock, or other similar transaction shall be subject to the same vesting conditions and restrictions as applicable to such underlying shares of Restricted Stock.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">10.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rights of Holders of Stock Units.</font></div></div>
  <p style="margin-left:10.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:4.42501580362787%;display:inline-flex;justify-content:flex-start;">10.5.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Voting and Dividend Rights.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Stock Units shall have no rights as stockholders of the Company. The Board may provide in an Award Agreement evidencing a grant of Stock Units that the holder of such Stock Units shall be entitled to receive, upon the Company&#x2019;s payment of a cash dividend on its outstanding shares of Stock, a cash payment for</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each Stock Unit held equal to the per-stock dividend paid on the shares of Stock. Such Award Agreement may also provide that such cash payment will be deemed reinvested in additional Stock Units at a price per unit equal to the Fair Market Value of a share of Stock on the date on which such dividend is paid.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:4.42501580362787%;display:inline-flex;justify-content:flex-start;">10.5.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Creditor&#x2019;s Rights.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A holder of Stock Units shall have no rights other than those of a general unsecured creditor of the Company. Stock Units represent an unfunded and unsecured obligation of the Company, subject to the terms and conditions of the applicable Award Agreement.</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">10.6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Termination of Service.</font></div></div>
  <p style="text-indent:3.389%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.63%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.389%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.63%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless the Board otherwise provides in an Award Agreement, in another agreement with the Grantee, or otherwise in writing after such Award Agreement is issued, but prior to the termination of a Grantee&#x2019;s Service, upon the termination of such Grantee&#x2019;s Service, any Restricted Stock or Stock Units held by such Grantee that have not vested, or with respect to which all applicable restrictions and conditions have not lapsed, shall immediately be deemed forfeited. Upon forfeiture of Restricted Stock or Stock Units, the Grantee shall have no further rights with respect to such Award, including but not limited to any right to vote Restricted Stock or any right to receive dividends or Dividend Equivalent Rights, as applicable, with respect to Restricted Stock or Stock Units.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">10.7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchase of Restricted Stock and Shares of Stock Subject to Stock Units.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Grantee of an Award of Restricted Stock or vested Stock Units shall be required, to the extent required by Applicable Laws, to purchase such Restricted Stock or shares of Stock subject to such vested Stock Units from the Company at a Purchase Price equal to the greater of (i) the aggregate par value of the shares of Stock represented by such Restricted Stock or such vested Stock Units or (ii) the Purchase Price, if any, specified in the Award Agreement relating to such Restricted Stock or such vested Stock Units. The Purchase Price shall be payable in a form described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 12 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or in consideration for future Service to be rendered by the Grantee to the Company or an Affiliate.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">10.8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delivery of Shares of Stock.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the expiration or termination of any restricted period and the satisfaction of any other conditions prescribed by the Board, the restrictions applicable to Restricted Stock or Stock Units settled in shares of Stock shall lapse, and, unless otherwise provided in the Award Agreement, a book-entry or direct registration (including transaction advices) or a certificate evidencing ownership of such shares of Stock shall, consistent with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3.9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, be issued, free of all such restrictions, to the Grantee thereof or the Grantee&#x2019;s beneficiary or estate, as the case may be. Neither the Grantee, nor the Grantee&#x2019;s beneficiary or estate, shall have any further rights with regard to a Stock Unit once the shares of Stock represented by such Stock Unit have been delivered in accordance with this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 10.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF UNRESTRICTED STOCK AWARDS AND OTHER EQUITY-BASED AWARDS</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">11.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrestricted Stock Awards.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board may, in its sole discretion, grant (or sell at par value or at such other higher purchase price determined by the Board) an Unrestricted Stock Award to any Grantee pursuant to which such Grantee may receive shares of Unrestricted Stock under the Plan. Unrestricted Stock Awards may be granted or sold as described in the preceding sentence in respect of Service rendered or, if so provided in the related Award Agreement or a separate agreement, to be rendered by the Grantee to the Company or an Affiliate or other valid consideration, in lieu of, or in addition to, any cash compensation due to such Grantee.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">11.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Equity-Based Awards.</font></div></div>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board may, in its sole discretion, grant Awards to Participants in the form of Other Equity-Based Awards, as deemed by the Board to be consistent with the purposes of the Plan. Awards granted pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 11.2 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may be granted with vesting, value and/or payment contingent upon the attainment of one or more performance goals. The Board shall determine the terms and conditions of such Other Equity-Based Awards on the Grant Date or thereafter. Unless the Board otherwise provides in an Award Agreement, in another agreement with the Grantee, or otherwise or in writing after the Award Agreement is issued, upon the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">termination of a Grantee&#x2019;s Service, any Other Equity-Based Awards held by such Grantee that have not vested, or with respect to which all applicable restrictions and conditions have not lapsed, shall immediately be deemed forfeited. Upon forfeiture of Other Equity-Based Awards, the Grantee shall have no further rights with respect to such Award.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM OF PAYMENT FOR OPTIONS AND RESTRICTED STOCK</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">12.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Rule.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.419%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.5%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payment of the Option Price for the shares of Stock purchased pursuant to the exercise of an Option or the Purchase Price, if any, for Restricted Stock shall be made in cash or in cash equivalents acceptable to the Company.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">12.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Surrender of Shares of Stock.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent the Award Agreement so provides, payment of the Option Price for shares of Stock purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock may be made all or in part through the tender or attestation to the Company of shares of Stock, which shall be valued, for purposes of determining the extent to which the Option Price or Purchase Price has been paid thereby, at their Fair Market Value on the date of such tender or attestation.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">12.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cashless Exercise.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to an Option only (and not with respect to Restricted Stock), to the extent permitted by law and to the extent the Award Agreement so provides, payment of the Option Price for shares of Stock purchased pursuant to the exercise of an Option may be made all or in part by delivery (on a form acceptable to the Board) of an irrevocable direction to a licensed securities broker acceptable to the Company to sell shares of Stock and to deliver all or part of the sales proceeds to the Company in payment of the Option Price and any withholding taxes described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 18.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or, with the consent of the Company, by issuing the number of shares of Stock equal in value to the difference between the Option Price and the Fair Market Value of the shares of Stock subject to the portion of the Option being exercised.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">12.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Forms of Payment.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent the Award Agreement so provides and/or unless otherwise specified in an Award Agreement, payment of the Option Price for shares of Stock purchased pursuant to exercise of an Option or the Purchase Price, if any, for Restricted Stock may be made in any other form that is consistent with Applicable Laws, regulations and rules, including, without limitation, Service by the Grantee thereof to the Company or an Affiliate.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF DIVIDEND EQUIVALENT RIGHTS</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">13.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Equivalent Rights.</font></div></div>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A Dividend Equivalent Right is an Award entitling the recipient to receive credits based on cash distributions that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares of Stock had been issued to and held by the recipient. A Dividend Equivalent Right may be granted hereunder to any Grantee, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that no Dividend Equivalent Rights may be granted in connection with, or related to, an Award of Options or SARs. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement therefor. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently (with or without being subject to forfeiture or a repayment obligation) or may be deemed to be reinvested in additional shares of Stock or Awards, which may thereafter accrue additional Dividend Equivalent Rights (with or without being subject to forfeiture or a repayment obligation). Any such reinvestment shall be at the Fair Market Value on the date of reinvestment. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or multiple installments, all determined in the sole discretion of the Board. A Dividend Equivalent Right granted as a component of another Award may provide that such Dividend Equivalent Right shall be settled upon exercise, settlement, or payment of, or lapse of restrictions on, such other award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other award. A Dividend Equivalent Right granted as a component of another Award may also contain terms and conditions different from such other Award&#x37e; provided, however, that Dividend Equivalent Rights credited pursuant to a Dividend Equivalent Right granted as a component of another Award which vests or is earned</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based upon the achievement of performance goals shall not vest unless the performance goals for such underlying Award are achieved, and if such performance goals are not achieved, the Grantee of such Dividend Equivalent Rights shall promptly forfeit and, to the extent already paid or distributed, repay to the Company payments or distributions made in connection with such Dividend Equivalent Rights.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">13.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Termination of Service.</font></div></div>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless the Board otherwise provides in an Award Agreement, in another agreement with the Grantee, or otherwise or in writing after the Award Agreement is issued, a Grantee&#x2019;s rights in all Dividend Equivalent Rights shall automatically terminate upon such Grantee&#x2019;s termination of Service for any reason.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF PERFORMANCE AWARDS </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">14.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Grant of Performance Awards.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and provisions of the Plan, the Board, at any time and from time to time, may grant Performance Awards to a Plan participant in such amounts and upon such terms as the Committee shall determine.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">14.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Value of Performance Awards.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Performance Award shall have an initial cash value or an actual or target number of shares of Stock that is established by the Board as of the Grant Date. The Board shall set performance goals in its discretion which, depending on the extent to which they are achieved, shall determine the value and/or number of shares of Stock subject to Performance Awards that will be paid out to the Grantee thereof.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">14.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Earning of Performance Awards.</font></div></div>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms of the Plan, after the applicable Performance Period has ended, the Grantee of Performance Awards shall be entitled to receive a payout of the value earned under such Performance Awards earned by such Grantee over such Performance Period.</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">14.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Form and Timing of Payment of Performance Awards.</font></div></div>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.398%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payment of the value earned under Performance Awards shall be made, as determined by the Committee, in the form, at the time, and in the manner described in the applicable Award Agreement. Subject to the terms of the Plan, the Committee, in its sole discretion, (i) may pay the value earned under Performance Awards in the form of cash, shares of Stock, or other Awards, or in a combination thereof, including shares of Stock and/or Awards, including shares of Stock and/or Awards that are subject to any restrictions deemed appropriate by the Committee, and (ii) shall pay the value earned under Performance Awards at the close of the applicable Performance Period, or as soon as reasonably practicable after the Committee has determined that the performance goal or goals relating thereto have been achieved&#x37e; provided that, unless specifically provided in the Award Agreement, such payment shall occur no later than the fifteenth (15th) day of the third (3rd) month following the end of the calendar year in which such Performance Period ends.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">14.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance Conditions.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The right of a Grantee to exercise or to receive a grant or settlement of any Performance Award, and the timing thereof, may be subject to such performance conditions as may be specified by the Board. The Board may use such business criteria and other measures of performance as it may deem appropriate in establishing any performance conditions.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:4.42501580362787%;display:inline-flex;justify-content:flex-start;">14.5.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance Goals Generally.</font></div></div>
  <p style="margin-left:0.84%;text-indent:5.971%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:5.971%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The performance goals for Performance Awards shall consist of one or more business criteria and a targeted level or levels of performance with respect to each of such criteria, as specified by the Committee. The Committee may determine that such Awards shall be granted, exercised and/or settled upon achievement of any single performance goal or of two (2) or more performance goals. Performance goals may differ for Awards granted to any one Grantee or to different Grantees.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:4.42501580362787%;display:inline-flex;justify-content:flex-start;">14.5.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payment of Awards&#x37e; Other Terms.</font></div></div>
  <p style="margin-left:0.84%;text-indent:5.974%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.407%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:5.974%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.407%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payment of such Awards shall be in cash, shares of Stock, other Awards, or a combination thereof, including shares of Stock and/or Awards that are subject to any restrictions deemed appropriate by the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.407%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Committee, in each case as determined in the sole discretion of the Committee. The Committee may, in its sole discretion, reduce the amount of a payment otherwise to be made in connection with such Awards. The Committee shall specify the circumstances in which such Performance Awards shall be paid or forfeited in the event of termination of Service by the Grantee prior to the end of a Performance Period or settlement of such Performance Awards. In the event payment of the Performance-Based Award is made in the form of another Award subject to Service-based vesting, the Committee shall specify the circumstances in which the Award will be paid out or forfeited in the event of a termination of Service.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:4.42501580362787%;display:inline-flex;justify-content:flex-start;">14.5.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance Measures.</font></div></div>
  <p style="margin-left:10.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:5.164%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The performance goals upon which the payment or vesting of a Performance Award may be conditioned may be based on any one of, or combination of, the following Performance Measures, as selected by the Committee, with or without adjustment (including pro forma adjustments): (a) net earnings or net income; (b) operating earnings&#x37e; (c) pretax earnings&#x37e; (d) earnings per share of stock&#x37e; (e) stock price, including growth measures and total stockholder return&#x37e; (f) earnings before interest and taxes&#x37e; (g) earnings before interest, taxes, depreciation and/or amortization&#x37e; (h) earnings before interest, taxes, depreciation and/or amortization as adjusted to exclude any one or more of the following: stock-based compensation expense&#x37e; income from discontinued operations&#x37e; gain on cancellation of debt&#x37e; debt extinguishment and related costs&#x37e; restructuring, separation, and/or integration charges and costs&#x37e; reorganization and/or recapitalization charges and costs&#x37e; impairment charges&#x37e; merger-related events&#x37e; gain or loss related to investments&#x37e; sales and use tax settlements&#x37e; and gain on non-monetary transactions&#x37e; (i) sales or revenue growth, whether in general, by type of product or service, or by type of customer&#x37e; (j) gross or operating margins&#x37e; (k) return measures, including return on assets, capital, investment, equity, sales or revenue&#x37e; (l) cash flow, including operating cash flow, free cash flow, cash flow return on equity and cash flow return on investment&#x37e; (m) productivity ratios&#x37e; (n) expense targets&#x37e; (o) market share&#x37e; (p) financial ratios as provided in credit agreements of the Company and its subsidiaries&#x37e; (q) working capital targets&#x37e; (r) completion of acquisitions of business or companies&#x37e; (s) completion of divestitures and asset sales&#x37e; (t) revenues under management&#x37e; (u) funds from operations&#x37e; (v) successful implementation of clinical trials, including components thereof&#x37e; (w) submitting regulatory filings&#x37e; (x) obtaining regulatory or marketing approvals&#x37e; (y) entering into contractual agreements&#x37e; (z) meeting contractual requirements&#x37e; (aa) achieving contractual milestones&#x37e; (bb) entering into collaborations&#x37e; (cc) receipt of grant funding&#x37e; (dd) developing or expanding manufacturing or production capacity&#x37e; (ee) any combination of any of the foregoing business criteria; and (ff) other measures of performance selected by the Committee.</font></p>
  <p style="margin-left:0.84%;text-indent:6.002%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.852%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.002%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.852%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance under any of the foregoing Performance Measure(s) may be used to measure the performance of the Company, Subsidiary, and/or Affiliate as a whole or any business unit or operating segment of the Company, Subsidiary, and/or Affiliate or any combination thereof, as the Committee may deem appropriate, and any of the above Performance Measures may be compared to the performance of a group of comparator companies, or published or special index that the Committee, in its sole discretion, deems appropriate. In addition, the Company, in its sole discretion may select performance under the Performance Measure specified in clause (e) above for comparison to performance under one or more stock market indices. The Committee also has the authority to provide for accelerated vesting of any Performance Award based on the achievement of performance goals pursuant to the Performance Measures specified in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:10.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:4.42501580362787%;display:inline-flex;justify-content:flex-start;">14.5.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Performance.</font></div></div>
  <p style="margin-left:0.84%;text-indent:5.967%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:5.967%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Committee may provide in any such Award that any evaluation of performance may include or exclude any of the following events that occur during a Performance Period and may make any other appropriate adjustments selected thereby: (a) asset write-downs&#x37e; (b) litigation or claims, judgments or settlements&#x37e; (c) the effect of changes in tax laws, accounting principles, or other laws or provisions affecting reported results&#x37e; (d) any reorganization or restructuring events or programs&#x37e; (e) extraordinary non-core, non-operating, or non-recurring items&#x37e; (f) acquisitions or divestitures&#x37e; (g) foreign exchange gains and losses&#x37e; (h) impact of shares of Stock purchased through share repurchase programs&#x37e; (i) tax valuation allowance reversals&#x37e; (j) impairment expense&#x37e; and (k) environmental expense.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:4.42501580362787%;display:inline-flex;justify-content:flex-start;">14.5.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Committee Discretion.</font></div></div>
  <p style="text-indent:3.376%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.278%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.376%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.278%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall have the discretion to adjust any Performance Award or the amount payable thereunder and may, in its sole discretion, alter the Performance Measures governing a Performance Award.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PARACHUTE LIMITATIONS</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a Grantee is a &#x201c;disqualified individual,&#x201d; as defined in Code Section 280G(c), then, notwithstanding any other provision of this Plan or of any other agreement, contract, or understanding heretofore or hereafter entered into by a Grantee with the Company or an Affiliate, except an agreement, contract, or understanding that expressly addresses Code Section 280G or Code Section 4999 (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and notwithstanding any formal or informal plan or other arrangement for the direct or indirect provision of compensation to the Grantee (including groups or classes of Grantees or beneficiaries of which the Grantee is a member), whether or not such compensation is deferred, is in cash, or is in the form of a benefit to or for the Grantee (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Benefit Arrangement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), any right to exercise, vesting, payment, or benefit to the Grantee under this Plan shall be reduced or eliminated:</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.675%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the extent that such right to exercise, vesting, payment, or benefit, taking into account all other rights, payments, or benefits to or for the Grantee under the Plan, all Other Agreements, and all Benefit Arrangements, would cause any exercise, vesting, payment, or benefit to the Grantee under this Plan to be considered a &#x201c;parachute payment&#x201d; within the meaning of Code Section 280G(b)(2) as then in effect (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parachute Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)&#x37e; and</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.675%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if, as a result of receiving such Parachute Payment, the aggregate after-tax amounts received by the Grantee from the Company under this Plan, all Other Agreements, and all Benefit Arrangements would be less than the maximum after-tax amount that could be received by the Grantee without causing any such exercise, vesting, payment or benefit to be considered a Parachute Payment.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as required by Code Section 409A or to the extent that Code Section 409A permits discretion, the Committee shall have the right, in the Committee&#x2019;s sole discretion, to designate those rights, payments, or benefits under this Plan, all Other Agreements, and all Benefit Arrangements that should be reduced or eliminated so as to avoid having such rights, payments, or benefits be considered a Parachute Payment&#x37e; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to the extent any payment or benefit constitutes deferred compensation under Code Section 409A, in order to comply with Code Section 409A, the Company shall instead accomplish such reduction by first reducing or eliminating any cash payments (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating any accelerated vesting of Performance Awards, then by reducing or eliminating any accelerated vesting of Options or SARs, then by reducing or eliminating any accelerated vesting of Restricted Stock or Stock Units, then by reducing or eliminating any other remaining Parachute Payments.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REQUIREMENTS OF LAW</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">16.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.386%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.546%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company shall not be required to offer, sell or issue any shares of Stock under any Award, whether pursuant to the exercise of an Option, a SAR, or otherwise, if the offer, sale or issuance of such shares of Stock would constitute a violation by the Grantee, any other individual or entity, or the Company or an Affiliate of any provision of the Company&#x2019;s certificate of incorporation or bylaws or of Applicable Laws, including without limitation any federal or state securities laws or regulations. If at any time the Company shall determine, in its discretion, that the listing, registration, or qualification of any shares of Stock subject to an Award upon any Stock Exchange or Securities Market or under any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the offering, sale issuance or purchase of shares of Stock in connection with any Award, no shares of Stock may be offered, issued or sold to the Grantee or any other individual or entity pursuant to the exercise of such Award unless such listing, registration or qualification shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused thereby shall in no way affect the date of termination of the Award. Without limiting the generality of the foregoing, upon the exercise of any Option or any SAR that may be settled in shares of Stock or the delivery of any shares of Stock underlying an Award, unless a registration statement under the Securities Act is in effect with respect to the shares of Stock subject to such Award, the Company shall not be required to offer, sell or issue such shares of Stock unless the Board has received evidence satisfactory to it that the Grantee or any other individual or entity exercising Option or SAR or accepting delivery of such shares may acquire such shares of Stock pursuant to an exemption from registration under the Securities Act. Any determination by the Board in connection with the foregoing shall be final, binding, and conclusive. The Company may register, but shall in no event be obligated to register, any shares of Stock or other securities issuable pursuant to the Plan pursuant to the Securities Act. The Company shall not be obligated to take any affirmative action in order to cause the exercise of an Option or a SAR or the issuance of shares of Stock or other securities pursuant to the Plan to comply with any Applicable Laws. As to any jurisdiction that expressly imposes the requirement that an Option (or SAR that may be settled in shares of Stock) shall not be exercisable until the shares of Stock covered by such Option (or SAR) are registered under the securities laws thereof or are exempt from registration, the exercise of such Option (or SAR) under circumstances in which the laws of such jurisdiction apply shall be deemed conditioned upon the effectiveness</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.546%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of such registration or the availability of such an exemption.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">16.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 16b-3.</font></div></div>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.379%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During any time when the Company has a class of equity securities registered under Section 12 of the Exchange Act, it is the intent of the Company that Awards pursuant to the Plan and the exercise of Options and SARs granted hereunder that would otherwise be subject to Section 16(b) of the Exchange Act will qualify for the exemption provided by Rule 16b-3 under the Exchange Act. To the extent that any provision of the Plan or action by the Board does not comply with the requirements of Rule 16b-3, such provision or action shall be deemed inoperative with respect to such Awards to the extent permitted by Applicable Laws and deemed advisable by the Board, and shall not affect the validity of the Plan. In the event that Rule 16b-3 is revised or replaced, the Board may exercise its discretion to modify this Plan in any respect necessary or advisable in its judgment to satisfy the requirements of, or to permit the Company to avail itself of the benefits of, the revised exemption or its replacement.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EFFECT OF CHANGES IN CAPITALIZATION</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">17.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Stock.</font></div></div>
  <p style="text-indent:3.633%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.633%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the number of outstanding shares of Stock is increased or decreased or the shares of Stock are changed into or exchanged for a different number of shares or kind of Capital Stock or other securities of the Company on account of any recapitalization, reclassification, stock split, reverse stock split, spin-off, combination of stock, exchange of stock, stock dividend or other distribution payable in capital stock, or other increase or decrease in shares of stock effected without receipt of consideration by the Company occurring after the Effective Date, the number and kinds of shares of Capital Stock for which grants of Options and other Awards may be made under the Plan, including, without limitation, the Share Reserve, shall be adjusted proportionately and accordingly by the Board. In addition, the number and kind of shares of Capital Stock for which Awards are outstanding shall be adjusted proportionately and accordingly by the Committee so that the proportionate interest of the Grantee therein immediately following such event shall, to the extent practicable, be the same as immediately before such event. Any such adjustment in outstanding Options or SARs shall not change the aggregate Option Price or SAR Exercise Price payable with respect to shares that are subject to the unexercised portion of such outstanding Options or SARs, as applicable, but shall include a corresponding proportionate adjustment in the per share Option Price or SAR Exercise Price, as the case may be. The conversion or exercise of any convertible securities of the Company shall not be treated as an increase in shares effected without receipt of consideration. Notwithstanding the foregoing, in the event of any distribution to the Company&#x2019;s stockholders of securities of any other entity or other assets (including an extraordinary dividend but excluding a non-extraordinary dividend of the Company) without receipt of consideration by the Company, the Board shall, in such manner as it deems appropriate, adjust (i) the number and kind of shares of Capital Stock subject to outstanding Awards and/or (ii) the aggregate and per share Option Price of outstanding Options and the aggregate and per share SAR Exercise Price of outstanding SARs as required to reflect such distribution.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">17.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reorganization in Which the Company Is the Surviving Entity Which Does not Constitute a Change in Control.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if the Company shall be the surviving entity in any reorganization, merger, or consolidation of the Company with one or more other entities which does not constitute a Change in Control, any Award theretofore granted pursuant to the Plan shall pertain to and apply to the Capital Stock to which a holder of the number of shares of Stock subject to such Award would have been entitled immediately following such reorganization, merger, or consolidation, with a corresponding proportionate adjustment of the per share Option Price or per share SAR Exercise Price of any outstanding Option or SAR so that the aggregate Option Price or SAR Exercise Price thereafter shall be the same as the aggregate Option Price or SAR Exercise Price of the shares of Stock remaining subject to the Option or SAR as in effect immediately prior to such reorganization, merger, or consolidation. Subject to any contrary language in an Award Agreement, in another agreement with the Grantee, or otherwise set forth in writing, any restrictions applicable to such Award shall apply as well to any replacement shares of Capital Stock subject to such Award, or received by the Grantee as a result of such reorganization, merger, or consolidation. In the event of any reorganization, merger, or consolidation of the Company described in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Awards subject to performance criteria may be adjusted (including any adjustments to the Performance Measures or other performance criteria applicable to such Awards deemed appropriate by the Board) to take into account such reorganization, merger, or consolidation.</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">17.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change in Control in which Awards are not Assumed.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise provided in the applicable Award Agreement, in another agreement with the Grantee, or as otherwise set forth in writing, upon the occurrence of a Change in Control in which outstanding Awards are not being assumed or continued, the following provisions shall apply to such Award, to the extent not assumed or continued:</font></p>
  <div style="text-indent:3.338%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the occurrence of such Change in Control, in each case with the exception of any Performance Award, all outstanding shares of Restricted Stock and all Stock Units and Dividend Equivalent Rights shall be deemed to have vested, and the shares of Stock and/or cash subject to such Awards shall be delivered&#x37e; and</font></div></div>
  <div style="text-indent:3.338%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Either of the following two actions shall be taken:</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:7.476%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:7.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.604%;text-indent:0;display:inline-flex;justify-content:flex-start;">(A)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at least fifteen (15) days prior to the scheduled consummation of the Change in Control, all Options and SARs outstanding hereunder shall become immediately exercisable and shall remain exercisable for a period of fifteen (15) days. With respect to the Company&#x2019;s establishment of an exercise window, any exercise of an Option or SAR during such fifteen (15)-day period shall be conditioned upon the consummation of the Change in Control and shall be effective only immediately before the consummation of the Change in Control, and upon consummation of the Change in Control, the Plan and all outstanding but unexercised Options and SARs shall terminate, with or without consideration (including, without limitation, consideration in accordance with clause (ii) below) as determined by the Board in its sole discretion. The Board shall send notice of an event that will result in such a termination to all Grantees who hold Options and SARs not later than the time at which the Company gives notice thereof to its stockholders; and/or</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:7.476%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:7.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.604%;text-indent:0;display:inline-flex;justify-content:flex-start;">(B)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Board may elect, in its sole discretion, to cancel any outstanding Awards of Options, SARs, Restricted Stock, Stock Units, and/or Dividend Equivalent Rights and pay or deliver, or cause to be paid or delivered, to the holder thereof an amount in cash or securities having a value (as determined by the Board acting in good faith), in the case of Restricted Stock, Stock Units, and Dividend Equivalent Rights (for shares of Stock subject thereto) equal to the formula or fixed price per share paid to holders of shares of Stock pursuant to such Change in Control and, in the case of Options or SARs, equal to the product of the number of shares of Stock subject to the Options or SARs multiplied by the amount, if any, by which (I) the formula or fixed price per share paid to holders of shares of Stock pursuant to such transaction exceeds (II) the Option Price or SAR Exercise Price applicable to such Options or SARs.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.338%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For Performance Awards denominated in Stock or Stock Units, if less than half of the Performance Period has lapsed, the Awards shall be converted into Restricted Stock or Stock Units assuming target performance has been achieved (or Unrestricted Stock if no further restrictions apply). If more than half the Performance Period has lapsed, the Performance Awards shall be converted into Restricted Stock or Stock Units based on actual performance to date (or Unrestricted Stock if no further restrictions apply). If actual performance is not determinable, then Performance Awards shall be converted into Restricted Stock or Stock Units assuming target performance has been achieved, based on the discretion of the Committee (or Unrestricted Stock if no further restrictions apply).</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.338%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:1.2%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Equity-Based Awards shall be governed by the terms of the applicable Award Agreement.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">17.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change in Control in which Awards are Assumed.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise provided in the applicable Award Agreement, in another agreement with the Grantee, or as otherwise set forth in writing, upon the occurrence of a Change in Control in which outstanding Awards are being assumed or continued, the following provisions shall apply to such Award, to the extent assumed or continued:</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Plan and the Options, SARs, Restricted Stock, Stock Units, Dividend Equivalent Rights, and Other Equity-Based Awards theretofore granted under the Plan shall continue in the manner and under the terms so provided in the event of any Change in Control to the extent that provision is made in writing in connection with such Change in Control for the assumption or continuation of the Options, SARs, Restricted Stock, Stock Units, Dividend Equivalent Rights, and Other Equity-Based Awards theretofore granted, or for the substitution for such Options, SARs, Restricted Stock, Stock Units, Dividend Equivalent Rights, and Other Equity-Based Awards theretofore granted for new stock options, stock appreciation rights, restricted stock, stock units, dividend equivalent rights, and other equity-based awards relating to the capital stock or other securities of a successor entity, or a parent or subsidiary thereof, with appropriate adjustments as to the number of shares (disregarding any consideration that is not common stock) and exercise prices of options and stock appreciation rights.</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">17.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjustments</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjustments under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to shares of Stock or Capital Stock of the Company shall be made by the Board, whose determination in that respect shall be final, binding, and conclusive. No fractional shares or other securities shall be issued pursuant to any such adjustment, and any fractions resulting from any such adjustment shall be eliminated in each case by rounding downward to the nearest whole share. The Board may provide in an applicable Award Agreement as of the Grant Date, in another agreement with the Grantee, or otherwise in writing at any time thereafter with the consent of the Grantee, for different provisions to apply to an Award in place of those described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sections 17.1, 17.2, 17.3 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 17 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">does not limit the Company&#x2019;s ability to provide for alternative treatment of Awards outstanding under the Plan in the event of a change in control event involving the Company that is not a Change in Control.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">17.6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No Limitations on Company.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The making of Awards pursuant to the Plan shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations, or changes of its capital or business structure or to merge, consolidate, dissolve, or liquidate, or to sell or transfer all or any part of its business or assets (including all or any part of the business or assets of any Subsidiary or other Affiliate) or to engage in any other transaction or activity.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GENERAL PROVISIONS</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclaimer of Rights.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No provision in the Plan or in any Award or Award Agreement shall be construed to confer upon any individual or entity the right to remain in the Service of the Company or an Affiliate, or to interfere in any way with any contractual or other right or authority of the Company or an Affiliate either to increase or decrease the compensation or other payments to any individual or entity at any time, or to terminate any Service or other relationship between any individual or entity and the Company or an Affiliate. In addition, notwithstanding anything contained in the Plan to the contrary, unless otherwise stated in the applicable Award Agreement, in another agreement with the Grantee, or otherwise in writing, no Award granted under the Plan shall be affected by any change of duties or position of the Grantee thereof, so long as such Grantee continues to provide Service. The obligation of the Company to pay any benefits pursuant to this Plan shall be interpreted as a contractual obligation to pay only those amounts described herein, in the manner and under the conditions prescribed herein. The Plan and Awards shall in no way be interpreted to require the Company to transfer any amounts to a third party trustee or otherwise hold any amounts in trust or escrow for payment to any Grantee or beneficiary under the terms of the Plan.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nonexclusivity of the Plan.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The adoption of the Plan shall not be construed as creating any limitations upon the right and authority of the Board to adopt such other incentive compensation arrangements (which arrangements may be applicable either generally to a class or classes of individuals or specifically to a particular individual or particular individuals) as the Board in its discretion determines desirable.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withholding Taxes.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company or an Affiliate, as the case may be, shall have the right to deduct from payments of any kind otherwise due to a Grantee any federal, state, or local taxes of any kind required by Applicable Laws to be withheld with respect to the vesting of or other lapse of restrictions applicable to an Award or upon the issuance of any shares of Stock upon the exercise of an Option or pursuant to any other Award. At the time of such vesting, lapse, or exercise, the Grantee shall pay in cash to the Company or an Affiliate, as the case may be, any amount that the Company or an Affiliate may reasonably determine to be necessary to satisfy such withholding obligation&#x37e; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that if there is a same-day sale of shares of Stock subject to an Award, the Grantee shall pay such withholding obligation on the day on which the same-day sale is completed. Subject to the prior approval of the Company or an Affiliate, which may be withheld by the Company or an Affiliate, as the case may be, in its sole discretion, the Grantee may elect to satisfy such withholding obligations, in whole or in part, (i) by causing the Company or an Affiliate to withhold shares of Stock otherwise issuable to the Grantee or (ii) by delivering to the Company or an Affiliate shares of Stock already owned by the Grantee. The shares of Stock so withheld or delivered shall have an aggregate Fair Market Value equal to such withholding obligations. The Fair Market Value of the shares of Stock used to satisfy such withholding obligation shall be determined by the Company or an Affiliate as of the date that the amount of tax to be withheld is to be determined. A Grantee who has made an election pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 18.3 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may satisfy such Grantee&#x2019;s withholding obligation only with shares of Stock that are not subject to any repurchase, forfeiture, unfulfilled vesting, or other similar requirements. The maximum</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">number of shares of Stock that may be withheld from any Award to satisfy any federal, state, or local tax withholding requirements upon the exercise, vesting, or lapse of restrictions applicable to such Award or payment of shares of Stock pursuant to such Award, as applicable, may not exceed such number of shares of Stock having a Fair Market Value equal to the minimum statutory amount required by the Company or an Affiliate to be withheld and paid to any such federal, state, or local taxing authority with respect to such exercise, vesting, lapse of restrictions, or payment of shares of Stock.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Captions.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The use of captions in the Plan or any Award Agreement is for convenience of reference only and shall not affect the meaning of any provision of the Plan or such Award Agreement.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Provisions.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Award granted under the Plan may contain such other terms and conditions not inconsistent with the Plan as may be determined by the Board, in its sole discretion.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Number and Gender.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to words used in the Plan, the singular form shall include the plural form, the masculine gender shall include the feminine gender, etc., as the context requires.</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Severability.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any provision of the Plan or any Award Agreement shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The validity and construction of this Plan and the instruments evidencing the Awards hereunder shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware, other than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Plan and the instruments evidencing the Awards granted hereunder to the substantive laws of any other jurisdiction.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">18.9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 409A of the Code.</font></div></div>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Plan is intended to comply with Code Section 409A to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan will be interpreted and administered to be in compliance with Code Section 409A. Any payments described in the Plan that are due within the &#x201c;short-term deferral period&#x201d; (as defined for purposes of Code Section 409A) will not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding any provision of the Plan to the contrary, to the extent required to avoid accelerated taxation and tax penalties under Code Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6)-month period immediately following the Grantee&#x2019;s Separation from Service will instead be paid on the first payroll date after the six (6)-month anniversary of the Grantee&#x2019;s Separation from Service (or the Grantee&#x2019;s death, if earlier).</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, notwithstanding anything to the contrary in the Plan, in the case of an Award that is characterized as deferred compensation under Code Section 409A, and pursuant to which settlement and delivery of the cash or shares of Stock subject to the Award is triggered based on a Change in Control, in no event will a Change in Control be deemed to have occurred for purposes of such settlement and delivery of cash or shares of Stock if the transaction is not also a &#x201c;change in the ownership or effective control of&#x201d; the Company or &#x201c;a change in the ownership of a substantial portion of the assets of&#x201d; the Company as determined under Treasury Regulation Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder). If an Award characterized as deferred compensation under Code Section 409A is not settled and delivered on account of the provision of the preceding sentence, the settlement and delivery will occur on the next succeeding settlement and delivery triggering event that is a permissible triggering event under Code Section 409A. No provision of this paragraph will in any way affect the determination of a Change in Control for purposes of vesting in an Award that is characterized as deferred compensation under Code Section 409A.</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.34%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, neither the Company nor the Committee will have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Grantee under Code Section 409A and neither the Company, nor an Affiliate, nor the Board will have any liability to any Grantee for such tax or penalty.</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* * *</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.51in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;text-indent:3.802%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To record adoption of the Plan by the Board on February 2, 2023, effectiveness of the Plan on February 2, 2023, and amendment of the Plan on December 6, 2023, the Company has caused its authorized officer to execute the Plan.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:43.333%;text-indent:5.882%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;text-indent:11.145%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Luke J. Albrecht		</font></p>
  <p style="margin-left:40%;text-indent:11.145%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Name: Luke J. Albrecht</font></p>
  <p style="margin-left:40%;text-indent:11.145%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title: General Counsel &amp; Secretary</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>4
<FILENAME>sndx-ex10_20.htm
<DESCRIPTION>EX-10.20
<TEXT>
<html>
 <head>
  <title>EX-10.20</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.20</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO AMENDED AND RESTATED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entered into as of the 26</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">day of February, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">MICHAEL A. METZGER </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and supplements the terms of that certain amended and restated executive employment agreement by and between the Parties, dated as of February 2, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Capitalized terms used and not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company employs Executive as its Chief Executive Officer upon the terms and conditions set forth in the Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee of the Company&#x2019;s Board of Directors approved certain changes to terms of Executive&#x2019;s employment and the parties are entering this Amendment specifying such changes.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive&#x2019;s Target Performance Bonus as set forth in the Agreement is hereby amended to a threshold of up to seventy percent (70%) of Executive&#x2019;s Annual Base Salary.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Benefits Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of twenty-four (24) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Severance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of twenty-four (24) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment shall be effective on the Execution Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*     *     *     *     *</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, the parties have executed this Amendment on the Execution Date written above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.419%;"></td>
    <td style="width:1.079%;"></td>
    <td style="width:1.955%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:37.714%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:3.889%;"></td>
    <td style="width:6.731%;"></td>
    <td style="width:37.628%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EXECUTIVE</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Luke J. Albrecht</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael A. Metzger</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Luke J. Albrecht</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael A. Metzger</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General Counsel</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;">.</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>5
<FILENAME>sndx-ex10_22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<html>
 <head>
  <title>EX-10.22</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.22</font></p></div>
  <p style="font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDED &amp; RESTATED</font></p>
  <p style="font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entered into as of the 27th day of April, 2020 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LUKE J. ALBRECHT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Certain capitalized terms used in this Agreement are defined in Article 6.</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company is a biopharmaceutical company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company desires to continue to employ Executive in the position set forth below, and Executive wishes to continue to be employed by the Company in such position, upon the terms and conditions set forth in this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.636%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">TERMS OF EMPLOYMENT</font></p>
  <div style="text-indent:6.549%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.669%;">1.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Appointment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Executive shall serve as Senior Vice President, General Counsel and Secretary, reporting to the President and Chief Operating Officer. As Senior Vice President, General Counsel and Secretary, Executive will have such duties and responsibilities as may be assigned to Executive. During Executive&#x2019;s employment with the Company, Executive shall (i) devote substantially all of Executive&#x2019;s business efforts to the Company provided, however, that Executive may participate in charitable, civic, educational, professional, community or industry affairs so long as such activities do not conflict with or are not detrimental to the Company&#x2019;s best interests, as determined in good faith by the Board, and (ii) faithfully and to the best of Executive&#x2019;s abilities and experience, and in accordance with the standards and ethics of the business in which the Company is engaged, perform all duties that may be required of Executive by this Agreement, the Company&#x2019;s policies and procedures, and such other duties and responsibilities as may be assigned to Executive from time to time. During Executive&#x2019;s employment with the Company, Executive shall not engage in any activity that conflicts with or is detrimental to the Company&#x2019;s best interests, as determined by the Board. Executive and the Company acknowledge that Executive&#x2019;s primary office will be located at the Company&#x2019;s New York City office, but that Executive may be required to spend a certain amount of time each month at the Company&#x2019;s Waltham headquarters.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employment Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Executive will be employed by the Company on an &#x201c;at-will&#x201d; basis. This means that either the Company or Executive may terminate Executive&#x2019;s employment at any time, for any reason, with or without Cause, and with or without advance notice (provided that Resignation for Good Reason (as defined below) requires certain advanced notice by Executive. It also means that Executive&#x2019;s job title, duties, responsibilities, reporting level, compensation and benefits, as well as the Company&#x2019;s personnel policies and procedures, may be changed with or without notice at any time in the Company&#x2019;s sole discretion. This at-will employment relationship shall not be modified by any conflicting actions or representations of any Company employee or other party before or during the term of Executive&#x2019;s employment.</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.643%;font-size:0;margin-top:3.65pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annual Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Executive&#x2019;s annual base salary shall be $390,719 per year (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Annual Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), payable in equal installments, less applicable deductions and withholdings, in accordance with the Company&#x2019;s standard payroll practices. Executive&#x2019;s Annual Base Salary shall be subject to review by the Company&#x2019;s compensation committee and may be increased or decreased from time to time, but shall not be reduced unless, and only to the extent that, the base salaries of all other similarly situated executives of the Company are proportionately reduced.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Executive will be entitled to participate in all of the employee benefits and benefit plans that the Company generally makes available to its full-time employees and executives and for which Executive is eligible in accordance with the Company&#x2019;s policies as in effect from time to time. These benefits are subject to the terms, conditions, and eligibility requirements that govern or apply to them.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In addition to Annual Base Salary, Executive shall be eligible to earn an annual performance bonus of up to forty percent (40%) of Executive&#x2019;s Annual Base Salary, which bonus shall be based upon Executive&#x2019;s attainment of objectives to be determined by the Board (or the compensation committee thereof, as such determination may be delegated by the Board to the compensation committee) and continued employment with the Company as described below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Target Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The amount of and Executive&#x2019;s eligibility for the Target Performance Bonus shall be determined in the sole discretion of the Board (or the compensation committee thereof, as such determination may be delegated by the Board to the compensation committee). If earned, any Target Performance Bonus shall be paid to Executive, less authorized deductions and applicable withholdings, on or before the February 15</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> following the applicable bonus year. Except as provided in Section 2.2, Executive shall be eligible to earn the Target Performance Bonus only if Executive is actively employed and in good standing with the Company on both the determination and payment dates for the Target Performance Bonus.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement of Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to Section 4.10(c), the Company shall reimburse Executive for Executive&#x2019;s necessary and reasonable business expenses incurred in connection with Executive&#x2019;s duties in accordance with the Company&#x2019;s generally applicable policies.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 2</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CHANGE IN CONTROL SEVERANCE BENEFITS</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon a Change in Control Termination, and subject to the limitations and conditions set forth in this Agreement, Executive shall be eligible to receive the benefits set forth in this Article 2.The receipt of any severance payments or benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and general release of claims (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in substantially the form attached hereto and incorporated herein as Exhibit A, Exhibit B or Exhibit C, as appropriate, which Release must become effective and irrevocable no later than the sixtieth (60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) day following Executive&#x2019;s termination of employment (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Release Deadline Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). If the Release does not become effective and irrevocable by the Release Deadline Date, Executive will forfeit any right to any severance payments or benefits under this Agreement. In no event will severance payments or benefits be paid or provided until the Release actually becomes effective and irrevocable.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Salary and Pro-Rata Bonus Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In consideration of Executive&#x2019;s execution and non-revocation of the Release by the Release Deadline Date, the Company shall pay Executive a severance payment equal to (a) the sum of Executive&#x2019;s Monthly Base Salary and Pro-Rata Bonus multiplied by (b) the number of months in the Change in Control Severance Period, less applicable withholdings. The severance payment shall be payable (except as set forth in Article 4) in a lump sum on the first regularly-scheduled payroll date occurring on or after the Release Deadline Date.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Health Continuation Coverage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Provided that Executive is eligible and has made the necessary elections for continuation coverage pursuant to COBRA under a health, dental or vision plan sponsored by the Company, the Company shall pay the applicable premiums (inclusive of premiums for Executive&#x2019;s dependents for such health, dental or vision plan coverage as in effect immediately prior to the date of the Change in Control Termination) for such continued health, dental or vision plan coverage following the date of the Change in Control Termination for up to the number of months equal to the Change in Control Benefits Period (but in no event after such time as Executive is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as Executive and Executive&#x2019;s dependents are no longer eligible for COBRA coverage); provided that if continued payment by the Company of the applicable premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Internal Revenue Code of 1986, as amended, or any statute or regulation of similar effect (including, without limitation, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing such continued payment, the Company will instead pay Executive on the first day of each month a fully taxable cash payment equal to the applicable premiums for that month, subject to applicable tax withholdings, for the remainder of the Change in Control Benefits Period. Such coverage shall be counted as coverage pursuant to COBRA. Executive shall be required to notify the Company immediately if Executive becomes covered by a health, dental or vision insurance plan of a subsequent employer. If Executive and Executive&#x2019;s dependents continue coverage pursuant to COBRA following the conclusion of the Change in Control Benefits Period, Executive will be responsible for the entire payment of such premiums required under COBRA for the duration of the COBRA period.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Section 2.3, (i) references to COBRA shall be deemed to refer also to analogous provisions of state law, and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by Executive under a Code Section 125 health care reimbursement plan, which amounts, if any, are the sole responsibility of Executive.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon a Change in Control Termination, (a) the vesting and  exercisability of all outstanding options to purchase the Company&#x2019;s common stock (or stock appreciation rights or other rights with respect to the stock of the Company issued pursuant to any equity incentive plan of the Company) that are held by Executive on the Termination Date shall be accelerated in full; (b) any reacquisition or repurchase rights held by the Company with respect to common stock issued or issuable (or with respect to other rights with respect to the stock of the Company issued or issuable) pursuant to any other stock award granted to Executive pursuant to any equity incentive plan of the Company shall lapse; and (c) the time period that Executive has to exercise any outstanding options to purchase the Company&#x2019;s common stock that are held by Executive on the Termination Date shall be extended for a period equal to the shorter of (i) twelve (12) months or (ii) the remaining term of the outstanding option.</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 3</font></p>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COVERED TERMINATION SEVERANCE BENEFITS</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon a Covered Termination, and subject to the limitations and conditions set forth in this Agreement, Executive shall be eligible to receive the benefits set forth in this Article 3.The receipt of any severance payments or benefits pursuant to this Agreement is subject to Executive signing and not revoking the appropriate Release, which Release must become effective and irrevocable no later than the Release Deadline Date. If the Release does not become effective and irrevocable by the Release Deadline Date, Executive will forfeit any right to any severance payments or benefits under this Agreement. In no event will severance payments or benefits be paid or provided until the Release actually becomes effective and irrevocable.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Salary Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In consideration of Executive&#x2019;s timely execution and non-revocation of the Release by the Release Deadline Date, the Company shall pay Executive a severance payment equal to Executive&#x2019;s Monthly Base Salary multiplied by the number of months in the Covered Termination Severance Period, less applicable withholdings. The severance payment shall be payable (except as set forth in Article 4) in a lump sum on the first regularly-scheduled payroll date occurring on or after the Release Deadline Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Health Continuation Coverage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Provided that Executive is eligible and has made the necessary elections for continuation coverage pursuant to COBRA under a health, dental or vision plan sponsored by the Company, the Company shall pay for the applicable premiums (inclusive of premiums for Executive&#x2019;s dependents for such health, dental or vision plan coverage as in effect immediately prior to the date of the Covered Termination) for such continued health, dental or vision plan coverage following the date of the Covered Termination for up to the number of months equal to the Covered Termination Benefits Period (but in no event after such time as Executive is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as Executive and Executive&#x2019;s dependents are no longer eligible for COBRA coverage); provided that if continued payment by the Company of the applicable premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Internal Revenue Code of 1986, as amended, or any statute or regulation of similar effect (including, without limitation, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing such continued payment, the Company will instead pay Executive on the first day of each month a fully taxable cash payment equal to the applicable premiums for that month, subject to applicable tax withholdings, for the remainder of the Covered Termination Benefits Period. Such coverage shall be counted as coverage pursuant to COBRA. Executive shall be required to notify the Company immediately if Executive becomes covered by a health, dental or vision insurance plan of a subsequent employer. If Executive and Executive&#x2019;s dependents continue coverage pursuant to COBRA following the conclusion of the Covered Termination Benefits Period, Executive will be responsible for the entire payment of such premiums required under COBRA for the duration of the COBRA period.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Section 3.3, (i) references to COBRA shall be deemed to refer also to analogous provisions of state law, and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by Executive under a Code Section 125 health care reimbursement plan, which amounts, if any, are the sole responsibility of Executive.</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Awards. Upon a Covered Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the vesting and exercisability of all outstanding options to purchase the Company&#x2019;s common stock (or stock appreciation rights or other rights with respect to the stock of the Company issued pursuant to any equity incentive plan of the Company) that are held by Executive on the Termination Date shall be accelerated as to the number of shares of common stock that would otherwise have vested during the twelve (12) month period following the Termination Date in accordance with the applicable options&#x2019; vesting schedule were the Executive to remain an employee of the Company during such twelve (12) month period (disregarding any other basis for acceleration of vesting during such twelve (12) month period);</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any reacquisition or repurchase rights held by the Company with respect to common stock issued or issuable (or with respect to other rights with respect to the stock of the Company issued or issuable) pursuant to any option to purchase the Company&#x2019;s common stock (or stock appreciation rights or other rights with respect to the stock of the Company) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) held by the Executive as of the Termination Date shall lapse as to the number of Restricted Shares that would otherwise have lapsed during the twelve (12) month period following the Termination Date in accordance with the option&#x2019;s </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">vesting schedule were the Executive to remain an employee of the Company during such twelve (12) month period (disregarding any other basis for acceleration of the lapsing of such reacquisition or repurchase rights during such twelve (12) month period); and</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the time period that Executive has to exercise any outstanding options to purchase the Company&#x2019;s common stock that are held by Executive on the Termination Date shall be extended for a period equal to the shorter of (i) twelve (12) months or (ii) the remaining term of the outstanding option.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 4</font></p>
  <p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LIMITATIONS AND CONDITIONS ON BENEFITS</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Rights Conditioned on Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Executive&#x2019;s rights to receive all severance benefits described in Article 2 and Article 3 shall be conditioned upon and subject to Executive&#x2019;s compliance with the limitations and conditions on benefits as described in this Article 4.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Continuation of Service Until Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Executive shall continue to provide service to the Company in good faith until the Termination Date, unless such performance is otherwise excused in writing by the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Release Prior to Payment of Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon the occurrence of a Change in Control Termination or a Covered Termination, as applicable, and prior to Executive earning any entitlement to any severance or separation benefits under this Agreement on account of such Change in Control Termination or Covered Termination, as applicable, Executive must execute the appropriate Release, and such Release must become effective in accordance with its terms, but in no event later than the Release Deadline Date. No amount shall be paid prior to such date. Instead, on the first regularly-scheduled payroll date occurring on or after the Release Deadline Date, the Company will pay Executive the severance amount that Executive would otherwise have received on or prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the severance amount being paid as originally scheduled. The Company may modify the Release in its discretion to comply with changes in applicable law at any time prior to Executive&#x2019;s execution of such Release. Such Release shall specifically relate to all of Executive&#x2019;s rights and claims in existence at the time of such execution and shall confirm Executive&#x2019;s obligations under the Confidentiality Agreement and any similar obligations under applicable law. It is understood that, as specified in the applicable Release, Executive has a certain number of calendar days to consider whether to execute such Release. If Executive does not execute and deliver such Release within the applicable period, no benefits shall be provided or payable under this Agreement, and Executive shall have no further rights, title or interests in or to any severance benefits or payments pursuant to this Agreement. It is further understood that if Executive is age 40 or older at the time of a Change in Control Termination or a Covered Termination, as applicable, Executive may revoke the applicable Release within seven (7) calendar days after its execution by Executive. If Executive revokes such Release within such subsequent seven (7) day period, no benefits shall be provided or payable under this Agreement pursuant to such Change in Control Termination or Covered Termination, as applicable.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Return of Company Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Not later than the Termination Date, Executive shall return to the Company all documents (and all copies thereof) and other property belonging to the Company that Executive has in his or her possession or control. The documents and property to be returned include, but are not limited to, all files, correspondence, email, memoranda, notes, notebooks, records, plans, forecasts, reports, studies, analyses, compilations of data, proposals, agreements, financial information, research and development information, marketing information, operational and personnel information, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones and servers), credit cards, entry cards, identification badges and keys, and any materials of any kind which contain or embody any proprietary or confidential </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">information of the Company (and all reproductions thereof in whole or in part). Executive agrees to make a diligent search to locate any such documents, property and information. If Executive has used any personally owned computer, server or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, then within ten (10) business days after the Termination Date, Executive shall provide the Company with a computer- useable copy of all such information and then permanently delete and expunge such confidential or proprietary information from those systems. Executive agrees to provide the Company access to Executive&#x2019;s system as requested to verify that the necessary copying and1or deletion is done.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cooperation and Continued Compliance with Restrictive Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">From and after the Termination Date, Executive shall cooperate fully with the Company in connection with its actual or contemplated defense, prosecution or investigation of any existing or future litigation, arbitrations, mediations, claims, demands, audits, government or regulatory inquiries, or other matters arising from events, acts or failures to act that occurred during the time period in which Executive was employed by the Company (including any period of employment with an entity acquired by the Company). Such cooperation includes, without limitation, being available upon reasonable notice, without subpoena, to provide accurate and complete advice, assistance and information to the Company, including offering and explaining evidence, providing truthful and accurate sworn statements, and participating in discovery and trial preparation and testimony. Executive also agrees to promptly send the Company copies of all correspondence (for example, but not limited to, subpoenas) received by Executive in connection with any such legal proceedings, unless Executive is expressly prohibited by law from so doing. The Company will reimburse Executive for reasonable out-of-pocket expenses incurred in connection with any such cooperation (excluding foregone wages, salary or other compensation) within thirty (30) days of Executive&#x2019;s timely presentation of appropriate documentation thereof, in accordance with the Company&#x2019;s standard reimbursement policies and procedures, and will make reasonable efforts to accommodate Executive&#x2019;s scheduling needs.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">From and after the Termination Date, Executive shall continue to abide by all of the terms and provisions of the Confidentiality Agreement (and any other comparable agreement signed by Executive), in accordance with its terms.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive acknowledges and agrees that Executive&#x2019;s obligations under this  Section 4.5 are an essential part of the consideration Executive is providing hereunder in exchange for which and in reliance upon which the Company has agreed to provide the payments and benefits under this Agreement. Executive further acknowledges and agrees that Executive&#x2019;s violation of this Section 4.5 inevitably would involve use or disclosure of the Company&#x2019;s proprietary and confidential information. Accordingly, Executive agrees that Executive will forfeit, effective as of the date of any breach, any right, entitlement, claim or interest in or to any unpaid portion of the severance payments or benefits provided in Article 2 or Article 3. If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 4.5 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Parachute Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Parachute Payment Limitation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If any payment or benefit (including payments and benefits pursuant to this Agreement) Executive would receive in connection with a Change in Control from the Company or otherwise (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this paragraph, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Company shall cause to be determined, before </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any amounts of the Payment are paid to Executive, which of the following two alternative forms of payment shall be paid to Executive: (A) payment in full of the entire amount of the Payment (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Full Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or (B) payment of only a part of the Payment so that Executive receives the largest payment possible without the imposition of the Excise Tax (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reduced Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). A Full Payment shall be made in the event that the amount received by Executive on a net after-tax basis is greater than what would be received by Executive on a net after-tax basis if the Reduced Payment were made, otherwise a Reduced Payment shall be made. If a Reduced Payment is made, (i) the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Executive shall have no rights to any additional payments and1or benefits constituting the Payment, and (ii) reduction in payments and1or benefits shall occur in the following order: (A) reduction of cash payments; (B) cancellation of accelerated vesting of equity awards other than stock options; (C) cancellation of accelerated vesting of stock options; and (D) reduction of other benefits paid to Executive. In the event that acceleration of compensation from Executive&#x2019;s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:3.65pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall make all determinations required to be made under this Section 4.6. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive&#x2019;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certain Reductions and Offsets</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. To the extent that any federal, state or local laws, including, without limitation, the Worker Adjustment and Retraining Notification Act or any other so- called &#x201c;plant closing&#x201d; laws, require the Company to give advance notice or make a payment of any kind to Executive because of Executive&#x2019;s involuntary termination due to a layoff, reduction in force, plant or facility closing, sale of business, change in control or any other similar event or reason, the benefits payable under this Agreement shall be correspondingly reduced. The benefits provided under this Agreement are intended to satisfy any and all statutory obligations that may arise out of Executive&#x2019;s involuntary termination of employment for the foregoing reasons, and the parties shall construe and enforce the terms of this Agreement accordingly.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Mitigation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise specifically provided herein, Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by any retirement benefits received by Executive after the date of a Change in Control Termination or Covered Termination (except as expressly provided in Sections 2.3 and 3.3 above).</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness of Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If Executive is indebted to the Company on the effective date </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of a Change in Control Termination or Covered Termination, the Company reserves the right to offset any severance payments and benefits under this Agreement by the amount of such indebtedness.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Application of Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any provision to the contrary in this Agreement, no amount deemed deferred compensation subject to Section 409A of the Code shall be payable pursuant to Article 2 or Article 3 unless Executive&#x2019;s termination of employment constitutes a &#x201c;separation from service&#x201d; with the Company within the meaning of Section 409A of the Code and the Department of Treasury Regulations and other guidance promulgated thereunder and, except as provided under Section 4.10(b) hereof, any such amount shall not be paid, or in the case of installments, commence payment, until the first regularly-scheduled payroll date occurring on or after the sixtieth (60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) day following Executive&#x2019;s separation from service. Any installment payments that would have been made to Executive during the sixty (60) day period immediately following Executive&#x2019;s separation from service but for the preceding sentence shall be paid to Executive on the first regularly-scheduled payroll date occurring on or after the sixtieth (60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) day after Executive&#x2019;s separation from service and the remaining payments shall be made as provided in this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Specified Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed at the time of his or her separation from service to be a &#x201c;specified employee&#x201d; for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive&#x2019;s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six (6)-month period measured from the date of Executive&#x2019;s &#x201c;separation from service&#x201d; with the Company (as such term is defined in the Treasury Regulations issued under Section 409A of the Code) or (ii) the date of Executive&#x2019;s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 4.10(b)shall be paid in a lump sum to Executive, and any remaining payments due under this Agreement shall be paid as otherwise provided herein.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Expense Reimbursements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. To the extent that any reimbursement payable pursuant to this Agreement is subject to the provisions of Section 409A of the Code, any such reimbursement payable to Executive pursuant to this Agreement shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred; the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year; and Executive&#x2019;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Installments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of Section 409A of the Code (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive&#x2019;s right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. All payments under this Agreement shall be subject to applicable withholding for federal, state and local income and employment taxes.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Duplication of Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The severance and other benefits provided in Article 2 and Article 3 are mutually exclusive of each other, and in no event shall Executive receive any severance or other benefits pursuant to both Article 2 and Article 3.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 5</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">TERMINATION WITH CAUSE OR BY VOLUNTARY RESIGNATION; OTHER RIGHTS AND BENEFITS</font></p>
  <p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination for Cause by the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Company shall terminate the Executive&#x2019;s employment with the Company for Cause, then upon such termination, the Company shall have no further obligation to Executive hereunder except for the payment or provision, as applicable, of (i) the portion of the Annual Base Salary for the period prior to the effective date of termination earned but unpaid (if any), (ii) all unreimbursed expenses (if any), subject to Sections 1.4 and 4.10(c), and (iii) other payments, entitlements or benefits, if any, in accordance with terms of the applicable plans, programs, arrangements or other agreements of the Company (other than any severance plan or policy) as to which the Executive held rights to such payments, entitlements or benefits, whether as a participant, beneficiary or otherwise on the date of termination (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). For the avoidance of doubt, Executive shall have no right to receive (and Other Benefits shall not include) any amounts under any Company severance plan or policy or pursuant to Article 2 or Article 3 upon Executive&#x2019;s termination for Cause.</font></div></div>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination by Voluntary Resignation by the Executive (other than Resignation for Good Reason)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon any voluntary resignation by Executive that is not a Resignation for Good Reason, the Company shall have no further obligation to the Executive hereunder except for the payment of (i) the portion of the Annual Base Salary for the period prior to the effective date of termination earned but unpaid (if any), (ii) all unreimbursed expenses (if any), subject to Section 1.4 and Section 4.10(c), and (iii) the payment or provision of any Other Benefits. For the avoidance of doubt, Executive shall have no right to receive (and Other Benefits shall not include) any amounts under any Company severance plan or policy or pursuant to Article 2 or Article 3 upon any voluntary resignation by Executive that is not a Resignation for Good Reason.</font></div></div>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Rights and Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Nothing in this Agreement shall prevent or limit Executive&#x2019;s continuing or future participation in any benefit, bonus, incentive or other plans, programs, policies or practices provided by the Company and for which Executive may otherwise qualify, nor shall anything herein limit or otherwise affect such rights as Executive may have under other agreements with the Company except as provided in Article 1, Article 4, Section 5.1 and Section 5.2 above. Except as otherwise expressly provided herein, amounts that are vested benefits or that Executive is otherwise entitled to receive under any plan, policy, practice or program of the Company at or subsequent to the date of a Change in Control shall be payable in accordance with such plan, policy, practice or program.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-0.027%;padding-left:0.027%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 6</font></p>
  <p style="text-indent:-0.027%;padding-left:0.027%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DEFINITIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise provided, for purposes of this Agreement, the following definitions shall apply:</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.549%;font-size:0;margin-top:0.1pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.669%;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, upon a reasonable determination by the Company, Executive&#x2019;s: (a) dishonest statements or acts with respect to the Company, any subsidiary or any affiliate of the Company or any subsidiary; (b) commission by or indictment for (i) a felony or (ii) any misdemeanor (excluding minor traffic violations) involving moral turpitude, deceit, dishonesty or fraud (&#x201c;indictment,&#x201d; for these purposes, meaning an indictment, probable cause hearing or any other procedure pursuant to which an initial determination of probable or reasonable cause with respect to such offense is made); (c) gross negligence, willful misconduct or insubordination with respect to the Company, any subsidiary or any affiliate of the Company or any subsidiary; (d) material breach of any of Executive&#x2019;s obligations under any agreement to which Executive and the Company or any subsidiary are a party; or (e) death or disability. </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0.1pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.398%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to clause (d), Executive will be given notice and a 30-day period in which to cure such breach, only to the extent such breach can be reasonably expected to be able to be cured within such period. Executive agrees that the breach of any confidentiality obligation to the Company or any subsidiary shall not be curable to any extent.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any natural person, entity or group within the meaning of Section 13(d) or 14(d) of the Securities Exchange Act of 1934, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), becomes the owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company&#x2019;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (i) on account of the acquisition of securities of the Company by any institutional investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#x2019;s securities in a transaction or series of related transactions that are primarily a private financing transaction for the Company or (ii) solely because the level of ownership held by any Exchange Act Person (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subject Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">There is consummated a merger, consolidation or similar transaction involving, directly or indirectly, the Company if, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (i) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (ii) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur; or</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">There is consummated a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportion as their ownership of the Company immediately prior to such sale, lease, license or other disposition.</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:7.677%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. Notwithstanding the foregoing or any other provision of this Agreement, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any affiliate and the participant shall supersede the foregoing definition with respect to stock awards subject to such agreement (it being understood, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply).</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Benefits Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of twelve (12) months commencing on the Termination Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Severance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of twelve (12) months commencing on the Termination Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Involuntary Termination Without Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Resignation for Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; either of which occurs on, or within three (3) months prior to, or within twelve (12) months following, the effective date of a Change in Control, provided that any such termination is a &#x201c;separation from service&#x201d; within the meaning of Treasury Regulation Section 1.409A- 1(h). Death and disability shall not be deemed Change in Control Terminations.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.</font></div></div>
  <div style="text-indent:6.821%;font-size:0;margin-top:3.65pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Syndax Pharmaceuticals, Inc. or, following a Change in Control, the surviving entity resulting from such transaction, or any subsequent surviving entity resulting from any subsequent Change in Control.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Confidentiality Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Executive&#x2019;s Assignment of Developments, Non- Disclosure, and Non-Solicitation Agreement with the Company (or any successor agreement thereto).</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Involuntary Termination Without Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Resignation for Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; provided that any such termination is a &#x201c;separation from service&#x201d; within the meaning of Treasury Regulation Section 1.409A-1(h). Death and disability shall not be deemed Covered Terminations. If an Involuntary Termination Without Cause or Resignation for Good Reason qualifies as a Change in Control Termination, it shall not constitute a Covered Termination.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Termination Benefits Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of nine (9) months commencing on the Termination Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Termination Severance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of nine (9) months commencing on the Termination Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Involuntary Termination Without Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Executive&#x2019;s dismissal or discharge by the Company for reasons other than Cause and other than as a result of death or disability.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.15</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Monthly Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means 1/12</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of the greater of (i) Executive&#x2019;s annual base salary (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation) as in effect on the date of a Change in Control Termination or a Covered Termination, as applicable, or (ii) in the case of a Change in Control Termination, Executive&#x2019;s annual base salary (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation) as in effect on the date of a Change in Control.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.16</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pro-Rata Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means 1/12</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of the greater of (i) the average Target Performance Bonus paid to Executive for the three years preceding the date of a Change in Control Termination (or such lesser number of years during which Executive has been employed by the Company), or (ii) the Target Performance Bonus, as in effect on the date of a Change in Control Termination.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.17</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Resignation for Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Executive&#x2019;s resignation from all employee positions Executive then holds with the Company within sixty (60) days following any of the following events taken without Executive&#x2019;s consent, provided Executive has given the Company written notice of such event within thirty (30) days after the first occurrence of such event and the Company has not cured such event within thirty (30) days thereafter:</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A decrease in Executive&#x2019;s total target cash compensation (base and bonus) of more than 10% (i.e., a material reduction in Executive&#x2019;s base compensation and a material breach by the Company of Executive&#x2019;s employment terms with the Company), other than in connection with a comparable decrease in compensation for all comparable executives of the Company;</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive&#x2019;s duties or responsibilities are materially diminished (not simply a change in title or reporting relationships); provided, that Executive shall not be deemed to have a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Resignation for Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; if the Company survives as a separate legal entity or business unit following the Change in Control and Executive holds materially the same position in such legal entity or business unit as Executive held before the Change in Control;</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Either (i) Executive is required to establish residence in a location more than 50 miles from Executive&#x2019;s current principal personal residence or (ii) there is an increase in Executive&#x2019;s round-trip driving distance of more than fifty (50) miles from Executive&#x2019;s current principal personal residence to the principal office or business location at which Executive is required to perform services (except for required business travel to the extent consistent with Executive&#x2019;s prior business travel obligations) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive&#x2019;s Principal Place of Business</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as a result of a change in location by the  Company  of Executive&#x2019;s Principal Place of Business; or</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.643%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The failure of the Company to obtain a satisfactory agreement from any successor to materially assume and materially agree to perform under the terms of this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.18</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the effective date of the Change in Control Termination, the Covered Termination or a termination for Cause, as applicable.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 7</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GENERAL PROVISIONS</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employment Status</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement does not constitute a contract of employment or impose upon Executive any obligation to remain as an employee, or impose on the Company any obligation (i) to retain Executive as an employee, (ii) to change the status of Executive as an at-will employee or (iii) to change the Company&#x2019;s policies regarding termination of employment.</font></div></div>
  <p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Any notices provided hereunder must be in writing, and such notices or any other written communication shall be deemed effective upon the earlier of personal delivery (including personal delivery by facsimile) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at Executive&#x2019;s address as listed in the Company&#x2019;s payroll records. Any payments made by the Company to Executive under the terms of this Agreement shall be delivered to Executive either in person or at the address as listed in the Company&#x2019;s payroll records.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">invalid, illegal or unenforceable provisions had never been contained herein.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If either party should waive any breach of any provisions of this Agreement, he, she or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Complete Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement, including Exhibit A, Exhibit B and Exhibit C, and the Confidentiality Agreement constitute the entire agreement between Executive and the Company and is the complete, final and exclusive embodiment of their agreement with regard to this subject matter, wholly superseding all written and oral agreements with respect to payments and benefits to Executive in the event of employment termination. It is entered into without reliance on any promise or representation other than those expressly contained herein.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment or Termination of Agreement; Continuation of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement may be changed or terminated only upon the mutual written consent of the Company and Executive. The written consent of the Company to a change or termination of this Agreement must be signed by an executive officer of the Company (other than Executive) after such change or termination has been approved by the Board. Unless so terminated, this Agreement shall continue in effect for as long as Executive continues to be employed by the Company or by any surviving entity following any Change in Control. In other words, if, following a Change in Control, Executive continues to be employed by the surviving entity without a Change in Control Termination and the surviving entity then undergoes a Change in Control, following which Executive is terminated by the subsequent surviving entity in a Change in Control Termination, then Executive shall receive the benefits described in Article 2 hereof.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The headings of the Articles and Sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive, and the Company, and any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly carried on by the Company, and their respective successors, assigns, heirs, executors and administrators, without regard to whether or not such person actively assumes any rights or duties hereunder; provided, however, that Executive may not assign any duties hereunder and may not assign any rights hereunder without the written consent of the Company, which consent shall not be withheld unreasonably.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Choice of Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Because of the Company&#x2019;s and Executive&#x2019;s interests in ensuring that disputes regarding this Agreement are resolved on a uniform basis, the parties agree that all questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of New York, without regard for any conflict of law principles. Further, the parties consent to the jurisdiction of the state and federal courts of the State of New York for all purposes in connection with this Agreement. The parties hereby irrevocably waive, to the fullest extent permitted by applicable law, any objection which Executive or the Company may now or hereafter have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Arbitration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. To ensure the rapid and economical resolution of any disputes that may arise under or relate to this Agreement or Executive&#x2019;s employment relationship, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.4in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">performance, enforcement, execution, or interpretation of this Agreement, Executive&#x2019;s employment with the Company, or the termination of Executive&#x2019;s employment (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), shall be resolved to the fullest extent permitted by law, by final, binding, and (to the extent permitted by law) confidential arbitration before a single arbitrator in the state where Executive is employed. The arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. Section 1 et seq., as amended, and shall be administered by the Judicial Arbitration &amp; Mediation Services, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">JAMS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in accordance with its then-current Employment Arbitration Rules &amp; Procedures (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">JAMS Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The JAMS Rules are also available online at</font><font style="color:#0000ff;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">http:11</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">www.jamsadr.com1rules-employment-arbitration1</font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The parties or their representatives may also call JAMS at 800.352.5267 if they have questions about the arbitration process. If the JAMS Rules are inconsistent with the terms of this Agreement, the terms of this Agreement shall govern. Notwithstanding the foregoing, this provision shall exclude Claims that by law are not subject to arbitration. The arbitrator shall:  (a) have the authority to compel adequate discovery for  the resolution of all Claims and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator&#x2019;s essential findings and conclusions and a statement of the award. The Company shall pay all JAMS fees in excess of the amount of filing and other court-related fees Executive would have been required to pay if the Claims were asserted in a court of law. EXECUTIVE AND THE COMPANY UNDERSTAND AND FULLY AGREE THAT BY ENTERING INTO THIS AGREEMENT, BOTH EXECUTIVE AND THE COMPANY ARE GIVING UP THE CONSTITUTIONAL RIGHT TO HAVE A TRIAL BY JURY, AND ARE GIVING UP THE NORMAL RIGHTS OF APPEAL FOLLOWING THE RENDERING OF A DECISION, EXCEPT AS THE FEDERAL ARBITRATION ACT AND APPLICABLE FEDERAL LAW ALLOW FOR JUDICIAL REVIEW OF ARBITRATION PROCEEDINGS. Nothing in this Agreement shall prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or final orders in such arbitrations may be entered and enforced as judgments or orders in the federal and state courts of any competent jurisdiction in compliance with Section 7.11 of this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Construction of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event of a conflict between the text of this Agreement and any summary, description or other information regarding this Agreement, the text of this Agreement shall control.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.821%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Circular 230 Disclaimer. THE FOLLOWING DISCLAIMER IS PROVIDED IN ACCORDANCE WITH THE INTERNAL REVENUE SERVICE&#x2019;S CIRCULAR 230 (21 C.F.R. PART 10). ANY TAX ADVICE CONTAINED IN THIS AGREEMENT IS INTENDED TO BE PRELIMINARY, FOR DISCUSSION PURPOSES ONLY AND NOT FINAL. ANY SUCH ADVICE IS NOT INTENDED TO BE USED FOR MARKETING, PROMOTING OR RECOMMENDING ANY TRANSACTION OR FOR THE USE OF ANY PERSON IN CONNECTION WITH THE PREPARATION OF ANY TAX RETURN. ACCORDINGLY, THIS ADVICE IS NOT INTENDED OR WRITTEN TO BE USED, AND IT CANNOT BE USED, BY ANY PERSON FOR THE PURPOSE OF AVOIDING TAX PENALTIES THAT MAY BE IMPOSED ON SUCH PERSON.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">14</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.94in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:3.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, the parties have executed this Agreement on the Effective Date written below.</font></p>
  <p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.	EXECUTIVE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	By:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name: Briggs W. Morrison, M.D.	Name: Luke J. Albrecht</font></p>
  <p style="font-size:10pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:   Chief Executive Officer	Date:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.47in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A:	Release (Individual Termination - Age 40 or Older)</font></p>
  <p style="font-size:10pt;margin-top:9.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B:	Release (Individual and Group Termination - Under Age 40)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C:	Release (Group Termination - Age 40 or Older)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.63in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.94in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A RELEASE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(INDIVIDUAL TERMINATION - AGE 40 OR OLDER)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:15.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) which I have executed and of which this Release is a part.</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:8.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I hereby confirm my obligations under the Confidentiality Agreement (or other comparable agreement that I have signed, if any).</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys&#x2019; fees, damages, indemnities and obligations of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including, but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; and claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended, the federal Age Discrimination in Employment Act of 1967, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ADEA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the federal Employee Retirement Income Security Act of 1974, as amended, the federal Americans with Disabilities Act of 1990,the California Fair Employment and Housing Act, as amended, the New York City Human Rights Law, as amended, the Massachusetts Fair Employment Practices Law, as amended, the South Carolina Human Affairs Law, as amended, tort law, contract law, wrongful discharge, discrimination, fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to (1) release the Company from its obligation to indemnify me pursuant to the Company&#x2019;s indemnification obligation pursuant to written agreement or applicable law; (2) release any claim by me against the Company relating to the validity or enforceability of this release or the Agreement; (3) prohibit me from exercising any non-waivable right to file a charge with the United States Equal Employment Opportunity Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EEOC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the National Labor Relations Board (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NLRB</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or any other government agency (provided, however, that I shall not be entitled to recover any monetary damages or to obtain non-monetary relief if the agency were to pursue any claims relating to my employment with the Company).</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have to assert claims for age discrimination under applicable law, including under the ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company&#x2019;s Chief Executive Officer; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth (8th) day after I execute this Release (provided that I do not revoke it).</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I hereby represent that I have been paid all compensation owed and for all hours worked, I have</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.63in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.94in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">received all the leave and leave benefits and protections for which I am eligible, pursuant to the federal Family and Medical Leave Act, any Company policy or applicable law, and I have not suffered any on- the-job injury or illness for which I have not already filed a workers&#x2019; compensation claim.</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I agree that I will not make any disparaging statements regarding the Company or its officers, directors, shareholders, members, agents or products jointly or severally. The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Printed Name</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> 	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A-2</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.63in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.94in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B RELEASE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(INDIVIDUAL AND GROUP TERMINATION - UNDER AGE 40)</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) which I have executed and of which this Release is a part.</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I hereby confirm my obligations under the Confidentiality Agreement (or other comparable agreement that I have signed, if any).</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys&#x2019; fees, damages, indemnities and obligations of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including, but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; and claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended, the federal Employee Retirement Income Security Act of 1974, as amended, the federal Americans with Disabilities Act of 1990,the California Fair Employment and Housing Act, as amended, the New York City Human Rights Law, as amended, the Massachusetts Fair Employment Practices Law, as amended, the South Carolina Human Affairs Law, as amended, tort law, contract law, wrongful discharge, discrimination, fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to (1) release the Company from its obligation to indemnify me pursuant to the Company&#x2019;s indemnification obligation pursuant to written agreement or applicable law; (2) release any claim by me against the Company relating to the validity or enforceability of this release or the Agreement; (3) prohibit me from exercising any non-waivable right to file a charge with the United States Equal Employment Opportunity Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EEOC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the National Labor Relations Board (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NLRB</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or any other government agency (provided, however, that I shall not be entitled to recover any monetary damages or to obtain non- monetary relief if the agency were to pursue any claims relating to my employment with the Company).</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:8.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; and (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier).</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I hereby represent that I have been paid all compensation owed and for all hours worked, I have received all the leave and leave benefits and protections for which I am eligible, pursuant to the federal Family and Medical Leave Act, any Company policy or applicable law, and I have not suffered any on- the-job injury or illness for which I have not already filed a workers&#x2019; compensation claim.</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:3.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I agree that I will not make any disparaging statements regarding the Company or its officers, directors, shareholders, members, agents or products jointly or severally. The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.63in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.94in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">proceedings).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Printed Name</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> 	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">B-2</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.63in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.94in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT C</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RELEASE</font></p>
  <p style="font-size:10pt;margin-top:8.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(GROUP TERMINATION - AGE 40 OR OLDER)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:15.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) which I have executed and of which this Release is a part.</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:8.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I hereby confirm my obligations under the Confidentiality Agreement (or other comparable agreement that I have signed, if any).</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys&#x2019; fees, damages, indemnities and obligations of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including, but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; and claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended, the federal Age Discrimination in Employment Act of 1967, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ADEA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the federal Employee Retirement Income Security Act of 1974, as amended, the federal Americans with Disabilities Act of 1990,the California Fair Employment and Housing Act, as amended, the New York City Human Rights Law, as amended, the Massachusetts Fair Employment Practices Law, as amended, the South Carolina Human Affairs Law, as amended, tort law, contract law, wrongful discharge, discrimination, fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to (1) release the Company from its obligation to indemnify me pursuant to the Company&#x2019;s indemnification obligation pursuant to written agreement or applicable law; (2) release any claim by me against the Company relating to the validity or enforceability of this release or the Agreement; (3) prohibit me from exercising any non-waivable right to file a charge with the United States Equal Employment Opportunity Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EEOC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the National Labor Relations Board (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NLRB</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or any other government agency (provided, however, that I shall not be entitled to recover any monetary damages or to obtain non-monetary relief if the agency were to pursue any claims relating to my employment with the Company).</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have to assert claims for age discrimination under applicable law, including under the ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.9in;min-height:1.04in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">21</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.94in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a &#x201c;group termination&#x201d; under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:8.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I hereby represent that I have been paid all compensation owed and for all hours worked, I have received all the leave and leave benefits and protections for which I am eligible, pursuant to the federal Family and Medical Leave Act, any Company policy or applicable law, and I have not suffered any on- the-job injury or illness for which I have not already filed a workers&#x2019; compensation claim.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.818%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I agree that I will not engage in any conduct that is injurious to the reputation of the Company or its parents, subsidiaries and affiliates, including but not limited to disparagement of the Company, its officers, Board members, employees and shareholders. The foregoing shall not be violated by a statement made in a deposition, trial or administrative proceeding in response to legal process; by any statement made to a government agency; or whenever I make any statement to a court, administrative tribunal or government agency as required by law.</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Printed Name</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> 	</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.9in;min-height:1.04in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">22</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>6
<FILENAME>sndx-ex10_23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<html>
 <head>
  <title>EX-10.23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.23</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO AMENDED AND RESTATED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entered into as of the 26</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">day of February, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LUKE J. ALBRECHT </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and supplements the terms of that certain amended and restated executive employment agreement by and between the Parties, dated as of April 27, 2020 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Capitalized terms used and not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company employs Executive as its General Counsel upon the terms and conditions set forth in the Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee of the Company&#x2019;s Board of Directors approved certain changes to terms of Executive&#x2019;s employment and the parties are entering this Amendment specifying such changes.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive&#x2019;s Target Performance Bonus as set forth in the Agreement is hereby amended to a threshold of up to forty-five percent (45%) of Executive&#x2019;s Annual Base Salary.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Benefits Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of eighteen (18) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Severance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of eighteen (18) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment shall be effective on the Execution Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*     *     *     *     *</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, the parties have executed this Amendment on the Execution Date written above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.419%;"></td>
    <td style="width:1.079%;"></td>
    <td style="width:1.955%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:37.714%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:3.889%;"></td>
    <td style="width:6.731%;"></td>
    <td style="width:37.628%;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EXECUTIVE</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael A. Metzger</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Luke J. Albrecht</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael A. Metzger</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Luke J. Albrecht</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;">.</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>7
<FILENAME>sndx-ex10_25.htm
<DESCRIPTION>EX-10.25
<TEXT>
<html>
 <head>
  <title>EX-10.25</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.25</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entered into as of the 26</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> day of February, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CATHERINE MADIGAN, M.D. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and supplements the terms of that certain executive employment agreement by and between the Parties, dated as of March 1, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Capitalized terms used and not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company employs Executive as its Chief Medical Officer upon the terms and conditions set forth in the Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee of the Company&#x2019;s Board of Directors approved certain changes to terms of Executive&#x2019;s employment and the parties are entering this Amendment specifying such changes.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive&#x2019;s Target Performance Bonus as set forth in the Agreement is hereby amended to a threshold of up to forty-five percent (45%) of Executive&#x2019;s Annual Base Salary.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Benefits Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of eighteen (18) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Severance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of eighteen (18) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment shall be effective on the Execution Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*     *     *     *     *</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, the parties have executed this Amendment on the Execution Date written above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.419%;"></td>
    <td style="width:1.079%;"></td>
    <td style="width:1.955%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:37.714%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:3.889%;"></td>
    <td style="width:6.731%;"></td>
    <td style="width:37.628%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EXECUTIVE</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Luke J. Albrecht</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Catherine Madigan, M.D.</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Luke J. Albrecht</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Catherine Madigan, M.D.</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General Counsel</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;">.</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>8
<FILENAME>sndx-ex10_27.htm
<DESCRIPTION>EX-10.27
<TEXT>
<html>
 <head>
  <title>EX-10.27</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entered into as of the 26</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> day of February, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">KEITH A. GOLDAN </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and supplements the terms of that certain executive employment agreement by and between the Parties, dated as of June 8, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Capitalized terms used and not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company employs Executive as its Chief Financial Officer upon the terms and conditions set forth in the Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee of the Company&#x2019;s Board of Directors approved certain changes to terms of Executive&#x2019;s employment and the parties are entering this Amendment specifying such changes.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive&#x2019;s Target Performance Bonus as set forth in the Agreement is hereby amended to a threshold of up to forty-five percent (45%) of Executive&#x2019;s Annual Base Salary.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Benefits Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of eighteen (18) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Severance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of eighteen (18) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment shall be effective on the Execution Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*     *     *     *     *</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, the parties have executed this Amendment on the Execution Date written above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.419%;"></td>
    <td style="width:1.079%;"></td>
    <td style="width:1.955%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:37.714%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:3.889%;"></td>
    <td style="width:6.731%;"></td>
    <td style="width:37.628%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EXECUTIVE</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Luke J. Albrecht</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Keith A. Goldan</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Luke J. Albrecht</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Keith A. Goldan</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General Counsel</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;">.</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>9
<FILENAME>sndx-ex10_30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<html>
 <head>
  <title>EX-10.30</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.30</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entered into as of the 26</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> day of February, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NEIL GALLAGHER, M.D., Ph.D. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and supplements the terms of that certain executive employment agreement by and between the Parties, dated as of March 30, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Capitalized terms used and not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company employs Executive as its President, Head of Research and Development, upon the terms and conditions set forth in the Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee of the Company&#x2019;s Board of Directors approved certain changes to terms of Executive&#x2019;s employment and the parties are entering this Amendment specifying such changes.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive&#x2019;s Target Performance Bonus as set forth in the Agreement is hereby amended to a threshold of up to fifty percent (50%) of Executive&#x2019;s Annual Base Salary.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Benefits Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of eighteen (18) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Severance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of eighteen (18) months commencing on the Termination Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment shall be effective on the Execution Date.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*     *     *     *     *</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, the parties have executed this Amendment on the Execution Date written above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.419%;"></td>
    <td style="width:1.079%;"></td>
    <td style="width:1.955%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:37.714%;"></td>
    <td style="width:0.94%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:3.889%;"></td>
    <td style="width:6.731%;"></td>
    <td style="width:37.628%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EXECUTIVE</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Luke J. Albrecht</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Neil Gallagher, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Luke J. Albrecht</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Neil Gallagher, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General Counsel</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;border-bottom:0.75pt solid #000000;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;">.</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>10
<FILENAME>sndx-ex10_31.htm
<DESCRIPTION>EX-10.31
<TEXT>
<html>
 <head>
  <title>EX-10.31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.31</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDED &amp; RESTATED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective:  February 7, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each member of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) who is not also serving as an employee of Syndax Pharmaceuticals, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or any of its subsidiaries will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy for his or her Board service. This policy may be amended at any time in the sole discretion of the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each non-employee director serving on the Board of the Company will receive an annual base cash fee for his or her services of $45,644. Each non-employee director other than the non-executive chairperson of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chair</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall also receive an annual award of deferred settlement restricted stock units to purchase 17,000 shares and the Chair shall also receive an annual award of deferred settlement restricted stock units to purchase 34,000 shares (each as adjusted for stock splits, stock dividends, recapitalization and similar events) of the Company&#x2019;s common stock on the same date that the Board awards annual stock option grants to the Company&#x2019;s executive officers (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Annual Option Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Each Annual Option Award will vest on the one-year anniversary of the date of grant, subject to the director&#x2019;s continued service to the Company.</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Newly appointed non-employee directors will receive at the time of his or her appointment to the Board, a one-time initial award of options to purchase 35,000 shares (as adjusted for stock splits, stock dividends, recapitalization and similar events) of the Company&#x2019;s common stock (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Director Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Each New Director Award will vest monthly over a three-year period.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Chair will also receive an annual cash retainer of $79,876 for his or her service in such role.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each non-employee director, other than the chairperson of such committee, who serves on the following committees will receive an annual cash retainer, for each committee on which he or she serves, as listed below:</font></p>
  <p style="margin-left:0.92%;text-indent:6.807%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.139%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Audit committee &#x2013; $11,410</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation committee &#x2013; $8,558</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Science &amp; Technology committee &#x2013; $8,558</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nominating and corporate governance committee &#x2013; $5,706</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each chairperson of the audit, compensation, nominating and corporate governance and science and technology committees will receive an additional annual cash retainer as follows:</font></p>
  <p style="margin-left:0.92%;text-indent:6.807%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.139%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Audit committee &#x2013; $22,822</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation committee &#x2013; $17,115</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Science &amp; Technology committee &#x2013; $17,115</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nominating and corporate governance committee &#x2013; $11,410</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company will also reimburse each of the directors for his or her travel expenses incurred in connection with his or her attendance at Board and committee meetings. All cash retainers will be paid in equal quarterly installments.</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>sndx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement No. 333-254661 on Form S-3 and Registration Statement Nos. 333-210412, 333-220172, 333-226678, 333-233083, 333-241654, 333-258628, and 333-263185 on Form S-8 of our reports dated February 27, 2024, relating to the financial statements of Syndax Pharmaceuticals, Inc. and subsidiaries and the effectiveness of Syndax Pharmaceuticals, Inc. and subsidiaries&#x2019; internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 27, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>12
<FILENAME>sndx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Michael A. Metzger, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Syndax Pharmaceuticals, Inc.;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 27, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.06%;"></td>
    <td style="width:1%;"></td>
    <td style="width:90.94%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael A. Metzger</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael A. Metzger</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>13
<FILENAME>sndx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Keith A. Goldan, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Syndax Pharmaceuticals, Inc.;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 27, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.92%;"></td>
    <td style="width:1%;"></td>
    <td style="width:91.08%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Keith A. Goldan</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Keith A. Goldan</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:3.6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>14
<FILENAME>sndx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Michael A. Metzger, Chief Executive Officer and Director of Syndax Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;), and Keith A. Goldan, Chief Financial Officer and Treasurer of the Company, each hereby certifies that, to the best of his knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) The Company&#x2019;s Annual Report on Form 10-K, for the year ended December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Annual Report&#x201d;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Annual Report.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 27, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.62%;"></td>
    <td style="width:3.24%;"></td>
    <td style="width:81.14%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By</font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael A. Metzger</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael A. Metzger</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 27, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.2%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:80.72%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By</font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Keith A. Goldan</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Keith A. Goldan</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer and Treasurer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* This certification accompanies the Annual Report, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Annual Report), irrespective of any general incorporation language contained in such</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">filing</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>15
<FILENAME>sndx-ex97.htm
<DESCRIPTION>EX-97
<TEXT>
<html>
 <head>
  <title>EX-97</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Syndax Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) providing for the Company&#x2019;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10D-1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Nasdaq Listing Rule 5608 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Listing Standards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Incentive Compensation is deemed &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in the Company&#x2019;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></div></div>
  <p style="text-indent:7.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee or, in the absence of such committee, the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each current and former Executive Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#x2019;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TSR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). A measure need not be presented in the Company&#x2019;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lookback Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#x2019;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recoverable Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Applicability of Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment Generally.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of this Policy, if there is an </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#x2019;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Impracticability of Recovery.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Recoupment may be determined to be impracticable if, and only if:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sources of Recoupment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification of Covered Officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#x2019;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification of Administrator.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No &#x201c;Good Reason&#x201d; for Covered Officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#x201c;good reason&#x201d; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#x2019;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Impairment of Other Remedies</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#x2019;s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SOX 304</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment; Termination</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10.	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Required Filings</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*	*	*	*	*</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Form of Executive Acknowledgment</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Syndax Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Syndax Pharmaceuticals, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreed and Acknowledged:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img207175068_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img207175068_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" F\!] # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WV1UCC9VX
M502?H*P/^$UT3_GX;_OFMF__ .0=<_\ 7)_Y&OG[%<&-Q4Z#2BMSVLIRZGC%
M)S;5K'M'_":Z)_S\-_WS2_\ "::)_P _#?\ ?->+8I*XO[3J]D>M_J_A_P"9
MGM7_  FFB_\ /PW_ 'S1_P )GHO_ #\-_P!\UXM24O[3J]D'^K^'_F9[5_PF
MFB_\_#?]\T?\)IHG_/PW_?->*TVC^TZO9!_J_A_YF>U_\)KHG_/PW_?-'_":
MZ)_S\-_WS7BE%']IUNR#_5_#_P S/:_^$UT3_GX;_OFE_P"$TT7_ )^&_P"^
M:\4 R:>!BFLQK/H@_P!7\/\ S,]H_P"$ST7_ )^&_P"^:/\ A--%_P"?AO\
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MO_/=O^^*/^$ST7_GX;_OFO&]M)MJO[2J]D'^KV'_ )F>R_\ "9Z+_P _#?\
M?-'_  F>B_\ /PW_ 'S7C)&*2G_:-7LA_P"KV&_F9[/_ ,)IHO\ S\-_WQ1_
MPFFB_P#/PW_?->+YHS1_:%7LA?ZO8?\ F9[1_P )IHO_ #\-_P!\T?\ "9Z+
M_P _#?\ ?->+YI<T_P"T*W9#_P!7L/\ S,]G_P"$ST7_ )^&_P"^:/\ A,]%
M_P"?AO\ OFO&,T9I?VA5[(7^KV'_ )F>S_\ "::+_P _#?\ ?-'_  FFB_\
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M,]I_X371/^?AO^^:/^$UT3_GX;_OFO%J6C^T*O9#_P!7<-_,SVC_ (331/\
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M,]M_X331/^?AO^^:/^$TT3_GX;_OFO$J*K^TJO9"_P!7<-_,SVW_ (331/\
MGX;_ +YH_P"$TT3_ )^&_P"^:\2I*:S&MV0_]7<-_,SV[_A--$_Y^&_[YH_X
M331/^?AO^^:\1HI_VA5[(?\ JYAOYF>W?\)IHG_/PW_?-'_"::)_S\-_WS7B
M-%/Z_5[(7^KF&_F9[;_PFNB?\_#?]\T?\)KHG_/PW_?->(TF*/[0J]D+_5W#
M?S,]O_X371/^?AO^^:/^$UT3_GX;_OFO$:*AYE5[(G_5[#?S,]N_X371/^?A
MO^^:/^$UT3_GX;_OFO$,44O[3K=D'^K^'_F9[?\ \)KHG_/PW_?-'_":Z)_S
M\-_WS7B%+2_M.MV0?ZOX?^9GMW_":Z)_S\-_WS1_PFNB?\_#?]\UXC2=*/[3
MK=D'^K^'_F9[?_PFNB?\_#?]\T?\)KHG_/PW_?->(49I_P!I5NR#_5_#_P S
M/;_^$UT3_GX;_OFC_A-=$_Y^&_[YKQ"C-']IUNR#_5[#_P S/;_^$UT3_GX;
M_OFC_A-=$_Y^&_[YKQ"BE_:=;L@_U?P_\S/;_P#A-=$_Y^&_[YH_X371/^?A
MO^^:\/I<T_[3K=D'^KV'_F9[?_PFNB?\_#?]\T?\)KHG_/PW_?->'T4?VG6[
M(/\ 5[#_ ,S/</\ A-=$_P"?AO\ OFC_ (371/\ GX;_ +YKQ#-%']IUNR#_
M %>P_P#,SV__ (371/\ GX;_ +YH_P"$UT3_ )^&_P"^:\0HI?VG6[(/]7\/
M_,SV_P#X371/^?AO^^:/^$UT3_GX;_OFO$**?]IUNR#_ %>P_P#,SV__ (37
M1/\ GX;_ +YH_P"$UT3_ )^&_P"^:\0HS1_:=;L@_P!7\/\ S,]O_P"$UT3_
M )^&_P"^:/\ A-=$_P"?AO\ OFO$*0FE_:=;L@_U?P_\S/</^$UT3_GX;_OF
MC_A-=$_Y^&_[YKP[-&:/[3K=D+_5_#_S,]Q_X371/^?AO^^:/^$VT3_GX;_O
MFO#LTF:?]IUNR%_8&'_F9[E_PFVB?\_#?]\T?\)MH?\ S\-_WS7AN:,T?VG6
M[(/[ P_\S/<O^$VT3_GX;_OFC_A-M$_Y^&_[YKPW-&:7]IUNR#^P,/\ S,]R
M_P"$VT/_ )^&_P"^:/\ A-M#_P"?AO\ OFO#<T9I_P!IUNR#^P,/_,SW+_A-
MM#_Y^&_[YH_X3;1/^?AO^^:\-S1FE_:=;L@_L##_ ,S/<O\ A-M#_P"?AO\
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M2 4P$H[T[%+BJ2! !3J3%+5%(*::=330 4VG4TU)<1M%%%!84444) %%%%,
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M E&*6BE<!IIN:<Q %,!R::8KZCC2<T\#BD(J@:&T9I#102+2448I %%)BC%
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MPE%%%,84VG4TT %,-/[4TTBDQM%%%"- HHHI@%%%%3< HHHIH HHHH ****
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M)D,****SN2%%%%, HHHI7 ****8!1112 **** "BBB@ HHHH **** "BBB@
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M,44$A1112$)2&EI#S0(2C%+BEQ0%A!2TN**!I!12T4K%)"4N***95@Q1113
M****0PHHHI7 ****.< HHHI.5QA1114W ****5P"BBB@ HHHH ****8!1112
M$PHHHH$%%%% !11132N,****TC  I*6DJQA1115(84444,04445(!1113 **
M**&#0&DI:2L)(S:"BBBI)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***86H$V-=LG IE!ZTE,R;%I*,T9IB"E'6DI0>:$$=R=>E.IJTZK1T!1
M110,**** "BBB@ H-%% AA%,J4BF8I$M#:*7%)BBQ%@HHHI %%%% !2&EI#0
M(2BBBF2%%%% PHHHH **** "BBB@ HHI0* 0E+BEQ3@*1:@-VYI-E2XI*1<5
M8A88IE22<5$*:%)CJ*2BF*XM%)24#N.HI*6@84444 %+244"%HI*6@04M)10
M M%%%( HHI::)DPKZ-T__D&VO_7%/Y"OG*OHW3_^0;:_]<4_D*]7*]Y?(^:X
M@^&G\_T'7@W6-P!U,;#]*\(EC,4K(PP5.#7OK+N1E/0C%>+>)K5K37[M"N%+
MDK]*US*%U&1'#M1*4Z??4R*0TM(:\D^J$I#UI>](>M!0E%%%, HHHH 2FGK3
MJ:>M2 4TTZFF@04AI:0T )24M)28TPHHHI%W"BBB@84444""BBB@8444E A:
M*2B@5Q:*2B@=Q:2BB@5PHHHH ****+BN%%%%%PN%%%% !1112N 4#FGB/-2+
M&!2N!$$)J94P*=C%-=PHHN%A6(45"6R::6)-%,M(4TE*:2F4%%%%#B 4445F
MT%PHHHI"84444""BBB@8AHH-%*X!1113$**6D%+5QEJ%Q**#16PPHS124@%W
M4;J2BD _-+G-1TM(5QYQ2&FYI:+@F%%%%0Y#$HHHJ6(****0!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444TQA1116B8[A1113 **** "BBB@+!24
MM)00T%%%%)DM#30*6@4""G4E+058****+E6"BBBDY#L%%%%*X!1112YF 444
M4KL:"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 PHHHH)"BBB@84
M4452B 4445HHV'82BBBK **** "BBB@ HHHH **** "BBB@ HHHH *2EI*F2
MN2PHHHK%JQF%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH$V-8XJ,
MFE<TRG8AL2EHI*9 AZT444 %*.M':@=:8=2PO2E[TB]*7O5(W0M%%%!04444
M %%%% !1110 &DQ2T4 )BFD5)2$4$M$.**DQ3#2(:$HHHI""DI:0T"$HHHIB
M"BBB@ HHHH ***4"@+,3&:4"GA:=BD4D-"TN*=12N6HH;BEI:*904C=*6D(S
M20B%ZCQBI'-,JC*3U$Q1BG4E(5Q,4E/I>#3'S$=+3BM&V@KF0E%+M-&#0.Z$
MHI=IHP: NA**7!HH"Z"BBEQ0%Q*6C%+00Y!11102/AC::98U&2QP*^B[$%=/
MME/41*/T%>%^$[-KWQ)91[<H) 7]A7O2*$15'0#%>QED=)2/F,_J)RA#MJ.K
M@_B#I!DCCU"-22ORL![]Z[RH;FVCN[=X95!5A@UZ%>DJL'$\?!XEX:LJB/!*
M0UN^)= FT:]8[";=S\C=OI6#FOG9P=.7+(_0*%6-:"G#9AWI#UI:0]:DV$HH
MHI@%)112 *:>M.IIZT@"FFG4TT""D-+2&@3$I*6DI#04F:#106&:,T44@#-&
M:** ;#-&:** N&:*** N%%%% @HHHH **** "BBB@+A1112$%%%% !1@GI3A
M&6J9(@* (5C)-3B,+UIX&*7K2 ;M%+BEJ-Y !QUI#0.X457)R<T$YY-%-(M(
M****904444T 44450!1114M""BBBI<1A112&I$&:,T44@"BBBD 4444$A2YI
M**<0%HHHK=,I!1113&&*,445+(8E%%% KA2YI**AL8N:,TE%1<89HS112&&:
M6DI: "BBBF 4444"84444 @HHHH **** "BBB@ HHHH **** "BBBK3&%%%%
M6""BBB@84444 %&*** L&*,444B6A,48I:*!)!BBBBCE*L%%%%2X,844446
M****FS ****+, HHHHLP"BBBBS **** "BBBA@%%%% !1112 **** "BBB@
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M_P#*']M8+^?\&>;45Z3_ ,*L3_H)-_W[H_X58G_02;_OW0\#7_E#^VL%_/\
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M;_OBJ>"K]A_VW@OY_P '_D>;T5W&C_#]=5LWG-\8]LSQXV9^Z<9K0_X5:O\
MT$F_[]U$<'6DKI!4SC!PDXREJO)GFU%>D_\ "K$_Z"3?]^Z3_A5B?]!-O^_=
M5]1K]C/^VL%_/^#/-Z*])_X58G_02;_OBC_A5J?]!)O^^*S> Q%_A_(T6=X&
MWQ_@_P#(\VHKTG_A5J?]!)O^^*/^%6)_T$F_[XI?V?B/Y?R#^V\#_/\ @_\
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M%6I_T$F_[XH_L_$?R_D+^V\#_/\ @_\ (\WHKTC_ (5:G_02;_OBC_A5J?\
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MV#^W,#_/^#_R/-Z*](_X5:G_ $$F_P"_='_"K4_Z"3?]^Z/J5;L']N8'^?\
M!_Y'F]%>D?\ "K4_Z"3?]\4?\*M3_H)-_P!\4OJ-;L']N8'^?\'_ )'F]%>D
M?\*M3_H)-_W[H_X5:G_02;_OW2^HU^P?VY@?Y_P?^1YO17I'_"K4_P"@DW_?
MNC_A5J?]!)O^_='U&OV#^W,#_/\ @_\ (\WHKTC_ (5:G_02;_OW1_PJU/\
MH)-_W[H^HU^P?VY@?Y_P?^1YO17I'_"K4_Z"3?\ ?NC_ (5:G_02;_OW1]1K
M]@_MS _S_@_\CS>BO2/^%6I_T$F_[]T?\*M3_H)-_P!^Z7U"O_*']N8'^?\
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M (5:G_02;_OW1_9];^4/[<P/\_X/_(\WHKTC_A5J?]!)O^_='_"K4_Z"3?\
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M%&_[]T?4,1_*+^U\'_/^#/,J*]-_X5,G_04;_OW2_P#"ID_Z"C?]^Z?U"O\
MRB_M?!_S_@SS&BO3?^%3)_T%&_[]T?\ "ID_Z"C?]^Z/J%?^4/[7PG\_X,\R
MHKTW_A4R?]!1O^_=5[_X8+96$]T-29O*0MMV=<4G@:Z5VBEFN$DTE+\&<!'4
ME>@6'PR2YLH;C^T6'F(&QLZ9JS_PJU/^@DW_ 'Q36"KM72-?[8P<79S_  9Y
MM17I/_"K$_Z"3?\ ?NC_ (58G_02;_OW5?4:_8?]M8+^?\&>;45Z3_PJQ/\
MH)-_W[H_X58G_02;_OW1]1K]@_MK!?S_ (,\VHKTG_A5B?\ 02;_ +]T?\*L
M3_H)-_W[H^HU^P?VU@OY_P &>;45Z3_PJQ/^@DW_ '[H_P"%6)_T$F_[]T?4
M:_8/[:P7\_X,\VHKTG_A5B?]!)O^_='_  JQ/^@DW_?NCZC7[!_;6"_G_!GF
MU%>D_P#"K$_Z"3?]^Z/^%6)_T$F_[]TOJ-?L']M8+^?\'_D>;45Z3_PJQ/\
MH)-_W[H_X58G_02;_OW1]1K]A?VU@OY_P?\ D>:TAKTO_A5B?]!)O^^*/^%6
M)_T$F_[XH^HU^P?VS@OY_P &>9$4TUZ=_P *K3_H)-_W[I#\*D/_ #$V_P"_
M='U&OV)><X+^?\&>8XIP2O3/^%5)_P!!)O\ OW2_\*K3_H)M_P!^Z7U"O_*"
MSC!?S_@SS/;BEQ7I?_"K$_Z"3?\ ?NC_ (56G_02;_OW1]0Q'\H_[9P7\_X,
M\UQ17I7_  JM/^@DW_?NC_A5:?\ 02;_ +]TOJ&(_E'_ &U@OY_P9YK17I7_
M  JM/^@DW_?NC_A5:?\ 02;_ +]T_J%?^4/[:P7\_P"#/-12UZ3_ ,*L3_H)
M-_W[H_X58G_02;_OW1]0K_RA_;6"_G_!GFU%>D_\*L3_ *"3?]^Z/^%6)_T$
MF_[]T?4*_P#*']M8+^?\&>;45Z3_ ,*L3_H)-_W[H_X58G_02;_OW1]0K_RA
M_;6"_G_!GFU!.!7I/_"K$_Z"3?\ ?ND/PK0C_D)M_P!^Z7U#$?RB_MK!?S_@
MSR]CDTVO3_\ A4R?]!1O^_='_"ID_P"@HW_?NJ^HU_Y3)YO@[_%^#/,:0UZ?
M_P *F3_H*-_W[H_X5,G_ $%&_P"_=+ZA7_E#^V,'_-^#/,*45Z=_PJ9/^@HW
M_?NC_A4R?]!1O^_='U"O_*']KX/^;\&>8TM>F_\ "ID_Z"C?]^Z/^%3)_P!!
M1O\ OW3^HU_Y0_M?!_S?@SS.BO3/^%3I_P!!-O\ OW2_\*G3_H)M_P!^Z/J-
M?^4/[7P?\WX,\RHKTW_A5"?]!-O^_='_  JA/^@FW_?NCZC7[!_:^#_F_!GF
M5%>F_P#"J$_Z";?]^Z/^%4)_T$V_[]T?4:_8/[7P?\WX,\RHKTW_ (50G_03
M;_OW0/A0F>=3;_OW1]1K]@_M?!_S?@SS*GI%)(P5$9B>!@5ZY9_#73(<?:',
MWZ5T=AX=TS31_H]JH^O-:PRVH_B=CFK9[0BOW:;9YIX=^'UY?NLU^I@@Z[3U
M85ZII^G6VF6B6UK&$1!CW/U-6@ !@# I:]2AAH45[NY\]B\=5Q+]]Z=@HHHK
MH.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5^.7JPHHHJC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *SM>_P"0#??]<6K1K.U[_D WW_7%JBI\#]#6C_%CZH?H
MW_(%LO\ KBO\JO51T;_D"V7_ %Q7^57J</A0JO\ $EZL****HS"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,#P?\ \@B;_K[F_P#0JWZP/!__ "")O^ON
M;_T*M^LJ'\*/H=.,_CS]0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.OZE<?%V\TQ[N0V<:_+%GY?NUZ?26L8R[A?WI1[?Y)_J%%%% PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *S?$'_(OWW_7%JTJS?$'_ "+]]_UQ:HJ?
M _0UH?Q8^J_,ETC_ ) ]G_UQ7^57:I:1_P @>S_ZXK_*KM.'PH57XY>K"BN
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M>C4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMC%$79KT:^;85/>OZQ_!69M4444@"BBB@ HHHH **** "BBB@ HHHH ****
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MR,?C5K4OAWH.J7!FN%NPQ.2([AE!^H%5LM.[?WI?>2M?B[?J>3^)]>EUJUT
M62FQLGN?+=9N4!V\A@.HKKO#7A>[T?Q?;WSZQIR1SHH^R6T;)OP.PZ9KN+CP
M?HMUHZZ7):_Z,O3!PP]\^M5]#\"Z+X?N//LEN3(.AFG:3'TS51:C)_/\29)N
M*7DOP9:\3^);+PQI3WEW( >D:9Y9CT'YUQ'@S1;WQ#KY\7:Y^[=P1:VYX**?
M7MU%=AXG\$Z-XO6)=6CF=8ONB.4H/TK/TKX8^'M&O([FT-^'C^Z'NW9?RS4T
M])<TOEY?\$JIK&T?G_78[*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,#PE_R#;G_K\E_G6_6!X2_Y!MS_ -?DO\ZWZRH?PT=.+_CR]3A_
MBS_R(-W_ +R_UKA?!W@G7?%'A/21J.IVW]D(BND$:LKX]">AKV+6M%LM?TU[
M"_1GMW.2%;!_.G:/I%IH>F0Z?8HR6\*A4#-D@?6M*:Y7)OK:WRN<\W>,4NE_
MQ/'H]*@'QA?3 O[@6,48'L":Y8W5W;/<^!.3)-<EU'L7W?RKWP>$M)'B,Z\(
MG^WE A?><8'3BH7\$:')XF7Q"ULW]H*  ^[C@8Z4X:<O-VU^^Z)?VN7O=?=8
M\TBTZSD^(Z:3K! L8(&\F)_NGY02<?6L^WABDD\8:?"!/I<!D,0;E4(7C'I7
MKVO^#=&\2%&U"&3>G1X9"C?F*FTWPMI.E:9)I]K;X@D&U]YW,WU/>E9N-GO9
MKUN[W*BU&5UY?*UMO4\U\,W>A:!\+)-0N+5&S&0XB #/P.,URWB(M#JF@:E:
M6\-DL\N52--KD;<_,1UZU[!:_#CP[:07<$<$QBN@1(CS%ASZ#M5=/A;X87R/
MW-RWD.7CWW#'!-7>]13?=?\ !1#7[MP76_X['&^&B3\:+LGJ8E_] KV:L&T\
M(:19:\^LP0N+UU"EBY(QC'2MZE?W(Q[+]6%O?E+O;\DOT"BBBD4%%%% !111
M0 4444 %%%% !1110 4444 %%%% !6;X@_Y%^^_ZXM6E6;X@_P"1?OO^N+5%
M3X'Z&M#^+'U7YDND?\@>S_ZXK_*KM4M(_P"0/9_]<5_E5VG#X4*K\<O5GFGQ
MOS_P@C;2 WVB+&?]ZO-K4:K-<^&[+Q-,G]D,J-;M$"HSG@'UKW_7_#NG>)M/
M^PZG&[P;@^%;:<@Y%5KKP=HUYI%MIDUNQM[;'E8;YEQTYJJ?NW?FG^'YD3?,
MDO)_C8\DO[:\U'XG-IPN+5;=;=!!'>(7C89.,#UJ:[\.WVB>$-9M6\0VLNTB
M0QPAAL!;./Z5Z;JO@/0M9@ABNH9AY*A4>*4H^!_M#FL/Q#X%^S>''L="CDD5
M_P#6QR/N:09Z;C4ZQA;Y?C>[&G>2?3_@=#C/#VD_\))KFE7-GI!L+2W1O.9U
M&V8\8/']:6:V6;XQ:K;+,+<-:3*'Z!>!S5N;P+J-]+:"RTF]TF6-U9IC>%EP
M",C:#WKT./P+HXU1]5ECD>_DC:.202$ @]>*T:5U+_%^*(BVDUY+\&>6V?G>
M"KFT75["WO[2>8+%>01@,?JQY-6O">GZ5+\6-4;[+"JFUBEB4J."Q.2/>O0+
M?X;^'K?4$O1'<R2(=RK+<,Z _P"Z>*LWG@30[[68M6DAF2[C  :*4H" ,#('
M6B$K--^:_()JZ:7E^9YAX=T.SU7XJ:W)=[S';[6" _*>.XJ77[W3=?.NPZ;I
M\*FSW"2YG0,,A<_+W%>I:=X1TC2M5N=2M8G%S<@"1F<D' QTK/N_AOX=O-0G
MO9()UEG!$@CF*JV1CH*RY7R1@^BM\R[KFE+N_P #Q6:..[^%^F37:K*Z7:IO
M89^7'2NL^)EK:6GPRTI+.*..,@,0@P"2HS7HD?@'0(] ;15MG^Q,<[2YR#[&
MH6^''AZ30DT:2*Y>S1RZAYV)!/N:V;3?_;T7]UK_ )$T_=Y6^B:^^]OS//;:
M.WU3QW;V>MMFU2TC,,;_ '2?+YXK!U"3R+?Q396,K/IT4Z!!G*K\O:O:M7\#
M:'K<$$5W#(!"H5&BD*-@#'4<TB^!=!31'T@6S?99""_S_.Q'JW6LI*\6O5>M
MW?4J#Y6F_+Y6[>IXK?Z7;6/@7PEJ4"E;N66+=)W.2>]?0>F,6TNU9CDF-<G\
M*Q;CP'H5SI-AIDL$AM;$J8%$AR".F3WKHH8D@A2*,81!M'TK:4D^:W5MKT,E
M%II^5OQ'T445F6%%%% !1110 4444 %%%% !6=KW_(!OO^N+5HUG:]_R ;[_
M *XM45/@?H:T?XL?5#]&_P"0+9?]<5_E5ZJ.C?\ (%LO^N*_RJ]3A\*%5_B2
M]6>7?'/_ )$R/_KYB_\ 0JXS7[6.\UCP5!+G8UJH('?YZ]M\0^&M-\46 LM4
MC>2$.KX5]IR#D52F\"Z%/<Z?</!(9+! D!\P\#.>?6KI6CO_ #7_  L92NY7
M7\K7S;/&]7#^'?&6NQZ0#%ML-X5..=W6B2ST23X176HR&*74I)'S(_+YW#C-
M>TMX-T5M;EU=K=FNY8_+<E\J5SGI6._PH\*R&?=;W.V<Y=!.VW.<\#H*SC%^
MSY7OIKZ,NZ4U)=_T2/*-3)6U\(E>H5R/S%=!X-MM.UWQAXA/B K+/%-B..;G
M8NP9(!KT:3X?^'Y!8AK>4BQSY'[P\9]?6FZQ\/?#^MWOVNYAF2;NT$QCS]<=
M:V<O>;\Y?C;7\#*$6HI/M%?=?_,YWQ7JF@Z7%INDQ6OVQIW"0H,%1GID'J*X
MGP_:F'XDZGITJ0?9Y;5"T$283DGC'K7KE]X"T'4;"WL[B"4QV^/+992'&/\
M:ZTFF> =!TG4SJ-K#-]I*!"SREL@=.M9I:MOS_%:%R=TDO+\&>;?#ZPT]?#&
MMS+!$+A#* P4;@,FN;M+FYA^%EHD;O'!)>PK*RG'RER#^E>U0?#W0+;4)[V&
M*=))P0ZB8A3GK\O2K-EX)T.PT1]'AMF-FQR5=MQS]3]:=^OE'3T?ZC?QW\V_
MO7Z'F6N6VGZ-K7AUO#[A9II$$BQ'&],\D^M97A71K35?$/BIKV/S-@8A6Z [
MZ];T;P!H&A79N;2&9I>QFE,FWZ9Z58T_P7HNF75]<VT,BR7N?.)D)SDYX].:
M):QDNZ?XA%V5O./X7/ ";AOARGSL;>&^D# G@#S.*]G\2Z>FN> 8+>UOX[4L
M(RCL3M)';CUK1B\!:';:#<Z1;P,+:=F=@S[CN)SG/UJMH_@IK;1'TC4[PW5H
M#^Z"95E'UH?O1<7Y/\$G^0HMQE&2Z7_%W.,\*ZDWAWQ'9Z+J^DQ1W;Q_N[FW
MC"*XSC)[FI/%(_M#XRZ-'9G,EN4>8K_=Y'-=IIWP_P!&T>:2YL5G-TRD+)<2
MF7;],T[PWX,@T2_N=1FE^TWUPQ+2G/ SG STJE+WXR?2[^_2PFK1DH]=/\SJ
M!P!2T45(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH P/!_\ R")O^ON;_P!"K?K \'_\@B;_ *^YO_0JWZRH?PH^ATXS^//U"BBB
MM3F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@# \(_P#(*N/^ON;_ -"K?K \(_\ (*N/^ON;_P!"K?K*A_#B
M=.,_CS]0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH P/"7_(-N?^OR7^=;]8'A+_D&W/\ U^2_SK?K
M*A_#1TXO^/+U"BBBM3F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "LWQ!_P B_??]<6K2K-\0?\B_??\ 7%JBI\#]
M#6A_%CZK\R72/^0/9_\ 7%?Y5=JEI'_('L_^N*_RJ[3A\*%5^.7JPHHHJC,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *SM>_Y -]_P!<6K1K.U[_ ) -]_UQ:HJ? _0UH_Q8^J'Z-_R!;+_KBO\
M*KU4=&_Y ME_UQ7^57J</A0JO\27JPHHHJC,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (170_\ H&P_K_C1>KV7WO\ R"V'[R^Y?YFC]LM?^?F'_OX*/MEK_P _,/\
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M_P @MA^\ON7^9H_;+7_GYA_[^"C[9:_\_,/_ '\%9W_"*Z'_ - V']?\:/\
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M_K_C1>KV7WO_ ""V'[R^Y?YFC]LM?^?F'_OX*/MEK_S\P_\ ?P5G?\(KH?\
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M]?\ &C_A%=#_ .@;#^O^-%ZO9?>_\@MA^\ON7^9H_;+7_GYA_P"_@H^V6O\
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MX*SO^$5T/_H&P_K_ (T?\(KH?_0-A_7_ !HO5[+[W_D%L/WE]R_S-'[9:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!@>#_ /D$3?\ 7W-_Z%6_6!X/
M_P"01-_U]S?^A5OUE0_A1]#IQG\>?J%%%%:G,%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &!X1_Y!5Q_U]S?
M^A5OU@>$?^05<?\ 7W-_Z%6_65#^'$Z<9_'GZA1116IS!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>$O\
MD&W/_7Y+_.M^L#PE_P @VY_Z_)?YUOUE0_AHZ<7_ !Y>H4445J<P4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^(
M/^1?OO\ KBU:59OB#_D7[[_KBU14^!^AK0_BQ]5^9+I'_('L_P#KBO\ *KM4
MM(_Y ]G_ -<5_E5VG#X4*K\<O5A1115&84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5G:]_R ;[_KBU:-9VO?\@&^
M_P"N+5%3X'Z&M'^+'U0_1O\ D"V7_7%?Y5>JCHW_ "!;+_KBO\JO4X?"A5?X
MDO5A1115&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBJO]I6/_ #^6_P#W\%']I6/_ #^6_P#W\%5SQ[D>SGV9:HJK_:5C_P _EO\
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M[7O^0#??]<6K1K.U[_D WW_7%JBI\#]#6C_%CZH?HW_(%LO^N*_RJ]5'1O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F>GD^7<#M]ID_\
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MBO\ *KU4=&_Y ME_UQ7^57J^EA\*/C:O\27JSS_XKK.^@VPMI%CE^U1;689
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &!X/\
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ML?\ GI+^=+ZA6'_:N'[O[CAZ2NY_X0^P_P">DOYT?\(?8?\ /27\Z7U"L/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#P?
M_P @B;_K[F_]"K?K \'_ /((F_Z^YO\ T*M^LJ'\*/H=.,_CS]0HHHK4Y@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH P/"/_ ""KC_K[F_\ 0JWZP/"/_(*N/^ON;_T*M^LJ'\.)TXS^//U"
MBBBM3F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@# \'_ /((F_Z^YO\ T*M^L#P?_P @B;_K[F_]"K?K*A_"CZ'3C/X\
M_4****U.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,#PC_R"KC_ *^YO_0JWZP/"/\ R"KC_K[F_P#0JWZR
MH?PXG3C/X\_4****U.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,#PE_P @VY_Z_)?YUOU@>$O^0;<_]?DO
M\ZWZRH?PT=.+_CR]0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K-\0?\B_??\ 7%JTJS?$'_(OWW_7%JBI
M\#]#6A_%CZK\R72/^0/9_P#7%?Y5=JEI'_('L_\ KBO\JNTX?"A5?CEZL***
M*HS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "L[7O^0#??]<6K1K.U[_D WW_ %Q:HJ? _0UH_P 6/JA^C?\ (%LO
M^N*_RJ]5'1O^0+9?]<5_E5ZG#X4*K_$EZL****HS"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,#P?_P @B;_K[F_]"K?K \'_ /((F_Z^YO\ T*M^LJ'\
M*/H=.,_CS]0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH P/"/_ ""KC_K[F_\ 0JWZP/"/_(*N/^ON
M;_T*M^LJ'\.)TXS^//U"BBBM3F"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@# \)?\@VY_P"OR7^=;]8'A+_D
M&W/_ %^2_P ZWZRH?PT=.+_CR]0HHHK4Y@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\0?\B_??]<6K2K-\0?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@# \'_ /((F_Z^YO\ T*M^L#P?_P @B;_K
M[F_]"K?K*A_"CZ'3C/X\_4****U.8**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,#PC_R"KC_ *^YO_0JWZP/
M"/\ R"KC_K[F_P#0JWZRH?PXG3C/X\_4****U.8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#PE_P @VY_Z
M_)?YUOU@>$O^0;<_]?DO\ZWZRH?PT=.+_CR]0HHHK4Y@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\0?\B_??\
M7%JTJS?$'_(OWW_7%JBI\#]#6A_%CZK\R72/^0/9_P#7%?Y5=JEI'_('L_\
MKBO\JNTX?"A5?CEZL****HS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "L[7O^0#??]<6K1K.U[_D WW_ %Q:HJ?
M_0UH_P 6/JA^C?\ (%LO^N*_RJ]5'1O^0+9?]<5_E5ZG#X4*K_$EZL****HS
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEI'_ "![/_KBO\JNTX?"A5?CEZL****HS"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L[7O\ D WW_7%JT:SM>_Y
M-]_UQ:HJ? _0UH_Q8^J'Z-_R!;+_ *XK_*KU4=&_Y ME_P!<5_E5ZG#X4*K_
M !)>K"BBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \'_ /((F_Z^
MYO\ T*M^L#P?_P @B;_K[F_]"K?K*A_"CZ'3C/X\_4****U.8**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#
MPC_R"KC_ *^YO_0JWZP/"/\ R"KC_K[F_P#0JWZRH?PXG3C/X\_4****U.8*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,#PE_P @VY_Z_)?YUOU@>$O^0;<_]?DO\ZWZRH?PT=.+_CR]0HHH
MK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K-\0?\B_??\ 7%JTJS?$'_(OWW_7%JBI\#]#6A_%CZK\R72/^0/9
M_P#7%?Y5=JEI'_('L_\ KBO\JNTX?"A5?CEZL****HS"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[7O^0#??]<6
MK1K.U[_D WW_ %Q:HJ? _0UH_P 6/JA^C?\ (%LO^N*_RJ]5'1O^0+9?]<5_
ME5ZG#X4*K_$EZL****HS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*^'GB#4/$$&L^)M38S0<I$C*ZC\:T/%W@[5M;\:Z1J5M' UE:*1(7DPV=P/
M_"MH37/3YW>S;?Z$M\KG)+[-EZF)\0;)_#WBK2/$<'R1AUBFP.V<FH;FY7Q]
M\2-.CA.^QL52X?T.00:]&\9>'O\ A)/#=S8(%\YD/EY. &[5SGPM\"7?@_3Y
MCJ7EF\D)7*-N^7.1S6=*:4;RWC>WS_R"HO=7+U5G\OZL<QJ\ LOCIITJ_=9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLY]F'MJ?\R^\H45>_L?4?^?27\J3^Q]1_P"?27\J7LY]F/VU/^9?>4:2K_\
M8^H_\^DOY4G]C:C_ ,^<OY4>RGV8_;4_YE]Y0I*O_P!C:C_SYR_E1_8VI?\
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MKO\ T"[C_OFCZO5_E?W,/K5#^=?>C'HK8_X177?^@7<?]\T?\(KKO_0+N/\
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M2K#(/44M%49C418U"HH51T IU%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 8'@_P#Y!$W_ %]S?^A5OU@>#_\ D$3?]?<W_H5;]94/X4?0Z<9_'GZA
M1116IS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7^57JHZ-_P @6R_ZXK_*KU.'PH57^)+U844451F%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8'@_P#Y!$W_ %]S?^A5OU@>#_\ D$3?]?<W_H5;
M]94/X4?0Z<9_'GZA1116IS!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!@>$?^05<?]?<W_H5;]8'A'_D%7'_
M %]S?^A5OUE0_AQ.G&?QY^H4445J<P4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 8'A+_ )!MS_U^2_SK?K \
M)?\ (-N?^OR7^=;]94/X:.G%_P >7J%%%%:G,%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OB#_D7[[_ *XM6E6;
MX@_Y%^^_ZXM45/@?H:T/XL?5?F2Z1_R![/\ ZXK_ "J[5+2/^0/9_P#7%?Y5
M=IP^%"J_'+U844451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %9VO?\@&^_ZXM6C6=KW_(!OO\ KBU14^!^AK1_
MBQ]4/T;_ ) ME_UQ7^57JHZ-_P @6R_ZXK_*KU.'PH57^)+U844451F%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 8'@_P#Y!$W_ %]S?^A5OU@>
M#_\ D$3?]?<W_H5;]94/X4?0Z<9_'GZA1116IS!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>$?^05<?]?<
MW_H5;]8'A'_D%7'_ %]S?^A5OUE0_AQ.G&?QY^H4445J<P4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'A+_
M )!MS_U^2_SK?K \)?\ (-N?^OR7^=;]94/X:.G%_P >7J%%%%:G,%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9O
MB#_D7[[_ *XM6E6;X@_Y%^^_ZXM45/@?H:T/XL?5?F2Z1_R![/\ ZXK_ "J[
M5+2/^0/9_P#7%?Y5=IP^%"J_'+U844451F%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %9VO?\@&^_ZXM6C6=KW_(!
MOO\ KBU14^!^AK1_BQ]4/T;_ ) ME_UQ7^57JHZ-_P @6R_ZXK_*KU.'PH57
M^)+U844451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61<>*-#M-333;C4
MX([USA86/S&M"]N5L[*>X<@+&C-S[#-?-6HVFH:]>7_C6)VV6UV&C '5<9JZ
M45*=I:);_H-Q]VZWZ'TY69-XBT>#6$TF74(4U!\%;<GYCGFH/"FK)K7ARSO%
M8,S1C?\ 7%>7:]_R<'IO^ZG_ *":NG2O5]G+L_P%"TJ<I]E<]KK-;Q!I*:J-
M+:_A%\02(,_-@5I#H*\<O/\ DND/_7&3^8K.FN:HHOK?\@>D'+L>Q$@#)Z5S
M]]XY\+Z9-Y5[K=I!)G&UVYKBOB?XAOI]4L_"VE3&*>\8!W'4*:V=&^%6@6=D
MGVN*6YN64>8\DA;GOC-.,%R\\MN@Y63Y>IUNFZYIFL)OTZ]BN5]8SFC5M<TS
M0;7[5JE[%:09"[Y#@9/2N>TCX=Z;H.NIJ.FR3QKSNB:5F!_#I7)_'@-/H-I9
MH"7EF0*/?=BAJ/-%1ZM!!-MW/4]/U*SU6T2ZL;A)X'&5D0Y!JRS*BEF. .IK
MR#X*ZI/;0W?A^^;%Q;N=JGLHKL_B/KHT+P?>2HV)Y$*Q?7BG7I^SE:.M]OF3
M2O-V9JZ=XKT+5[R2TT_5+>XN(SAXT;)!J36/$>CZ BOJVH0VBM]TRG&:\#^$
MT%WI?Q!,-V"LEP/,(/?(S77_ !NC2631HW&4:9 1[%Q6E2BHSA%/XK!3?-*2
M[?Y7.U_X6;X*_P"ADL?^^S_A6Q-XDT:WTM=3EU&!+%AD3D_*16#:> O"[VL1
M-I&21ZBL3XM64%A\.Y;>V3;$JD ?A64^1:+NOS'37.T>BV-_:ZE:K<V4Z3P-
M]UT/!J/4M5L-'M3=:A=1VT (!>0X&3TKQ+X7^(;WPI=P:+K)86ETH:WD;H">
M:[;XPL'\"NRG(,L9!_&KJTN2:2U384??ERLZR\\4Z'I^F1:E=ZG;PV4N-DS'
MY6SZ5E?\+-\%?]#)8_\ ?9_PJOX8T6QUOP!I$%_")8Q"" ?J:X/XM>%-'TC3
M;![*U$;//M8CN,4^2*J^S?>Q--\\%+RN>CQ?$CP;-*L<?B&R9V.  YY_2NG1
MUD170@JPR".XKC=&\!>'FTJRG-D/,,2,3QUP*[*-%BC5%&%48%1-06B"+;UZ
M$=S=06<+37$JQQKU9N@J#3M6L-6B:6PNH[B-3@LAR :XKQOX);65O-0N=0F$
M$4+LD,;LG(&1G!YK&^!;^7X8U LQ*I<GECGM1""E3E-O8N<6DFN]CT_4-4L=
M)@\^_NH[>+^\YP*HZ9XN\/ZS-Y.FZK;7,G]V-LFO,-'MW^(OCZ_FU"23^S[
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M1_:V*[_@/^PL%_*_O9Z;_P ++L/^?*X_,4?\++L/^?*X_,5YE12_M;%=_P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKK7V5@U\0?F&",<4E%:OM?\ X'X/\!MNR?>W_!_+\3MZ***R*"BBB@ HHHH
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MJJFKFNJB_P!+!-6FFMG/_,CT70+-O!3ZQYTR7R3N5D:9B/O],9IOC2[U/5=
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M^K)EI&'I^K+E%%%0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M---IY5O[I_*DVM_=/Y4AW&&BG;6_NG\J3:W]T_E2*N)12[6_NG\J-K?W3^5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!\"IJ*.5=@YY=R'[':_P#/M#_WP*/L=K_S[0_]\"IJ*7*NP<\NY!]CM?\
MGVA_[X%'V.U_Y]H?^^!4]%'*NP<\NY!]CM?^?:'_ +X%'V.U_P"?:'_O@5/1
M1RKL'/+N0?8[7_GVA_[X%'V.U_Y]H?\ O@5/11RKL'/+N0?8[7_GVA_[X%'V
M.U_Y]H?^^!4]%'*NP<\NY!]CM?\ GVA_[X%'V.U_Y]H?^^!4]%'*NP<\NY!]
MCM?^?:'_ +X%'V.U_P"?:'_O@5/11RKL'/+N0?8[7_GVA_[X%*+2V'2WB'_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!@>#_\ D$3?]?<W_H5;]8'@_P#Y!$W_ %]S?^A5OUE0
M_A1]#IQG\>?J%%%%:G,%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &!X1_P"05<?]?<W_ *%6_6!X1_Y!5Q_U
M]S?^A5OUE0_AQ.G&?QY^H4445J<P4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 8'A+_D&W/\ U^2_SK?K \)?
M\@VY_P"OR7^=;]94/X:.G%_QY>H4445J<P4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5F^(/^1?OO^N+5I5F^(/\
MD7[[_KBU14^!^AK0_BQ]5^9+I'_('L_^N*_RJ[5+2/\ D#V?_7%?Y5=IP^%"
MJ_'+U844451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9VO?\@&^_ZXM6C6=KW_ " ;[_KBU14^!^AK1_BQ]4/T
M;_D"V7_7%?Y5>JCHW_(%LO\ KBO\JO4X?"A5?XDO5A1115&84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!@>#_ /D$3?\ 7W-_Z%6_6!X/_P"01-_U]S?^
MA5OUE0_A1]#IQG\>?J%%%%:G,%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &!X1_Y!5Q_U]S?^A5OU@>$?^05
M<?\ 7W-_Z%6_65#^'$Z<9_'GZA1116IS!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>$O\ D&W/_7Y+_.M^
ML#PE_P @VY_Z_)?YUOUE0_AHZ<7_ !Y>H4445J<P4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^(/^1?OO\ KBU:
M59OB#_D7[[_KBU14^!^AK0_BQ]5^9+I'_('L_P#KBO\ *KM4M(_Y ]G_ -<5
M_E5VG#X4*K\<O5A1115&84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5G:]_R ;[_KBU:-9VO?\@&^_P"N+5%3X'Z&
MM'^+'U0_1O\ D"V7_7%?Y5>JCHW_ "!;+_KBO\JO4X?"A5?XDO5A1115&844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!@>#_\ D$3?]?<W_H5;]8'@_P#Y
M!$W_ %]S?^A5OUE0_A1]#IQG\>?J%%%%:G,%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &!X1_P"05<?]?<W_
M *%6_6!X1_Y!5Q_U]S?^A5OUE0_AQ.G&?QY^H4445J<P4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'A+_D&
MW/\ U^2_SK?K \)?\@VY_P"OR7^=;]94/X:.G%_QY>H4445J<P4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^(/^
M1?OO^N+5I5F^(/\ D7[[_KBU14^!^AK0_BQ]5^9+I'_('L_^N*_RJ[5+2/\
MD#V?_7%?Y5=IP^%"J_'+U844451F%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %9VO?\@&^_ZXM6C6=KW_ " ;[_KB
MU14^!^AK1_BQ]4/T;_D"V7_7%?Y5>JCHW_(%LO\ KBO\JO4X?"A5?XDO5A11
M15&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!@>#_ /D$3?\ 7W-_Z%6_
M6!X/_P"01-_U]S?^A5OUE0_A1]#IQG\>?J%%%%:G,%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &!X1_Y!5Q_
MU]S?^A5OU@>$?^05<?\ 7W-_Z%6_65#^'$Z<9_'GZA1116IS!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>
M$O\ D&W/_7Y+_.M^L#PE_P @VY_Z_)?YUOUE0_AHZ<7_ !Y>H4445J<P4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5F^(/^1?OO\ KBU:59OB#_D7[[_KBU14^!^AK0_BQ]5^9+I'_('L_P#KBO\
M*KM4M(_Y ]G_ -<5_E5VG#X4*K\<O5A1115&84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:]_R ;[_KBU:-9VO?
M\@&^_P"N+5%3X'Z&M'^+'U0_1O\ D"V7_7%?Y5>JCHW_ "!;+_KBO\JO4X?"
MA5?XDO5A1115&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>#_\ D$3?
M]?<W_H5;]8'@_P#Y!$W_ %]S?^A5OUE0_A1]#IQG\>?J%%%%:G,%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'L_^N*_RJ[5+2/\ D#V?_7%?Y5=IP^%"J_'+U844451F%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VO?\@&^_ZX
MM6C6=KW_ " ;[_KBU14^!^AK1_BQ]4/T;_D"V7_7%?Y5>JCHW_(%LO\ KBO\
MJO4X?"A5?XDO5A1115&84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(S!5+
M'@ 9->'Z_P#%36;3QV;:SD!TF&X$,OR ]_7Z55.#G/D0-6BY=CW&BH+*Z2]L
MH;F,Y250P/UKSC5O%^L6OQ?LM BG4:?*JEH]@R<J3UIPIN4^1;Z_@"UBY+9*
MYZ=10.E>;W/BS5X_BI'HBSK]A:-V*;!G((QS4Q7-)174'I%R['I%%<SXR\96
MGA'3O/E'FSOQ'$.K&N*@O_B7KT8N[01V%N_S(KJK$BG&+DK]!M6W/6Z*\_\
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MA1115&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <]XVUM-!\+7=V[8)0HOU
M((%>7:#X8M[_ .%]W=7$\)O;P?:1N<;@V,5H?%2XE\1>(-.\*6LA"RG?-M/(
MVD?TK2B^#%K% (5\1:HL8&-H*XQ6M.*5)R;LY;>B_P""5*7+*,>VK^>QH_"?
M73J?A@6DS SV;&$C.>!Q7)Z]_P G!Z;_ +J?^@FH?"]HWP\^)1TA[B62UO5
M1Y.[$_\ UJL_$",Z!\3-)\32JS6I(5V X "X_K71%Q]O&HMI)_?8F'N0J0?;
M]4SV@=!7CEY_R72'_KC)_,5Z3'XKT1]/%W_:5OY6W).\5YCX=E/BSXN7.K6B
MDV%LKQB4=&)P17/1B_:I]KW^X4FO8R\[?F1>*2=9^,FF65P<P1;6V'H3DUZM
MK6NV'A?3!<WB3>0@P!#$7/'L*\P^)-A<^'_&6G>*H(G>WB8";8.@')KT&P\3
M^'?$6FQNUY;2*R@M&[#(^M/>A"W3?[QR5JS<MFE;^O4R=/\ BUX7U/4HK&'[
M<MQ+P@EM2OZFN>^-&RY?1K-^5FGCR/4;ZR/$\ND2?$S1UTIX&"EMXA.<=*O_
M !2!NO&_AFUW,%&'('J'%73IQE*F[6N_R&GRRFGLHW_!E?PJI\$?$>323\EG
M>J7C4] 2<"MSXNZE)<6UCX=M6)FU"0QL!_=(S_2D^+&DM#;67B"V3]_8R!F/
M?:.:Q? D\GCSQL->N%)@LX4\O=TWC@_SHC^]Y9R^SO\ +8EOV=Y+[2T]=G_F
M9WA[38/#?Q@M-/B79OA0D#N=G-;/QRF^S_V3,%+;)4;:!DG#@TWQ*@M?C7I=
MP!@N,9'^[4OQH8+-H;,< 3QDD_[XI\W.Z,O.WXEJ*C4DE_+^A=TKXKR3R6UJ
M="OU#D+O-M)@?CBK?QAD\WX?RR8(W*3@_2NSL]9TT6<0-[#G;_>KC/C%-%/X
M!G>)U=2&Y4^U856F]%U7YBH;KT_0XJZT*Y\+Z=I7BS14("HOVF->XVC_ !KI
M?B#KMMXA^%Z7ULX(>2/<.X.>]=EX7M(K[P1:6TZ!XY(0"#_NBO"?'>FZGX,G
MN-)0,VE7<RO&3T7!_P 370WSU?9OH]/OV_R%0VC47;7_ #/>? 7_ "(^D_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$U%YL****W.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,#PE_R#;G_K\E_G6_6!X2_Y!MS_ -?DO\ZWZRH?
MPT=.+_CR]0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K-\0?\ (OWW_7%JTJS?$'_(OWW_ %Q:HJ? _0UH
M?Q8^J_,ETC_D#V?_ %Q7^57:I:1_R![/_KBO\JNTX?"A5?CEZL****HS"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPCI4T,2I-YT(\P#YN6'?K7I\7^J7Z5HXV5_-K[K?YD*5Y6\KCZ***DL****
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M2/\ D#V?_7%?Y5=JEI'_ "![/_KBO\JNTX?"A5?CEZL****HS"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[7O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@# \'_\ ((F_Z^YO_0JWZP/!_P#R")O^ON;_ -"K?K*A
M_"CZ'3C/X\_4****U.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,#PC_P @JX_Z^YO_ $*M^L#PC_R"KC_K
M[F_]"K?K*A_#B=.,_CS]0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH P/"7_(-N?\ K\E_G6_6!X2_
MY!MS_P!?DO\ .M^LJ'\-'3B_X\O4****U.8**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?$'_(OWW_7%JTJS?$'_
M "+]]_UQ:HJ? _0UH?Q8^J_,ETC_ ) ]G_UQ7^57:I:1_P @>S_ZXK_*KM.'
MPH57XY>K"BBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K.U[_ ) -]_UQ:M&L[7O^0#??]<6J*GP/T-:/\6/J
MA^C?\@6R_P"N*_RJ]5'1O^0+9?\ 7%?Y5>IP^%"J_P 27JPHHHJC,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \'_\ ((F_Z^YO_0JWZP/!
M_P#R")O^ON;_ -"K?K*A_"CZ'3C/X\_4****U.8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#PC_P @JX_Z
M^YO_ $*M^L#PC_R"KC_K[F_]"K?K*A_#B=.,_CS]0HHHK4Y@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/"
M7_(-N?\ K\E_G6_6!X2_Y!MS_P!?DO\ .M^LJ'\-'3B_X\O4****U.8****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/!_P#R")O^
MON;_ -"K?K \'_\ ((F_Z^YO_0JWZRH?PH^ATXS^//U"BBBM3F"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M \(_\@JX_P"ON;_T*M^L#PC_ ,@JX_Z^YO\ T*M^LJ'\.)TXS^//U"BBBM3F
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@# \)?\ (-N?^OR7^=;]8'A+_D&W/_7Y+_.M^LJ'\-'3B_X\O4**
M**U.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *S?$'_(OWW_ %Q:M*LWQ!_R+]]_UQ:HJ? _0UH?Q8^J_,ETC_D#
MV?\ UQ7^57:I:1_R![/_ *XK_*KM.'PH57XY>K"BBBJ,PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.U[_D WW_7
M%JT:SM>_Y -]_P!<6J*GP/T-:/\ %CZH?HW_ "!;+_KBO\JO51T;_D"V7_7%
M?Y5>IP^%"J_Q)>K"BBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \
M'_\ ((F_Z^YO_0JWZP/!_P#R")O^ON;_ -"K?K*A_"CZ'3C/X\_4****U.8*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,#PC_P @JX_Z^YO_ $*M^L#PC_R"KC_K[F_]"K?K*A_#B=.,_CS]
M0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH P/"7_(-N?\ K\E_G6_6!X2_Y!MS_P!?DO\ .M^LJ'\-
M'3B_X\O4****U.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *S?$'_(OWW_7%JTJS?$'_ "+]]_UQ:HJ? _0UH?Q8
M^J_,ETC_ ) ]G_UQ7^57:I:1_P @>S_ZXK_*KM.'PH57XY>K"BBBJ,PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M.U[_ ) -]_UQ:M&L[7O^0#??]<6J*GP/T-:/\6/JA^C?\@6R_P"N*_RJ]5'1
MO^0+9?\ 7%?Y5>IP^%"J_P 27JPHHHJC,**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6;X@_Y%^^_ZXM6E6;X@_Y%^^_ZXM45/@?H:T/XL?5?F2Z1_P @>S_Z
MXK_*KM4M(_Y ]G_UQ7^57:</A0JOQR]6%%%%49A1110 4444 %%%% !1110
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M2"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,<MR,U;UZ9]<UR#1+=CY49\R=E[%3]T_45+B[I+J.W*WS=#>T+4I]5T];N:
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M/SK'.^)F_-A1116QRA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!@>$O^0;<_]?DO\ZWZP/"7_(-N?^OR7^=;
M]94/X:.G%_QY>H4445J<P4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5F^(/\ D7[[_KBU:59OB#_D7[[_ *XM45/@
M?H:T/XL?5?F2Z1_R![/_ *XK_*KM4M(_Y ]G_P!<5_E5VG#X4*K\<O5A1115
M&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5G:]_R ;[_ *XM6C6=KW_(!OO^N+5%3X'Z&M'^+'U0_1O^0+9?]<5_
ME5ZJ.C?\@6R_ZXK_ "J]3A\*%5_B2]6<OXUT*]UVPMX;)4+QW$<C;VQPK FM
M#Q'IUQJ?A^YL[8*9I$*J&.!G%;%%5]GE\[_E_D9_:YO*QRDWAB>[\$VVE2L(
M[N&$*K*<@-CUK+ET?Q1KEO;Z9JUG:6]C%A6DBGWLX' R,>U=_13;O)R[N_S)
M44H\OE;Y''^'_#5[I?B/6+N58Q;7*HL)#9)PN.1VJE;^$-26V\1I((PU]<"6
MWP^<@)CGTYKO:*&[JWE;\O\ (IZN[]?PL<#_ &#XAO?"=IIMW:6L4]LP V3;
M@R@=<U)'X5U-?%-SJ!6+R)+"*!3OYWKUXKNJ*3U<GW_RL.#Y59=K?C<XW1_#
M>H67@J72IEC%TSNP ?(P22.:R;?P?K>D?V7J.GQ037UM"\4EO)(%1MQZ[O85
MZ115.3<G+J_^#_F1&"22[7_&W^1C:+_;,CM+JMK;VQZ!()-X_.L[Q=H-[K-_
MH<MHL92SNS++N;'R[<<>M=512OJGV+BW&_\ 6YR6I^'+RVU&/5]#""[P%FA9
MMJ2@<<GVI^EZ+J \0:G=WT,*07( 38^XD;<'(KJJ*7_!_$&_T_ X+PYX*O=,
M\5WE_=2*]F"5M$W [4[<=JV?#FCWNF7^H27"1K%/,SH5;).3WKI**%I:W16$
M];^>IRVCZ#>V7C+5-3F5!;7$,:1D-DY!.<BLOQ7IGBK5-:B%KI]G<:7$<[);
MC;O/4$C'8UWM%'\OD"TYO,Y>/_A)KK1[JVN--LK61HRD7DS[AR/I5[PWHQTK
M188+E$:Y*@S'@Y;OS6U13OOYBMLC@+CPGJT<NMVMG'#]@NX5,(,F#YA;+<=J
MZ[0K*;3](AMIP!(@YP<BM&BI2MMV2^X;U=_7\=SBO$&BZXWBBVU73K:WO(XX
MV0Q3S; N2.E9O_"(ZY<6&M^?#;QW%^K[$67*@GMFO1Z*$K6\OU'>SOZ?@<9J
M?AK4;OX?)HT2Q_;! (R"^%R ._X54/AS7=%U=-3T:"WN))H(XKB*:78HVKC@
M]Z[ZBJ;;;?G?\+$V_*WXW.,\*Z#K%EK^IZIJD<,;7CA@D<FX+@8KLZ**&]$N
MPW=MMA1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#S[XB:'JUS<V6HZ) \MPI\F15&?D<X8
M_@*T-5\("Y\&6NDPJF^U 9%89#$=J[&BJYGR<OG<=_>4NRL>?:>DOE0VDO@I
MHYD 4W+1)LS_ 'L=<58TC2+^#XB:A?R6CI:26L*))CY21G('TKN:*?M'>_K^
M(EHFN_Z'FTXN]!\6ZWJ]Q;O';3;4AE/1F*X&/QKI?".ERVNGO?78_P!.O#YD
MN?X3TQ6U>:?;WX47";PIR!VS5D  8 P*7-[MOE\AS?,[_P!;6/-X;?5M,\07
MTEWH%SJ?FR%H9T"E47L.:I:59^)/#_AG5#;:/</>W$LCQ1JHR 6SZ^E>K44<
MVEO*P^9WOYW.!\,76H:=9K:'PQJ44LF3)/(5/)]>]4+>VU33M4U,77AVZU&2
MX?\ =72A2J#&._->FT4W*[;[D)6_,XWX?Z9?Z;:Z@+^U>W:6Y+J&&,C'44OB
MG2;^/6;+7=-A-Q);OF:!!\TB@< >^378T4G-N2EV_P K!%**:WN<D]SJ7B>Q
MFL[G1;K3D*];C!R?;%9-O<^(;70VT%M"NI)-IB^UJ!Y9!R,XSGO7H=%*ZU5M
M&/MY'FFJ^$;^S\-:#I]I US);7,;3&,= #R:T_%^D7]]?>''M;625;>Z#S%1
M]Q=IY-=Q15^U=T_.XU)_@U]YQ/C'2;^_U7P_+:VLDJ6\C&5E'W!M[UG6\&L>
M'O%FIWT>B7=]%=[2AAP-N%QSFO1Z*F,VE;U_$;E=6\K?<[GG?_"/ZG>V6M:I
M<VS+=W<;B"WQ\Z@KC:??-4KKP]JS^%?#5LMA,9K:=6F3'*#;U->HT4U.VWE^
M *37X_BK'&^+]+OKZVTE;6V>5HGS)M_A^7O6,+35=-\0W<UUH-SJD<J*(7C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8II\'ZN?^6<?_?P5Z-12_LVCYE?VSB.R^[_@GFQ\&ZP?^6<7_?P4T^#-8/\
MRRB_[^"O2Z*7]ET?,?\ ;>)[+[O^">8GP5K)_P"647_?P4T^"-:/_+*+_OX*
M]0HI?V50\RO[<Q/9?=_P3RP^!];/_+*+_OX*:? NN?\ /*+_ +^"O5:*G^R:
M'=C_ +>Q79?=_P $\G/@/7/^>47_ '\%-/@+73_RQA_[^BO6J*7]CX?N_P"O
MD5_K!B^R^[_@GD?_  @&O?\ /&'_ +^BE7X?ZZ3\T40'_705ZW11_8^'[O\
MKY#_ -8<7V7W?\$\WLOAQ.[ W<_ECN%P:Z[2O#&G:4 T40:3NY%;5%=5' T*
M+O&.IQ8C,\5B%:<M.R#ITHHHKK//,#PC_P @JX_Z^YO_ $*M^L#PC_R"KC_K
M[F_]"K?K*A_#B=.,_CS]0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ,#P?_R")O\ K[F_]"K?K \'_P#(
M(F_Z^YO_ $*M^LJ'\*/H=.,_CS]0HHHK4Y@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/"/_(*N/^ON;_T*
MM^L#PC_R"KC_ *^YO_0JWZRH?PXG3C/X\_4****U.8**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#PE_R#;G
M_K\E_G6_6!X2_P"0;<_]?DO\ZWZRH?PT=.+_ (\O4****U.8**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?$'_(O
MWW_7%JTJS?$'_(OWW_7%JBI\#]#6A_%CZK\R72/^0/9_]<5_E5VJ6D?\@>S_
M .N*_P JNTX?"A5?CEZL****HS"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L[7O^0#??]<6K1K.U[_D WW_7%JBI
M\#]#6C_%CZH?HW_(%LO^N*_RJ]5'1O\ D"V7_7%?Y5>IP^%"J_Q)>K"BBBJ,
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@# \'_P#((F_Z^YO_ $*M^L#P
M?_R")O\ K[F_]"K?K*A_"CZ'3C/X\_4****U.8**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#PC_ ,@JX_Z^
MYO\ T*M^L#PC_P @JX_Z^YO_ $*M^LJ'\.)TXS^//U"BBBM3F"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M\)?\@VY_Z_)?YUOU@>$O^0;<_P#7Y+_.M^LJ'\-'3B_X\O4****U.8**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S
M?$'_ "+]]_UQ:M*LWQ!_R+]]_P!<6J*GP/T-:'\6/JOS)=(_Y ]G_P!<5_E5
MVJ6D?\@>S_ZXK_*KM.'PH57XY>K"BBBJ,PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.U[_D WW_ %Q:M&L[7O\
MD WW_7%JBI\#]#6C_%CZH?HW_(%LO^N*_P JO51T;_D"V7_7%?Y5>IP^%"J_
MQ)>K"BBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MP/!__((F_P"ON;_T*M^L#P?_ ,@B;_K[F_\ 0JWZRH?PH^ATXS^//U"BBBM3
MF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2/\ D#V?_7%?Y5=JEI'_ "![/_KBO\JNTX?"A5?CEZL****HS"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[7O\
MD WW_7%JT:SM>_Y -]_UQ:HJ? _0UH_Q8^J'Z-_R!;+_ *XK_*KU4=&_Y ME
M_P!<5_E5ZG#X4*K_ !)>K"BBBJ,PHHHH **** "BBB@ HHHH **** "BBB@
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MHH P/!__ "")O^ON;_T*MFYN8[:(R2' %8GA)@FBSLQP!=3?^A5G:I?M=W!
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.U[_D
MWW_7%JT:SM>_Y -]_P!<6J*GP/T-:/\ %CZH?HW_ "!;+_KBO\JO51T;_D"V
M7_7%?Y5>IP^%"J_Q)>K"BBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]-_S(E&RBUU_I'5#Q!IC:P=)%TIO0H<Q=\51OO&_A_3;^2QNK\)<1J&9-A.
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M?NR:ZJGTN/K8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4445J<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5F^(/^1?OO^N+5I5F^(/^1?OO^N+5%3X'Z&M#^+'U7YDND?\
M('L_^N*_RJ[5+2/^0/9_]<5_E5VG#X4*K\<O5A1115&84444 %%%% !1110
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MI11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"BBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 A4$Y(!/TI:** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/!__
M "")O^ON;_T*M\C(P:P/!_\ R")O^ON;_P!"K?K*A_"CZ'3C/X\_4R+_ $.*
MXS)#\CGMZUS]QIUS;L0\9/NO-=O2%0PP1D5G4PL)ZK0THXVI35GJC@"K+U!'
MUI*[EK&U<Y:!#]13?[-LO^?:/\JYW@I=SK690ZQ.%-1GI7>_V99?\^T?Y4?V
M78_\^L?Y5/U&7<I9G#^5GGYJ,UZ'_95A_P ^L?Y4?V38?\^D7Y5+R^?=%+-:
M?\K/.&IAKTG^R-/_ .?2+\J/['T[_GSB_*I_LZ?=%K-Z?\K/,C3#7I_]C:=_
MSYQ?]\TG]BZ;_P ^4/\ WS4O+9_S(I9S3_E9Y::C->K?V)IG_/E#_P!\TG]A
MZ9_SXP_]\TGE<_YD6L[I?RL\G-,:O6_["TO_ )\8?^^:3^P=*_Y\(?\ OFI>
M55/YD6L]I?RO\#R%JC->Q?V#I7_/A!_WS2?V!I/_ #X0?]\U+RBI_,BEG]+^
M1_@>-FHS7M'_  C^D?\ 0/@_[YI/^$>T?_H'P?\ ?-2\GJ?S(M<0T?Y'^!XJ
M:C->W?\ ".Z/_P! Z#_OFD_X1S1O^@=;_P#?-2\EJ_S(I<1T?Y'^!X?2@$]
M37M__"-Z-_T#;?\ [YI5\.Z.ARNG0 _[M+^Q*G\R*_UDH_R/\#Q>#3[NY<+%
M;R-GN%.*Z_1/ $\[+-J#"./KM4YS]:]&@M+>V&(850?[(J:NNAD].#O4=SS\
M5Q!6J+EI+E_,K6-A;Z=;K!;1A$ Z"K-%%>NDHJR/ E)R?-)W9@>$?^05<?\
M7W-_Z%6_6!X1_P"05<?]?<W_ *%6_6=#^'$Z,9_'GZA1116IS!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@
M>$O^0;<_]?DO\ZWZP/"7_(-N?^OR7^=;]94/X:.G%_QY>H4445J<P4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^
M(/\ D7[[_KBU:59OB#_D7[[_ *XM45/@?H:T/XL?5?F2Z1_R![/_ *XK_*KM
M4M(_Y ]G_P!<5_E5VG#X4*K\<O5A1115&84444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTX?"A5?CEZL****HS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L[7O\ D WW_7%JT:SM>_Y -]_UQ:HJ? _0UH_Q
M8^J'Z-_R!;+_ *XK_*KU4=&_Y ME_P!<5_E5ZG#X4*K_ !)>K"BBBJ,PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@# \'_ /((F_Z^YO\ T*M^L#P?_P @
MB;_K[F_]"K?K*A_"CZ'3C/X\_4****U.8**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#P?_P @B;_K[F_]"K?K
M \'_ /((F_Z^YO\ T*M^LJ'\*/H=.,_CS]0HHHK4Y@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/"/_ ""K
MC_K[F_\ 0JWZP/"/_(*N/^ON;_T*M^LJ'\.)TXS^//U"BBBM3F"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M \)?\@VY_P"OR7^=;]8'A+_D&W/_ %^2_P ZWZRH?PT=.+_CR]0HHHK4Y@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K-\0?\B_??]<6K2K-\0?\ (OWW_7%JBI\#]#6A_%CZK\R72/\ D#V?_7%?
MY5=JEI'_ "![/_KBO\JNTX?"A5?CEZL****HS"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[7O\ D WW_7%JT:SM
M>_Y -]_UQ:HJ? _0UH_Q8^J'Z-_R!;+_ *XK_*KU4=&_Y ME_P!<5_E5ZG#X
M4*K_ !)>K"BBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \'_ /((
MF_Z^YO\ T*M^L#P?_P @B;_K[F_]"K?K*A_"CZ'3C/X\_4****U.8**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,#PC_R"KC_ *^YO_0JWZP/"/\ R"KC_K[F_P#0JWZRH?PXG3C/X\_4****
MU.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,#PE_P @VY_Z_)?YUOU@>$O^0;<_]?DO\ZWZRH?PT=.+_CR]
M0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K-\0?\B_??\ 7%JTJS?$'_(OWW_7%JBI\#]#6A_%CZK\R72/
M^0/9_P#7%?Y5=JEI'_('L_\ KBO\JNTX?"A5?CEZL****HS"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[7O^0#?
M?]<6K1K.U[_D WW_ %Q:HJ? _0UH_P 6/JA^C?\ (%LO^N*_RJ]5'1O^0+9?
M]<5_E5ZG#X4*K_$EZL****HS"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,#P?_P @B;_K[F_]"K?K \'_ /((F_Z^YO\ T*M^LJ'\*/H=.,_CS]0HHHK4
MY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH P/"/_ ""KC_K[F_\ 0JWZP/"/_(*N/^ON;_T*M^LJ'\.)TXS^
M//U"BBBM3F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@# \)?\@VY_P"OR7^=;]8'A+_D&W/_ %^2_P ZWZRH
M?PT=.+_CR]0HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K-\0?\B_??]<6K2K-\0?\ (OWW_7%JBI\#]#6A
M_%CZK\R72/\ D#V?_7%?Y5=JEI'_ "![/_KBO\JNTX?"A5?CEZL****HS"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "L[7O\ D WW_7%JT:SM>_Y -]_UQ:HJ? _0UH_Q8^J'Z-_R!;+_ *XK_*KU
M4=&_Y ME_P!<5_E5ZG#X4*K_ !)>K"BBBJ,PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6_M"S_Y^H?\ OL4?VA9?\_</_?8HYX]P]G/L6:*K?VC9?\_<'_?8I/[2LO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5F^(/^1?OO\ KBU:59OB#_D7[[_KBU14^!^AK0_BQ]5^9+I'_('L_P#KBO\
M*KM4M(_Y ]G_ -<5_E5VG#X4*K\<O5A1115&84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:]_R ;[_KBU:-9VO?
M\@&^_P"N+5%3X'Z&M'^+'U0_1O\ D"V7_7%?Y5>JCHW_ "!;+_KBO\JO4X?"
MA5?XDO5A1115&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,J@_EFK(((!!R#WH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7>_X+0A*T%'RM^+U/,Y[N\M3XE6S^]-JXC?/3:5YS72VGAO5(+S2+VRCL+5
MZF=HW(,J8Z>]=3#X/TR'^T<"1OM\OFR[CG#8QQZ5%IO@RTTVZ2=+Z^E$9RL<
MLVY1^%.+M*_I^"L:5'S-M%#XFEAX(N^<'"\CZBN9\2>']-L=,TJ[M;9(;IRB
MO,@^9@2 17H^MZ+:Z]IDEA=EQ"^,[#@\'-0ZAX;LM2M;>WG,FRW*E-K8/'3^
M5*-E;_$G\M":EW3Y8[V?X['%:II5GX>\8:<^E6R6[O;,7,8QO.>]9^DZ7?\
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MYA? MC'>-/#>WT2LVXPQS83/TKIXT$<:H"2% &32;NNWD9VU'4444AA1110
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MRU#4-%AM["Z( E2?<1GVI]?N_'8F_P"OX'>T5S^K^)X[(00V<7VF\N /*BZ
MYZ9/85!8ZSXB:_BBU'18;>"3_EI'/O(_"A*XWM<Z>B@=** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)&DJE74,I[&E5510JC '
M%+10!3N=)L+NYCN;BUCDFC.4=AR*N 8&!THHH\@"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/!_\
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M%6_4T/X<37&?QY^H4445J<P4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 8'A+_D&W/_7Y+_.M^L#PE_R#;G_K
M\E_G6_65#^&CIQ?\>7J%%%%:G,%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %9OB#_ )%^^_ZXM6E6;X@_Y%^^_P"N
M+5%3X'Z&M#^+'U7YDND?\@>S_P"N*_RJ[5+2/^0/9_\ 7%?Y5=IP^%"J_'+U
M844451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCV_JX/>Z.FHH'2BI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 8'@_P#Y!$W_ %]S?^A5OU@>#_\
MD$3?]?<W_H5;]94/X4?0Z<9_'GZA1116IS!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>$?^05<?]?<W_H5
M;]8'A'_D%7'_ %]S?^A5OUE0_AQ.G&?QY^H4445J<P4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'A+_ )!M
MS_U^2_SK?K \)?\ (-N?^OR7^=;]94/X:.G%_P >7J%%%%:G,%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OB#_D
M7[[_ *XM6E6;X@_Y%^^_ZXM45/@?H:T/XL?5?F2Z1_R![/\ ZXK_ "J[5+2/
M^0/9_P#7%?Y5=IP^%"J_'+U844451F%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %9VO?\@&^_ZXM6C6=KW_(!OO\
MKBU14^!^AK1_BQ]4/T;_ ) ME_UQ7^57JHZ-_P @6R_ZXK_*KU.'PH57^)+U
M844451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'@__ )!$W_7W-_Z%
M6_6!X/\ ^01-_P!?<W_H5;]94/X4?0Z<9_'GZA1116IS!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>$?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'@_P#Y!$W_
M %]S?^A5OUB>%[::UTN5)XGC<W,K .,'!;@UMUE05J<;G1BVG7FUW"BBBM3G
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@# \(_\ (*N/^ON;_P!"K?K%\,6\UMILZ3Q/&QNI6 88)!/!K:K*
M@K4T=&+:=>37<****U.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,#PE_R#;G_K\E_G6_6+X9MYK:PN$GB>
M-FNI& 88R">#6U65%6IHZ,6TZTFNX4445J<X4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^(/^1?OO\ KBU:54-;
MBDGT2\BB1GD:(A549)-14^!^AK0=JL?5#M(_Y ]G_P!<5_E5VJFF(\6EVL;J
M5=8E!4]0<5;IP^%$U?C?J%%%%40%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9VO?\@&^_P"N+5HU1UF)YM%O(XD+
MNT1"JHR2:BI\#-*.E2/J@T;_ ) ME_UQ7^57JIZ5&\6DVD<BE76)05(P0<5<
MIP^%!5_B2]6%%%%49A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAW_GZ;_O@T?\+!\._P#/TW_?!HNA?4L1_(_N.HHKE_\ A8/A[_GZ?_O@T?\
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MBN6_X6'X=_Y^G_[X-'_"PO#O_/V__?!H#ZEB/Y']QU-%<M_PL+P[_P _;?\
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MQU-%<M_PL/P[_P _;?\ ?!H_X6'X=_Y^V_[X- ?4L3_(_N.IHKEO^%A^'?\
MG[;_ +X-'_"P_#O_ #]M_P!\&@/J6)_D?W'4T5RW_"P_#G_/VW_?!I/^%B>'
M/^?MO^^#0'U+$_R/[CJJ*Y;_ (6'X<_Y^V_[XH_X6'X<_P"?MO\ OBBX?4L3
M_(_N.IHKEO\ A8?AS_G[;_OBC_A8?AS_ )^V_P"^* ^I8G^1_<=317+?\+#\
M.?\ /VW_ 'Q1_P +#\.?\_;?]\4!]2Q'\C^XZFBN6_X6'X<_Y^V_[XH_X6'X
M<_Y^V_[XHN'U+$?R/[CJ:*Y;_A8?AS_G[;_OBC_A8?AS_G[;_OB@/J6)_D?W
M'4T5RW_"P_#G_/VW_?%'_"P_#G_/VW_?%%P^I8C^1_<=317+?\+#\.?\_C?]
M\4?\+#\.?\_;?]\47#ZEB?Y']QU-%<M_PL/PY_S]M_WQ1_PL/PY_S^-_WQ1<
M/J6)_D?W'4T5RW_"P_#G_/XW_?%'_"P_#G_/VW_?%%P^I8G^1_<=317+?\+#
M\.?\_;?]\4?\+#\.?\_;?]\47#ZEB?Y']QU-%<M_PL/PY_S]M_WQ1_PL/PY_
MS]M_WQ2N@^I8G^1_<=317+?\+#\.?\_;?]\4?\+#\.?\_;?]\470?4L3_(_N
M.IHKEO\ A8?AS_G[;_OBC_A8?AS_ )^V_P"^*+H/J6)_Y]O[CJ:*Y;_A8?AS
M_G[;_OBC_A8?AS_G[;_OBBZ#ZEB?Y']QU-%<M_PL/PY_S]M_WQ1_PL/PY_S^
M-_WQ1="^I8C^1_<=317+?\+#\.?\_C?]\4?\+#\.?\_C?]\470_J6)_D?W'4
MT5RO_"P_#G_/VW_?%'_"Q/#G_/XW_?%%T'U+$_R/[CJJ*Y7_ (6)X<_Y_&_[
MXH_X6)X<_P"?QO\ OBBZ#ZEB?Y']QU5%<K_PL3PY_P _C?\ ?%'_  L3PY_S
M^-_WQ1=!]2Q/\C^XZJBN5_X6)X<_Y_&_[XH_X6)X<_Y_&_[XHN+ZEB/Y']QU
M5%<K_P +$\.?\_C?]\4?\+$\.?\ /XW_ 'Q1</J6(_D?W'545RO_  L3PY_S
M^-_WQ1_PL3PY_P _C?\ ?%%T'U+$?R/[CJJ*Y7_A8GAS_G\;_OBC_A8GAS_G
M\;_OBBZ#ZEB/Y']QU5%<K_PL3PY_S^-_WQ1_PL3PY_S^-_WQ1=!]2Q'\C^XZ
MJBN5_P"%B>'/^?QO^^*/^%B>'/\ G\;_ +XHN@^IXC^1_<=517*_\+$\-_\
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M;^XZJBN5_P"%B>'/^?MO^^#1_P +$\.?\_;?]\&BZ#ZEB?\ GV_N.JHKE?\
MA8GAS_G[;_O@T?\ "Q/#G_/VW_?!HN@^I8G_ )]O[CJJ*Y7_ (6)X<_Y^V_[
MX-'_  L3PY_S]M_WP:+H/J6)_P"?;^XZJBN5_P"%B>'/^?MO^^#1_P +$\.?
M\_;?]\470?4L3_S[?W'545RO_"Q/#G_/VW_?%+_PL/PY_P _;?\ ?%%T'U+$
M_P#/M_<=317+?\+#\.?\_;?]\4G_  L/PY_S]M_WQ3#ZEB?^?;^XZJBN5_X6
M'X<_Y^V_[XH_X6)X<_Y^V_[XH#ZCB?\ GV_N.JHKE?\ A8GAS_G[;_OBC_A8
MGAS_ )^V_P"^* ^I8G_GV_N.JHKE?^%B>'/^?QO^^*/^%B>'/^?QO^^* ^I8
MG_GV_N.JHKE?^%B>'/\ G\;_ +XH_P"%A^'/^?QO^^*5P^I8G_GV_N.JHKE?
M^%A^'/\ G[;_ +XH_P"%A^'/^?MO^^*+H7U+$?R/[CJJ*Y7_ (6)X<_Y_&_[
MXH_X6)X<_P"?QO\ OBBZ#ZEB/Y']QU5%<K_PL/PY_P _;?\ ?%'_  L/PY_S
M]M_WQ1=!]2Q'\C^XZJBN5_X6'X<_Y_&_[XH_X6)X<_Y_&_[XHN@^I8C^1_<=
M517*_P#"Q/#G_/XW_?%'_"Q/#G_/XW_?%%T'U+$?R/[CJJ*Y7_A8GAS_ )_&
M_P"^*/\ A8GAS_G\;_OBBZ#ZEB/Y']QU5%<K_P +$\.?\_C?]\4?\+$\.?\
M/XW_ 'Q1=!]2Q'\C^XZJBN5_X6)X<_Y_&_[XH_X6)X<_Y_&_[XHN@^I8C^1_
M<=517*_\+$\.?\_C?]\4?\+$\.?\_C?]\470?4L1_(_N.JHKE?\ A8GAS_G\
M;_OBC_A8GAS_ )_&_P"^*+H/J6(_D?W'545RO_"Q/#G_ #^-_P!\4?\ "Q/#
MG_/XW_?%%T'U+$?R/[CJJ*Y7_A8GAS_G\;_OBC_A8GAS_G\;_OBBZ#ZEB/Y'
M]QU5%<K_ ,+$\.?\_C?]\4?\+$\.?\_C?]\470?4L1_(_N.JHKE?^%B>'/\
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MO_G\;_OBC_A8OAO_ )_&_P"^*+H/J6(_D?W'545RO_"Q?#?_ #^-_P!\4?\
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MHI@+FC-)10 N:,TE%,0N:,TE%(8N:,TE% "YI:;2BF-"T444RPHHHH ****
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MM;1B E+116@T%%%(* %I#2TG:BPA****PDC-H****AH04444@"BBB@ HHHH
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MG7K/PVC=?"5Z64@$-@_C7DUW_P ?D_\ UT;^=*?Q_)$Y0G&O73=]=SV'3O\
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MB@:0E+114M"DA*2E-)7.S-A1112$%%%% !1110 4444 %%%% !1110 4444
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MD<US5)0]6GU0EA(1KNM%VONNC/6HO%'ASQ5H<=GKLHM98P!O9L9/MBJ$6E>
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MHHH **** "BBB@=PHHHH$Q#24M)6,XD204445D0%%%% !1110 4444 %%%%
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M6-%)1FF6@-%%%4AA1110P"BBBH:$%%%%2T,*0TM(:0"44N*3%(0HZ4M)1FF
MM%)FC-!*%HI,T9IQ>I0M%)FC-;I@+3:7-% "4=Z6B@!:,XI,T'FDR6Q=U+3*
M7-0Y AU%-S1FHYBA:*3-&:5P%HI,T9H 6BDS0#2$+1113!A1110 4444 %%%
M% !1110 4444 %%%%- (>M(:7'-&*N+&)12XI#5C"BBBD 4444 +244N*";!
M24N*,4F)H2BEQ1B@20E.I,4M!=@HHHI#"BBBD(****0PHHHH ****0!1110
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M:W_Z"\O_ '[%+_PI:W_Z"\O_ '[%>J45/)$K^VL=_P _/P7^1Y7_ ,*6M_\
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M_P"@O+_W[%'_  I:W_Z"\O\ W[%>J44<J#^V\=_S\_!?Y'E?_"E[?_H+R_\
M?L4?\*7M_P#H+R_]^Q7JE%'*@_MO'?\ /S\%_D>5_P#"E[?_ *"\O_?H4?\
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M6M_^@O+_ -^Q7J<7^J3_ '13J9@\ZQW_ #\_!?Y'E7_"EK?_ *"\O_?L4?\
M"EK?_H+R_P#?L5ZK10']MX[_ )^?@O\ (\J_X4M;_P#07E_[]BC_ (4M;_\
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M_P AB7_OT*]6HHY(A_;.-_G_  7^1Y,?@A;G_F,R_P#?H4G_  H^V_Z#,O\
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M/*O^%*V__07E_P"_8H_X4K;_ /07E_[]BO5:*.5!_;.._G_!?Y'E/_"E;?\
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ML%_O,/5'41?ZI/\ =%.IL7^J3_=%.IG,]PHHHH$%%%% !1110 4444 %%%%
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M7FF>"I[BRN9+>8 X>,X(XKS^X?7/"_AK3/$L6N7MT9<&6&XE+*1@=!^-=O\
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MSRS=JYOP!H$LNI3>)=8G1]1NAA(P?N+G(&*FE\3[:W_1%5/A\WM^K/2J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&\_X\KC_KFW\JFJ&\_P"/
M*X_ZYM_*@J/Q(Y_P!_R)ME_P+_T(UTU<SX _Y$VR_P"!?^A&NFI+8WQG^\3]
M7^9YQ\9M3OM+\(B:PNI;:7<1OC;!Z5R%[/K7@RRT?6H]:O+V*Z"^;%<2%AR!
MT_.ND^.N?^$*&/[[?RJGH7P_U;7;+3+SQ!JT%S9PQJT4$,93'RCKV/:BCO)]
MI+[K*Z,*EK13ZI_?T.ETG5+"#6KN]N?$2,NU2]LTG$65].U=-)XATB+3HM0D
MU"!;.4@1S%OE;/3%>/Z1I<5_X_\ %-B5RICPH]Q'Q7.Z-<7>J75CX(<$G3KA
M&?/HIR?YTXOF48KJD_E?7[B'[O,Y=&T_NT/?+[Q7H.FK&U[JMM )1E"[8W#V
MK,\6^.-/\/>&SJL5U#)O_P!3SPYXZ?G7 :)9Z=<>.M7M]?QLA0K"DG0(&X(!
MKGH(VN?A_P"(5D0S6D$\GV9I!NV_O,<9]JB3O"Z[)_*]OO-*:]])][?.U_N/
M9M \::3JV@KJ3ZA;A5'[TAN$^M6K'Q=H&KR/!IVK6US,H.4C?)%<$=7T30/A
MS9R-9)/YQ5?+BPN3G'/%<E>^=:_$31ID\B 3Q$F*! F!N PV.IK62O5<%M>W
MSM<Q3<:7.^USM_ 6M:AJ/CK7;:YNI)(89&6-&;(7FO3Z\@^&O_)0_$?_ %U?
M^=>OT/X(>B'_ ,O)KS84445)04444 %%%% !1110 4444 %%%% !1110 444
M4 %<K\0O^15;_KXB_P#0A755ROQ"_P"15;_KXB_]"%)['5@O]YAZHZB+_5)_
MNBG4V+_5)_NBG4SF>YY1\:=3U&PM](CL+^>T\ZX*NT+;21MK+EN]8\$>(-%'
M]K75_:WZC>EQ)N(.!T_.I_CR)6MM%$+!9#<MM+#(!VU@Z1%?R>.K.'Q?,'DC
MA!LGC78A^7T_*BAT_P 3^:ML%=:?]N_C=ZGM5_XJT/27CCU'4[>VD<#"R-@F
MK,VM:;;Z>+^6]B2T(R)B?EQ7ANG:?J&L^,?$%M/?V<#[BJB\A\S V=5]*GUC
M29=$\(6D<FM1ZA%:WB;HXPPW@#[G-).\5)Z7M^(-6DXKI_D>O6GC#P[?E1:Z
MQ:RESM78^<FLG0+JR@U74YF\0K=JH!:(R9$(R?RKD?!NDG5O%O\ ;?V!-/M%
M@14MWVG+ ]1CCFN<T/3EU/5_%UF;L6A<)MD.<#YCZ4]4]M>5O\4@23CJ]+K\
M3V6/QIX=N!,+?6+65XE+,JOTP,USOA#XFZ=XCU/4+1[NW7R9"(<'ETQUKC],
MOY?#>HV^C:SIUO<^=$XBN;>)4##ISW/6K'P[L]/BU3Q4OD0K*ERPC^0 A=HZ
M4U:[>ZL_PL)WM;9W7XW/3X_%F@2R^7'JMLS^9Y>T-SN]*AE\;^&8+H6TNMVB
MSDX"%^<UY=\,=)TXWVNZQ>*[M!=28!;Y1@]<>M9/B;4;?7O"NH7^GV<-G##,
MRAI$5I&(;!PPY%2Y62?DG]XXKF;7G8]&\8?$JR\.:K86<=Q PG/[QF/W!D5=
MUZ^L+^XTJYA\1):PRLIC"R8$WS=O7TKRO68K>:#P?<74:.7!$CNN<_,.M=!\
M4XX8M=\,):JBQ"6/8$  ^_VJU&SBGOSM$Q?/JMG"_P"9ZAJ'B?0]&D2+4=4M
M[>1N@D;!-2W'B#2;2SCN[B_@CMY/N2,W#5Y+H<.G7_BG7O\ A(6#2(6$:RG@
M)G@C-<5J,L\G@AXS)(UJM_,(F8D\;AT_"HC>5EU=OQ=BE'_+\+GT19^+- O[
MW['::K;37'7RT;)K9KPC6-.M])\:>%39)Y1EB)<CJW ZU[LOW1]*NWN\WFU]
MQ"E>5O)/[Q:***DH**** "BBB@ HHHH **** "N4^(?_ "+*?]?D'_H8KJZY
M3XA_\BRG_7Y!_P"ABD]CJP/^\P]4=6.@HH'044SE/)_BQK&HZ;K?A^.RO9H$
MEN"LBQM@,-O>N[;Q9H5B$M[S5;>*X2-2Z.V".,\UYM\9O^0_X;_Z^3_Z#6>=
M.MM1^,<L5RA=/LP.W/!_=T4[NFEYR_ F2_>R?:,?Q=CV2P\0:3JEH]W8ZA!<
M6\?WI$;(%>;?$?Q]9F&RM]"UN-K@W 618)/F Q7GLL]SIMOXHM[%GC@748T(
M0X"H4YZ5K^+;?0X/"7AQK 1&Y>1"[@#<>.YI0M/DFMKQ_']"I>ZI1ZVE^"_,
M]-T^6*3Q)8M)K_[]K:(FR,G)XZX]ZW;GQCX=L[T6=QK%K'<DX\MGYS7C5\\T
M?Q(@>WSYHT^#;C_=-;GPTM=!OM#N+C5RCWOGMYC2\LOS'&,U2U2]+_BT2M/P
M7_DJ9Z?J/B?0](1'U#4[>V5QE3(V,UEZSXZT:Q\,SZQ:ZA;SQH"$*MD,V.!7
M*^)=;TRX\21:%:V*37'D.PFF 9$ Z\'ZUPN@P>9H?C"UG\N986D*@+\H( Y4
M=JS;;B[=F_N=C6*2E%/JU^)Z7;>,;#Q7X*N;@:U#92A"9)$?:8AQR:Z:QU33
M]*\/PW%YJL;P ?\ 'S(_#?C7DUS!8I\"KY[>.)93"0Y10#_#UJO<$2MX3M[]
MV736W;QG"GY1UK9KWY1CIJE^%S)/1-]F_N9[7I_B'2-5MI+FPU""XAC!+O&V
M0HZU1/CKPLJJQURS 8X!W]37F-TL%GX_N;?1#BT;3[@SHA^0-LXXZ5S>A:19
MR_"S6+V2/=.CDJQYV_+VK-OW7/HE?\;&BCTZWM]ZN>Q^,?&<>B:9!]@VW%Y>
MG9:J.0QQD5H:?J9TC0(KGQ%>P0R/\[.QP!GG%>+*\D>I>![NZ=C;"2,;F.1G
M8:]'^(FB2:Y;Z<UE?PP7$1WQQRJ663CICI5-<L;KJVO1+^KD1?-))]K_ #.C
MDU+3_$^E3Q:/JRN^#B2W?D''%<]\/_$UU<WE[X>U1R]]8/Y>\]7 &2?UJEX"
M\0JVM7>D7FFI;7L ^>2)55&P,YP*S?#"'4/C1J]_:G_1H?,C=AT9C@TX)>TM
MT:;^[9_H$O@;>Z:_'H>OT445(PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'2PK(****!A1110 4444 %%%% !1110 5RGQ#_Y%E/\ K\@_]#%=77*?$/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39/
M]4_^Z:=39/\ 5/\ [IH&MSE_A[_R*J_]?$O_ *&:ZJN5^'O_ "*J_P#7Q+_Z
M&:ZJDMCIQO\ O,_5A1113.4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *CN/^/:7_ '#_ "J2H[C_ (]I?]P_RH''
M<YOX?_\ (HV__723_P!"-=17+_#_ /Y%&W_ZZ2?^A&NHI+8Z,;_O$_5A1113
M.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *AO/\ CRN/^N;?RJ:H;S_CRN/^N;?RH*C\2.?\ ?\ (FV7_ O_ $(U
MTU<SX _Y$VR_X%_Z$:Z:DMC?&?[Q/U?YA1113.8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y7XA?\BJW_7Q%_Z$
M*ZJN5^(7_(JM_P!?$7_H0I/8ZL%_O,/5'41?ZI/]T4ZFQ?ZI/]T4ZF<SW"BB
MB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5RGQ#_P"193_K\@_]#%=77*?$/_D64_Z_(/\ T,4GL=6!_P!YAZHZ
ML=!10.@HIG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1102 "2< 4 %%43
MK6E@D'4;0$?]-E_QH_MK2O\ H)6G_?Y?\:"_93[,O451_MK2O^@E:?\ ?Y?\
M:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7
M_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2
MO^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:
MTK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/
M93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E
M:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H
M)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,
MO451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\
M?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_
M '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451
M_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\
M:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7
M_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2
MO^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:
MTK_H)6G_ '^7_&@/93[,O451_MK2O^@E:?\ ?Y?\:/[:TK_H)6G_ '^7_&@/
M93[,O4V3_5/_ +IJG_;6E?\ 02M/^_R_XTR36M+\I_\ B8VG0_\ +9?\:!JE
M.^S,;X>_\BJO_7Q+_P"AFNJKBO 6JZ?!X95);ZVC;SY3M:4 _>/O73_VUI7_
M $$K3_O\O^-);'3C:<WB)Z/=EZBJ/]M:5_T$K3_O\O\ C1_;6E?]!*T_[_+_
M (TSE]E/LR]15'^VM*_Z"5I_W^7_ !H_MK2O^@E:?]_E_P : ]E/LR]15'^V
MM*_Z"5I_W^7_ !H_MK2O^@E:?]_E_P : ]E/LR]15'^VM*_Z"5I_W^7_ !H_
MMK2O^@E:?]_E_P : ]E/LR]15'^VM*_Z"5I_W^7_ !H_MK2O^@E:?]_E_P :
M ]E/LR]15'^VM*_Z"5I_W^7_ !H_MK2O^@E:?]_E_P : ]E/LR]15'^VM*_Z
M"5I_W^7_ !H_MK2O^@E:?]_E_P : ]E/LR]15'^VM*_Z"5I_W^7_ !H_MK2O
M^@E:?]_E_P : ]E/LR]15'^VM*_Z"5I_W^7_ !H_MK2O^@E:?]_E_P : ]E/
MLR]15'^VM*_Z"5I_W^7_ !H_MK2O^@E:?]_E_P : ]E/LR]15'^VM*_Z"5I_
MW^7_ !H_MK2O^@E:?]_E_P : ]E/LR]15'^VM*_Z"5I_W^7_ !H_MK2O^@E:
M?]_E_P : ]E/LR]15'^VM*_Z"5I_W^7_ !H_MK2O^@E:?]_E_P : ]E/LR]4
M=Q_Q[2_[A_E57^VM*_Z"5I_W^7_&H[C6M+-M*!J-IG8?^6R^GUH&J4[[,R?A
M_P#\BC;_ /723_T(UU%<9X$U73X/"L"2WUM&XDD^5I0#]X^]=+_;6E?]!*T_
M[_+_ (TEL=&,IS>(GH]V7J*H_P!M:5_T$K3_ +_+_C1_;6E?]!*T_P"_R_XT
MSF]E/LR]15'^VM*_Z"5I_P!_E_QH_MK2O^@E:?\ ?Y?\: ]E/LR]15'^VM*_
MZ"5I_P!_E_QH_MK2O^@E:?\ ?Y?\: ]E/LR]15'^VM*_Z"5I_P!_E_QH_MK2
MO^@E:?\ ?Y?\: ]E/LR]15'^VM*_Z"5I_P!_E_QH_MK2O^@E:?\ ?Y?\: ]E
M/LR]15'^VM*_Z"5I_P!_E_QH_MK2O^@E:?\ ?Y?\: ]E/LR]15'^VM*_Z"5I
M_P!_E_QH_MK2O^@E:?\ ?Y?\: ]E/LR]15'^VM*_Z"5I_P!_E_QH_MK2O^@E
M:?\ ?Y?\: ]E/LR]15'^VM*_Z"5I_P!_E_QH_MK2O^@E:?\ ?Y?\: ]E/LR]
M15'^VM*_Z"5I_P!_E_QH_MK2O^@E:?\ ?Y?\: ]E/LR]15'^VM*_Z"5I_P!_
ME_QH_MK2O^@E:?\ ?Y?\: ]E/LR]15'^VM*_Z"5I_P!_E_QH_MK2O^@E:?\
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MUI7_ $$K3_O\O^- >RGV9>HJC_;6E?\ 02M/^_R_XT?VUI7_ $$K3_O\O^-
M>RGV9>HJC_;6E?\ 02M/^_R_XT?VUI7_ $$K3_O\O^- >RGV9>HJC_;6E?\
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M%^&O^@+:?]\5O44K!]:K_P [^]F#_P (7X:_Z MI_P!\4?\ "%^&O^@+:?\
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M 'Q1_P (7X:_Z MI_P!\5O446#ZU7_G?WLP?^$+\-?\ 0%M/^^*/^$+\-?\
M0%M/^^*WJ*+!]:K_ ,[^]F#_ ,(7X:_Z MI_WQ1_PA?AK_H"VG_?%;U%%@^M
M5_YW][,'_A"_#7_0%M/^^*/^$+\-?] 6T_[XK>HHL'UJO_._O9@_\(7X:_Z
MMI_WQ39/!?AL1L1HUIG!_@KH*;)_JG_W319 L57O\;^]G >"/"VA7WAQ9KK2
M[:63SY5W,N3@,<5T?_"%^&O^@+:?]\53^'O_ "*J_P#7Q+_Z&:ZJA+0Z<9B:
MRQ$TIO=]68/_  A?AK_H"VG_ 'Q1_P (7X:_Z MI_P!\5O446.;ZU7_G?WLP
M?^$+\-?] 6T_[XH_X0OPU_T!;3_OBMZBBP?6J_\ ._O9@_\ "%^&O^@+:?\
M?%'_  A?AK_H"VG_ 'Q6]118/K5?^=_>S!_X0OPU_P! 6T_[XH_X0OPU_P!
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M[,'_ (0OPU_T!;3_ +XH_P"$+\-?] 6T_P"^*WJ*+!]:K_SO[V8/_"%^&O\
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M46#ZU7_G?WLP?^$+\-?] 6T_[XH_X0OPU_T!;3_OBMZBBP?6J_\ ._O9@_\
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MV8/_  A?AK_H"VG_ 'Q1_P (7X:_Z MI_P!\5O446#ZU7_G?WLP?^$+\-?\
M0%M/^^*/^$+\-?\ 0%M/^^*WJ*+!]:K_ ,[^]F#_ ,(7X:_Z MI_WQ1_PA?A
MK_H"VG_?%;U%%@^M5_YW][,'_A"_#7_0%M/^^*/^$+\-?] 6T_[XK>HHL'UJ
MO_._O9@_\(7X:_Z MI_WQ1_PA?AK_H"VG_?%;U%%@^M5_P"=_>S!_P"$+\-?
M] 6T_P"^*/\ A"_#7_0%M/\ OBMZBBP?6J_\[^]F#_PA?AK_ * MI_WQ5W3M
M!TK297DT^PAMW<;6:-<$BM&BG8F6(JR5I2;7JPHHHH,@HHHH **** "BBB@
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MM_\ KI)_Z$:ZBN7^'_\ R*-O_P!=)/\ T(UU%);'1C?]XGZL****9S!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
M-Y_QY7'_ %S;^535#>?\>5Q_US;^5!4?B1S_ ( _Y$VR_P"!?^A&NFKF? '_
M ")ME_P+_P!"-=-26QOC/]XGZO\ ,****9S!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*_$+_D56_Z^(O\ T(5U
M5<K\0O\ D56_Z^(O_0A2>QU8+_>8>J.HB_U2?[HIU-B_U2?[HIU,YGN%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KE/B'_R+*?]?D'_ *&*ZNN4^(?_ "+*?]?D'_H8I/8ZL#_O,/5'5CH*
M*!T%%,Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_/W%_WU1_:EC_S]Q?\ ?5>8T4<P?V-#^9GIW]J6/_/W%_WU1_:EC_S]Q?\
M?5>8T4<P?V-#^9GIW]J6/_/W%_WU1_:EC_S]Q?\ ?5>8T4<P?V-#^9GIW]J6
M/_/W%_WU1_:EC_S]Q?\ ?5>8T4<P?V-#^9GIW]J6/_/W%_WU1_:EC_S]Q?\
M?5>8T4<P?V-#^9GIW]J6/_/W%_WU1_:EC_S]Q?\ ?5>8T4<P?V-#^9GIW]J6
M/_/W%_WU1_:EC_S]Q?\ ?5>8T4<P?V-#^9GIW]J6/_/W%_WU1_:EC_S]Q?\
M?5>8T4<P?V-#^9GIW]J6/_/W%_WU1_:EC_S]Q?\ ?5>8T4<P?V-#^9GIW]J6
M/_/W%_WU4<^IV)MY0+J(DH?XO:O-:*.8%D\%]IG5^![NWM/"\$5Q,D<@D<E6
M.#]XUT?]J6/_ #]Q?]]5YC11<TJY5"I4<W)ZNYZ=_:EC_P _<7_?5']J6/\
MS]Q?]]5YC11S&?\ 8T/YF>G?VI8_\_<7_?5']J6/_/W%_P!]5YC11S!_8T/Y
MF>G?VI8_\_<7_?5']J6/_/W%_P!]5YC11S!_8T/YF>G?VI8_\_<7_?5']J6/
M_/W%_P!]5YC11S!_8T/YF>G?VI8_\_<7_?5']J6'_/W%_P!]5Y@:::.8/[&I
M_P S/4/[5L/^?N'_ +ZH_M6P_P"?N'_OJO+3331S#_L:G_,SU3^UM/\ ^?R'
M_OJC^UM/_P"?R'_OJO*33#1S!_8M/^9GK']KZ?\ \_D/_?5']KZ=_P _D/\
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MO^?C^Y'U)_PE6@_]!:T_[^"C_A*M!_Z"UI_W\%?+=%'.'^K-+_GX_N1]2?\
M"5:#_P!!:T_[^"C_ (2K0?\ H+6G_?P5\MT4<X?ZLTO^?C^Y'U)_PE6@_P#0
M6M/^_@H_X2K0?^@M:?\ ?P5\MT4<X?ZLTO\ GX_N1]2?\)5H/_06M/\ OX*/
M^$JT'_H+6G_?P5\MT4<X?ZLTO^?C^Y'U)_PE6@_]!:T_[^"C_A*M!_Z"UI_W
M\%?+=%'.'^K-+_GX_N1]2?\ "5:#_P!!:T_[^"C_ (2K0?\ H+6G_?P5\MT4
M<X?ZLTO^?C^Y'U)_PE6@_P#06M/^_@H_X2K0?^@M:?\ ?P5\MT4<X?ZLTO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY*6)FUVE^AS?\N.VJ_,]AHHHKD-0HHHH **** "BBB@ HHHH **** "BBB@
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MY;ZUI44D[;!Y!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %-D_U3_[IIU-D_P!4_P#NF@:W/(]+N"^@Q0YX2XF_]"-2UG:*
M3]@<=O/D_P#0C6C69]QRJ+:04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ----.--- #3332FD-!0PTAI3330,2F&G&FF@8TTTTXTTT%#3332FFF@
M8TTTTXTTT%#3333C3#2&(:8:>:8:!B&F&G&FF@H::::<:8:!B&FFG&F4#$-,
M-.---!0TTTTXTTT#&FFFG&FF@H::::4TTTAC3333C330,::::<:::"AIIII3
M330,::0TIIIH&-IIIU--!0VFFG&F&@8AIM*:2@H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "NE\/ZBT6F26.[Y9KN!L?1JYJKNE%AJ=H!T,\>?^^A0C&O!3@T_7[CZN
M'044#H**V/RT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(KV3D[G+?Q>]5UA?LO\ TD5/:I;^\1^&O#MMXCU76WO[O4,I>2*HCNG0 9]
M:W=+N+OPWXG71)[@S6-P +;?DL&ZG+'D\53\!7=M!J6NK-<11G[;)P[@=_>K
M4^-?\=V<ML"T&GD2&3'#9&, ]Z%I**6UM?N_SL5B/BF^M]/O7Z'=4445)(44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\+75I<1R7.OWU['&?EBF"[1^5=+11S.]Q/7<P]+\,V^EZG>WJ3R2-=@!D8#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO_SRNO\ O^:3_A4WA;_GE=?]_P UW-%%D']I8S_GX_O.&_X5+X6_YY77_?\
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M>5U_W_-'_"H_"O\ SRNO^_YKNJ*+(/[2QG_/U_><+_PJ/PK_ ,\KK_O^:/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !39/]4_^Z:=39/\ 5/\ [IH&MSE_A[_R*J_]?$O_ *&:ZJN5
M^'O_ "*J_P#7Q+_Z&:ZJDMCIQO\ O,_5A1113.4**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CN/^/:7_ '#_ "J2
MH[C_ (]I?]P_RH''<YOX?_\ (HV__723_P!"-=17+_#_ /Y%&W_ZZ2?^A&NH
MI+8Z,;_O$_5A1113.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *AO/\ CRN/^N;?RJ:H;S_CRN/^N;?RH*C\2.?\
M ?\ (FV7_ O_ $(UTU<SX _Y$VR_X%_Z$:Z:DMC?&?[Q/U?YA1113.8****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY7XA?\BJW_7Q%_Z$*ZJN5^(7_(JM_P!?$7_H0I/8ZL%_O,/5'41?ZI/]T4ZF
MQ?ZI/]T4ZF<SW"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5RGQ#_P"193_K\@_]#%=77*?$/_D64_Z_(/\
MT,4GL=6!_P!YAZHZL=!10.@HIG*%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %-D_U3_[IIU-D_P!4_P#NF@:W.7^'O_(JK_U\2_\ H9KJJY7X>_\ (JK_
M -?$O_H9KJJ2V.G&_P"\S]6%%%%,Y0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ J.X_X]I?\ </\ *I*CN/\ CVE_
MW#_*@<=SF_A__P BC;_]=)/_ $(UU%<O\/\ _D4;?_KI)_Z$:ZBDMCHQO^\3
M]6%%%%,Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ J&\_P"/*X_ZYM_*IJAO/^/*X_ZYM_*@J/Q(Y_P!_P B;9?\
M"_\ 0C735S/@#_D3;+_@7_H1KIJ2V-\9_O$_5_F%%%%,Y@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?B%_R*K?
M]?$7_H0KJJY7XA?\BJW_ %\1?^A"D]CJP7^\P]4=1%_JD_W13J;%_JD_W13J
M9S/<****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7*?$/_ )%E/^OR#_T,5U=<I\0_^193_K\@_P#0Q2>QU8'_
M 'F'JCJQT%% Z"BF<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39/]4_^Z:=39/\
M5/\ [IH&MSE_A[_R*J_]?$O_ *&:ZJN5^'O_ "*J_P#7Q+_Z&:ZJDMCIQO\
MO,_5A1113.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *CN/^/:7_ '#_ "J2H[C_ (]I?]P_RH''<YOX?_\ (HV_
M_723_P!"-=17+_#_ /Y%&W_ZZ2?^A&NHI+8Z,;_O$_5A1113.8**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AO/\
MCRN/^N;?RJ:H;S_CRN/^N;?RH*C\2.?\ ?\ (FV7_ O_ $(UTU<SX _Y$VR_
MX%_Z$:Z:DMC?&?[Q/U?YA1113.8**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Y7XA?\BJW_7Q%_Z$*ZJN5^(7_(JM
M_P!?$7_H0I/8ZL%_O,/5'41?ZI/]T4ZFQ?ZI/]T4ZF<SW"BBB@04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RGQ#
M_P"193_K\@_]#%=77*?$/_D64_Z_(/\ T,4GL=6!_P!YAZHZL=!10.@HIG*%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %-D_U3_[IIU-D_P!4_P#NF@:W
M.7^'O_(JK_U\2_\ H9KJJY7X>_\ (JK_ -?$O_H9KJJ2V.G&_P"\S]6%%%%,
MY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J.X_X]I?\ </\ *I*CN/\ CVE_W#_*@<=SF_A__P BC;_]=)/_ $(U
MU%<O\/\ _D4;?_KI)_Z$:ZBDMCHQO^\3]6%%%%,Y@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&\_P"/*X_ZYM_*
MIJAO/^/*X_ZYM_*@J/Q(Y_P!_P B;9?\"_\ 0C735S/@#_D3;+_@7_H1KIJ2
MV-\9_O$_5_F%%%%,Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KE?B%_R*K?]?$7_H0KJJY7XA?\BJW_ %\1?^A"
MD]CJP7^\P]4=1%_JD_W13J;%_JD_W13J9S/<****!!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*?$/_ )%E/^OR
M#_T,5U=<I\0_^193_K\@_P#0Q2>QU8'_ 'F'JCJQT%% Z"BF<H4444 %%%%
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MR_X%_P"A&NFKF? '_(FV7_ O_0C734EL;XS_ 'B?J_S"BBBF<P4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ROQ"_
MY%5O^OB+_P!"%=57*_$+_D56_P"OB+_T(4GL=6"_WF'JCJ(O]4G^Z*=38O\
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M'_H8I/8ZL#_O,/5'5CH**!T%%,Y0HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *;)_JG_ -TTZFR?ZI_]TT#6YXWH\973"_9IY?\ T(U=JQI=F7\(17"C
M[MQ-N_[[-5ZS/M8U%-R\FT%%%%!84444 %%%% !1110 4444 %%%% !1110
M4444 %!HI#TH 8U1M4C5$U T,-1L:>:C:@M$;5&U2,:B:@M#&J-J>U1M2+1&
MU1M4C5$U!2&-4;4]JC:@M$;5&U2-434%H8U1M3S4;4BD,:HFJ1JB:@M#&J,T
M\U&U!:(VJ-JD:HVH*1&:2E-)06%%%% !1110 4444 %%%% !1110 4444 %%
M%% !5BRMS=7*Q*,D@FJ]=C\/-&;4=9DN"I,5O&Q;CCD&A&&)K*C2E4?0]A^'
M0QX%TT>BG^9KJ:YGX?C'@RQ'IN_]"-=-6JV/S?&_[S4]7^84444SF"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N5
M^(7_ "*K?]?$7_H0KJJY7XA?\BJW_7Q%_P"A"D]CJP7^\P]4=1%_JD_W13J;
M%_JD_P!T4ZF<SW"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5RGQ#_Y%E/\ K\@_]#%=77*?$/\ Y%E/^OR#
M_P!#%)['5@?]YAZHZL=!10.@HIG*8&J^(VTW7],TP6X<7LA0OG&WC-;KMLC9
M_0$UPOBL[?'7AP^D['_QRF[]4\57U_\ 9]7N=.M;8846^#OX[YH^PK;Z_@[?
MY"^VT]M/Q1J67C2"9+Q[FWD1;>Y6W'EJ7+%AUP*ZB-Q)&KKG##(R*\6L[O4-
M#T*^%O?S&?\ M:"-YSC<X(YS76SWVIZ_XA32+34I["..#S'FAQN8YQCFJM=*
MWE^2;$G[O-+N_P '9'?45YD^OZMI<>N:--?33W%G;K/'=N?G^9L8]*'B\0V_
MA^/7AXAO)'##-LQ781GUQFH<DKM[63OZEV>W77\/^'/3:K7U]!IUH]U<L5B0
M98@9KC-3O)=3L8;N#7KZRD:,DP6@5CGW!YKFKB^U'7O &K1SZC<J]G(8_,8#
M?( /XA3L]5V_SL3=:/O_ )7/0=8\3IIUOIT\$7G1WK[5).,#&<UNQOOB5\8W
M*#BO)-4T^[MO"7AQ/[1GN))'!1I,#9E.@Q6K++K'AOQ#HL4FM75[#>@AHIL!
M4PN>,415Y2CYV_!,%>237:_XO]#N;/6+:^O;FTB6426[!7+1D#IG@]ZT*\O/
MB_4-/O\ Q$9KAY4BNHH($;I'O';\:Z32-$UD&WOKCQ#>R[\,]LVW8/IQFG;;
MY?B5-<KM_73_ #-?Q)JYT'P]>ZHL0E-M$7"$XW5S,/CC5H+>WOM4T:*VT^;&
M9DFWD9Z<?C6G\1/^2?ZU_P!>Q_I7)I<3>*O"=IH]G93H-J^9)-&5'&.A[]*4
M-6[]U]W4J27LT]KW_)6/48I%EB613E6 (K-U_6#HFG?:A$)/G"[2<=:YCPKJ
M%^VO:_8SW4DD-H$6%#T3Y.U8UQJ5YJ&@:I]KN'F\J^58]W\(QTJ:UXQ;CV3^
M]K_,CX6E+T_"YZ;8W/VRQ@N"NWS$#8],U8KRZUN=7U+Q-!HUMJUQ9VRV"29B
MQD$G'>ETF/Q#?ZC?Z2_B.]5;-?,%R-N]\D\$8Q@8K22LW\W\A;)<WE^*N>H4
M5Y=!XLU2W\*^6]P\UX9A$)W/S8+8S5S4'UGPA/8WD^M7>HPSRI"\4^,*6.,C
M I17-:VSV_/]0=]5U70]%HKSFR;6O$&LZE;)KEW9PPRML:+!('IR*=X<U>]U
M/PW=PWVKRP30W,L2W0(WL%; Z\5,7S1YEZ_H5;[MCT2BO+;'6M3T[Q0M@=5O
M[Z&>)V#7:A=I5<_+CK5SPP/$&NVD]Y-K-Q$L:LD:(0=Y(X)XZBG_ )7_ !L3
M?=>=OO5ST:D8X4GT%>=+XHOD\/75B]RW]J),;5)2?F+8^]7<::EPFCP"ZD:2
M?RAO9NI..:'\+:_K2X]G8Y6Q\7^(-5GG&GZ%!+#$Y7>UQM)P<=*VU\1!,V]U
M;/'>K"\K(%)0;1G&[I7%>#Y_$<=S>KIME8RVWG-EII2K?>.>*UM1U._/BR:Q
M>=A;FRG9H@?ER%J(M^SB^K5__);A/W9/R=OQL=+X=UHZ[IHNS"(L_P (.:UZ
M\D\/:3K!\+S:C::_>6PA&]+=-NQL#H>,U-_PD&O:QJ.GV=K>/;^<%CF96Y4X
MY8>IIJ5^6/5V_%7N#TNWM=_F>JT5Y_/+JM[K_P#PCL&LW4+6R*\MTN-[;A^5
M)9:IK6FW>I:/+=27\T2$P3R'YR N>W>FY)*_K;SL.S_+\?\ AST$G S6?I^K
MVVI23I LH:%RC;XRO(],]:XOPI<W=R\$^H^(=02Y=?GLKE55<^W<U5M==UV7
M2?$+PSS3S07$BQ <L@!X"U5K7"*YDVO(].HKB?"<LDDZ/<^(;Z>9U!-I=!5*
MGO@=:[:AJQ*=PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM04B-JC:I&J-J"T1M4;4]JC:@M##11104%%%% !1110 4444 %%%% !1110
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M:WO_ %<YS0_#T^EZK?W4DD;)<.64+U -<Q_PKW5([$K#=P>>MY+<HK9V,&/
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M!11R(?\ K%BNR^Y_YGSX?A?XI/\ RY1_]_13#\+?%1_Y<H_^_HKZ&HHY$/\
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MF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N5^(7_ "*K?]?$7_H0KJJY7XA?\BJW_7Q%_P"A"D]CJP7^\P]4=1%_
MJD_W13J;%_JD_P!T4ZF<SW"BBB@04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5RGQ#_Y%E/\ K\@_]#%=77*?$/\
MY%E/^OR#_P!#%)['5@?]YAZHZL=!10.@HIG*%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5'<?\>TO^X?Y5)4=Q_Q[2_[A_E0..YS?P_\ ^11M_P#KI)_Z$:ZBN7^'_P#R
M*-O_ -=)/_0C744EL=&-_P!XGZL****9S!1110 4444 %%%% !1110 4444
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MNKKE/B'_ ,BRG_7Y!_Z&*3V.K _[S#U1U8Z"B@=!13.4**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "FR?ZI_P#=-.ILG^J?_=-
MUN<O\/?^157_ *^)?_0S755ROP]_Y%5?^OB7_P!#-=526QTXW_>9^K"BBBF<
MH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5'<?\>TO^X?Y5)4=Q_Q[2_[A_E0..YS?P__ .11M_\ KI)_Z$:ZBN7^
M'_\ R*-O_P!=)/\ T(UU%);'1C?]XGZL****9S!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-Y_QY7'_ %S;^535
M#>?\>5Q_US;^5!4?B1S_ ( _Y$VR_P"!?^A&NFKF? '_ ")ME_P+_P!"-=-2
M6QOC/]XGZO\ ,****9S!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7*_$+_D56_Z^(O\ T(5U5<K\0O\ D56_Z^(O
M_0A2>QU8+_>8>J.HB_U2?[HIU-B_U2?[HIU,YGN%%%% @HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE/B'_R+*?]
M?D'_ *&*ZNN4^(?_ "+*?]?D'_H8I/8ZL#_O,/5'5CH**!T%%,Y0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ ILG^J?\ W33J;)_JG_W30-;G+_#W_D55
M_P"OB7_T,UU5<K\/?^157_KXE_\ 0S754EL=.-_WF?JPHHHIG*%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W'_'
MM+_N'^525'<?\>TO^X?Y4#CN<W\/_P#D4;?_ *Z2?^A&NHKE_A__ ,BC;_\
M723_ -"-=126QT8W_>)^K"BBBF<P4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<E<YZL2*WJ**"ZM1U)N;W>H4444$!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !45RADM9D499D8#ZXJ6B@:=G<P_"
M&GW.F>&K6TNTV3)NW+G.,DFMRBB@JK4=2;F]WJ%%%%! 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>,=.N=4\/M
M;6D>^4S1MMSC@,":WZ*#2E4=.:FMT-0$1J#U %.HHH,PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[QEIM
MUJNAI;VD?F2BYB?&<<!@370T4&E*HZ4U-;H!THHHH,PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@_L^L=?17(?\)1>?W(_RI/\ A*+W^Y%^5'^L."[O[@_L^L=A17'_ /"47O\
M<B_*C_A*;W^Y%^5'^L."[O[@_L^L=A17'?\ "4WO]R+\J/\ A*;W^Y%^5'^L
M."[O[@_L^L=C17'?\)3>_P!R+\J/^$JO?[D7Y4?ZPX+N_N#ZA6.QHKCO^$JO
M?[D7Y4?\)5>_W(ORI_ZP8+N_N#^SZWD=C17'?\)5>_W(ORH_X2J]_N1?E2_U
M@P7=_</^SZWD=C17'?\ "57O]R+\J/\ A*KW^Y%^5'^L."[O[@_L^MY'8T5Q
MW_"57O\ <B_*D_X2J]_N1?E1_K!@N[^X7U"L=E17&_\ "57O]R+\J/\ A*KW
M^Y%^5/\ U@P7=_</^SZWD=E17&_\)5>_W(ORH_X2J]_N1?E1_K!@N[^X/[.K
M^1V5%<=_PE-[_<B_*E_X2F]_N1?E2_UAP7=_<+^SZQV%%<?_ ,)3>_W(_P J
M/^$IO?[D?Y4?ZPX+N_N#^SZQV%%<?_PE-[_<B_*D_P"$IO?[D7Y4?ZPX+N_N
M#^SZQV-%<=_PE-[_ '(ORI?^$HO?[D?Y4?ZPX+N_N#^SZQV%%<A_PE%[_<C_
M "H_X2B]_N1_E1_K#@N[^X/J%8Z^BN0_X2B]_N1_E1_PE%[_ '(_RH_UAP7=
M_<'U"L=?17(?\)1>_P!R/\J/^$HO/[D?Y4?ZPX+N_N#ZA6.OHKD/^$HO/[D?
MY4?\)1>?W(_RH_UAP7=_<']GUCKZ*Y'_ (2>\_N1_E33XHO1_!'^5'^L."[O
M[@^H5CL**XW_ (2J]_N1?E1_PE5[_<B_*G_K!@N[^X?]GUO([*BN-_X2J]_N
M1?E1_P )5>_W(ORI?ZP8+N_N#^SZWD=E17&_\)5>_P!R+\J/^$JO?[D7Y4_]
M8,%W?W!_9U?R.RHKC?\ A*KW^Y%^5'_"57O]R+\J/]8,'W?W!_9U?R.RHKC?
M^$JO?[D7Y4?\)5>_W(ORI?ZP8+N_N#^SJWD=E17&_P#"57O]R+\J/^$JO?[D
M7Y4_]8,%W?W!_9U;R.RHKC?^$JO?[D7Y4?\ "57O]R+\J/\ 6#!=W]P?V=6\
MCLJ*XW_A*KW^Y%^5*/%5[_<B_*C_ %@P7=_<']GUO([&BN/_ .$IO?[D7Y4#
MQ1>?W(_RI?ZPX+N_N%_9]8["BN0_X2F['\$?Y4T^*[OLD?Y4_P#6#!]W]P_[
M/K>1V-%<9_PE=[_<B_*D_P"$KOO[D7Y4_P"W\'W?W!_9];R.THKB_P#A++[^
MY%^5'_"67W]R+\J/[?P?=_<']G5_([2BN+_X2R^_N1?E1_PEE]_<B_*C^W\'
MW?W!_9U?R.THKB_^$LOO[D7Y4?\ "67W]R+\J/[?P?=_<']G5_([2BN+_P"$
MLOO[D7Y4?\)9??W(ORH_M_!]W]P?V=7\CM**XO\ X2R^_N1?E1_PEE]_<B_*
MC^W\'W?W!_9U?R.THKB_^$LOO[D7Y4?\)9??W(ORH_M_!]W]P?V=7\CM**XO
M_A++[^Y%^5'_  EE]_<B_*C^W\'W?W!_9U?R.THKB_\ A++[^Y%^5'_"67W]
MR+\J/[?P?=_<']G5_([2BN+_ .$LOO[D7Y4?\)9??W(ORH_M_!]W]P?V=7\C
MM**XO_A++[^Y%^5'_"67W]R+\J/[?P?=_<']G5_([2BN+_X2R^_N1?E1_P )
M9??W(ORH_M_!]W]P?V=7\CM**XO_ (2R^_N1?E1_PEE]_<B_*C^W\'W?W!_9
MU?R.THKB_P#A++[^Y%^5'_"67W]R+\J/[?P?=_<']G5_([2BN,_X2N^_N1?E
M1_PE=]_<B_*E_K!@^[^X/[.K^1V=%<9_PE=]_<B_*D_X2R^_N1?E3_M_!]W]
MP?V=7\CM**XO_A++[^Y%^5'_  EE]_<B_*C^W\'W?W!_9U?R.THKB_\ A*[[
M^Y%^5+_PE=]_<B_*E_;^#[O[A_V=7\CLZ*XO_A*[[^Y%^5'_  EE]_<B_*C^
MW\'W?W"_LZOY':45Q?\ PEE]_<B_*C_A++[^Y%^5/^W\'W?W!_9U?R.THKB_
M^$LOO[D7Y4?\)9??W(ORH_M_!]W]P?V=7\CM**XO_A++[^Y%^5'_  EE]_<B
M_*C^W\'W?W!_9U?R.THKB_\ A++[^Y%^5'_"67W]R+\J/[?P?=_<']G5_([2
MBN+_ .$LOO[D7Y4?\)9??W(ORH_M_!]W]P?V=7\CM**XO_A++[^Y%^5'_"67
MW]R+\J/[?P?=_<']G5_([2BN+_X2R^_N1?E1_P )9??W(ORH_M_!]W]P?V=7
M\CM**XO_ (2R^_N1?E1_PEE]_<B_*C^W\'W?W!_9U?R.THKB_P#A++[^Y%^5
M+_PE=]_<B_*C^W\'W?W!_9U?R.SHKC/^$KOO[D7Y4G_"67W]R+\J/[?P?=_<
M']G5_([2BN+_ .$LOO[D7Y4?\)9??W(ORH_M_!]W]P?V=7\CM**XO_A++[^Y
M%^5'_"5WW]R+\J/[?P?=_<']G5_([2BN+_X2N^_N1?E2KXKOC_!%^5+_ %@P
M7=_<']GUO([.BN/_ .$IO?[D?Y4?\)3>_P!R/\J7^L."[O[@_L^MY'845Q__
M  E-[_<C_*C_ (2B]_N1_E1_K#@N[^X7]GUCL**X_P#X2B]_N1?E1_PE-[_<
MB_*C_6'!=W]P?4*QV%%<<?%5[_<B_*F_\)7??W(ORI_ZP8+N_N'_ &?6\CLZ
M*XS_ (2N^_N1?E1_PE=]_<B_*C_6#!]W]P?V=7\CLZ*XO_A*[[^Y%^5'_"5W
MW]R+\J?]OX/N_N'_ &=7\CM**XS_ (2N^_N1?E2?\)7??W(ORH_M_!]W]PO[
M.K^1VE%<7_PEE]_<B_*C_A++[^Y%^5']OX/N_N#^SJ_D=I17%_\ "5WW]R+\
MJ/\ A*[[^Y%^5+^W\'W?W#_LZOY':45REAXEO+F_A@=(PKM@X%=77H83&TL7
M%RI;(YJU"=%VF,F_U,G^Z?Y5YRWWS]:]&F_U,G^Z?Y5YR_WV^M?.<4;TOG^A
MW9;]KY#:***^4/4"BEQ11<=Q**7%&*+B$HI<48H'<2EHQ1B@+B44N*,4"N)1
M10* #'-/ XH%+5(3"BD%+38"4&B@UF G>EI.]+5( HHHIB"BBBF 4444@"BB
MBF 4444 %%%% !1112 **** "BBB@ HHHH **** "BBB@!,4N*6BD TBDP:?
M28HL.XWFDI^*0BD%QM+11B@8E%'2C- !11FC- PHHS1F@ HHS1F@ HHS1F@
MHHS1F@ HHS1F@ I:3-**!"T444R1!2T44#"BBB@5PH-%% #&%)3FIE,M"TE%
M)04+124H%!(44[%&*0"44N*7% #:*=MI0* NAN*2I-M+M%,7,1XHQ4F,44!<
MCQ1BI*0T@&@4M%%(3"BEHH"XF*,4ZBF REI<48H8[C:2GXHQ2"XSFBGXII%
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M^DQ28 **,44""BBB@ HHHH **** $Q12T46&)BDQ3J*D9'BBG4AIC&T4M%(
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MK* %YS70D9&#2TAJZM6=67--W80@H[',ZKX+T[4;DW46;:Y/)ECZU1'@-IV
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M@0=:,444 )BE%% H 6C-%% !FES2450!FC-%% "YI,T447 ***2I8!1FBBD
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M !1110 48HHH&&*0TM(:: 2DI:2F 4444P"BBEH ,48HHH ,48HHH ,4444
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MM&:!#J*;FC-,+#J2DS1F@+"TE)FB@+#J*;1F@8M+3:,T A:*3-&:8!112XH
M!2XH IU%A"8HI:*8KA111180AHI324@"BBB@ HHHH **** "E%)2B@ HHHI@
M%%%%, HHHH ****E@)10:2D X4E)1FDRA:*3-)0ACZ*:#2BJ)8M%)F@4F(#2
M4IIII%(0T444Q@*<*;1F@!U!IM% Q:*3-% K"T44O-(+"4H-%% K"YHS3:*
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MR'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA-L(0G=R W3/M7*Z7I.FZ/9?V;K7@Z]O=0A9E6XMK8R)<+DE6#9P.".O2A)
M=LWB<'5M#BCB5K#5H6>.<G!5PNX*1[@_G4>E^+%U'Q;J6C>2$CM@?*FS_K"N
M!(/P+54U_3;B3P7936&FM;7VG/%=6]FAWE&4\IQUX)Z=:PM3T'5K'P=I%Y86
M\LNL+YOVA50E_P#2%.\D#NI*_3%"28':>&=9EU_2WU!X%BA>>1;?!)WQJ<!C
M[D@U734(C\07T[[# )1IOG_:]O[PCS -F?[O>M32-/32='L]/CQMMXECR.Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *1ONGZ4M(WW3]*3V SM"_Y!H_ZZ-_.M*LW0O^0:/^NC?SK2KFP7^[P]$:U_
MXDO4,4F*6BNHR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BB@]* "BJIGNL_\>?_ )%%'GW?_/E_Y%%9>VCV?W/_ "+Y'_31:HJKY]W_
M ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_
M )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y
M'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7
M_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%
M'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31
M:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44
M>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]
MG]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJK
MY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_
M\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_
M ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_
M ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_
M )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y
M'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7
M_D44>?=_\^7_ )%%'MH]G]S_ ,@Y'_31:HJKY]W_ ,^7_D44>?=_\^7_ )%%
M'MH]G]S_ ,@Y'_31:I&^Z?I5;S[O_GR_\BBD,]V01]B_\BBDZT>S^Y_Y!R/^
MFB#0O^0:/^NC?SK2K*T]+VRM?):T#'<3D2CN:M^?=_\ /E_Y%%886:A0A&2=
MTET?^1I5CS3;37WHM455\^[_ .?+_P BBCS[O_GR_P#(HKH]M'L_N?\ D9\C
M_IHM455\^[_Y\O\ R**//N_^?+_R**/;1[/[G_D'(_Z:+5%5?/N_^?+_ ,BB
MCS[O_GR_\BBCVT>S^Y_Y!R/^FBU157S[O_GR_P#(HH\^[_Y\O_(HH]M'L_N?
M^0<C_IHM455\^[_Y\O\ R**//N_^?+_R**/;1[/[G_D'(_Z:+5%5?/N_^?+_
M ,BBCS[O_GR_\BBCVT>S^Y_Y!R/^FBU157S[O_GR_P#(HH\^[_Y\O_(HH]M'
ML_N?^0<C_IHM455\^[_Y\O\ R**//N_^?+_R**/;1[/[G_D'(_Z:+5%5?/N_
M^?+_ ,BBCS[O_GR_\BBCVT>S^Y_Y!R/^FBU157S[O_GR_P#(HH\^[_Y\O_(H
MH]M'L_N?^0<C_IHM455\^[_Y\O\ R**//N_^?+_R**/;1[/[G_D'(_Z:+5%5
M?/N_^?+_ ,BBCS[O_GR_\BBCVT>S^Y_Y!R/^FBU157S[O_GR_P#(HH\^[_Y\
MO_(HH]M'L_N?^0<C_IHM455\^[_Y\O\ R**//N\?\>7_ )%%'MH]G]S_ ,@Y
M'_31:HJFD]]M_>62[O\ 9E&*=Y]W_P ^7_D44E7BUL_N?^0<C\OO1:HJKY]W
M_P ^7_D44>?=_P#/E_Y%%/VT>S^Y_P"0<C_IHM455\^[_P"?+_R**//N_P#G
MR_\ (HH]M'L_N?\ D'(_Z:+5%5?/N_\ GR_\BBCS[O\ Y\O_ "**/;1[/[G_
M )!R/^FBU157S[O_ )\O_(HH\^[_ .?+_P BBCVT>S^Y_P"0<C_IHM455\^[
M_P"?+_R**//N_P#GR_\ (HH]M'L_N?\ D'(_Z:+5%5?/N_\ GR_\BBCS[O\
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M#D?]-%JBJOGW?_/E_P"111Y]W_SY?^111[:/9_<_\@Y'_31:HJKY]W_SY?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img207175068_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img207175068_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2JJ17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C R.C W(#$P.C$W.C$R   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,CHP-R Q,#HQ-3HU,@ R,#(S.C R.C W(#$P.C$U.C4R      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  &/T         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ =@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M<]6[=D3VLUUIS;RVZ$??3/OCBNC:>)8O-:1%C(SN8X%*:UT*I.RLS-E\3Z'
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MIE)2DM!CW^E1;UETMDEV*%5D V, V3[YR#@^@I(-0L9[EFEL!+F0,D,5NBY
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M[HI0H'08H I26T[3%A>RB,G.S Z>F:<D,ZHZFZ8[@0O'W>O^/Z4[$<Z(Q:W
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M%!04%!04_\  $0@"(P2H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M   ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!
M!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25
MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/D
MY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'
M" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!
M"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S
M]/7V]_CY^O_:  P# 0 "$0,1 #\ _5.BBB@"O?3_ &>V=_09KX]_:D^.GCCX
M?>/M,L?#VN_8+&ZTF&\,0M(7^=Y)03ET8]%4=>U?76N?\@Z;_=(KX&_;2_Y*
M-X<_[%VU_P#1LU>QE4(U,2HS5UJ?$\88BMALKE4H3<976J=F<W_PUA\5?^AK
M;_P M?\ XU1_PUA\5?\ H:V_\ +7_P"-5Y)17V_U/#_\^U]R/P+^VLS_ .@B
M?_@3_P SUO\ X:P^*O\ T-;?^ %K_P#&J/\ AK#XJ_\ 0UM_X 6O_P :KR2B
MCZGA_P#GVON0O[:S/_H)G_X$_P#,];_X:P^*O_0UM_X 6O\ \:H_X:P^*O\
MT-;?^ %K_P#&J\DHH^IX?_GVON0?VUF?_03/_P "?^9ZW_PUA\5?^AK;_P
M+7_XU1_PUA\5?^AK;_P M?\ XU7DE%'U/#_\^U]R#^VLS_Z"9_\ @3_S/6_^
M&L/BK_T-;?\ @!:__&J/^&L/BK_T-;?^ %K_ /&J\DHH^IX?_GVON0?VUF?_
M $$S_P# G_F>M_\ #6'Q5_Z&MO\ P M?_C5'_#6'Q5_Z&MO_   M?_C5>244
M?4\/_P ^U]R#^VLS_P"@F?\ X$_\SUO_ (:P^*O_ $-;?^ %K_\ &J/^&L/B
MK_T-;?\ @!:__&J\DHH^IX?_ )]K[D']M9G_ -!,_P#P)_YGK?\ PUA\5?\
MH:V_\ +7_P"-4?\ #6'Q5_Z&MO\ P M?_C5>244?4\/_ ,^U]R#^VLS_ .@F
M?_@3_P SUO\ X:P^*O\ T-;?^ %K_P#&J/\ AK#XJ_\ 0UM_X 6O_P :KR2B
MCZGA_P#GVON0?VUF?_03/_P)_P"9ZW_PUA\5?^AK;_P M?\ XU1_PUA\5?\
MH:V_\ +7_P"-5Y)11]3P_P#S[7W(/[:S/_H)G_X$_P#,];_X:P^*O_0UM_X
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M ,^U]R#^VLS_ .@F?_@3_P SUO\ X:P^*O\ T-;?^ %K_P#&J/\ AK#XJ_\
M0UM_X 6O_P :KR2BCZGA_P#GVON0?VUF?_03/_P)_P"9ZW_PUA\5?^AK;_P
MM?\ XU1_PUA\5?\ H:V_\ +7_P"-5Y)11]3P_P#S[7W(/[:S/_H)G_X$_P#,
M];_X:P^*O_0UM_X 6O\ \:H_X:P^*O\ T-;?^ %K_P#&J\DHH^IX?_GVON0?
MVUF?_03/_P "?^9ZW_PUA\5?^AK;_P  +7_XU1_PUA\5?^AK;_P M?\ XU7D
ME%'U/#_\^U]R#^VLS_Z"9_\ @3_S/6_^&L/BK_T-;?\ @!:__&J/^&L/BK_T
M-;?^ %K_ /&J\DHH^IX?_GVON0?VUF?_ $$S_P# G_F>M_\ #6'Q5_Z&MO\
MP M?_C5'_#6'Q5_Z&MO_   M?_C5>244?4\/_P ^U]R#^VLS_P"@F?\ X$_\
MSUO_ (:P^*O_ $-;?^ %K_\ &J/^&L/BK_T-;?\ @!:__&J\DHH^IX?_ )]K
M[D']M9G_ -!,_P#P)_YGK?\ PUA\5?\ H:V_\ +7_P"-4?\ #6'Q5_Z&MO\
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M?^AK;_P M?\ XU7DE%'U/#_\^U]R#^VLS_Z"9_\ @3_S/6_^&L/BK_T-;?\
M@!:__&J/^&L/BK_T-;?^ %K_ /&J\DHH^IX?_GVON0?VUF?_ $$S_P# G_F>
MM_\ #6'Q5_Z&MO\ P M?_C5'_#6'Q5_Z&MO_   M?_C5>244?4\/_P ^U]R#
M^VLS_P"@F?\ X$_\SUO_ (:P^*O_ $-;?^ %K_\ &J/^&L/BK_T-;?\ @!:_
M_&J\DHH^IX?_ )]K[D']M9G_ -!,_P#P)_YGK?\ PUA\5?\ H:V_\ +7_P"-
M4?\ #6'Q5_Z&MO\ P M?_C5>244?4\/_ ,^U]R#^VLS_ .@F?_@3_P SUO\
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M)_YGI?\ PTE\2/\ H9I/_ 6#_P"-T?\ #27Q(_Z&:3_P%@_^-UYI12^IX?\
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M/_C=>:44?4\/_P ^U]R#^VLS_P"@F?\ X$_\STO_ (:2^)'_ $,TG_@+!_\
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MC_H9I/\ P%@_^-UYI11]3P__ #[7W(/[:S/_ *"9_P#@3_S/2_\ AI+XD?\
M0S2?^ L'_P ;H_X:2^)'_0S2?^ L'_QNO-**/J>'_P"?:^Y!_;69_P#03/\
M\"?^9Z7_ ,-)?$C_ *&:3_P%@_\ C='_  TE\2/^AFD_\!8/_C=>:44?4\/_
M ,^U]R#^VLS_ .@F?_@3_P STO\ X:2^)'_0S2?^ L'_ ,;H_P"&DOB1_P!#
M-)_X"P?_ !NO-**/J>'_ .?:^Y!_;69_]!,__ G_ )GI?_#27Q(_Z&:3_P !
M8/\ XW1_PTE\2/\ H9I/_ 6#_P"-UYI11]3P_P#S[7W(/[:S/_H)G_X$_P#,
M]+_X:2^)'_0S2?\ @+!_\;H_X:2^)'_0S2?^ L'_ ,;KS2BCZGA_^?:^Y!_;
M69_]!,__  )_YGI?_#27Q(_Z&:3_ ,!8/_C='_#27Q(_Z&:3_P !8/\ XW7F
ME%'U/#_\^U]R#^VLS_Z"9_\ @3_S/2_^&DOB1_T,TG_@+!_\;H_X:2^)'_0S
M2?\ @+!_\;KS2BCZGA_^?:^Y!_;69_\ 03/_ ,"?^9Z7_P -)?$C_H9I/_ 6
M#_XW1_PTE\2/^AFD_P# 6#_XW7FE%'U/#_\ /M?<@_MK,_\ H)G_ .!/_,]+
M_P"&DOB1_P!#-)_X"P?_ !NC_AI+XD?]#-)_X"P?_&Z\THH^IX?_ )]K[D']
MM9G_ -!,_P#P)_YGI?\ PTE\2/\ H9I/_ 6#_P"-T?\ #27Q(_Z&:3_P%@_^
M-UYI11]3P_\ S[7W(/[:S/\ Z"9_^!/_ #/2_P#AI+XD?]#-)_X"P?\ QNC_
M (:2^)'_ $,TG_@+!_\ &Z\THH^IX?\ Y]K[D']M9G_T$S_\"?\ F>E_\-)?
M$C_H9I/_  %@_P#C='_#27Q(_P"AFD_\!8/_ (W7FE%'U/#_ //M?<@_MK,_
M^@F?_@3_ ,STO_AI+XD?]#-)_P" L'_QNC_AI+XD?]#-)_X"P?\ QNO-**/J
M>'_Y]K[D']M9G_T$S_\  G_F>E_\-)?$C_H9I/\ P%@_^-T?\-)?$C_H9I/_
M  %@_P#C=>:44?4\/_S[7W(/[:S/_H)G_P"!/_,]+_X:2^)'_0S2?^ L'_QN
MC_AI+XD?]#-)_P" L'_QNO-**/J>'_Y]K[D']M9G_P!!,_\ P)_YGI?_  TE
M\2/^AFD_\!8/_C='_#27Q(_Z&:3_ ,!8/_C=>:44?4\/_P ^U]R#^VLS_P"@
MF?\ X$_\STO_ (:2^)'_ $,TG_@+!_\ &Z/^&DOB1_T,TG_@+!_\;KS2BCZG
MA_\ GVON0?VUF?\ T$S_ / G_F>E_P##27Q(_P"AFD_\!8/_ (W1_P -)?$C
M_H9I/_ 6#_XW7FE%'U/#_P#/M?<@_MK,_P#H)G_X$_\ ,]+_ .&DOB1_T,TG
M_@+!_P#&Z7_AI+XC\?\ %32?^ L'_P ;KS.CTH^IX?\ Y]K[D/\ MK,_^@F?
M_@3_ ,S[8_8_^+'BCQ]J/B&#Q#JC:BEJMN8<PQQ[-WF[ON*,YVCKZ5]7U\/_
M +"/_(:\4_[MK_[6K[@'2OA,RA&GBIQ@K+3\C^AN%:U7$911J5I.4G?5ZO=B
MT445Y9]:%%%% &?KG_(.E_W37P-^VE_R4;PY_P!B[:_^C)J^^=<_Y!TO^Z:^
M!OVTO^2C>'/^Q=M?_1DU>WD_^]KT9\#QO_R*)>J/ ****^_/YP"BBBF 4444
M %=7-\+?$\/@.+QFVED>&I6*)?>?%RWF&/&S=N^\".GZ5RGTK[/\(> M1^)7
M['GACP]I:@7-W?D-(V-L48O9"[GUVJ"<=3@"O/QF(>&4)+9NWR/H\ERR.:2J
MT]>:,6XI=7I:Y\P>#?A)XK^(&DZAJ>@Z5]LTZP.+B\DN(H8H_EW$$R.N<#DX
MZ#KC(SF>%? ^M^.+F\MM"L'U">SMGNYU61$V1+C<WS$9ZC@<GMWKZ&_:8\41
M_"WPOI?PC\,V\UGI\=K'<:A>E"K7F2>,XYW,I9F'&1M' 85K_L&Z####XOUV
M[*K$/(L49N!DDLPS[DQUQO&U%AY8CI]G[SUZ>1X:IF5/+(R;DD^=Z6O:^FG3
MYGRGH>BWGB+5[/2].@:[U"[E2&"%2!O9C@#)QCGN< #N.M;^E_"OQ1K/C6Z\
M)V>DM+X@M=XELO/B7;LQN^8L%[CH>_>O??@S\)H?#O[3GBJ2^C%MH_A8S7JM
M(<HBR#,)/_;-RV?5*Y3]K!-1\!_'R^U71[ZYTF;4;2&YCN+&=H7P5\MAE2#R
M8R??FM%C75K*E3MK&_S,9Y%'"X+ZYB4]*G*TNW5K3NCGC^R7\5^WA-CZ?\3"
MU_\ CM8?C+X ^//A_H<NL^(-!.G:9&RH\YO+=\%C@<)(QZX[5]!?LP>-O$.O
M?"WXFW6IZ[J6HW-I;%K>:[O))7A/DR'*,Q)4Y /'I7RYJ_Q"\4^(;%K/5?$^
ML:E:L0S6]Y?RRQDCD':S$9!Z>E3AZV+J590GRVCOOU-<=@LGPV#I8BFJEZB;
M5W'2SMKH=+X8_9Y^(?C+1XM5TGPQ<3V$W,<LTT5N77^\JR."5/8XP>U<7XB\
M-ZIX2U2;3=9L)]-OXOO07"%&]C[@XX(X/:O2+?XU?%'XC:YX<T33==O;>\3R
M[2U@TQS:K*<_?D"X#< 9)^4 '@<UWW[<FLV-UXT\/:9&\4^K6-BPO9(QC&\J
M44XZ'AFQV# UI"O7CB(TJMK.^WZG+5R_ 5,NGB\,Y7@TGS6LV^WH> ^$O!NL
M^/-<AT?0;%]0U&56=8594^51DDLQ  QZUDSP/;320RHT4T;%'C88*L"<@CU_
M^O7U1^RE;Z7\*_A_X@^*/B%2EM(Z6%HV,L8]ZAV7CG+$#C_GFU<#^UMX"3PG
M\3I=8LE!T;Q GV^WECYC\P_ZT \YRWS_ $D%%/&<V)=%K1?GU(KY)['*Z>.Y
MKRW<>T7I%_-H\2*A<9/-&W KZ2^'_P"S9X/\2?!?2?'.N^)+S08VDD:_ED=/
M)2))I(]J IG>VU0.3R> > ?(?BIIO@72]<@MO >IZEK&FK#NGO-0&"9"2-JK
MY<9& .I').!TK>GBZ=6;IP3NOT.'$Y/7PF'CB*LHI22:5U=W\MSB\8HXQ[U]
M!_#_ /9S\-P?#RW\;?$OQ++X=TF\VFSM[/'FNI^Z3E7+%ADA%4G SD<@9_Q<
M_9^T7P]X#M?'7@;7I?$7A>1ECF^T!?-A+':&) 7^(A2I4%21UYQ*QU!U/9W\
MKVTOV-I9#C8X?ZPTMN:UUS6[V['AFWI[T*,MTR*^HE_9E^'VD_#OPKXQ\2>+
M-0T73K^RAN+Q69'9Y9(E98X%6,GJ6/1SA>G4CP'X@6_ABQ\47=OX.N[R_P!!
MC"K#=WY'F3':"S;0B%1DX&1G@^O%4<7#$-QII^MM##'9/7RZFIUW'6UE?757
MO8@\'^!==\?7UU9>'].DU.[MK=KJ2&-E#"-2 Q 8C<<L!M&3STK)L[*:^OX;
M2",O<32+$D9P,LQP!DGCG_\ 77T+^PJ0OQ>U+//_ !)I>?\ MM#70?'/X06$
MGBS2/B1X0*7&BW>JQ1ZE#" !;W G"-)[9?*MZ-SDAN.:ICO98F5&>UM'YGK4
M,A6)RZ&.I-MW:DO+35>G4^?_ !)\)_%7A/Q1IGAW5=)-IK.I>7]DM?/B<R;W
M*+\RL5&6&.2*Z^3]D_XJQHSGPFVT#/RWULQ_(2YKV+]H\8_:K^&8Z\Z?[?\
M+X_^?RJY^T(WQ:7XT6__  @X\1BQ-I"$^QB3["),MNW;OW6<8SNKD6/KS5/E
M<5=-Z^1[+X>P5)U^=3DH245RVOJMWH?(FMZ#J/AO4)=/U6PN=-OHCA[>ZB*.
M/3@@<>AZ']:O^)? ^M^$;;2;C5M/>RAU2W%W9NS*PEB."&^5CC@C@X//(KZ1
M_;0MHM8\3?#W366#_A*+B Q7;0J,X=XU0>XW^;M!_P!KWKL_VR? UM<?"+2;
MJR59)O#,T,,FWK'!(JIC'N?*K:.8_P )R5N>]SAJ<-J/USDDW[&S6VM]6GZ(
M^.E\#ZVW@^3Q4+!CH$=S]C:\WJ )< [=N=V.>N,>]80&[@?G7W7K'PU@T?\
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MU\'=>M8!?)JNBZA$9["_5=ID08RK#)&X;AR.""#QG [;]B4A?C43C(&F3_\
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M_&#4+^UT,VD9LHEEFDO)BB\G"J,*22>>V/EZC->UZ/\ LU?#/XD:7JMO\/\
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M;^5[,W'W6:.:8[<<;LB0' /(5J[&;Q1^T9%J\T'_  B_A)K>+=MOPS")\#/
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MS6%?#5J'+K.IS_+73\3Z6_8*(_X2SQ7DA<V$?I_?/^)J[^R*P_X0?XL G&Z
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M./F)1F 4 'J<YVX!YQ\L:;XHUK1K66UL-7U"QMI9%EDAMKIXT=U(*L0" 2"
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M\1?CYXLU_68;>TU&XTK9-%;(R(I1XDP Q)& HSD]37G'[.[?\956/S$!KW4
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M_P"31_S/CZC/2OL'_AWNW_0^+_X*/_M]'_#O=O\ H?%_\%'_ -OI_P!K8/\
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MC_F?'W6@G-?8/_#O=O\ H?%_\%'_ -OH_P"'>[?]#XO_ (*/_M]']JX+^?\
M!A_J=G7_ #X_\FC_ )GQ\3FC-?8/_#O=O^A\7_P4?_;Z/^'>[?\ 0^+_ ."C
M_P"WT?VM@]N?\&'^I^=?\^/_ ":/^9\?45]@_P##O=O^A\7_ ,%'_P!OH_X=
M[M_T/B_^"C_[?3_M;!_S_@P_U/SK_GQ_Y-'_ #/CZBOL'_AWNW_0^+_X*/\
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M8/\ G_!A_J=G7_/C_P FC_F?-7PD_P"2K>#/^PU9?^CTK]6(O]6GTKY&T/\
M8G/@/Q5X=UP^,A>BRU*"X\C^R]F_RW\S&[SCC.S&<'K7UO%S&G/:OF<UQ-+%
M3C*D[I'ZMP=E6+RNA5IXN'*V[[I_E<F]*6FJV:=7A'Z$8/C+_D"S_P"X:_)7
MN:_6KQE_R!9_]TU\J_\ #OI^1_PGB_\ @H_^WU]%E&+HX7G]L[7L?F?&63XW
M-O8?5(<W+>^J6]NY\?T5]@#_ ()\N>/^$\'_ (*/_M]+_P .]V_Z'Q?_  4?
M_;Z^A_M;!_S_ (,_,_\ 4[.O^?/_ )-'_,^/J*^P?^'>[?\ 0^+_ ."C_P"W
MT?\ #O=O^A\7_P %'_V^C^UL'_/^##_4[.O^?'_DT?\ ,^/J*^P?^'>[?]#X
MO_@H_P#M]'_#O=O^A\7_ ,%'_P!OH_M;!_S_ (,/]3LZ_P"?'_DT?\SX^HK[
M!_X=[M_T/B_^"C_[?1_P[W;_ *'Q?_!1_P#;Z7]K8/\ G_!A_J?G7_/C_P F
MC_F?'U%?8/\ P[W;_H?%_P#!1_\ ;Z/^'>[?]#XO_@H_^WT?VM@_Y_P8?ZGY
MW_SY_P#)H_YGQ]FBOL'_ (=[M_T/B_\ @H_^WT?\.]V_Z'Q?_!1_]OI_VM@_
MY_P8?ZGYU_SY_P#)H_YGQ]FBOL'_ (=[M_T/B_\ @H_^WT?\.]V_Z'Q?_!1_
M]OH_M;!_S_@P_P!3LZ_Y\?\ DT?\SX^S17V#_P .]V_Z'Q?_  4?_;Z/^'>[
M?]#XO_@H_P#M]+^UL'_/^##_ %.SK_GQ_P"31_S/CZC-?8/_  [W;_H?%_\
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MT/B_^"C_ .WT_P"UL'_/^##_ %.SK_GQ_P"31_S/C[-%?8/_  [W;_H?%_\
M!1_]OH_X=[M_T/B_^"C_ .WT?VM@_P"?\&'^IV=?\^/_ ":/^9\?45]@_P##
MO=O^A\7_ ,%'_P!OH_X=[M_T/B_^"C_[?1_:V#_G_!A_J?G7_/C_ ,FC_F?'
MU%?8/_#O=O\ H?%_\%'_ -OH_P"'>[?]#XO_ (*/_M]+^U<%_/\ @P_U/SK_
M )\_^31_S/CZBOL'_AWNW_0^+_X*/_M]'_#O=O\ H?%_\%'_ -OI_P!K8/\
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MC_R:/^9\?[J2OL'_ (=[M_T/B_\ @H_^WT?\.]V_Z'Q?_!1_]OI_VM@]^?\
M!A_J?G7_ #Y_\FC_ )GQ]17V#_P[W;_H?%_\%'_V^C_AWNW_ $/B_P#@H_\
MM]']K8/^?\&'^IV=?\^/_)H_YGQ]17V#_P .]V_Z'Q?_  4?_;Z/^'>[?]#X
MO_@H_P#M]']K8/\ G_!A_J=G7_/C_P FC_F?'U%?8/\ P[W;_H?%_P#!1_\
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M8HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !24M)0!B^*/]7I_P#U]+_Z ]:\/^K7Z5D>*/\ 5Z?_ -?2
M_P#H#UKP_P"K7Z4 24444 8/C+_D"S_[IK=K"\9?\@6?_=-;M "T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH Q?%'^KT__KZ7_P!
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MPOX^UW0OMWBWPR"-)U#[9<1_9LDD_NTD$;\D_?4UA_&C]DGX1?M"7MK>^/\
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MDTG"2W1I&K"6TKFOS2BF;O4C%.4_E4&@M+24M PHHHH **** "BBB@ HHHH
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MK"US_D-:5_NS?^R5NT +1110 4444 9^N?\ (.E_W32Z#_R ]/\ ^O>/_P!
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M 4A?TKC)':1V=V+NQRS,<D_4U[KX9^&/AS4_V4?$GC"73#+XGM=36VM[P32
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M3Z#I:1:6O$/K HHHH **** "BBB@ HHHH **** "DI:2@#"US_D-:5_NS?\
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MI^FZ_?W\&NWTVH2R(H 82Q(-B,<C9"".!\K>M>8_MQ> YO#?CG1O&5FOV?\
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M %:_2LCQ1_J]/_Z^E_\ 0'K7A_U:_2@"2BBB@#!\9?\ (%G_ -TUNUA>,O\
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M\]\CBO<_?%''I6'MZO\ ,SK^IX>]^1'Q3X\_X)_W<+O/X.\0QW$?\-GJZ['
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M\!4M%+F;W8U",=D-V+Z"EP!2T4BQ-HHVCTI:* $I:** "BBB@ HHHH ****
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M851] !5QFX:HRJ4HUH\LSY@TC6[;68W\K=%/'Q-;2C;)"WHR\_@>AZCBK_\
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M\H [ZBFJU.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#WAZT\.V26]M&% ZD=?\\5KUY%2HZCNSZ:C1C1ARH3%+1161T!1110 4444
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MEC0?W1BIQUI:PE)RW9VQC&*M%6#%+114E!1110 4444 %%%% !1110 4444
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M0=+_ +II=!_Y >G_ /7O'_Z *37/^0=+_NFET'_D!Z?_ ->\?_H H OT444
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M[74;"=;FSN4$D4B]P?;J#['D=#S6C7G/0]Q--704444AA1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>%=%EU;5+C[+81;=\NQGQN8*.%!/4CM7Y^=">/>OKCX\3,WP9N,D_-Y&??\
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MB@#/US_D'2_[II=!_P"0'I__ %[Q_P#H I-<_P"0=+_NFET'_D!Z?_U[Q_\
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MC^6*]P,G"_PR8&2O0]1CH/I#/3%>;4IRIRY9'N4:T*\>:#)**2EK,W"BBB@
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MD/(0$!HH& QQ)(-VQ(_3]HHVBEH **** "BBB@ HHHH **** "BBB@ HHHH
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MRB\+U4Y(Q5>S<OA1G*K&FKR9[SFEKQE?C_I:R!CXN\%SJ3Q"NK1H3]'WG/\
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M2-# _P!TRL(40GV#,">^!QS7+?'CPQI_QS^&]G\8O#$*IJ$$:V^OZ?'\S(R
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MQ'>-\2[;6;?6+%F43+<V[R*6.,L"IZYPN[:5]L_8M)_X;*_:]_[#.F_RNO\
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MSL145[1/>P-&7+S3V/ /$'[#/PXUR\%Q;G5M&]8=/NDV$^N)$?'T' K3TO\
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M#FONGPAX3DOKR_U75+1HX;JW:SBM+E.3$Q!<NIZ;MJ@*>< YZX'&ZQ\(-?\
M#=Z\WAQH]3L68[+2>7RYX1QA0[9#KUZ[3TSDY-=N#Q*H-IO<]S!UHQ@X2=GW
M/FK7M'_9.CAMI]!UAM*U""6.9+FTGOFD!4@E<2!A@XQTSSP0>:]K^$^L+J'Q
M'\-WND2M+8:E#*S2!2 ]LT!D4D$#'SB+J!UQ]=UO#/C_ %C_ $<^'FL0?E,U
M[>0[/Q\MW8C\*T_ FG#PK-<3Z8D6M:M,#%+JTV8[=5R#LA4$LXR!EN-V!S@
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MIQ5DOQ/2T_X*G3<_\6T7_P 'I_\ D:E_X>H3'_FF:_\ @]/_ ,C5XMX!\*^
M/BKX=^,GB"T\&?\ "/VNAZ"EWI5B-6N+H6DX23<_F$KOW%0<,"!C %=1K'P\
M^%_P7^&'P_UCQ'\/=3\>Q>([)+J^\06NK301V+NJMY2+'\C$;C@.1G:>3SA)
MU);,RK9/PK1J_5Y8&?M;I<O-K=Q4M^>VB\]7M<[_ /X>G3#I\,UST'_$\/\
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MT*KO^< A2-P4Y  -ZBLGPSXAB\5:+:ZI;VUU:VUT&>);V$PRM'N(5RA^90X
M8!@& 8;@IR!K4 %(QVC-+45U(T-K-(B&1T0L$'5B!TH \;^,7[9/P:^ 6M1Z
M1XZ\>6.C:LZACI\,$]Y<1@C<IDC@1VC!!!!<#(/%=KX&^,G@SXE>!W\7^%_$
M=CKWAV-'>2]L9/,$>Q0SJZ@;D<*02C ,,CCFOE/_ ()8Z3:>*?A9XQ^*6II'
M?^.?%GB6^?4]4D :8(I7; &/S+&"2P7/\0]!7+>#=*M_AG^WO^T/X2\,6T.F
M^%]8\"?VY=Z;:1A(8KP)$ ZJ.%+>;,QXY,E 'KW_  ]$_9EQ_P E,^O_ !(-
M3_\ D:NM\9?MW_ [X?\ AWPKKNO^./L&E>*+1K[2)_[)OI/M,*L%9MJ0%DP2
M.'"GVKY5_P""<?Q6^,F@_L[^"-"\.? G_A*O!G]H7"'Q9_PE]E9[8WNW,K_9
M'4R?N]S<9^;;QU%=+^V]KWB3PO\ MQ?LY:GX2\*_\)IXAM[/5#:: -1CT_[4
M3&0P\^0%(\*6;G.=N.IH ^C?A#^V_P#!7X\>,HO"G@;QK_;FO20R7"VG]E7M
MOF-!EFWRP(G [9R>U>[5YK\$?''Q!\=:/J%S\0OAG_PK#4(;@1V]A_;]OJ_V
MB/:#YF^%0$YR-IYXS7I5 !3<TK=#7RQ\6OC5XO\ #_Q"U?3]*U@VEA"T8CA^
MSPOMS$A/+(2>2>]>7F.84LMI*K53:;MH>QE>5U\VK.A0:32OK_P$SZF+<4;J
M^*?^&@O'_P#T,#?^ D'_ ,11_P -!>/^?^*@8C&?^/6#_P"(KY[_ %LP/\LO
MN7^9]/\ ZDYC_/#[W_\ (GVMFC)KXI'[07C[MXA.#P#]D@YX_P"N=+_PT%X_
M;_F8&]?^/2#_ .(_SFG_ *U8/=PE;T7^8O\ 4O,+V]I#[W_D?:O-&:^*?^&@
MO'_7_A(&'_;I!Z_]<Z7_ (:"\?\ 3_A(&R.O^BVY_P#9*7^M>"_DE]R_S&N"
M\Q;MSP^]_P#R)]J;N<4N37RQ\)?C5XO\0?$+1]/U76#=6$[2"2'[/"F[$;$<
MJ@/4 \'M7:_M&?$GQ!X)NM$BT+4/L'GK,TV(8WWXV;?OJ<=3TKU(9WAZF#GC
M4GRQ=NE^GGYGD5>'<72QU/+Y.//-76KMU\K].Q[ES1FOG'X"_%KQ1XO\<26&
MM:H;VT^R/(L9@B3#AT .54'H6_.E^/?Q:\4>#_&T5AHNJ&RM?L:2-&((GRY=
MP3EE)Z ?E1_;>'^I_7K/EO;S_,7^KV+^O_V?>//:][NWY?H?1N[G%+7Q1_PT
M%\0/^A@;/_7I!_\ &Z](^ OQ:\4>+O&TUAK.J&]M/LCR+&8(TPX= #E5!Z%O
MSKEPO$>$Q5:-"$9)R[I?YG;C.%,=@L/+$5)1:CV;_P CZ/S2TWTIU?5GQ844
M44 %%(:K7VH0:;9SW=Y<16EK C2S3S.$CC0#+,S'   YR>!0!:HJM>7\&GV<
M]W=3QVUK!&TDL\SA4C4#)9F/  '))J=6#=#GZ<T .HHHH 2EHHH **** "BB
MB@!H4 Y YIU%% !1110 4444 <9\8M/O=4^&VMV]@C27!C1_+0$LZ+(K2* .
MI*!ACOFOC_Q5??\ "/\ C?P'XK@\/:AXGL[%[R"\MM(LOM<[1RPCRSMR!PRC
MEB.^,\5]XR#<A%>:>)/@GIVJ:C+>Z1>SZ%=2-ND6%1) Y[MY9^Z?]T@=202<
MUZ&%Q"HW36YZ6%Q$:<73GLSP#QC\=_"WB32/L=S\%/'+PY5B+CPRFTLI#*?]
M9V(!_"NM^$,ESXB^(7A_4;:UN+-%ADO+N&X79)#&\#+Y;CLWF.G'JA_NUWB_
M W5KA@+_ ,7>9;YY6ST\1/C_ 'GD<9]\5Z'X1\%Z3X+T_P"S:7;>6KG=+*[E
MY)6'=F/7^0[ "M*N)I.GRP-IXBE"FXPUN6/$2Z3'IDUSK$%O-9P*7;[1$) /
MH"#DGC@#).!7S]J7[0_@'POKUY8PWNE>$KFV<QR1P:1)-.K="2\<>P''8;OK
MV'L7Q5MYI/#MM-&&,%K=QS7"J,GRP&&?H&*L?9<UXIXBU1O OQCM?$9\):QX
MGTJ]T+['*-#T[[4RSI/O5F&<#Y6(Y.>F,@5C0A%IR:N?(8JK.,E&+L;/AW]I
MOP]K6M6>FZ3XSM]8O;J01PVMYILT'F$]%$@C55S[Y^E>V>&?$T'B*%P(VMKR
M' GMG/S1D\@Y[@]B/0]""*\%UKXR:'JC6LC?![QNT]I+Y]NTOAM1Y<H! =3O
MX//6O2O \,EQX\O;J'FUALS%*RGY2[.I0?4!6/MN']ZE4A'EO:PJ-6:DHWO?
MU_4Z7XF3S6_@;56MR5=D5'9>HC9U60^V$+<]NM?)7B?X9?#K_A>ELOBYX;#1
M=6T9[HS7FH-;Q_;%F .'+C V' 3H.U?:UU;I=6TD,J+)%(I1T<95@1@@CN#Z
M5Y;XD^$-O=2Q>=H.E>*;.+(MX=3MXWGME/55:0$,..N5/ SGK7-&5M#U)1N[
MGCFH?!_]GNU^RW6D>,-,TN^MIHYTN+?Q%'(XV'<5PSD8..W/I7L'A_4([OQY
MX>N]-F6XMKV"7=-"0RR0&(N&R.J[A'@^X]:R/^%.:/=D)'\*]!MCG!DN[.R5
M/KF/><?A^%>D^"_ \'A>-9'\J2[$2P)Y,0BB@A7&V.-,\*, >^!P   Y-$Q3
MN=32TE+61L%%%% !24M)0!A:Y_R&M*_W9O\ V2MVL+7/^0UI7^[-_P"R5NT
M+1110 4444 9^N?\@Z7_ '32Z#_R ]/_ .O>/_T 4FN?\@Z7_=-+H/\ R ]/
M_P"O>/\ ] % %^BBB@ HHHH *:S?*3TI6^Z<5@>,O"=KXXTG^RM0N+B/3))
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MB@ I*6DH Q?%'^KT_P#Z^E_] >M>'_5K]*R/%'^KT_\ Z^E_] >M>'_5K]*
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M3/%=M;6VJVOVRUM[B.Z6W=V$;R(<H74$"0 X8*X(W*K8RH(U=HI:* "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 8OBC_5Z?_U]+_Z
M]:\/^K7Z5D>*/]7I_P#U]+_Z ]:\/^K7Z4 24444 8/C+_D"S_[IK=K"\9?\
M@6?_ '36[0 M%%% !1110 4444 %%%% !1110 4444 %%%% !28I:* $HI:*
M $HI:* $HI:* $Q1BEHH 3;12T4 )1BEHH 2EHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I&^Z:6D(SUH \'_:(_9%\.?M'>*O"/B/5/%7
MB[PGK7A=;A=-OO"6HQ64R&79N;S&B=@V$X*E>"<U8^#/[('@+X*^*+KQ9:R:
MUXN\<74/V>;Q7XOU)]1U)H\8*B1@%7(X)502."<<5[AC-&T&@#RKPC^SOX<\
M%_&_QQ\5+&]U67Q#XOMH+6_MKB6)K2-(515,2B,,IP@SN=N]'[._[._AS]F7
MX>S^#O"][JE_IDU_-J#RZM+'),))0H8 QQH-ORC VYZ\FO5&P,G]:\X^%?QT
MT#XP>)O'>CZ!9ZB%\&ZK_8M[J%Q'&MM/<A<R) RR%F"<!BRKR1C/6@#-^ /[
M-?A3]G7X:7O@309]0UG0KV\N+RX777BG9VF55DC.R-%*$*!@KW.2:\KL/^"<
MO@/P[?,GA[QS\2_#'A9[K[8W@_1_%#P:.7W!CF+86P2 3\^>!SQ7TWXG\06'
MA#PWJNNZG,+;3=+M);RYF./W<4:%W;\%4_E7-?!;XNZ!\=OACH'COPR9QHNL
M0F6&.Z"I-$5=D='5690RNC*0&(R#R: ,/Q9^SKX<\9?';P3\5[V]U6+Q%X1M
M;BTL;6":,6LB3)(CF53&7)Q*V-KKR!G/(-CX]?L[^"_VCO"=OH?C&QFD%G<"
M[L-0L9C!>6$P&!)#(/NGV((.!D< CTE>,CI2GIZ4 >,?!/\ 9AT_X)^(-0US
M_A/_ (@>.]2N[467G>-?$#:@((0X?;&H1 IR,Y()Z\C)IOPL_90\)_"/X;^.
MO!.CZAK5SI7C&]O;Z_FOIX7GC>ZB6*01,L2JJA5!4,K8)Y)Z5[3SZ_K2=,YH
M ^>=2_89^'&M?LVZ+\%;^;6KOPYHLIN--U-KI$U&VG\R1Q*LBQA"P\UQS&1@
M]">:JZI^PSX4\1_#W1?">O>-O'GB5-*\21>*(]6UK5X[O4)KF./RTCDEDA.8
M@@ VA0>."*]G\?\ Q0\*_"NRT^[\5:W:Z)!J-[%IUF+@G=<7,APD4:@99C[
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M^ ?!M]XIU&QU+0=/T*WGEN!MC\QX[MF$D)96VG;G[H]\_7/C#]A+P5JWPE\
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M+\":-%XZ^+>IZ[\2_#^L-K.@^/+'28+"33GVQJ(A:HQC:/\ =*S#(+-SD<Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@#/US_D'2_[II=!_Y >G_P#7O'_Z *37/^0=+_NFET'_ ) >G_\
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M= ;9<$[Y%D"E5PK'<1@@$YXI:&'U'%^R5?V4N3O9V[;[;GH9)Z4;C7EOP_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *2EI* ,7Q1_J]/_ .OI?_0'K7A_U:_2LCQ1_J]/
M_P"OI?\ T!ZUX?\ 5K]* )**** ,'QE_R!9_]TUN<YK#\9?\@6?_ '36W2 ,
MD=32Y-<+\5/'\_@FPL8-.MEO=:U.;[-90.?EW$@;FQS@9'YU0T[P[\18-0L[
MJZ\865U$9%:YT_\ L]4C5#C<$<?,2.V<9[UPSQ:C5=*,6VM[6LK^K1WPP<G2
M56<U%.]KWUMVLG^)Z3FC<:YCQ7\1/#_@?RCK>IQV32_<BP7D;W"*"Q'OC%);
M_$CP[?>&;C7X-3CETJW&99T5B8^G#)C<#@YP1W%;/$4HR<7-76MK[&*PU=Q4
MU!V>SMOY'4;J"V!7#V/QH\'ZEK$>EVVN0R7LA"HNQPC,<8 ?&TDY'&:T_%7Q
M$\/>"(X6UK4H[,S?ZN/:SNWN%4$X_"I6+P[BYJHK+K<IX3$*:@Z;N]E9W9TN
M[WHW5C>&?%FE>,-/%]I%]'>VN<%DR"I]&4@$''/('454\?>,8/ OA6^U>9?,
M,"?NXSD"20\*N0#@$X&>U:2K4XTW6YO=6MS*-&I*JJ*C[S=K>9TF<\4F[UKS
MCP9\;M!\1>%Y=1N[Q8+FRMUFU&.."4+!DD<97YAD'IGI5VQ^-7@_5+AX;35_
MM,B6[7+"*WE8"-5W$\)U _AZYXQFN>&.PTTFJBUVU.F67XN#DG3?N[Z,[H-R
M:"U<=X7^+GA3QCJ1L-)U=+B[P2(7B>)FQUV[U&>AX%0ZU\:/!WA^\N+2_P!9
MC@N;>4PR0^5(S*P /0+DCD?,./>M'BZ'+S\ZMWNB%@\3S^S]G+FWM9W^X[C-
M&[\JYFZ^(GAVQ\.KKTVJP+I+\+< DACS\H &2PP?E SP?2G>&?B!H/C&PN+[
M2=2CNK6W_P!<S*8_+XS\P8 CCUJOK%'F45-7?2YD\-747-P=MKV=K]O4Z/=Q
M2[N/2N'L?C/X.U+6H])M=<BFOI'\M%6-]K-V ?;M.?K3-7^-?@[1;R]M+W65
MM[BSD$,T9@D+!B.@ 7YOPSCCUK-XS#)<SJ*WJC98+%.7*J4K]K,[K=[T;C7F
M6F_$9/$'Q4M].T[7H&TY+)FFTQ[219C)U#AV0#&"O\78\=ZM2?'SP+#*(GUU
M48NT9#6\HP00#GY..HY/'O4+'X>W-*:2O;=?YFDLNQ2:BJ<F[)[/3\/(]$W'
MM2;N.M>9_$SXSV7@FUT5[5X;S^TIE(D^8HEOGYY 0/F(';.><\]*S_&'QBT_
M4-/T%O#GB:#3Y;Z[0AKFRF82Q!RK(,QG:2W'('3J.M1/,,/"4H<RO&WXFE/*
M\74C"?(U&5];/IZ(]<4GZTO//-<MXJ^(WA[P1Y0UG4X[1Y1N2,*SNPS][8H+
M8SQG&*?;_$3P_=>%YO$,6I1S:1",R7$:L=G3(*XW \CC&:ZWB*,9.#FKKS_$
MXUA:[A&:INST3L]7V7F=-NI,Y[UQ&G_&;P?J>M1Z5;:W#+>2$*@".$9CC@.1
MM)YZ9KME)-.E6IUDW3DG;L15H5:+2JQ<;]U87=@9IOG*.K ?6N$^-GCBX\">
M [J]LF"7\S+;P.<?*S9^89XR "1GC(K@;+]FW^U-*74M4\1:D/$TT?F-<QR#
M8CD9'!&X@9[,.G&*X,1C*D:KHX>GSR2N];)'I8? TIT57Q%7DBW9:7;MOVT/
M>&DPI.>/6CSAD_,/SKY\\/\ B[5=8^$WCS1=:N/M6I:)%-;M.3EF3:P&3U/*
MM\W<8^M>=^#?#?PSU/1;'^V_$>I6.LRDK+;01$QJQ8A<'R2.1@]>]>;4SKWH
M*E%>\KZR4=G;LSTZ>1/EJ.K-^Z[>[%RT:NGNK*Q]D"08#;ACZ]:/.49RZ_G7
MSG\=O"-IX(^%_AO1+:>>2QM]0/[R5@7PRR,<X4#C)[>E9GA7X9?"OQ?JT6G:
M5XFUBYOY%+K%LV#@9/S-"!T]ZUGFE6.(^K1@N;3>5M^VFIE3RFE+#?6G4ERW
MEJH-[=]=+GU"K'.*?4,*B-57T&!^535]$CYD****8!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4E+24 86N?\AK2O\ =F_]DK=K"US_ )#6E?[LW_LE;M "T444 %%%
M% &?KG_(.E_W32Z#_P @/3_^O>/_ - %)KG_ "#I?]TTN@_\@/3_ /KWC_\
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M;*+;M:*2W9^<NM?VM_PH_P#9RU.XUE]"\/6EU>)/K4]D+^&QN/.(@D>%SM<
M*X4G. #CT/N7PS^&Z>./CKX>\5S_ !ZT?X@:[H$$DIM-*TFUAD:W8%"CR6\O
MW0S]&!QDX W$GZIM/!'AZR\-CP];Z)I\&@JK1C3([5%M@I))7RP-N"23C'>J
M_A/X;^%/ ?G'PWX;TK0?.QYO]FV4=OOQTSL49_&ERG5BN)_;T90IQY'[]M(/
M2<FVFW%R6[6C-^3YHV^E?'?[)OCKPYX,\8?%OP]KNKV6DZ]>>,+C[+I]W*L<
M]QYCE4\M3R^3_=S@$$X!%?9&U>GKZ5S5]\-/"6I>)(O$-WX9TFYUV(KY>IS6
M,3W*;?N[9"NX8SQ@\4SYS!8Z&'P]?#U$VJBCMT<7<^:/V$]'L(_"OQ,U5M/C
MN+M_$]TK.T89V6((\:YQV9F8#L3FOGSXL?&C7?C;\%?$&O:]\1M!TJ-[Q4MO
MA[#I\$ESM690K&5CYRD#+%@,<'IG:/TI\.^$=#\(P7,&AZ/8Z1#<S-<3QV-N
MD*RRM@-(P4#<QP,D\G%8L_P?\"W>J7NHS>#M!EU&\5DN;I]-A,DZL,,';;E@
M1P<]:7*?38?B2A3S"ICJM)R;E%K9M*.ZU32OIJM5;0^5))H?$W[1W[-5S.$O
MTF\-O/ND 8,PMG<-TZA@#GU JW<:#H>H?M<?&;2=7D_L_P .:CX15M3>*3RE
M"&.(/*3T!"DG..^><G/U?:_#SPQ9ZAI-[!X>TN*\TB$V^G3QV48DLHB""D3!
M<QK@D87 P:G_ .$*\/\ ]N7FM'1=/_M>]@^RW-_]E3SYH1C]V[XW,O ^4G'
MI\IR2S^.T(M+V;AOWJ<Z?RV/C'X1>-Y/ 'Q6\$_#[1O$_AWXG^'KJUNHM+U2
MPA0:AHR^66VRF-F&P@8.?F)R3C&#=_8]\?> /AWX!\4:3X[U'2]"\9+JERFM
M)KDB1W%USQG><RC!88&>2>/FY^M?"_PO\(>";V>\\/\ AC1]$NYUVRSZ?8Q0
M.ZYS@E5!(SS3/$7PK\&^+]2CU'7/"FBZQ?Q *EU?Z?%-*@!R &920,\T):EX
MC/<-B83I2IM*?+>2:4FTV[M)6UYM;=5?<^9_BE%HGCG]L'X%36ZV^I:+<Z;<
M7EJRJ&B=5CDEB=1CH"%8''88Z<;'[=UK;VOA/X>+##'"I\869.P!?F82DD^Y
MY)KZ/F\%^'[C6M/U:;1=/EU;3XVBL[Z2V1I[=&!!6-R-R @D$ C.:?XA\)Z)
MXKAMXM;TFQUB.VF%Q!'?VZ3+%*,X=0P.&&3@CD4N7<Y*>=JG7PM11?+1BU:^
M^LG?\?P/DZU\8>&O!?[=OC2_\2ZMIVBVK^'K>&*XU*X2%-Y$)*AG(&2!T![5
MQ/A>UC\4:7^U1K/A* MX-OK)TL3;QE89YUAD,K1C !Y)/'9U]<U[Y-^S.GB#
M]I+Q)XV\3:=H>N^%=1TN&TM[&^A^T2I,GEY8QO'L ^1N0Q/(XKW32=%T_0=/
MAL--LK>QL85V16]M$L<:#T"@  46=CU:^>8?#QA]73E)PI)ZZ+DLWI;>ZMY:
MGR3X+^(WA;7OV([S0=.UJPO=<M/!MS]JT^"96GAV1%&+IU7DC!8<YR,]:\XO
MO(T_X=?LMZQXA0MX&LYF_M%Y ?L\4IV^2\O8#(;KV#=*^W=/^$?@C26U-K+P
MAH=H=4C:&^,.G0I]JC;)9)<+\ZG)R&R#6K'X.T&'PZ/#\>C6":&L?DKIJVR"
MW"==OEXVX]L4<MSFAG]&E4FZ=-VG-S=VKKFC*+L[;KFT9\H>)O$GA_XE?ME?
M#6[^']]:ZO+ING73ZUJ6E2B2$6[(PC221,JV&R ,]7%8O[..CV6H?L[_ !W%
MU9PS>?JFK1RLT8)95MU*@GT!8D>F>U?8OA7P)X<\#VLMMX=T'3="@E;?)'IM
MI';J[>I" 9/O1IG@/PWH>F7^G:=H&FV&GZ@[R7=K:VD<<5PSC#M(J@!RPX)(
M.1UIV,ZF?P5!8:G!V7(DV]?=E*6OSEIVL>4?L2W$DW[,O@HRNSLL,R@L<D 3
MR #\ /TKU?QYX;7QEX)U[0FD\H:G83V9?!^7S(V3/'UJ[H/A_3/"NDV^F:/I
M]KI>G6X(BM+.%88HP22=J* !R2>!WJ_C/THL?.8K%^WQL\5!6YI.27:[N?#'
M[+O[3_AGX#^!9_AO\33=>%=<\/WD\:"6SFF$RNYDX\M6.=S-SC!&T@G-7?A/
MJUU^TW^US)\3M+L+BW\%>%[%K"SO;E2HN9"LB_*/4^;(<<[0%W8+ 5]9^*?A
M;X.\<7$4_B'PMHVN3Q+MCEU&PBN&0>@+J<5O:;I5GH]C#96-K#9VD*[(X($"
M(BCH !P!4\I]/7SW!WKXG#T'&O634FY7BN;XG%6O=^;TN?#'[-/PUT7XNZI^
MT3X9UVW6:SO-=8!U WPR>=<[9$/9U."./8YYK._96\"^*OAO^V-J?ASQ7/+>
MW=AX?DAM;Z0'%Q:K)$(60GJNWY>I(*E>U?=&@^"O#_A6ZU"YT71-/TJYU"3S
MKR:RM4A>YDR3OD*@%VRS<G)Y-7I-%T^;5H-3>RMWU&"-X8KMHE,J1L5+(K8R
M%)520.#M'I1RK0UK<4U*CQ-.,/W=6*C9_9:BE=>MM?\ @%U:=35^M.JCX,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ I*6DH Q?%'^KT__ *^E_P#0'K7A_P!6
MOTK(\4?ZO3_^OI?_ $!ZUX?]6OTH DHHHH P?&7_ "!9_P#=-;9Z5B>,O^0+
M/_NFMNDP/(OCA;W&E:QX2\5K ]Q9:/=,;L1C+)&^WY\>@Q_*N;^-GC;2M4\/
MVNK^'/&5S%J2F..*QTV^,8D#')+QCY@V/7&*]^DA26,JZAE88(/(-8^G^"?#
MVCWAN[+1-/M+K))GAM41^>O(&:\7$8&I4E/V4DE/?NGM='NX7,*5)4O:PNZ=
M[;6:;O9W3\SP76/[0MOC%J4EUXHC\)2W%G#]CO+VT2=)(PBAE5I" AW!L\\G
M-6[CPG%IOP]\?ZW!XIM_$BZA&%FDM+9(8A(I&6^1BI//)'OZFO>=6\-Z7X@@
M6'4]/M=0A4Y5+J%9 #ZX8&FQ^&M)BTIM+33;5=-88:S$*^41Z;,8_2N193K*
M[O?FZO=JVU['6\Z=J;C&W+RW5HZJ+3WM?IW/"/']G%#\!_!4\<2QR1/9O&T:
MX*L8\DC'J?SJOX@%]9_&O6)+CQ/#X2DGM8OL=Y=6D<\<L6T JK2$!/F#=^3F
MO?[KPSI-[IT%A/IUK/8P[?*MI(5:--OW<*1@8[>E+K'AO2O$$21:GIUK?Q*<
MA+F%9%!]@P-.KE<JCNI6^'O]E-=->I-'.(TTTXWOS=G\33ZIKI^)Y]\&_"<&
MEZEKNM6_BFW\3#49%$TEI;+#&)5ZM\C%23GDC^IKI_BK;M=?#?Q)&B;W^PS8
M'7/R&NAT[2[/1[-+:PM(+*W3[L4$81%^@'%6F4,,'D5ZM/"1AAG0BK73[O?U
MU/)JXV53$K$RU:MV6VVR2/ %\3:1J'[.DNF6NH6\VH0Z4/.M5<&2/!4'<O4<
MGOC-=!'KH^'OP TS6-/L89+J&P@9-R_*&EV;G)'49;)YYQUKT2#P+X<MUN5B
MT+3HQ=#;/LM4'FC.<-@?,,\\UIQZ99QV"V26L*6:Q^4MNJ ($QC;MZ8QVKAA
M@*L=7))\O*O*W4[ZF94I^[RMQYW-IO>_0^89M:N;CXA> KV\\7V7B"YEN &2
MSMXX_LNXJI0LO)R6(PW(Q7?_  MM89_BA\23+$CGS8D&Y03M(?(^AQT]J]*M
M? GANSVK!H&FPA)!,HCM(U D'1Q@?>'KUK0M-"T_3[NZNK6QM[>YNB#<311*
MK2D?WB!D]3UK##Y7.G44Y2O[U^O\MGN=&(S>%6DZ<(-7CR]%]KFV27H?.7@_
MP_H^M?"N>WU75TT-+77)&L;J4@I%* "HVM@$=3@FI=0\5:QXH\#>/=+1;/4;
MVS6!GU?25(6\C##<6QP2%4YQQ@$=N??_ /A#]"_L^6P_L:P^PS.9)+;[,GEN
MQZL5Q@GWJQI>@Z;H=K]FTZQM[&VSGRK>)47)[X H65S24%.RM9^9<LY@Y2J2
MA?WN97MIJF_/6VVW4X+P)XU\#Q>&?#]I:W^FQ2,L:0VF]/-68C'W>H;<2">Y
M/7GG"^%VFVMY\6OB-/- DLD<L409U!(5M^Y?H=H_(5Z?;^"]!M-4;48-$L(K
M]F+FZCMD$I8]3N SFKMGH>GZ;>75U:6-O;7-T0T\T,2J\I'0L0,MU[UUQP=2
M3I.HU[CZ+?2QY[QT(JLJ:=ZBZO\ O)GE>I*/^&D-/4# _L1^.WWFYZ5R7PO\
M4>&='^'7BJUUJ^L8GDN[EFM9G7S)5V@#"]3D@]J]_GT/3Y-0&HM96[:@L?E+
M=&,>8%Y^7=C..3Q7GWPS^#]MX:L;D:]I^F:C?M>/<0W B$C(IQCYF4$$8/3U
MKCJ8&LJZE"SYN;?9727Z'?2S"@\*X3NG%02[OE<G^IY1>6UWH_P<\ W&I*\4
M-OK*3,TJG]W$7<C/' QSSZCZ5VWQMUS3/$'AWPU-I=[;WL*:Y!&TMLZLH.UB
M1D'&1D5[1>:9::E9O:7=M%<VL@VM#*@9&'H0>*SX_!>@1V,-FFBZ>MG#+YT<
M MD$:2=G"XP&]QS5_P!F3C"5.,ERM16W8S_M:$JL*TH:QE)Z;:GD\.H:?X;^
M.^OW/B2>*T2:RB_LZXO&"1! JAPI;@'(/?UKDY)(M2TGXN:KI05= N?+$+Q\
M1R2#[[#L>23GW%?1FK>'=+UZ-8M3TZUOXP=RI=0K(H/KA@:<VA:<VF'36L+9
M[ KL:U:)3&5]-N,8]J<\KG-.#DN7WFN]Y*VH4\VA3<9\GO)16^GNM/3S=OS/
M!/B%9P0_ ?P3-%"J2QM9R(R#:58IDD'L2?SKZ%ASY*?0?RJG<^&]*O-/AL)]
M.M9;*';Y5O)"K1IM^[M4C QV]*T54*  , =*]##85T*DIM[J*^X\S%8Q8BE&
MG;5.3_\  K'F7[0?A>Z\4?#JX%E"UQ=6<JW20H,LX7(8 =_E8G Y..*R-*_:
M4\*_\(S'/>33Q:JL/SV*P.69\8(# ;>O0DCCKBO9-H(QCBL23P/X=DU#[<^A
MZ<U]NW_:6M4,F[UW8SGWK&OA:_MG6PTU'F5G=7]&M5J=&'QF']@L/BJ;DHNZ
ML[;VNGH]-#PGPCHM_P#\*K^(GB34H&MI-=BFGBB?.?+ <@\]LN<9'09[UV/P
M/\#^'=4^&^BWUWH6GW-XP=C<2VL;R$B1L98CMCKFO6;JQM[VSEM;B!)[>52C
MPR*&5P>H(/!IFF:7::/916=C;16EK']R&% B+SG@#@<FLJ&61HU(3EJE&VO=
MN]S;$9M+$4IP2Y7*2>G1)6L>,_M31AO#F@@@,IU)1M.,'Y'XY_E7J&B^"?#V
MCW$5WI^B:?9W:K\L]O:HC\CGD*#S6CJV@Z=KT<2:C8V]\D;!T6XB60*P[@$<
M'WJ^JA< # '2NJG@U'$SKRUO:WE:YQ5,:YX6GAHW7+S7\[V #T-/I,?G2UZ6
MVAY@4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH PM<_P"0UI7^[-_[)6[6
M%KG_ "&M*_W9O_9*W: %HHHH **** ,_7/\ D'2_[II=!_Y >G_]>\?_ * *
M37/^0=+_ +II=!_Y >G_ /7O'_Z * +])BEHH 0*!1M I:* $VBC:*6B@!-M
M)L%.HH 3;1CM2T4 )1M%+10 FT48I:* $Q2;13J* $VBC:*6B@!H4+S2[12T
M4 )BDVCI3J* $Q1BEHH 3%&T4M% ";:*6B@!-HI-HYIU% "!0*6BB@ HHHH
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M'3+*&:]MXI$A12KRJIR%QW-:[*&7!Z53ETFVF8LT2DGVH ;_ &[IO_01M?\
MO^O^-']NZ;_T$;7_ +_K_C2?V':?\\4_[Y%']AVG_/%/^^10 O\ ;NF_]!&U
M_P"_Z_XT?V[IO_01M?\ O^O^-)_8=I_SQ3_OD4?V':?\\4_[Y% "_P!NZ;_T
M$;7_ +_K_C1_;NF_]!&U_P"_Z_XTG]AVG_/%/^^11_8=I_SQ3_OD4 +_ &[I
MO_01M?\ O^O^-']NZ;_T$;7_ +_K_C2?V':?\\4_[Y%']AVG_/%/^^10 O\
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M_C2?V':?\\4_[Y%']AVG_/%/^^10 O\ ;NF_]!&U_P"_Z_XT?V[IO_01M?\
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M - Z]_[Y3_XNC_A*5_Z!U[_WRG_Q=;/DI_<'Y4>2G]P?E0!C?\)2O_0.O?\
MOE/_ (NC_A*5_P"@=>_]\I_\76SY*?W!^5'DI_<'Y4 8W_"4K_T#KW_OE/\
MXNC_ (2E?^@=>_\ ?*?_ !=;/DI_<'Y4>2G]P?E0!C?\)2O_ $#KW_OE/_BZ
M/^$I7_H'7O\ WRG_ ,76SY*?W!^5'DI_<'Y4 8W_  E*_P#0.O?^^4_^+H_X
M2E?^@=>_]\I_\76SY*?W!^5'DI_<'Y4 8W_"4K_T#KW_ +Y3_P"+H_X2E?\
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M'Y4 8W_"4K_T#KW_ +Y3_P"+H_X2E?\ H'7O_?*?_%UL^2G]P?E1Y*?W!^5
M&-_PE*_] Z]_[Y3_ .+H_P"$I7_H'7O_ 'RG_P 76SY*?W!^5'DI_<'Y4 8W
M_"4K_P! Z]_[Y3_XNC_A*5_Z!U[_ -\I_P#%UL^2G]P?E1Y*?W!^5 &-_P )
M2O\ T#KW_OE/_BZ/^$H7MIU[_P!\I_\ %UL^2G]P?E1Y*?W!^5 &(6.L7MI<
M"":$0!@1* ,[MOH3Z5NT!0O08I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML3UIU !12-TIJL2V,_Y_S_*@!]%(W3TIJMN;'7Z4 /HI&SCCK358\9)_$8H
M?1110 444C?=.* %HIF\].]*#0 ZBDIJMGOF@!]%(>*8&)]^.: )**9N_/TI
M-Q_"@"2BF[MO6F[\MC]* )**:K9IU !1110 44C=/2F[^?7Z4 /HJ,.<9]L\
M&G*2<&@!U%(WW3BF[S]* 'T4U6.XBG4 %%%(QVJ3TH 6BF;CQGJ?:E+>^* '
M44P,WI1OXSGCUH ?1358YIU !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRLH/S(V<D'(K)@^">G!]4FO=:UK4[K5)[*XO+B[FB+2M:S&6,82)51<X4J@
MPHQABS%W0M2+6_$WCC2+WPUHZSZ#/K&MW4V^3[%,(+*WC@9V)'G$RLK[!G*!
MLXPN<C,\1_$KQ/:Z?XKN-.NM'BMO"-JW]I7]UITLBWMV(1*T4$(N%,:A67YF
M=^7 'W23Z+=^%[6]\5Z;K\LDWVNQMI[6&/*^6!*8RS$8SN_=*!SC!/'-<?XH
M^!NE^*'UV-]=UK3M.UN7[3?Z=8S0I#+.(U02[C$9 ?DC.W?L)094@D$N@U*M
MKXP\<:]KUYIEE+H6D_V?I%C>7EQ?6,T^RZE60O$$69/E 53G=E>F&W97*T?X
MQ:_XLT[P\EJ^C^&[NX\.CQ#J-]JT+S6\46=H$:"6,[2<N69_D4*,,6ROH+>
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MH5F>/G5]7M_V:]&\-S^$]8LFUJ*TL3J<LMG]G9KN=-[ )<&4!O,; \O/(R
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MT[4K*.>***!@%'I2[1114B#:,=*;1130"CFEVCFBBF FT'((X/6EVBBB@!,
M#@8I=H]*** $VA< # Z4NT444 &T4FU?3VHHH 7:*-HHHH ,4;1Z444 &* H
M7H,444 !4'@C-&T=<<T44 &T48%%%+J 8%&T=<444P#:/2C:/2BBD ;12;1U
MQS111U -HXXI=H'08HHI@-50.!P.E+M&,8XHHIC @=>]&T-U&?K112)ZBE0<
MY%!'?O110,;2;1Z444"08[?UI0H[#'THHH&+@ <<4G;';THHH *=M'I110 @
MZTZBBDP$-)DT44( R:,FBBF  TZBB@ HHHH 0T@HHH$#49-%%( R:.U%%'0
MR:=110AA1112 ****: ****8"4F3114C0+3J** "BBB@04444 %%%%- (:3)
;HHI@.I*** $!I?XJ** %HHHH :#1110)'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img207175068_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img207175068_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *%!& # 2(  A$! Q$!_\0
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MKE?!-V+'5;[16D#IN+PL#D''7'X8_*@#NZ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^E "44N#Z48/I0 E%+@^E&#Z4 )12X/I1@^E "44N#Z48/I0 E%+@^E&#Z4
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MKSKX3W.IW'C?Q0VJ?+<G86C!R%SV% 'H?_")Z=_STO/_  *?_&C_ (1/3O\
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MX%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\
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MX%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\
M")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_Q
MH_X1/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?
MXUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=
M_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1
M/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8
MHQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]
M+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^
M>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!
M@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]+S_P
M*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_
MX%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\
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MX%2?XUO8HQ0!@_\ ")Z=_P ]+S_P*D_QH_X1/3O^>EY_X%2?XUO8HQ0!@_\
M")Z=_P ]+S_P*D_QK.UK0[;2[.*ZM9[M95N(@";AR,%@#P377XK$\5\:.G_7
MS#_Z&* -P]:*#UHH *.]%'>@##\+?\@=_P#KYF_]#-5_'.J2:-X.U*]A"&1(
MB &Z<U8\+?\ ('?_ *^9O_0S69X^\*W7BW1XK"VNE@ F#R;LX9>XXH \GDTV
M+0]*\!ZCN<6LEP]U<2MT1F/3/IQ706M]+XAUG7?&^U9+32;9X[!6&4=L<DC^
MM==XM\"G7?!=IX>L98K9+=D(W@D;1U J;5O!\W_"!-X>T"6"Q=E5'<KD,O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7D%M\4/%#^)+;1KCPQY=Q*PW*&R57N37KJ]: '4444 %8?BO_D#I_P!?,/\
MZ&*W*P_%?_('3_KYA_\ 0Q0!N'K10>M% !1WHH[T 8?A;_D#O_U\S?\ H9K<
MK#\+?\@=_P#KYF_]#-;E #)(Q+&\;=&!!_&O&_B!H=AH.L^#K:P@$:-J6]C_
M !,Q]37LQKDO%WA!O$VIZ+=BZ\C^S;CSBNW._P!J .M'W12TB]!2T %%%% !
M1110 4444 %%%%  >E9VK6.FWEL'U2"&6& ^8#, 0I'>M$]*Y7QSX7O/%FB#
M3K74FL06S(5&=X]* .#U&^G^*'BBUTFQM6'AZPF$DTY&W>1Z&O8D01HJ+PJ@
M*/H*\KT[X9>*-,2&*V\8R1P1D?NUB ! [5ZI&"L:*QW$  GU.* )**** "BB
MB@ HHHH **** $)P*R]4U33+.:*TO;F&&>XRL(DQDGVK4;H:Y?QIX+L_&.GK
M%*YANHCN@N%ZH: /+]3TO4_"GQ&T1]8U%M:L[B4B!9VR8F)ZX]J]W7^E>;Z#
M\+I;;7H]6\0ZQ)JT\"A;<.,!,5Z0* '4444 %%%% "&O'?B+XEL]9\2V_A62
M_%A:VKB:]FD; D'9 .]>PD?G7/:EX'\.:O>R7E]I4$UQ(/F=AR: //?@M>:<
MFK^(K.TECVM/OA1>Z#N*]D%</X+^'5GX/U/4+Z)HY'N6_=87'E)_=KN!^5 "
MT444 %(:6B@#SOXPZ<VI^#H[=;R&U)N4_>3-M%<;JEKXG^'%M8:['XC?5++*
MK)!*WRD'L!7KWB3P[8>)]'ETV_CWQ.,J>ZMV(KSZP^#]P;RT36=>FU#3;4YC
MM6&![9H [G7IC=>"+R=5(:6SWA1SC*YQ7BWA;0O%UWX!75[#7#:QV6\PVL9P
M' .6W^_UKZ#$,8MQ $ C"[ O8#&,5YC+\*M2@U&[&E>))[/3;J0O):@>O44
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M [[PEJDFH:!!-/(7D)(+'J<&NA%>=_#ZZ0>'K=6E4?,W!/O7?1W$.T?OH_\
MOH4 6!THJ'SX?^>L?_?0I?/A_P">J?\ ?0H DJO=W4=G:R7$K )&N3FG_:(?
M^>L?_?0KE=>N)-9U.#1[0AH@P>X8'HHH VM-UA;S3Q=SC[.C'"[CUK45@R[@
M<@UQ-[MU36;?28)$6QM<&;Y@.E=@DT"(%66/:.!\PH L45%Y\/\ SU3_ +Z%
M'GP_\]4_[Z% #SUK%\4W,UIH$\T$ACD&,,.U:IGAS_K8_P#OH5S_ (TN(_\
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M%>:Z=-(=:U8=@RUT?@:Z2,ZD&D _?=S[4 3+J^I>4+LZC+S/MV8&,;L5?O\
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M$JD^7R <]A0!?$]^6/\ Q-;C\A2^=?\ _05N/R%4/M(R=IH^T&@"_P"=?_\
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M'-2BLC3[N-E&9D_[ZK3\^'_GJG_?0H <>:\[CUF^7Q! 7OI#&][Y)BXQMKT
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M4Q*VZ1LFO8L<YKR#QS=B#QM.I('[A: (#=?,:3[4:QS>*23O'YT?;%_OC\Z
M-C[4:/M//-8_VQ?[P_.D^V+D?,/SH ;JZ+>FW@9BJR7"J2.O6NXL?AQ92@?Z
M?>#Z2&O/I9@]Y988'_24[^]>ZZ9T'X4 <Y_PK*Q_Z"-[_P!_#1_PK&P_Z"-[
M_P!_37<TM '"'X96/3^T;WG_ *:FO/M7M%TRSU>PCD9DC=E#,<FO>L<U\_\
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MW@N+U+R_>7R/M"=0AZ8]\5RW@O7=5TWQ181Z?;:S);7C!;K^T%RHSW4B@#Z
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MPE>:-XVU[6II8VAU CRU4\C'K1H7A&\TOQ_K6ORRQFWOHPB*IY'/>NVQ1B@
M'2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGQOJ5EX"NO$UUIBQ[<-!"6Y9">": .D_X170O^@3:?\ ?L4G_"+:'_T";/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI5E:)#(O1BO(_&DDMXGE61XE9U^ZQ7)'T- $@%/I!2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8?BO_D#I_U\P_\ H8K<K#\5_P#('3_KYA_]
M#% &X>M%!ZT4 %'>BCO0!A^%O^0._P#U\S?^AFMRL/PM_P @=_\ KYF_]#-;
ME !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MA^*_^0.G_7S#_P"ABMRL/Q7_ ,@=/^OF'_T,4 ;AZT4'K10 4444 8NC6E]I
MUD\$MO&29I'!$G9F)%:&^Z_Y]D_[^5:HH J[[K_GV3_OY1ONO^?9/^_E6J*
M*N^Z_P"?9/\ OY1ONO\ GV3_ +^5:HH J[[K_GV3_OY1ONO^?9/^_E6J* *N
M^Z_Y]D_[^4;[K_GV3_OY5JB@"KONO^?9/^_E&^Z_Y]D_[^5:HH J[[K_ )]D
M_P"_E&^Z_P"?9/\ OY5JB@"KONO^?9/^_E&^Z_Y]D_[^5:HH J[[K_GV3_OY
M1ONO^?9/^_E6J* *N^Z_Y]D_[^4;[K_GV3_OY5JB@"KONO\ GV3_ +^4;[K_
M )]D_P"_E6J* *N^Z_Y]D_[^4;[K_GV3_OY5JB@"KONO^?9/^_E&^Z_Y]D_[
M^5:HH J[[K_GV3_OY1ONO^?9/^_E6J* *N^Z_P"?9/\ OY1ONO\ GV3_ +^5
M:HH J[[K_GV3_OY1ONO^?9/^_E6J* *N^Z_Y]D_[^4;[K_GV3_OY5JB@"KON
MO^?9/^_E&^Z_Y]D_[^5:HH J[[K_ )]D_P"_E&^Z_P"?9/\ OY5JB@"KONO^
M?9/^_E&^Z_Y]D_[^5:HH J[[K_GV3_OY1ONO^?9/^_E6J* *N^Z_Y]D_[^4;
M[K_GV3_OY5JB@"KONO\ GV3_ +^4;[K_ )]D_P"_E6J* *N^Z_Y]D_[^4;[K
M_GV3_OY5JB@"KONO^?9/^_E&^Z_Y]D_[^5:HH J[[K_GV3_OY1ONO^?9/^_E
M6J* *N^Z_P"?9/\ OY1ONO\ GV3_ +^5:HH J[[K_GV3_OY1ONO^?9/^_E6J
M* *V^ZQ_Q[K_ -_*:3<E@?LJ?7S*MT4 5,W.[_CV3'KYE*6N3C-LA^LE6J*
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M\^R?]_*-]U_S[)_W\JU10!5WW7_/LG_?RC?=?\^R?]_*M44 5=]U_P ^R?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *P+GQQX8L]0>PN=;LX[E&VNC2<*
M?0GH#[$UOUP?@FRLO.\1Z'>V<$L]KJ+NPEB#%XI/F1CD<]Z .X@N(;J%9K>6
M.6)QE7C8,I'L14E<=/X#CL)VO/"]]+H]R3EHD.ZWD/\ M(>GU%);>,KG2KE+
M'Q99BPE8[4O8_FMY#]?X3[&@#LJ:[K&C.[!549+,< "A'61%=&#(PR&4Y!%>
M1_&S7+BV&EZ9$[+!*7EF4'A]N H/L,D_EZ4 >E'Q+H(.#K>F@C_IZ3_&C_A)
M=!_Z#>F_^!:?XUX1I>H65Y:*1&@=1AE*CBKWF6G_ #R3_OD4 >T_\)+H/_0;
MTW_P+3_&C_A)=!_Z#>F_^!:?XUXMYEI_SR3_ +Y%'F6G_/)/^^10![3_ ,)+
MH/\ T&]-_P# M/\ &C_A)=!_Z#>F_P#@6G^->+>9:?\ /)/^^11YEI_SR3_O
MD4 >T_\ "2Z#_P!!O3?_  +3_&C_ (270?\ H-Z;_P"!:?XUXMYEI_SR3_OD
M4>9:?\\D_P"^10![3_PDN@_]!O3?_ M/\:/^$ET'_H-Z;_X%I_C7BWF6G_/)
M/^^11YEI_P \D_[Y% 'M/_"2Z#_T&]-_\"T_QH_X270?^@WIO_@6G^->+>9:
M?\\D_P"^11YEI_SR3_OD4 >T_P#"2Z#_ -!O3?\ P+3_ !H_X270?^@WIO\
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M -!O3?\ P+3_ !H_X270?^@WIO\ X%I_C7BWF6G_ #R3_OD4>9:?\\D_[Y%
M'M/_  DN@_\ 0;TW_P "T_QH_P"$ET'_ *#>F_\ @6G^->+>9:?\\D_[Y%'F
M6G_/)/\ OD4 >T_\)+H/_0;TW_P+3_&C_A)=!_Z#>F_^!:?XUXMYEI_SR3_O
MD4>9:?\ /)/^^10![3_PDN@_]!O3?_ M/\:/^$ET'_H-Z;_X%I_C7BWF6G_/
M)/\ OD4>9:?\\D_[Y% 'M/\ PDN@_P#0;TW_ ,"T_P :/^$ET'_H-Z;_ .!:
M?XUXMYEI_P \D_[Y%/A6"XF2&*W5Y'.U5"\DT >S?\)+H/\ T&]-_P# M/\
M&C_A)=!_Z#>F_P#@6G^->1W>ES6$0ENM.:&,G&YX\#-,L[%M0+BSL3,4^]L3
M.* /7_\ A)=!_P"@WIO_ (%I_C1_PDN@_P#0;TW_ ,"T_P :\@>P>.]%FU@P
MN2,B+R_F/&>GTJ&>.*UE,4]L(I!U5TP10![+_P )+H/_ $&]-_\  M/\:/\
MA)=!_P"@WIO_ (%I_C7BZM;.P584+$X "]34UU:BR95NK(PEAE1)'C- 'L7_
M  DN@_\ 0;TW_P "T_QH_P"$ET'_ *#>F_\ @6G^->+>9:?\\D_[Y%20)#<S
M+#!;"21SA55<DT >R_\ "2Z#_P!!O3?_  +3_&C_ (270?\ H-Z;_P"!:?XU
MXW<11VD[07%L(Y5^\K+@BHO,M/\ GDG_ 'R* /:?^$ET'_H-Z;_X%I_C1_PD
MN@_]!O3?_ M/\:\6\RT_YY)_WR*/,M/^>2?]\B@#VG_A)=!_Z#>F_P#@6G^-
M'_"2Z#_T&]-_\"T_QKQ;S+3_ )Y)_P!\BCS+3_GDG_?(H ]I_P"$ET'_ *#>
MF_\ @6G^-'_"2Z#_ -!O3?\ P+3_ !KQ;S+3_GDG_?(H\RT_YY)_WR* /:?^
M$ET'_H-Z;_X%I_C1_P )+H/_ $&]-_\  M/\:\6\RT_YY)_WR*/,M/\ GDG_
M 'R* /:?^$ET'_H-Z;_X%I_C1_PDN@_]!O3?_ M/\:\6\RT_YY)_WR*/,M/^
M>2?]\B@#VG_A)=!_Z#>F_P#@6G^-'_"2Z#_T&]-_\"T_QKQ;S+3_ )Y)_P!\
MBCS+3_GDG_?(H ]I_P"$ET'_ *#>F_\ @6G^-'_"2Z#_ -!O3?\ P+3_ !KQ
M;S+3_GDG_?(H\RT_YY)_WR* /:?^$ET'_H-Z;_X%I_C1_P )+H/_ $&]-_\
M M/\:\6\RT_YY)_WR*/,M/\ GDG_ 'R* /:?^$ET'_H-Z;_X%I_C1_PDN@_]
M!O3?_ M/\:\6\RT_YY)_WR*/,M/^>2?]\B@#VG_A)=!_Z#>F_P#@6G^-'_"2
MZ#_T&]-_\"T_QKQ;S+3_ )Y)_P!\BCS+3_GDG_?(H ]I_P"$ET'_ *#>F_\
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M-&QO[IKV_P#X0:R_Y\A_WTW^-'_"#67_ #Y#_OIO\: /$-C?W31L;^Z:]O\
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M3]=EMHEEL0HCB4G:<$GGZY_2O0O^$%LO^?/_ ,>;_&C_ (06R_Y\_P#QYO\
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MK^D6@DMI_.3RYVDWO_ST9N,L3ZUTFJ:/8:U9?8]1MEN+?<&\MB0,CITJ]10
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M;X,7U]JOAN^FU"ZEN7%UM1I6+$#:.*Y#Q9\8K?Q%X9O-*M])FMWN%"^8\P8
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M@_X7U@7=OXEL[J!;,N\$T+9W,HZ_T- 'O-%%% !1110 4444 %%%% !1110
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M_P#@#%_\36;\-M*N]&\#V-I?0-!<#<S1MP5R>_O764 8H\'^& 01X<T@$?\
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MCV=U:!(K^* 2KD8RAR#CI7L(10Q8*-QZG'-(R*XPRAA[C- '@U_8^5\*M<U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA\+H9(?AUI"R@ABC,,^A8D?I77T %%%% !1110 4444 %%%% !1110 4444
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MT6U\,OX?CM!_9\BX=2>6/J3ZUO44 <'HGPGT+1M2AO6GO+QK<Y@CN9 4B/L
M!6QXJ\$Z5XM2%KSS8;F#_57,#;9$]LUTE% ',^%_ ND^%6FEMC/<74XQ)<7+
M[G8>E8<GP<\./J+SB6]2U>3S&LEEQ#GZ8S^M>A44 1P016T$<$*!(HU"HJ]
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M?[<9.&_&HO#GA :)J5YJMYJ,NI:G=@+)<21K& HZ *O KIJ* "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \Z^,PSX1LQZZA%_)JY?3=+GD^,":6^?L5L6U$+[M& #^>*]MHH
M^>M,TR\F^&MG=V]M)<)IVM--/#&NYB@VYX'7I777FI6_CKQ_X:GT!)9K?3"T
MMW<^6RJF<'820.>.GO7J]8/BSQ98>#].AO=025XY91$HB&3G!/\ 0T >:07]
MOI>I?$/3+UF@O+V*9[:-T;]XHC<D@XQC%4[?_D _#7_K\/\ Z'7M&CZI#K6D
M6NI6P80W,8D0,,'!]:NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Y7\>/\ D4-/_P"O\?\ HMZ]4KROX\?\BCI_
M_7^/_1;T =?\/?\ DGVA_P#7HM=+7-?#W_DGVA_]>BUTM !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-'Q8T.[T+
MQ5(#-,^GWA-Q;AW)53_$HSZ$_D17TO7(_$3PC_PE_APVT(47L+B2!SV/0C\1
M_2@#@_@AHEW,T^N74TQMX@8+6-G.W/\ $P'3@<?B:]JK-T#1X- T.TTRW "0
M1A2?[Q[G\36E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI?\ @9)_C1Y]S_T%M2_\#)/\: /=:*\*\^Y_Z"VI?^!DG^-'GW/_ $%M2_\
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MI?\ @9)_C1Y]S_T%M2_\#)/\: /=:*\*\^Y_Z"VI?^!DG^-'GW/_ $%M2_\
M R3_ !H ]UHKPKS[G_H+:E_X&2?XT>?<_P#06U+_ ,#)/\: /=:*\*\^Y_Z"
MVI?^!DG^-'GW/_06U+_P,D_QH ]UHKPKS[G_ *"VI?\ @9)_C1Y]S_T%M2_\
M#)/\: /=:*\*\^Y_Z"VI?^!DG^-'GW/_ $%M2_\  R3_ !H ]UHKPKS[G_H+
M:E_X&2?XT>?<_P#06U+_ ,#)/\: /=:*\*\^Y_Z"VI?^!DG^-17-]<6UN\IU
MC45VCJ;Q_P#&@#WJBO#/!_B6\U(W%I<WUV[P@,CF=LLO3GGMQ^==9YLW_/[=
M?]_V_P : /1Z*\X\V;_G]NO^_P"W^-'FS?\ /[=?]_V_QH ]'HKSCS9O^?VZ
M_P"_[?XT>;-_S^W7_?\ ;_&@#T>BO./-F_Y_;K_O^W^-'FS?\_MU_P!_V_QH
M ]'HKSCS9O\ G]NO^_[?XT>;-_S^W7_?]O\ &@#T>BO./-F_Y_;K_O\ M_C1
MYLW_ #^W7_?]O\: /1Z*\X\V;_G]NO\ O^W^-'FS?\_MU_W_ &_QH ]'HKSC
MS9O^?VZ_[_M_C1YLW_/[=?\ ?]O\: /1Z*\X\V;_ )_;K_O^W^-'FS?\_MU_
MW_;_ !H ]'HKSCS9O^?VZ_[_ +?XU%/?SVB"1;^Y#]LS,?T- 'IE%8GA?67U
MG2_-F $L;E&([X[_ *UMT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!R^F>.]+U/Q9>^'%CFBO+8D9DQMDQUVX-6M/\5VFH^*]1\/Q
MP3K<V"*\DC8V,#CISGOZ5XY?:3>2^*O%7B#2V;^T-&O%N$4=&3^(8^@_+-:/
MA+Q='<>._$'B*WT^[NHIK:)GAMU#.GW0QP3R 0>E 'N%%9VCZ]IFOV@N=-NX
MYTZ,!PR'T93R#]:T:  C(P>E<5X)8Z/JNM>%9,A;2<W5D#WMY3NP/HV1^-=K
M7&>,U.CZMI'BF('%K)]FO,?Q02''/T;!_$T =G7.:[X-L=8G6_MI)-.U:/F.
M^M?E?Z,.C#V-=$K*ZAE(*D9!'<4M '%6_BK4_#\ZV/B^W54)VQ:K;J?)D_WQ
M_ ?T^E<]\:;A)_"5J\4BO&]TA5E.01M:O4;BWANX'@N(DEB<89'&017B/Q4\
M,1:!I*M87<R:?+<K_H+'<B/AOF4GD#&>/>@#S*SNI;2421-@]QV(KI(-4$\8
M8'![CTKE4Z5/%(T3;E/- '4?;3ZT?;3ZUS_VV3T%'VV3T% '0?;3ZT?;3ZUS
M_P!MD]!1]MD]!0!T'VT^M'VT^M<_]MD]!1]MD]!0!T'VT^M'VT^M<_\ ;9/0
M4?;9/04 =!]M/K1]M/K7/_;9/04?;9/04 =!]M/K1]M/K7/_ &V3T%'VV3T%
M '0?;3ZT?;3ZUS_VV3T%'VV3T% '0?;3ZT?;3ZUS_P!MD]!1]MD]!0!T'VT^
MM'VT^M<_]MD]!1]MD]!0!T'VT^M'VT^M<_\ ;9/04?;9/04 =!]M/K1]M/K7
M/_;9/04?;9/04 =!]M/K1]M/K7/_ &V3T%'VV3T% '0?;3ZT?;3ZUS_VV3T%
M'VV3T% '0?;3ZT?;3ZUS_P!MD]!1]MD]!0!T'VT^M'VT^M<_]MD]!1]MD]!0
M!T'VT^M'VT^M<_\ ;9/04?;9/04 =!]M/K1]M/K7/_;9/04?;9/04 =!]M/K
M1]M/K7/_ &V3T%'VV3T% '0?;3ZT?;3ZUS_VV3T%'VV3T% '0?;3ZT?;3ZUS
M_P!MD]!1]MD]!0!OM?[%+,V *Q;Z^DO'^8D(/NK5=KAI?O'\*8: .C\$N4U6
M?'>+^HKT(3<=:\T\*RF+4Y2!G,?]17;"[?'W10!J^=[T>=[UE?:W_NBC[6_]
MT4 :OG>]'G>]97VM_P"Z*/M;_P!T4 :OG>]'G>]97VM_[HH^UO\ W10!J^=[
MT>=[UE?:W_NBC[6_]T4 :OG>]'G>]97VM_[HH^UO_=% &KYWO1YWO65]K?\
MNBC[6_\ =% &KYWO1YWO65]K?^Z*/M;_ -T4 :OG>]'G>]97VM_[HH^UO_=%
M &G)="-<GKV%9LTK2N6<Y/\ *F^89#D]:0T =W\/V/\ 9\X[><?Y"NTKBO '
M_'C/_P!=C_(5VM !115;48KF;3;F*SD$=R\;")R<!6QP: +-%>4IXY\8>#V$
M7C#0GNK13C[?9X/'KQP?H=IKI;SQQ8:CX%U36M!N/.>WA/RE"&C8^H/I^7%
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MAM&3ZCNQKWBWTC3+2Q>QMM.M(;23.^".!5C;/7*@8-4O^$.\+_\ 0MZ/_P"
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M.FZ=+++9:?:VTDQS*\$*H7/JQ Y_&@#RWQA&-:^,^@:3M5H+2)9&7' Y+']
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M2C_A$+7TKJ** .7_ .$0M?2C_A$+7TKJ** .7_X1"U]*/^$0M?2NHHH Y?\
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MV2*]8^Q6O_/M#_W[%3(BHH5%"J.@ P!0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>:9*[(ES$T99>HR.M>>S_#3Q!=Z1IVGW'B"V:'395>U1;<@$ _QG.2:]1HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img207175068_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img207175068_3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X3B^17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C Q.C(P(#$S.C,R.C,U   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,3HR," Q,SHQ.3HP.  R,#(R.C Q.C(P(#$S.C$Y.C X      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  )Q$         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ J $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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MIY$/W.PODW7_ #\O^E0W-E+<PM'+,SJ1T.*?(A-QZ(RM$8"S>"7EH9&2M/\
M=>@IRW-(M\IB?:I]BR>3)L;[K;3@_2H_[2]ZAIGH0A"2T8O]H-M+8.T'!..,
MTG]I>]+4KV46']I>]+_:#;0V#M)P#VS1J#I10G]I>]']I>]&H_9(/[2]ZU]
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M'T_E631O<U*='_KD_P!X5)70T:*Z#E"BF 44 %'48H \UT+3_$WASXC7%G'
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MC_UR?[PKRSZWH:-%;G*%%, KFM;U:#3M39)-)%S'Y2-)*L89CDL"O3DX (%
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M[<*L>2V3(./^_3_I70PSI<01S1DF.10ZDC'!&12:L-.X_-&:0PS1F@ S1F@
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M #S;_ODT68<T>X>5)_SS;_ODT>5)_P \V_[Y-%F'-'N'E2?\\V_[Y-'E2?\
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M%!04%!04%!04%/_  !$( :8"@@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MJ[6N-/FF:WCFRO,B@$C;G/0CM2]I()3RZ%N915]%ZG.?\)I>_P!^;_OHT?\
M":7O]^;_ +Z-;-KX0EOKF*WMK=[B>5@L<42;F=CT  ZGVJY9_#F_OH=1EALV
M*:?'YMUNPIB7<%R02">2!@<T^>8I5,NAI.,5]WHOO9S7_":7O]^;_OHT?\)I
M>_WYO^^C6I_PC8 R5P/4CBC_ (1H?W.^.E+VDNYI; ;<J,O_ (32]_OS?]]&
MC_A-+W^_-_WT:U/^$;']W]*/^$;']W]*7M7W'RX'?D1E_P#":7O]^;_OHT?\
M)I>_WYO^^C6I_P (V/[OZ4?\(V/[OZ4_:2[ARX'^1&7_ ,)I>_WYO^^C1_PF
ME[_?F_[Z-:G_  C8_N_I1_PC0_N_I1[27<.7!?\ /M&7_P )I>_WYO\ OHT?
M\)I>_P!^;_OHUJ?\(T/[OZ4?\(V/[OZ4>TEW#EP7\B,O_A-+W^_-_P!]&C_A
M-+W^_-_WT:U/^$;']W]*/^$;']W]*/:2[ARX'^1&7_PFE[_?F_[Z-'_":7O]
M^;_OHUJ?\(V/[OZ4?\(V/[OZ4>TEW#EP/\B,O_A-;W^_-_WT:Z7P*VH>,=4,
M;/-'9PC=-)D_@H]S@UG?\(T/[E==J]^OPU\#Q0VX5=3O"=I(Y#$<M_P$$"MZ
M+<W=O1'S6>8O#X;#JGAJ:]I-V7ZOY'>Z/XH\/>'?$5E:W5Y#"RDYC13(XPI/
MS!0<'ZUZ!_PM'PJL8)OL9Z9M9?Y;*^//!)>Z\3([N'E9)"9)6!RVT\DGK7J$
M,K1K9HY9WQM_B/Z;FX_ 552J[Z(^-PF0490_>R;E?7;_ "/;_P#A:WAAU9H[
MB22)3M:1;60*I]R5J.Z^*OAZ!U6+S+L$9W0QC'ZXKQ-5^R_:25"L'SO.>_\
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M:54"+Q=8$ [ANR/PQOQ^-*?@>TRL9/%>G!FX,88D?7);/Z51_LO5/^@A<?\
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MP#D;AW_^O4'VSMG&#Q7,_P!I#^]1_:0_O4<VUP6#46VEN=-]NQGGC&>O^?\
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MVD)Z?#-_<W_P3Z,.I+G[P_$TG]I+_>'YU3\+^!=3UK1Q=SRQVY#LNUI,8 _
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M7JO.R@YP<5TVN:[9Z7IL=C9(L-O"GEQ1J>%4=/\ /O7C/CGQ(]M;R10L3>7
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M>&/%UE=N=MNY\B;TV-W)] <'\*Z+XE?#^[L-6FU'3[9[BQN6WL(DW&.0G)!
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MP.5S^3&I5MD$]QDF-RFWDE"1^2'\P:+>0KQ5]$4(;2[:01AVWR+EY(QNXP<
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M\/\ W_6OT1_X1NV_N#]*/^$;MO[@_2CZG3#_ (B-G'\L/N?^9^=W_#/?C/\
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M@CWK]%O^$;MO[@_2C_A&[;_GF*P>#I-6>QZ\O$+-9KEE"#7H_P#,_-EOA/\
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M#_GPB_[_ "T?\*%\8?\ /A#_ -_EK] CX>MC_P LQ2?\([;_ //,4OJ\!_\
M$0<W[1^Y_P"9^?O_  H7QA_SX1?]_E_PH_X4+XP_Y\(?^_R_X5^@/_"/VW_/
M,4A\/VW_ #S%+V$.X_\ B(.;]H_<_P#,_/\ _P"%#^+_ /GPA_[_ "TG_"A_
M%W>QB_[_ "U^@'_"/VW_ #S'Y"F?\(_;?\\Z7L(=P_XB#F_:/W/_ #/@+_A0
M_B[_ )\(_P#O\M>D>%/#WBO3]/CM-5TTR&)=J313*Q8#H&!(KZU_X1^V[1C]
M*9_PC]M_SS%:0@J;NF>9F'%N/S2DJ>)A%VVT=U^)XCX7NI]&L&AGTVZ+F0L-
M@0_+@ <[O;]:U3K2%MQTF[+>NQ/_ (NO6&\.VS?\LQ2?\(W;?\\Q5.QX4<TK
MQ5E%?C_F>/W-U9W4ADET&:5_[SPQ$_GNIMW-87Q3[3X?DG"# \V")L?FU>P_
M\([;?\\Q2'P[;?\ /,5.AJLWQ/9?C_F>+26^D262VK>&F-N#N$7V>+8#ZXW8
MS45OIFA6:R+%X89%D^\!#'S_ ./5[9_PCMM_SS%-;P[;?\\Q1IU-%G6+V3_/
M_,\3L]+T+3YO.M_#,D<N,!_*0D?^/U-':Z'"X=/"RJV<[A:0@Y]<YZU[+_PC
MMM_SS%'_  CMM_SS%%X@\YQ4M]?O_P SR>34+.:0.^AS,P& QBB)_P#0JL+X
MA2-0%TR\4#T2/_XJO3SX=MO[E)_PCMM_<%*Z)_M2N]TOQ_S/,?\ A)!_T#+S
M_OE/_BJ/^$D51C^S;W'^XG_Q5>F-X=MO^>8I/^$=M_\ GF*7,+^TJW9?C_F>
M-^*+U]:L8H8-/ND99-Q\P* 1@Y_BZ]*\T\:>'/%.L6;V.F:?Y4,F1--)(H9@
M>P&3@&OJT^'K?_GF*/\ A'[<?\LQ3=3W>4TP^:UL/7C744VN][?F?"/_  H_
MQ7_SXQ>_[Q:3_A2'BO\ Y\8_^_JU]V_\(_;?\\Q1_P (_;]HQ7)[.)]?_KYF
MW:/W/_,^$?\ A2/BK_GPC_[^K3H_@;XKD; L(OQE6ONLZ!;]XQ0-!MQTC%'L
MXC_U\S;K&/W/_,^-U_95\?X'_$KM?_ B/_&BOT9&EPX^Z**]M86!\;+CG,FV
M^6/W/_,KT444SXT****8!1110 4444 %%%% !1110 4444 %%%% !1112 3T
MYQ7Y._\ !1*8_$G]O+X2^"E)EM85T^.53SCSKQC+^'EHIK]8CGM_.OR8^-K'
M5/\ @KAX2@RQ6">Q'R\G"V[2?U_6M(;F<]C]7-(A%OIL$8&-J ?I5RH[<;84
M'M4E0:!111[]NM !24OUX^M%.P7$Q0>>]+[TE( I:2EH$%%%% PHHHH ****
M "BBB@ IE/IE( -,IYIE*Y0C4E*U)2+"F&GTPTF C4VG-3:D84VG4VI*$IM.
MIM(I!3*?3*D84444#&TUJ=36J2D)3*?3*"@IM.IM(I!1114C&4444BAE(U+2
M-4C0E%%%(H:U)2M25)2$:FTYJ;0,:W6BANM%(!E%%%26(U)2M24EN/H>E444
M5]/RGQQE4445PGI!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** $;
MI7Y,?'53X7_X*T>"[YOE74)]/(Y_OQM;_P UK]:/:OR:_P""EA;X;?MF_"'X
M@3+MLXOLDC=@PM;WS7!_X#,HJZ>YG4V/UAA_U2_0=*DJOI\HFLX77D,H/Z58
MJ#3I<*^4_P!K+3V^*GQO^#OP<UC5KK2_ WB9-4U#6+:QN'MY-5^RP*T=HTBX
M/EG>S,N>0O4$*1]5UYG\=OV>_"O[06AZ;9>('U+3=0TF[6^TK7-#NS::AITX
M_P"6D$N#M)P."". <9"D-;DO8^?_ (Y?L4C0/@:G@WX065WJ/A^'Q+'KFI^!
MKSQ!-;QZI:B/9)I\=RS%HD8[9,.V-Q)R"%QX;\89/ &O?L=Z%X1\!?#?4M!3
M3/B38:9J_P /M6OYHK@7S[M]N;J21BJRAE E#  -GCM]>:5^QKINA_#S5/"V
MG_%+XH6=QJFJ+J][XDA\2[=7N)EC$0#7'E?<V*BD;>0BY/%2:?\ L5>!--\#
MZ9X<74/$-S):^);;Q9=:U>WZW&HZIJ$+95[J:2-MX( !"A>G&.2=+HCE9P/P
M \*_#O\ 9#^%WBCXD^+/A7_PH!FGBL]1@_X2*X\2>9 &00R;HS)MS)*R[57(
MQD\8KO?C1X@@^.W[+6J>+?A[X_U?0=&DTR[U6'5]$C-I<WD4,,P\G,J!X095
M&6 5L)@$;LU[^/E[XYX/^<UD^+/#-KXT\*ZSH%[)+%9:K9S6,[VY42+')&48
MJ6# $!CC(/..*F^M[#L?G]\:K?3[[_@G?^SK!K.CZAXBTN?4O#<=YI&EH[WE
M_"8V$D$*JRLTCC*J P))7!%>F_\ !.6"">W^)^J>$M,U;PU\)9M8AM?#GAO7
MKMIKS3YH8BMZ'1I9#%F0J=C,2,$G(P:]ON/V9_#%U\-/AWX'>_U8:3X&O]-U
M'3IDFB\^:2RQY(F)C*LIP-P4*3C@BMWPM\%]%\%_%#Q3XVT:\U&RG\3)$=3T
M9)4_LZ6Y0 "[$>S<LQ4!696 8 $J6&:&U87*[W.^_'-+2#_/^>__ ->EJ#4*
M*** "BBB@ HHHH *93Z928 :93S3*DH1J2E:DH+04PT^F&DP$:FTYJ;4C"F?
MK]*>W0^F.>:^>?BI^U)KVA_$C4O ?PR^&6H?%?Q-HUK'>:XL&J0Z=::<D@+1
M(\T@;=,P&X1@#Y2,$X(#M=V&W8^@VXSGBFU\T>+OVN/%EOXL\/\ @[P5\'-3
M\4^-K[P_!XCU'1=1UJVT@Z9!*=@C9Y<B257&"H QQSU"VOBM^TYX[\%_$SP[
MX"\)_"#_ (3CQ+JF@?V]=6G_  D]OI_V-1)Y<D9DDB*R%6*C<&&<\+WHY&Q<
MZZGT;UQ3*Y3X6>)/%?BSP?;ZEXS\&_\ "!Z]))(LNB_VI%J(C4,0K>=$ AW#
MG';/->?_ !V_:DT7X(^*/#'AN70]6US6-?O[*S1[:W=+*U2YG\E9)KDJ54_+
M(5C&68IR%&&&?*]B^96N>U^OY44ISGD$=N:2I-%L-IK4ZFM4L:$IE/IE(H*;
M3J;04@HHHJ1C****3*&4C4M(U2-"4444F4-:DI6I*DI"-3:<U-H&-;K10W6B
MI8#****3*$:DI6I*2W*Z'I5%%%?4K8^.,JBBBO//2"BBBF 4444 %%%% !11
M10 4444 %%%% !1110 4444 '].:_.C_ (+(> 7U3X5>%_$\$6]]'U3RI7 ^
MY#.A4G_OM(A^-?HO7D/[5?PLB^,7P-\6>&'53+?6,B0,_1)@-T3'Z.JG\*<7
MRLB:NAO[(_Q$B^*7[.'@#Q$DWGRW&DP17+9S_I$2^5,/PD1Q^%>P5^:__!'7
MXM.WA_QE\*M5=H-2TBZ.IVEO-D.L3D),FWL$E52?>:OTH_STXIR5F$7=!112
M<]J@L6D9L FCT_*D;)X]N]%FM]Q71XY\?/CU/\)VL]+T;2X]6\07<1N MPS"
M&WBR0'<+RQ9@P !'W6)/0%/@#\?+CXK37>DZWI<>D^(+:'[0!;LQAN(@0K.N
M[D%6905)/W@0>N-#XP?!ZX\;:E:ZYH\EHNL00?9)(;XLD-S"'++EU#%"I9R#
MM/#D8I/@_P#!VX\$ZI<:[K#V9UB6W-G%#8,SPV\)=6?YV52[,R(<[1@(!BOI
M.7 ?4.:_[SMU/A_:YU_;/)R?[/WOI_PYZMGTI>?2F\^PS61XQNM1L/".M7.D
MQ>?JT-C/)9PE<[YA&QC7'?+ #'?-?/0CSR4;GVM2:IP<WTU)+CQ5HMGK$6DS
MZQ80:K+CR[&2Y19WSTPA.X_@*U*_.C_A6;:_C5)[F2^GN_\ 2'NI7+/(6YW,
MQYR?7WK[7^ ^H:KK'PE\.W6L327%Z8I$$\N=\T*RNL,A)Y):(1MD]=V>]>_F
M&4_4:4:O-?6WX7/C,CXFI9UB*E"$;<JO^-K/S/0*6D_&O*OB1^TGX,^%^NKH
M^IRWE[J:[3-!I]OYIMP0"#(20!D$':"6P0<<C/B4J-2M+EIQN?7UL12P\>>K
M*R/5<BEK)\+^*-*\::#::SHMXM]IMTNZ.901T."I! *L",%3R#6K6<HN$G&6
MZ-83C4BI1>C%HHHJ2PIE*V?H,9-9>C^)M'\0-.NE:K8ZF;=MDPL[E)3&>>&V
MDX/!Z^E4HRDM%HC-S2:5]7T-(FF^GY4I.T$_K7C_ ,9_VCM*^$5]!I4>F7&O
MZS(HEDLX9!$D$9S@R.0<$X.  > 2<97-T:%3$3Y*:N9XC%4L)3=6O*T4>O-V
MI*XGX3_%C2?BYX=.IZ='+:7$+B*[L;@ 2P2$!N<=5(/RL.H'J"!VM9U*<J4G
M":LT;T:T*]-5*;NGLQ:8:?3.K8QFLF;"-25R_CKXF>'?AU;VTFN7_P!G>X)\
MB"&-YII-OWB$0$[1D9.,#(J;P3\0- ^(NE-J/A[48]1MU?RY JE)(G_NNC ,
MI^H%;?5ZJA[5P?+WZ',L50=7V"FN==+Z_<=#G'M7Q[K7B3Q=^RW^T-\3]?D^
M&7BKXB>$?'GV/4+*\\&Z?]MN;6[@@$+P7$8(*HP&X/T&< ,2VW["7G'O3!G/
ML#QGIUK!2WL=4E=GQ)^U%?:5\3O"7A*]UWX%_$Z3XGW6C"]TO6O!NGL9O#]Z
MX.()KQ'3;MDY(96 5MV W3*U#]F74?CA\;OA9:?'#PM>>)H;/X<;=8U"-[B.
MV755N%^1KFW9%,FUG.T-@\D CFON_P"\A(Z^O4__ *Z3^(^F<T^?302A?<\D
M\=_"/QI)I_A#2?AA\2/^%9:%H, M)K#^PH-7^UPIY:Q1^9</NCV*A&X$D[LG
MH*Y7]L[POK/BKPK\.X=$TF^UB:U\?:+=SII]N\S10)*Q>5PH.U%ZEB,#VKZ%
MIGL:RYF7RJU@XZC&#R,44?CD^]'H.]2:(;36IU-:I*0E,I],I%!3:=3:"D%%
M%%0QC#0>^>,=<\8H_BZ9[?7VKXQ^,">(/B-X\UB2XO+B&RTV^EM+.TCE*)$L
M;[-X _B?&_=R?F Z  >OEN72S&;A%VL?.YYGE'(J$:U97N[(^RZ1NP[UYC^S
MSX@U?7/ ]S;ZW,]W=Z7?/8+=2DEYD$<;J6/<CS-F>IV<Y.36;^UK\4-;^$7P
M*U[7O#?DIX@=[?3["XN-OEV\UQ,D*S-N!4A"^[!&,J,\9KAQ&'EAZTJ$GJCU
ML%C(8W#PQ-->[)7/7^O3FBOFO2_V=_B-\+O#GBK5O#GQ?\7>-/%EYX?NH;>Q
M\3W23V?]IL 8KB!6&+<*P8!/F7YER<+BO)?@7XKATKP'\3;'4_'GQ2C^+5IX
M4N;G4/#7CV_8?8I$B9FN[!-@ C\P?*R,<*5Z9&<?9\U[,ZG4M:Z/NQO7MZTG
M7IS7P3^Q#87WC[4/#/B'5_$W[0B:C9Z:FIW4_BZ_;_A%]1<J%9(6;+3(2^]0
M2"0N>U?8NF_$31OB1X=UM_AUXL\.^(=4MX&CBGM;Z.^M[6X9&\KSQ"Y.W<,D
M9!(!Q4SI\KL73J<RUT.P:DZ<G@>M?(7P:\9>.KKX5_M)_P#"5>,+O7_$'A_5
M-3L[?4X ;58/)L4V?9XT;$(!&1M.<DDDL=U>5?L9_$^_\1_%3X<V7A#XF^-?
MB1!>Z%+<>/[/Q1/-<VFCW(A0Q""2:)2,SY0!2^0OWCUJO8O5D^VV1^AYHH/K
MZC/-%<AU(91110QB-24K4E);E=#TJBBBOJ5L?'&51117GGI!1113 **** "B
MBB@ HHHH **** "BBB@ HHHH **** "H;N$7%N\;#*L,?Y_6IJ0C-(#\@/VE
MM)U']B/]M[0/BSI-K,/#.L71GO(;485]PV7D/]TET;S5W'[YS_!7Z/\ PP_:
MO^&?QD\</X3\'^(H=>U:/2(]:E:T7,20N4 0L<?O!YB;DZKG# '(KYX_X*B>
M _'_ ,1OAU9:/X.\,:;KEB91<7\TDN;^-E.4$",H7URP8L0=H4<U^?W_  3^
M\3:E\&_VR_!]KJ]M=:0^HR2:-=VUU$T4G[Y"(U*L ?\ 7+$?PK>W,KG/S<KL
M?O1]>:#]<4BD,JD="./2H=0\_P"QS?92%GVD*6&1G_/^>QYIS5.+DU>QT+6Q
MXA\6_P!JS2/AOXF;0[/1;GQ'>VY O&AE6**$D!@BL0=[@8)& !DC.0<>G^ O
MB+HOQ(\.VNK:/<%X9PVZWEPLL+ X9'7/!!_ ]1P0:^5/%G@V32?%FM2ZEINH
M7GV^^EO8[JTLI+C=YC;V5A&K%&#$@9 4@#!X('L'[.'@FZ\-V>H3W,!M3>7#
MW)MS@F'*1HJ9'&=L08@$@%B,UW8ZOE\,'0J82:E.;6E]?.ZZ6/CLKQF:8C-<
M1A<71<:<+V;6GE9];GN72BE-)7)YGV'0\U^.'QB3X1Z#:R6]B=6UG4':*SLR
MY13M +NY /RKE>!R2P'')'$? G]I;4?B!XB3P_XHT>WTS4[I7>SN+$MY,Q5"
MS1E6)(;:K,.2"%(X(R?0/C!\+_\ A8UCI\UI/#;:QIK2-;/<J3%(KJ \3XY
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M,HHHI,H1J2E:DI+<KH>E4445]2MCXXRJ***\\](****8!1110 4444 %%%%
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M&II1E>R;=DK=7Y'HWB[]L71?#_BR73-/\/7VMV%O*T-SJ4$J1KN#88Q(1^\
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MA0%MN6;  &X8[SX7_$2S^)OA.'6+6![.4.T%S9R'+6\R@$IGOPP8'N&4X!)
MS_BUX"N_&NEV4NF211ZMILS30)<,1%,K(4>-B < @@[L'!4=B:^@EF=3%5H8
M/,5:*>NFNFUSXJ/#]#+Z%?-,DO*K--QN]%?LCSCX9_M+WNM^.K?PMXFTRTM9
MKUREI?6&X1B0#(1T=CC." P/4@8P<U[]V ZC'^17S9X%_9[UZZ^).F^)/$%I
M!I5CILOVF.W%PLTTTRYV#*Y"J#\V<DD8&!DX^DSWYSS^?O7F9Q#"PKI85JWE
ML?1<-3S"M@T\Q34_/<Q_$?A/0?$\$8UW1M-U>*W!9/[2M8YQ'Q\Q&\$#WX'3
MFN>\+?%SP!K&K)X<T'7M-DNH1Y<-K; I&P'01' 5_HI/0U/\8M#U'Q%\,]>T
M[2][7D\*@11GYY4#JTD:^I>,.H'^U7R(WA72I'>+1;V-=;@(DC6-L2V3J01+
M(N T00_,2V.G<D9[,MRY9AAI.I4?N]+Z+SL>1GV?O(\92C3H<W/O)+SVOY>9
M]R7MG;WUM/;WD,=Q:3(4EAF0,CJ>""&&"/K7SUXY_9=^'=Y;:E)I%ZVE:K)&
MYM8!? V_FX^52K G!.,C/T'%9?C?XP:SXVO)+;2)'T_2E.T21C:\GO[?S^E<
MC;^%9]2D./-NI2=Q9F9N?<D_6GA,NQ5%<[J<NI\MG/'."G5]A2H>U:ZO]#V/
M]EWQY:Z]\-X='G6&QU30#]BN8% C&WG9)CU(!!/<J3WKJ_B!\5-/\*VKP6LJ
MW6I/\L<2G)R>Y]J\ T?X/RV%[<7<$ILYI_OLLS9/Y?YSFNGTWX<VMFVZ:ZEF
M<]2N <?4\UA4PF%59U)SNNQR5N,\PJ818?"4.5VMS-_DCD-:DU/Q%=O<ZE>R
MRR.<[1(0J^P [5S5YX?B1RV,M_>(R:]MC\-Z;"N?LN__ 'V)KE/B+I]E8Z,)
M[>!()O-51M[@YR/TKW\/B:/-R4XV/RK$8?%^]6KU.:_G<\KN($@'UZYKE/$%
MNDROP#[8X/M71ZC=98C.?2N7U-][$9KTIW,\.G?4^A/V.?B?<WD=_P"!]0E:
M8649NM.9VR1%NP\7/4 L"/9B.U?4'/U]_6OS?^&'C5?AU\3M!U^7(M(9_*N]
MO>!QM?\ ('=_P&OT;M;B.\MXIX9%GAE4.DD9RKJ>A!]#7Y[FV'5&OSQ5E(_I
MO@[,7C,O5*I*\H.WR'-UHHZ\CD45X3[GWZ[C****3*$:DI6I*2W*Z'I5%%%?
M4K8^.,JBBBO//2"BBBF 4444 %%%% !1110 4444@$_GC.*\>C^-'B;Q9KWB
M%/A_X+L?%&@^';UM+OM4OM=_L][FYCQY\-E&()5E\O(0F62%3("H. 6KV$].
MN,<_I7S7\-?%=U^SE9^,O"/B/PEXKU)XM<U'6=&O/#N@W6IPZK;7=S+<J@E@
MC9()D=WB99VC PK9VMN%(E[GIUK\;-&;XA>)_#]U?Z#9Z;H4-D)M2;Q!:F1;
MRYDDC%K-;!M\#9$6TOQ(9L+RISK3?&3X?VOAF?Q'-XY\-P^'H+HV,NK2:O;K
M:1W .#"TQ?8)!_=)S[5\M_M(?#OQ#XS^(7Q$EMO"VL7VGZG8>"XD:WLI7$OE
M:S+)<*KH#EHT;<^T_(I!/K7K7Q4T^;P?\>/AUXWNM"U'5_!NE:/J6E"/0]+F
MU&32[R8P&*<6MNCR[&BAEAW1H=NX!MJN:!79Z]HWCKPUXD9$TGQ!I6JL]E'J
M2K9WL4Q-I(6\NXPK']TQ1MK_ '3M."<5Q&G_ +0OA[4/B!K>C?;M,3PUIOAN
MT\2GQ5_:D;6;PS2SQDEON!%$!;S-Y!#=L<^6VNJKX3^.&J^,;7P-XGMO#WBK
MPE%9Z;!I_ANY,IO8[ZZD=;F*.,_9&F^TQRAKCRU.]B[(RL!X=X+\/_$CX9^"
M-%N+'P3K*:KJ'P\T+3H)I_#LVH?V=/;:A+)=2/;A3BXMXIEFBCEP9'C4)O(*
MEV%<^T?$_P"T!X#\._"/6_B1#XDTW7?">E022R7NBW\%PDSH,>3&^\1M*S84
M(6&68#O67#^TAX5U_4/ <7A76O#OB*#Q1<RQL\?B.SCFM88X'E>5(MY:X975
M(WCC.4+ECP#7@7AOP'XG\2>$?VIM)MK7Q9K,_BS3([C1=2\4Z*NF3:JS::;<
MY46\$:.)8BA1HT<+Y;,/F#'LO$EU>?$A?@%>:+X>\2"/1-<DBU*/4M OK&2T
M(T6Z0EUGB0[-\BH) "A8[0Q-%A7/=]!^+O@3Q1KXT/1O&GAW5M;:W6\&FV.J
MV\UR8&1767RU8ML*NA#8P0RG."*AL_C9\/-2\7MX4M/'GAFZ\4K-);MH<.L6
M[WPE0$O'Y ??N7:V5QD;3GH:^9? GPOUO3?@Y^R?:Q^&]4TO5-'U+&IB&P>*
MXTZ*;3[Q9WE&S,6YW3<S@ LRYY(K%^!=Y=KXG^"'AWQ7:W'@^'P8U[8Z3=ZA
MHVKVMSKMS);RQ+%,T]E':PLT8>9DCN9R\D:[2>M'*-29]S^OMP:^4]2UQKGX
MS>)YD?A;KR/^^ $_]EKZL;T'^>:^&[BZ.B?%CQ3;/(7/]J7#9/<&5CC]:_+^
M/9RA@:=NDK_@?6</Q4J\[]C5\3>)RLUZSO\ O/,8=?0XKP[Q9X@>YN)/GW<U
MU7Q4OI=%UZ;D_9[Q?/B;L?[P_ _SKQ[5=6$DKG=FOS7"\V(BJK=]#Z:K^Z]Q
M"7UT7SDU@W<QW$]JFFO@>]9UQ-NSS7M4XG VC6\"^9<>.-&6//R3B0X_NJ"3
M^E>K>)KH&-L^F37&?!C33)J>J:@R92" 1*W^TQR0/P7]:V_%5X%=ER3_ /KK
MQ,=)5L9&*^RO^">IADXT;GO7[,/C"?4=)30)XE:WMKAE24-SM8!]N,#N3R>>
M?:OJ37/AYIOB#0WLS"@CEC,<D;@LLBL,$-S7R#^R;:,]T9MI_>7)(]P%5?Y@
MU]TVXQ"@]J_;\MRG"?5*<Y4_>DD[];^3W7R/@<=BJD\1.-_=[=#R7PE^SSIV
MCZPEYJFHWVK6]O(LMK8W$RM#&P;<"<1J[D$ C>S<]<\5Z]SU[TM)7UTJM6HH
MJK-RMW/G<-@<-@^98:FH)N[LK78=<#L?Q_3ZXKYW\;?ME:-X=\23:9I'A^\\
M0VMO*89]0AG6.,L#AC$"#Y@'(R=H)!P<8-?1!KY/U7]GO7_#-\VGZ;X=D\0Z
M:K_Z+>V]U;H5CS\HF65T(8#&2@8'&>^T>QE5'"UY2^LM+M=V1\WQ'C<QP-*$
M\OI.;;ULKO\ KN?1OP_\?:3\2O"]MKFC.[6TI*/#, LL$@^]&XR<,/J0<@C@
MUT=<!\&?AS)\-_"=Q:74D9OKZ[:^N4@8M%&Y1$"(2!D!8T&<#)R<#.!W_0X)
MKS,3&%.K*-)^Z?18&I6J8:$L0K3:U0M,I],R#R.17,=VAS/C#X<>'O':VYUJ
MP:>:WXBN;>XEMIT4]5$L3*^#U*YQ6AX=\-Z;X5TN+3M*LTLK2/)V+EBS'JS,
M22S'NQ.3U//-:IIM:>WJN'LW)\O8PCA:$:KKQ@N=];:_>>5?%?\ 9O\ !'Q0
MT?64N?#^GVVLWT#*FL0VJ+<QR$?*Y<#<2"!U/(!%?,G[%_QJ3X2W7B?X9>.[
MI=*.E3R36[W#'9&P?;-$/8MAUQUW,>XK[HOITM;2:>0X2-"Y;V R:^'?">CV
M_P 2_&.O>-M3LX6EOKDF%5C &U<*I/KA0H_ TZ=/VCLS]7X;_P"%+ 8G"XZ3
M=!<K6NJE?3EOIJKW/KWPK\4_"OCB1HM#UVSU"=1S%'( _N=IYKI_3)P>M?*&
MH?#O39IHKJVA^P7T1W17=HQBE0^H(KI--^('CS1-,FLTU&TU:3;BWNK^ B6(
M^K;" _Z'WK6>'EL>?B^&X-\V J:=I;_>M'^!U_QY\>&PLX/"FFSE-8U5?WKQ
MMAK:VZ._L6&57ZD]JXG1=+6ULHH8(UC@C0(BJ, *!P/I6/X=\-3V<U]J^M7K
M:EK-X^^>XD !8]%4#LH'0#CGM71V[.QYB8H!ZD5UTH>S5CZ.AA:>7X=8:B[M
M:M]WY>2Z?>8OC/P+#XHT_9,/+FC^:*>/[\;=B/\ /:JGAOXO?$CP.J:;?Z7'
MXJM(_ECN&EV38''+8^;ZD9_IURWR>7Y;%@I&!N'2LZ1H(Y"KG(]N!6M2$9[G
M7&I&M2]ABJ2J16R?3T:LU]Y6U[XX_$#6;5HM,T:P\.!AAIIYC<R#Z* !^>:\
M?U[0?$>O73W6K^+]7N;C[W[J<Q*OIM .!SCIZ5Z]J(B\ES$5X&2!CI7GNO:D
MD$<SR$QJHSN/0#UK@J4H16I[V4TJ%%M86C&-_*[^]W?XGKW[,?CS4]5L]3\,
MZSJ#ZK=Z:$EMKN;_ %KPOD;7/\14K][J0P]*]T]<\&OD#]BG49?%7Q(\<ZO&
MI73[6TM[2,GH2SNW\D_6OH[Q;\7?"7@CQ%HN@ZSJ\=KJ^L3""SLP"TCEC@$X
M!VKNXRV 3Q7CPDJBO$_,^)\ Z.<UL/AH:Z-I+:\4WIY;G8E?6BD5MR@@@@^E
M+5;:'QFNS&;>O?/J,U\RZI\#];\+WCZ?IGAY]=TQ686ES;7-O&4BS\BRK*Z$
M,HP,H&!"YXSM'TW36[5ZF S*METI2I).^]_(^=SK(,)GU.-/%7]UW33LSB?A
M+X!?X>^&Y[:X>-KZ^NFO;H0D^4CE$0(A(&0J1HN<#)!.!G [+_\ 53O;\/K7
MQ=\9F\1?$OQQK2W5[<0Z=IM[-9VMBDC)'&L3%=Y4'[S$;B3GA@!@ "M\+A*F
M<8B<Y.SW9AF.8X7A?!4XV]U>ZO\ @L^S_P#]=,KQ+]F'7]=GL=<T#6;J74$T
ML6\EK=7#EY LOF Q%CR0IBR,Y(#XS@#&U^TC-J8^'(M=/EDMX+Z]BM+Z:,D%
M8'##&1T#/Y:'V?'>L)9?.&-^IS=FVE]YV4LZI5<K_M2$7RV;MZ;GH&F^)M'U
MNZGM=/U:QO[F#_70VURDCQ\X^8*21SQS7B/[1GC62ZOK;PO:2X1OWUT4/;L"
M??\ I[UX;;^";SP'-%K^E7#66HV+"6WEC.,OG 4^H8G:0<Y#$=#S<NO$<GBS
MQ1J6LRL6^U3LR>R9.T?E@_C7TE/)?J>(BY.ZM<_(<\XSAFF62HT%:3=OEY>9
MV'AC11?316Z?*H&7;T'^)KTFWMH;&$16ZA$'YGWK#\*V)TS2D,@ N)@'<^F>
M@_SZUJF?\_2N7&595I\D7[J/A<MP\</34VO>98+=*K7%Y';PO+(<(!FJUUJD
M-GD22;6QG:.2/?%7=:TZWF^#^I>)OG M+C<W!+/"H"G:HZG<PY]C7F.RTCN>
M_1I5,1)QI=+M^B.1UKX@6NBVK75UY<$ .!O)W$]@ .I^E>1>./C=I?B22.SA
M\RVMXR2&D(Q(W\QC%=9^TEX>TCP#XR^'\GB*UO9O#EUI^_4+&PF E>="?-VL
MQQG+(",C@'&"<UYM\<-*\%R?"3PIXR\/>';GP5J&K7EQ NCR:E+=I/;1_>N%
M:0!@-Y"]ASW S7KX*"I*-2IK)_@77RJI4C.,Y)./37R\K=45+G4!(F5(.[!&
MTY&/45C7LX8]>E<5X(\0/)Y]@[[E4;XP?X?4?RXK;GOOESG KW.:ZN?/_572
MERD6I2!MWZUVWPF_:>\3_!^6VT^3&L^&@PWV$Q)>%<C/DOU4^QXKSFZO P..
M]8EY^\SWKCKTJ=:/+-7/?RW$XC 5%4HR:9^M>AZY9>)M%L=6TV=+G3[V%9X)
MDZ,K $?C_DU>KY"_83^*CSVVH> M0FW&W4WVG9_N$_O8P/9B&'^\U?7GXY]_
M\^V*_.L50>&J.FS^C<KQL<QPL,0M]GZC:***Y&>P(U)2M24EN5T/2J***^I6
MQ\<95%%%>>>D%%%%, HHHH **** "BBB@ HHHH 0_P!,_P"?6LK6_%&E>&[K
M2;?4KV.RFU:\^P60D&//G\J241@@<'9%(>?[N,Y(%:U?+/[6FC7_ ,0/B9X
MT/19)/[:\,Z?J7CFTCA<Y-W:&W2U5@",J[2R)@GD;O>FNQ+/HVS\7:/J7BK5
M/#=M?QSZYID%O=7EFH)>&*8R")B<8^;R9. <_+S@$9U_J1[D?_7SC_)K\_\
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M-O9I96U];VTDZ+%(JG?,]RWF=]L+ Y1"#E"Y]QM\V<]^_P"'U_S[=:\V\/\
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M,%I/7T/M36M8CL;(S2W,<:QGE_,&,5X3\5/B&_B2-;6T!CME_P!:YX,N.G_
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M</B:3I8BFIQ[-)K\3D/&'B34/%&MWFJ:I=RW^H74ADFN+A]S.Q]3V., 8X
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M#/'I7ALDVYB2WS>G?C^M?<GP?OI/VCOBQ/KGC&>WSH,"26F@QAECW9P7PQ/
M8#()))*@\#%<E^UY^RCJ-OK%YXX\%6#7=E<%I]3TNT4^9%)R6FC0=5.<LHZ'
MD<'CZ&&+]G-4:S]X_/L5D:E2>+P4?<3VW=NY\BF8=''S5$\W0+@9]:KM(R[A
MTV]5/\/K^M1R*S,&)QZ8KT+GS'+RZ$[,!G)J)IO[HXIFT%AR3_6MKPOX-UOQ
MOJBZ?X?TF[U>];GRK2(N5'J2.%'N>*3DHZR=C6,)5&E%-OM8R1/TXS]*#./3
MFO;X?V*_BY<6Z2_\(];INYV2:E"&'U&ZM+2OV$?BG?W0^TV^EZ;&PP6GOE?'
MX(&S7,\71_F1Z4<KQLGI1E]Q\]Y:1\ ;I/X5ZDGL ._6OUN^"'A67P1\(O"6
MB7"[+FTT^)9E/59"-S@^X8FO&_@I^P_HGP[U:UUSQ+J \1ZM;,)(+=$*6D3C
MHVTDER#@C/ QT-?3A.3G^=?.9EBX5K0ALC]%X=RFM@>:MB%:35K=AC=:*&ZT
M5X+/MD,HHHI,H1J2E:DI+<KH>E4445]2MCXXYG(XHR*;17CW/<L.R*,BFT4P
ML.R*,BFT4!8=D49%-HH"P[(HR*;10%AV11D4VB@+#LBC(IM% 6'9%&13:* L
M.R*,BFT4!8=D49%-HH"P[(HR*;10%AV11D4VB@+#LBC(IM% 6'9%&13:* L.
MR*,BFT4!8=D49%-HH"P[(HR*;10%AV11D4VB@+#LBC(IM% 6'9%&13:* L.R
M*,BFT4!8=D49%-HH"QX=\>/V2_"_QQU1-8FNKC1-<5!$]Y:*K"=!T#J1SCH"
M"#^E<U\-_P!@GP!X,U!;_6);KQ9=1G,<=^%6W4_]<U'S?\")'M7TM16/L:;E
MS6U/>AGV9T\,L)"O)06EK].U][#+6V@L;>."WB2&&,!41$ 50!@  < >W:I<
MBFT5J>#N[L7\:\Q^-O[/?A3XY:&UMK%FMOJ<:_Z+JMN@%Q W;!_B7U4\?SKT
MVCWSC^=*24U:6QT8?$UL)45:A-QDNJ/Q_P#B[\%/$WP/\3'2]>MBUK(Q^R:C
M I,%RF>"I['D94\C/T)Y_3+@*1\S'G'3I7[#>+?!NB>.]%FTCQ!IEOJNFS??
MM[A PS_>'H1ZC!KYTU+_ ()[^ [C4OM%AJNM:9;;MWV6.:.15]E9T+?F37CR
MP,HO]V]#]WR?Q$P[HJ&8IJ2ZI73_ ,F?&_A+P5J'Q*\1:?X=TF SWE\_E_*"
M1&G\4C>BJ.?R'4BOU:\/Z/!X=T+3]+MO^/:SMX[>/_=10H_0"N5^%_P4\)_"
M&P>#P_I_E7,JA9KVX8RW$O/\3GG'7@8'M7=MG.37?1H^S3ON?GW%O$JX@Q$5
M2BU3A>U]VWU8E%%%=!\(AM-:G4UJEC0E,I],I%!3:=3:"D(<\XI.%Z 9ZC@<
M?Y_K3J/S_"IO9W$U<^3?@!97>O?M)>-?$%MITVDZ;;_:%F@E&PHSR#;&Z]F)
M5G([$?2OJ_IQU[5%#;1022O%#'&TS!Y610-[!0N6XY. !SV ':I?4_SKHQ-?
MV\DSCP6$^JTW!N[;;/'/BM^RKX ^+#37=YIITG69 3_:>EGR9"_]YQ]U^V21
MFOFO6/\ @G/XDM\-I7B_3;L$YV7D$D3?]]+NR?PK[TKY1_;Z_:R\4?LL^'?"
MM]X4T_1]0N=4O)8)UUB"65%14# KY<D9!R?6M:&+Q$+0A(X<9D^!Q'[RK"S[
MK0Y+P'_P3L:.^2Y\:>)8YH$.?L>CQD%_8R../P7UKZZ\%^ _#_P[T9-*\.:3
M;:79)U2W7YG/]YF.2Q]SFOSB_9[_ ."GWQ.^*WQK\'^$=:T'PC;:5J]^EM<2
MV-E=+,B$'[C-<L <XZJ:_3I6W*#WQ^5+%5Z\M)R-<OR_!X6-\/#7N]P?D>M)
M2MCC_/\ GI3<CH*\X]WY U-I6[4GTY^E*U@T&MUHH/4\T>O:D5UL,HHY].:*
MG4H1J2ANWYT4NI70]*HHHKZE;'QQRF[I]*7--#<"C=7B'OV'9HS3=U&ZF*P[
M-&:;NHW4!8=FC--W4;J L.S1FF[J-U 6'9HS3=U&Z@+#LT9INZC=0%AV:,TW
M=1NH"P[-&:;NHW4!8=FC--W4;J L.S1FF[J-U 6'9HS3=U&Z@+#LT9INZC=0
M%AV:,TW=1NH"P[-&:;NHW4!8=FC--W4;J L.S1FF[J-U 6'9HS3=U&Z@+#LT
M9INZC=0%AV:,TW=1NH"P[-&:;NHW4!8=FC--W4;J L.S1FF[J-U 6'9HS3=U
M&Z@+#LT4W=1NH&.S1DTW=1NH%;N+]:*3=1NH'86BDW4;J $IK4M(U2-"4RGT
MRD4%-IU-H*04445(QA[T=J**3V*&U^;_ /P6/_Y%'X?_ /80N/\ T6*_1_O7
MYP?\%C_^11^'W_80N/\ T6*UH?Q$<^(_AL^&_P!C?_DY_P"'&>/^)M'S^!K]
M8[/XL_&?QU\2O'6@>"H/!,5AX:O%M@^MI=B1@RG!S&Y!^Z<].HK\G/V.?E_:
M?^&_7C5X_P"1K],/AW\(S\4/CM\9G_X3#Q3X6^Q:K"I7PWJ7V03%E?\ UGRG
M=C;QZ9/K4Y@WSPL>YP_3H.AB:E:WNI6NKZ\R6WHSU7Q#\5/B'\/KCX9:5XF@
M\.2ZMXCUI]/U Z6EPT"P]4,)=@P?'4L&&<UQ/B3X_?%?^W_B9/H-GX/;PYX*
MG(N4U,7,=U/$$+D(5?83A2.<#..#71_M&VAT_P =? >U,TUP(/$"1^=</N>3
M"*-S'NQQR?4UXG=>$?A%X@^)GQMN/B3>V=C>VM_G3Y)-1:WG \H[C%$KCS2#
MMQ\K9.!CG!\FI*2>C_JQ]?E^%PE2DJU2G>\;Z*__ "\MM==//0]E^(G[1OBJ
M'X;_  QUSPGI6FVNI>-;R"U%OK2R/#"TJ\',;*<;L?-CE><<UK?#OXR^-K/X
MM+\//B+IFBIJ=WI[:C::CX>EE:!D4D,KI(=R_P 7S' RN,<YKY[\0#7_ !M\
M"OV?X?$=_J$&H7_B:."/4%DV7?D-(PBE5\9#A-N#R>%.37HGPA\,I\*OVAO$
M7A3Q==7FM:YK5@7\/>*=6N7GN)K09W6VYFX=2,_*.=I/ *BI525S:KE^$IX>
M<;)R2GHM])V33\ENNQTUO\;/BI\5[S6M2^%V@>'G\*:7</:I=:_+,)=2D3[Q
M@\LA57H 7XY'/4!FJ_M?'_A3EGXDT_0EA\27&L#P_)I5]/B*TO>2?,D &4"@
M'@ \XXP36+^R[\5_"OPB^&.I^#_&6MV?AW7O#=_=1W5K?R^7+*I<NKHK8,FX
M$8*@DC;QR,Y7PAT7P?JOP=\7ZO\ $Q(-)\*>-O$T][8)J;_9_E<YB=6R/+)*
M,0V<87/0T^:32:>YG/"X:E.:J4+4X2BHVO>2>_KI[Q[-X7\0?%32-!\3W?CF
MP\,!K.P:YL+G0I)C%)($<F-UD.[ VKDYP0W'2O.Y/VG/%5_\//A@VF:7H\OC
M/QP\R0F\,D6G6YC?!+#<7;.5P V3^0KEOAOX@N-!\3>/O 7A[QB_CWP#;>&9
MKVUO7F%S_9LF"BP>>O# C/&<#;@ 8-7? ^C_  Q\2_LL_#G1_B+J5GI(GBFD
MTZZN+H6LD,B2/EHY"0!C</O'!)'!XH<G+1"^IX>B^:M#FNX[)[.$GM?H[-KR
M['T)\+[SQ]=:9>+X_LM&MM1CGVP2Z')(T$\116WXD.X'<67!_NYZ$5VM?.G[
M*'C#6-0UCQSX9G\2OXX\.:!<P1Z5XBD.\S*Z$M$91Q(4P!GGKUP5 ^BE_P 1
M6].7,DT?+YCAWA<3*F[=-KVU5^NOWGI=%%%?6K8_/#D-U&ZF9-&37A'T;0_=
M1NIF31DT"L/W4;J9DT9- 6'[J-U,R:,F@+#]U&ZF9-&30%A^ZC=3,FC)H"P_
M=1NIF31DT!8?NHW4S)HR: L/W4;J9DT9- 6'[J-U,R:,F@+#]U&ZF9-&30%A
M^ZC=3,FC)H"P_=1NIF31DT!8?NHW4S)HR: L/W4;J9DT9- 6'[J-U,R:,F@+
M#]U&ZF9-&30%A^ZC=3,FC)H"P_=1NIF31DT!8?NHW4S)HR: L/W4;J9DT9-
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M1DT447 ,FC)HHHN 9-&3111< R:,FBBBX!DT9-%%%P#)HR:**+@&31DT447
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MOGKZ'U ^BF9HS3N ^BF9HS1<!]%,S1FBX#Z*9FC-%P'T4S-&:+@/HIF:,T7
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MF^'<$+,R^*M*O9#SYA26!C^"[Z]E12221X<I2D[MGJ&K?M<W,FY;?2;<+_M
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M,^EBS-N,6GVH31>=Y) QMS_=X(*D<$5V?BI/AZWB[X+?\*L&C?\ "9KJ=O\
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M[C2M;TNSUG2[D!9['4+=)X)0#N =&!!&0#R#R!Q7Q(GP2^'8_P""C$GAO_A
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MP [ IPR*02Q!ZX&,>GI2F>:.\$<JH)02HCV[F ].G'X56BDFMX05G:.+GY&
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M_1E!"A2$'.<U]KY';K_G_/YUYEX\_9M^&WQ,UPZSXA\+P7NID -<1S2V[28
M W^4Z[\  9;/ QTK&5"*V_K\#V:'$4Y5>;$125GLF[\UF_MKJELTEV/FZ;X7
M:?\ '?X2^!-6\&>#8I+?PC<W6GWGA"]U$Q"Y!*F54ND(R^_#ASM!W$GT/:?#
M']GP:?HWC'4%^$UOX#UR;29K'38U\1OJ,LS21N'!+.8U!.S#<$9;IFOI;PUX
M9TCP=HMOI&AZ?!I>F6X(AM;6,(B DD\#N222>Y)/4FM3(JXTE>[.*OGU>471
MI-J%VU=RO9N^OO6?7=-^9\P^*/@WXQU#]D/PUX*M](,GB:S:S\ZQ^TQ#8$F#
M-ER^PX'/#?2OIV'*PQJ1R% I<BC(K6,%';M8\?$XRIBH\L[?%*6G>5K_ )#M
MU&[V!^M-R*,BM#S["M)M4L>BC/-<UJ&I7%_:9A=D0X(5<C\R.?\ ]5=)D?UJ
MK'IMK'(76+G/?I^7XUY&88>OBHQA2GRKJ:4Y1CJT<_8:'=72JTF86^_N9<<\
M]!G/7!]*KW6BW#2,L:-&IP' 4!<=R3WZ=A79;AVI=_U'X\5YTN'\*TE=IKJ6
MJLCS^33LRA1&GE@?PD\XQWSWIALVVGY/*A5MIV?."3VY/!KOVCC*D>6N#U&!
MS]:@FTVWG55*E O $9*_RKSY\.-*\*A<:RZG",A=<NQ1%8!05R1C\13IG,GD
MSF<C#9 RV=OK_P#6YKM&T>U^7:AC4<E4P ?KQ^=1G0;;=U?;GCGD?0^E<4L@
MQ2=DT7[6)R\ERI5/,C7[NW:&ZY[=,9_&F1Q64DR1W28FD7!\M@0".Y^7GC''
M2NG_ .$?B:0N7Y(XVH,@_6FIX9MVSYKY.<C8H 'U!SFE3R7&0E;E7S!U(V,:
MX9(_W**R(B[ML9QNSZC\*KV,,<SS><B,2>/,VM@'L!76+I,&TAR\@.1C=M S
MZ8JW%''!&J(N%4 #_P#6:ZXY#7JN]>27H3[6*V.(6SN(YG"1R);G. JE&;H,
M XZ'TI$FD_>"5,PEC\LG.3P<>HZ<_45W,B),NV1=_?G_ #Q52XTN"XZ;HN1G
MRSC.#GG_ !ZUM5R&M%WHSO;N)548]GJ]AY)7[*L9/&]2JC(YXR<\?2GA=-DA
M$B-* _1F7=CCTY_E4MWX;$SX215BYSN4D\_B ?J:8OAMHX&@4H8SQNR1QQCC
M!YZ]ZSG1S",>6=&,K?UY G#N9E[;6L05$YW'YF9=I8GU 'T]*C%BZ^7!$[K(
MQ(5D("EL'OGCZ8K3?PO)*Y)D1!N!'5OJ,<?UK2CT=%EB>23?Y9W 8ZD=,_3V
MKCAE>(KU$W344WK9_P#!+<XVT.=;3KKY%5=HC(.3%ROKSU]>?>B-[RWN&$4[
M85OFVR[F_F1_^KI7:%LGVZ>],:.-D9&C4HW5<#!KVGDCC_#K-&7M%U1R$.J7
MRW0C:1O*QC#OG^9SW]?H*?>7%QND/F;DR"NY]V.QQDGTZ5U2V\4<8C6-5C'.
MT#BI%5%&U5 7N,#'\JF635Y_%B&_O#VL5LCE+71;MK>:)XI%R2%8$ \CK]X&
MK\>A3SHT4Y6-/[T;?R&./_UUNY_SUHR*ZJ60X2#4I7D_,3JR>QS]QX5$C!59
M1'C =RS,![C/7\:JW/A>24 ;<A>>6&#[#_/YUU612[AZUI4R7"3Z- JTNK.,
MDT6XWF0[UA!SQPOL#T]ZKK930HY+[(,9VJS1J3W'49[5W>X?YYIK;77##(].
M,?E7!+AZC]B;0_;,XRP\_P YC*J^4X^5F)QCVW'Z9Q3Y+*YN(RHW.C-U 9L
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M (0T_P#/Y_Y"_P#KT?\ "&G_ )_/_(7_ ->BBCZM2_E#ZW6_F#_A#3_S^?\
MD+_Z]'_"&G_G\_\ (7_UZ**/JU+^4/K=;^8/^$-/_/Y_Y"_^O1_PAI_Y_/\
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MO_KT?\(:?^?S_P A?_7HHI?5J7\H?6ZW\P?\(:?^?S_R%_\ 7H_X0T_\_O\
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M_P (6W_/[_Y"_P#KTG_"&-_S^_\ D+_Z]%%)X>DMD+ZU6_F%_P"$+;_G]_\
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,!1117=RKL>7S,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img207175068_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img207175068_4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )4 M0# 2(  A$! Q$!_\0
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M2\[4?^?6U_\  EO_ (W1YVH_\^MK_P"!+?\ QNKM% %+SM1_Y];7_P "6_\
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MT>=J/_/K:_\ @2W_ ,;J[10!2\[4?^?6U_\  EO_ (W1YVH_\^MK_P"!+?\
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MZNT4 4O.U'_GUM?_  );_P"-T>=J/_/K:_\ @2W_ ,;J[10!2\[4?^?6U_\
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M6_\ C='G:C_SZVO_ ($M_P#&ZNT4 4O.U'_GUM?_  );_P"-T>=J/_/K:_\
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M\;.K1RE_NE1@Y4?WOTJ[5*7_ )#-K_U[S?\ H4= $5Y_Q\/^'\J*+S_CX?\
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M>EU/XI>(IOB5KG@_P[X8T[4YM)L(+Z2XU#67M/,$N["(JVTG.5ZD@<UX7?\
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MY .H?]<9/_0*UJR;S_D ZA_UQD_] K6H **** "BBB@ HHHH **** "BBB@
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M 'R1?>$_$MA\+XXH]*\03>&[/QO8W>AZ;<V\]U?VFE1.O!BPTJQKM;:C#>%
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MZ]J/CBTL_$&J7=];V_AO18+VUU"VN4"!//-I+Y4@"F-A+)&% 1AA3NKZ:HH
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M[XD^*O@KQ7XA;P_86.@0WD3Z?IEQ/.[M/"$,HD>).K ?NR!M"YW.6PN_\7O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMNB@"&X:=5'D1QR'OYDA3^2FH/.U'_GUM?\ P);_ .-U=HH I>=J/_/K:_\
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M+?\ QNCSM1_Y];7_ ,"6_P#C=7:* *7G:C_SZVO_ ($M_P#&Z/.U'_GUM?\
MP);_ .-U=HH I>=J/_/K:_\ @2W_ ,;H\[4?^?6U_P# EO\ XW5VB@"EYVH_
M\^MK_P"!+?\ QNCSM1_Y];7_ ,"6_P#C=7:* *7G:C_SZVO_ ($M_P#&Z/.U
M'_GUM?\ P);_ .-U=HH I>=J/_/K:_\ @2W_ ,;H\[4?^?6U_P# EO\ XW5V
MB@"EYVH_\^MK_P"!+?\ QNCSM1_Y];7_ ,"6_P#C=7:* *7G:C_SZVO_ ($M
M_P#&Z/.U'_GUM?\ P);_ .-U=HH I>=J/_/K:_\ @2W_ ,;H\[4?^?6U_P#
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M];7_ ,"6_P#C=7:* *7G:C_SZVO_ ($M_P#&Z/.U'_GUM?\ P);_ .-U=HH
MI>=J/_/K:_\ @2W_ ,;H\[4?^?6U_P# EO\ XW5VB@"EYVH_\^MK_P"!+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_?E?\*/[%T__ )\+7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
MORO^% %VBJ7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\^%K_
M -^5_P */[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\ GPM?
M^_*_X4 7:*I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\
MSX6O_?E?\*/[%T__ )\+7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GP
MM?\ ORO^% %VBJ7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\
M^%K_ -^5_P */[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\
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M/^'\J*+S_CX?\/Y44 1WG_(!U#_KC)_Z!6M63>?\@'4/^N,G_H%:U !1110
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M);P@2-_O/]YOQ-:\N7X?=RJOR]V/WN[_  1%\54V2@OO?^1X8/BK\=O'V/\
MA&OA[;^&;.3D7.LL?,4=C^\*9_!#3Q\'/CGXJ^?7_BI%HX;_ )9Z/&P*^WR+
M%_,_6OI.BE_:7)_ I0C\KO[Y7']4YOXDY/YV7X6/FW_AC_4[SY]4^*OB2_F/
MWGW,,_\ ?4C?SH_X8S6'FU^(OB2!_P"]YF?Y$5])44?VQC?Y_P (_P"0?4</
M_+^+_P SYM_X9E^(>B_-H?QGUD!?NP7@E*#_ ,C,/_':;]E_:4\%_P"KN=!\
M:PIT5]B,1[Y$)S^)KZ4HH_M2M+^-",_6*_-68?4X+X)./HW^MSYJ/[5/BSP6
MP'C_ .&&J:7;#[U_89:/WP&&T_\ ?RO0O!_[3GPW\:;$MO$EOI]RW'V?5,VS
M ^FYOE)^C&O4F4,I!&0>"#7GGC#]GOX>^.-[ZEX8LDN&ZW-DOV:7/J6CQN/^
M]FCVV K?Q*3@^\7=?=+_ ##V>)I_!-2]5^J_R/089H[B%)8I%EB<;E=""K#U
M!'6GU\T3?LN^+?AW,]U\+OB!>::@)<:7JC;H6/7D@%#^,?XTS_AH;XD_"QA%
M\2_ 4MQ8)PVLZ-@ICU."4)/H63Z4_P"SE6UPE53\OAE]SW^38OK3I_QX./GN
MOO7ZGTU17G_@#X\>!_B5Y<>BZ[ ;U_\ EPNCY-QGT"-][_@.17H%>55HU*,N
M2K%I^>AVPG&HN:#N@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH *I2_\
MAFU_Z]YO_0HZNU2E_P"0S:_]>\W_ *%'0!%>?\?#_A_*BB\_X^'_  _E10!'
M>?\ (!U#_KC)_P"@5K5DWG_(!U#_ *XR?^@5K4 %%%% !1110 4444 %%%%
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M]0.;^TT^W@N#NW9D6-5;GOR#0!MT5#<+.RCR)(XSW\R,O_)A4'E:C_S]6O\
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M . S?_'*/*U'_GZM?_ 9O_CE %VD91(I5@&5A@@C((JGY6H_\_5K_P" S?\
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M32G'O%W_ "U7S1<<92;Y9/E?9Z?\ ]WHHHKR3M"BBB@ HHHH **** "BBB@
MJE+_ ,AFU_Z]YO\ T*.KM4I?^0S:_P#7O-_Z%'0!%>?\?#_A_*BB\_X^'_#^
M5% $=Y_R =0_ZXR?^@5K5DWG_(!U#_KC)_Z!6M0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6T5LO\WW;+HX>-&\MY/=]_Z[!1117GG4%%%% !1110 4444 %%%% ",H=2K
M,IZ@C(JJ=)L6()LK<GU\I?\ "K=%.[6PA%4*H"@ #H!2T44AA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<CXR^$G@[X@
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M!=O&N<(TD:L0,^A- &Q14-Q>06:@SS1PAN 9'"Y_.H/[:T__ )_[7_O\O^-
M%VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO
M_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U
M_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_
M -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__
M )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*
MI?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :
M/[:T_P#Y_P"U_P"_R_XT 7:PO&WC32?A[X:O-=UNY%K86JY8]6=OX40=V)X
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M_P#G_M?^_P O^-']M:?_ ,_]K_W^7_&@"[15+^VM/_Y_[7_O\O\ C2KK-@S
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M;\D8UJL:,'.7_#^1S'Q5\4:E^T7\1%^&'A.Z:+PQ8N)->U:'E6VMR@/0@$8
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M:3SM.N8GDCG<QP/$C1AIED<%4:,,&/ S0!V]%<+>?&WP=8Z7;7\NHW/DW!N
M(TTVZ>>+[.0)S+"L1DB$99=QD50NY<]17;03QW4,<T,BRPR*'22-@RLI&001
MU!% $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445A^-/&6E>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^8O\ XBKM% %+[!/_ -!*Z_[YB_\
MB*/L$_\ T$KK_OF+_P"(J[10!2^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XB
MKM% %+[!/_T$KK_OF+_XBC[!/_T$KK_OF+_XBKM% %+[!/\ ]!*Z_P"^8O\
MXBC[!/\ ]!*Z_P"^8O\ XBKM% %+[!/_ -!*Z_[YB_\ B*/L$_\ T$KK_OF+
M_P"(J[10!2^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XBKM% %+[!/_T$KK_O
MF+_XBC[!/_T$KK_OF+_XBKM% %+[!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^
M8O\ XBKM% %+[!/_ -!*Z_[YB_\ B*/L$_\ T$KK_OF+_P"(J[10!2^P3_\
M02NO^^8O_B*/L$__ $$KK_OF+_XBKM% %+[!/_T$KK_OF+_XBC[!/_T$KK_O
MF+_XBKM% %+[!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^8O\ XBKM% %+[!/_
M -!*Z_[YB_\ B*/L$_\ T$KK_OF+_P"(J[10!2^P3_\ 02NO^^8O_B*/L$__
M $$KK_OF+_XBKM% %+[!/_T$KK_OF+_XBC[!/_T$KK_OF+_XBKM% %+[!/\
M]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^8O\ XBKM% %+[!/_ -!*Z_[YB_\ B*/L
M$_\ T$KK_OF+_P"(J[10!2^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XBKM%
M%+[!/_T$KK_OF+_XBC[!/_T$KK_OF+_XBKM% %+[!/\ ]!*Z_P"^8O\ XBE6
MQF5@3J%RP]"L7/\ XY5RB@ HHHH **** "BBB@ HHHH **** "J4O_(9M?\
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M.NHM6N(YW:)H,&2</OF$!DD4*[,.?GW8&/H3P/J5WK/@KP_J&H#%_=:?;SW
MV[<2-&K-QVY)JO<_#CPE>:9I^G7'A?19]/T]BUG:2:?"T5L2<DQH5PAS_= K
MHZ (;BZ2U4%UD8'C]W$S_P#H(-0?VM!_SSNO_ 27_P")J[10!2_M:#_GG=?^
M DO_ ,31_:T'_/.Z_P# 27_XFKM% %+^UH/^>=U_X"2__$T?VM!_SSNO_ 27
M_P")J[10!2_M:#_GG=?^ DO_ ,31_:T'_/.Z_P# 27_XFKM% %+^UH/^>=U_
MX"2__$T?VM!_SSNO_ 27_P")J[10!2_M:#_GG=?^ DO_ ,31_:T'_/.Z_P#
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MT'_/.Z_\!)?_ (FKM%>-5JSK3=2H[M]3OA"-.*C!62*7]K0?\\[K_P !)?\
MXFC^UH/^>=U_X"2__$U=HK(LI?VM!_SSNO\ P$E_^)H_M:#_ )YW7_@)+_\
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M#M-EX>L$=>DDD0E<?\"?)_6CGS6M\,(4UYMR?X67XAR931^*<ZC\DHK\;O\
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M^>G!<W=ZO[W=G'B<TQF*7)4J/E[+1?<K(I?VM!_SSNO_  $E_P#B:5=5A9@
MESD\<VLH_P#9:N45Z9Y04444 %%%% !1110 4444 %%%% !5*7_D,VO_ %[S
M?^A1U=JE+_R&;7_KWF_]"CH BO/^/A_P_E11>?\ 'P_X?RHH CO/^0#J'_7&
M3_T"M:LF\_Y .H?]<9/_ $"M:@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BLK7?%6B^%X?.UC5['2HL9W7MRD0/TW$5Y9XF_:^^&7AO<J:S-
MK,R]8M,MVD_)VVH?^^JZZ.$Q&(_A4W+T1C4K4J7QR2/:**^:O^&HO&OC+Y?
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MC$N]>HY>K;+UY\9O!ECD/KD+G_IC&\G_ *"IK'NOVB/"-OGRWO;G_KE;X_\
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MHJE_9,'_ #TNO_ N7_XJC^R8/^>EU_X%R_\ Q5 %VBJ7]DP?\]+K_P "Y?\
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M_D ZA_UQD_\ 0*UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JE+_R&;7_ *]YO_0HZNU2E_Y#-K_U[S?^A1T 17G_ !\/^'\J*+S_
M (^'_#^5% $=Y_R =0_ZXR?^@5K5DWG_ " =0_ZXR?\ H%:U !1110 4444
M%%%% !1110 445P_QJM=-OOASJ-MJ^LV^@:?-+;+)?WL/FVR?Z1&0DZ[E!B<
M@1OEE&UR"1UH [*SO(-0M8;JUFCN;:=%EBFA<.DB,,JRL."""""*FKY*FUCP
M;K$.F1^*=&\.Z1X.M].U>VT_^SEC_LB]U!&@!N+3Y5'F,IE$?4AED"LQ!)^E
M?A]_:7_" ^&O[9\W^U_[,MOMOGY\SS_*7S-V><[LYSWH Z"BH;B9X5!2WDN"
M>T948_[Z(J#[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\
MT#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?
M/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\
M] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT
M52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?
M/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"
M[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO
M_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[
M15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[Z
MB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ
M+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^
MHO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K
M_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#
M;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ
M_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^W
MS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#
M;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+
M[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/
MM\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[
M?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\
MBZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN
M@"[15+[?/_T#;K_OJ+_XNE6^F9@#I]RH]2T7'_C] %RBBB@ HHHH **** "B
MBB@ HHHH *I2_P#(9M?^O>;_ -"CJ[5*7_D,VO\ U[S?^A1T 17G_'P_X?RH
MHO/^/A_P_E10!'>?\@'4/^N,G_H%:U9-Y_R =0_ZXR?^@5K4 %%%% !1110
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M% !17B<^O^#]-_:-OXY/$%A#?7'AZ:*\6751YL;K*C>6,ONBVQJTFQ=H&7<
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M'0[+5KO3;F[A\Z;3IS<VQWL DAC>/=M!PQVR.!D'&<CG!J_10 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I2_P#(
M9M?^O>;_ -"CJ[5*7_D,VO\ U[S?^A1T 17G_'P_X?RHHO/^/A_P_E10!'>?
M\@'4/^N,G_H%:U9-Y_R =0_ZXR?^@5K4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !5*7_D,VO_ %[S?^A1U=JE+_R&;7_KWF_]"CH
MBO/^/A_P_E11>?\ 'P_X?RHH CO/^0#J'_7&3_T"M:LF\_Y .H?]<9/_ $"M
M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I2_\AFU
M_P"O>;_T*.KM4I?^0S:_]>\W_H4= $5Y_P ?#_A_*BB\_P"/A_P_E10!'>?\
M@'4/^N,G_H%:U9-Y_P @'4/^N,G_ *!6M0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %4I?^0S:_P#7O-_Z%'5VJ4O_ "&;7_KWF_\
M0HZ (KS_ (^'_#^5%%Y_Q\/^'\J* ([S_D ZA_UQD_\ 0*UJR;S_ ) .H?\
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M+(_?P[^+\/\ [#.G^&7UN*PO/!ZVMQ!?16DD_@*QN+R;[1<K,$U*YD9FO(D
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MX9M[/3/#,<6C>7)::?#J]EJ+173F=OM,S#3K6$2J(54*[&-BV!Z-^T)\ ?\
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M?\/Y447G_'P_X?RHH CO/^0#J'_7&3_T"M:LF\_Y .H?]<9/_0*UJ "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?XHK\VCEJ8JE2ERS>OHW^2/I&BOF[_AJ+Q__ -$)\2?]]7'_ ,BT?\-1>/\
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MFWQJV]4.X'*AOF Z \]:HM\,?!S7VG7I\)Z&;S35C2RN#IL/F6JQG,8B;;E
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M,'_/2Z_\"Y?_ (JBB@ _LF#_ )Z77_@7+_\ %4?V3!_STNO_  +E_P#BJ**
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M #TNO_ N7_XJBB@ _LF#_GI=?^!<O_Q5']DP?\]+K_P+E_\ BJ** #^R8/\
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M^!<O_P 51_9,'_/2Z_\  N7_ .*HHH /[)@_YZ77_@7+_P#%4?V3!_STNO\
MP+E_^*HHH /[)@_YZ77_ (%R_P#Q5']DP?\ /2Z_\"Y?_BJ** #^R8/^>EU_
MX%R__%4?V3!_STNO_ N7_P"*HHH /[)@_P">EU_X%R__ !5']DP?\]+K_P "
MY?\ XJBB@ _LF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJBB@ _LF#_GI=?\
M@7+_ /%4?V3!_P ]+K_P+E_^*HHH /[)@_YZ77_@7+_\51_9,'_/2Z_\"Y?_
M (JBB@ _LF#_ )Z77_@7+_\ %4?V3!_STNO_  +E_P#BJ** #^R8/^>EU_X%
MR_\ Q5']DP?\]+K_ ,"Y?_BJ** #^R8/^>EU_P"!<O\ \53[?3H;>;S5\UI-
>I4-),[X!()QN)]!^5%% %>\_X^'_  _E1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>sndx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-27T16:17:52.1049+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.syndax.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:sndx="http://www.syndax.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>995455 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureBasisOfPresentation" id="Role_DisclosureBasisOfPresentation">
        <link:definition>995465 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreements" id="Role_DisclosureCollaborativeResearchAndLicenseAgreements">
        <link:definition>995485 - Disclosure - Collaborative Research and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995495 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShare" id="DisclosureLossEarningsPerShare">
        <link:definition>995505 - Disclosure - (Loss) Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements" id="Role_DisclosureSignificantAgreements">
        <link:definition>995515 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>995525 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995535 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995545 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995555 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>995565 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995575 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayable" id="Role_DisclosureLoanPayable">
        <link:definition>995585 - Disclosure - Loan Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995595 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995605 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformation" id="Role_DisclosureSupplementalCashFlowInformation">
        <link:definition>995615 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995625 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995635 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareTables" id="DisclosureLossEarningsPerShareTables">
        <link:definition>995645 - Disclosure - (Loss) Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995655 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995665 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>995675 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>995695 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995705 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableTables" id="Role_DisclosureLoanPayableTables">
        <link:definition>995715 - Disclosure - Loan Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995725 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationTables" id="Role_DisclosureSupplementalCashFlowInformationTables">
        <link:definition>995735 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>995755 - Disclosure - Collaborative Research and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>995765 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" id="Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
        <link:definition>995775 - Disclosure - Leases - Summary of Future Minimum Lease Payments under Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail" id="DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail">
        <link:definition>995785 - Disclosure - (Loss) Earnings per Share - Computation of Basic and Diluted Earnings (Loss) per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" id="DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail">
        <link:definition>995795 - Disclosure - (Loss) Earnings per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail" id="DisclosureLossEarningsPerShareAdditionalInformationDetail">
        <link:definition>995805 - Disclosure - (Loss) Earnings per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail" id="Role_DisclosureSignificantAgreementsAdditionalInformationDetail">
        <link:definition>995815 - Disclosure - Significant Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" id="Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail">
        <link:definition>995825 - Disclosure - Property and Equipment, Net - Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>995835 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" id="Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail">
        <link:definition>995845 - Disclosure - Fair Value Measurements - Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail" id="Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail">
        <link:definition>995855 - Disclosure - Fair Value Measurements - Significant Unobservable Inputs in the Fair Value Measurement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail">
        <link:definition>995865 - Disclosure - Fair Value Measurements - Summary of Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995875 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail">
        <link:definition>995885 - Disclosure - Fair Value Measurements - Summary of Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>995895 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>995905 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" id="Role_DisclosureCommonStockAdditionalInformationDetail">
        <link:definition>995915 - Disclosure - Common Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail" id="Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>995925 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>995935 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail" id="Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail">
        <link:definition>995945 - Disclosure - Stock-Based Compensation - Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail" id="Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail">
        <link:definition>995955 - Disclosure - Stock-Based Compensation - Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail">
        <link:definition>995965 - Disclosure - Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail">
        <link:definition>995975 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails">
        <link:definition>995985 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail" id="Role_DisclosureLoanPayableAdditionalInformationDetail">
        <link:definition>995995 - Disclosure - Loan Payable - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail" id="Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail">
        <link:definition>996005 - Disclosure - Loan Payable - Summary of Maturities of Principal Obligations Under Long-term Debt (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>996015 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail">
        <link:definition>996025 - Disclosure - Income Taxes - Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail">
        <link:definition>996035 - Disclosure - Income Taxes - Components of Deferred Tax (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail">
        <link:definition>996045 - Disclosure - Income Taxes - Summary of Reconciliation of Company's Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>996055 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail" id="Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail">
        <link:definition>996065 - Disclosure - Supplemental Cash Flow Information - Supplemental Disclosures of Cash Flow (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="sndx-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="sndx-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="sndx-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="sndx-20231231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="sndx-20231231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="sndx-20231231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="sndx-20231231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="sndx-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:href="sndx-20231231.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:href="sndx-20231231.xsd#Role_DisclosureBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="sndx-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreements" xlink:href="sndx-20231231.xsd#Role_DisclosureCollaborativeResearchAndLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:href="sndx-20231231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShare" xlink:href="sndx-20231231.xsd#DisclosureLossEarningsPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements" xlink:href="sndx-20231231.xsd#Role_DisclosureSignificantAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="sndx-20231231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="sndx-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="sndx-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="sndx-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="sndx-20231231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="sndx-20231231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayable" xlink:href="sndx-20231231.xsd#Role_DisclosureLoanPayable" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="sndx-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="sndx-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformation" xlink:href="sndx-20231231.xsd#Role_DisclosureSupplementalCashFlowInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sndx-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="sndx-20231231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareTables" xlink:href="sndx-20231231.xsd#DisclosureLossEarningsPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="sndx-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="sndx-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="sndx-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="sndx-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="sndx-20231231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="sndx-20231231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableTables" xlink:href="sndx-20231231.xsd#Role_DisclosureLoanPayableTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="sndx-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationTables" xlink:href="sndx-20231231.xsd#Role_DisclosureSupplementalCashFlowInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail" xlink:href="sndx-20231231.xsd#DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:href="sndx-20231231.xsd#DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#DisclosureLossEarningsPerShareAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureSignificantAgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" xlink:href="sndx-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="sndx-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureCommonStockAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails" xlink:href="sndx-20231231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureLoanPayableAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail" xlink:href="sndx-20231231.xsd#Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#axisDefault" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClinicalTrialMember" xlink:label="sndx_ClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClassOfWarrantOrRightIssued" xlink:label="sndx_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesTwoWarrantsMember" xlink:label="sndx_SeriesTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdditionalDefaultInterestRate" xlink:label="sndx_AdditionalDefaultInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockWarrantsIssued" xlink:label="sndx_NumberOfCommonStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NonRefundableUpFrontPaymentReceived" xlink:label="sndx_NonRefundableUpFrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_OfferingPricePerShare" xlink:label="sndx_OfferingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" xlink:label="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UcbLicenseAgreementMember" xlink:label="sndx_UcbLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityElectedNotToDraw" xlink:label="sndx_LineOfCreditFacilityElectedNotToDraw"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PrepaymentFee" xlink:label="sndx_PrepaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CostsRelatedToCostSharingCollaborations" xlink:label="sndx_CostsRelatedToCostSharingCollaborations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ComputerAndOfficeEquipmentMember" xlink:label="sndx_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RemainingContractualObligation" xlink:label="sndx_RemainingContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommitmentAndContingenciesTable" xlink:label="sndx_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsReceived" xlink:label="sndx_UpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityMinimumCashCovenantWaived" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenantWaived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceMethodologiesAndAssumptions" xlink:label="us-gaap_ValuationAllowanceMethodologiesAndAssumptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ServiceBasedOptionsMember" xlink:label="sndx_ServiceBasedOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedMilestoneExpenses" xlink:label="sndx_AccruedMilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodSharesDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndSeventeenPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndSeventeenPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueOfWarrants" xlink:label="sndx_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CurrentPortionOfCapitalLease" xlink:label="sndx_CurrentPortionOfCapitalLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ReturnToProvisionTrueUp" xlink:label="sndx_ReturnToProvisionTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantCashlessExerciseShares" xlink:label="sndx_WarrantCashlessExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AmortizedLossesReacquiredDebtNoncurrent" xlink:label="sndx_AmortizedLossesReacquiredDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice" xlink:label="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantExpirationTerm" xlink:label="sndx_WarrantExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesB1PurchaseAgreementMember" xlink:label="sndx_SeriesB1PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentTrancheTwoMember" xlink:label="sndx_DebtInstrumentTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CapitalLeaseLessCurrentPortion" xlink:label="sndx_CapitalLeaseLessCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_HerculesCapitalIncMember" xlink:label="sndx_HerculesCapitalIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue" xlink:label="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement" xlink:label="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketProgramMember" xlink:label="sndx_AtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentInterestOnlyPeriodExpirationDate" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RevenueRecognizedUponTransferOfLicenseAgreement" xlink:label="sndx_RevenueRecognizedUponTransferOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteCorporationMember" xlink:label="sndx_IncyteCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPayments" xlink:label="sndx_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock" xlink:label="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DerivativeLiabilityExpectedTimingOfTerminationRight" xlink:label="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SignificantAgreementsDisclosureTextBlock" xlink:label="sndx_SignificantAgreementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MaximumBeneficialOwnershipLimitationPercentage" xlink:label="sndx_MaximumBeneficialOwnershipLimitationPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeesMember" xlink:label="sndx_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FederalBondsMember" xlink:label="sndx_FederalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DepreciationAndRelatedAdjustment" xlink:label="sndx_DepreciationAndRelatedAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValueOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RevenueFromContractWithCustomerMilestoneMethodFactors" xlink:label="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PrepaidStateAndLocalTaxes" xlink:label="sndx_PrepaidStateAndLocalTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" xlink:label="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MichaelMetzgerMember" xlink:label="sndx_MichaelMetzgerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CowenAndCompanyLLCMember" xlink:label="sndx_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PrepaidSubscriptions" xlink:label="sndx_PrepaidSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementCashConsideration" xlink:label="sndx_CollaborationAndLicenseAgreementCashConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LeaseCommencementDate" xlink:label="sndx_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndNineteenPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndNineteenPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaymentOfFacilityCharges" xlink:label="sndx_PaymentOfFacilityCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncomeTaxesTable" xlink:label="sndx_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedMilestoneCosts" xlink:label="sndx_AccruedMilestoneCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingOneMember" xlink:label="sndx_FollowOnPublicOfferingOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_GrossProceedsFromOffering" xlink:label="sndx_GrossProceedsFromOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesOneWarrantsMember" xlink:label="sndx_SeriesOneWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MilestoneExpensesPaid" xlink:label="sndx_MilestoneExpensesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfEndOfTermChargeToFutureDraws" xlink:label="sndx_PercentageOfEndOfTermChargeToFutureDraws"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfSeriesOfWarrants" xlink:label="sndx_NumberOfSeriesOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_OfferingCost" xlink:label="sndx_OfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DerivativeLiabilityMember" xlink:label="sndx_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandTwentyThreePerformanceAwardsMember" xlink:label="sndx_TwoThousandTwentyThreePerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TermLoanMember" xlink:label="sndx_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ParValueAdjustments" xlink:label="sndx_ParValueAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EquityPlansMember" xlink:label="sndx_EquityPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LicenseAgreementsExpirationPeriod" xlink:label="sndx_LicenseAgreementsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BeginToExpireInTwoThousandAndTwentySixMember" xlink:label="sndx_BeginToExpireInTwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationPayableCurrent" xlink:label="sndx_CollaborationPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationReceivable" xlink:label="sndx_CollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ScenarioTwoMember" xlink:label="sndx_ScenarioTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentTrancheThreeMember" xlink:label="sndx_DebtInstrumentTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClinicalTrialCostPolicyTextBlock" xlink:label="sndx_ClinicalTrialCostPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfFacilityChargeOfFutureDraws" xlink:label="sndx_PercentageOfFacilityChargeOfFutureDraws"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BiotechnologyValueFundLPMember" xlink:label="sndx_BiotechnologyValueFundLPMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingTwoMember" xlink:label="sndx_FollowOnPublicOfferingTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MilestonePaymentDue" xlink:label="sndx_MilestonePaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingsMember" xlink:label="sndx_FollowOnPublicOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FirstAmendmentToLoanAndSecurityAgreementMember" xlink:label="sndx_FirstAmendmentToLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LicenseAgreementMember" xlink:label="sndx_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockConvertedToWarrants" xlink:label="sndx_NumberOfCommonStockConvertedToWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="us-gaap_EquityMethodInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantsExercisedPeriod" xlink:label="sndx_WarrantsExercisedPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationExpenseDueToCounterparty" xlink:label="sndx_CollaborationExpenseDueToCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeWithholdingsEspp" xlink:label="sndx_EmployeeWithholdingsEspp"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DevelopmentCostsAssociatedWithClinicalTrials" xlink:label="sndx_DevelopmentCostsAssociatedWithClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeStockPurchasePlanMember" xlink:label="sndx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ContractualObligationsTerm" xlink:label="sndx_ContractualObligationsTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod" xlink:label="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityMinimumCashCovenant" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantCashlessExerciseAmount" xlink:label="sndx_WarrantCashlessExerciseAmount"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommonStockDisclosureTextBlock" xlink:label="sndx_CommonStockDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock" xlink:label="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:label="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfWarrantsExercisedInCashlessExercise" xlink:label="sndx_NumberOfWarrantsExercisedInCashlessExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClassOfWarrantOrRightTerm" xlink:label="sndx_ClassOfWarrantOrRightTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdditionalTermLoanMember" xlink:label="sndx_AdditionalTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DevelopmentAndRegulaotryMilestonesExpenses" xlink:label="sndx_DevelopmentAndRegulaotryMilestonesExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesOneAndSeriesTwoWarrantsMember" xlink:label="sndx_SeriesOneAndSeriesTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfIncomeTaxContingencyRealized" xlink:label="sndx_PercentageOfIncomeTaxContingencyRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandFifteenOmnibusIncentivePlanMember" xlink:label="sndx_TwoThousandFifteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UCBBiopharmaMember" xlink:label="sndx_UCBBiopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" xlink:label="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontLicenseFeesPaid" xlink:label="sndx_UpfrontLicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_VitaePharmaceuticalsIncMember" xlink:label="sndx_VitaePharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommitmentAndContingenciesLineItems" xlink:label="sndx_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember" xlink:label="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsExchangedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExpirationOfTheEspp" xlink:label="sndx_ExpirationOfTheEspp"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IndefiniteCarryforwardPeriodMember" xlink:label="sndx_IndefiniteCarryforwardPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BayerPharmaAgMember" xlink:label="sndx_BayerPharmaAgMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NoncashOperatingLeaseExpense" xlink:label="sndx_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DirectPlacementOfferingMember" xlink:label="sndx_DirectPlacementOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketStockOfferingMember" xlink:label="sndx_AtTheMarketStockOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentAllocatedToEquityPurchase" xlink:label="sndx_UpfrontPaymentAllocatedToEquityPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedClinicalCostsCurrent" xlink:label="sndx_AccruedClinicalCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndSevenStockIncentivePlanMember" xlink:label="sndx_TwoThousandAndSevenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaymentForEndOfTermFees" xlink:label="sndx_PaymentForEndOfTermFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BriggsWMorrisonMember" xlink:label="sndx_BriggsWMorrisonMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AllerganLicenseAgreementMember" xlink:label="sndx_AllerganLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncomeTaxesLineItems" xlink:label="sndx_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MarketReserveMember" xlink:label="sndx_MarketReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInCollaborationReceivable" xlink:label="sndx_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedContractualObligation" xlink:label="sndx_AccruedContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LoanAndSecurityAgreementMember" xlink:label="sndx_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentAllocatedToLicenseFee" xlink:label="sndx_UpfrontPaymentAllocatedToLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExpirationOfTheEsppShares" xlink:label="sndx_ExpirationOfTheEsppShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteSharePurchaseAgreementMember" xlink:label="sndx_IncyteSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantsMember" xlink:label="sndx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementsTable" xlink:label="sndx_FairValueMeasurementsTable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:label="us-gaap_DerivativeLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfEmployeesRetirement" xlink:label="sndx_NumberOfEmployeesRetirement"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantExerciseShares" xlink:label="sndx_PreFundedWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ScenarioOneMember" xlink:label="sndx_ScenarioOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AggregatePotentialMilestonePayable" xlink:label="sndx_AggregatePotentialMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_KyowaKirinCoLtdMember" xlink:label="sndx_KyowaKirinCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_GlobalAndUnitedStatesMember" xlink:label="sndx_GlobalAndUnitedStatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IndemnificationObligationsClaimsReserves" xlink:label="sndx_IndemnificationObligationsClaimsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantsToPurchaseCommonStockMember" xlink:label="sndx_WarrantsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInContractualObligation" xlink:label="sndx_IncreaseDecreaseInContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NonRefundableCashPaymentsMember" xlink:label="sndx_NonRefundableCashPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketEquityOfferingSalesAgreementMember" xlink:label="sndx_AtTheMarketEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice" xlink:label="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PotentialMilestonePaymentsReceivable" xlink:label="sndx_PotentialMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" xlink:label="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementsLineItems" xlink:label="sndx_FairValueMeasurementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EasternCooperativeOncologyGroupMember" xlink:label="sndx_EasternCooperativeOncologyGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementMember" xlink:label="sndx_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommercializationMilestonesAndTieredRoyalties" xlink:label="sndx_CommercializationMilestonesAndTieredRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborativeResearchAndLicenseAgreementsTextBlock" xlink:label="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract" xlink:label="sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ValuationTechniqueBlackScholesModelMember" xlink:label="sndx_ValuationTechniqueBlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod" xlink:label="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesWarrantsMember" xlink:label="sndx_SeriesWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaidInKindInterestAndInterestReversal" xlink:label="sndx_PaidInKindInterestAndInterestReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct" xlink:label="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment allocation to performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award annual increase percentage in number of shares available for grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage In Number Of Shares Available For Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series two warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Two Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series 2 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Vested Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments under capital leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, to be Paid, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdditionalDefaultInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional default interest rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdditionalDefaultInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Default Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdditionalDefaultInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Default interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfCommonStockWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfCommonStockWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfCommonStockWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyPendingClaimsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Pending Claims, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyPendingClaimsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification obligations, claims outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NonRefundableUpFrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable up front payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NonRefundableUpFrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Up Front Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NonRefundableUpFrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front license fee received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating Lease Liability Payments Due After Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_OfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_OfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_OfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments to be returned upon termination of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments To Be Returned Upon Termination Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments returned upon termination of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name of Property [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UcbLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UCB license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UcbLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ucb License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UcbLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCB License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityElectedNotToDraw_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility elected not to draw.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityElectedNotToDraw_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Elected Not To Draw</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityElectedNotToDraw_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility elected not to draw</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liability, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PrepaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PrepaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Other Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from Incyte Share Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CostsRelatedToCostSharingCollaborations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs related to cost sharing collaborations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CostsRelatedToCostSharingCollaborations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs Related To Cost Sharing Collaborations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CostsRelatedToCostSharingCollaborations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External costs related to cost-sharing collaborations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of restricted stock units vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and computer equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer And Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RemainingContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining contractual obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RemainingContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Contractual Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RemainingContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment premium of principal amount outstanding thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayment Premium Of Principal Amount Outstanding Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment premium of principal amount outstanding thereafter prior to maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Performance Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Two Performance Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty two performance awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NY_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NEW YORK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NY_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value pre-funded common stock warrants from direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from pre-funded common stock warrant from direct offering, net, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenantWaived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility minimum cash covenant waived.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenantWaived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Minimum Cash Covenant Waived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenantWaived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum cash covenant waived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Cash Flow Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options canceled, forfeited or expired, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ex-U.S. Countries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee service share based compensation recognized stock options not met.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Recognized Stock Options Not Met</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized compensation expense related to stock option not met</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceMethodologiesAndAssumptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Methodologies and Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceMethodologiesAndAssumptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance for deferred tax assets, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantees and Indemnifications [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ServiceBasedOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">service based options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ServiceBasedOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Based Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ServiceBasedOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Based Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedMilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued milestone expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedMilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Milestone Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedMilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued milestone expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Direct Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from direct offering,net, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndSeventeenPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and seventeen performance awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndSeventeenPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Seventeen Performance Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndSeventeenPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Performance Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested, exercisable or expected to vest, Weighted Average Exercise Price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of right-of-use liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lender Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Frequency of Payment and Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-only period, terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CurrentPortionOfCapitalLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of capital lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CurrentPortionOfCapitalLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Portion Of Capital Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ReturnToProvisionTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Return to provision true up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ReturnToProvisionTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Return to provision true up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ReturnToProvisionTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Return to provision true up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested, exercisable or expected to vest, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantCashlessExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, cashless exercise shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantCashlessExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Cashless Exercise Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantCashlessExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Cashless Exercise Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seven and two thousand fifteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seven And Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2007 and 2015 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury and Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury and Federal Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital repricing warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Repricing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deemed dividend transferred to the warrant holders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repricing Series 1 and 2 warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AmortizedLossesReacquiredDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortized losses reacquired debt noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AmortizedLossesReacquiredDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortized Losses Reacquired Debt Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AmortizedLossesReacquiredDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized final fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum period allowed to increase beneficial ownership limitation after notice.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Period Allowed To Increase Beneficial Ownership Limitation After Notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum period allowed to increase beneficial ownership limitation after notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock purchase under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantees and Indemnifications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant expiration term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Expiration Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesB1PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesB1PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesB1PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eddingpharm Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense related to stock option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument tranche two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CapitalLeaseLessCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital lease, less current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CapitalLeaseLessCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Lease Less Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock purchase under ESPP, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_HerculesCapitalIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules Capital, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_HerculesCapitalIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules Capital Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_HerculesCapitalIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee service share based compensation recognized stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Recognized Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments allocated to equity purchase fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments Allocated To Equity Purchase Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Up-front payment allocated to preferred stock value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated standalone selling price of license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Standalone Selling Price Of License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated standalone selling price of license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-market program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest only period expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Only Period Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-only period expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided (used in) operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis spread on variable rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RevenueRecognizedUponTransferOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognized upon transfer of license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RevenueRecognizedUponTransferOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognized Upon Transfer Of License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RevenueRecognizedUponTransferOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized upon transfer of license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in follow-on public stock offering, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incyte corporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incyte Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incyte Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 200,000,000 and 100,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 84,826,632 and 68,111,385 shares outstanding at December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registration Payment Arrangement by Arrangement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registration Payment Arrangement by Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront milestone payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of warrants upper limit after exercise as percentage of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Warrants Upper Limit After Exercise As Percentage Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of common stock can be held upon exercise of warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">(Loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2019-12 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses recognized on the sale or maturity of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Realized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability expected timing of the termination right.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability Expected Timing Of Termination Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected timing of the Termination Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decreases related to prior period positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales and maturities of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value at the market offering net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value At The Market Offering Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from "at-the-market" offering, net, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award payroll deductions offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Payroll Deductions Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Periodic payroll deductions offering periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SignificantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant agreements disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SignificantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Agreements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SignificantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation expense, total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MaximumBeneficialOwnershipLimitationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum beneficial ownership limitation percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MaximumBeneficialOwnershipLimitationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Beneficial Ownership Limitation Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MaximumBeneficialOwnershipLimitationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum beneficial ownership limitation percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option granted to certain employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of RSU, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FederalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FederalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FederalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal bonds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DepreciationAndRelatedAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation and related adjustment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DepreciationAndRelatedAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Related Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DepreciationAndRelatedAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Basis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General business credit carryovers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct offering, offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Deposit on Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment on term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment on term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from contract with customer milestone method factors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Milestone Method Factors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment agreement terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Pre Funded Warrants Exercised For Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Pre Funded Warrants Exercised For Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from License Fees Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award offering period discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Offering Period Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PrepaidStateAndLocalTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid state and local taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PrepaidStateAndLocalTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid State and Local Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PrepaidStateAndLocalTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid State and Local Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares at the market offering net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares At The Market Offering Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from "at-the-market" offering, net, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Increase (Decrease), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate maximum borrowing capacity increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Line of Credit Facility, Increase (Decrease), Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Machinery and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate maximum borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosures of Cash Flow Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income Per Share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments under Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MichaelMetzgerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Michael Metzger [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MichaelMetzgerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Michael Metzger [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MichaelMetzgerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Michael Metzger [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cowen and Company LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cowen And Company L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cowen and Company LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital deemed dividend from repricing warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Deemed Dividend From Repricing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend from repricing Series 1 and 2 warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PrepaidSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Subscriptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PrepaidSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Subscriptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PrepaidSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PrepaidSubscriptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic (loss) earnings per share attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementCashConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement cash consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementCashConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Cash Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementCashConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 16)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance obligation period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndNineteenPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen performance awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndNineteenPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Performance Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndNineteenPerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Performance Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PaymentOfFacilityCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of facility charges.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PaymentOfFacilityCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Facility Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PaymentOfFacilityCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility charge paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties recorded during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tangible Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Tangible Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, stock options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options vested, exercisable or expected to vest, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedMilestoneCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued milestone costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedMilestoneCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued milestone costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedMilestoneCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued milestone costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on public offering one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted (loss) earnings per share attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_GrossProceedsFromOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_GrossProceedsFromOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_GrossProceedsFromOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized tax benefit--end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized tax benefit--beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesOneWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series one warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesOneWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series One Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesOneWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series 1 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Service (IRS) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Revenue Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MilestoneExpensesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Expenses Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MilestoneExpensesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Expenses Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MilestoneExpensesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone expenses paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Principal Obligations Under Long-term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets (liabilities):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options exercised, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfEndOfTermChargeToFutureDraws_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of end of term charge to future draws.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfEndOfTermChargeToFutureDraws_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of End Of Term Charge To Future Draws</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfEndOfTermChargeToFutureDraws_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of end of term charge to future draws</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Option Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfSeriesOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of series of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfSeriesOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Series Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfSeriesOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of series of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized income tax benefits that would affect effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Product and Service [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of revenue [extensible list]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Contingencies [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Company's Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_OfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_OfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_OfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandTwentyThreePerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Performance Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandTwentyThreePerformanceAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Performance Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment Under Capital Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Weighted Average Exercise Price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value direct offering common stock warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Direct Offering Common Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct offering, common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ParValueAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Par Value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ParValueAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Par Value Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ParValueAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Par Value Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deemed dividend due to warrant reset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EquityPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EquityPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EquityPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LicenseAgreementsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements expiration period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LicenseAgreementsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LicenseAgreementsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost-sharing collaborations recorded as a reduction to research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BeginToExpireInTwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Begin to expire in 2026.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BeginToExpireInTwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Begin To Expire In Two Thousand And Twenty Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BeginToExpireInTwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Begin to Expire in 2026 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period to recognize compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested, exercisable or expected to vest, Weighted Average Remaining Contractual Term, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration payable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset, capitalized research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available through November 30, 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, Expenses required to be capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, tranche three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClinicalTrialCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Trial Cost [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClinicalTrialCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Cost [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClinicalTrialCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfFacilityChargeOfFutureDraws_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of facility charge of future draws.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfFacilityChargeOfFutureDraws_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Facility Charge Of Future Draws</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfFacilityChargeOfFutureDraws_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of facility charge of future draws</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BiotechnologyValueFundLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biotechnology Value Fund, L.P.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BiotechnologyValueFundLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biotechnology Value Fund L P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BiotechnologyValueFundLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biotechnology Value Fund, L.P. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on public offering two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MilestonePaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MilestonePaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MilestonePaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosures of Non-Cash Investing and Financing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive potential common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on public offerings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offerings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FollowOnPublicOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offerings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FirstAmendmentToLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First amendment to loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FirstAmendmentToLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Amendment To Loan And Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FirstAmendmentToLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Amendment to Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, stock options cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs in the Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfCommonStockConvertedToWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock converted to warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfCommonStockConvertedToWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Converted To Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfCommonStockConvertedToWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock converted to warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Investment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantsExercisedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantsExercisedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantsExercisedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic (loss) earnings per share attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationExpenseDueToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration expense due to counterparty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationExpenseDueToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Expense Due To Counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationExpenseDueToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration expense due to counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeWithholdingsEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee withholdings ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeWithholdingsEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee withholdings ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeWithholdingsEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee withholdings ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DevelopmentCostsAssociatedWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development costs associated with clinical trials.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DevelopmentCostsAssociatedWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Costs Associated With Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DevelopmentCostsAssociatedWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development costs associated with clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Direct Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from direct offering, net, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Employee and Non-Employee Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of diluted net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance 1/1/2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance 12/31/2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ContractualObligationsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligations term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ContractualObligationsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligations Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ContractualObligationsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of contractual obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Accretion) amortization of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards expiration period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforward expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility minimum cash covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Minimum Cash Covenant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum cash covenant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantCashlessExerciseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, cashless exercise, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantCashlessExerciseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Cashless Exercise Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantCashlessExerciseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Cashless Exercise Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommonStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommonStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommonStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantor Obligations, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registration Payment Arrangement, Arrangement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registration Payment Arrangement, Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantor Obligations, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of warrants lower limit after exercise as percentage of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Warrants Lower Limit After Exercise As Percentage Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of common stock can be held upon exercise of warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential milestone payments upon achievement of milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestone Payments Upon Achievement Of Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments to be made</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfWarrantsExercisedInCashlessExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised in cashless exercise.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfWarrantsExercisedInCashlessExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Exercised In Cashless Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfWarrantsExercisedInCashlessExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued and Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, stock options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current State Income Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdditionalTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdditionalTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AdditionalTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used in calculating:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DevelopmentAndRegulaotryMilestonesExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulaotry milestones Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DevelopmentAndRegulaotryMilestonesExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and regulaotry milestones Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DevelopmentAndRegulaotryMilestonesExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulaotry milestones expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesOneAndSeriesTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series one and series two warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesOneAndSeriesTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series One And Series Two Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesOneAndSeriesTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series 1 and Series 2 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercised, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfIncomeTaxContingencyRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of income tax contingency realized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfIncomeTaxContingencyRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Income Tax Contingency Realized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfIncomeTaxContingencyRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of income tax contingency realized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment premium of principal amount outstanding in second year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayment Premium Of Principal Amount Outstanding In Second Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment premium of principal amount outstanding in second year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandFifteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen omnibus incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandFifteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Omnibus Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandFifteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair value of derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UCBBiopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UCB Biopharma.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UCBBiopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U C B Biopharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UCBBiopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCB Biopharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Series 1 and Series 2 warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset, capitalized start-up and other costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Start Up And Other Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized start-up and other costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fees paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front license fee paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_VitaePharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vitae Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_VitaePharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vitae Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_VitaePharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vitae Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets before valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incyte collaboration agreement and share purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incyte Collaboration Agreement And Share Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incyte Collaboration Agreement and Share Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pre-funded warrants exchanged for common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Pre Funded Warrants Exchanged For Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized (gain) loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExpirationOfTheEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration of the ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExpirationOfTheEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiration of the ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliations recurring basis liability value additions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IndefiniteCarryforwardPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indefinite carryforward period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IndefiniteCarryforwardPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Carryforward Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IndefiniteCarryforwardPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite Carryforward Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BayerPharmaAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bayer Pharma AG .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BayerPharmaAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bayer Pharma Ag [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BayerPharmaAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bayer Pharma AG [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash operating lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Operating Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and rights outstanding, measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DirectPlacementOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct placement offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DirectPlacementOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Placement Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DirectPlacementOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Placement Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketStockOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market stock offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketStockOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Stock Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketStockOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentAllocatedToEquityPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment allocated to equity purchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentAllocatedToEquityPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Allocated To Equity Purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentAllocatedToEquityPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front payment allocated to equity purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Unvested, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Unvested, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loans Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedClinicalCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedClinicalCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedClinicalCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical study and trial costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost-Sharing Collaborations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at December 31, 2023 and December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndSevenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and seven stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndSevenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Seven Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandAndSevenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2007 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value common stock warrant with direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Common Stock Warrant With Direct Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrant with direct offering, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) Earnings per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PaymentForEndOfTermFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for end-of term fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PaymentForEndOfTermFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for end-of term fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options canceled, forfeited or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BriggsWMorrisonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Briggs W. Morrison [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BriggsWMorrisonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Briggs W. Morrison [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_BriggsWMorrisonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Briggs W. Morrison [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AllerganLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Allergan license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AllerganLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allergan License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AllerganLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allergan License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate payment obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MarketReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">market reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MarketReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Reserve [MEMBER]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_MarketReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market Reserve [MEMBER]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in collaboration receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Collaboration Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contractual obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contractual Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AccruedContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contractual obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash included in current and noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan And Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pre funded warrants cashless exchanged for common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Pre Funded Warrants Cashless Exchanged For Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants cashless exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit Facility, Lender</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentAllocatedToLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment allocated to license fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentAllocatedToLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Allocated To License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_UpfrontPaymentAllocatedToLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front payment allocated to license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExpirationOfTheEsppShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">expiration of the ESPP shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ExpirationOfTheEsppShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">expiration of the ESPP shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings to date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total principal outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incyte share purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incyte Share Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncyteSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incyte Share Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment premium of principal amount outstanding in first year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayment Premium Of Principal Amount Outstanding In First Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment premium of principal amount outstanding in first year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Inducement Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Inducement Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Measurements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value at the market offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value At The Market Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market, offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM Offering, offering cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Wall Street Journal Prime Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfEmployeesRetirement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of employees retirement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfEmployeesRetirement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Employees Retirement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NumberOfEmployeesRetirement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of employees retirement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PreFundedWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrant cashless exercise, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PreFundedWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrant exercise, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PreFundedWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded warrant exercise, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available through April 30, 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AggregatePotentialMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential milestone payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AggregatePotentialMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Potential Milestone Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AggregatePotentialMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate potential milestone payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_KyowaKirinCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Kyowa Kirin Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_KyowaKirinCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Kyowa Kirin Co Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_KyowaKirinCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Kyowa Kirin Co., Ltd. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_GlobalAndUnitedStatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Global and united states.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_GlobalAndUnitedStatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Global And United States [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_GlobalAndUnitedStatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Global and U.S. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IndemnificationObligationsClaimsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indemnification obligations claims reserves.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IndemnificationObligationsClaimsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Obligations Claims Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IndemnificationObligationsClaimsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification obligations claims, reserves established</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reported Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock exercised non option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion at Fair Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://fasb.org/us-gaap/role/label/axisDefault">Portion at Fair Value Measurement [Member] [Default]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase agreement obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Purchase Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions by the company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest expense related to the loan agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in contractual obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contractual Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_IncreaseDecreaseInContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in contractual obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Weighted Average Remaining Contractual Term, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NonRefundableCashPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable cash payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NonRefundableCashPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Cash Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_NonRefundableCashPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Refundable Cash Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market equity offering sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AtTheMarketEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Equity Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement consideration transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Consideration Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loans Payable, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest only period extendable upon partial or full draw of Tranche 2.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Only Period Extendable Upon Partial Or Full Draw Of Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-only period, extendable upon partial or full draw of Tranche 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PotentialMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential milestone payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PotentialMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestone Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PotentialMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment receivable upon achievement of development and commercial milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement allocated consideration received to derivative liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Allocated Consideration Received To Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocated consideration received to derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares authorized for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets research credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_FairValueMeasurementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EasternCooperativeOncologyGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eastern Cooperative Oncology Group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EasternCooperativeOncologyGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eastern Cooperative Oncology Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_EasternCooperativeOncologyGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eastern Cooperative Oncology Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares pre funded common stock warrants from direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Pre Funded Common Stock Warrants From Direct Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from pre-funded common stock warrant from direct offering, net, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value pre-funded common stock warrant offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Pre Funded Common Stock Warrant Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded common stock warrants offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value pre funded common stock warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Pre Funded Common Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Waltham, Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short and long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incyte Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Incyte Share Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommercializationMilestonesAndTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercialization milestones and tiered royalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommercializationMilestonesAndTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercialization Milestones And Tiered Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CommercializationMilestonesAndTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercialization milestones and tiered royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name of Property [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative research and license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Research And License Agreements [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Research and License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares used in calculating diluted earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted (loss) earnings per share attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securities Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ValuationTechniqueBlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation technique Black Scholes Model.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ValuationTechniqueBlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique Black Scholes Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_ValuationTechniqueBlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black Scholes Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets research credits expiration period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research Credits Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets research credits expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, Weighted Average Exercise Price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, Weighted Average Exercise Price, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Earnings (Loss) per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_SeriesWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PaidInKindInterestAndInterestReversal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PaidInKindInterestAndInterestReversal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paid in kind interest and interest reversal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PaidInKindInterestAndInterestReversal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest And Interest Reversal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock units vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, new shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Incyte Share Purchase Agreement shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of termination after first commercial sale of first licensed product.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Termination After First Commercial Sale Of First Licensed Product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of termination after first commercial sale of first licensed product</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ClinicalTrialMember" xlink:to="sndx_ClinicalTrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ClassOfWarrantOrRightIssued" xlink:to="sndx_ClassOfWarrantOrRightIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_SeriesTwoWarrantsMember" xlink:to="sndx_SeriesTwoWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AdditionalDefaultInterestRate" xlink:to="sndx_AdditionalDefaultInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NumberOfCommonStockWarrantsIssued" xlink:to="sndx_NumberOfCommonStockWarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyPendingClaimsNumber" xlink:to="us-gaap_LossContingencyPendingClaimsNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NonRefundableUpFrontPaymentReceived" xlink:to="sndx_NonRefundableUpFrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_OfferingPricePerShare" xlink:to="sndx_OfferingPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" xlink:to="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UcbLicenseAgreementMember" xlink:to="sndx_UcbLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LineOfCreditFacilityElectedNotToDraw" xlink:to="sndx_LineOfCreditFacilityElectedNotToDraw_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PrepaymentFee" xlink:to="sndx_PrepaymentFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CostsRelatedToCostSharingCollaborations" xlink:to="sndx_CostsRelatedToCostSharingCollaborations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ComputerAndOfficeEquipmentMember" xlink:to="sndx_ComputerAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_RemainingContractualObligation" xlink:to="sndx_RemainingContractualObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="sndx_CommitmentAndContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember" xlink:to="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NY" xlink:to="stpr_NY_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UpfrontPaymentsReceived" xlink:to="sndx_UpfrontPaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LineOfCreditFacilityMinimumCashCovenantWaived" xlink:to="sndx_LineOfCreditFacilityMinimumCashCovenantWaived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet" xlink:to="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceMethodologiesAndAssumptions" xlink:to="us-gaap_ValuationAllowanceMethodologiesAndAssumptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndemnificationGuaranteeMember" xlink:to="us-gaap_IndemnificationGuaranteeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ServiceBasedOptionsMember" xlink:to="sndx_ServiceBasedOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AccruedMilestoneExpenses" xlink:to="sndx_AccruedMilestoneExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodSharesDirectOffering" xlink:to="sndx_StockIssuedDuringPeriodSharesDirectOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TwoThousandAndSeventeenPerformanceAwardsMember" xlink:to="sndx_TwoThousandAndSeventeenPerformanceAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FairValueOfWarrants" xlink:to="sndx_FairValueOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CurrentPortionOfCapitalLease" xlink:to="sndx_CurrentPortionOfCapitalLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ReturnToProvisionTrueUp" xlink:to="sndx_ReturnToProvisionTrueUp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_WarrantCashlessExerciseShares" xlink:to="sndx_WarrantCashlessExerciseShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember" xlink:to="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" xlink:to="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AmortizedLossesReacquiredDebtNoncurrent" xlink:to="sndx_AmortizedLossesReacquiredDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice" xlink:to="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_WarrantExpirationTerm" xlink:to="sndx_WarrantExpirationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_SeriesB1PurchaseAgreementMember" xlink:to="sndx_SeriesB1PurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DebtInstrumentTrancheTwoMember" xlink:to="sndx_DebtInstrumentTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CapitalLeaseLessCurrentPortion" xlink:to="sndx_CapitalLeaseLessCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_HerculesCapitalIncMember" xlink:to="sndx_HerculesCapitalIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions" xlink:to="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue" xlink:to="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement" xlink:to="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AtTheMarketProgramMember" xlink:to="sndx_AtTheMarketProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate" xlink:to="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_RevenueRecognizedUponTransferOfLicenseAgreement" xlink:to="sndx_RevenueRecognizedUponTransferOfLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IncyteCorporationMember" xlink:to="sndx_IncyteCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UpfrontPayments" xlink:to="sndx_UpfrontPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock" xlink:to="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight" xlink:to="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet" xlink:to="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_SignificantAgreementsDisclosureTextBlock" xlink:to="sndx_SignificantAgreementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_MaximumBeneficialOwnershipLimitationPercentage" xlink:to="sndx_MaximumBeneficialOwnershipLimitationPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_EmployeesMember" xlink:to="sndx_EmployeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FederalBondsMember" xlink:to="sndx_FederalBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DepreciationAndRelatedAdjustment" xlink:to="sndx_DepreciationAndRelatedAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValueOfferingExpenses" xlink:to="sndx_StockIssuedDuringPeriodValueOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors" xlink:to="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:to="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PrepaidStateAndLocalTaxes" xlink:to="sndx_PrepaidStateAndLocalTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" xlink:to="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_MichaelMetzgerMember" xlink:to="sndx_MichaelMetzgerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CowenAndCompanyLLCMember" xlink:to="sndx_CowenAndCompanyLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants" xlink:to="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PrepaidSubscriptions" xlink:to="sndx_PrepaidSubscriptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CollaborationAndLicenseAgreementCashConsideration" xlink:to="sndx_CollaborationAndLicenseAgreementCashConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LeaseCommencementDate" xlink:to="sndx_LeaseCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TwoThousandAndNineteenPerformanceAwardsMember" xlink:to="sndx_TwoThousandAndNineteenPerformanceAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PaymentOfFacilityCharges" xlink:to="sndx_PaymentOfFacilityCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentCharges" xlink:to="us-gaap_TangibleAssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IncomeTaxesTable" xlink:to="sndx_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AccruedMilestoneCosts" xlink:to="sndx_AccruedMilestoneCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FollowOnPublicOfferingOneMember" xlink:to="sndx_FollowOnPublicOfferingOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_GrossProceedsFromOffering" xlink:to="sndx_GrossProceedsFromOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_SeriesOneWarrantsMember" xlink:to="sndx_SeriesOneWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_MilestoneExpensesPaid" xlink:to="sndx_MilestoneExpensesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PercentageOfEndOfTermChargeToFutureDraws" xlink:to="sndx_PercentageOfEndOfTermChargeToFutureDraws_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NumberOfSeriesOfWarrants" xlink:to="sndx_NumberOfSeriesOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_OfferingCost" xlink:to="sndx_OfferingCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DerivativeLiabilityMember" xlink:to="sndx_DerivativeLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TwoThousandTwentyThreePerformanceAwardsMember" xlink:to="sndx_TwoThousandTwentyThreePerformanceAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TermLoanMember" xlink:to="sndx_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant" xlink:to="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ParValueAdjustments" xlink:to="sndx_ParValueAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_EquityPlansMember" xlink:to="sndx_EquityPlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LicenseAgreementsExpirationPeriod" xlink:to="sndx_LicenseAgreementsExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_BeginToExpireInTwoThousandAndTwentySixMember" xlink:to="sndx_BeginToExpireInTwoThousandAndTwentySixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CollaborationPayableCurrent" xlink:to="sndx_CollaborationPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CollaborationReceivable" xlink:to="sndx_CollaborationReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ScenarioTwoMember" xlink:to="sndx_ScenarioTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DebtInstrumentTrancheThreeMember" xlink:to="sndx_DebtInstrumentTrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ClinicalTrialCostPolicyTextBlock" xlink:to="sndx_ClinicalTrialCostPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PercentageOfFacilityChargeOfFutureDraws" xlink:to="sndx_PercentageOfFacilityChargeOfFutureDraws_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_BiotechnologyValueFundLPMember" xlink:to="sndx_BiotechnologyValueFundLPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FollowOnPublicOfferingTwoMember" xlink:to="sndx_FollowOnPublicOfferingTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_MilestonePaymentDue" xlink:to="sndx_MilestonePaymentDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FollowOnPublicOfferingsMember" xlink:to="sndx_FollowOnPublicOfferingsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FirstAmendmentToLoanAndSecurityAgreementMember" xlink:to="sndx_FirstAmendmentToLoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LicenseAgreementMember" xlink:to="sndx_LicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NumberOfCommonStockConvertedToWarrants" xlink:to="sndx_NumberOfCommonStockConvertedToWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsMember" xlink:to="us-gaap_EquityMethodInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_WarrantsExercisedPeriod" xlink:to="sndx_WarrantsExercisedPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CollaborationExpenseDueToCounterparty" xlink:to="sndx_CollaborationExpenseDueToCounterparty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_EmployeeWithholdingsEspp" xlink:to="sndx_EmployeeWithholdingsEspp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DevelopmentCostsAssociatedWithClinicalTrials" xlink:to="sndx_DevelopmentCostsAssociatedWithClinicalTrials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValueDirectOffering" xlink:to="sndx_StockIssuedDuringPeriodValueDirectOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_EmployeeStockPurchasePlanMember" xlink:to="sndx_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ContractualObligationsTerm" xlink:to="sndx_ContractualObligationsTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" xlink:to="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod" xlink:to="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LineOfCreditFacilityMinimumCashCovenant" xlink:to="sndx_LineOfCreditFacilityMinimumCashCovenant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_WarrantCashlessExerciseAmount" xlink:to="sndx_WarrantCashlessExerciseAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CommonStockDisclosureTextBlock" xlink:to="sndx_CommonStockDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock" xlink:to="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:to="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NumberOfWarrantsExercisedInCashlessExercise" xlink:to="sndx_NumberOfWarrantsExercisedInCashlessExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ClassOfWarrantOrRightTerm" xlink:to="sndx_ClassOfWarrantOrRightTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AdditionalTermLoanMember" xlink:to="sndx_AdditionalTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DevelopmentAndRegulaotryMilestonesExpenses" xlink:to="sndx_DevelopmentAndRegulaotryMilestonesExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_SeriesOneAndSeriesTwoWarrantsMember" xlink:to="sndx_SeriesOneAndSeriesTwoWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PercentageOfIncomeTaxContingencyRealized" xlink:to="sndx_PercentageOfIncomeTaxContingencyRealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TwoThousandFifteenOmnibusIncentivePlanMember" xlink:to="sndx_TwoThousandFifteenOmnibusIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UCBBiopharmaMember" xlink:to="sndx_UCBBiopharmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" xlink:to="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UpfrontLicenseFeesPaid" xlink:to="sndx_UpfrontLicenseFeesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_VitaePharmaceuticalsIncMember" xlink:to="sndx_VitaePharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="sndx_CommitmentAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember" xlink:to="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock" xlink:to="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ExpirationOfTheEspp" xlink:to="sndx_ExpirationOfTheEspp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions" xlink:to="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IndefiniteCarryforwardPeriodMember" xlink:to="sndx_IndefiniteCarryforwardPeriodMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_BayerPharmaAgMember" xlink:to="sndx_BayerPharmaAgMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NoncashOperatingLeaseExpense" xlink:to="sndx_NoncashOperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DirectPlacementOfferingMember" xlink:to="sndx_DirectPlacementOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AtTheMarketStockOfferingMember" xlink:to="sndx_AtTheMarketStockOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UpfrontPaymentAllocatedToEquityPurchase" xlink:to="sndx_UpfrontPaymentAllocatedToEquityPurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AccruedClinicalCostsCurrent" xlink:to="sndx_AccruedClinicalCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TwoThousandAndSevenStockIncentivePlanMember" xlink:to="sndx_TwoThousandAndSevenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering" xlink:to="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PaymentForEndOfTermFees" xlink:to="sndx_PaymentForEndOfTermFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_BriggsWMorrisonMember" xlink:to="sndx_BriggsWMorrisonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AllerganLicenseAgreementMember" xlink:to="sndx_AllerganLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sndx_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="sndx_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_MarketReserveMember" xlink:to="sndx_MarketReserveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IncreaseDecreaseInCollaborationReceivable" xlink:to="sndx_IncreaseDecreaseInCollaborationReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AccruedContractualObligation" xlink:to="sndx_AccruedContractualObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LoanAndSecurityAgreementMember" xlink:to="sndx_LoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock" xlink:to="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_UpfrontPaymentAllocatedToLicenseFee" xlink:to="sndx_UpfrontPaymentAllocatedToLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ExpirationOfTheEsppShares" xlink:to="sndx_ExpirationOfTheEsppShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IncyteSharePurchaseAgreementMember" xlink:to="sndx_IncyteSharePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:to="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PreFundedWarrantsMember" xlink:to="sndx_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="sndx_FairValueMeasurementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" xlink:to="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NumberOfEmployeesRetirement" xlink:to="sndx_NumberOfEmployeesRetirement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PreFundedWarrantExerciseShares" xlink:to="sndx_PreFundedWarrantExerciseShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ScenarioOneMember" xlink:to="sndx_ScenarioOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AggregatePotentialMilestonePayable" xlink:to="sndx_AggregatePotentialMilestonePayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_KyowaKirinCoLtdMember" xlink:to="sndx_KyowaKirinCoLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_GlobalAndUnitedStatesMember" xlink:to="sndx_GlobalAndUnitedStatesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IndemnificationObligationsClaimsReserves" xlink:to="sndx_IndemnificationObligationsClaimsReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_WarrantsToPurchaseCommonStockMember" xlink:to="sndx_WarrantsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_IncreaseDecreaseInContractualObligation" xlink:to="sndx_IncreaseDecreaseInContractualObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_NonRefundableCashPaymentsMember" xlink:to="sndx_NonRefundableCashPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AtTheMarketEquityOfferingSalesAgreementMember" xlink:to="sndx_AtTheMarketEquityOfferingSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice" xlink:to="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo" xlink:to="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PotentialMilestonePaymentsReceivable" xlink:to="sndx_PotentialMilestonePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" xlink:to="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_FairValueMeasurementsLineItems" xlink:to="sndx_FairValueMeasurementsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_EasternCooperativeOncologyGroupMember" xlink:to="sndx_EasternCooperativeOncologyGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering" xlink:to="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CollaborationAndLicenseAgreementMember" xlink:to="sndx_CollaborationAndLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CommercializationMilestonesAndTieredRoyalties" xlink:to="sndx_CommercializationMilestonesAndTieredRoyalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock" xlink:to="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract" xlink:to="sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_ValuationTechniqueBlackScholesModelMember" xlink:to="sndx_ValuationTechniqueBlackScholesModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod" xlink:to="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_SeriesWarrantsMember" xlink:to="sndx_SeriesWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PaidInKindInterestAndInterestReversal" xlink:to="sndx_PaidInKindInterestAndInterestReversal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct" xlink:to="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="89.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationPayableCurrent" xlink:label="sndx_CollaborationPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CapitalLeaseLessCurrentPortion" xlink:label="sndx_CapitalLeaseLessCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CurrentPortionOfCapitalLease" xlink:label="sndx_CurrentPortionOfCapitalLease"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationReceivable" xlink:label="sndx_CollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sndx_CollaborationPayableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="sndx_CapitalLeaseLessCurrentPortion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sndx_CurrentPortionOfCapitalLease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="sndx_CollaborationReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementMember" xlink:label="sndx_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DirectPlacementOfferingMember" xlink:label="sndx_DirectPlacementOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingOneMember" xlink:label="sndx_FollowOnPublicOfferingOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingTwoMember" xlink:label="sndx_FollowOnPublicOfferingTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" xlink:label="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodSharesDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantExerciseShares" xlink:label="sndx_PreFundedWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeWithholdingsEspp" xlink:label="sndx_EmployeeWithholdingsEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ParValueAdjustments" xlink:label="sndx_ParValueAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantCashlessExerciseShares" xlink:label="sndx_WarrantCashlessExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantCashlessExerciseAmount" xlink:label="sndx_WarrantCashlessExerciseAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_28"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_DirectPlacementOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueDirectOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesDirectOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_PreFundedWarrantExerciseShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_EmployeeWithholdingsEspp" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_ParValueAdjustments" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_WarrantCashlessExerciseShares" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_WarrantCashlessExerciseAmount" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DirectPlacementOfferingMember" xlink:label="sndx_DirectPlacementOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingOneMember" xlink:label="sndx_FollowOnPublicOfferingOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingTwoMember" xlink:label="sndx_FollowOnPublicOfferingTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValueOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_DirectPlacementOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueOfferingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteSharePurchaseAgreementMember" xlink:label="sndx_IncyteSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DepreciationAndRelatedAdjustment" xlink:label="sndx_DepreciationAndRelatedAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingsMember" xlink:label="sndx_FollowOnPublicOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInCollaborationReceivable" xlink:label="sndx_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketStockOfferingMember" xlink:label="sndx_AtTheMarketStockOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NoncashOperatingLeaseExpense" xlink:label="sndx_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DerivativeLiabilityMember" xlink:label="sndx_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaidInKindInterestAndInterestReversal" xlink:label="sndx_PaidInKindInterestAndInterestReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_IncyteSharePurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sndx_DepreciationAndRelatedAdjustment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sndx_IncreaseDecreaseInCollaborationReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_AtTheMarketStockOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sndx_NoncashOperatingLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_DerivativeLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sndx_PaidInKindInterestAndInterestReversal" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MichaelMetzgerMember" xlink:label="sndx_MichaelMetzgerMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BriggsWMorrisonMember" xlink:label="sndx_BriggsWMorrisonMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sndx_MichaelMetzgerMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sndx_BriggsWMorrisonMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborativeResearchAndLicenseAgreementsTextBlock" xlink:label="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SignificantAgreementsDisclosureTextBlock" xlink:label="sndx_SignificantAgreementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="sndx_SignificantAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommonStockDisclosureTextBlock" xlink:label="sndx_CommonStockDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="sndx_CommonStockDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayable" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClinicalTrialCostPolicyTextBlock" xlink:label="sndx_ClinicalTrialCostPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sndx_ClinicalTrialCostPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CostsRelatedToCostSharingCollaborations" xlink:label="sndx_CostsRelatedToCostSharingCollaborations"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfIncomeTaxContingencyRealized" xlink:label="sndx_PercentageOfIncomeTaxContingencyRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IndemnificationObligationsClaimsReserves" xlink:label="sndx_IndemnificationObligationsClaimsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sndx_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_CostsRelatedToCostSharingCollaborations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sndx_SummaryOfSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_PercentageOfIncomeTaxContingencyRealized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_IndemnificationObligationsClaimsReserves" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementMember" xlink:label="sndx_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_GlobalAndUnitedStatesMember" xlink:label="sndx_GlobalAndUnitedStatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DevelopmentCostsAssociatedWithClinicalTrials" xlink:label="sndx_DevelopmentCostsAssociatedWithClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NonRefundableCashPaymentsMember" xlink:label="sndx_NonRefundableCashPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteCorporationMember" xlink:label="sndx_IncyteCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LicenseAgreementMember" xlink:label="sndx_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPayments" xlink:label="sndx_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_KyowaKirinCoLtdMember" xlink:label="sndx_KyowaKirinCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:label="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommercializationMilestonesAndTieredRoyalties" xlink:label="sndx_CommercializationMilestonesAndTieredRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsReceived" xlink:label="sndx_UpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementCashConsideration" xlink:label="sndx_CollaborationAndLicenseAgreementCashConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" xlink:label="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" xlink:label="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice" xlink:label="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement" xlink:label="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RevenueRecognizedUponTransferOfLicenseAgreement" xlink:label="sndx_RevenueRecognizedUponTransferOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationReceivable" xlink:label="sndx_CollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationExpenseDueToCounterparty" xlink:label="sndx_CollaborationExpenseDueToCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentAllocatedToEquityPurchase" xlink:label="sndx_UpfrontPaymentAllocatedToEquityPurchase"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NonRefundableUpFrontPaymentReceived" xlink:label="sndx_NonRefundableUpFrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PotentialMilestonePaymentsReceivable" xlink:label="sndx_PotentialMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct" xlink:label="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue" xlink:label="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentAllocatedToLicenseFee" xlink:label="sndx_UpfrontPaymentAllocatedToLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RevenueFromContractWithCustomerMilestoneMethodFactors" xlink:label="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sndx_GlobalAndUnitedStatesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_DevelopmentCostsAssociatedWithClinicalTrials" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sndx_NonRefundableCashPaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_IncyteCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_LicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_KyowaKirinCoLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CommercializationMilestonesAndTieredRoyalties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentsReceived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationAndLicenseAgreementCashConsideration" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_RevenueRecognizedUponTransferOfLicenseAgreement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationReceivable" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationExpenseDueToCounterparty" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentAllocatedToEquityPurchase" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_NonRefundableUpFrontPaymentReceived" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_PotentialMilestonePaymentsReceivable" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentAllocatedToLicenseFee" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LeaseCommencementDate" xlink:label="sndx_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sndx_LeaseCommencementDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantsToPurchaseCommonStockMember" xlink:label="sndx_WarrantsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeStockPurchasePlanMember" xlink:label="sndx_EmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sndx_WarrantsToPurchaseCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sndx_EmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantsMember" xlink:label="sndx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockConvertedToWarrants" xlink:label="sndx_NumberOfCommonStockConvertedToWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BiotechnologyValueFundLPMember" xlink:label="sndx_BiotechnologyValueFundLPMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockWarrantsIssued" xlink:label="sndx_NumberOfCommonStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClassOfWarrantOrRightIssued" xlink:label="sndx_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsExchangedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_NumberOfCommonStockConvertedToWarrants" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_BiotechnologyValueFundLPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_NumberOfCommonStockWarrantsIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_ClassOfWarrantOrRightIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AllerganLicenseAgreementMember" xlink:label="sndx_AllerganLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPayments" xlink:label="sndx_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_VitaePharmaceuticalsIncMember" xlink:label="sndx_VitaePharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UcbLicenseAgreementMember" xlink:label="sndx_UcbLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:label="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UCBBiopharmaMember" xlink:label="sndx_UCBBiopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClinicalTrialMember" xlink:label="sndx_ClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AggregatePotentialMilestonePayable" xlink:label="sndx_AggregatePotentialMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EasternCooperativeOncologyGroupMember" xlink:label="sndx_EasternCooperativeOncologyGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LicenseAgreementMember" xlink:label="sndx_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LicenseAgreementsExpirationPeriod" xlink:label="sndx_LicenseAgreementsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BayerPharmaAgMember" xlink:label="sndx_BayerPharmaAgMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedMilestoneExpenses" xlink:label="sndx_AccruedMilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MilestonePaymentDue" xlink:label="sndx_MilestonePaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInContractualObligation" xlink:label="sndx_IncreaseDecreaseInContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RemainingContractualObligation" xlink:label="sndx_RemainingContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ContractualObligationsTerm" xlink:label="sndx_ContractualObligationsTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedContractualObligation" xlink:label="sndx_AccruedContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontLicenseFeesPaid" xlink:label="sndx_UpfrontLicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DevelopmentAndRegulaotryMilestonesExpenses" xlink:label="sndx_DevelopmentAndRegulaotryMilestonesExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MilestoneExpensesPaid" xlink:label="sndx_MilestoneExpensesPaid"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_AllerganLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_UpfrontPayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_VitaePharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_UcbLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_UCBBiopharmaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_ClinicalTrialMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_AggregatePotentialMilestonePayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_EasternCooperativeOncologyGroupMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_LicenseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_LicenseAgreementsExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_BayerPharmaAgMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_AccruedMilestoneExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_MilestonePaymentDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_IncreaseDecreaseInContractualObligation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractualObligation" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_RemainingContractualObligation" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_ContractualObligationsTerm" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_AccruedContractualObligation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_UpfrontLicenseFeesPaid" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_DevelopmentAndRegulaotryMilestonesExpenses" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_MilestoneExpensesPaid" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ComputerAndOfficeEquipmentMember" xlink:label="sndx_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sndx_ComputerAndOfficeEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ValuationTechniqueBlackScholesModelMember" xlink:label="sndx_ValuationTechniqueBlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementsTable" xlink:label="sndx_FairValueMeasurementsTable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementsLineItems" xlink:label="sndx_FairValueMeasurementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DerivativeLiabilityExpectedTimingOfTerminationRight" xlink:label="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="sndx_ValuationTechniqueBlackScholesModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_FairValueMeasurementsLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sndx_FairValueMeasurementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_FairValueMeasurementsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_FairValueMeasurementsLineItems" xlink:to="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="sndx_FairValueMeasurementsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:label="us-gaap_DerivativeLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" xlink:label="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DerivativeLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract" xlink:label="sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FederalBondsMember" xlink:label="sndx_FederalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sndx_FederalBondsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PrepaidSubscriptions" xlink:label="sndx_PrepaidSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PrepaidStateAndLocalTaxes" xlink:label="sndx_PrepaidStateAndLocalTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="sndx_PrepaidSubscriptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="sndx_PrepaidStateAndLocalTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidRent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedClinicalCostsCurrent" xlink:label="sndx_AccruedClinicalCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedMilestoneCosts" xlink:label="sndx_AccruedMilestoneCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sndx_AccruedClinicalCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sndx_AccruedMilestoneCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember" xlink:label="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantsMember" xlink:label="sndx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CowenAndCompanyLLCMember" xlink:label="sndx_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketEquityOfferingSalesAgreementMember" xlink:label="sndx_AtTheMarketEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BiotechnologyValueFundLPMember" xlink:label="sndx_BiotechnologyValueFundLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesWarrantsMember" xlink:label="sndx_SeriesWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesOneWarrantsMember" xlink:label="sndx_SeriesOneWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesTwoWarrantsMember" xlink:label="sndx_SeriesTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockConvertedToWarrants" xlink:label="sndx_NumberOfCommonStockConvertedToWarrants"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesOneAndSeriesTwoWarrantsMember" xlink:label="sndx_SeriesOneAndSeriesTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockWarrantsIssued" xlink:label="sndx_NumberOfCommonStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantExpirationTerm" xlink:label="sndx_WarrantExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock" xlink:label="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfSeriesOfWarrants" xlink:label="sndx_NumberOfSeriesOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClassOfWarrantOrRightTerm" xlink:label="sndx_ClassOfWarrantOrRightTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_OfferingPricePerShare" xlink:label="sndx_OfferingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_GrossProceedsFromOffering" xlink:label="sndx_GrossProceedsFromOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_OfferingCost" xlink:label="sndx_OfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantsExercisedPeriod" xlink:label="sndx_WarrantsExercisedPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice" xlink:label="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock" xlink:label="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MaximumBeneficialOwnershipLimitationPercentage" xlink:label="sndx_MaximumBeneficialOwnershipLimitationPercentage"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueOfWarrants" xlink:label="sndx_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfWarrantsExercisedInCashlessExercise" xlink:label="sndx_NumberOfWarrantsExercisedInCashlessExercise"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="sndx_CowenAndCompanyLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sndx_AtTheMarketEquityOfferingSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_BiotechnologyValueFundLPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_SeriesWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_SeriesOneWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_SeriesTwoWarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfCommonStockConvertedToWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_SeriesOneAndSeriesTwoWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfCommonStockWarrantsIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_WarrantExpirationTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfSeriesOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_ClassOfWarrantOrRightTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_OfferingPricePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_GrossProceedsFromOffering" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_OfferingCost" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_WarrantsExercisedPeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_MaximumBeneficialOwnershipLimitationPercentage" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_FairValueOfWarrants" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfWarrantsExercisedInCashlessExercise" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantsMember" xlink:label="sndx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EquityPlansMember" xlink:label="sndx_EquityPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MarketReserveMember" xlink:label="sndx_MarketReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketProgramMember" xlink:label="sndx_AtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeStockPurchasePlanMember" xlink:label="sndx_EmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_EquityPlansMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_MarketReserveMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_AtTheMarketProgramMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_EmployeeStockPurchasePlanMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeesMember" xlink:label="sndx_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandFifteenOmnibusIncentivePlanMember" xlink:label="sndx_TwoThousandFifteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndSevenStockIncentivePlanMember" xlink:label="sndx_TwoThousandAndSevenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeStockPurchasePlanMember" xlink:label="sndx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ServiceBasedOptionsMember" xlink:label="sndx_ServiceBasedOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndSeventeenPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndSeventeenPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndNineteenPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndNineteenPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandTwentyThreePerformanceAwardsMember" xlink:label="sndx_TwoThousandTwentyThreePerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfEmployeesRetirement" xlink:label="sndx_NumberOfEmployeesRetirement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExpirationOfTheEspp" xlink:label="sndx_ExpirationOfTheEspp"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExpirationOfTheEsppShares" xlink:label="sndx_ExpirationOfTheEsppShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sndx_EmployeesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_TwoThousandFifteenOmnibusIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_TwoThousandAndSevenStockIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_EmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_ServiceBasedOptionsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_TwoThousandAndSeventeenPerformanceAwardsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_TwoThousandAndNineteenPerformanceAwardsMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_TwoThousandTwentyThreePerformanceAwardsMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember" order="9.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_NumberOfEmployeesRetirement" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ExpirationOfTheEspp" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ExpirationOfTheEsppShares" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_HerculesCapitalIncMember" xlink:label="sndx_HerculesCapitalIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ScenarioOneMember" xlink:label="sndx_ScenarioOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TermLoanMember" xlink:label="sndx_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LoanAndSecurityAgreementMember" xlink:label="sndx_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ScenarioTwoMember" xlink:label="sndx_ScenarioTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdditionalTermLoanMember" xlink:label="sndx_AdditionalTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FirstAmendmentToLoanAndSecurityAgreementMember" xlink:label="sndx_FirstAmendmentToLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentTrancheTwoMember" xlink:label="sndx_DebtInstrumentTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityElectedNotToDraw" xlink:label="sndx_LineOfCreditFacilityElectedNotToDraw"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentTrancheThreeMember" xlink:label="sndx_DebtInstrumentTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaymentOfFacilityCharges" xlink:label="sndx_PaymentOfFacilityCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentInterestOnlyPeriodExpirationDate" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfFacilityChargeOfFutureDraws" xlink:label="sndx_PercentageOfFacilityChargeOfFutureDraws"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfEndOfTermChargeToFutureDraws" xlink:label="sndx_PercentageOfEndOfTermChargeToFutureDraws"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaymentForEndOfTermFees" xlink:label="sndx_PaymentForEndOfTermFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PrepaymentFee" xlink:label="sndx_PrepaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityMinimumCashCovenant" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityMinimumCashCovenantWaived" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenantWaived"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdditionalDefaultInterestRate" xlink:label="sndx_AdditionalDefaultInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="sndx_HerculesCapitalIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sndx_ScenarioOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sndx_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="sndx_LoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sndx_ScenarioTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sndx_AdditionalTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="sndx_FirstAmendmentToLoanAndSecurityAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sndx_DebtInstrumentTrancheTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_LineOfCreditFacilityElectedNotToDraw" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sndx_DebtInstrumentTrancheThreeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_PrimeRateMember_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PaymentOfFacilityCharges" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfFacilityChargeOfFutureDraws" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfEndOfTermChargeToFutureDraws" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PaymentForEndOfTermFees" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForFees" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PrepaymentFee" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_LineOfCreditFacilityMinimumCashCovenant" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_LineOfCreditFacilityMinimumCashCovenantWaived" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_AdditionalDefaultInterestRate" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AmortizedLossesReacquiredDebtNoncurrent" xlink:label="sndx_AmortizedLossesReacquiredDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="sndx_AmortizedLossesReacquiredDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LoansPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncomeTaxesTable" xlink:label="sndx_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IndefiniteCarryforwardPeriodMember" xlink:label="sndx_IndefiniteCarryforwardPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncomeTaxesLineItems" xlink:label="sndx_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BeginToExpireInTwoThousandAndTwentySixMember" xlink:label="sndx_BeginToExpireInTwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceMethodologiesAndAssumptions" xlink:label="us-gaap_ValuationAllowanceMethodologiesAndAssumptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod" xlink:label="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod" xlink:label="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sndx_IndefiniteCarryforwardPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sndx_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sndx_BeginToExpireInTwoThousandAndTwentySixMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesTable" xlink:to="sndx_IncomeTaxesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceMethodologiesAndAssumptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ReturnToProvisionTrueUp" xlink:label="sndx_ReturnToProvisionTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="sndx_ReturnToProvisionTrueUp" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" xlink:label="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementMember" xlink:label="sndx_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommitmentAndContingenciesTable" xlink:label="sndx_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_GlobalAndUnitedStatesMember" xlink:label="sndx_GlobalAndUnitedStatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NonRefundableCashPaymentsMember" xlink:label="sndx_NonRefundableCashPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesB1PurchaseAgreementMember" xlink:label="sndx_SeriesB1PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommitmentAndContingenciesLineItems" xlink:label="sndx_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPayments" xlink:label="sndx_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="us-gaap_EquityMethodInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DevelopmentCostsAssociatedWithClinicalTrials" xlink:label="sndx_DevelopmentCostsAssociatedWithClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sndx_GlobalAndUnitedStatesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sndx_CommitmentAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sndx_NonRefundableCashPaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="sndx_SeriesB1PurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="sndx_UpfrontPayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_EquityMethodInvestmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="sndx_DevelopmentCostsAssociatedWithClinicalTrials" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="sndx_CommitmentAndContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementMember" xlink:label="sndx_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DirectPlacementOfferingMember" xlink:label="sndx_DirectPlacementOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingOneMember" xlink:label="sndx_FollowOnPublicOfferingOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingTwoMember" xlink:label="sndx_FollowOnPublicOfferingTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" xlink:label="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodSharesDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering" xlink:label="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantExerciseShares" xlink:label="sndx_PreFundedWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeWithholdingsEspp" xlink:label="sndx_EmployeeWithholdingsEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ParValueAdjustments" xlink:label="sndx_ParValueAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantCashlessExerciseShares" xlink:label="sndx_WarrantCashlessExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantCashlessExerciseAmount" xlink:label="sndx_WarrantCashlessExerciseAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_DirectPlacementOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueDirectOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesDirectOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_PreFundedWarrantExerciseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_EmployeeWithholdingsEspp" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_ParValueAdjustments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_WarrantCashlessExerciseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_WarrantCashlessExerciseAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DirectPlacementOfferingMember" xlink:label="sndx_DirectPlacementOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingOneMember" xlink:label="sndx_FollowOnPublicOfferingOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant" xlink:label="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingTwoMember" xlink:label="sndx_FollowOnPublicOfferingTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValueOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValueOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses" xlink:label="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_DirectPlacementOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValueOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteSharePurchaseAgreementMember" xlink:label="sndx_IncyteSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DepreciationAndRelatedAdjustment" xlink:label="sndx_DepreciationAndRelatedAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FollowOnPublicOfferingsMember" xlink:label="sndx_FollowOnPublicOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInCollaborationReceivable" xlink:label="sndx_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketStockOfferingMember" xlink:label="sndx_AtTheMarketStockOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NoncashOperatingLeaseExpense" xlink:label="sndx_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DerivativeLiabilityMember" xlink:label="sndx_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaidInKindInterestAndInterestReversal" xlink:label="sndx_PaidInKindInterestAndInterestReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_IncyteSharePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sndx_DepreciationAndRelatedAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_FollowOnPublicOfferingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sndx_IncreaseDecreaseInCollaborationReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_AtTheMarketStockOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sndx_NoncashOperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sndx_DerivativeLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sndx_PaidInKindInterestAndInterestReversal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MichaelMetzgerMember" xlink:label="sndx_MichaelMetzgerMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BriggsWMorrisonMember" xlink:label="sndx_BriggsWMorrisonMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sndx_MichaelMetzgerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sndx_BriggsWMorrisonMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sndx_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CostsRelatedToCostSharingCollaborations" xlink:label="sndx_CostsRelatedToCostSharingCollaborations"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfIncomeTaxContingencyRealized" xlink:label="sndx_PercentageOfIncomeTaxContingencyRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IndemnificationObligationsClaimsReserves" xlink:label="sndx_IndemnificationObligationsClaimsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_CostsRelatedToCostSharingCollaborations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_PercentageOfIncomeTaxContingencyRealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sndx_IndemnificationObligationsClaimsReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementMember" xlink:label="sndx_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_GlobalAndUnitedStatesMember" xlink:label="sndx_GlobalAndUnitedStatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DevelopmentCostsAssociatedWithClinicalTrials" xlink:label="sndx_DevelopmentCostsAssociatedWithClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NonRefundableCashPaymentsMember" xlink:label="sndx_NonRefundableCashPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteCorporationMember" xlink:label="sndx_IncyteCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LicenseAgreementMember" xlink:label="sndx_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPayments" xlink:label="sndx_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_KyowaKirinCoLtdMember" xlink:label="sndx_KyowaKirinCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:label="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommercializationMilestonesAndTieredRoyalties" xlink:label="sndx_CommercializationMilestonesAndTieredRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsReceived" xlink:label="sndx_UpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementCashConsideration" xlink:label="sndx_CollaborationAndLicenseAgreementCashConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" xlink:label="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" xlink:label="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice" xlink:label="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement" xlink:label="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RevenueRecognizedUponTransferOfLicenseAgreement" xlink:label="sndx_RevenueRecognizedUponTransferOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationReceivable" xlink:label="sndx_CollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationExpenseDueToCounterparty" xlink:label="sndx_CollaborationExpenseDueToCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentAllocatedToEquityPurchase" xlink:label="sndx_UpfrontPaymentAllocatedToEquityPurchase"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NonRefundableUpFrontPaymentReceived" xlink:label="sndx_NonRefundableUpFrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PotentialMilestonePaymentsReceivable" xlink:label="sndx_PotentialMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct" xlink:label="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue" xlink:label="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPaymentAllocatedToLicenseFee" xlink:label="sndx_UpfrontPaymentAllocatedToLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RevenueFromContractWithCustomerMilestoneMethodFactors" xlink:label="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sndx_GlobalAndUnitedStatesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_DevelopmentCostsAssociatedWithClinicalTrials" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sndx_NonRefundableCashPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_IncyteCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_LicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_KyowaKirinCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CommercializationMilestonesAndTieredRoyalties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationAndLicenseAgreementCashConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_RevenueRecognizedUponTransferOfLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_CollaborationExpenseDueToCounterparty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentAllocatedToEquityPurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_NonRefundableUpFrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_PotentialMilestonePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_UpfrontPaymentAllocatedToLicenseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LeaseCommencementDate" xlink:label="sndx_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sndx_LeaseCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantsToPurchaseCommonStockMember" xlink:label="sndx_WarrantsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeStockPurchasePlanMember" xlink:label="sndx_EmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sndx_WarrantsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sndx_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantsMember" xlink:label="sndx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockConvertedToWarrants" xlink:label="sndx_NumberOfCommonStockConvertedToWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BiotechnologyValueFundLPMember" xlink:label="sndx_BiotechnologyValueFundLPMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockWarrantsIssued" xlink:label="sndx_NumberOfCommonStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClassOfWarrantOrRightIssued" xlink:label="sndx_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsExchangedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_NumberOfCommonStockConvertedToWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_BiotechnologyValueFundLPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_NumberOfCommonStockWarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_ClassOfWarrantOrRightIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AllerganLicenseAgreementMember" xlink:label="sndx_AllerganLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPayments" xlink:label="sndx_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_VitaePharmaceuticalsIncMember" xlink:label="sndx_VitaePharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UcbLicenseAgreementMember" xlink:label="sndx_UcbLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:label="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UCBBiopharmaMember" xlink:label="sndx_UCBBiopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClinicalTrialMember" xlink:label="sndx_ClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AggregatePotentialMilestonePayable" xlink:label="sndx_AggregatePotentialMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EasternCooperativeOncologyGroupMember" xlink:label="sndx_EasternCooperativeOncologyGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LicenseAgreementMember" xlink:label="sndx_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LicenseAgreementsExpirationPeriod" xlink:label="sndx_LicenseAgreementsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BayerPharmaAgMember" xlink:label="sndx_BayerPharmaAgMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedMilestoneExpenses" xlink:label="sndx_AccruedMilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MilestonePaymentDue" xlink:label="sndx_MilestonePaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInContractualObligation" xlink:label="sndx_IncreaseDecreaseInContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_RemainingContractualObligation" xlink:label="sndx_RemainingContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ContractualObligationsTerm" xlink:label="sndx_ContractualObligationsTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedContractualObligation" xlink:label="sndx_AccruedContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontLicenseFeesPaid" xlink:label="sndx_UpfrontLicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DevelopmentAndRegulaotryMilestonesExpenses" xlink:label="sndx_DevelopmentAndRegulaotryMilestonesExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MilestoneExpensesPaid" xlink:label="sndx_MilestoneExpensesPaid"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_AllerganLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_UpfrontPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_VitaePharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_UcbLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_UCBBiopharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_ClinicalTrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_AggregatePotentialMilestonePayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_EasternCooperativeOncologyGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_LicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_LicenseAgreementsExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_BayerPharmaAgMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_AccruedMilestoneExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_MilestonePaymentDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_IncreaseDecreaseInContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_RemainingContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_ContractualObligationsTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_AccruedContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_UpfrontLicenseFeesPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_DevelopmentAndRegulaotryMilestonesExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sndx_MilestoneExpensesPaid" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ComputerAndOfficeEquipmentMember" xlink:label="sndx_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sndx_ComputerAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail">
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementsLineItems" xlink:label="sndx_FairValueMeasurementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueMeasurementsTable" xlink:label="sndx_FairValueMeasurementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ValuationTechniqueBlackScholesModelMember" xlink:label="sndx_ValuationTechniqueBlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DerivativeLiabilityExpectedTimingOfTerminationRight" xlink:label="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sndx_FairValueMeasurementsLineItems" xlink:to="sndx_FairValueMeasurementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="sndx_ValuationTechniqueBlackScholesModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_FairValueMeasurementsLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_FairValueMeasurementsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_FairValueMeasurementsLineItems" xlink:to="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_FairValueMeasurementsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FederalBondsMember" xlink:label="sndx_FederalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sndx_FederalBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember" xlink:label="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantsMember" xlink:label="sndx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CowenAndCompanyLLCMember" xlink:label="sndx_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketEquityOfferingSalesAgreementMember" xlink:label="sndx_AtTheMarketEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BiotechnologyValueFundLPMember" xlink:label="sndx_BiotechnologyValueFundLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesWarrantsMember" xlink:label="sndx_SeriesWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesOneWarrantsMember" xlink:label="sndx_SeriesOneWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesTwoWarrantsMember" xlink:label="sndx_SeriesTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockConvertedToWarrants" xlink:label="sndx_NumberOfCommonStockConvertedToWarrants"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesOneAndSeriesTwoWarrantsMember" xlink:label="sndx_SeriesOneAndSeriesTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfCommonStockWarrantsIssued" xlink:label="sndx_NumberOfCommonStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:label="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantExpirationTerm" xlink:label="sndx_WarrantExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock" xlink:label="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfSeriesOfWarrants" xlink:label="sndx_NumberOfSeriesOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ClassOfWarrantOrRightTerm" xlink:label="sndx_ClassOfWarrantOrRightTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_OfferingPricePerShare" xlink:label="sndx_OfferingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_GrossProceedsFromOffering" xlink:label="sndx_GrossProceedsFromOffering"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_OfferingCost" xlink:label="sndx_OfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_WarrantsExercisedPeriod" xlink:label="sndx_WarrantsExercisedPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice" xlink:label="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock" xlink:label="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MaximumBeneficialOwnershipLimitationPercentage" xlink:label="sndx_MaximumBeneficialOwnershipLimitationPercentage"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FairValueOfWarrants" xlink:label="sndx_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfWarrantsExercisedInCashlessExercise" xlink:label="sndx_NumberOfWarrantsExercisedInCashlessExercise"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" xlink:label="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="sndx_CowenAndCompanyLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sndx_AtTheMarketEquityOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sndx_BiotechnologyValueFundLPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_SeriesWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_SeriesOneWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_SeriesTwoWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfCommonStockConvertedToWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_SeriesOneAndSeriesTwoWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfCommonStockWarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_WarrantExpirationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfSeriesOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_ClassOfWarrantOrRightTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_OfferingPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_GrossProceedsFromOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_OfferingCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_WarrantsExercisedPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_MaximumBeneficialOwnershipLimitationPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_FairValueOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_NumberOfWarrantsExercisedInCashlessExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PreFundedWarrantsMember" xlink:label="sndx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EquityPlansMember" xlink:label="sndx_EquityPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_MarketReserveMember" xlink:label="sndx_MarketReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AtTheMarketProgramMember" xlink:label="sndx_AtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeStockPurchasePlanMember" xlink:label="sndx_EmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sndx_EquityPlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_MarketReserveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_AtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeesMember" xlink:label="sndx_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandFifteenOmnibusIncentivePlanMember" xlink:label="sndx_TwoThousandFifteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ServiceBasedOptionsMember" xlink:label="sndx_ServiceBasedOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndSeventeenPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndSeventeenPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndSevenStockIncentivePlanMember" xlink:label="sndx_TwoThousandAndSevenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndNineteenPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndNineteenPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeStockPurchasePlanMember" xlink:label="sndx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandTwentyThreePerformanceAwardsMember" xlink:label="sndx_TwoThousandTwentyThreePerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember" xlink:label="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet" xlink:label="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NumberOfEmployeesRetirement" xlink:label="sndx_NumberOfEmployeesRetirement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" xlink:label="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExpirationOfTheEspp" xlink:label="sndx_ExpirationOfTheEspp"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ExpirationOfTheEsppShares" xlink:label="sndx_ExpirationOfTheEsppShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sndx_EmployeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_TwoThousandFifteenOmnibusIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_ServiceBasedOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_TwoThousandAndSeventeenPerformanceAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_TwoThousandAndSevenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_TwoThousandAndNineteenPerformanceAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sndx_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_TwoThousandTwentyThreePerformanceAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_NumberOfEmployeesRetirement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ExpirationOfTheEspp" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sndx_ExpirationOfTheEsppShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_HerculesCapitalIncMember" xlink:label="sndx_HerculesCapitalIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ScenarioOneMember" xlink:label="sndx_ScenarioOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_TermLoanMember" xlink:label="sndx_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LoanAndSecurityAgreementMember" xlink:label="sndx_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_ScenarioTwoMember" xlink:label="sndx_ScenarioTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdditionalTermLoanMember" xlink:label="sndx_AdditionalTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_FirstAmendmentToLoanAndSecurityAgreementMember" xlink:label="sndx_FirstAmendmentToLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentTrancheTwoMember" xlink:label="sndx_DebtInstrumentTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityElectedNotToDraw" xlink:label="sndx_LineOfCreditFacilityElectedNotToDraw"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentTrancheThreeMember" xlink:label="sndx_DebtInstrumentTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaymentOfFacilityCharges" xlink:label="sndx_PaymentOfFacilityCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentInterestOnlyPeriodExpirationDate" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo" xlink:label="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter" xlink:label="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfFacilityChargeOfFutureDraws" xlink:label="sndx_PercentageOfFacilityChargeOfFutureDraws"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PercentageOfEndOfTermChargeToFutureDraws" xlink:label="sndx_PercentageOfEndOfTermChargeToFutureDraws"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaymentForEndOfTermFees" xlink:label="sndx_PaymentForEndOfTermFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PrepaymentFee" xlink:label="sndx_PrepaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityMinimumCashCovenant" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenant"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LineOfCreditFacilityMinimumCashCovenantWaived" xlink:label="sndx_LineOfCreditFacilityMinimumCashCovenantWaived"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AdditionalDefaultInterestRate" xlink:label="sndx_AdditionalDefaultInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="sndx_HerculesCapitalIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sndx_ScenarioOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sndx_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="sndx_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sndx_ScenarioTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sndx_AdditionalTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="sndx_FirstAmendmentToLoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sndx_DebtInstrumentTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_LineOfCreditFacilityElectedNotToDraw" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sndx_DebtInstrumentTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PaymentOfFacilityCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfFacilityChargeOfFutureDraws" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PercentageOfEndOfTermChargeToFutureDraws" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PaymentForEndOfTermFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_PrepaymentFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_LineOfCreditFacilityMinimumCashCovenant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_LineOfCreditFacilityMinimumCashCovenantWaived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sndx_AdditionalDefaultInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncomeTaxesLineItems" xlink:label="sndx_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncomeTaxesTable" xlink:label="sndx_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IndefiniteCarryforwardPeriodMember" xlink:label="sndx_IndefiniteCarryforwardPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_BeginToExpireInTwoThousandAndTwentySixMember" xlink:label="sndx_BeginToExpireInTwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceMethodologiesAndAssumptions" xlink:label="us-gaap_ValuationAllowanceMethodologiesAndAssumptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod" xlink:label="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod" xlink:label="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="sndx_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sndx_IndefiniteCarryforwardPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sndx_BeginToExpireInTwoThousandAndTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceMethodologiesAndAssumptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommitmentAndContingenciesLineItems" xlink:label="sndx_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CommitmentAndContingenciesTable" xlink:label="sndx_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationAndLicenseAgreementMember" xlink:label="sndx_CollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_GlobalAndUnitedStatesMember" xlink:label="sndx_GlobalAndUnitedStatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NonRefundableCashPaymentsMember" xlink:label="sndx_NonRefundableCashPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_SeriesB1PurchaseAgreementMember" xlink:label="sndx_SeriesB1PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_UpfrontPayments" xlink:label="sndx_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="us-gaap_EquityMethodInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DevelopmentCostsAssociatedWithClinicalTrials" xlink:label="sndx_DevelopmentCostsAssociatedWithClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="sndx_CommitmentAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sndx_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sndx_GlobalAndUnitedStatesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sndx_NonRefundableCashPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="sndx_SeriesB1PurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="sndx_UpfrontPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_EquityMethodInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="sndx_DevelopmentCostsAssociatedWithClinicalTrials" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sndx_CommitmentAndContingenciesTable" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sndx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermLoansPayable" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="sndx_CollaborationReceivable" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sndx_CollaborationPayableCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="sndx_CapitalLeaseLessCurrentPortion" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCash" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sndx_CurrentPortionOfCapitalLease" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationReceivable" xlink:label="sndx_CollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CollaborationPayableCurrent" xlink:label="sndx_CollaborationPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CapitalLeaseLessCurrentPortion" xlink:label="sndx_CapitalLeaseLessCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_CurrentPortionOfCapitalLease" xlink:label="sndx_CurrentPortionOfCapitalLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sndx_DepreciationAndRelatedAdjustment" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sndx_NoncashOperatingLeaseExpense" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sndx_PaidInKindInterestAndInterestReversal" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="7" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sndx_IncreaseDecreaseInCollaborationReceivable" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="12" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DepreciationAndRelatedAdjustment" xlink:label="sndx_DepreciationAndRelatedAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_NoncashOperatingLeaseExpense" xlink:label="sndx_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_PaidInKindInterestAndInterestReversal" xlink:label="sndx_PaidInKindInterestAndInterestReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_IncreaseDecreaseInCollaborationReceivable" xlink:label="sndx_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="sndx_AccruedClinicalCostsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AccruedClinicalCostsCurrent" xlink:label="sndx_AccruedClinicalCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="sndx_AmortizedLossesReacquiredDebtNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayableCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LongTermLoansPayable" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_AmortizedLossesReacquiredDebtNoncurrent" xlink:label="sndx_AmortizedLossesReacquiredDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" xlink:label="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="sndx-20231231.xsd#sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sndx_CostsRelatedToCostSharingCollaborations" name="CostsRelatedToCostSharingCollaborations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_CommitmentAndContingenciesTable" name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_EmployeesMember" name="EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_UpfrontLicenseFeesPaid" name="UpfrontLicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering" name="StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_IncreaseDecreaseInCollaborationReceivable" name="IncreaseDecreaseInCollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_ScenarioTwoMember" name="ScenarioTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_MichaelMetzgerMember" name="MichaelMetzgerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_UcbLicenseAgreementMember" name="UcbLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions" name="EmployeeServiceShareBasedCompensationRecognizedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement" name="EstimatedStandaloneSellingPriceOfLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_TwoThousandTwentyThreeInducementIncentivePlanMember" name="TwoThousandTwentyThreeInducementIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_SeriesOneWarrantsMember" name="SeriesOneWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_WarrantCashlessExerciseShares" name="WarrantCashlessExerciseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_PercentageOfIncomeTaxContingencyRealized" name="PercentageOfIncomeTaxContingencyRealized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_CollaborativeResearchAndLicenseAgreementsTextBlock" name="CollaborativeResearchAndLicenseAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock" name="ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_PotentialMilestonePaymentsUponAchievementOfMilestone" name="PotentialMilestonePaymentsUponAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_DerivativeLiabilityMember" name="DerivativeLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" name="UpfrontPaymentsToBeReturnedUponTerminationOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_PrepaymentFee" name="PrepaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_AtTheMarketStockOfferingMember" name="AtTheMarketStockOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_NumberOfEmployeesRetirement" name="NumberOfEmployeesRetirement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_ClassOfWarrantOrRightTerm" name="ClassOfWarrantOrRightTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_ExpirationOfTheEspp" name="ExpirationOfTheEspp" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sndx_SeriesWarrantsMember" name="SeriesWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_LineOfCreditFacilityMinimumCashCovenantWaived" name="LineOfCreditFacilityMinimumCashCovenantWaived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sndx_CollaborationExpenseDueToCounterparty" name="CollaborationExpenseDueToCounterparty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_AdditionalDefaultInterestRate" name="AdditionalDefaultInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" name="CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_RevenueFromContractWithCustomerMilestoneMethodFactors" name="RevenueFromContractWithCustomerMilestoneMethodFactors" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_CollaborationAndLicenseAgreementCashConsideration" name="CollaborationAndLicenseAgreementCashConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_EquityPlansMember" name="EquityPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_CollaborationPayableCurrent" name="CollaborationPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_IncyteSharePurchaseAgreementMember" name="IncyteSharePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_FollowOnPublicOfferingOneMember" name="FollowOnPublicOfferingOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_GlobalAndUnitedStatesMember" name="GlobalAndUnitedStatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_AggregatePotentialMilestonePayable" name="AggregatePotentialMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_DerivativeLiabilityExpectedTimingOfTerminationRight" name="DerivativeLiabilityExpectedTimingOfTerminationRight" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_NumberOfWarrantsExercisedInCashlessExercise" name="NumberOfWarrantsExercisedInCashlessExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_PaymentOfFacilityCharges" name="PaymentOfFacilityCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_WarrantExpirationTerm" name="WarrantExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" name="AdjustmentsToAdditionalPaidInCapitalRepricingWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_DebtInstrumentTrancheTwoMember" name="DebtInstrumentTrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_WarrantsExercisedPeriod" name="WarrantsExercisedPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_LicenseAgreementsExpirationPeriod" name="LicenseAgreementsExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear" name="PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_PrepaidStateAndLocalTaxes" name="PrepaidStateAndLocalTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_ClinicalTrialMember" name="ClinicalTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_DirectPlacementOfferingMember" name="DirectPlacementOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_NumberOfSeriesOfWarrants" name="NumberOfSeriesOfWarrants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_EmployeeWithholdingsEspp" name="EmployeeWithholdingsEspp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_BriggsWMorrisonMember" name="BriggsWMorrisonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_CommercializationMilestonesAndTieredRoyalties" name="CommercializationMilestonesAndTieredRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_OfferingPricePerShare" name="OfferingPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_UCBBiopharmaMember" name="UCBBiopharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_ExpirationOfTheEsppShares" name="ExpirationOfTheEsppShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_AtTheMarketEquityOfferingSalesAgreementMember" name="AtTheMarketEquityOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_ValuationTechniqueBlackScholesModelMember" name="ValuationTechniqueBlackScholesModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_SignificantAgreementsDisclosureTextBlock" name="SignificantAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_TwoThousandAndNineteenPerformanceAwardsMember" name="TwoThousandAndNineteenPerformanceAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice" name="MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod" name="DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_GrossProceedsFromOffering" name="GrossProceedsFromOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_MarketReserveMember" name="MarketReserveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember" name="IncyteCollaborationAgreementAndSharePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_ParValueAdjustments" name="ParValueAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_SeriesTwoWarrantsMember" name="SeriesTwoWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" name="StockIssuedDuringPeriodSharesAtTheMarketOfferingNet" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_NumberOfPreFundedWarrantsExchangedForCommonStock" name="NumberOfPreFundedWarrantsExchangedForCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_BeginToExpireInTwoThousandAndTwentySixMember" name="BeginToExpireInTwoThousandAndTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_MaximumBeneficialOwnershipLimitationPercentage" name="MaximumBeneficialOwnershipLimitationPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodSharesDirectOffering" name="StockIssuedDuringPeriodSharesDirectOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_PercentageOfEndOfTermChargeToFutureDraws" name="PercentageOfEndOfTermChargeToFutureDraws" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" name="StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_FairValueMeasurementsTable" name="FairValueMeasurementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_LineOfCreditFacilityMinimumCashCovenant" name="LineOfCreditFacilityMinimumCashCovenant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_BayerPharmaAgMember" name="BayerPharmaAgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_IncyteCorporationMember" name="IncyteCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_AccruedClinicalCostsCurrent" name="AccruedClinicalCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_MilestoneExpensesPaid" name="MilestoneExpensesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_PrepaidSubscriptions" name="PrepaidSubscriptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_FederalBondsMember" name="FederalBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_FollowOnPublicOfferingsMember" name="FollowOnPublicOfferingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod" name="DeferredTaxAssetsResearchCreditsExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_AccruedContractualObligation" name="AccruedContractualObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_ClinicalTrialCostPolicyTextBlock" name="ClinicalTrialCostPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_TwoThousandAndSevenStockIncentivePlanMember" name="TwoThousandAndSevenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering" name="StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_KyowaKirinCoLtdMember" name="KyowaKirinCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant" name="StockIssuedDuringPeriodValuePreFundedCommonStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_TwoThousandTwentyThreePerformanceAwardsMember" name="TwoThousandTwentyThreePerformanceAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_IncreaseDecreaseInContractualObligation" name="IncreaseDecreaseInContractualObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses" name="StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_ReturnToProvisionTrueUp" name="ReturnToProvisionTrueUp" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_CommonStockDisclosureTextBlock" name="CommonStockDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_IndefiniteCarryforwardPeriodMember" name="IndefiniteCarryforwardPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_LineOfCreditFacilityElectedNotToDraw" name="LineOfCreditFacilityElectedNotToDraw" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_BiotechnologyValueFundLPMember" name="BiotechnologyValueFundLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_ServiceBasedOptionsMember" name="ServiceBasedOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_UpfrontPayments" name="UpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_SeriesB1PurchaseAgreementMember" name="SeriesB1PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_CurrentPortionOfCapitalLease" name="CurrentPortionOfCapitalLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_MilestonePaymentDue" name="MilestonePaymentDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_RevenueRecognizedUponTransferOfLicenseAgreement" name="RevenueRecognizedUponTransferOfLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock" name="NumberOfPreFundedWarrantsCashlessExchangedForCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_CommitmentAndContingenciesLineItems" name="CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_UpfrontPaymentAllocatedToLicenseFee" name="UpfrontPaymentAllocatedToLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract" name="AvailableForSaleSecuritiesFairValueDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_NumberOfCommonStockConvertedToWarrants" name="NumberOfCommonStockConvertedToWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_DevelopmentCostsAssociatedWithClinicalTrials" name="DevelopmentCostsAssociatedWithClinicalTrials" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_FairValueMeasurementsLineItems" name="FairValueMeasurementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_CollaborationReceivable" name="CollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_DebtInstrumentTrancheThreeMember" name="DebtInstrumentTrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_DepreciationAndRelatedAdjustment" name="DepreciationAndRelatedAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_NumberOfPreFundedWarrantsExercisedForCommonStock" name="NumberOfPreFundedWarrantsExercisedForCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sndx_TwoThousandFifteenOmnibusIncentivePlanMember" name="TwoThousandFifteenOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValueDirectOffering" name="StockIssuedDuringPeriodValueDirectOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_HerculesCapitalIncMember" name="HerculesCapitalIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_AdditionalTermLoanMember" name="AdditionalTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_NonRefundableUpFrontPaymentReceived" name="NonRefundableUpFrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_ScenarioOneMember" name="ScenarioOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_PaymentForEndOfTermFees" name="PaymentForEndOfTermFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo" name="DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValueOfferingExpenses" name="StockIssuedDuringPeriodValueOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_FairValueOfWarrants" name="FairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_PercentageOfFacilityChargeOfFutureDraws" name="PercentageOfFacilityChargeOfFutureDraws" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_PreFundedWarrantExerciseShares" name="PreFundedWarrantExerciseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_WarrantCashlessExerciseAmount" name="WarrantCashlessExerciseAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_PaidInKindInterestAndInterestReversal" name="PaidInKindInterestAndInterestReversal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_UpfrontPaymentAllocatedToEquityPurchase" name="UpfrontPaymentAllocatedToEquityPurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_DevelopmentAndRegulaotryMilestonesExpenses" name="DevelopmentAndRegulaotryMilestonesExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock" name="ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember" name="TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_TwoThousandAndSeventeenPerformanceAwardsMember" name="TwoThousandAndSeventeenPerformanceAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_SeriesOneAndSeriesTwoWarrantsMember" name="SeriesOneAndSeriesTwoWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice" name="CollaborationAndLicenseAgreementConsiderationTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_CapitalLeaseLessCurrentPortion" name="CapitalLeaseLessCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_DebtInstrumentInterestOnlyPeriodExpirationDate" name="DebtInstrumentInterestOnlyPeriodExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_OfferingCost" name="OfferingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear" name="PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sndx_AmortizedLossesReacquiredDebtNoncurrent" name="AmortizedLossesReacquiredDebtNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_RemainingContractualObligation" name="RemainingContractualObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct" name="PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_EasternCooperativeOncologyGroupMember" name="EasternCooperativeOncologyGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_FirstAmendmentToLoanAndSecurityAgreementMember" name="FirstAmendmentToLoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_NumberOfCommonStockWarrantsIssued" name="NumberOfCommonStockWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant" name="StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet" name="StockIssuedDuringPeriodValueAtTheMarketOfferingNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember" name="TwoThousandAndTwentyTwoPerformanceAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_AllerganLicenseAgreementMember" name="AllerganLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_AccruedMilestoneExpenses" name="AccruedMilestoneExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_ContractualObligationsTerm" name="ContractualObligationsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_FollowOnPublicOfferingTwoMember" name="FollowOnPublicOfferingTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" name="DeferredTaxAssetsCapitalizedStartUpAndOtherCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_NonRefundableCashPaymentsMember" name="NonRefundableCashPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_AccruedMilestoneCosts" name="AccruedMilestoneCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_IndemnificationObligationsClaimsReserves" name="IndemnificationObligationsClaimsReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants" name="AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_PotentialMilestonePaymentsReceivable" name="PotentialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue" name="UpfrontPaymentsAllocatedToEquityPurchaseFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_AtTheMarketProgramMember" name="AtTheMarketProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_VitaePharmaceuticalsIncMember" name="VitaePharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering" name="StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter" name="PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet" name="EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sndx_UpfrontPaymentsReceived" name="UpfrontPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182275872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 19, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNDX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Syndax Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001395937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,965,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0162505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">35 Gatehouse Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building D<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Floor 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">419-1400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,452,441,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176049072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 295,394<span></span>
</td>
<td class="nump">$ 74,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">275,304<span></span>
</td>
<td class="nump">401,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term deposits</a></td>
<td class="nump">6,885<span></span>
</td>
<td class="nump">8,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CollaborationReceivable', window );">Collaboration receivable, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,293<span></span>
</td>
<td class="nump">1,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">580,876<span></span>
</td>
<td class="nump">489,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-Term Investments</a></td>
<td class="nump">29,829<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">612,880<span></span>
</td>
<td class="nump">497,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,961<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CollaborationPayableCurrent', window );">Collaboration payable, net</a></td>
<td class="nump">7,232<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">39,856<span></span>
</td>
<td class="nump">24,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of right-of-use liability</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CurrentPortionOfCapitalLease', window );">Current Portion Of Capital Lease</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">58,096<span></span>
</td>
<td class="nump">29,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use liability, less current portion</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CapitalLeaseLessCurrentPortion', window );">Capital Lease Less Current Portion</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">58,684<span></span>
</td>
<td class="nump">29,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at December 31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 200,000,000 and 100,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 84,826,632 and 68,111,385 shares outstanding at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,456,370<span></span>
</td>
<td class="nump">1,161,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">218<span></span>
</td>
<td class="num">(806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(902,400)<span></span>
</td>
<td class="num">(693,040)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">554,196<span></span>
</td>
<td class="nump">467,449<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 612,880<span></span>
</td>
<td class="nump">$ 497,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CapitalLeaseLessCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital lease, less current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CapitalLeaseLessCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CollaborationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CollaborationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CurrentPortionOfCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of capital lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CurrentPortionOfCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162175995920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">84,826,632<span></span>
</td>
<td class="nump">68,111,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162175802928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 139,709<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 139,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of revenue [extensible list]</a></td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 163,032<span></span>
</td>
<td class="nump">$ 118,499<span></span>
</td>
<td class="nump">$ 88,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">66,922<span></span>
</td>
<td class="nump">33,258<span></span>
</td>
<td class="nump">25,241<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">229,954<span></span>
</td>
<td class="nump">151,757<span></span>
</td>
<td class="nump">113,489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(229,954)<span></span>
</td>
<td class="num">(151,757)<span></span>
</td>
<td class="nump">26,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(3,137)<span></span>
</td>
<td class="num">(1,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">21,163<span></span>
</td>
<td class="nump">5,872<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">20,594<span></span>
</td>
<td class="nump">2,419<span></span>
</td>
<td class="num">(1,294)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(209,360)<span></span>
</td>
<td class="num">(149,338)<span></span>
</td>
<td class="nump">24,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common stockholders</a></td>
<td class="num">$ (209,360)<span></span>
</td>
<td class="num">$ (149,338)<span></span>
</td>
<td class="nump">$ 24,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income Per Share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (loss) earnings per share attributable to common stockholders</a></td>
<td class="num">$ (2.98)<span></span>
</td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (loss) earnings per share attributable to common stockholders</a></td>
<td class="num">$ (2.98)<span></span>
</td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (loss) earnings per share attributable to common stockholders</a></td>
<td class="nump">70,370,519<span></span>
</td>
<td class="nump">60,760,906<span></span>
</td>
<td class="nump">52,064,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (loss) earnings per share attributable to common stockholders</a></td>
<td class="nump">70,370,519<span></span>
</td>
<td class="nump">60,760,906<span></span>
</td>
<td class="nump">53,622,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162175970576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (209,360)<span></span>
</td>
<td class="num">$ (149,338)<span></span>
</td>
<td class="nump">$ 24,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="num">(851)<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (208,336)<span></span>
</td>
<td class="num">$ (150,189)<span></span>
</td>
<td class="num">$ (24,975)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182361856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Direct Placement Offering [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Direct Placement Offering [Member]</div>
</th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>Direct Placement Offering [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 252,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (568,628)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,881,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet', window );">Proceeds from "at-the-market" offering, net, Value</a></td>
<td class="nump">5,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet', window );">Proceeds from "at-the-market" offering, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueDirectOffering', window );">Proceeds from direct offering, net, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodSharesDirectOffering', window );">Proceeds from direct offering,net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,802,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase under ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PreFundedWarrantExerciseShares', window );">Pre-funded warrant cashless exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from Incyte Share Purchase Agreement</a></td>
<td class="nump">24,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from Incyte Share Purchase Agreement shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (gain) loss on investments</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of RSU, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_EmployeeWithholdingsEspp', window );">Employee withholdings ESPP</a></td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 6,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options, Shares</a></td>
<td class="nump">842,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 24,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,926<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">408,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="num">(543,702)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,983,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet', window );">Proceeds from "at-the-market" offering, net, Value</a></td>
<td class="nump">19,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet', window );">Proceeds from "at-the-market" offering, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueDirectOffering', window );">Proceeds from direct offering, net, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodSharesDirectOffering', window );">Proceeds from direct offering,net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,840,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase under ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PreFundedWarrantExerciseShares', window );">Pre-funded warrant cashless exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,832,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">16,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (gain) loss on investments</a></td>
<td class="num">(851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of RSU, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_EmployeeWithholdingsEspp', window );">Employee withholdings ESPP</a></td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 11,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options, Shares</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,276,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (149,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,338)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">467,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,161,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(806)<span></span>
</td>
<td class="num">(693,040)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,111,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet', window );">Proceeds from "at-the-market" offering, net, Value</a></td>
<td class="nump">42,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet', window );">Proceeds from "at-the-market" offering, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueDirectOffering', window );">Proceeds from direct offering, net, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodSharesDirectOffering', window );">Proceeds from direct offering,net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,432,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase under ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PreFundedWarrantExerciseShares', window );">Pre-funded warrant cashless exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">30,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (gain) loss on investments</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of RSU, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_EmployeeWithholdingsEspp', window );">Employee withholdings ESPP</a></td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 5,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options, Shares</a></td>
<td class="nump">662,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (209,360)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(209,360)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 554,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,456,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="num">$ (902,400)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,826,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_EmployeeWithholdingsEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee withholdings ESPP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_EmployeeWithholdingsEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PreFundedWarrantExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrant exercise, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PreFundedWarrantExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares at the market offering net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_StockIssuedDuringPeriodSharesDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value direct offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_StockIssuedDuringPeriodSharesDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value at the market offering net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_StockIssuedDuringPeriodValueDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value direct offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_StockIssuedDuringPeriodValueDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182206192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses', window );">At-the-market, offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_DirectPlacementOfferingMember', window );">Direct Placement Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueOfferingExpenses', window );">Direct offering, offering expenses</a></td>
<td class="nump">$ 14,044<span></span>
</td>
<td class="nump">$ 10,535<span></span>
</td>
<td class="nump">$ 5,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_FollowOnPublicOfferingOneMember', window );">Follow-on Public Offering One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses', window );">At-the-market, offering expenses</a></td>
<td class="nump">$ 1,086<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value at the market offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_StockIssuedDuringPeriodValueOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_StockIssuedDuringPeriodValueOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_DirectPlacementOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sndx_DirectPlacementOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_FollowOnPublicOfferingOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sndx_FollowOnPublicOfferingOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182503920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (209,360)<span></span>
</td>
<td class="num">$ (149,338)<span></span>
</td>
<td class="nump">$ 24,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DepreciationAndRelatedAdjustment', window );">Depreciation</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">(Accretion) amortization of investments</a></td>
<td class="num">(14,803)<span></span>
</td>
<td class="num">(3,382)<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PaidInKindInterestAndInterestReversal', window );">Non-cash interest income (expense)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Changes in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">30,951<span></span>
</td>
<td class="nump">16,019<span></span>
</td>
<td class="nump">13,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">676<span></span>
</td>
<td class="num">(2,972)<span></span>
</td>
<td class="num">(1,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IncreaseDecreaseInCollaborationReceivable', window );">Collaboration receivable, net</a></td>
<td class="nump">10,706<span></span>
</td>
<td class="num">(3,474)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">5,611<span></span>
</td>
<td class="num">(1,319)<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">14,867<span></span>
</td>
<td class="nump">9,421<span></span>
</td>
<td class="nump">2,769<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(160,601)<span></span>
</td>
<td class="num">(133,675)<span></span>
</td>
<td class="nump">29,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sales of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short and long-term investments</a></td>
<td class="num">(354,606)<span></span>
</td>
<td class="num">(495,346)<span></span>
</td>
<td class="num">(294,719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="nump">472,215<span></span>
</td>
<td class="nump">308,933<span></span>
</td>
<td class="nump">253,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">117,609<span></span>
</td>
<td class="num">(186,188)<span></span>
</td>
<td class="num">(40,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDepositOnLoan', window );">Payment on term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,996)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP</a></td>
<td class="nump">910<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">5,128<span></span>
</td>
<td class="nump">11,459<span></span>
</td>
<td class="nump">6,336<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">264,132<span></span>
</td>
<td class="nump">172,254<span></span>
</td>
<td class="nump">118,464<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">221,140<span></span>
</td>
<td class="num">(147,609)<span></span>
</td>
<td class="nump">106,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;beginning of year</a></td>
<td class="nump">74,471<span></span>
</td>
<td class="nump">222,080<span></span>
</td>
<td class="nump">115,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;end of year</a></td>
<td class="nump">295,611<span></span>
</td>
<td class="nump">74,471<span></span>
</td>
<td class="nump">222,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">295,394<span></span>
</td>
<td class="nump">74,356<span></span>
</td>
<td class="nump">221,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_IncyteSharePurchaseAgreementMember', window );">Incyte Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public stock offering, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_FollowOnPublicOfferingsMember', window );">Follow-on Public Offerings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public stock offering, net</a></td>
<td class="nump">215,955<span></span>
</td>
<td class="nump">161,965<span></span>
</td>
<td class="nump">81,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_AtTheMarketStockOfferingMember', window );">At-the-Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public stock offering, net</a></td>
<td class="nump">42,139<span></span>
</td>
<td class="nump">19,425<span></span>
</td>
<td class="nump">5,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_DerivativeLiabilityMember', window );">Derivative Liability [Member] | Incyte Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public stock offering, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_DepreciationAndRelatedAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and related adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_DepreciationAndRelatedAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_IncreaseDecreaseInCollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in collaboration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_IncreaseDecreaseInCollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PaidInKindInterestAndInterestReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paid in kind interest and interest reversal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PaidInKindInterestAndInterestReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDepositOnLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from resulting from payment, receipt or drawdown of cash deposit to guarantee a loan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDepositOnLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sndx_IncyteSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sndx_IncyteSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_FollowOnPublicOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sndx_FollowOnPublicOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_AtTheMarketStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sndx_AtTheMarketStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sndx_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sndx_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176925840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (209,360)<span></span>
</td>
<td class="num">$ (149,338)<span></span>
</td>
<td class="nump">$ 24,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182400400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 27, 2024, several of our named executive officers entered into amendments to their employment agreements providing, in part, for increases in their change in control benefits. For Mr. Metzger, in the event of an involuntary termination without cause or resignation for good reason within three (3) months prior to, or within twelve (12) months following, a change in control, he will receive (i) an amount equal to 24 months of base salary, payable in a lump sum, (ii) an amount equal to 24 months of the target annual incentive award, payable in a lump sum, and (iii) continuation of health benefits for 24 months. For Drs. Gallagher and Madigan and Messrs. Albrecht and Goldan, in the event of an involuntary termination without cause or resignation for good reason within three (3) months prior to, or within twelve (12) months following, a change in control, each will receive (i) an amount equal to 18 months of base salary, payable in a lump sum, (ii) an amount equal to 18 months of the target annual incentive award, payable in a lump sum, and (iii) continuation of health benefits for 18 months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During our last fiscal quarter, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408 for the purchase or sale of our securities, except as set forth below:</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:16.76%;"></td>
      <td style="width:14.88%;"></td>
      <td style="width:14.76%;"></td>
      <td style="width:13.58%;"></td>
      <td style="width:1%;"></td>
      <td style="width:15.58%;"></td>
      <td style="width:1%;"></td>
      <td style="width:22.44%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and Title</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Type of Plan</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Adoption Date</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Duration or End Date</span></p></td>
      <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Number of Securities to be Sold</span></p></td>
      <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description of Trading Arrangement</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Metzger</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rule 10b5-1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;trading arrangement</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">01/05/2023</span></span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/22/2023</span></span></p></td>
      <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
      <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales of shares intended to satisfy the affirmative defense of Rule 10b5&#8211;1(c)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Briggs W. Morrison</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">M.D. - Director</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rule 10b5-1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;trading arrangement</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">02/09/2023</span></span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/06/2023</span></span></p></td>
      <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">466,167</span></p></td>
      <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales of shares intended to satisfy the affirmative</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     </tr>
    </table>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:16.76%;"></td>
      <td style="width:14.88%;"></td>
      <td style="width:14.76%;"></td>
      <td style="width:13.58%;"></td>
      <td style="width:1%;"></td>
      <td style="width:15.58%;"></td>
      <td style="width:1%;"></td>
      <td style="width:22.44%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">defense of Rule 10b5&#8211;1(c)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) </span><span style="font-size:11pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination</span></span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of Rule 10b5-1 trading arrangement, each of which the reporting person terminated prior to the sale of all plan securities.</span></p><span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sndx_MichaelMetzgerMember', window );">Michael Metzger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Michael Metzger<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer and Director<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">01/05/2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">12/22/2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sndx_BriggsWMorrisonMember', window );">Briggs W. Morrison [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Briggs W. Morrison<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">M.D. - Director<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">02/09/2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">12/06/2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">466,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:11pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination</span></span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of Rule 10b5-1 trading arrangement, each of which the reporting person terminated prior to the sale of all plan securities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sndx_MichaelMetzgerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sndx_MichaelMetzgerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sndx_BriggsWMorrisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sndx_BriggsWMorrisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162180007328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc. (&#8220;the Company&#8221; or &#8220;Syndax&#8221;) is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's two lead product candidates are revumenib and axatilimab. The Company is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, (&#8220;KMT2Ar&#8221;), also known as mixed lineage leukemia rearranged, (&#8220;MLLr&#8221;), acute leukemias including acute lymphoblastic leukemia, (&#8220;ALL&#8221;), and acute myeloid leukemia, or AML, and nucleophosmin 1, also known as NPM1, mutant AML. The Company is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The Company is developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor, (&#8220;CSF-1R&#8221;), in chronic graft-versus-host disease, (&#8220;cGVHD&#8221;), as well as idiopathic pulmonary fibrosis, (&#8220;IPF&#8221;). The Company plans to continue to leverage the technical and business expertise of its management team and scientific collaborators to license, acquire and develop additional therapeutics to expand its pipeline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company&#8217;s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it will be several years before any of its product candidates is approved, if ever, and the Company begins to generate revenue from sales of such product candidates. Accordingly, management expects to incur substantial losses on the ongoing development of its product candidates and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management believes that the cash, cash equivalents and short-term investments balances as of December 31, 2023, should enable the Company to maintain its planned operations for at least 12 months from the issuance date of these financial statements. The Company&#8217;s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds were not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and selling, general and administrative activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to challenges and risks specific to its business and ability to execute on the strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of the Company&#8217;s late-stage product candidate; delays or problems in the supply of the Company&#8217;s products, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing the Company&#8217;s intellectual property rights; complying with applicable regulatory requirements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178204064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has prepared the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178312608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s consolidated financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents include all highly liquid investments maturing within 90 days or less from the date of purchase. Cash equivalents include money market funds, corporate debt securities, U.S. government agency notes, and overnight deposits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> All investments in marketable securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses excluded from earnings and reported net of tax in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. Unrealized losses that are determined to be other-than-temporary, based on current and expected market conditions, are recognized in earnings. Declines in fair value determined to be credit related are charged to earnings. The cost of marketable securities sold is determined by the specific identification method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents, restricted cash, and short and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company&#8217;s cash, cash equivalents, and short and long-term investments were deposited in accounts at two financial institutions, and at times, such deposits may exceed federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#8217;s available-for-sale investments primarily consist of government money market funds, corporate debt securities, commercial paper, credit card asset-backed securities and overnight deposits and potentially subject the Company to concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0e6f7b74-b212-412d-a290-cfa9eb6e858f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). Assets under capital leases are amortized over the shorter of their useful lives or lease term using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value. To date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such impairments have been recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. The Company recognize revenue following the five &#8211; step model prescribed under FASB Accounting Standards Codification (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASC 606), Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: (i) identify contract(s) with customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Revenue from non-refundable, up-front fees allocated to the licenses related to the Company's intellectual property, are recognized as the license is transferred to the customer and the customer is able to use and benefit from the license. This generally takes place over the related know-how transfer period, or if applicable, over the term of transfer of future updates to the intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Development Milestone Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company evaluates whether milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license fees and earnings in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commercial Milestone Payments and Royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: For arrangements that include sales-based royalties, including milestone payments based on the level of commercial sales, and the license is deemed to be the predominant item to which the royalties or commercial milestones relate, the Company will recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date no commercial milestone payments or royalties have been achieved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When no performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability. Upfront payment contract liabilities resulting from the Company&#8217;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information on our collaboration and license arrangements, please read </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 4, Collaborative Research and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to these consolidated financial statements. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include payroll and personnel expenses, consulting costs, external contract research and development expenses, and allocated overhead, including rent, equipment depreciation, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. The Company expenses upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In instances where the Company enters into cost-sharing arrangements, all research and development costs reimbursed by the collaborators are accounted for as reductions to research and development expense. During the years ended December 31, 2023 and 2022, the Company has incurred external costs related to Incyte cost-sharing collaboration. During the year ended December 31, 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company incurred </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> external costs related to cost-sharing collaborations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical study and trial costs are a component of research and development expenses. The Company expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific contract tasks using data such as patient enrollment, clinical site activations, or other information provided to us by our vendors. Depending on the progression of the contract and timing of invoicing and payment the research and development expense can be an accrued expense or a prepaid expense. Prepaid clinical study and trial costs are included in short-term deposits on the accompanying consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax bases of assets and liabilities and for loss and credit carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is provided to reduce the net deferred tax assets to the amount that will more likely than not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Guarantees and Indemnifications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. The Company has standard indemnification arrangements under office leases (as described in Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to these consolidated financial statements) that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the Company&#8217;s lease. Through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had not experienced any losses related to these indemnification obligations and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related reserves were established.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for all stock option awards granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value of the stock option grants and is recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved. The Company accounts for forfeitures as they occur.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Loss) Earnings Per Share</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic earnings per share is computed by dividing undistributed net income attributable to Syndax by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178176880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CollaborativeResearchAndLicenseAgreementsTextBlock', window );">Collaborative Research and License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Collaborative Research and License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incyte Collaboration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, the Company entered into license and collaboration agreement (the "Incyte License and Collaboration Agreement") with Incyte Corporation ("Incyte") covering the worldwide development and commercialization of axatilimab. Also, in September 2021 the Company entered into a share purchase agreement with Incyte, ("Incyte Share Purchase Agreement" and together with Incyte License and Collaboration Agreement, the Incyte Agreements"). Under the terms of the Incyte Agreements, Incyte will receive exclusive commercialization rights outside of the United States, subject to its royalty payment obligations set forth below. In the United States, Incyte and the Company will co-commercialize axatilimab, with the Company having the right to co-promote axatilimab with Incyte, subject to the Company&#8217;s exercise of its co-promotion option. Incyte will be responsible for leading all aspects of commercialization of axatilimab in the United States. The Company and Incyte will share equally the profits and losses from co-commercialization efforts in the United States. The Company and Incyte have agreed to co-develop axatilimab and to share development costs associated with global and U.S. &#8211; specific clinical trials, with Incyte responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of such costs and the Company responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of such costs. Each company will be responsible for funding any of its own independent development activities. Incyte is responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of future development costs for trials that are specific to ex-U.S. countries. All development costs related to the collaboration with Incyte will be subject to a joint development plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Incyte Agreements, in December 2021, Incyte paid the Company a non-refundable cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">117.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,421,523</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with an aggregate purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.62</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Additionally, under the terms of the Incyte Agreements, the Company is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">220.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in future contingent development and regulatory milestones and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">230.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commercialization milestones as well as tiered royalties ranging in the mid-teens percentage on net sales of the licensed product comprising axatilimab in Europe and Japan and low double digit percentage in the rest of the world outside of the United States. The Company's right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of licensed patent rights covering the licensed product in that particular country, (b) a specified period of time after the first post - marketing authorization sale of a licensed product in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Incyte Agreement and the Incyte Share Purchase Agreement were executed on the same date and negotiated simultaneously. Management therefore concluded that the Incyte Agreements are to be combined for accounting purposes and therefore allocated the total consideration to the units of account identified. The common stock issued to Incyte was recorded at fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Pursuant to the Letter Agreement, Incyte is permitted to terminate the Incyte Agreement, under circumstances under which the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million would be returned to Incyte and a cash settlement on the sale of the Company's common stock would be made to make the parties whole (the &#8220;Letter Agreement&#8221;). In connection with the closing of this transaction in December 2021, the Company determined that the cash settlement feature of the Letter Agreement represented an embedded derivative requiring bifurcation and separate accounting recognition at fair value. The Letter Agreement terminated in March 2022. Accordingly, the Company initially allocated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the total consideration received to the derivative liability. As of December 31, 2022, the fair value of the derivative is zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluated the terms of the Incyte Agreement and determined it is within the scope of Accounting Standard Update </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018-18, Collaborative Arrangements (Topic 808)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and has elements that are within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 808</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company identified the following promises in the Incyte Agreements that were evaluated under the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: (i) delivery of a license for axatilimab to develop, commercialize, and conduct medical affairs and (ii) services to be performed in accordance with the development plan. The Company also evaluated whether certain options outlined within the Incyte Agreements represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Incyte and therefore are not considered separate performance obligations within the Incyte Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the above promises and determined that the license for axatilimab represents the only performance obligation within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The license for axatilimab is considered functional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intellectual property and distinct from other promises under the contract as Incyte can benefit from the license on its own or together with other readily available resources. The services performed by the Company to obtain regulatory approval of axatilimab are not complex or specialized, could be performed by another qualified third party, are not expected to significantly modify or customize the license given that axatilimab is late-stage intellectual property that has completed its Phase 1/2 trial and is currently enrolling in a global pivotal Phase 2 trial, and the services are expected to be performed over a short period of time. Therefore, the license represents a separate performance obligation within a contract with a customer under the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at contract inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers the collaborative research and development activities and manufacturing activities to be separate units of account within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 808</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and are not deliverables under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company and Incyte are both active participants in the activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities in the arrangement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company identified contract promises for the license of intellectual property and know-how rights for axatilimab. The Company determined that the license was capable of being distinct from the ongoing collaboration activities. After the allocation to the common stock and derivative liability, the total transaction price to be allocated to the Incyte Agreement is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company estimated the standalone selling price of the license to be the entire $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, based on an application of the income approach by measuring the fair value of the discounted cash flows from commercialization. Significant assumptions included in the valuation included judgments relating to the probability of achieving both regulatory and commercial milestones, forecasted future cash flows and the election of the discount rate. As the Company concluded the license was distinct, revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized upon transfer of the license to Incyte in the year ended December 31, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential preclinical, development, and regulatory variable consideration milestone payment under this agreement is zero, as achievement of those milestones is uncertain and highly susceptible to factors outside the Company&#8217;s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based royalties, including milestones based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate. The company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Company considers the collaborative research and development activities and manufacturing activities to be separate units of account within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 808</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and are not deliverables under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Topic 606</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company and Incyte are both active participants in the activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities in the arrangement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a collaboration receivable due from Incyte related to the Company's development and pre-commercialization costs under the Incyte Agreements and has recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a collaboration payable due to Incyte for development and pre-commercialization costs incurred by Incyte as of December 31, 2023. Both expenses and cost offset are recorded as part of research and development and selling, general and administrative expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CollaborativeResearchAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative research and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CollaborativeResearchAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178406096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for leases in accordance with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASC 842, Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and determines whether an arrangement is a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. For leases that do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The ROU asset also includes any lease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company identified three existing long-term building leases under ASC 842 that are classified as operating leases. In September 2016, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,207</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in Waltham, MA, with a lease commencement date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2017</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 17, 2021, the Company signed a 36-month extension to the lease for the Waltham, MA office with aggregate payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with a lease commencement date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2015, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,039</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of space in New York, NY, which commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2016</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In February 2021, the Company signed an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month extension to the lease for the New York office, which commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In August 2022, the Company signed a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month extension to the lease for the New York office, with aggregate payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">689,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with a lease commencement date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month operating lease f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,217</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sq</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uare feet of space in New York, NY, with aggregate payments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with a lease commencement date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remaining lease terms as of December 31, 2023, for the facility in Waltham, MA and the two facilities in New York, NY, were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the consolidated balance sheet includes a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating lease ROU asset and a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ROU liability. The Company used a weighted average discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to calculate its lease obligations, and an increase or decrease in the rate does not have a significant impact on the ROU asset or ROU liability. The ROU asset is amortized on a straight-line basis over the remainder of the lease term. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">743,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in operating lease expense and made approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">924,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in lease payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the Company&#8217;s operating leases, were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;"></td>
        <td style="width:3.401%;"></td>
        <td style="width:1%;"></td>
        <td style="width:39.208000000000006%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.401%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the Company&#8217;s capital leases as of December 31, 2023 and 2022, were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,864</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22,441</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162175797728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(Loss) Earnings per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. (Loss) Earnings per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted (loss) earnings per share are calculated as follows (in 000s):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.352%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.902000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.022%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">209,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149,338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">209,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149,338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,371</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,761</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,065</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective of Dilutive Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,429</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non - vested restricted stock units (RSUs)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive potential common shares</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Shares used in calculating diluted (loss) earnings per share</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,371</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,761</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,623</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in 000s):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.34%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.74%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,685</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested RSUs</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">309</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information related to the Company's common stock see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 12, Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162180043024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_SignificantAgreementsDisclosureTextBlock', window );">Significant Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Significant Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vitae Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2017, the Company entered into a license agreement (the &#8220;Allergan License Agreement&#8221;) with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan (&#8220;Allergan&#8221;), under which Allergan granted the Company an exclusive, sublicensable, worldwide license to a portfolio of preclinical, orally available, small molecule inhibitors of the interaction of menin with Mixed Lineage Leukemia (&#8220;MLL&#8221;) protein (the &#8220;Menin Assets&#8221;). The Company made a nonrefundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Allergan in the fourth quarter of 2017. Additionally, subject to the achievement of certain milestone events, the Company may be required to pay Allergan up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in one-time development and regulatory milestone payments over the term of the Allergan License Agreement. In the event that the Company or any of its affiliates or sublicensees commercializes the Menin Assets, the Company will also be obligated to pay Allergan low single to low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in potential one-time, sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, the Company may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with Allergan. The Company is solely responsible for the development and commercialization of the Menin Assets. Each party may terminate the Allergan License Agreement for the other party&#8217;s uncured material breach or insolvency; and the Company may terminate the Allergan License Agreement at will at any time upon advance written notice to Allergan. Allergan may terminate the Allergan License Agreement if the Company or any of its affiliates or sublicensees institutes a legal challenge to the validity, enforceability, or patentability of the licensed patent rights. Unless terminated earlier in accordance with its terms, the Allergan License Agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the date of the first commercial sale of the product in such country.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of the Allergan License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility. As the processes or activities that were acquired along with the license do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset acquisition. As a result, in 2017, the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as research and development expense in the consolidated statements of operations. Since the inception of the agreement, the Company achieved certain development and regulatory milestones resulting in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in expense, which included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million paid in the first quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">UCB Biopharma Sprl</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2016, the Company entered into a license agreement (the &#8220;UCB License Agreement&#8221;) with UCB Biopharma Sprl (&#8220;UCB&#8221;), under which UCB granted to the Company a worldwide, sublicensable, exclusive license to UCB6352, which the Company refers to as axatilimab, an Investigational New Drug Application-ready anti-CSF-1R monoclonal antibody. The Company made a nonrefundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to UCB in the third quarter of 2016. Additionally, subject to the achievement of certain milestone events, the Company may be required to pay UCB up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">119.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in one-time development and regulatory milestone payments over the term of the UCB License Agreement. In the event that the Company or any of its affiliates or sublicensees commercializes axatilimab, the Company will also be obligated to pay UCB low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in potential one-time, sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, the Company may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with UCB. The Company will be solely responsible for the development and commercialization of axatilimab, except that UCB is performing a limited set of transitional chemistry, manufacturing and control tasks related to axatilimab. Each party may terminate the UCB License Agreement for the other party&#8217;s uncured material breach or insolvency; and the Company may terminate the UCB License Agreement at will at any time upon advance written notice to UCB. UCB may terminate the UCB License Agreement if the Company or any of its affiliates or sublicensees institutes a legal challenge to the validity, enforceability, or patentability of the licensed patent rights. Unless terminated earlier in accordance with its terms, the UCB License Agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the date of the first commercial sale of the product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of the UCB License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility. As the processes or activities that were acquired along with the license do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset acquisition. As a result, in 2016, the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as research and development expense in the consolidated statements of operations. Since the start of the license agreement, the Company achieved certain development and regulatory milestones and has recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as research and development expense. Additionally, in connection with its most recent amendment of the UCB License Agreement, in the second quarter of 2022 the Company paid UCB $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is recognized as a milestone expense. In the fourth quarter of 2023, UCB achieved a development and regulatory milestone resulting in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expense, which has been recorded in accrued expenses as of December 31, 2023. The Company paid the amount to UCB in the first quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bayer Pharma AG (formerly known as Bayer Schering Pharma AG)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2007, the Company entered into a license agreement (the &#8220;Bayer Agreement&#8221;) with Bayer Schering Pharma AG (&#8220;Bayer&#8221;) for a worldwide, exclusive license to develop and commercialize entinostat and any other products containing the same active ingredient. Under the terms of the Bayer Agreement, the Company paid a nonrefundable up-front license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is responsible for the development and marketing of entinostat. The Company recorded the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million license fee as research and development expense during the year ended December 31, 2007, as it had no alternative future use. The Company will pay Bayer royalties on a sliding scale based on net sales, if any, and make future milestone payments to Bayer of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the event that certain specified development and regulatory goals and sales levels are achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_SignificantAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_SignificantAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178138800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Property and Equipment, net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.200000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.200000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178253552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash and cash equivalents, restricted cash, accounts payable, and accrued expenses approximated their estimated fair values due to the short-term nature of these financial instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quoted prices (unadjusted) in active markets that are accessible at the market date for identical unrestricted assets or liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques the Company utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.411%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.798%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Carrying<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">275,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">275,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">600,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">305,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,356</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481,271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">421,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no material impairments of our assets measured and carried at fair value during the years ended December 31, 2023, and 2022. In addition, there have been no changes in valuation techniques during the years ended December 31, 2023, and 2022. The fair value of Level 1 instruments classified as cash equivalents are valued using quoted market prices in active markets. The fair value of Level 2 instruments classified as cash equivalents and short and long-term investments was determined other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and fair value is determined using models or other valuation methodologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The short-term and long-term investments are classified as available-for-sale securities. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the remaining contractual maturities of the available-for-sale securities were 1 to 15 months, and the balance in the Company&#8217;s accumulated other comprehensive income was comprised solely of activity related to the Company&#8217;s available-for-sale securities. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains or losses recognized on the sale or maturity of available-for-sale securities during the three years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. As a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the same periods. The Company has a limited number of available-for-sale securities in insignificant loss positions as of December 31, 2023, which the Company does not intend to sell and has concluded will not be required to sell before recovery of the amortized cost for the investment at maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The following table summarizes the available-for-sale securities (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.235%;"></td>
        <td style="width:1.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.812%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.812%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.812%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.812%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>(Losses)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,806</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">US Treasury</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,111</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">304,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">305,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">321,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">321,425</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">US Treasury</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">566</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">806</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">421,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178204064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.482000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.283000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable on investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid subscriptions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid state and local taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178188976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.652%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.604%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical study and trial costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,375</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued milestone costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expense and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,856</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178218512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CommonStockDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The holders of each share of common stock are entitled to one vote per share held and are entitled to receive dividends, if and when declared by the Board, and to share ratably in the Company&#8217;s assets available for distribution to stockholders, in the event of liquidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the Company entered into a sales agreement with Cowen and Company, LLC, or TD Cowen, under which the Company could, from time to time, issue and sell shares of its common stock having aggregate sales proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in a series of one or more at-the-market, or ATM, equity offerings, or the 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Program. On May 26, 2023, the Company terminated the 2021 ATM Program. Prior to termination the Company sold shares under the 2021 ATM Program for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company entered into a new sales agreement with TD Cowen under which the Company could, from time to time, issue and sell shares of its common stock having aggregate sales proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, in a series of one or more ATM equity offerings, or the 2023 ATM Program. TD Cowen is not required to sell any specific share amounts but acts as the Company&#8217;s sales agent, using commercially reasonable efforts consistent with its normal trading and sales practices. Pursuant to the new sales agreement, shares will be sold pursuant to the previous shelf registration statement on Form S-3ASR (Registration No. 333-254661), which became automatically effective upon filing on March 24, 2021. The Company&#8217;s common stock will be sold at prevailing market prices at the time of the sale, and as a result, prices may vary. In the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">2,719,744</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares of common stock under the 2023 ATM Program, with net proceeds of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,802,144</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,142,856</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The offering price for the securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each Pre-Funded Warrant,</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On January 24, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">86,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85,998</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, under a cashless exercise. On April 12, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">273,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">272,996</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, under a cashless exercise. On May 9, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">498,142</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">498,137</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, under a cashless exercise. As of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">285,714</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were considered issued and outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, in connection with the Incyte License and Collaboration Agreement and Share Purchase Agreement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,421,523</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, with net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company recorded the equity issuance at a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on the market price of the stock on the date of issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,840,909</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The offering price for the securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, with gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">172.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, offset by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of issuance cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,432,431</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The offering price for the securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, with gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">230.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, offset by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of issuance cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has reserved for future issuance the following shares of common stock pursuant to the following outstanding securities or equity plans:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:26.28%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issuable under pre-funded warrants</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">285,714</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At-the-market program</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,280,256</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs and Options to purchase common stock</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,204,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity plans</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,403,382</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2015 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,732,614</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,906,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CommonStockDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CommonStockDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178244144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2015, the Company&#8217;s board of directors adopted its 2015 Omnibus Incentive Plan (&#8220;2015 Plan&#8221;), which was subsequently approved by its stockholders and became effective upon the closing of the IPO on March 8, 2016. The 2015 Plan replaced the 2007 Stock Plan (&#8220;2007 Plan&#8221;) and allows for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, dividend equivalent rights, performance awards, annual incentive awards, and other equity-based awards to the Company&#8217;s executives and other employees, non-employee members of the board of directors, and consultants of the Company. Any options or awards outstanding under the Company&#8217;s 2007 Plan remain outstanding and continue to govern the terms of any equity grants that remain outstanding under the 2007 Plan. Any shares of common stock related to awards outstanding under the 2007 Plan that thereafter terminate by expiration, forfeiture, cancellation or otherwise without the issuance of such shares will be added to, and included in, the 2015 Plan reserve amount. The Company initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock for the issuance of awards under the 2015 Plan. The 2015 Plan provides that the number of shares reserved and available for issuance under the 2015 Plan will automatically increase each January 1, beginning on January 1, 2017, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company&#8217;s board of directors. On January 1, 2024, the shares available for issuance under the 2015 was increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,393,065</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, the Company's board of directors adopted its 2023 Inducement Plan (the &#8220;2023 Inducement Plan&#8221;), which became effective March 1, 2023. The 2023 Inducement Plan allows for the granting of nonqualified stock options, restricted stock units, and other awards under the 2023 Inducement Plan to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, an inducement material to such persons entering into employment with the Company. The Company initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,900,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock for the issuance of awards under the 2023 Inducement Plan. On December 6, 2023, the Company's board of directors increased the reserve by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,191,732</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for issuance under the 2015 Plan and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211,650</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for issuance under the 2023 Inducement Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees and related to the Employee Stock Purchase Plan in the consolidated statements of operations as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.42%;"></td>
        <td style="width:2.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,147</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,003</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,019</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,317</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options and Restricted Stock Units</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">74.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of unrecognized compensation cost related to employee and non-employee unvested stock options and RSUs granted under the 2015 Plan and the 2023 Inducement Plan, which is expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. Stock compensation costs have not been capitalized by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the straight-line method to the extent achievement of the performance condition is probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, the Company granted to certain employees </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">583,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options that contain performance-based vesting criteria (&#8220;2019 Performance Awards&#8221;), primarily related to the achievement of certain clinical and regulatory development milestones related to product candidates. In the fourth quarter of 2020, one performance milestone, for the 2019 Performance Awards, was achieved. The Company recorded approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">128,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of stock compensation related to the achievement of the performance milestone for years ended December 31, 2022. As of December 31, 2022, all other performance milestones were not achieved, and the associated awards have been cancelled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the Company granted to certain employees </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">140,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance-based stock options (&#8220;2022 Performance Awards&#8221;), primarily related to the achievement of certain regulatory development milestones related to product candidates. Recognition of stock-based compensation expense associated with these performance-based stock options commences when the performance condition is considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the first quarter of 2022, management estimated one of the milestones, for the 2022 Performance Awards, was probable of achievement. The Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">258,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">479,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of stock compensation expense for these awards for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">140,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options outstanding were unvested, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options had been cancelled.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the first quarter of 2023, the Company granted to certain employees </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">129,550</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance-based RSUs, primarily related to the achievement of certain regulatory development milestones related to product candidates. Recognition of stock-based compensation expense associated with these performance-based RSUs commences when the performance condition is considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, in connection with the retirement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> employees, the Company entered into severance and consulting agreements. Under these agreements the Company extended the vesting term for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,728</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unvested options, which would not have otherwise vested and extended the exercise period of the vested options post termination of the consulting agreement. The Company accounted for the change as a modification of an equity award under ASC 718. As a result of the modifications, the Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of incremental stock compensation expense in 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model with the weighted-average assumptions noted in the table below. Expected volatility for the Company&#8217;s common stock was determined based on an average of the historical volatility of the Company's public stock price. The Company estimated the expected term of its employee stock options using the &#8220;simplified&#8221; method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The contractual life of the option was used for the estimated life of the non-employee grants. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free interest rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. The Company accounts for forfeitures when they occur. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The grant date fair values of options issued to employees and non-employees were estimated using the Black-Scholes option-pricing model with the following assumptions: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.75%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.618%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.03</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.04</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.02</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85.84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of employee and non-employee option activity under the Company&#8217;s equity award plans is presented below (in thousands, except share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.96%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.3%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,981,677</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,800,691</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">662,042</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.08</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled, forfeited or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,684,858</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,468,638</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested, or expected to<br/>&#160;&#160;&#160;vest</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,684,858</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of options granted during the years ended December 31, 2023, 2022 and 2021, was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.64</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The fair value is being expensed over the vesting period of the options (usually </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_91e0244e-9f65-4985-ba1b-f7857d8ad080;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) on a straight-line basis as the services are being provided.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">662,042</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options exercised for the year ended December 31, 2023, resulting in total proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million options exercised for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, resulting in total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million; and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">842,424</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options exercised for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, resulting in total proceeds of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The intrinsic value of options exercised during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. In accordance with the Company&#8217;s policy, the shares were issued from a pool of shares reserved for issuance under the 2015 Plan and 2023 Inducement Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs awarded to Board of Directors or employees vest on either i) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one &#8211; year anniversary date of the related grant or ii) 25% on each anniversary for 4 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our RSU activity:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.609%;"></td>
        <td style="width:2.519%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.177%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.697%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.999%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">224,788</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.02</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">308,550</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested&#8212;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">519,436</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 had a weighted average grant date fair value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.94</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair values of RSUs vested in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">705,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2015, the Company&#8217;s Board adopted the ESPP, which was subsequently approved by the Company&#8217;s stockholders and became effective in 2016. The ESPP authorized the initial issuance of up to a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the Company&#8217;s employees. The number of shares of common stock available under the ESPP will automatically increase on January 1st of each year, continuing until the expiration of the ESPP, in an amount equal to the lesser of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, or (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. On January 1, 2024, the shares of common stock reserved for issuance under the ESPP was increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,982,614</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under the terms of the ESPP, eligible employees can elect to acquire shares of the Company&#8217;s common stock through periodic payroll deductions during a series of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> offering periods. Purchases under the ESPP are affected on the last business day of each offering period at a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% discount to the lower of closing price on that day or the closing price on the first day of the offering period. The Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,797</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares during </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ESPP is considered a compensatory plan with the related compensation cost expensed over the six-month offering period. For the years ended December 31, 2023, 2022 and 2021 the Company recorded stock-based compensation expense related to the ESPP of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">308,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">166,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">175,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> respectively.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Benefit Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a Section 401(k) defined contribution savings plan for its employees. The plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis, subject to legal limitations. Company contributions to the plan may be made at the discretion of the Board. For the years ended December 31, 2023, 2022 and 2021, the Company made </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">712,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">444,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contributions to the plan, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178176880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loan Payable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Loan Payable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2020, the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;). In December 2021, the Company entered into Amendment No. 1 to the Company&#8217;s Loan Agreement (the &#8220;First Amendment&#8221; and the Loan Agreement, as amended, the &#8220;Amended Loan Agreement&#8221;) with several banks and financial institutions or entities from time-to-time party thereto (collectively, the &#8220;Lender&#8221;) and Hercules, in its capacity as administrative agent for itself and the Lender.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 23, 2022, the Company made a prepayment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to satisfy in full all of the Company's principal and interest obligations and related fees under the Amended Loan Agreement. The payoff amount paid by the Company in connection with the termination of the Amended Loan Agreement was pursuant to a payoff letter with Hercules and included payment of (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as an end-of term fee and (b) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a pre-payment fee. Hercules released all security interests held on the assets of the Company and its subsidiaries. The Amended Loan Agreement was fully terminated as of September 23, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of pre-payment fee, of interest expense related to the initial advance pursuant to the Amended Loan Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162175872672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized current state income expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the year ending December 31, 2023 as a result of investment income earned in Syndax Securities Corporation. The Company recognized no income taxes in the years ended December 31, 2022 and 2021, due to the utilization of tax attributes to offset current year federal and state taxable income, immaterial investment income earned at Syndax Securities Corporation, the historical losses incurred and the need for a full valuation allowance on deferred tax assets. The Company&#8217;s current year profit and historical losses before income tax for the periods presented was generated entirely in the United States.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes computed at the statutory federal income tax rate to the provision for income taxes as reflected in the financial statements is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.493%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.382%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.382%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.382%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General business credit carryovers</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Return to provision true up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s deferred tax are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.200000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.200000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets (liabilities):</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,765</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,124</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized start-up and other costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,859</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,374</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,562</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets before valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,081</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowances</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,081</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">72.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized research expenses, and capitalized start-up costs. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized start-up costs, partially offset by a decrease to other deferred tax assets.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">136.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">63.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in federal and state Net Operating Losses (&#8220;NOLs&#8221;), respectively, which may be available to offset future taxable income. The Company has generated federal NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">114.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and state NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which have indefinite carryforward period. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal NOLs and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million the Company&#8217;s state NOLs will begin to expire at various dates starting in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had federal and state research credits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, which began to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Under the Internal Revenue Code provisions, certain substantial changes in the Company&#8217;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards which could be used annually to offset future taxable income. The Company last completed an analysis from January 1, 2021 through December 31, 2022 and determined that no ownership changes had occurred in that period. Prior analyses determined that on March 30, 2007, August 21, 2015 and May 4, 2020, ownership changes had occurred. The Company may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, its ability to use its pre- change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted in the United States on March 27, 2020. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides extensive tax changes in response to the COVID-19 pandemic, the provisions did not have a significant impact on the Company&#8217;s financial results. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminates the option to deduct research and development expenditures currently and requires taxpayers to amortize them, over five years for domestically incurred expenditures and over fifteen years for foreign incurred expenditures, pursuant to IRC Section 174. As of December 31, 2023, the Company has recorded a deferred tax asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">79.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the Capitalized IRC Section 174 expenditures, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">53.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million relate to expenses required to be capitalized under the TCJA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, and 2022, the Company had uncertain tax positions of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to research and development credits, which reduce the deferred tax assets with a corresponding decrease to the valuation allowance. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest or penalties were recorded for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company expects none of the unrecognized tax benefits to decrease within the next 12 months related to expired statutes or settlement with the taxing authorities. Due to the Company&#8217;s valuation allowance as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company&#8217;s unrecognized tax benefits, if recognized, would affect the effective tax rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.493%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.922000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.922000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.922000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefit--beginning of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases related to prior period positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefit--end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files tax returns in the U.S. and various states. All tax years since inception (October 11, 2005) remain open to examination by major tax jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service or state tax authorities if they have or will be used in a future period. The Company is currently not under examination by the Internal Revenue Service or any other jurisdictions for any tax years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162175954528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Commitments and Contingencies</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incyte &#8211; In September 2021, the Company entered into the Incyte Agreement and Incyte Stock Purchase Agreement. Under the terms of the Incyte Agreement, Incyte will receive exclusive commercialization rights of axatilimab outside of the United States.  In the United States, Incyte and the Company will co-commercialize axatilimab, with the Company having the right to co-promote the product with Incyte. In exchange for these rights, Incyte agreed to pay a non-refundable cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and in addition a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million equity investment. In certain cases, the Company is required to assist Incyte and is responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of development costs associated with global and U.S. specific clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eddingpharm&#8212;In April 2013, the Company entered into a License and Development Agreement (the &#8220;Eddingpharm License Agreement&#8221;) and a Series B-1 purchase agreement (the &#8220;Eddingpharm Purchase Agreement&#8221;) with Eddingpharm International Company Limited (&#8220;Eddingpharm&#8221;). Under the terms of the Eddingpharm License Agreement, Eddingpharm, in exchange for rights to develop and commercialize entinostat in China and certain other Asian countries, purchased $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Series B-1 and agreed to make certain contingent milestone and royalty payments based on revenue targets. In certain cases, the Company is required to assist Eddingpharm, and Eddingpharm is required to reimburse the Company for any out-of-pocket expenses incurred in providing this assistance, including reimbursement for person-hours above a certain cap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may be subject to various claims and proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contingent liabilities recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, or 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178312608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17. Supplemental Cash Flow Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.913%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.2170000000000005%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.2170000000000005%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.2170000000000005%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosures of Cash Flow Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosures of Non-Cash Investing and Financing<br/>&#160;&#160;&#160;Activities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance costs included in accounts payable and accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182514768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Estimates</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents include all highly liquid investments maturing within 90 days or less from the date of purchase. Cash equivalents include money market funds, corporate debt securities, U.S. government agency notes, and overnight deposits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> All investments in marketable securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses excluded from earnings and reported net of tax in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. Unrealized losses that are determined to be other-than-temporary, based on current and expected market conditions, are recognized in earnings. Declines in fair value determined to be credit related are charged to earnings. The cost of marketable securities sold is determined by the specific identification method.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents, restricted cash, and short and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company&#8217;s cash, cash equivalents, and short and long-term investments were deposited in accounts at two financial institutions, and at times, such deposits may exceed federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#8217;s available-for-sale investments primarily consist of government money market funds, corporate debt securities, commercial paper, credit card asset-backed securities and overnight deposits and potentially subject the Company to concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0e6f7b74-b212-412d-a290-cfa9eb6e858f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). Assets under capital leases are amortized over the shorter of their useful lives or lease term using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value. To date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such impairments have been recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. The Company recognize revenue following the five &#8211; step model prescribed under FASB Accounting Standards Codification (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASC 606), Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: (i) identify contract(s) with customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Revenue from non-refundable, up-front fees allocated to the licenses related to the Company's intellectual property, are recognized as the license is transferred to the customer and the customer is able to use and benefit from the license. This generally takes place over the related know-how transfer period, or if applicable, over the term of transfer of future updates to the intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Development Milestone Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company evaluates whether milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license fees and earnings in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commercial Milestone Payments and Royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: For arrangements that include sales-based royalties, including milestone payments based on the level of commercial sales, and the license is deemed to be the predominant item to which the royalties or commercial milestones relate, the Company will recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date no commercial milestone payments or royalties have been achieved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When no performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability. Upfront payment contract liabilities resulting from the Company&#8217;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information on our collaboration and license arrangements, please read </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 4, Collaborative Research and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to these consolidated financial statements. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include payroll and personnel expenses, consulting costs, external contract research and development expenses, and allocated overhead, including rent, equipment depreciation, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. The Company expenses upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In instances where the Company enters into cost-sharing arrangements, all research and development costs reimbursed by the collaborators are accounted for as reductions to research and development expense. During the years ended December 31, 2023 and 2022, the Company has incurred external costs related to Incyte cost-sharing collaboration. During the year ended December 31, 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company incurred </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> external costs related to cost-sharing collaborations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_ClinicalTrialCostPolicyTextBlock', window );">Clinical Costs</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical study and trial costs are a component of research and development expenses. The Company expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific contract tasks using data such as patient enrollment, clinical site activations, or other information provided to us by our vendors. Depending on the progression of the contract and timing of invoicing and payment the research and development expense can be an accrued expense or a prepaid expense. Prepaid clinical study and trial costs are included in short-term deposits on the accompanying consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax bases of assets and liabilities and for loss and credit carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is provided to reduce the net deferred tax assets to the amount that will more likely than not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees and Indemnifications</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Guarantees and Indemnifications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. The Company has standard indemnification arrangements under office leases (as described in Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to these consolidated financial statements) that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the Company&#8217;s lease. Through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had not experienced any losses related to these indemnification obligations and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related reserves were established.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for all stock option awards granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value of the stock option grants and is recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved. The Company accounts for forfeitures as they occur.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">(Loss) Earnings Per Share</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Loss) Earnings Per Share</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic earnings per share is computed by dividing undistributed net income attributable to Syndax by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_ClinicalTrialCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Cost [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_ClinicalTrialCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//460/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178312608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments under Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the Company&#8217;s operating leases, were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;"></td>
        <td style="width:3.401%;"></td>
        <td style="width:1%;"></td>
        <td style="width:39.208000000000006%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.401%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178499952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earnings (Loss) per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted (loss) earnings per share are calculated as follows (in 000s):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.352%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.902000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.022%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">209,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149,338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">209,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149,338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,371</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,761</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,065</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective of Dilutive Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,429</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non - vested restricted stock units (RSUs)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive potential common shares</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Shares used in calculating diluted (loss) earnings per share</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,371</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,761</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,623</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in 000s):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.34%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.74%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,685</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested RSUs</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">309</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information related to the Company's common stock see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 12, Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178419344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.200000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.200000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176775520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques the Company utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.411%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.798%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Carrying<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">275,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">275,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">600,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">305,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,356</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481,271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">421,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The following table summarizes the available-for-sale securities (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.235%;"></td>
        <td style="width:1.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.812%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.812%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.812%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.812%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>(Losses)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,806</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">US Treasury</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,111</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">304,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">305,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">321,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">321,425</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">US Treasury</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">566</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">806</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">421,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178365648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.482000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.283000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable on investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid subscriptions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid state and local taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178485792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.652%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.604%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical study and trial costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,375</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued milestone costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expense and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,856</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178430096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has reserved for future issuance the following shares of common stock pursuant to the following outstanding securities or equity plans:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:26.28%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issuable under pre-funded warrants</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">285,714</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">At-the-market program</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,280,256</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs and Options to purchase common stock</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,204,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity plans</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,403,382</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2015 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,732,614</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,906,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162179583984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees and related to the Employee Stock Purchase Plan in the consolidated statements of operations as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.42%;"></td>
        <td style="width:2.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,147</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,003</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,019</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,317</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The grant date fair values of options issued to employees and non-employees were estimated using the Black-Scholes option-pricing model with the following assumptions: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.75%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.618%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.03</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.04</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.02</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85.84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Employee and Non-Employee Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of employee and non-employee option activity under the Company&#8217;s equity award plans is presented below (in thousands, except share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.96%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.3%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,981,677</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,800,691</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">662,042</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.08</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled, forfeited or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,684,858</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,468,638</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested, or expected to<br/>&#160;&#160;&#160;vest</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,684,858</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our RSU activity:</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.609%;"></td>
        <td style="width:2.519%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.177%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.697%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.999%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">224,788</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.02</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">308,550</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested&#8212;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">519,436</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 had a weighted average grant date fair value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.94</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair values of RSUs vested in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">705,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178202080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes computed at the statutory federal income tax rate to the provision for income taxes as reflected in the financial statements is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.493%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.382%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.382%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.382%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General business credit carryovers</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Return to provision true up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s deferred tax are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.200000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.200000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets (liabilities):</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,765</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,124</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized start-up and other costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,859</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,374</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,562</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets before valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,081</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowances</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,081</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Reconciliation of Company's Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.493%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.922000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.922000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.922000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefit--beginning of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases related to prior period positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefit--end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178191168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Disclosures of Cash Flow Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.913%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.2170000000000005%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.2170000000000005%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.2170000000000005%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosures of Cash Flow Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosures of Non-Cash Investing and Financing<br/>&#160;&#160;&#160;Activities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance costs included in accounts payable and accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162174918064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Claim </div>
<div>Segment</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU No. 2019-12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember', window );">Guarantees and Indemnifications [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Indemnification obligations, claims outstanding | Claim</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IndemnificationObligationsClaimsReserves', window );">Indemnification obligations claims, reserves established</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Cost-Sharing Collaborations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CostsRelatedToCostSharingCollaborations', window );">External costs related to cost-sharing collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PercentageOfIncomeTaxContingencyRealized', window );">Percentage of income tax contingency realized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CostsRelatedToCostSharingCollaborations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs related to cost sharing collaborations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CostsRelatedToCostSharingCollaborations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_IndemnificationObligationsClaimsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification obligations claims reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_IndemnificationObligationsClaimsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PercentageOfIncomeTaxContingencyRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of income tax contingency realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PercentageOfIncomeTaxContingencyRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176278736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from Incyte Share Purchase Agreement shares</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">12,432,431<span></span>
</td>
<td class="nump">7,840,909<span></span>
</td>
<td class="nump">3,802,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,848,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CollaborationReceivable', window );">Collaboration receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from Incyte Share Purchase Agreement shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability', window );">Allocated consideration received to derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement', window );">Upfront payments returned upon termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement', window );">Estimated standalone selling price of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_RevenueRecognizedUponTransferOfLicenseAgreement', window );">Revenue recognized upon transfer of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CollaborationReceivable', window );">Collaboration receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CollaborationExpenseDueToCounterparty', window );">Collaboration expense due to counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member] | Non-Refundable Cash Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_UpfrontPayments', window );">Upfront milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
<td class="nump">$ 117,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PotentialMilestonePaymentsUponAchievementOfMilestone', window );">Potential milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CommercializationMilestonesAndTieredRoyalties', window );">Commercialization milestones and tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member] | Global and U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DevelopmentCostsAssociatedWithClinicalTrials', window );">Development costs associated with clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member] | Global and U.S. [Member] | Incyte Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DevelopmentCostsAssociatedWithClinicalTrials', window );">Development costs associated with clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member] | Ex-U.S. Countries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DevelopmentCostsAssociatedWithClinicalTrials', window );">Development costs associated with clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement allocated consideration received to derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement consideration transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CollaborationExpenseDueToCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration expense due to counterparty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CollaborationExpenseDueToCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CommercializationMilestonesAndTieredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercialization milestones and tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CommercializationMilestonesAndTieredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_DevelopmentCostsAssociatedWithClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development costs associated with clinical trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_DevelopmentCostsAssociatedWithClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated standalone selling price of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PotentialMilestonePaymentsUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PotentialMilestonePaymentsUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_RevenueRecognizedUponTransferOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized upon transfer of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_RevenueRecognizedUponTransferOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments to be returned upon termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=sndx_NonRefundableCashPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=sndx_NonRefundableCashPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sndx_GlobalAndUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sndx_GlobalAndUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sndx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sndx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162174982992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lease option to termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,487,000<span></span>
</td>
<td class="nump">$ 1,039,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Future minimum lease payments under capital leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,864,000<span></span>
</td>
<td class="nump">$ 22,441,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Waltham, Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_LeaseCommencementDate', window );">Lease Commencement Date</a></td>
<td class="text">Mar.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, Operating Lease, Option to Extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On August 17, 2021, the Company signed a 36-month extension to the lease for the Waltham, MA office with aggregate payments of $1.6 million, with a lease commencement date of March 1, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">36 years<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">62 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_LeaseCommencementDate', window );">Lease Commencement Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2023<span></span>
</td>
<td class="text">Sep.  01,  2022<span></span>
</td>
<td class="text">Mar.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182267232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments under Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176174592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings per Share - Computation of Basic and Diluted Earnings (Loss) per Share (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (209,360)<span></span>
</td>
<td class="num">$ (149,338)<span></span>
</td>
<td class="nump">$ 24,926<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common stockholders</a></td>
<td class="num">$ (209,360)<span></span>
</td>
<td class="num">$ (149,338)<span></span>
</td>
<td class="nump">$ 24,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding</a></td>
<td class="nump">70,370,519<span></span>
</td>
<td class="nump">60,760,906<span></span>
</td>
<td class="nump">52,064,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,558,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings (loss) per share</a></td>
<td class="nump">70,370,519<span></span>
</td>
<td class="nump">60,760,906<span></span>
</td>
<td class="nump">53,622,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,429,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Non-Vested Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182634528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per common share</a></td>
<td class="nump">10,685<span></span>
</td>
<td class="nump">7,982<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Non-Vested Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per common share</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sndx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per common share</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sndx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sndx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182264320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings per Share - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from Incyte Share Purchase Agreement shares</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">12,432,431<span></span>
</td>
<td class="nump">7,840,909<span></span>
</td>
<td class="nump">3,802,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162174760016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
<th class="th"><div>Mar. 31, 2007</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,032,000<span></span>
</td>
<td class="nump">$ 118,499,000<span></span>
</td>
<td class="nump">$ 88,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,856,000<span></span>
</td>
<td class="nump">$ 24,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_AllerganLicenseAgreementMember', window );">Allergan License Agreement [Member] | Vitae Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_UpfrontPayments', window );">Upfront milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PotentialMilestonePaymentsUponAchievementOfMilestone', window );">Potential milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_LicenseAgreementsExpirationPeriod', window );">License expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DevelopmentAndRegulaotryMilestonesExpenses', window );">Development and regulaotry milestones expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_MilestoneExpensesPaid', window );">Milestone expenses paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_UcbLicenseAgreementMember', window );">UCB License Agreement [Member] | UCB Biopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_UpfrontPayments', window );">Upfront milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PotentialMilestonePaymentsUponAchievementOfMilestone', window );">Potential milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_LicenseAgreementsExpirationPeriod', window );">License expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_MilestonePaymentDue', window );">Milestone payment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_LicenseAgreementMember', window );">License Agreement [Member] | Bayer Pharma AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_UpfrontLicenseFeesPaid', window );">Up-front license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_LicenseAgreementMember', window );">License Agreement [Member] | Bayer Pharma AG [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Aggregate payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_AggregatePotentialMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_AggregatePotentialMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_DevelopmentAndRegulaotryMilestonesExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulaotry milestones Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_DevelopmentAndRegulaotryMilestonesExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_LicenseAgreementsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_LicenseAgreementsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_MilestoneExpensesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Expenses Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_MilestoneExpensesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_MilestonePaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_MilestonePaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PotentialMilestonePaymentsUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PotentialMilestonePaymentsUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_UpfrontLicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_UpfrontLicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sndx_AllerganLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sndx_AllerganLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sndx_VitaePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sndx_VitaePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sndx_UcbLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sndx_UcbLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sndx_UCBBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sndx_UCBBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sndx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sndx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sndx_BayerPharmaAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sndx_BayerPharmaAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182629536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">$ 419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(411)<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sndx_ComputerAndOfficeEquipmentMember', window );">Office and Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sndx_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sndx_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162180201568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176036064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 275,304<span></span>
</td>
<td class="nump">$ 401,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">29,829<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">295,394<span></span>
</td>
<td class="nump">74,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">275,304<span></span>
</td>
<td class="nump">401,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">29,829<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">600,527<span></span>
</td>
<td class="nump">481,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">295,394<span></span>
</td>
<td class="nump">59,496<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">295,394<span></span>
</td>
<td class="nump">59,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">275,304<span></span>
</td>
<td class="nump">401,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">29,829<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 305,133<span></span>
</td>
<td class="nump">$ 421,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178367728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains or losses recognized on the sale or maturity of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162171856960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 304,916<span></span>
</td>
<td class="nump">$ 422,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">305,133<span></span>
</td>
<td class="nump">421,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">160,657<span></span>
</td>
<td class="nump">321,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">160,806<span></span>
</td>
<td class="nump">321,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=sndx_FederalBondsMember', window );">Federal Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">28,998<span></span>
</td>
<td class="nump">36,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">28,958<span></span>
</td>
<td class="nump">36,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">47,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">47,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">68,111<span></span>
</td>
<td class="nump">64,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 68,157<span></span>
</td>
<td class="nump">$ 64,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=sndx_FederalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=sndx_FederalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162175893712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 807<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable on investments</a></td>
<td class="nump">1,227<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PrepaidSubscriptions', window );">PrepaidSubscriptions</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PrepaidStateAndLocalTaxes', window );">Prepaid state and local taxes</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,293<span></span>
</td>
<td class="nump">$ 1,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PrepaidStateAndLocalTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid State and Local Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PrepaidStateAndLocalTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PrepaidSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Subscriptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PrepaidSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176925104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_AccruedClinicalCostsCurrent', window );">Accrued clinical study and trial costs</a></td>
<td class="nump">$ 16,346<span></span>
</td>
<td class="nump">$ 14,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related costs</a></td>
<td class="nump">11,172<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,450<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_AccruedMilestoneCosts', window );">Accrued milestone costs</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">888<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 39,856<span></span>
</td>
<td class="nump">$ 24,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_AccruedMilestoneCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_AccruedMilestoneCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176362496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2023</div></th>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 09, 2023</div></th>
<th class="th"><div>Apr. 12, 2023</div></th>
<th class="th"><div>Mar. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public stock offering, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">12,432,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,840,909<span></span>
</td>
<td class="nump">3,802,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,906,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,906,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_NumberOfPreFundedWarrantsExercisedForCommonStock', window );">Number Of Pre Funded Warrants Exercised For Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,137<span></span>
</td>
<td class="nump">272,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_OfferingPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_GrossProceedsFromOffering', window );">Gross proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember', window );">Incyte Collaboration Agreement and Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public stock offering, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sndx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_NumberOfPreFundedWarrantsExercisedForCommonStock', window );">Number Of Pre Funded Warrants Exercised For Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_OfferingPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sndx_SeriesWarrantsMember', window );">Series Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_OfferingPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sndx_AtTheMarketEquityOfferingSalesAgreementMember', window );">At The Market Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public stock offering, net</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sndx_CowenAndCompanyLLCMember', window );">Cowen and Company LLC [Member] | At The Market Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public stock offering, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_GrossProceedsFromOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_GrossProceedsFromOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_NumberOfPreFundedWarrantsExercisedForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Pre Funded Warrants Exercised For Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_NumberOfPreFundedWarrantsExercisedForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_OfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_OfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sndx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sndx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sndx_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sndx_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sndx_AtTheMarketEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sndx_AtTheMarketEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sndx_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sndx_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182311616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Common Stock Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">23,906,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sndx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">285,714<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sndx_EquityPlansMember', window );">Equity plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">3,403,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">11,204,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sndx_AtTheMarketProgramMember', window );">At-the-market program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">7,280,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sndx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">1,732,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sndx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sndx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sndx_EquityPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sndx_EquityPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sndx_AtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sndx_AtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sndx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sndx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162171074032">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($) </div>
<div>Employee </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Dec. 06, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,906,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based compensation, stock options granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based compensation, stock options vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,684,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,951,000<span></span>
</td>
<td class="nump">$ 16,019,000<span></span>
</td>
<td class="nump">$ 13,317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="nump">$ 12.64<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662,042<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">842,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Stock options exercised | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,128,000<span></span>
</td>
<td class="nump">$ 11,459,000<span></span>
</td>
<td class="nump">$ 6,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions by the company | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
<td class="nump">444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sndx_TwoThousandAndNineteenPerformanceAwardsMember', window );">2019 Performance Awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions', window );">Stock compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sndx_TwoThousandAndNineteenPerformanceAwardsMember', window );">2019 Performance Awards | Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option granted to certain employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sndx_TwoThousandTwentyThreePerformanceAwardsMember', window );">Two Thousand Twenty Three Performance Awards [Member] | Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option granted to certain employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember', window );">2022 Performance Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based compensation, stock options vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based compensation, stock options cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions', window );">Stock compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,000<span></span>
</td>
<td class="nump">$ 479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option granted to certain employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting period, description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one &#8211; year anniversary date of the related grant or ii) 25% on each anniversary for 4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units vested | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">$ 705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.94<span></span>
</td>
<td class="nump">$ 15.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_TwoThousandFifteenOmnibusIncentivePlanMember', window );">2015 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,191,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant', window );">Common stock outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_TwoThousandFifteenOmnibusIncentivePlanMember', window );">2015 Plan [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,393,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_TwoThousandTwentyThreeInducementIncentivePlanMember', window );">2023 Inducement Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,211,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember', window );">2007 and 2015 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock option | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_TwoThousandAndSevenStockIncentivePlanMember', window );">2007 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based compensation, stock options vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_NumberOfEmployeesRetirement', window );">Number of employees retirement | Employee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308,000<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued under plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,797<span></span>
</td>
<td class="nump">28,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_ExpirationOfTheEspp', window );">Expiration of the ESPP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_ExpirationOfTheEsppShares', window );">expiration of the ESPP shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod', window );">Periodic payroll deductions offering periods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate', window );">Offering period discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares authorized for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sndx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,982,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 had a weighted average grant date fair value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.94</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair values of RSUs vested in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">705,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation recognized stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_ExpirationOfTheEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration of the ESPP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_ExpirationOfTheEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_ExpirationOfTheEsppShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>expiration of the ESPP shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_ExpirationOfTheEsppShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_NumberOfEmployeesRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_NumberOfEmployeesRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award annual increase percentage in number of shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award offering period discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award payroll deductions offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sndx_TwoThousandAndNineteenPerformanceAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sndx_TwoThousandAndNineteenPerformanceAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sndx_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sndx_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sndx_TwoThousandTwentyThreePerformanceAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sndx_TwoThousandTwentyThreePerformanceAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sndx_TwoThousandFifteenOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sndx_TwoThousandFifteenOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sndx_TwoThousandTwentyThreeInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sndx_TwoThousandTwentyThreeInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sndx_TwoThousandAndSevenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sndx_TwoThousandAndSevenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sndx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sndx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162174668032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense, total</a></td>
<td class="nump">$ 30,951<span></span>
</td>
<td class="nump">$ 16,019<span></span>
</td>
<td class="nump">$ 13,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense, total</a></td>
<td class="nump">14,147<span></span>
</td>
<td class="nump">6,016<span></span>
</td>
<td class="nump">4,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense, total</a></td>
<td class="nump">$ 16,804<span></span>
</td>
<td class="nump">$ 10,003<span></span>
</td>
<td class="nump">$ 8,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162179461248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 10 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">75.13%<span></span>
</td>
<td class="nump">77.87%<span></span>
</td>
<td class="nump">85.84%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="nump">2.52%<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162176819376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment Arrangement, Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Beginning balance</a></td>
<td class="nump">7,981,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">3,800,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(662,042)<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="num">(842,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled, forfeited or expired</a></td>
<td class="num">(435,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Ending balance</a></td>
<td class="nump">10,684,858<span></span>
</td>
<td class="nump">7,981,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, Ending balance</a></td>
<td class="nump">5,468,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested, exercisable or expected to vest, Ending balance</a></td>
<td class="nump">10,684,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted Average Exercise Price</a></td>
<td class="nump">23.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted Average Exercise Price</a></td>
<td class="nump">8.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled, forfeited or expired, Weighted Average Exercise Price</a></td>
<td class="nump">23.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">17.78<span></span>
</td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">14.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested, exercisable or expected to vest, Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">$ 17.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested, exercisable or expected to vest, Weighted Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 55,091<span></span>
</td>
<td class="nump">$ 88,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options Exercised, Aggregate Intrinsic Value</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">43,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested, exercisable or expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 55,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162170274704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - Non-Vested Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning balance | shares</a></td>
<td class="nump">224,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">308,550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(9,102)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(4,800)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending balance | shares</a></td>
<td class="nump">519,436<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested, Beginning balance | $ / shares</a></td>
<td class="nump">$ 18.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">24.94<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">13.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">20.36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested, Ending balance | $ / shares</a></td>
<td class="nump">$ 22.17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 had a weighted average grant date fair value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.94</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair values of RSUs vested in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">705,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178202080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Units Activity (Parenthetical) (Details) - Restricted Stock Units (RSUs) [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share</a></td>
<td class="nump">$ 24.94<span></span>
</td>
<td class="nump">$ 15.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units vested</a></td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">$ 705,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162175997328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDepositOnLoan', window );">Payment on term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,996<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PrepaymentFee', window );">Prepayment Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=sndx_HerculesCapitalIncMember', window );">Hercules [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDepositOnLoan', window );">Payment on term loan</a></td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_PaymentForEndOfTermFees', window );">Payment for end-of term fees</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense related to the loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PaymentForEndOfTermFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for end-of term fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PaymentForEndOfTermFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_PrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_PrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDepositOnLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from resulting from payment, receipt or drawdown of cash deposit to guarantee a loan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDepositOnLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=sndx_HerculesCapitalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=sndx_HerculesCapitalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sndx_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sndx_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162171929984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">$ 72,900<span></span>
</td>
<td class="nump">$ 35,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceMethodologiesAndAssumptions', window );">Valuation allowance for deferred tax assets, description</a></td>
<td class="text">The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased by $72.9 million in 2023 due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized research expenses, and capitalized start-up costs. The valuation allowance increased by $35.9 million in 2022 due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized start-up costs, partially offset by a decrease to other deferred tax assets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating losses</a></td>
<td class="nump">$ 136,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating losses</a></td>
<td class="nump">63,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Uncertain tax positions</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax asset</a></td>
<td class="nump">79,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Deferred tax assets, Expenses required to be capitalized</a></td>
<td class="nump">53,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties recorded during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized income tax benefits that would affect effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod', window );">Operating loss carryforward expiration period</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred tax assets research credits</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod', window );">Deferred tax assets research credits expiration period</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Indefinite Carryforward Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating losses</a></td>
<td class="nump">$ 114,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating losses</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Begin to Expire in 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating losses</a></td>
<td class="nump">22,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current State Income Expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod', window );">Operating loss carryforward expiration period</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred tax assets research credits</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod', window );">Deferred tax assets research credits expiration period</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Begin to Expire in 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating losses</a></td>
<td class="nump">$ 62,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets research credits expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceMethodologiesAndAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the methodologies and assumptions on which the valuation allowance is based for deferred tax assets for which it is more likely than not that all or a portion of the deferred tax asset will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceMethodologiesAndAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=sndx_IndefiniteCarryforwardPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=sndx_IndefiniteCarryforwardPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=sndx_BeginToExpireInTwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=sndx_BeginToExpireInTwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162170106528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">General business credit carryovers</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(34.90%)<span></span>
</td>
<td class="num">(24.10%)<span></span>
</td>
<td class="num">(19.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_ReturnToProvisionTrueUp', window );">Return to provision true up</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_ReturnToProvisionTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return to provision true up</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_ReturnToProvisionTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162170103968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 32,664<span></span>
</td>
<td class="nump">$ 23,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">11,765<span></span>
</td>
<td class="nump">8,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts', window );">Capitalized start-up and other costs</a></td>
<td class="nump">68,859<span></span>
</td>
<td class="nump">45,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">79,562<span></span>
</td>
<td class="nump">48,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity based compensation</a></td>
<td class="nump">10,276<span></span>
</td>
<td class="nump">5,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals</a></td>
<td class="nump">2,795<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">205,957<span></span>
</td>
<td class="nump">133,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="num">(205,957)<span></span>
</td>
<td class="num">(133,081)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset, capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset, capitalized start-up and other costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162183605504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Company's Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit--beginning of year</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior period positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit--end of year</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162182552704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=sndx_SeriesB1PurchaseAgreementMember', window );">Eddingpharm Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase agreement obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member] | Global and U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_DevelopmentCostsAssociatedWithClinicalTrials', window );">Development costs associated with clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member] | Non-Refundable Cash Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_UpfrontPayments', window );">Upfront milestone payable</a></td>
<td class="nump">$ 117,000,000<span></span>
</td>
<td class="nump">$ 117,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember', window );">Incyte Agreement [Member] | Equity Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sndx_UpfrontPayments', window );">Upfront milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_DevelopmentCostsAssociatedWithClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development costs associated with clinical trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_DevelopmentCostsAssociatedWithClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sndx_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sndx_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sndx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=sndx_SeriesB1PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=sndx_SeriesB1PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sndx_GlobalAndUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sndx_GlobalAndUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=sndx_NonRefundableCashPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=sndx_NonRefundableCashPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140162178147136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information - Supplemental Disclosures of Cash Flow (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,059<span></span>
</td>
<td class="nump">$ 1,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M$=M79ML;Q=?M6Z=[KA2OVLL5HQJV$="_+[GF_^[&O,C:O;A<_ =02P,$%
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M@H2E2!@'P22[!H]V#8QVW=_]V-Y5BU56"^NN6+87]-'UU97)ID;D6)LB8?-
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MC'8YM&/*&0#0GQR+,JKSU%>ZX6*O9DC5$%';*W8T&MAPI;R#'>\\.U&24SZ
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MX: BKE'QR:8@-8.\S-03=3*1:&@F+;7"'*!K8^)5"FW'# 4+'R)4*@.&NFN
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M!U@7K'9RRF 8O@\/HL,W-UHFB6&_8<U16DL2C3%;'M\>HUO_&74^"=ZUU/%
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MI,VY137H TDFM,6BF$X3A304)FD/ 8<3CVH+C+'#J6=."WM3P4T.:9I22A.
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MW2PY.UQ$U_'GS,+%Z%K^V2A9*4\OX'GM $Z^H W&[]M7_P=02P,$%     @
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M+M5?;VZ^P/S_/EK0!=7O@!6T0@T.?]T99?*YNJN5#L"7GHX-:MCJ0>GU&@B
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M5UI2<K]?L#MG1YQDF:("EENTC<E=+4Y 5V+"4B&4IAB0950P]8B4RAOL1_K
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M7L#W:P?=C'_0 ?D'S^__#U!+ P04    "  FA%M8#FH?<OX-  # *0  &0
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M'<#[F=:N7= %W8])-_\"4$L#!!0    ( ":$6UC[=CB]&@0  )L)   9
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MO,8.UCG% %V QI(#R5DPCL)T',,H"L>C&(9)&(V&O=O5"OV5!&H%-\[+;KS
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M6H#G$X/37W5!"IK?BES\!U!+ P04    "  FA%M8+J&+=M\"  "!!@  &0
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M8<^DC!>)?Q!?*[GA&9T(D)\PHHRM\"\#I%OLSY5\QY>9"-Q![.H*-.(95<7
M^KPLM7J62"_LVE0 $#C5ZQ7AVQ ^PQ* M(I(F$F5MF^LT#DKN 5JPH871K"5
M+'@12YXQ60!0Y?2I%76,F#24M# 0P!C'3CS'*2_6@I50 $)2;E%*JBQA2P&]
M8H&R 2Q*0P.<,:B4>"ZY3!P@S0NS$GC),LF7,I-VQUZ!4CQ+ZUF^!A@G"2N
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M:FP.ZN/M>M"E0L"J-EB2%]%E6;/)@,NRADM9IA]TFL(I 0D)LVIV"X:4UO1
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MB<_/(K#M5:5]\:8.UX.U\739"(\EW>[0L@'M%\;X_H4##/?%Y;]02P,$%
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M96[;E9'=#KC7JV\1GLXC@&L^&DK<&QN!1MDAZF8;H1HN?-#KJ@"?I<R^2D"
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M$;IA;3*9%G"0]#G?Q,C _)_$?/X&W:<H8B,U'$@ALTPWC17WBY/^FK[6.NQ
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MX_9Y@W[K<Z=<YLS@E1+?>&Z+<7 :0(X+5@O[H-:?L,UGZ/ R)8Q?8=W8#M(
MLMI85;;.Q*#DLMG9<_L.6PZGT1L.2>N0>-Y-(,_RFEDV&6FU!NVL"<T=?*K>
MF\AQZ8KR:#7=<O*SD\>ZJ@32*ULFX(J9 FZI3C"33;WIX4:AI3C..LQ:S&F#
MF;R!&2=PIZ0M#-S('//7 "$1[%@F&Y;39"_B-69]2.,C2*(DW8.7=EFG'B_]
MMZQO&IV!'Y=S8S5],3]W9=]@#W9CNRXZ-Q7+<!Q0FQC4*PPFAP?Q<72QA_F@
M8S[8A_Z?]=J+N9MQ?-*'OP?K?4>FVSH#50G+.6I7J9ZKE"M7XI:X]WXFP1:J
M-DSFYD/O%?(U-YE0IJ;8H!9O!)I)BV1@H6(\AW=P>'":Q,D%G9*C:'A&>WQT
M=G:R%_FSDA\]^DRN"(K+)1 =N.62R8RDWLR8FHX(F3+T&7"9B=IEQMWXR%3M
MOHV*O;"Y0.])2EW3/3[3D#04A-@,(\<EC?TZ@%TU#[?ZM42]]%/)@ _0M&ZG
M[0;?9=/O?\R;J7G']))+ P(7Y!KU3X8!Z&82-8)5E>_^N;(T2_RQH.&-VAG0
M_4(INQ%<@.YW,/D-4$L#!!0    ( ":$6UCOIS_Z318  .!%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;*U<ZY/;-I+_5U"S=7MVE4;S2.PDCNVJ
ML?,X5R5W+D_V]L/5?8!(2$*&)+0$.;+NK[]?=P,@*%$<K^^J-FL-130:_7Y!
MK_>N??!;8SKUN:X:_^9BVW6[5U=7OMB:6ONEVYD&WZQ=6^L.?[:;*[]KC2YY
M45U=W5Y?O[RJM6TNWK[F9Q_;MZ]=WU6V,1];Y?NZUNWAG:G<_LW%S45\\,EN
MMAT]N'K[>J<WYMYT?]M];/'758)2VMHTWKI&M6;]YN+NYM6[FQ]H ;_QG];L
M??99T5%6SCW0'Q_*-Q?7A)&I3-$1"(U_'LU[4U4$"7C\(P"]2'O2POQSA/X+
M'QZ'66EOWKOJ[[;LMF\NOK]0I5GKONH^N?V_F7"@%P2O<)7G_U=[>??%MQ>J
MZ'WGZK 8&-2VD7_UYT"(;,'WUV<6W(8%MXRW;,18_J0[_?9UZ_:JI;<!C3[P
M47DUD+,-<>6^:_&MQ;KN[;UP0[FUNK>;QJYMH9M.W16%ZYO.-AOUT56VL,:K
M9_'3\]=7';8F %=%V.:=;'-[9IN;6_6[:[JM5S\WI2G' *Z <T+\-B+^[G86
MXD^F6*IO;A;J]OKVFQEXWR1"?,/POCD#;^K$_W6W\ET+P?GOJ1,+O&^GX9$V
MO?([79@W%U 7;]I'<_'VKW^Y>7G]XPRVWR9LOYV#_O9GWUF(I/%3B'WA4O7'
MUBC@MM.M9@V!#!2N\3A]B>]+M;:-;@JK*^4[/( N=E[9AEXB<V"[ X2UVZJ_
M+>^7ZM>[NX]0TW_T%J>%A#;0:5JA.H>_'HPR:5_=E$I[V($=;>M5M]6=TNLU
M%!6?#:#L7$L(Z)I8X@DQO&\Z65I9O;*5[6P 14M*ZXO*^;XUX13$2-K]W#K9
MB<Y)"^CSTT>/FTWA5S@?WC"?83$]]BC[EJ1I6$%_[4QK7;EDVK]W]4XW![8J
M?H8^8,W6PA*TT,V*X;?6-(51^ZV!77O4MM*KRO ZO/NHL47OU1J"Z]I 7MNI
ME:FL>01\<&1%.&GO&E[80R=;(8)MB[[&F0'>C[$TC[KJ&3_;/8&MABPU&T?G
MQ=GL&-!?__+][<UW/WHRR#W. W&!!261.8"-D()6K5M7$SH^EQI!4MX(G!WV
M;(E]I>6_ENKGL\CI%3R36O<=20J(D;'5MLJP#'H%$]@X(ACL>V<@Z0V8S:)>
MF+:#JX/DAU7P(:XU4?"9AN:S:0OK6;#^[,L-"<]2W?DH:%'H+/ B.H?G6# E
M=0M>$YE@O2+,]%Z+I-,SOS,%V6TY#],BXZ*P?^_ZJAQA&2%"&/H=HS1BZV),
M-APV'H6IW9I'.B&+C&[; [&:Y$,.1D05O<.KF=JQ'(R82DPOMAJZBA6J@1,/
M3'%%T;?"OE+X"JK81L(0,E:@A%L1+T@/Z37F0N'@P_X'CV"FOE"IO?*.9)84
MQ4 9 :,VZJ%Q^P9<&\MHP60<2ZGS)[:-F-(7VR2L13@I!(K>:@D%T+V;4(HG
M$5[.>(\7R7N\F'4![[7?JI\A"V 9P9QR(K,0IKW;,5C%#TSVP#9%U9?@=57!
MI&VVU0'B@>^)7[!,G; $-!+322H'1OYP#9TYB# 9[Y-Y2)JTZUL(D3?+\SO6
MK@%S$>H\&-+_IH2$%ZZ%6288I5EURAN(',OI0ES:QCV:MF$G!F?6% ?2/58-
M,K3T'85\6+QS'C*_5#.L>9E8\W*6-9] !=AYXCZ=98HSLP"F.7,$=637BPJZ
M"OMA6!?:X<V"WB1.\8==9<H-Z1K):%61&(L4,]F,JF#Q+\E80BTKN]&#X4@@
M]JPK/?XCY27CN2<C4EF$$H"\.K#C;H-?V+4.-D8,^EUPM*+DT?N2+6PNL3O[
M@[YAX8@'D.W)RL-?\GFBVZO@^ 8+T9C/G4)X6G-X.LO#[Q(/OYOEX>\L9>Q9
M[Y-,37'R*\"HNZH:*0N.40\O#C+,9T^\96JE2.$29O32ZQ RC(D*[=!PA6+,
MV>?U#4*%BJWJ!O8V!%/.<]#RF=6K%)TT&BK1;.2-!+*!QI&+TY\)60W#7O<5
MVS>6 3"]AJ1N*=-[-*2PL+\+"(N%!86@:'X!ZMLP&,1!Q</650@&?+":K/#=
M8:G^-F :\)/0LATY<I$#WOL2WS>0VIKL0'M8<"C&0524JAC1L00%\S&$&HL)
MMQ.)L%1(48BGS*.,J">H%*T!/)),I@HS;JO;C;PPP/N#'9IG,DSS'*ZC))IE
M6T"K2,Q3D&!+'(O3/':CM8$'*^><RO=)ZK^?%==[P^&!^A1CW2F)GP4Q;;M.
MX*K_0 "L^9,W(20AFL6312,5A$;2!_"E 4UV+5D<B0)%PKSD/Y)"M*!;YG6/
MXHTATL;C& _3=X'&Q=::M7()NQ(DY^H%Y3_M@OQ7?'2)1_3*IG7];B%*_)"O
M(4.VT6U)ST *!P_';M,%OH7 %A8O9!6,*2*-<= .KPAI-AE2@62SANZ'Q/(?
MYN,(APW)8H<H?*W>BRA_LOYABOVSX,X$%7-[B#<C6A1'CG]Q[,G$:_LM9"@8
ML.BO<FM*<I3S'R!Z^88MR0[^'S(&/E"$M_HS9JQ9,%V<X!O5&_@NU7V_HK@\
MP"#7&+*"DT"0<3X]UI><8F_8XG%8(D9)2W5#$M^].SJC[?IHSAIV 8AF*<Z1
M(#:$-QS!PMX;LO:F)/>/$V YO'\I3MR?"A]E*T/&*K%QL,U BS>(N,GN6>5@
M2%BWNIM*@P#8>;&2/BM>901'$FYBJ#V<F0\4*AX<1\H177L8D8,P%",A47ZB
M!$G)UE3EF;SVU,WFS($)@O&V%4<[2([9G&>AYC\9J<+.U91OTK'TCLQ,.#[R
M,C$1W>5*%P\@4QX<3$:P_/C_+N,SEN7F>JA+7L_:EH\MV:R0:%-2L2/J3%8>
M9P%-6Y5IZ&KTV*3'T<FWI41(Y(3)O0,>"!_=0WJC]['N0]5#HO E(15\+=-=
M"@4A:Z059MU74"*2]B"4(8-^AC]:PT*\IOCH@'C J^=44.#OI2Q2Z)WM( (<
MVXJ ZIK<)04E:4.V&_@L.R @&>_;RG+%]F3^$$OUN_Z3ZP"["J0=ZF.VIKC=
M#-8T8$:(<% ';4 NQ<D#E1YMZX/:6_CGABL6,6IOO+ARA(04C97SDI55O&]F
M)>M#3=O6(9[\C2SH;R! &2@Z*6*S$*=%[(EMY$G%3V*1DL7LT9H]F5A0UPX@
MJ-1GB(^Q/M*&NHE49/.R'1Z4%-Z9P6ZF&HU4+$<BQG8]E+M(A+$)&:^E^CM5
M%]E"YS69<3V*HBS=LHD^V>58DL4,D]0U%&O1*R8+KD-1CCW>NG)[.),/M-[Z
ML(OUI&?A;(-3:#F='$@E" X'S8A(H'15A.Q#*CY9D084Z/;&-%-E+9+1(8:'
MX7=<?5B <D*C81L/Q_=(P$R3I0;SPGL["._M$_4!\ +X?!+ 9'LF!786RKDB
MP0GHD3M/9R%3)Z]R 9H<AW2JR+1P3<Y+)N\XNH%!J"VI\L:YDB67-K0%>2_+
MQ>+ +.9H:]85%V%C^<Z6)O0GQ!?O8TI/ @6<C&2-%)I((9$T1QSVR8;+Z0.E
M\ZP=(NQ]-'QL;]FMW_P(*VAV\,VEH<J$0:I@5V2XV?K^<G?_+F^9W4,12[A?
MCZW*(==ZIN[NWZN7UR^?+U0D-N?-[T/9PTO"_3X0TZM7ZIE]'A.;H3SRS#\/
MY>CPYH]X+W^1L,]R@E%)9JB,,BQ>BK4I9>1O\57CM31.$; 4AEY[?!XSD#,O
MQ4CKB[<FK7H&L*><8,EZ!M9I.BN<$$#X^9,MU6_ @5LOD+H/L"X521+5DI)?
M?S4F/-6/('#@(IF\A>IWEW@.45P;\J+AL&4\5Q7AQU1]7,3]5SIAMNLN['I2
M)0B6)X CL\2DA!EJ!Z!)I6+;*3V@5)2R4"K=>S%-*WB'-0*P5!H-L$G@\7KP
MN(CH.J2BB$'):0]Q03P.%;TOMS!)$9W0KN+4U2*+WNT 5TB5%DO-;SVLP>=@
MRZ6Q$"W_-'$HCGHTE9-(ZW?$!S@EI/"C/H@Q?76F"P4)X?)1'9>$>".8#!P'
M6ZR84,!H9223UL4V- R&FGWF+Z0@$XK&J49X*NA#=%130::R#X;2.0$20Z0/
MU HA;B5$I!PU2E:BP-._+9*%T*HAAYSY6[A01Z$F%:$2B<0S6?\TOLN,L+M(
MV%0;H[U"J3VIISM.3)5K<\$R(3ODDO&&/"IE3Q 01'^Z"H6Q0>QHBUG.:"J>
M/+)%[6P5['<"%Q6(;'W(NDYY8IF3S5AMB>%G# 9W*D7VR=!3]%1>ZHIHY"&G
M7%=AP-S#7+!?B>G@K%?4['/8@LU9PZSK&@PB'U,LG:5SWDGT9BA96\M1D)%Y
M)":&)6?<5%X<X74YZ JCP32G3AQ/>P2"Q_@TI/J#)N9J%7I:T4P0(RDGH%B+
M8_ZU:L ;[[F$JLL_>^J%Y^W$*$L<7%;5E(#>Q::9K!\2B)16,;M"\9@8!AX7
MV\M^%_D3P@-6GS!-$"VLF'-2^EBAMHDWUC%UAVV71,.84T\8)(+SR1UTQ9GT
M*_4+>:FVI=@C4ZS8>*+\WU]*7;F-JQ;A:V)>?:J9J0K-"D=,D1&#A!4#723/
MD#F2T@")6%@6MIL2\5=#ML9VIJ:O!BE.&$D+/6V0<5^X/A:NO:VJ":<=L@UN
M#A'&206BY##>H;?[M(H,J'IJR1*9AWJ98"Y%)@ZU![5/CY(J<22!%"*6->+S
MYRF0ISA^ZOP#4RC;3=0:(OQHN$*^!##G]%T/<P+ED7%E!SL./BGGJ4Q>I3I#
MI*C\HCRC1ED><$0>]3LB;.:KC\S]2<Q\'(\LU:_1K"^8(7'/:)^YSMV'#@LI
M0S-2@B/#,M#TM&&5JR_%"2% 2N)&Q?S0#CY!@C*+\C&;K\ !*M*#G*3)', X
MD@$3<^;/D([:.!+8",VY83K'[<R4GR!_TI9,.V:NF)N3R$FK1Q,:E)S#CKMZ
MJ5<5)RVH$[:3.#9([^!A\B$HF6H@@4MAXW$M,W) ;UH3K%OIV)NWAC-'JH[%
MRBH #:VZ$.-&!$+%=G@SQ2E!#">2PVC>.E-L&U>YS4%\9G6( %) O@&DCJD;
MLD?"3;>%- =ROY;&LW1%4ZR'5%V*79Q @J78]>GA$_I?WTHC?.7:H263Z)7Y
M@P7USJFN1ONI?W<P-M\NL$U:^T@Y=X9N2&/4W4#T1=!"_P4C+?.5AF$>\F9V
M@/'M"*4L1I\L-WP=J/&Q<RZ%<;JSA<"S"Q-[H_^% ,*Z55+:1H3MFL94Z;4%
MDS-H 6^ZP'=P7\3QI#1/"M,B#CH$#T1QSA;<SOU\R[6IH:A<9N5C6=]W:4[J
M"<*DT'VG[;&IRPW240%6S 6/?-HTJ"BH3Q2+10]CB!3T.7D%WIU&-$IS-,Z8
M6- '(Q25(KG2+'W617"(2<EMK.VQCR6C<3!=RMR&UV@6<@V]LB&FI6.$)> $
MLY!5*^:BE Q_:+C!(V72/=<.\["&6\2<Q#LF]*7?:AY$&JNSYN!GED&ML?6J
M;_U@5@9;03.97* O8@UTS74.+"K[,+C"I:UYH8-/&09,I2M@:+::Q@Y,O0(7
MXW0T0\"'VW$0M\TT*A=Z/^;0AZ8X=&9,CY'A.T'D#!XWZFB6,>X-AIW?_OR^
MLZ-P-\,D]<W\//1[/&!A>D];3UJW60!GVM8CJ"K]Z;N^#,.C/ 8X&+JC.9<G
M;<X9I2OB3@*?;SV(NP^&(8JD;4L)B4V6<-"<Q##7$ //UL$3>2_LR,/2-%62
M3&6G_8,/Y1&X*)VJ!#N 9/0;,L=2J$^X4I]:4-6A$0V-D/@Q=[O1WDCEBXY!
M7ACQ5 F=XH8</M+.(76*B&=G&5)M8H&M^>TU-6B=Y;B$_40(6B1UF><##0M3
M *>YR=[V9C"LI-7'UG:I/H8'Q=,BD==UN'<GK?[4K@W')$/"4B JDH4'*UVQ
M'^#[(?-QP3 [>C,_//J!![34'_KS]%#;_/(SO;(,YDF)GNKH90R?:8KLS$S_
M.E2HCCM*M(2HPF63(C18X\C7:$8W[_\<1\(3D=9IPRM%K-A2IOKGKRX0RC0-
M(2,LJ6_?'O#%GAL(HDFFT9(K &[+%9VC]('Z'U+R")F#.(1L@,&,3BK51BJ[
MJ$'=*7[9L[Q(S3+I&CLF$S*2;I(9(4G,.SE<)*AI.CZ41SD53)U&"4G&5BPU
M(8;RKE10)\&$:BIAD28Z>%/ ]\A693B<$U[S6<?<+ZO+$I YR.>A4M^O29EE
MK+[K#AJ\ZKM8G6<;%&&,TLI0PR0Q"6M/TD ."FC>(C\>(U8;$_ICA/RE("^C
MC)*9#?T[FAWPVS 5>-K[K&C*T'<CMD5J,S%>7*M_B=3)J^@23C)I:3JMZKLC
M&\O7;XK#F+UI"HF;VQ1L\>8<F3>A"I"Y_KX)URU&-)"L&XXK7C5(@\(!+)N2
MCDS)O,4;1K)OYF>R?^TUIY=!:3\@NJF;U-:;-H)?,:3]Q#9T@V1'VM%UJ?'X
M$XC%5T'PSW%P%5:'^SIN#4!0^07,  2$@E!).F (*W<PP7Y&@@]3!ERL"U8C
MA.4[<(N<K]P@2@4Y+J0#T:W=<0V#G7B27)J7@H*,L#P=%_.A<SK@'^<=\P*K
M'%Z.%$=>GFGR$K$OBR-PHOUBH7Z3[[\\?WX>&]%R649T,^)S"'K3E)6C^2J>
MB.YDQCVFCS$G7),AH\*<I>=%I6U-]#?(S6BH*W,&(7\,P;]PJ#H<%VCXKA@G
M0@OU:%T54D=0&<9H5(>2BT$TR\%UW_QZU+EY0R8C,:1U_68[D40<)P_EW&S?
MN$%*I>DC?AY?$J#R*Q-(AA==W[$HX.Q''L*98:@0[FXT]R< _IF]A? I.NBH
MIDG3;1)VI?F9;'H[7=8:-;;I[M(&?UONC88#142"AH>CP>3!/UB$9$_,A S7
M#6[F+PK<TTC\Y3N.X8E.$#]]=C#DZT"=-^,D^3R3K]Q.-%4"EUB1HQY<,C%"
MF.9R>"+QC<XI'-NG@HND)D6."WDH2"O/G08&\6Y2R#_AU1@]?G.JT)MUPZ'X
MG)$<E4#B.),<\%GO>VFIXQF-=PZ=N.?2JQH/SH6;D%15E/L*$=!0[-"CXDU2
MV>/&7FHXCJ@2LXZ4R\5K>-[')M]Q&S#)]^2V*>H96AQGI0#_K8VE<-NGFW3L
M.69S].%JP<W\W8)GO\&L/%<_QW+]1[#J?@O'-RGB7PE+0>SI%F7J"> +SU^$
M$;0^W%(JD5%SFLF#;!+RA7LN(?HX#@3O#_!JGV,I:,\_%6#*2TWMT V"ZIY-
M;>CQN4:V];D5S&\3QSO$/]F*-WX*X[R;V+6L.8<XC)H?)SO _RNF:E<A6\_G
MBDO"G'NX F68<)\ ."M"PU6%F_F["I],P?9=??"^#R,@=R6, DUD9G?_6]<X
M"CSK<Q<CY_<Y-UKW%9NK7[@K8VO))2S=BJ(;LGI8L!LO$,[S#H&!OZ3X9G(\
M[9VC6(O'UU+!)0.?HC&D>/Q@Y<I4GMU#S.D(/.X0#*V4@T@D.1DE#I--IIM9
M?#EON/1'$Z"]Y_HH_3+(@L"%SE(8^Q^L$V\30I<V4C*<TZ>SL 7%*6B<-5C3
M=-F6AC,1+*2VS5.7@JF#F7Y1X$P:<97]Z$9MD$?13XOP%>&FD]_?2$_3SY?<
MR8]V#*_+;Y_\CC2,AB8KL\;2Z^5W+RY4*S\G(G]T;L<_X;%R7>=J_DCM!=/2
M"_A^[:!<X0_:(/VHR]O_!5!+ P04    "  FA%M89DM\9L$"  #[!0  &0
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M6$)C2I4U@/VEA(K;3NP!7:L[^Q=02P,$%     @ )H1;6$$^0]_M @  <08
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC55-;]LP#+WG5Q!>,;1
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M'.4A&$5V3)J1>$*%P&P/59@S>P"XGL?I**)"XS*#4FIN]Z?;'%H>$ 6:90<
MM)7STG4+X! 5ACM7P +5TEUT[>%:"5/?!MNW[5WZHKY";L7KB_@GIFC[&G)<
MD*H_&%,?5/7EMEX86;H+Y5P:NIZZZ8K^!U!9 ?J^D-)L%M9!^X<Q^Q=02P,$
M%     @ )H1;6!HZ0)2C @  "P8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&ULE53;;MLP#'W/5Q#N4+1 5U^2])H8:-H&RT.'HMT%P[ 'Q69BH;+D
M27+3_OTHV?%2( W0%XNDR,-#T>1HI?23*1 MO)1"FG%06%M=A*')"BR9.585
M2KI9*%TR2ZI>AJ;2R'(?5(HPB:*3L&1<!NG(V^YU.E*U%5SBO093ER73KQ,4
M:C4.XF!M>.#+PCI#F(XJML1'M-^K>TU:V*'DO$1IN)*@<3$.KN*+R<#Y>X<?
M'%=F0P97R5RI)Z?,\G$0.4(H,+,.@='QC-<HA ,B&G];S*!+Z0(WY37ZU-=.
MM<R9P6LE?O+<%N/@+( <%ZP6]D&MOF!;S]#A94H8_X55XSN, LAJ8U79!A.#
MDLOF9"_M.VP$G+T7D+0!B>?=)/(L;YAEZ4BK%6CG36A.\*7Z:"+'I6O*H]5T
MRRG.IH]U50FD5[9,P#4S!4RI3S"33;_=PQU\8W.!YG 46DKHPL*L!9\TX,D[
MX'$"=TK:PL"MS#%_"Q 2TXYNLJ8[278BWF!V#/WX")(HZ>_ ZW?E]SU>_V/E
MWS8V [^OYL9J^G7^;*N^P1YLQW;C=&$JEN$XH'DQJ)\Q2/?WXI/H<@?S0<=\
ML O]+?,;;C*A3$UI0"VV]W%; 3M3;"_@%S+=]A.H&UC.4;N.]%Q'7%L2]XE[
M!S,)ME"U83(WA[T/T^W-I$5RL% QGL,GV-\[2^+DDJ3D*!J>TQD?G9^?[D3^
MJN1GCSZ3SP3%Y1*(#DRY9#(CK3<SIB81(5.&VLUE)FI7&7?[(E.U^P<J]NH&
MP$>24==TCR^T%0TE(3;#R''IQ_X[@&V]#3<&M$2]]&O(@$_0S&IG[3;=53/@
M_]V;-7G']))+ P(7%!H=GPX#T,WJ:12K*C_N<V5I>7BQH&V-VCG0_4(INU9<
M@F[_I_\ 4$L#!!0    ( ":$6UC^]]C2'04  *8?   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;+V9;4_K-A3'OXJ53=.]$I#&?>!A;25HV(8T[M"M
MV%Z@O7"3D]:Z3MS9+H7I?OC924@:EKI$,KR!/)V_[9_MP_GC\9:+;W(%H-!3
MRC(Y\59*K2]\7T8K2(D\X6O(])N$BY0H?2N6OEP+('$>E#(?]WHC/R4T\Z;C
M_-F=F([Y1C&:P9U <I.F1#Q? >/;B1=X+P^^TN5*F0?^=+PF2YB#NE_?"7WG
M5RHQ32&3E&=(0#+Q+H.+$/=-0/[%GQ2V<N<:F:$L./]F;F[BB=<S/0(&D3(2
M1/]ZA!DP9I1T/_XI1;VJ31.X>_VB_DL^>#V8!9$PX^PO&JO5Q#OS4 P)V3#U
ME6]_@W) 0Z,7<2;SGVA;?MOS4+21BJ=EL.Y!2K/B-WDJ0>P$]$=[ G 9@%\%
M!(,] ?TRH/\J .,] 8,R8)"3*8:2<PB)(M.QX%LDS-=:S5SD,/-H/7R:F7F?
M*Z'?4AVGIO-BOA%/T)PN,YK0B&0*7481WV2*9DMTQQF-*$ATC"[CF)K9(@S=
M9,6:,W/W*01%*/L\]I7ND='UH[+UJZ)UO*?U *-;GJF51-=9#'%3P-=#J<:#
M7\9SA:V*(40GJ!\<(=S#?70_#]&G'S^C&2,T17-8ZA6K6KHY>[LH;@D/WQX>
MO/3),M9^-7?]7+=_8.[^.#QW#[_K6'2C()5_MTU3T="@O2&3>R[DFD0P\71R
MD2 >P9O^]$,PZOW<!M.E6.A(K %X4 $>V-2G7S;I H39&SK/"I(CE<4BDNB[
M93U=%;K#7->DWL=I,/8?=R%96^X*R9%8 ]*P@C2T0KI)UX0* P)%*R*6T,:C
MD!CM\.B]XF%MI"L/1V(-'J.*Q\C*XW)^C[[P$[W9@_-CG> >;L&LHM9M9U7J
MNNU<BH6.Q!H$3RN"IQ^5UTY= G8I%CH2:P ^JP"?69?H;$6R)2":-9@*FD5T
MS>!H]^E<D2PF(I;H?AT395[&?*T@1@]*;  EA$EH16_M0E?T]O&8GK0Q=M2%
M!N/SBO'Y^S&^T1M @:"ZT+I.$ETB'Z1M[4Q7VO:1[:/MJ L-VD&OKF-[UE[]
MNB%"9PG024'3U/5I#&F1.DR-*JUIV"[=E9Y3M="56A/KCCT(/BH7ERVYHNQ2
M+72EUJ2,:\K87D,U5ROB"T:7Q<(]0I$Q+Q)ITRY-HC#,OQ>.II4R_E_I^;K4
MLG>F,SI':DUTM0<*K [ AJXD=X3*=B4"35"_UW8Y;F77/UBFVGO3F=U[N)N@
MMC>!W=_,N%3'<UVTFS4UXXR1!1=OR9<NS<O,J5KH2JV)M#9#P?##\J5+2S1S
MJA:Z4FM2KBU68/=8UT^Z.C+_AHKT"I9Z?S-B2E+%\P?'LES246-)MS)VZL"<
MJH6E6GLV:H*KG55@]1736YK1=)/:=[=3T^14+72EUL17^Z;@[,-VMU-_Y%0M
M=*76I%P[I\!N,*ZEHFF^H3<2D@U#C.H_WJT0[4)]] Q$M$7.[)&=@;V']\&U
M]\%V[W,'(H),$>TW>:(M9\130(H\Z028KTK(HF>=) FC_[87/J6^\1IUKCD9
MOJI][+WHRLR56I-9;6RPM:2?WI*G@YG0+M%UCSI5"UVI-?'5C@7CC\J$V*4=
MF3E5"UVI-2G7Y@;;S<W;,^$!H>'^3&B/[ S,J:/Q=PXV4Q#+_(!8^SJSQHHS
MSNII=0A]F1^]^O7GQ0GV+1%+JGT-@T2']DY.=04KBD/AXD;Q=7Y,NN!*\32_
M7 &)09@/]/N$<_5R8QJHCN:G_P%02P,$%     @ )H1;6">Y@#N2"   U4\
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MQ5Q6!?3G"R'4YDU5P78GO\N_ %!+ P04    "  FA%M8W'OR/,8'   62
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M*J\?0E,?B&Q3/:'D*1,B2ZJ7:QXL>%X6D.\OLTSL#LH*]H\"NOT/4$L#!!0
M   ( ":$6UCH&8 OLP(  ,L&   9    >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;(V5;6_:,!#'O\HIJZ96HLT#$"B#2&U1M4FMADJ[:9KVPB0'L>K$F>U
M^?:SG1"Q$MC>@)W<W>__]\-EO.'B5::("MXRELN)DRI5C%Q7QBEF1%[Q G/]
M9LE%1I2>BI4K"X$DL4D9<P//"]V,T-R)QO;93$1C7BI&<YP)D&66$;&]1<8W
M$\=W=@^>Z"I5YH$;C0NRPCFJEV(F],QMJB0TPUQ2GH/ Y<2Y\4>W0Q-O [Y1
MW,B],1@G"\Y?S>1+,G$\(P@9QLI4(/IOC7?(F"FD9?RN:SH-TB3NCW?5[ZUW
M[65!)-YQ]ITF*ITX0P<27)*2J2>^^8RUG[ZI%W,F[2]LZEC/@;B4BF=ULE:0
MT;SZ)V_U.NPE!,&1A*!."*SN"F153HDBT5CP#0@3K:N9@;5JL[4XFIM-F2NA
MWU*=IZ('U)8D7,*\VA7@2[@O52D0'FE.LS(#&P(SLM5[H224>8("OA8HB*+Y
M"NH*YU-4A+(+. .:PW/*2TGR1(Y=I54:EAO7BFXK1<$115.,KZ#K=R#P@BZ\
MS*=P?G;Q=QE7FVR<!HW3P-;M'G4J)6+GO?(./%"RH(RJ;0<4AX6Q2I,.W%,9
M$P8_D AX)'I%= 3\O%E()?11^M5FK!+0:Q=@KM=(%B3&B:/OCT2Q1B?Z^,$/
MO4\G['4;>]U3U2.]6KTV3556:+/,#5U'OG\=CMUU"ZO7L'K_8O7;6%56?X\5
M>D=0_0;5/XEZ3E'WFJ5"T0;L'P"]=ES8X,+3.*[TGC-[XHOZQ+>!PP.P/_2"
M=O:@80].LLT!'0'-BE)AHB^1]HQ2M=$'!_1+?WC=3A\V].%_..?-Y:C6@.WN
M1IN,X>'1"OWN.QGN7F\R;?Z1B!7-I:Z_U&G>U4#;$%7KK":*%[9=+;C2S<\.
M4_VU06$"]/LEYVHW,1VP^7Y%?P!02P,$%     @ )H1;6'HZEVR.!    !<
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M9K0YQOU8'EZ^&K]6Q[OED6,+4YT-WQ&VB3..$EA+2.MR+.?$JN/6ZD'0O#R
M7%$A:%K>;H%$P)2!?+^F\I/4#^H/FD-O_U]02P,$%     @ )H1;6*N/^6^6
M P  1Q   !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULS5AM3]LP$/XK
M5B9-3!KDK6^PMA(0IDT:6T7%]F':!Y-<&PO'SFR'LG\_VPFA:=,(I'S@2^.7
MN\=WS_DNN4XW7-S+%$"AQXPR.7-2I?(SUY5Q"AF6)SP'IG=67&18Z:E8NS(7
M@!.KE%$W\+R1FV'"G/G4KBW$?,H+10F#A4"RR#(L_ET Y9N9XSM/"S=DG2JS
MX,ZG.5[#$M1MOA!ZYM8H"<F 2<(9$K":.>?^6>1;!2OQD\!&;HV1<>6.\WLS
M^9K,',]8!!1B92"P?CS )5!JD+0=?RM0IS[3*&Z/G] _6^>U,W=8PB6GOTBB
MTIDS<5 "*UQ0=<,W7Z!R:&CP8DZE_46;2M9S4%Q(Q;-*65N0$58^\6-%Q):"
M/SJ@$%0*P:["X(!"6"F$+U485 H#RTSIBN4AP@K/IX)OD##2&LT,+)E66[M/
MF(G[4@F]2[2>FA]]XU)^0%=8,,+6$N4@T#+% M Q6G %3!%,441H8>*#EA 7
M@B@"$ET]QK1(($$KP3-TR;.\4-C&DJ]*!;WW7=]<<X+%U3*9WB[ACR)0F- /
M^AQI%N345=H?8Y4;5[9?E+8'!VSW W3-F4JU+4P;T@1P-1$U&\$3&Q=!)V($
M\0D*_8\H\(*PQ:#+EZL'+>K1R]7]#F_".K:AQ1L<P+O*<LK_@8Z:XO$]^I&;
MZ+31W EC*L^9S'$,,T>7%@GB 9SY^W?^R/O41E&?8%%/8 WZ!C5] XL>'J#O
M7-_]I.OB?]Z]^#]6SXFTJ!/I]S<-C+XJR.2?-O8'?;+?)UC4$UB#_6'-_K#S
M\AKVCVOZY3/]T*@[<;/N)%7=8;KNT*>Z$Y=UQY:9M@"4A@RM(>8]^3#WO=%D
M.'4?MIG=EQJ?3H*F4+0OY-42#1I&-0VC3AJ^<W;\$Z3QZ48_!(G-L$SH6T:4
M1$<WRUM=P7]?0W8'HO6&=1[QVAO6)UC4$UB#VG%-[?A-Y/>X3_;[!(MZ FNP
M/ZG9G[R5_)[L)67HG>YD][Z,'_H[R;TO<R"Y3VL.3E_S@EX4(D[U-RQ:4,PZ
M$[H3]K57JD^PJ">P!IV^]_PQZ[V)E*[,Z"D O:)%?:$U0[#53_AO):\K2QJ)
MO?O6;I'QQSMYW2*SF]CN5H>5@5C;3E5J"PNFRO:B7JV[X7/; ^ZL7Y@NV79N
MSS!EBWV-Q9HPB2BL-*1W,M;VB+)K+2>*Y[:/N^-*=X5VF.I.'X01T/LKKONU
M:F(.J/\[F/\'4$L#!!0    ( ":$6UA2J>/8K@(  *<'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0U+GAM;*U56V_:,!3^*U8F3:VTD2N4=B$2MVE,K81:
M;7N8]N F!V(UL3/;0/OO=^R$#%I /%1"Q':^[SLWYYQX(^23R@$T>2X+K@9.
MKG5UX[HJS:&DJB,JX/AF(61)-6[ETE65!)I94EFX@>?UW)(R[B2Q/9O+)!8K
M73 .<TG4JBRI?!E!(38#QW>V!_=LF6MSX"9Q19?P /I'-9>X<UN5C)7 %1.<
M2%@,G*%_,XT,W@)^,MBHG34QD3P*\60VLVS@>,8A*"#51H'B8PUC* HCA&[\
M;32=UJ0A[JZWZE]M[!C+(U4P%L4OENE\X/0=DL&"K@I]+S;?H(FG:_1242C[
M3S8UMG?MD'2EM"@;,GI0,EX_Z7.3AQV"'QTA! TA>$WH'B&$#2$\UT+4$*)S
M"=V&8$-WZ]AMXB94TR268D.D0:.:6=CL6S;FBW%S3QZTQ+<,>3JYN!5*79(I
ME9SQI2(52/*04PGD,QEF&3/5I 69\?I*FMI>3$!35EPB0AFDBEV-GA@]-VVL
MCFNKP1&K/KD37.>*3'D&V3[?Q0C:,()M&*/@I.!WRCLDB#Z1P O"0_Z<ID\@
M[9#0/TJ?G$\/#M"GY]/]$\D(VYJ&5B\\HM<6<]X6<T052\GO6T22F892_3G@
MYJB6C0[+FHYUHRJ:PL#!EJ1 KL%)/G[P>]Z70QE_3[')>XI-WTELKS916YOH
ME'HRER(%R!192%'B9Y6^:&AJ-%_)-,>>1X9+"8"]6!__OD:UE:ZU8F;!.NGW
M/,^+W?5N#=ZB_" *\>?O R=O@5?]R+OVKO=QT[>XL(^7-HI:7)T5=Z<CE2"7
M=A0HDHH5U_57W9ZVTV9HF^RK\S%.H7IH_)>I1]@=E4O&%2E@@9)>YPJ]DO58
MJ#=:5+;O/0J-7=0N<YRD( T WR^$T-N-,=#.YN0?4$L#!!0    ( ":$6UA_
M$%[3O D  +6%   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;,W<;6_:
M6!K&\:]BL:O5C+13L!,(R2:1DOCYL6JWLR]&\\*!$V*-P8SM-*VT'WYM,! 7
MYP0Z?VG;%RT/OG_GV,:7;/>&R^<L_Z-X%*)4OLS317'5>RS+Y46_7TP>Q3PN
MWF5+L:C>><CR>5Q63_-9OUCF(IZNBN9I7QL,1OUYG"QZUY>KU][GUY?94YDF
M"_$^5XJG^3S.O]Z*-'N^ZJF]S0L?DMEC6;_0O[Y<QC/Q492?EN_SZEE_JTR3
MN5@42;90<O%PU;M1+R+MO"Y8+?%K(IZ+%X^5>E7NL^R/^HDSO>H-ZAF)5$S*
MFHBK?SZ+.Y&FM53-X\\&[6W'K M?/M[HYFKEJY6YCPMQEZ7_2:;EXU5OW%.F
MXB%^2LL/V;,MFA4:UMXD2XO5W\ISL^R@ITR>BC*;-\75#.;)8OUO_*79$"\*
M*J>[0&L*M&\+3E\I.&D*3@XM.&T*3@\M&#8%PT,+1DW!Z-"5/FL*S@X=8=P4
MC \M.&\*SK\M&+VVXP:;/3<X= QUN[/W]O:K)9O=K1Z\O]7-#E</WN/J9I>K
M!^]S=;/3UQ_X_OH3OSI<]+B,KR_S[%G)Z^4KKWZP.N96]=51DBSJ>/A8YM6[
M25577G],9HOD(9G$BU*YF>5"5(=^62B_*#?3:5(?P'&J.(MU#-6'\T^Z*.,D
M_;E:XM-'7?GI[S]?]LMJ'K76GS1CWJ['U%X94U6";%$^%HJQF(II1[TEKS]Y
MJ]Y]8WQ- O2K#;C=BMIF*]YJ4M%]2M\I)^H_%6V@#3HF="<OCR;EIEP]ZRC7
M#QY='764&_)R74PVY8.NT4UY>1#GTG+KK<DOJO+!:M-I'>7VP9/OW'2.O/RC
M6&Y&[]QT[L&C:R<=Y=[AY5WK[A]>KG:4!W]MTX6'EW=MNNC@C\VWFZYU")YL
M@^QDY9V\XE7G!VE\G^5Q?;JAW.1YO)@U87:SF"IAMIB\MH3R[^IA$:_.5PKE
M-[^2%:<4\^+WKFQ;3^.T>QKUV=Q%L8PGXJI7G:X5(O\L>M?_^)LZ&ORK*Q=(
M3"<Q@\1,$K-(S"8QA\1<$O-(S">Q@,1"$HL@K)5FI]LT.Y7IUQ\J,<XGCTI<
M9==4?*XNXY:KJ!)?J@O#0G0%DU0\-IA(3"<Q@\1,$K-(S"8QA\3<-39:8?7=
MA\_7ZNAD<%*=_E6GOI]?ID['DNKX]/Q\;TE_?\GQ6#L=[RT8D&L2DE@$8:VX
M&&[C8BB-BYO))'\2TTTZ%%WQ(!6.C0<2TTG,(#&3Q"P2LTG,(3%WC0U?',HG
MY^/A:#\=AGO'O':JG>TOZ)/3"T@L)+$(PEH!,MH&R$@>(&DJ\EF\4/QD4B?(
M[EZ0\EL@YO<B_UWYK_)K4L9">?\8Y_-J(D]E,HG30G$6D^U"7<$C'?G8X"$Q
MG<0,$C-)S"(QF\0<$G-)S",QG\0"$@M)+(*P5H"=;0/L[,>X_7-&IAF)Z21F
MD)A)8A:)V23FD)A+8AZ)^206D%A(8A&$M=)LO$VSL?1T[-/R(<^J9)HGJ2C*
MK JD9?PUOD\[[_M(J6,3B<1T$C-(S"0QB\3L\=Y5T7"P^M.^*'+(05T2\TC,
M)[& Q$(2BR"L%3;GV[ YEX;-^ZRLSH*2.&W'S?KDJ<R4>Z',XVEG]$CA8Z/G
M?.^3O[I3N/?1U\E1#1(S2<PB,9O$'!)S2<PC,9_$ A(+22R"L%;VJ(-M^-0-
M6[([3[-9+F9Q665.=PZ]=MHC=X\-GT9[F3YG@\[T0<<U4,U$-0O5;%1S4,U%
M-0_5?%0+4"U$M8C2VDGTHA-2E2;1YM:W^+),\G6WXU<1YYW9(Y6.SA[YO-3!
M:AY=_ZFGHQ,Q4,U$-0O5;%1S4,U%-0_5?%0+4"U$M8C2VF&D[<)(PQN Y.31
MJ41J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%C?;F7;D0'3:BM'8&[3JJ56F+X[7^
M(G;J&*JNTY[2."OSK[LKM$+:<R0?X.A$0KNE4<U -1/5+%2S4<U!-1?5/%3S
M42U M1#5HD9K=7-^DY;M1-IU1=??>Y,D4K"],;1)'649)UU? ;N52T='#ZGI
MJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ4:.UFDJET;/KL%;E+=:?[F[ES9'U
M K=)MEQU1TH;(N4C'1U-:"\VJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):1&GM
M_-HU>*OK]LO_>X.DBO9[HYJ.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@645H[
MW7;=WZJT'?.XADFY=71"H4W<J&:@FHEJ%JK9J.8TVIOW>UUT6 _5?%0+4"U$
MM8C2VN&S:]96Y=W:?Z&!4BX?'45H][:ZWXJLJN?#CL/ 0 <V4<U"-1O5'%1S
M4<U#-1_5 E0+42VBM'88[9JY57DW]_?W4Z+-W*BFJ_N]X=JPLSW30 <V4<U"
M-1O5'%1S4<U#-1_5 E0+42VBM/9O(NY:NS5Y:_<1#95RZ=CP037]C;64M&<:
MZ$1,5+-0S48U!]5<5/-0S4>U -5"5(LHK1U&N^YN3=Y%_3T-E0WY\K1CU'72
M<2<?^^C 09NZ4<U$-0O5;%1S4,WM^"BIG2>P'CJNCVH!JH4=VZ3S+EM$#=N.
M#FT7'?)>[.#;NSJRRRBY=?29#-J$C6H&JIFH9FD=#;OCCH^6C0[KH)J+:AZJ
M^:@6H%J(:A&EM<-GUX2MR9NPI3U'M_%7D3<_R*;<6-*N(_DX1P<3VHN-:@:J
MF:AFH9J-:@ZJN:CFH9J/:@&JA:@645H[O78-V]KIC]%UU,R#2C=2TU'-0#43
MU2Q4LU'-0347U3Q4\U$M0+40U2)*:Z?;KB=<D_>$?]<]);3Y&]5T5#.TCA]X
M[KJ\-]%A+52S4<U!-1?5/%3S42U M1#5(DIK9]"NKUN3_W+WI^4OZ];'M+E0
M?!#BU2_%R:VCPP?MS48U ]7,1GLSRBQT6!O5'%1S4<U#-1_5 E0+42VBM';X
M[-JN-7G;]7?=G*K>"N(OR?QI+K]?A79IHYJ.:@:JF:AFH9J-:@ZJN:CFH9J/
M:@&JA:@645H[T':MW-KX![E?A39^HYJ.:@:JF:AFH9J-:@ZJN:CFH9J/:@&J
MA:@645H[W7:]X=K!O>%-(T-VGR:S56MF9TBA+>&HIJ.:@6JFMM^NKG:WJUOH
MP#:J.:CFHIJ':CZJ!:@6HEI$:>L$ZA>/0I1Z7,;7EW.1S\2=2--"F61/B[(>
MY,6K2BX>ZF^O7-QHO?[>Z[?JA:EVO&ZI%T[7ZZYZ$:Y>[^^&O;Y<QC,1Q/DL
MJ4[ 4O%036'P[FS84_)D]KA]4F;+JY[:4^ZSLLSFJX>/(IZ*O%Z@>O\AR\K-
MDWJ YRS_8[6:U_\#4$L#!!0    ( ":$6UBJ"OH^<@,  #T1   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;+5876^;,!3]*Q:;ID[J"H9\M4N0NG35
M*NTC6M?M8=J#"S>)5<#,-DGW[V<#)9!0MZG(2X+AWL.YQ\=PS7C-^)U8 DAT
M'T>)F%A+*=,SVQ;!$F(B3E@*B;HR9SPF4@WYPA8I!Q+F27%DNXXSL&-"$\L?
MY^=FW!^S3$8T@1E'(HMCPO]]@(BM)Q:V'DY\IXNEU"=L?YR2!5R#O$EG7(WL
M"B6D,22"L@1QF$^L<WPVQ4.=D$?\I+ 6M6.D2[EE[$X/KL*)Y6A&$$$@-011
M?RN80A1I),7C;PEJ5??4B?7C!_3+O'A5S"T1,&71+QK*Y<0:62B$.<DB^9VM
M/T%94%_C!2P2^2]:E[&.A8),2!:7R8I!3)/BG]R70M02<.^1!+=,<)^;X)4)
M7EYHP2POZX)(XH\Y6R.NHQ6:/LBUR;-5-331TW@MN;I*59[T9UPY@LM_B"0A
M^O@WHZF:(WF,OBH'O4.FJT<7( F-WJJPF^L+=/3Z+7J-:()^+%DF5+P8VU(1
MU+>Q@Y+,AX*,^PB9"PA.D(>/D>NX7DOZ]/GI;C/=5K)4VKB5-FZ.YSVES2PB
MB43G=0W0[\\J&EU)B,6?MDH+Z%X[M%Z<9R(E 4PLM?H$\!58_IM7>."\;ZN[
M(["&"EZE@F=";SH$-AY8<"9:Y[B &^1P^BFR\GOX=&ROZ@698QH\>Q7/GI'G
M>1!D<181":%:QTJ(@!+]I&BC6"#U:[=_U\-XBV-+D'?Z",E^1;+_(C$3D&T\
M^SL41ELD=R-<IYWBH*(X,%*L6?P+Q+? 6^UMQ-C7WAV!-<H=5N4.#[?(AUVJ
MT!%80X51I<*HVT4^VG5F;\N:QI &R].*Y:F1Y6=0+^PEBT)T%:><K4"3%$:?
M&@'WG:&.P!JU8V?SIG8.Y]02NR,AND)K*E'K67"W;BWQZE[$@^&67Y\(:G+=
M]!#8^'+V+S.>4)EQR,E>TGM];/:L&7'ON3I$\X WW0/V#NA:8VNRMQ(=H365
MV/0GV-R@[._:W0X$>]M/V2>"FEPW;0HV]RG?YG,:%):=LCC-)'#TO,; #+SW
ME'6$UI1ATPKAP0'-VVF/U!5:4XE-EX2-[<<+S#O<:?%WO6N,*9C:M;VM_K#P
MA? %302*8*Z2G).A<@@O]NK%0+(TW^[>,JDVS_GA$D@(7 >HZW/&Y,- [Z"K
M+R;^?U!+ P04    "  FA%M8</V]@&T"  #0!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6RM5%UOTS 4_2M6F- FC25-NH)&&JD?0^QAJ-H8/" >
MW.2VL>;8F>VTW;_GVDY#.[K" R^)[=QS?,_)O3==2_6H2P!#-A47>AB4QM17
M8:CS$BJJ+V0- K\LI*JHP:U:AKI60 L'JG@81]$@K"@309:ZLYG*4MD8S@3,
M%-%-55'U/ 8NU\.@%VP/[MBR-/8@S-*:+N$>S$,]4[@+.Y:"52 TDX(H6 R#
M4>]JTK?Q+N ;@[7>61.K9"[EH]W<%,,@L@D!A]Q8!HJO%4R <TN$:3RUG$%W
MI07NKK?LGYQVU#*G&B:2?V>%*8?!AX 4L* --W=R_1E:/9>6+Y=<NR=9M[%1
M0/)&&UFU8,R@8L*_Z:;U80?0&[P"B%M _!+0?P60M(#$"?69.5E3:FB6*KDF
MRD8CFUTX;QP:U3!A_^*]4?B5(<YD,X4%H<PSH:(@UT\-J_$7F7/R!0OH'1D5
M!;-N4TYNA"\9Z_WI% QE_ PC'NZGY/3DC)P0)LC74C8:B70:&LS-WA#F;1YC
MGT?\2AZ]F-Q*84I-KD4!Q3Y!B*(Z9?%6V3@^RCB%_((DO7,21W%R(*')O\/C
M(^DDG=&)XTO^8O0YF7$JS+[?Y,=HKHW"FOYYR#K/W#_,;/O\2M<TAV& C:Q!
MK2#(WK[I#:*/AV3_)[(]$_J="?UC[&@JDN;,5Q%L<!1I."38LPP<BYU#*ZR/
M*(K2<+6KY,^H)-F-\BF&.\U1@5JZF:%)+AMA?#5UI]U8&KEN?'$^QG'EI\MO
M&C_K;JE:,J$)AP521A?O+P.B_/SP&R-KUX)S:;"AW;+$D0O*!N#WA91FN[$7
M=$,\^P502P,$%     @ )H1;6 N4=<06!   E!,  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#DN>&ULS5C;;MLX$/T50ELL6F ;B;K:6=M +B@V0+))XUX>
MBGV@Y;%%1")=DK+;OU]25B5?),5!]9 76Y1FCLZ,9D9''&VX>)()@$(_LI3)
ML94HM3JW;1DGD!%YQE? ])4%%QE1>BF6MEP)(//"*4MMUW%".R.469-1<>Y!
M3$8\5REE\""0S+.,B)^7D/+-V,+6KQ./=)DH<\*>C%9D"5-0GU</0J_L"F5.
M,V"2<H8$+,;6!3Z_<AWC4%A\H;"1.\?(A#+C_,DL;N9CRS&,((58&0BB_]9P
M!6EJD#2/[R6H5=W3..X>_T+_4 2O@YD1"5<\_4KG*AE; PO-84'R5#WRS3]0
M!A08O)BGLOA%F]+6L5"<2\6STEDSR"C;_I,?92)V'+#?XN"6#NZI#E[IX!6!
M;ID585T3128CP3=(&&N-9@Z*W!3>.AK*S&.<*J&O4NVG)A\(%>@+27- =T!D
M+D _(R71>S35%3//4T!\@6HK62PI(RRF)$474H*V)FR.;BF9T90JJFU*J#DB
M:L<7O;T&16CZ3J-_GEZCMV_>H3>(,O0IX;G4&')D*QV386;')?_++7^WA?\U
MQ&?(PW\AUW&]!O>KT]W=?7=;9[)*IUNETRWPO.?36:;FHBTU]PP]0IP+0=FR
ML/J7,U&=N"222O3M5N.C&P69_*\I-ULR?C,9,P'.Y8K$,+9TBTL0:[ F?_Z!
M0^?OIDSU!+:7-Z_*F]>%/IDF7*CW"D2FZV$-4A55V!3R%B<L<,R,6D_<*/ <
M?V2O=X,Y-O,=[/MA9;9'TZ]H^ITT;SE;GL1R"Q/LLAP.W.$!R6.KP ^'S12#
MBF+02?&*"/'35-"V"K_=038#T5@]G4 OK9Z>P/9B#JN8P]?4=6&?>>L);"]O
M496WZ)E:D0F"[SE=D[2MDJ.&2@Z\X6&_'9M%OA>TM-N@XC?H:2H,CEDV385C
MLZZI,*QH#ON9"L.3IL*Q5?M4P$[]GG<Z27[B2K^O2=$>C:]9Y^BVH>,$;G3
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M$N+[&Z1]1[*ROH1Y8%(R6C=3( EP/4&-;QB3+QU]K]/>XRW^!U!+ P04
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MV:CFH)J+:AZJ^:@6H%J(:A&ER8EL"Q36:]_;Q4(+%JAFHYJ#:BZJ>:CFHUJ
M:B&J190FQ7/4]C!&ZA[&1=VKGT_%7?R8I8N%F"6S]733:4JOK\OO/M_XI7,<
M>H2WFFYX5]+4J_9-&JHYJ.:BFH=J/JH%J!:B6D1I<M+:BL9(7='XIYPF,9OG
MTW1='N7*]WV=+:?&VSD;H>U.!*?>;.\8H04-5'-1S4,U']4"5 M1+:(T.49M
M06,$%#1>./.P>E-]1XZH9J.:@VHNJGFHYJ-:@&HAJD64)@>Q[6R,7KNS,4([
M&ZAFHYJ#:BZJ>:CFHUJ :B&J190FQ[/M;(R.=#::J:_6Q6V:U1,6')O[2@WV
MCAO:V6BTHY<4T*VZJ.:AFH]J :J%J!91FARDMO\Q4O<_?G3 V?<J@_IA](X?
MVAA!-0?57%3S4,U'M0#50E2+*$T.:=L_&5FO/1A%>RNH9J.:@VHNJGFHYJ-:
M@&HAJD64)L>SK;>,U/66WO.PCO8K)-IDK%N:N7OV$VVNH)J#:BZJ>:CFHUJ
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MG!X\]?OD%TW]6GI@:L/I3!2X)DI;@@ZH^@52=XPLJCMY)0W=\%4SI4<;*FM
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M,2YX;6RM5=]OVC 0_E=.V311:24A_.C:022@JU9IE1"(]:'J@TD.8C6),]M
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MM,N8?E8HC0.=+X70^XU)4/W^@K]02P,$%     @ )H1;6/&Y,S6I P  Z1$
M !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULK9AK;],P%(;_BA40 @F6
M2V_K:"-M328F,3$Q+A\0']SDM(EP[&"[ZY#X\=A.&IHUBUK)7]I<_#['?D]\
M$GNV9?R7R  D>BP(%7,GD[*\<%V19%!@<<9*H.K.BO$"2W7*UZXH.>#4B KB
M!IXW=@N<4R><F6MW/)RQC20YA3N.Q*8H,/]S!81MYX[O["Y\SM>9U!?<<%;B
M-=R#_%K><77F-I0T+X"*G%'$835W+OV+V#<"T^);#ENQ=XST4):,_=(G-^G<
M\72/@$ B-0*KOP=8 "&:I/KQNX8Z34PMW#_>T:_-X-5@EEC @I'O>2JSN7/N
MH!16>$/D9[;] /6 1IJ7,"+,+]I6;2>!@Y*-D*RHQ:H'14ZK?_Q8&[$G\(?/
M"():$#P5C)\1#&K!X-@(PUHP/%8PJ@5FZ&XU=F-<A"4.9YQM$=>M%4T?&/>-
M6OF54_V@W$NN[N9*)\./#%-TA__@)0'T#EVF::X3B FZH=5CJ-/Y.@*)<_)&
MM?AZ'Z'7+]^@ERBGZ$O&-@+35,Q<J3JCD6Y2!UY4@8-G OL!NF549@+%-(6T
M#7#5*)JA!+NA7 6]Q'LHSU P>(L"+PBZ.M0OCR Y0P/?R <=\NAX>5?T^'BY
MWV/&H,GKP/ &S_*64J502+Y1TUJB'Q]5 W0CH1 _.WIW5=&&W31=K2Y$B1.8
M.ZH<"> /X(2O7OAC[WV7T39AD4U8; G62LFP2<FPCQZJ6692H>:3!%X@HJ9>
M5RIZ*:>FHH*-#4R_-!Y";^8^[/M[V"+PIM-QNU7<QVFY,6K<&/6[P:&L#;D&
MZ/*A5W^J#S9A404;[9DQ])[8&EL*V/)VW'@[[O7V _!D0T"@'[=0+('_1'^1
M*?27:PY0U8/Z3I?QO?!3C;<)BVS"8DNP5H8F388F5LOSQ&9*;,(BF[#8$JR5
MDO,F)>=6RO/Y8;WT1T^G_Z(WUJD>VX3%EF MCZ>-Q].C/%9?E@AH^HZM*J]7
M %V?D%?3@T+K>P=6]X8\U6J;L-@2K&6U[_W_LO>.,5L8MS_)#+A^TW;Z7)/&
M?6^T17^X4XVV2HMMT=I6[RVB_%ZK;ZAZC$%(!(]J!2] +:$)EI BR9 RWM02
MA'<OW\X,] 8XM<);I44UK5WR#CYX;,6L4N#N+6D+X&NSER!0PC945DO"YFJS
M7W%I5NE/KB_T/H99*O_'5)L@MYBO<RH0@95">F<356=XM:]0G4A6FH7SDDFU
M##>'&> 4N&Z@[J\8D[L3':#9W0G_ 5!+ P04    "  FA%M8*ZB%,Y0&   2
M)0  &0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6S%6EUOVS84_2N$5PPM
MT,86Y<_,,= X+19@Q8(FZ1Z*/= 2;1.52)6DXF38C]^E)$MVJ+"V*F,OMCYX
MS[V'Y+T\E#3="/E-K2G5Z#&.N+KHK+5.SKM=%:QI3-292"B'.TLA8Z+A5*ZZ
M*I&4A)E1''5QKS?LQH3QSFR:7;N1LZE(=<0XO9%(I7%,Y-,EC<3FHN-UMA<^
ML]5:FPO=V30A*WI+]7UR(^&L6Z*$+*9<,<&1I,N+SGOO?.X/C$'6X@NC&[5S
MC R5A1#?S,EU>-'IF8AH1 -M( C\/= YC2*#!'%\+T [I4]CN'N\1?^8D0<R
M"Z+H7$1_L5"O+SKC#@KIDJ21_BPVO]."4!9@("*5_:)-WG:$.RA(E19Q80P1
MQ(SG_^2QZ(@=@W'O!0-<&.!G!E[_!0._,/ SHGED&:TKHLEL*L4&2=,:T,Q!
MUC>9-;!AW SCK99PEX&=GEWS0,04W9%'JM []#X,F>E>$J%KGD\2T]FOKZ@F
M+'H#+>YOK]#K5V_0*\0XNEN+5!$>JFE70S &LAL4CB]SQ_@%QQY&GP37:X4^
M\)"&^P!=8%%2P5LJE]B)>$6#,^1[;Q'N8;\FH/GAYM@1CE_VK)_A^8?T[-<_
MX"ZZUC16?]?U50[5KX<RJ7RN$A+0BP[DJJ+R@79FO_[B#7N_U?%L"6R/=;]D
MW7>A&]90311%KT.:'[TQ$^6!1&D^E4@$E8/P@-9U0XX]S+!- 7J8C?"DUYMV
M'W;YV:W\P6ZKO< '9> #9^!?[ @1)( I"51*&B)-'A%1BFKU%BZJ0++$-*^C
MX?9TMZ9H+N*$\">T)@HE4CPP2 %$ZKHI"T*#R3*-(D1BD7*-Q#*[Q*',U\0'
M?]EMZ/Z(_9/C%19UK9E"7!@@3254&'-3H 5%L9 41>P;C9[ EG#3Z@R9Z.O"
M9,7 AVCQA%Z-\-D$RE44F48P_B8E49A2 VWBV+8V]VI[.)$,EA4&KD,)=9X;
M5&.XHIS*DI+I %C1S 6^0I$ 8V#/0Q20A&G#'F#-)"<R6"/Z"(L?M'AK-5&:
M2/TN35 @%*R*!Y+T!Q9)_'^1W&< T'#*(/ G0%B"-P--T#8G380"/-5.[[.Z
MFN*<T@UKRK!,S:$S83[2$-A'M1U1EWY#JSYX_K!OE1&GTX:41B6ED9/2K2::
M'DPHQQKL$!KZ XN/TV-#/N.2S]C)YQZR0X)$X-D\2H3*5$0MF;%%QK.H.)TU
MI#(IJ4R<5*ZLC*AC,;%8C"9#BX?34T,>7J^2=KTCF4!A^% 402B+WU,FRVJ_
M4TQJQ5S/(CSP1Q9A=T1-&>^(6>\'Z@/6,"->/U,HIU");\$%@\+]]1.-%U36
M:B\WYK'BJRVT_1[ 50_@]E1G@=46\Y;0]IE7<MMSZMI\[*F"BBH13'$2:9;-
M\D!((Z["5)HB:Y97J+A,U,]RWYKEU@SWK=7E!>7I59K9<XOF>V["7/%L)6?Y
M")J<78 .6#)MU!S1L!].(Q")RR7L@!'-_D T9 UA!:G5TYXME2T^SM":CEJE
MNCVW&-ZN[<X$;4E\%(1/(66\2LMXPQ83M"6-4C _A>+Q*LGCN37/GWM*!Q8<
M*9]@<[,A,C32G!6*UY&=;GR0W\-:VJ<01EZEC#RW-*I9A:LM"<CQ$!*\ENW8
MRMVQO1=V.V]*KM)*WK%BR29WX."Z'<'@]FL']Q02"U<2"[LEUO/RA?Y%UQSV
M5(PST/?SW2E^DU%W%CJWLV/3O2VT_:ZIM!CVVBMTN%4-UA;:/O-*@V&GTCEZ
MOUK [6U8O;YOY;K;;5-:E<#";H%UW)X5VU+*KEYNCTT95;H+NW573?9>TI79
MQ JS3X+=4?%89^A.VY8D5-$GIQ!DN!)D>-!BVK:JS-I"VV=>*3/<[F.F FYW
MAF-L/\MP>VW*JE)=^) G3<[IVY(^*NB>0FWA2FWA<8O3MR7Q5# _A13#E13#
M;H4T3T&(<8WR 2_ZH7C:4TM^8K]&L2?O*>257\DKWRVO?GK+\ /\E[8,;K.F
MM"OIY+L?8S7=,A2P>T,ZML;4[;PIN4H=^6YUU-Z6X0>.7MHRN,V:\M]Y+7R(
MC/I)R>'V<?0+XU/(,+^287Z_Q3?EK8JMMM#VF5=BRS_LZ=>ADJ. VTWP(;9?
M.[B]'LNJN_-U24SE*OOH!HJQ>1.=?YU17BT_['F??<[R[/JE=S[//\^I8/*O
MA3X1"3F@4$27 -D[&P$!F7^ DY]HD63?L"R$UB+.#M>40.>9!G!_*83>GA@'
MY6=0L_\ 4$L#!!0    ( ":$6U@E"1)^QP,  '<-   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8T+GAM;*U7RW+;-A3]%0P[[3@SCOC0PY8K:<86DS2+)!JY
MCT6G"XB\%#$A 18 )?OO"X 4+:D@I$4V$@'><W#/P>MRMF?\N\@!)'HI"RKF
M7BYE]>#[(LFAQ&+ *J#J3<9XB:5J\JTO*@XX-:"R\*,@F/@E)M1;S$S?BB]F
MK)8%H;#B2-1EB?GK$Q1L/_="[]"Q)MM<Z@Y_,:OP%IY!_E&MN&KY'4M*2J""
M,(HX9'/O,7R(0P,P$7\2V(NC9Z2E;!C[KAN?T[D7Z(R@@$1J"JS^=K"$HM!,
M*H]_6U*O&U,#CY\/[!^->"5F@P4L6?$7264^]^X]E$*&ZT*NV?XW: 6--5_"
M"F%^T;Z-#3R4U$*RL@6K#$I"FW_\TAIQ! @G/8"H!43G@%$/8-@"AM<"1BU@
M9)QII!@?8BSQ8L;9'G$=K=CT@S'3H)5\0O6\/TNNWA*%DXO/-&$EH-_Q"PCT
M'CVK=976!2"6H34DC":D(-C,D.I9<;8C9L;5@D,GT"4KJUI"BK!$SQ++6C+^
MBCY""AP71Z%HC24@R5Q<-S%(3(IW,U\JA3I//VG5/#5JHAXU882^,"IS@3[0
M%-)3 E]9T_D3'?QYBIR,,20#- QO411$0TM"R^OAD04>7P\/'6J&W6P/#=^P
MA^]#EH'9:/^;D=/)OD4KX E0B?Y^W C)U>[\QS8;S6@C^VCZR'H0%4Y@[JDS
M20#?@;?XY:=P$OQJ<_)'DL4_B.S$Y5'G\LC%?MA34GF;'&V+K-T,HML>7#EO
ML[6A#P/#KT_NW2(8Z 6P._;KJJCX4M2)PG&G<.Q4J'>X$0CB%E%U.ZG#X2!O
M Q0R(FVZ&M(P.LDE'$9GPJQA030^4]83-K5+FW32)DYIGU3Z1D8MU!LA4,(A
M)1(EF/-7M@,N;,HFUES"LY27$]MD!.=3YD[P9CP(@I_?.=;I72?USLGTE='W
MZI2LU8FP44<^O*AB0H!5GYOH)K2DU"B^ %1+T0Z,+P+';A/N.Q/NG4S+'-,M
M($+1#A=U<]7A0I5#F";6S>FFNQF.!M,>+RX@H]$@[#'C C*<6FP\<6/:N3%U
M4JU!UISJ^[GJ[F?):T!U9?-B:EG/9TO>/9YC 3BY3\2%P5NQ$SB'^R9SX-:R
M(KBLY(J8^!!S=A $]SV9'Y5IH3/SMYN;O-TN???'!:Y^TY<MTJW1&=/H\X\J
MTA+XUE3VZBQE-95-\=7U=E\/CZ9F/NM_TE\5IM)]HVD^2;Y@OB54H (R11D,
M[M1]P)LJOVE(5IFZ=\.DJJ+-8ZZ^C(#K /4^8TP>&GJ [EMK\1]02P,$%
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M+#4H/YS3?P[4+H#VITK9EXE[0?,O)OD+4$L#!!0    ( ":$6U@\=X@BC00
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M.5(&5]>H2]6CH]X86;IF.I,&6[-;YCAM05D'/)]+:=8;>T$[O^-_4$L#!!0
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M%6=P"P_[<UGF<R?"G_Z[H20-R_N+MBP/8=^Y@7Q3K+[S77VCO/<_4$L#!!0
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M_K+\/HD2+BXXI]N*^O074$L#!!0    ( ":$6UCA[%X1] $  *(G   3
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M4')O<',O8V]R92YX;6Q02P$"% ,4    "  FA%M8F5R<(Q &  "<)P  $P
M            @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M ":$6UC-EN+Y_P@  &\W   8              " @0X(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  FA%M854VG)94&  #$'   &
M            @(%#$0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ )H1;6/)RN";! @  B0@  !@              ("!#A@  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ":$6UB+/N&*@P4  .D9
M   8              " @04;  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  FA%M8?*ZP"A0#  "["0  &               @(&^(
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ )H1;6/5ZU'_N
M"P  )X0  !@              ("!""0  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( ":$6UBT/+H.)0,  !L+   8              "
M@2PP  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  FA%M8
M)+TT2UX)  #D,0  &               @(&',P  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ )H1;6#=,*N1F @  B08  !@
M     ("!&ST  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M ":$6U@DW+>7!@<  %X<   9              " @;<_  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ )H1;6/-A7TYZ"0  ZQ8  !D
M             ("!]$8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  FA%M8Y^7F^GP"  "(!0  &0              @(&E4   >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ":$6UBHJ_I@&!4
M /P\   9              " @5A3  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ )H1;6 YJ'W+^#0  P"D  !D              ("!
MIV@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  FA%M8
M%S!9L 4'  !8$@  &0              @('<=@  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( ":$6UC[=CB]&@0  )L)   9
M      " @1A^  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ )H1;6$QI;Y:V"0  -R(  !D              ("!:8(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  FA%M8+J&+=M\"  "!!@
M&0              @(%6C   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( ":$6U@L#O:(F0@  +(6   9              " @6R/  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ )H1;6*9?GF_B
M @  B@8  !D              ("!/)@  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  FA%M8D3=J>-@"  "0!@  &0
M@(%5FP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ":$
M6U@H(NY%7@<  -<3   9              " @62>  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ )H1;6"88?:Q/$0  :S8  !D
M         ("!^:4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  FA%M8-)!U]%D$   ["@  &0              @(%_MP  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ":$6UC/HYSC0 P  !\A
M   9              " @0^\  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ )H1;6.Y?>ZQ*!0  KPP  !D              ("!AL@
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  FA%M8MQ^-
M9:("   :!@  &0              @($'S@  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( ":$6UCOIS_Z318  .!%   9
M  " @>#0  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M)H1;6&9+?&;! @  ^P4  !D              ("!9.<  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  FA%M8P2S%_TP$  "."@  &0
M            @(%<Z@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( ":$6UC<!B(ZY@(  &L&   9              " @=_N  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ )H1;6%Q[MCJ !
M]@H  !D              ("!_/$  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  FA%M803Y#W^T"  !Q!@  &0              @(&S
M]@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ":$6U@6
M[K?9Y (  '(&   9              " @=?Y  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ )H1;6,4F9_0& P  7P8  !D
M     ("!\OP  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ":$6U@GN8 [D@@  -5/   9              "
M@>$3 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ )H1;
M6-Q[\CS&!P  %D@  !D              ("!JAP! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    "  FA%M8Z!F +[,"  #+!@  &0
M        @(&G) $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( ":$6UAZ.I=LC@0    7   9              " @9$G 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ )H1;6*N/^6^6 P  1Q
M !D              ("!5BP! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    "  FA%M84JGCV*X"  "G!P  &0              @($C, $
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ":$6UA_$%[3
MO D  +6%   9              " @0@S 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ )H1;6*H*^CYR P  /1$  !D
M ("!^SP! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  F
MA%M8</V]@&T"  #0!0  &0              @(&D0 $ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ":$6U@+E'7$%@0  )03   9
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M970U,RYX;6Q02P$"% ,4    "  FA%M8O<D&6=X+  #&I   &0
M    @(&450$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M ":$6UB[0X5BH@,  -,3   9              " @:EA 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ )H1;6#_J63QZ$@  &@@! !D
M             ("!@F4! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    "  FA%M8 O"L8YL#  "Q#@  &0              @($S> $ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( ":$6UC[(-NU7@,
M !(*   9              " @05\ 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ )H1;6+Z9\75Z!0  LA\  !D              ("!
MFG\! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  FA%M8
MIR0LS@P$   W#0  &0              @(%+A0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( ":$6UA1 LKUWP(   H'   9
M      " @8Z) 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ )H1;6/&Y,S6I P  Z1$  !D              ("!I(P! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  FA%M8*ZB%,Y0&   2)0
M&0              @(&$D $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( ":$6U@E"1)^QP,  '<-   9              " @4^7 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ )H1;6!+*O'6&
M P  ,0L  !D              ("!39L! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    "  FA%M8.RN6,@8#  #1"   &0
M@($*GP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( ":$
M6U@\=X@BC00  'T?   9              " @4>B 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ )H1;6%-;.I30 @  RP<  !D
M         ("!"Z<! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4
M    "  FA%M82KM0T4@#  #P%   #0              @ $2J@$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ":$6UB7BKL<P    !,"   +
M  "  86M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ":$6UBZ&KLP3P4  "<M
M   /              "  6ZN 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  FA%M8%MUK%"8"  !C*   &@              @ 'JLP$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  FA%M8X>Q>$?0!  "B)P
M$P              @ %(M@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..3 !, ,L4  !MN $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>217</ContextCount>
  <ElementCount>362</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Collaborative Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreements</Role>
      <ShortName>Collaborative Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - (Loss) Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShare</Role>
      <ShortName>(Loss) Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayable</Role>
      <ShortName>Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995645 - Disclosure - (Loss) Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareTables</Role>
      <ShortName>(Loss) Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Collaborative Research and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaborative Research and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Leases - Summary of Future Minimum Lease Payments under Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments under Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995785 - Disclosure - (Loss) Earnings per Share - Computation of Basic and Diluted Earnings (Loss) per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail</Role>
      <ShortName>(Loss) Earnings per Share - Computation of Basic and Diluted Earnings (Loss) per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995795 - Disclosure - (Loss) Earnings per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail</Role>
      <ShortName>(Loss) Earnings per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995805 - Disclosure - (Loss) Earnings per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail</Role>
      <ShortName>(Loss) Earnings per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Significant Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail</Role>
      <ShortName>Significant Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Property and Equipment, Net - Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Fair Value Measurements - Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Fair Value Measurements - Summary of Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Common Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail</Role>
      <ShortName>Common Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Common Stock - Schedule of Common Stock Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Stock-Based Compensation - Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail</Role>
      <ShortName>Stock-Based Compensation - Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Stock-Based Compensation - Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-Based Compensation - Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Units Activity (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Loan Payable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail</Role>
      <ShortName>Loan Payable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Income Taxes - Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Income Taxes - Components of Deferred Tax (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail</Role>
      <ShortName>Income Taxes - Components of Deferred Tax (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Income Taxes - Summary of Reconciliation of Company's Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Company's Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sndx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Supplemental Cash Flow Information - Supplemental Disclosures of Cash Flow (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail</Role>
      <ShortName>Supplemental Cash Flow Information - Supplemental Disclosures of Cash Flow (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sndx-20231231.htm">sndx-20231231.htm</File>
    <File>sndx-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img207175068_0.jpg</File>
    <File>img207175068_1.jpg</File>
    <File>img207175068_2.jpg</File>
    <File>img207175068_3.jpg</File>
    <File>img207175068_4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="667">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sndx-20231231.htm": {
   "nsprefix": "sndx",
   "nsuri": "http://www.syndax.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "sndx-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "sndx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 300,
   "keyCustom": 62,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 41,
   "hidden": {
    "total": 15,
    "http://fasb.org/us-gaap/2023": 11,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 217,
   "entityCount": 1,
   "segmentCount": 77,
   "elementCount": 795,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 667,
    "http://xbrl.sec.gov/dei/2023": 40,
    "http://xbrl.sec.gov/ecd/2023": 19
   },
   "report": {
    "R1": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:DepositsAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_07dde341-6b8e-4d35-a0a4-24bc46311598",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07dde341-6b8e-4d35-a0a4-24bc46311598",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e282358-b6f3-4650-be0c-94030a98bc79",
      "name": "sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_bbef3127-bb0c-4874-825e-07108d441436",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bbef3127-bb0c-4874-825e-07108d441436",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness",
     "longName": "995455 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureBasisOfPresentation",
     "longName": "995465 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreements",
     "longName": "995485 - Disclosure - Collaborative Research and License Agreements",
     "shortName": "Collaborative Research and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "sndx:CollaborativeResearchAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "sndx:CollaborativeResearchAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995495 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShare",
     "longName": "995505 - Disclosure - (Loss) Earnings per Share",
     "shortName": "(Loss) Earnings per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements",
     "longName": "995515 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "sndx:SignificantAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "sndx:SignificantAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "995525 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995535 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "995545 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995555 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "995565 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "sndx:CommonStockDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "sndx:CommonStockDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995575 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayable",
     "longName": "995585 - Disclosure - Loan Payable",
     "shortName": "Loan Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995595 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995605 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformation",
     "longName": "995615 - Disclosure - Supplemental Cash Flow Information",
     "shortName": "Supplemental Cash Flow Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995635 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareTables",
     "longName": "995645 - Disclosure - (Loss) Earnings per Share (Tables)",
     "shortName": "(Loss) Earnings per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "995655 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995665 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "995675 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables",
     "longName": "995695 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sndx:CommonStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sndx:CommonStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995705 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995725 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationTables",
     "longName": "995735 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
     "longName": "995755 - Disclosure - Collaborative Research and License Agreements - Additional Information (Detail)",
     "shortName": "Collaborative Research and License Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_2b797780-f333-41ad-9804-9f77932b06b7",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "sndx:CommonStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_56286884-2fcc-4f47-8d67-14db89877f0b",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "sndx:CollaborativeResearchAndLicenseAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
     "longName": "995765 - Disclosure - Leases - Additional Information (Detail)",
     "shortName": "Leases - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail",
     "longName": "995775 - Disclosure - Leases - Summary of Future Minimum Lease Payments under Operating Leases (Detail)",
     "shortName": "Leases - Summary of Future Minimum Lease Payments under Operating Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
     "longName": "995785 - Disclosure - (Loss) Earnings per Share - Computation of Basic and Diluted Earnings (Loss) per Share (Detail)",
     "shortName": "(Loss) Earnings per Share - Computation of Basic and Diluted Earnings (Loss) per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e282358-b6f3-4650-be0c-94030a98bc79",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail",
     "longName": "995795 - Disclosure - (Loss) Earnings per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share (Detail)",
     "shortName": "(Loss) Earnings per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_5b6fd47e-9446-44a8-8162-95fdb9778785",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b6fd47e-9446-44a8-8162-95fdb9778785",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
     "longName": "995805 - Disclosure - (Loss) Earnings per Share - Additional Information (Detail)",
     "shortName": "(Loss) Earnings per Share - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_2b797780-f333-41ad-9804-9f77932b06b7",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "sndx:CommonStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
     "longName": "995815 - Disclosure - Significant Agreements - Additional Information (Detail)",
     "shortName": "Significant Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_65848bf9-3945-493c-98fa-73d365aadae6",
      "name": "sndx:UpfrontPayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "sndx:SignificantAgreementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail",
     "longName": "995825 - Disclosure - Property and Equipment, Net - Property and Equipment, Net (Detail)",
     "shortName": "Property and Equipment, Net - Property and Equipment, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
     "longName": "995835 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
     "longName": "995845 - Disclosure - Fair Value Measurements - Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value (Detail)",
     "shortName": "Fair Value Measurements - Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6cacdbd9-72ea-4585-80a2-d53f1908716b",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "longName": "995875 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail",
     "longName": "995885 - Disclosure - Fair Value Measurements - Summary of Available-for-Sale Securities (Detail)",
     "shortName": "Fair Value Measurements - Summary of Available-for-Sale Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "longName": "995895 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "longName": "995905 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "sndx:AccruedClinicalCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "sndx:AccruedClinicalCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
     "longName": "995915 - Disclosure - Common Stock - Additional Information (Detail)",
     "shortName": "Common Stock - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8419044-984d-4ea5-bd39-f4268be140ef",
      "name": "sndx:NumberOfPreFundedWarrantsExercisedForCommonStock",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "sndx:CommonStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail",
     "longName": "995925 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuance (Detail)",
     "shortName": "Common Stock - Schedule of Common Stock Reserved for Future Issuance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "sndx:CommonStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_38a4d3d9-61d6-470e-85bb-48eeea883916",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "sndx:CommonStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
     "longName": "995935 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "sndx:CommonStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail",
     "longName": "995945 - Disclosure - Stock-Based Compensation - Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan (Detail)",
     "shortName": "Stock-Based Compensation - Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85e6672e-416a-4bb1-ba66-37049365978f",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail",
     "longName": "995955 - Disclosure - Stock-Based Compensation - Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model (Detail)",
     "shortName": "Stock-Based Compensation - Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail",
     "longName": "995965 - Disclosure - Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_99c86d68-0de1-42ee-8712-d5c4c9fb7189",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
     "longName": "995975 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_707b5fb4-b3b3-44e7-845a-f9f779873732",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_707b5fb4-b3b3-44e7-845a-f9f779873732",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails",
     "longName": "995985 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Parenthetical) (Details)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Units Activity (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_92d9f658-4420-4f6b-8599-bdb04a896f5e",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
     "longName": "995995 - Disclosure - Loan Payable - Additional Information (Detail)",
     "shortName": "Loan Payable - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:PaymentsForProceedsFromDepositOnLoan",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d",
      "name": "sndx:PrepaymentFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "996015 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "us-gaap:ValuationAllowanceMethodologiesAndAssumptions",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "us-gaap:ValuationAllowanceMethodologiesAndAssumptions",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail",
     "longName": "996025 - Disclosure - Income Taxes - Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes (Detail)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail",
     "longName": "996035 - Disclosure - Income Taxes - Components of Deferred Tax (Detail)",
     "shortName": "Income Taxes - Components of Deferred Tax (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail",
     "longName": "996045 - Disclosure - Income Taxes - Summary of Reconciliation of Company's Unrecognized Tax Benefits (Detail)",
     "shortName": "Income Taxes - Summary of Reconciliation of Company's Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_99c86d68-0de1-42ee-8712-d5c4c9fb7189",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07dde341-6b8e-4d35-a0a4-24bc46311598",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "996055 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3636803-aef2-421b-a81e-02758a0838f3",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail",
     "longName": "996065 - Disclosure - Supplemental Cash Flow Information - Supplemental Disclosures of Cash Flow (Detail)",
     "shortName": "Supplemental Cash Flow Information - Supplemental Disclosures of Cash Flow (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a32d41ce-57b9-43e7-bf72-ce00185e4cef",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201912Member",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU No. 2019-12 [Member]",
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r735"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Accretion) amortization of investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "sndx_AccruedClinicalCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AccruedClinicalCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical costs current.",
        "label": "Accrued Clinical Costs Current",
        "terseLabel": "Accrued clinical study and trial costs"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_AccruedContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AccruedContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contractual obligation.",
        "label": "Accrued Contractual Obligation",
        "terseLabel": "Accrued contractual obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_AccruedMilestoneCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AccruedMilestoneCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued milestone costs",
        "label": "Accrued milestone costs",
        "terseLabel": "Accrued milestone costs"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_AccruedMilestoneExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AccruedMilestoneExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued milestone expenses.",
        "label": "Accrued Milestone Expenses",
        "terseLabel": "Accrued milestone expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r176",
      "r582"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r34",
      "r491",
      "r494",
      "r553",
      "r592",
      "r593",
      "r842",
      "r843",
      "r844",
      "r852",
      "r853",
      "r854"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "sndx_AdditionalDefaultInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AdditionalDefaultInterestRate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional default interest rate.",
        "label": "Additional Default Interest Rate",
        "terseLabel": "Default interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r611",
      "r852",
      "r853",
      "r854",
      "r920",
      "r948"
     ]
    },
    "sndx_AdditionalTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AdditionalTermLoanMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional term loan.",
        "label": "Additional Term Loan [Member]",
        "terseLabel": "Additional Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r219",
      "r220",
      "r221",
      "r222",
      "r232",
      "r277",
      "r278",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r431",
      "r432",
      "r433",
      "r461",
      "r462",
      "r463",
      "r464",
      "r472",
      "r473",
      "r474",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r514",
      "r515",
      "r520",
      "r521",
      "r522",
      "r523",
      "r531",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r565",
      "r566",
      "r567",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "sndx_AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedDividendFromRepricingWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital deemed dividend from repricing warrants.",
        "label": "Adjustments To Additional Paid In Capital Deemed Dividend From Repricing Warrants",
        "terseLabel": "Deemed dividend from repricing Series 1 and 2 warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_AdjustmentsToAdditionalPaidInCapitalRepricingWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalRepricingWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital repricing warrants.",
        "label": "Adjustments To Additional Paid In Capital Repricing Warrants",
        "verboseLabel": "Deemed dividend transferred to the warrant holders",
        "negatedLabel": "Repricing Series 1 and 2 warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r393"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_AggregatePotentialMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AggregatePotentialMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential milestone payable.",
        "label": "Aggregate Potential Milestone Payable",
        "terseLabel": "Aggregate potential milestone payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r770",
      "r780",
      "r806"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r773",
      "r783",
      "r809"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r774",
      "r784",
      "r801",
      "r810",
      "r814",
      "r822"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "sndx_AllerganLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AllerganLicenseAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allergan license agreement.",
        "label": "Allergan License Agreement [Member]",
        "terseLabel": "Allergan License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock compensation expense",
        "verboseLabel": "Share based compensation expense, total",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r438"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_AmortizedLossesReacquiredDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AmortizedLossesReacquiredDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": "us-gaap_LoansPayable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized losses reacquired debt noncurrent.",
        "label": "Amortized Losses Reacquired Debt Noncurrent",
        "terseLabel": "Amortized final fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of diluted net loss per common share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r178",
      "r209",
      "r253",
      "r267",
      "r271",
      "r292",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r478",
      "r482",
      "r518",
      "r575",
      "r643",
      "r735",
      "r747",
      "r880",
      "r881",
      "r930"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r182",
      "r209",
      "r292",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r478",
      "r482",
      "r518",
      "r735",
      "r880",
      "r881",
      "r930"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "sndx_AtTheMarketEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AtTheMarketEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market equity offering sales agreement.",
        "label": "At The Market Equity Offering Sales Agreement [Member]",
        "terseLabel": "At The Market Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_AtTheMarketProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AtTheMarketProgramMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market program [Member]",
        "label": "At-the-market program [Member]",
        "documentation": "At-the-market program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_AtTheMarketStockOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AtTheMarketStockOfferingMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market stock offering.",
        "label": "At The Market Stock Offering [Member]",
        "terseLabel": "At-the-Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r766"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r766"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r766"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r305",
      "r574"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r305",
      "r568",
      "r859"
     ]
    },
    "sndx_AvailableForSaleSecuritiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "AvailableForSaleSecuritiesFairValueDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Securities Fair Value Disclosure [Abstract]",
        "label": "Available For Sale Securities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "sndx_BayerPharmaAgMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "BayerPharmaAgMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer Pharma AG .",
        "label": "Bayer Pharma Ag [Member]",
        "terseLabel": "Bayer Pharma AG [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_BeginToExpireInTwoThousandAndTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "BeginToExpireInTwoThousandAndTwentySixMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Begin to expire in 2026.",
        "label": "Begin To Expire In Two Thousand And Twenty Six [Member]",
        "terseLabel": "Begin to Expire in 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_BiotechnologyValueFundLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "BiotechnologyValueFundLPMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biotechnology Value Fund, L.P.",
        "label": "Biotechnology Value Fund L P [Member]",
        "terseLabel": "Biotechnology Value Fund, L.P. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_BriggsWMorrisonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "BriggsWMorrisonMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Briggs W. Morrison [Member]",
        "label": "Briggs W. Morrison [Member]",
        "documentation": "Briggs W. Morrison [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent liabilities",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r69",
      "r475"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r117",
      "r118"
     ]
    },
    "sndx_CapitalLeaseLessCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CapitalLeaseLessCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital lease, less current portion.",
        "label": "Capital Lease Less Current Portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value [Member]",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r173",
      "r706"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r135"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH\u2014end of year",
        "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH\u2014beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r114",
      "r206"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r114"
     ]
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r165",
      "r166",
      "r218",
      "r277",
      "r278",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r307",
      "r461",
      "r472",
      "r473",
      "r485",
      "r486",
      "r487",
      "r497",
      "r498",
      "r508",
      "r514",
      "r515",
      "r519",
      "r520",
      "r521",
      "r531",
      "r535",
      "r536",
      "r537",
      "r549",
      "r565",
      "r566",
      "r590",
      "r591"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r165",
      "r166",
      "r277",
      "r278",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r303",
      "r307",
      "r461",
      "r472",
      "r473",
      "r474",
      "r485",
      "r486",
      "r487",
      "r488",
      "r497",
      "r498",
      "r499",
      "r502",
      "r508",
      "r514",
      "r515",
      "r519",
      "r520",
      "r521",
      "r531",
      "r535",
      "r536",
      "r537",
      "r549",
      "r565",
      "r566",
      "r590",
      "r591",
      "r833"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r219",
      "r231",
      "r298",
      "r465"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r252",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r604",
      "r605",
      "r606",
      "r607",
      "r725",
      "r830",
      "r847"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price per share",
        "verboseLabel": "Warrant exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "sndx_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right issued.",
        "label": "Class Of Warrant Or Right Issued",
        "terseLabel": "Warrant issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ClassOfWarrantOrRightTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ClassOfWarrantOrRightTerm",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right term.",
        "label": "Class Of Warrant Or Right Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ClinicalTrialCostPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ClinicalTrialCostPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial Cost [Policy Text Block]",
        "label": "Clinical Trial Cost [Policy Text Block]",
        "terseLabel": "Clinical Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ClinicalTrialMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial.",
        "label": "Clinical Trial [Member]",
        "terseLabel": "Clinical Trial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "sndx_CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement allocated consideration received to derivative liability.",
        "label": "Collaboration And License Agreement Allocated Consideration Received To Derivative Liability",
        "terseLabel": "Allocated consideration received to derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CollaborationAndLicenseAgreementCashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CollaborationAndLicenseAgreementCashConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement cash consideration.",
        "label": "Collaboration And License Agreement Cash Consideration",
        "terseLabel": "Total cash consideration"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CollaborationAndLicenseAgreementConsiderationTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CollaborationAndLicenseAgreementConsiderationTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement consideration transaction price.",
        "label": "Collaboration And License Agreement Consideration Transaction Price",
        "terseLabel": "Total transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Incyte Agreement [Member]",
        "verboseLabel": "Incyte Share Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CollaborationExpenseDueToCounterparty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CollaborationExpenseDueToCounterparty",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration expense due to counterparty.",
        "label": "Collaboration Expense Due To Counterparty",
        "terseLabel": "Collaboration expense due to counterparty"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CollaborationPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CollaborationPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration payable, net",
        "label": "Collaboration Payable, Current",
        "documentation": "Collaboration Payable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CollaborationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CollaborationReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration receivable, net",
        "documentation": "Collaboration receivable",
        "label": "Collaboration receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Cost-Sharing Collaborations [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "sndx_CollaborativeResearchAndLicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CollaborativeResearchAndLicenseAgreementsTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative research and license agreements.",
        "label": "Collaborative Research And License Agreements [Text Block]",
        "terseLabel": "Collaborative Research and License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r921"
     ]
    },
    "sndx_CommercializationMilestonesAndTieredRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CommercializationMilestonesAndTieredRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercialization milestones and tiered royalties.",
        "label": "Commercialization Milestones And Tiered Royalties",
        "terseLabel": "Commercialization milestones and tiered royalties"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CommitmentAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CommitmentAndContingenciesLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CommitmentAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CommitmentAndContingenciesTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Table]",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 16)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r84",
      "r576",
      "r630"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r309",
      "r310",
      "r691",
      "r876"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Shares available for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "sndx_CommonStockDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CommonStockDisclosureTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock disclosure.",
        "label": "Common Stock Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r852",
      "r853",
      "r920",
      "r945",
      "r948"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r631"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r98",
      "r631",
      "r649",
      "r948",
      "r949"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value, 200,000,000 and 100,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 84,826,632 and 68,111,385 shares outstanding at December 31, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r578",
      "r735"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Deferred tax assets (liabilities):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r188",
      "r190",
      "r196",
      "r569",
      "r586"
     ]
    },
    "sndx_ComputerAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ComputerAndOfficeEquipmentMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and computer equipment.",
        "label": "Computer And Office Equipment [Member]",
        "terseLabel": "Office and Computer Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r149"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r380"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Milestone payment received",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Aggregate payment obligation",
        "totalLabel": "Contractual Obligation, Total",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "sndx_ContractualObligationsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ContractualObligationsTerm",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations term.",
        "label": "Contractual Obligations Term",
        "terseLabel": "Period of contractual obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r729",
      "r944"
     ]
    },
    "sndx_CostsRelatedToCostSharingCollaborations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CostsRelatedToCostSharingCollaborations",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs related to cost sharing collaborations.",
        "label": "Costs Related To Cost Sharing Collaborations",
        "terseLabel": "External costs related to cost-sharing collaborations"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r333",
      "r360",
      "r556",
      "r709",
      "r711"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CowenAndCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CowenAndCompanyLLCMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen and Company LLC.",
        "label": "Cowen And Company L L C [Member]",
        "terseLabel": "Cowen and Company LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_CurrentPortionOfCapitalLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "CurrentPortionOfCapitalLease",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of capital lease.",
        "label": "Current Portion Of Capital Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current State Income Expense",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r850",
      "r917"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Loan Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r208",
      "r329",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r345",
      "r352",
      "r353",
      "r355"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r94",
      "r95",
      "r137",
      "r138",
      "r214",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r534",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r848"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": "us-gaap_LoansPayable",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Borrowings to date",
        "totalLabel": "Total principal outstanding",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r138",
      "r356"
     ]
    },
    "sndx_DebtInstrumentInterestOnlyPeriodExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DebtInstrumentInterestOnlyPeriodExpirationDate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest only period expiration date.",
        "label": "Debt Instrument Interest Only Period Expiration Date",
        "terseLabel": "Interest-only period expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DebtInstrumentInterestOnlyPeriodExtendableUponPartialOrFullDrawOfTrancheTwo",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest only period extendable upon partial or full draw of Tranche 2.",
        "label": "Debt Instrument Interest Only Period Extendable Upon Partial Or Full Draw Of Tranche Two",
        "terseLabel": "Interest-only period, extendable upon partial or full draw of Tranche 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r331"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r534",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r848"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r720",
      "r923"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r214",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r534",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r848"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r55",
      "r58",
      "r80",
      "r81",
      "r83",
      "r86",
      "r126",
      "r127",
      "r214",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r534",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r848"
     ]
    },
    "sndx_DebtInstrumentTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DebtInstrumentTrancheThreeMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, tranche three.",
        "label": "Debt Instrument Tranche Three [Member]",
        "terseLabel": "Tranche 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_DebtInstrumentTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DebtInstrumentTrancheTwoMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument tranche two",
        "label": "Debt Instrument Tranche Two [Member]",
        "terseLabel": "Tranche 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Issuance costs included in accounts payable and accrued expenses",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Cost",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains or losses recognized on the sale or maturity of available-for-sale securities",
        "totalLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset, capitalized research and development costs.",
        "label": "Deferred Tax Assets Capitalized Research And Development Costs",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_DeferredTaxAssetsCapitalizedStartUpAndOtherCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedStartUpAndOtherCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset, capitalized start-up and other costs.",
        "label": "Deferred Tax Assets Capitalized Start Up And Other Costs",
        "terseLabel": "Capitalized start-up and other costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Net, Total",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "sndx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carryforwards expiration period.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Expiration Period",
        "terseLabel": "Operating loss carryforward expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other temporary differences",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "sndx_DeferredTaxAssetsResearchCreditsExpirationPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DeferredTaxAssetsResearchCreditsExpirationPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets research credits expiration period.",
        "label": "Deferred Tax Assets Research Credits Expiration Period",
        "terseLabel": "Deferred tax assets research credits expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred tax assets research credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Total",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "terseLabel": "Deferred tax assets, Expenses required to be capitalized",
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Equity based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowances",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contributions by the company",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Assets, Current",
        "terseLabel": "Short-term deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50"
     ]
    },
    "sndx_DepreciationAndRelatedAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DepreciationAndRelatedAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation and related adjustment.",
        "label": "Depreciation And Related Adjustment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total",
        "negatedLabel": "Changes in fair value of derivative liability",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "terseLabel": "Derivative Liability",
        "totalLabel": "Derivative Liability, Total",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r517",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r644",
      "r646",
      "r647",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r711",
      "r946"
     ]
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]",
        "terseLabel": "Derivative Liability:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Current",
        "terseLabel": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "sndx_DerivativeLiabilityExpectedTimingOfTerminationRight": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DerivativeLiabilityExpectedTimingOfTerminationRight",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability expected timing of the termination right.",
        "label": "Derivative Liability Expected Timing Of Termination Right",
        "terseLabel": "Expected timing of the Termination Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "sndx_DerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DerivativeLiabilityMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability.",
        "label": "Derivative Liability [Member]",
        "terseLabel": "Derivative Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r70",
      "r71",
      "r72",
      "r73",
      "r213"
     ]
    },
    "sndx_DevelopmentAndRegulaotryMilestonesExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DevelopmentAndRegulaotryMilestonesExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulaotry milestones Expenses",
        "label": "Development and regulaotry milestones Expenses",
        "terseLabel": "Development and regulaotry milestones expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_DevelopmentCostsAssociatedWithClinicalTrials": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DevelopmentCostsAssociatedWithClinicalTrials",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development costs associated with clinical trials.",
        "label": "Development Costs Associated With Clinical Trials",
        "terseLabel": "Development costs associated with clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_DirectPlacementOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "DirectPlacementOfferingMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct placement offering.",
        "label": "Direct Placement Offering [Member]",
        "terseLabel": "Direct Placement Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r396",
      "r427",
      "r428",
      "r430",
      "r731"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r766"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r766",
      "r802"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net (loss) income Per Share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Basic (loss) earnings per share attributable to common stockholders",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r234",
      "r237",
      "r244",
      "r245",
      "r246",
      "r250",
      "r506",
      "r507",
      "r570",
      "r587",
      "r713"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share Basic [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r241",
      "r244"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Diluted (loss) earnings per share attributable to common stockholders",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r237",
      "r244",
      "r245",
      "r246",
      "r250",
      "r506",
      "r507",
      "r570",
      "r587",
      "r713"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) Earnings per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r247",
      "r248",
      "r249"
     ]
    },
    "sndx_EasternCooperativeOncologyGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "EasternCooperativeOncologyGroupMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eastern Cooperative Oncology Group.",
        "label": "Eastern Cooperative Oncology Group [Member]",
        "terseLabel": "Eastern Cooperative Oncology Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r447",
      "r468"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r918"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r918"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r918"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r918"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "General business credit carryovers",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r918"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related costs",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period to recognize compensation expense",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to stock option",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "EmployeeServiceShareBasedCompensationRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation recognized stock options.",
        "label": "Employee Service Share Based Compensation Recognized Stock Options",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "EmployeeServiceShareBasedCompensationRecognizedStockOptionsNotMet",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation recognized stock options not met.",
        "label": "Employee Service Share Based Compensation Recognized Stock Options Not Met",
        "terseLabel": "Recognized compensation expense related to stock option not met"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP to Purchase Common Stock",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_EmployeeWithholdingsEspp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "EmployeeWithholdingsEspp",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee withholdings ESPP",
        "label": "Employee withholdings ESPP",
        "terseLabel": "Employee withholdings ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "verboseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r167",
      "r192",
      "r193",
      "r194",
      "r215",
      "r216",
      "r217",
      "r220",
      "r228",
      "r230",
      "r251",
      "r297",
      "r304",
      "r367",
      "r431",
      "r432",
      "r433",
      "r463",
      "r464",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r505",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r553",
      "r592",
      "r593",
      "r594",
      "r611",
      "r670"
     ]
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Member]",
        "terseLabel": "Equity Investment [Member]",
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_EquityPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "EquityPlansMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity plans [Member]",
        "label": "Equity plans [Member]",
        "documentation": "Equity plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r770",
      "r780",
      "r806"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r767",
      "r777",
      "r803"
     ]
    },
    "sndx_EstimatedStandaloneSellingPriceOfLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "EstimatedStandaloneSellingPriceOfLicenseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated standalone selling price of license agreement.",
        "label": "Estimated Standalone Selling Price Of License Agreement",
        "terseLabel": "Estimated standalone selling price of license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "sndx_ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ExerciseOfWarrantsLowerLimitAfterExerciseAsPercentageOfCommonStock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants lower limit after exercise as percentage of common stock.",
        "label": "Exercise Of Warrants Lower Limit After Exercise As Percentage Of Common Stock",
        "terseLabel": "Minimum percentage of common stock can be held upon exercise of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ExerciseOfWarrantsUpperLimitAfterExerciseAsPercentageOfCommonStock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants upper limit after exercise as percentage of common stock.",
        "label": "Exercise Of Warrants Upper Limit After Exercise As Percentage Of Common Stock",
        "terseLabel": "Maximum percentage of common stock can be held upon exercise of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ExpirationOfTheEspp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ExpirationOfTheEspp",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration of the ESPP",
        "label": "Expiration of the ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ExpirationOfTheEsppShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ExpirationOfTheEsppShares",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "expiration of the ESPP shares",
        "label": "expiration of the ESPP shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r510",
      "r513"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r510",
      "r513"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Grant Date Fair Values of Options Issued to Employees and Non-employees Estimated Using Black-Scholes Option Pricing Model",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Significant Unobservable Inputs in the Fair Value Measurement",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r510",
      "r558",
      "r559",
      "r560",
      "r721",
      "r722",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r74",
      "r343",
      "r721",
      "r722"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r721",
      "r722"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r383",
      "r388",
      "r510",
      "r558",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r383",
      "r388",
      "r510",
      "r559",
      "r721",
      "r722",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r510",
      "r560",
      "r721",
      "r722",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Fair Value",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r75"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value",
        "negatedLabel": "Change in fair value",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodStartLabel": "Beginning Balance 1/1/2022",
        "periodEndLabel": "Ending Balance 12/31/2022",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "sndx_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis liability value additions.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r558",
      "r559",
      "r560",
      "r721",
      "r722",
      "r727",
      "r728",
      "r729"
     ]
    },
    "sndx_FairValueMeasurementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FairValueMeasurementsLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurements.",
        "label": "Fair Value Measurements [Line Items]",
        "terseLabel": "Fair Value Measurements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_FairValueMeasurementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FairValueMeasurementsTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurements [Table]",
        "label": "Fair Value Measurements [Table]",
        "terseLabel": "Fair Value Measurements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants.",
        "label": "Fair Value Of Warrants",
        "terseLabel": "Total fair value of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_FederalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FederalBondsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Bonds [Member]",
        "label": "Federal Bonds [Member]",
        "documentation": "Federal bonds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "terseLabel": "Future minimum lease payments under capital leases",
        "totalLabel": "Finance Lease, Liability, to be Paid, Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "sndx_FirstAmendmentToLoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FirstAmendmentToLoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First amendment to loan and security agreement.",
        "label": "First Amendment To Loan And Security Agreement [Member]",
        "terseLabel": "First Amendment to Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_FollowOnPublicOfferingOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FollowOnPublicOfferingOneMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on public offering one.",
        "label": "Follow On Public Offering One [Member]",
        "terseLabel": "Follow-on Public Offering One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_FollowOnPublicOfferingTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FollowOnPublicOfferingTwoMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on public offering two.",
        "label": "Follow On Public Offering Two [Member]",
        "terseLabel": "Follow-on Public Offering Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_FollowOnPublicOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "FollowOnPublicOfferingsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on public offerings.",
        "label": "Follow On Public Offerings [Member]",
        "terseLabel": "Follow-on Public Offerings [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r774",
      "r784",
      "r810"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r774",
      "r784",
      "r810"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r774",
      "r784",
      "r810"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r774",
      "r784",
      "r810"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r774",
      "r784",
      "r810"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_GlobalAndUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "GlobalAndUnitedStatesMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global and united states.",
        "label": "Global And United States [Member]",
        "terseLabel": "Global and U.S. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_GrossProceedsFromOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "GrossProceedsFromOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from offering.",
        "label": "Gross Proceeds From Offering",
        "terseLabel": "Gross proceeds from offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "terseLabel": "Guarantor Obligations, Nature",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Domain]",
        "terseLabel": "Guarantor Obligations, Nature",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "terseLabel": "Guarantees and Indemnifications",
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "sndx_HerculesCapitalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "HerculesCapitalIncMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Capital, Inc.",
        "label": "Hercules Capital Inc [Member]",
        "terseLabel": "Hercules [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r766"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r123"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r654"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r654"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r442",
      "r448",
      "r453",
      "r459",
      "r466",
      "r469",
      "r470",
      "r471",
      "r609"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Net tax provision",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r161",
      "r229",
      "r230",
      "r258",
      "r446",
      "r467",
      "r588"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r444",
      "r445",
      "r453",
      "r454",
      "r458",
      "r460",
      "r603"
     ]
    },
    "sndx_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "sndx_IncreaseDecreaseInCollaborationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IncreaseDecreaseInCollaborationReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in collaboration receivable.",
        "label": "Increase Decrease In Collaboration Receivable",
        "terseLabel": "Collaboration receivable, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r845"
     ]
    },
    "sndx_IncreaseDecreaseInContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IncreaseDecreaseInContractualObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in contractual obligation.",
        "label": "Increase Decrease In Contractual Obligation",
        "terseLabel": "Increase in contractual obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sndx_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in research and development expense.",
        "label": "Increase Decrease In Research And Development Expense",
        "terseLabel": "Cost-sharing collaborations recorded as a reduction to research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive potential common shares",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r246",
      "r395"
     ]
    },
    "sndx_IncyteCollaborationAgreementAndSharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IncyteCollaborationAgreementAndSharePurchaseAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte collaboration agreement and share purchase agreement.",
        "label": "Incyte Collaboration Agreement And Share Purchase Agreement [Member]",
        "terseLabel": "Incyte Collaboration Agreement and Share Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_IncyteCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IncyteCorporationMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte corporation.",
        "label": "Incyte Corporation [Member]",
        "terseLabel": "Incyte Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_IncyteSharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IncyteSharePurchaseAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte share purchase agreement.",
        "label": "Incyte Share Purchase Agreement [Member]",
        "terseLabel": "Incyte Share Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_IndefiniteCarryforwardPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IndefiniteCarryforwardPeriodMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite carryforward period.",
        "label": "Indefinite Carryforward Period [Member]",
        "terseLabel": "Indefinite Carryforward Period [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndemnificationGuaranteeMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Guarantees and Indemnifications [Member]",
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "sndx_IndemnificationObligationsClaimsReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "IndemnificationObligationsClaimsReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification obligations claims reserves.",
        "label": "Indemnification Obligations Claims Reserves",
        "terseLabel": "Indemnification obligations claims, reserves established"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r774",
      "r784",
      "r801",
      "r810",
      "r814",
      "r822"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r826"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r826"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r826"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r143",
      "r195",
      "r257",
      "r533",
      "r655",
      "r745",
      "r947"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "verboseLabel": "Interest expense related to the loan agreement",
        "totalLabel": "Interest Expense, Debt, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r349",
      "r357",
      "r723",
      "r724"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204",
      "r205"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable on investments",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r256"
     ]
    },
    "sndx_KyowaKirinCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "KyowaKirinCoLtdMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyowa Kirin Co., Ltd.",
        "label": "Kyowa Kirin Co Ltd [Member]",
        "terseLabel": "Kyowa Kirin Co., Ltd. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_LeaseCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LeaseCommencementDate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease Commencement Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lease option to extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Lease option to termination",
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments under Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year three.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due After Year Two",
        "label": "Lessee Operating Lease Liability Payments Due After Year Two",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term of contract",
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r209",
      "r292",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r479",
      "r482",
      "r483",
      "r518",
      "r629",
      "r714",
      "r747",
      "r880",
      "r930",
      "r931"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r139",
      "r580",
      "r735",
      "r849",
      "r873",
      "r924"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r172",
      "r209",
      "r292",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r479",
      "r482",
      "r483",
      "r518",
      "r735",
      "r880",
      "r930",
      "r931"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total Liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r91",
      "r92",
      "r93",
      "r96",
      "r209",
      "r292",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r479",
      "r482",
      "r483",
      "r518",
      "r880",
      "r930",
      "r931"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_LicenseAgreementsExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LicenseAgreementsExpirationPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements expiration period.",
        "label": "License Agreements Expiration Period",
        "terseLabel": "License expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r848"
     ]
    },
    "sndx_LineOfCreditFacilityElectedNotToDraw": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LineOfCreditFacilityElectedNotToDraw",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility elected not to draw.",
        "label": "Line Of Credit Facility Elected Not To Draw",
        "terseLabel": "Line of credit facility elected not to draw"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Frequency of Payment and Payment Terms",
        "terseLabel": "Interest-only period, terms",
        "documentation": "Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Increase (Decrease), Net",
        "terseLabel": "Aggregate maximum borrowing capacity increase",
        "totalLabel": "Line of Credit Facility, Increase (Decrease), Net, Total",
        "documentation": "Amount of increase (decrease) of the credit facility."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDescription",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate Description",
        "terseLabel": "Interest rate description",
        "documentation": "Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r848"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Aggregate maximum borrowings",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "sndx_LineOfCreditFacilityMinimumCashCovenant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LineOfCreditFacilityMinimumCashCovenant",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility minimum cash covenant.",
        "label": "Line Of Credit Facility Minimum Cash Covenant",
        "terseLabel": "Minimum cash covenant"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_LineOfCreditFacilityMinimumCashCovenantWaived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LineOfCreditFacilityMinimumCashCovenantWaived",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility minimum cash covenant waived.",
        "label": "Line Of Credit Facility Minimum Cash Covenant Waived",
        "terseLabel": "Minimum cash covenant waived"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan and security agreement.",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable",
        "totalLabel": "Total",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r138",
      "r941"
     ]
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": "us-gaap_LoansPayable",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Current",
        "terseLabel": "Current portion of term loan",
        "totalLabel": "Loans Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r214",
      "r347"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r214",
      "r347"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r214",
      "r347"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Investments, Total",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": "us-gaap_LoansPayable",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Term loan, less current portion",
        "totalLabel": "Loans Payable, Noncurrent, Total",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Indemnification obligations, claims outstanding",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r878"
     ]
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MA",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Waltham, Massachusetts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_MarketReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "MarketReserveMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "market reserve",
        "label": "Market Reserve [MEMBER]",
        "documentation": "Market Reserve [MEMBER]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "sndx_MaximumBeneficialOwnershipLimitationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "MaximumBeneficialOwnershipLimitationPercentage",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum beneficial ownership limitation percentage.",
        "label": "Maximum Beneficial Ownership Limitation Percentage",
        "terseLabel": "Maximum beneficial ownership limitation percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r389",
      "r562",
      "r589",
      "r621",
      "r622",
      "r673",
      "r675",
      "r677",
      "r678",
      "r687",
      "r702",
      "r703",
      "r717",
      "r725",
      "r730",
      "r736",
      "r882",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "sndx_MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "MaximumPeriodAllowedToIncreaseBeneficialOwnershipLimitationAfterNotice",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period allowed to increase beneficial ownership limitation after notice.",
        "label": "Maximum Period Allowed To Increase Beneficial Ownership Limitation After Notice",
        "terseLabel": "Maximum period allowed to increase beneficial ownership limitation after notice"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_MichaelMetzgerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "MichaelMetzgerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Michael Metzger [Member]",
        "label": "Michael Metzger [Member]",
        "documentation": "Michael Metzger [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_MilestoneExpensesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "MilestoneExpensesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Expenses Paid",
        "label": "Milestone Expenses Paid",
        "terseLabel": "Milestone expenses paid"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_MilestonePaymentDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "MilestonePaymentDue",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment due.",
        "label": "Milestone Payment Due",
        "terseLabel": "Milestone payment payable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r389",
      "r562",
      "r589",
      "r621",
      "r622",
      "r673",
      "r675",
      "r677",
      "r678",
      "r687",
      "r702",
      "r703",
      "r717",
      "r725",
      "r730",
      "r736",
      "r882",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "stpr_NY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "NY",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "New York [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r163"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r116",
      "r142",
      "r170",
      "r187",
      "r189",
      "r194",
      "r209",
      "r219",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r242",
      "r253",
      "r266",
      "r270",
      "r272",
      "r292",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r507",
      "r518",
      "r585",
      "r651",
      "r668",
      "r669",
      "r715",
      "r745",
      "r880"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net (loss) income attributable to common stockholders",
        "totalLabel": "Net (loss) income attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r223",
      "r224",
      "r225",
      "r226",
      "r234",
      "r235",
      "r243",
      "r246",
      "r253",
      "r266",
      "r270",
      "r272",
      "r715"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued and Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r774",
      "r784",
      "r801",
      "r810"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "sndx_NonRefundableCashPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NonRefundableCashPaymentsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable cash payments.",
        "label": "Non Refundable Cash Payments [Member]",
        "terseLabel": "Non-Refundable Cash Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NonRefundableUpFrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NonRefundableUpFrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable up front payment received.",
        "label": "Non Refundable Up Front Payment Received",
        "terseLabel": "Up-front license fee received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "terseLabel": "Ex-U.S. Countries [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationSupplementalDisclosuresOfCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Investing and Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NoncashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NoncashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash operating lease expense.",
        "label": "Noncash Operating Lease Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NumberOfCommonStockConvertedToWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NumberOfCommonStockConvertedToWarrants",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock converted to warrants.",
        "label": "Number Of Common Stock Converted To Warrants",
        "terseLabel": "Number of common stock converted to warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NumberOfCommonStockWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NumberOfCommonStockWarrantsIssued",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock warrants issued.",
        "label": "Number Of Common Stock Warrants Issued",
        "terseLabel": "Number of common stock warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NumberOfEmployeesRetirement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NumberOfEmployeesRetirement",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employees retirement.",
        "label": "Number Of Employees Retirement",
        "terseLabel": "Number of employees retirement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "sndx_NumberOfPreFundedWarrantsCashlessExchangedForCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NumberOfPreFundedWarrantsCashlessExchangedForCommonStock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pre funded warrants cashless exchanged for common stock.",
        "label": "Number Of Pre Funded Warrants Cashless Exchanged For Common Stock",
        "terseLabel": "Pre-funded warrants cashless exchange"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NumberOfPreFundedWarrantsExchangedForCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NumberOfPreFundedWarrantsExchangedForCommonStock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pre-funded warrants exchanged for common stock.",
        "label": "Number Of Pre Funded Warrants Exchanged For Common Stock",
        "terseLabel": "Pre-funded warrants exchange"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NumberOfPreFundedWarrantsExercisedForCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NumberOfPreFundedWarrantsExercisedForCommonStock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Pre Funded Warrants Exercised For Common Stock",
        "label": "Number Of Pre Funded Warrants Exercised For Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NumberOfSeriesOfWarrants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NumberOfSeriesOfWarrants",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of series of warrants.",
        "label": "Number Of Series Of Warrants",
        "terseLabel": "Number of series of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_NumberOfWarrantsExercisedInCashlessExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "NumberOfWarrantsExercisedInCashlessExercise",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised in cashless exercise.",
        "label": "Number Of Warrants Exercised In Cashless Exercise",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_OfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "OfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering cost.",
        "label": "Offering Cost",
        "terseLabel": "Offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_OfferingPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "OfferingPricePerShare",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering price per share.",
        "label": "Offering Price Per Share",
        "terseLabel": "Offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment Under Capital Lease [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "(Loss) income from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r266",
      "r270",
      "r272",
      "r715"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Total operating lease liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of right-of-use liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Right-of-use liability, less current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r545"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset, net",
        "verboseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r734"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r734"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized (gain) loss on investments",
        "terseLabel": "Unrealized gain (loss) on marketable securities, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r291"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r874"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r772",
      "r782",
      "r808"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r775",
      "r785",
      "r811"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r775",
      "r785",
      "r811"
     ]
    },
    "sndx_PaidInKindInterestAndInterestReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PaidInKindInterestAndInterestReversal",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest income (expense)",
        "documentation": "Paid in kind interest and interest reversal.",
        "label": "Paid In Kind Interest And Interest Reversal"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ParValueAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ParValueAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par Value adjustment",
        "label": "Par Value Adjustments",
        "documentation": "Par Value Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PaymentForEndOfTermFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PaymentForEndOfTermFees",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for end-of term fees",
        "label": "Payment for end-of term fees"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PaymentOfFacilityCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PaymentOfFacilityCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of facility charges.",
        "label": "Payment Of Facility Charges",
        "terseLabel": "Facility charge paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsForProceedsFromDepositOnLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromDepositOnLoan",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Deposit on Loan",
        "terseLabel": "Payment on term loan",
        "negatedLabel": "Payment on term loan",
        "documentation": "The net cash inflow or outflow from resulting from payment, receipt or drawdown of cash deposit to guarantee a loan during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of short and long-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "sndx_PercentageOfEndOfTermChargeToFutureDraws": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PercentageOfEndOfTermChargeToFutureDraws",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of end of term charge to future draws.",
        "label": "Percentage Of End Of Term Charge To Future Draws",
        "terseLabel": "Percentage of end of term charge to future draws"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PercentageOfFacilityChargeOfFutureDraws": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PercentageOfFacilityChargeOfFutureDraws",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of facility charge of future draws.",
        "label": "Percentage Of Facility Charge Of Future Draws",
        "terseLabel": "Percentage of facility charge of future draws"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PercentageOfIncomeTaxContingencyRealized": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PercentageOfIncomeTaxContingencyRealized",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of income tax contingency realized.",
        "label": "Percentage Of Income Tax Contingency Realized",
        "terseLabel": "Percentage of income tax contingency realized"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInFirstYear",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment premium of principal amount outstanding in first year.",
        "label": "Percentage Of Prepayment Premium Of Principal Amount Outstanding In First Year",
        "terseLabel": "Percentage of prepayment premium of principal amount outstanding in first year"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingInSecondYear",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment premium of principal amount outstanding in second year.",
        "label": "Percentage Of Prepayment Premium Of Principal Amount Outstanding In Second Year",
        "terseLabel": "Percentage of prepayment premium of principal amount outstanding in second year"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingThereafter",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment premium of principal amount outstanding thereafter.",
        "label": "Percentage Of Prepayment Premium Of Principal Amount Outstanding Thereafter",
        "terseLabel": "Percentage of prepayment premium of principal amount outstanding thereafter prior to maturity date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Based Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of termination after first commercial sale of first licensed product.",
        "label": "Period Of Termination After First Commercial Sale Of First Licensed Product",
        "terseLabel": "Period of termination after first commercial sale of first licensed product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]",
        "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "sndx_PotentialMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PotentialMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payments receivable.",
        "label": "Potential Milestone Payments Receivable",
        "terseLabel": "Milestone payment receivable upon achievement of development and commercial milestone"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PotentialMilestonePaymentsUponAchievementOfMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PotentialMilestonePaymentsUponAchievementOfMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payments upon achievement of milestone.",
        "label": "Potential Milestone Payments Upon Achievement Of Milestone",
        "terseLabel": "Potential milestone payments to be made"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PreFundedWarrantExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PreFundedWarrantExerciseShares",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrant cashless exercise, shares",
        "documentation": "Pre-funded warrant exercise, shares",
        "label": "Pre-funded warrant exercise, shares"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre funded warrants.",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r631"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r631",
      "r649",
      "r948",
      "r949"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at December 31, 2023 and December 31, 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r577",
      "r735"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r718",
      "r874"
     ]
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid rent",
        "label": "Prepaid Rent",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r874"
     ]
    },
    "sndx_PrepaidStateAndLocalTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PrepaidStateAndLocalTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid state and local taxes",
        "label": "Prepaid State and Local Taxes",
        "documentation": "Prepaid State and Local Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PrepaidSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PrepaidSubscriptions",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Subscriptions",
        "label": "Prepaid Subscriptions",
        "terseLabel": "PrepaidSubscriptions"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_PrepaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "PrepaymentFee",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Fee",
        "label": "Prepayment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prime Rate [Member]",
        "verboseLabel": "Wall Street Journal Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Aggregate purchase price",
        "terseLabel": "Proceeds from issuance of common stock in follow-on public stock offering, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from License Fees Received",
        "terseLabel": "License fees",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales and maturities of short-term investments",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r860"
     ]
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from sales of equipment",
        "documentation": "The cash inflow from sale of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Stock options exercised",
        "terseLabel": "Proceeds from stock option exercises",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r21"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from ESPP",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r187",
      "r189",
      "r202",
      "r209",
      "r219",
      "r229",
      "r230",
      "r253",
      "r266",
      "r270",
      "r272",
      "r292",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r477",
      "r480",
      "r481",
      "r507",
      "r518",
      "r571",
      "r584",
      "r610",
      "r651",
      "r668",
      "r669",
      "r715",
      "r732",
      "r733",
      "r746",
      "r844",
      "r880"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r150",
      "r155",
      "r156"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r175",
      "r583"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r573",
      "r583",
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r150",
      "r155",
      "r581"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation",
        "terseLabel": "Purchase agreement obligation",
        "totalLabel": "Purchase Obligation, Total",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r382",
      "r389",
      "r422",
      "r423",
      "r424",
      "r561",
      "r562",
      "r589",
      "r621",
      "r622",
      "r673",
      "r675",
      "r677",
      "r678",
      "r687",
      "r702",
      "r703",
      "r717",
      "r725",
      "r730",
      "r736",
      "r739",
      "r875",
      "r882",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r382",
      "r389",
      "r422",
      "r423",
      "r424",
      "r561",
      "r562",
      "r589",
      "r621",
      "r622",
      "r673",
      "r675",
      "r677",
      "r678",
      "r687",
      "r702",
      "r703",
      "r717",
      "r725",
      "r730",
      "r736",
      "r739",
      "r875",
      "r882",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r767",
      "r777",
      "r803"
     ]
    },
    "us-gaap_RegistrationPaymentArrangementArrangementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RegistrationPaymentArrangementArrangementDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Payment Arrangement, Arrangement [Domain]",
        "terseLabel": "Registration Payment Arrangement, Arrangement",
        "documentation": "Identifies and describes the contingent obligation arising from a commitment made to the recipient of the entity's financial instruments to endeavor (a) to file a registration statement for the resale of those financial instrument (demand or \"piggyback\" rights granted to the recipient) or for the resale of equity shares that are issuable upon exercise or conversion of those financial instruments and (b) for the registration statement to be declared effective by the Securities and Exchange Commission within a specified grace period."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "us-gaap_RegistrationPaymentArrangementByArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RegistrationPaymentArrangementByArrangementAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Payment Arrangement by Arrangement [Axis]",
        "terseLabel": "Registration Payment Arrangement by Arrangement",
        "documentation": "Information pertinent to describing and quantifying a commitment or performance under a commitment to a recipient of an entity's shares (such as to shareholders of an acquired entity) to register the recipient's holdings of such shares, by payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r555",
      "r929"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_RemainingContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "RemainingContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining contractual obligation.",
        "label": "Remaining Contractual Obligation",
        "terseLabel": "Remaining contractual obligation"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r333",
      "r360",
      "r556",
      "r710",
      "r711"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r912"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r440",
      "r938"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r768",
      "r778",
      "r804"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r769",
      "r779",
      "r805"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r776",
      "r786",
      "r812"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash included in current and noncurrent assets",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846",
      "r939",
      "r942"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r836",
      "r846"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Non-Vested Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r128",
      "r579",
      "r596",
      "r601",
      "r608",
      "r632",
      "r735"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r215",
      "r216",
      "r217",
      "r220",
      "r228",
      "r230",
      "r297",
      "r304",
      "r431",
      "r432",
      "r433",
      "r463",
      "r464",
      "r489",
      "r492",
      "r493",
      "r496",
      "r505",
      "r592",
      "r594",
      "r611",
      "r948"
     ]
    },
    "sndx_ReturnToProvisionTrueUp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ReturnToProvisionTrueUp",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesComputedAtStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return to provision true up",
        "label": "Return to provision true up",
        "terseLabel": "Return to provision true up"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "totalLabel": "Total revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r265",
      "r268",
      "r269",
      "r273",
      "r274",
      "r276",
      "r378",
      "r379",
      "r564"
     ]
    },
    "sndx_RevenueFromContractWithCustomerMilestoneMethodFactors": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "RevenueFromContractWithCustomerMilestoneMethodFactors",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from contract with customer milestone method factors.",
        "label": "Revenue From Contract With Customer Milestone Method Factors",
        "terseLabel": "Milestone payment agreement terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r704"
     ]
    },
    "sndx_RevenueRecognizedUponTransferOfLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "RevenueRecognizedUponTransferOfLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognized upon transfer of license agreement.",
        "label": "Revenue Recognized Upon Transfer Of License Agreement",
        "terseLabel": "Revenue recognized upon transfer of license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Upfront payment allocation to performance obligation",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Year",
        "terseLabel": "Performance obligation period",
        "documentation": "Year in which remaining performance obligation is expected to be recognized, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r390",
      "r855"
     ]
    },
    "sndx_ScenarioOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ScenarioOneMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario one.",
        "label": "Scenario One [Member]",
        "terseLabel": "Available through April 30, 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ScenarioTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ScenarioTwoMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario two.",
        "label": "Scenario Two [Member]",
        "terseLabel": "Available through November 30, 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r390",
      "r831",
      "r855"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Earnings (Loss) per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]",
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r237",
      "r241",
      "r244"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Provision for Income Taxes Computed at Statutory Federal Income Tax Rate to Provision for Income Taxes",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r510"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Summary of Maturities of Principal Obligations Under Long-term Debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]",
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r912"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r394",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Employee and Non-Employee Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r126",
      "r127",
      "r128",
      "r179",
      "r180",
      "r181",
      "r252",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r604",
      "r605",
      "r606",
      "r607",
      "r725",
      "r830",
      "r847"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r615",
      "r617",
      "r619",
      "r674",
      "r676",
      "r679",
      "r688",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r705",
      "r726",
      "r739",
      "r883",
      "r943"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r274",
      "r716"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative [Member]",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_SeriesB1PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "SeriesB1PurchaseAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 purchase agreement.",
        "label": "Series B1 Purchase Agreement [Member]",
        "terseLabel": "Eddingpharm Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_SeriesOneAndSeriesTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "SeriesOneAndSeriesTwoWarrantsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series one and series two warrants.",
        "label": "Series One And Series Two Warrants [Member]",
        "terseLabel": "Series 1 and Series 2 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_SeriesOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "SeriesOneWarrantsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series one warrants.",
        "label": "Series One Warrants [Member]",
        "terseLabel": "Series 1 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_SeriesTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "SeriesTwoWarrantsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series two warrants.",
        "label": "Series Two Warrants [Member]",
        "terseLabel": "Series 2 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_SeriesWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "SeriesWarrantsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series warrants.",
        "label": "Series Warrants [Member]",
        "terseLabel": "Series Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_ServiceBasedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ServiceBasedOptionsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "service based options.",
        "label": "Service Based Options [Member]",
        "terseLabel": "Service Based Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award annual increase percentage in number of shares available for grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage In Number Of Shares Available For Grant",
        "terseLabel": "Common stock outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting period, description",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Number of Shares, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted",
        "verboseLabel": "Restricted stock units granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Unvested, Ending balance",
        "periodStartLabel": "Number of Shares, Unvested, Beginning balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested, Ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested, Beginning balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "verboseLabel": "Restricted stock units vested",
        "negatedLabel": "Number of Shares, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "verboseLabel": "Fair value of restricted stock units vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionAwardsToEmployeesAndNonEmployeesRelatedToEmployeeStockPurchasePlanDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r394",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "terseLabel": "Common stock exercised non option",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Shares authorized for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock reserved for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award offering period discount rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period Discount Rate",
        "terseLabel": "Offering period discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, Ending balance",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted Average Exercise Price, Ending balance",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options Exercised, Aggregate Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options canceled, forfeited or expired",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled, forfeited or expired, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Share-based compensation, stock options cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock option granted to certain employees",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based compensation, stock options granted",
        "verboseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, Ending balance",
        "periodStartLabel": "Options outstanding, Beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, Weighted Average Exercise Price, Ending balance",
        "periodStartLabel": "Options outstanding, Weighted Average Exercise Price, Beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested, exercisable or expected to vest, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Share-based compensation, stock options vested",
        "verboseLabel": "Options vested, exercisable or expected to vest, Ending balance",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested, exercisable or expected to vest, Weighted Average Exercise Price, Ending balance",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "sndx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award payroll deductions offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Payroll Deductions Offering Period",
        "terseLabel": "Periodic payroll deductions offering periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r400",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationGrantDateFairValuesOfOptionsIssuedToEmployeesAndNonEmployeesEstimatedUsingBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term, Ending balance",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityParentheticalDetails",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value per share",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested, exercisable or expected to vest, Weighted Average Remaining Contractual Term, Ending balance",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Share-based compensation, stock options vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, Shares",
        "periodStartLabel": "Beginning balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFairValuesOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-Term Investments, Total",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r839"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r207"
     ]
    },
    "sndx_SignificantAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "SignificantAgreementsDisclosureTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant agreements disclosure.",
        "label": "Significant Agreements Disclosure [Text Block]",
        "terseLabel": "Significant Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r167",
      "r192",
      "r193",
      "r194",
      "r215",
      "r216",
      "r217",
      "r220",
      "r228",
      "r230",
      "r251",
      "r297",
      "r304",
      "r367",
      "r431",
      "r432",
      "r433",
      "r463",
      "r464",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r505",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r553",
      "r592",
      "r593",
      "r594",
      "r611",
      "r670"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r615",
      "r617",
      "r619",
      "r674",
      "r676",
      "r679",
      "r688",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r705",
      "r726",
      "r739",
      "r883",
      "r943"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r251",
      "r564",
      "r602",
      "r612",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r652",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r670",
      "r740"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r390",
      "r831",
      "r832",
      "r855"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r251",
      "r564",
      "r602",
      "r612",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r652",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r670",
      "r740"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r771",
      "r781",
      "r807"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodSharesAtTheMarketOfferingNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesAtTheMarketOfferingNet",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares at the market offering net.",
        "label": "Stock Issued During Period Shares At The Market Offering Net",
        "terseLabel": "Proceeds from \"at-the-market\" offering, net, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodSharesDirectOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesDirectOffering",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value direct offering.",
        "label": "Stock Issued During Period Shares Direct Offering",
        "terseLabel": "Proceeds from direct offering,net, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock purchase under ESPP, Shares",
        "verboseLabel": "Number of shares issued under plan",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r98",
      "r128"
     ]
    },
    "sndx_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares exercise of warrants.",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "terseLabel": "Exercise of Series 1 and Series 2 warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Common stock, new shares issued",
        "terseLabel": "Proceeds from Incyte Share Purchase Agreement shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r98",
      "r128",
      "r604",
      "r670",
      "r689"
     ]
    },
    "sndx_StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesPreFundedCommonStockWarrantsFromDirectOffering",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares pre funded common stock warrants from direct offering.",
        "label": "Stock Issued During Period Shares Pre Funded Common Stock Warrants From Direct Offering",
        "terseLabel": "Proceeds from pre-funded common stock warrant from direct offering, net, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of RSU, Shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Proceeds from exercise of stock options, Shares",
        "verboseLabel": "Stock options exercised, shares",
        "negatedLabel": "Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r98",
      "r128",
      "r406"
     ]
    },
    "sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value at the market offering expenses.",
        "label": "Stock Issued During Period Value At The Market Offering Expenses",
        "terseLabel": "At-the-market, offering expenses",
        "verboseLabel": "ATM Offering, offering cost"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodValueAtTheMarketOfferingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValueAtTheMarketOfferingNet",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value at the market offering net.",
        "label": "Stock Issued During Period Value At The Market Offering Net",
        "terseLabel": "Proceeds from \"at-the-market\" offering, net, Value"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value common stock warrant with direct offering.",
        "label": "Stock Issued During Period Value Common Stock Warrant With Direct Offering",
        "terseLabel": "Issuance of common stock warrant with direct offering, value"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodValueDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValueDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value direct offering.",
        "label": "Stock Issued During Period Value Direct Offering",
        "terseLabel": "Proceeds from direct offering, net, value"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value direct offering common stock warrant.",
        "label": "Stock Issued During Period Value Direct Offering Common Stock Warrant",
        "terseLabel": "Direct offering, common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Stock purchase under ESPP",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r98",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock issued at fair value",
        "verboseLabel": "Proceeds from Incyte Share Purchase Agreement",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r98",
      "r128",
      "r611",
      "r670",
      "r689",
      "r746"
     ]
    },
    "sndx_StockIssuedDuringPeriodValueOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValueOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value offering expenses.",
        "label": "Stock Issued During Period Value Offering Expenses",
        "terseLabel": "Direct offering, offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValuePreFundedCommonStockWarrant",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value pre funded common stock warrant.",
        "label": "Stock Issued During Period Value Pre Funded Common Stock Warrant",
        "terseLabel": "Pre-funded common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value pre-funded common stock warrant offering expenses.",
        "label": "Stock Issued During Period Value Pre Funded Common Stock Warrant Offering Expenses",
        "terseLabel": "Pre-funded common stock warrants offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value pre-funded common stock warrants from direct offering.",
        "label": "Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering",
        "terseLabel": "Proceeds from pre-funded common stock warrant from direct offering, net, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r128"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101",
      "r102",
      "r119",
      "r633",
      "r649",
      "r671",
      "r672",
      "r735",
      "r747",
      "r849",
      "r873",
      "r924",
      "r948"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r557"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r557"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r557"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Company's Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r132",
      "r133"
     ]
    },
    "sndx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment charge",
        "totalLabel": "Tangible Asset Impairment Charges, Total",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r122"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r928"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "sndx_TwoThousandAndNineteenPerformanceAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TwoThousandAndNineteenPerformanceAwardsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nineteen performance awards.",
        "label": "Two Thousand And Nineteen Performance Awards [Member]",
        "terseLabel": "2019 Performance Awards"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_TwoThousandAndSevenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TwoThousandAndSevenStockIncentivePlanMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and seven stock incentive plan.",
        "label": "Two Thousand And Seven Stock Incentive Plan [Member]",
        "terseLabel": "2007 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_TwoThousandAndSeventeenPerformanceAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TwoThousandAndSeventeenPerformanceAwardsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and seventeen performance awards.",
        "label": "Two Thousand And Seventeen Performance Awards [Member]",
        "terseLabel": "2017 Performance Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_TwoThousandAndTwentyTwoPerformanceAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TwoThousandAndTwentyTwoPerformanceAwardsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Performance Awards [Member]",
        "label": "Two Thousand And Twenty Two Performance Awards [Member]",
        "documentation": "Two thousand and twenty two performance awards."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_TwoThousandFifteenOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TwoThousandFifteenOmnibusIncentivePlanMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen omnibus incentive plan.",
        "label": "Two Thousand Fifteen Omnibus Incentive Plan [Member]",
        "terseLabel": "2015 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seven and two thousand fifteen stock incentive plan.",
        "label": "Two Thousand Seven And Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2007 and 2015 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_TwoThousandTwentyThreeInducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TwoThousandTwentyThreeInducementIncentivePlanMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Inducement Plan [Member]",
        "label": "Two Thousand Twenty Three Inducement Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Three Inducement Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_TwoThousandTwentyThreePerformanceAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "TwoThousandTwentyThreePerformanceAwardsMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Performance Awards [Member]",
        "documentation": "Two Thousand Twenty Three Performance Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r219",
      "r220",
      "r221",
      "r222",
      "r232",
      "r277",
      "r278",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r431",
      "r432",
      "r433",
      "r461",
      "r462",
      "r463",
      "r464",
      "r472",
      "r473",
      "r474",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r514",
      "r515",
      "r520",
      "r521",
      "r522",
      "r523",
      "r531",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r565",
      "r566",
      "r567",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRevenueExtensibleList",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "terseLabel": "Type of revenue [extensible list]",
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_UCBBiopharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UCBBiopharmaMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Biopharma.",
        "label": "U C B Biopharma [Member]",
        "terseLabel": "UCB Biopharma [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury and Government [Member]",
        "terseLabel": "US Treasury and Federal Bonds [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r727",
      "r944"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r727",
      "r729",
      "r940"
     ]
    },
    "sndx_UcbLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UcbLicenseAgreementMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB license agreement.",
        "label": "Ucb License Agreement [Member]",
        "terseLabel": "UCB License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail": {
       "parentTag": "us-gaap_LoansPayable",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableSummaryOfMaturitiesOfPrincipalObligationsUnderLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefit--end of year",
        "periodStartLabel": "Unrecognized tax benefit--beginning of year",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r450"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfCompanySUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decreases related to prior period positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest or penalties recorded during the period",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized income tax benefits that would affect effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "sndx_UpfrontLicenseFeesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UpfrontLicenseFeesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fees paid.",
        "label": "Upfront License Fees Paid",
        "terseLabel": "Up-front license fee paid"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_UpfrontPaymentAllocatedToEquityPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UpfrontPaymentAllocatedToEquityPurchase",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment allocated to equity purchase.",
        "label": "Upfront Payment Allocated To Equity Purchase",
        "terseLabel": "Up-front payment allocated to equity purchase"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_UpfrontPaymentAllocatedToLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UpfrontPaymentAllocatedToLicenseFee",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment allocated to license fee.",
        "label": "Upfront Payment Allocated To License Fee",
        "terseLabel": "Up-front payment allocated to license fee"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_UpfrontPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UpfrontPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "terseLabel": "Upfront milestone payable"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_UpfrontPaymentsAllocatedToEquityPurchaseFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UpfrontPaymentsAllocatedToEquityPurchaseFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments allocated to equity purchase fair value.",
        "label": "Upfront Payments Allocated To Equity Purchase Fair Value",
        "verboseLabel": "Up-front payment allocated to preferred stock value"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_UpfrontPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UpfrontPaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments received.",
        "label": "Upfront Payments Received",
        "terseLabel": "License agreement upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_UpfrontPaymentsToBeReturnedUponTerminationOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "UpfrontPaymentsToBeReturnedUponTerminationOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments to be returned upon termination of agreement.",
        "label": "Upfront Payments To Be Returned Upon Termination Of Agreement",
        "terseLabel": "Upfront payments returned upon termination of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r147",
      "r148",
      "r151",
      "r152"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ValuationAllowanceMethodologiesAndAssumptions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceMethodologiesAndAssumptions",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Methodologies and Assumptions",
        "terseLabel": "Valuation allowance for deferred tax assets, description",
        "documentation": "Describes the methodologies and assumptions on which the valuation allowance is based for deferred tax assets for which it is more likely than not that all or a portion of the deferred tax asset will not be realized."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "sndx_ValuationTechniqueBlackScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "ValuationTechniqueBlackScholesModelMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique Black Scholes Model.",
        "label": "Valuation Technique Black Scholes Model [Member]",
        "terseLabel": "Black Scholes Model [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureLoanPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "sndx_VitaePharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "VitaePharmaceuticalsIncMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vitae Pharmaceuticals, Inc.",
        "label": "Vitae Pharmaceuticals Inc [Member]",
        "terseLabel": "Vitae Pharmaceuticals Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_WarrantCashlessExerciseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "WarrantCashlessExerciseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant, cashless exercise, amount",
        "label": "Warrant Cashless Exercise Amount",
        "documentation": "Warrant Cashless Exercise Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_WarrantCashlessExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "WarrantCashlessExerciseShares",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant, cashless exercise shares",
        "label": "Warrant Cashless Exercise Shares",
        "documentation": "Warrant Cashless Exercise Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "negatedLabel": "Deemed dividend due to warrant reset",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r366"
     ]
    },
    "sndx_WarrantExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "WarrantExpirationTerm",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant expiration term.",
        "label": "Warrant Expiration Term",
        "terseLabel": "Warrant expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and rights outstanding, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Weighted average expected term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "sndx_WarrantsExercisedPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "WarrantsExercisedPeriod",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised period.",
        "label": "Warrants Exercised Period",
        "terseLabel": "Warrants exercised period"
       }
      }
     },
     "auth_ref": []
    },
    "sndx_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.syndax.com/20231231",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase common stock.",
        "label": "Warrants To Purchase Common Stock [Member]",
        "terseLabel": "Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSignificantUnobservableInputsInFairValueMeasurementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r932",
      "r934",
      "r937"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Shares used in calculating diluted earnings (loss) per share",
        "terseLabel": "Diluted (loss) earnings per share attributable to common stockholders",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r246"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average common shares used in calculating:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.syndax.com/20231231/taxonomy/role/DisclosureLossEarningsPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetail",
      "http://www.syndax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average common shares outstanding",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Basic (loss) earnings per share attributable to common stockholders",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r246"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482804/825-20-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482804/825-20-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//230/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//460/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0000950170-24-021253-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-021253-xbrl.zip
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M#]#0')#D8>>1_!]_85^ Z,@I*LE:B0@.@@CI"(CH"+#U("Y 3A("_!=H^XN
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MV(90I BE-QQ(M[W4B#:\D]; 1$7"?QP<F:>F#R7UE\A T/ S[2^V#0]%@QK
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MYGR^"\1:&<EAAPQT&:4VCW101*SVG0-CCZ G'R"B-96![D882)=*3SX:#,>
MRS)MP^F!@B?R4E-=4PM&<@")L .B-\(#E):>EG5U_TYZQC4&L/M#4+ Q+I3U
MCFR'['Y[(%40(P.@!W%-%'T]D)B0(0SGRM(.)F@[*M$CA) O>-+2I2/OVNKK
M-!S(X*ELTVE@<^ (:M/ITWSFWW-9J.&X,^X:X7ZXURJRMLXA\U+J92$J"5R*
M2P:R7X5# \$Y80?@XI@9T/4 )?0+870$V/81E6):@Q@A!Y1?S+X9N0A(_* 6
MD(1PZTC;:>:R/A(C$:)J]<!GN0< #<0LM2F 9*9MUCP!Y .U6S\>^?-QO\.
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M,;"E![4^0BC=M4=)J$$,7'[K%6Z8%[E<^TH#T$?T'Y56BQ A+!*I"$Q ^?1
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MT[>.V.+!!_ (VR.=GTK-?/#R^RU258=%T;L$VH-K1[D6\-[)ZL;H[;B$+L*
M[_J"]?V3+-Q8T*.[6W_"80YX6'=SSG")6A6@MBW8&"@=I00(;5^S2 =9:>":
MS6?&W!+$K*;_M&I&P*D5"QJR$,=34+O!D@V0#8$/@#$I=S!ZYMN2O84XWAP_
MAM* 4'5@0>_4\>@SSMY2HEIX4ZEF/KHHCW8!0[L1=A19Q;N+%*[97$/,+6W
M?).;@*91F^7^ ""PH(=CBZ9I\-K\76_O(@L']T=<XQM<:YPN4!_5#9&.+=B
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MZ-N:QP] <"H814T.S&9'8&[=VS;']BI<J0$F@NM<.)XBHNWP(4/!31(VP.:
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MM; UH@]84#<CQM@C&\8U3U:T!;<9N>M"QC>.^3Q!(D1":__K[[GO'$4EW]9
M.%;YK.^[:T:)\!(@,U]LTCA@04PGLVX K1[W&7%< *&,.=@PBL]LEAK@4=:9
MM(&4J#G^*8!ACM3_ZY3YUT-T' NZ>_)H]S6;.]&MYE,,#?9/<U[3E[XYQ9OO
M,4"_<5'@\: <JG@Z^+YO'GF_5,NQK/$J<<>*G@+3F1-)42T:R,KNP6]W4.YA
MI.J>N9\JGS:)BJH+CQ(@9O(5U)$#'^-\M75Z8<$D="\//HMGYW]SD<7*L@/Y
M5'!.)]"9[^[)7">V>L4K:(+2::.E9J5NO=EI2W,G_;[3];:3?* ;[G$^EL4E
MA6UMEDM!%>FP7O<TYN<=]%JVU'S>I.<Y2U(SG6*M\]X_]]M@YC\Y>W<!D5'R
ME/_$X69*45F;6$T_RGDSR[00!L9S'>RL<[K4&^H=YV8MV]1]Q;X6NHHTD7N\
M%3K&LB&7K;.BF5[MZ<'6UKCI,O^T_%NQ:?0443TG^^I%;V_?7,O7V>HL?@TU
MG?'7&)4'8T)1)57R4^VF5='#4_O/#XB>GQ$DS!8M%__,X*&^<B((L38FSNED
M$=RP6!)@4&8E\ZCQ(,W\>4)1EV&=A&%=6EBX$U.U<(>QM9'^_@?.>DV<4>S]
MHQ?;8MY^*W-7+6FS/C?8S%M_9*)UNFAZI7N&OWK.6>JS>H[%M[L;\!0SS0(K
MB\EI.R:SAO)29\[.JY9//Y^'+J@^YBR'NEVLG[@.=F_B-#L2Q-L*I/5NE.#J
MA9'FJ^.-SK!\*\L3)4,> <T*H!-"B,NIF9UPF^1C_+J]UT[,(W*SU=I@,9*\
MC!?NW>$M;/!"!3A?5QU>6U)O0;@+65 %J8V8D_:?< 2C3NJ*1G:F-H_;?1)"
M'9FU"2F1[4)M2!7(;^9\\.3[\-F?CQI#^%R<QOK412?/$P-WZ)?YW6)@I^@6
MT"CM=8O1-?>J^\\0;XOF..]E7?[.F>E\LM7\F9P<4?Y!KQCHPYO:.CWA'C?9
MW1?3I$P0[\.LT?;%L5,GE#[E#_)I<M]@8&?ON JL0Y!G1A@^,TOG4_G<R,;A
MJLA:;&)<>O?:F:XH9YGCL%B90T/L[""IYJOK9/4)D#-S-,N/E^.N 1#08HM9
M 5_^4G5JHF#Y>*]HY.RHOXS8J=%NZ%0NP^>UFVN6B\OY3B[T$S$Q]N@!HV?1
M@^P'.E]*>^P;RV>,<1O69GH_-//5_;A#1M@W7CEBXWO'39YTIDC!5EPM&^7$
M&,[KE?1PQL7\J3R^F(5OW!+XD7G)@,Q[T&6GP0!R8^K$M1%(&$0/^:32SOU$
M3* ,50C,0CB<263*FXRT\HSJ\SG5#6X#KUP,_9FU]( Q!_Z(T;.D3J=7JM\,
MW'VW"'/WW*!-R4+1PKD<93D/S;:_O=[5Y?;EN]+EVJ0(0<@]GZ7[-6E3^A4?
MII@6\N#7&]>:NO(;WV!J IZ@2F-UOTEGY1G->0:G/6?*SK.0'AUY2T\]EF>S
M&J"&_F3P7;^TU/X[4K714744IF_4F'NV2V76JMXY6,!J0'Q<'[:.B<B5$@M*
M<;GZMD-EK8'C$L=AAS9+U#WW&1OE)PO7XNA<N96^6'+DD!6(U-2%,5I[E=;-
M^/F!7=\<H%:-OX8\N333RO^U=U/GS7_(QM3_J%A/_M&H 78<WC9CN<L=SVX+
MSP"7PY?&O>SUYY^ST[U$"3VKF#OZ>#!.'!C::Z%^U^K)PON]3RI)Q&8U'Y.K
MCM[08K>*>CXP>_(FLM)JP]-/,&S1.'8M/T_@EC"_4H]E%-]8E45+/2MT0U(3
MEM77S [W>SC//&TA<P$^[4OGYSRYFAMK9*+ *=IZN*#Z+2D*QK>I4/* P6#
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M"@-L(FT9PSF(&9K<19:JW&Q7\;=*NX]:/]8<@38'IV)! T?0[=:)5-"9\T"
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M[RTNF@ ?,2NGC<\5FUDDS[SINHU> M]#@'V+G.O[-6TD+ZU*6\V+O3*.*EI
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M(KO7#:V]^%7#%TQG_@QXY3&?XRXU#:-C#<('@@5M=EL!/KRS!;2O);YY691
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MD@G #I$R[P%/ZBTD;@Y!.\(Q9)BH0_X&ND'UH+8UNIVY\Q6H8*[4PRM,W6&
M%X Z ;A*#P(%,GQ4PK36.P#(+!_AD-'+\2R,(_+M:O96P'/7@ RNWS)P2NZH
MTA< )5/Q'"B9C]?R@?+R=OY-6F:6$Y5\0?>JI4&D_KJ$^E&G]GL%E7?4(.ZS
M38*UTAEIVQNX@DI51YZ6*WOKZ1CYI%OBPL2^/]!N"-9D#DW2]X[0IZR*&B,6
MJA4O&D8%LZ?F*P(:[&'03O/@C\!/@B4<XP#=ZQ04T_E!]RG,V >@<&>+(A:A
MB#R[_+T5ZSU_!:2:@!IZIQ3=P+'\4L%H-QCEBC]ZT!39K09TNK6EW37S\*9#
MJZR!*G<H]R#4;QE7=%830,/>:&7M!>J;-@2\.32]20H%<D /<V":ZW< %_UB
M^H=,2 PMA+/8K25V49QN\$(B1R4MU NH(ZU]%X?-F/5=";X4*>"/FX6Q-OM<
MLVVQ)'21B_(IJKA.6BSQ"'V//]?H?M;1ET>&*I[LW93?UFNA=6!]$:M=1&_%
MJ]1=E&UQY9.HY5.H\[NV!SS_X,+'*C]QB=B7JI$B+G&S JU*CA9_>"A?'AW!
ME7^?>Q__"].O:WK_JR\0^W5-[W]'^G5-[S]+OZ[I_3=-O[KK7]WU_\;TJ[O^
MU5W_+TR_NNM?W?7_QO2KN_[57?]WI2D>L-\^;]34ZZV+*:]&!)?'3@X16;?;
M4[:C78Q#[1WI3YQMK#^_Y.6_MRW$8SU%1VRF>\,>"J<*+KICB[[0N9F=FCPS
M@B&KZ=0OLZ+A<Z%?./[PRT5YT8MX9>:=-)\UD!W$9X0K&Q<?G@PQ,&UN%WQ/
M.62><+XHCM?P[BDFU'M;7>=\:,N'A9K5=(RGN:9=#71Y=A!S,L9CFUDV2R]+
M.*_,S\W*@"(@JB[M5& ;\T.TQ52Y]2>U(%UHBYTOIK0%W6 @QZRLZ"J(N;V5
MSNR !7'UY^>OV VKE55&7_;&TQB9()C(\^ T;>&2-#%P=,MZHCM^7 V\?F4#
M2H(<ED,4V0AH";+*%4U?0ICW%(T3+5"*/U==UQC.$ <57IE9'^F38!:5UW&@
MCE$(M>IM0PS4LU'5#] 9EQC[S&.<FB46"Z?I+JHCN60I=M_)LI"?+A8RB2DC
M]TUNRF3<(A&EJ9W'NY$"CG >:&+@<[%,U#])Z]9<$ZL?/FOC[S^:__%2WFBG
M&&+@Q8J08JIDQF#V=4N1)7LZS=ZRTJ#^T?E7DR2&,>LUSQW/(1VUJA'MT]0^
M-R74MVENY95,51</F3R'P9_5=%N)^M\0F,]5<7&(R-S^',,77K1OM5 S(S<9
M[%>NY@_WVQH6=.Z6>IUITDC<LY%=S;G>%^QUQ7N-+3VQ_98B.=< V?0XX59F
MI> Z"RM_(L=U\\M8T#-V\RSDY]9"TX_(STQW;!<J52, )\0$=9?,D0Z_2HL9
MMBJ?RT VF-71UY5GXA]$Y 4HK3<D1$S:#UBRL1]G='36MJ0V3GR4XV0F=3G0
MJ)#]-N@Q#91EOIHSQWSB8B7\_NM;0S<$5'DH-1G[/(R4M-OU2K[8CU&NL_GZ
MVZ76O+4:?7<I4\A?X3PR;+AV2-:,PEJ:X5&$0]- N/^ZPLD1731?S;M(1XY4
M,X(RX5?33/EE>:BIT7I'71#7W0^ALR\]1> P33,N[0H^JR9E%MJM,F"H(0IL
MPX*HAS6<+ <TY406IUA#"!I(3OBX0UGFV#WX(,5FN=9)9M9XMTYX;NKH/4OR
MMSH&N:+>U11RZU'"7&E-(&\Q8D'3.NCDI]@$APR:C%G_W.6A)7V(B(N9 KQ=
MT"J@/TI)(ON-F7_^2WY%_RUUH_-WPD"WC?#QX49?(LE][[Z[VD^]=ZKCPT&7
MY@3H!MX)<7F=,%(M!V.BJFE"BKK0\ S=!NJGAA):9R!"K%/#Q!3J+8X/\^@#
M=VC&X)(-M*3=EKD\A/).9TJNC-WAB\O8<R68KL:7*L:0]<Y\R;116) _&P#C
M%^[*F5Y-IUV@&7^!-H<Y0<)8HX7:HE!O+^]U3FI00AMH6!9W!,V'M0+Y4V^)
MV3^E+-/S[3>HQ_#U;<>+WUTZ]GJ2Z"9>/WW23E[-%(<O&P_':6VID"O:=XY)
M++XYZ\^0(L?N[E+#ZJ=I8QT,0W<D8$'J/5L58/C8J.29"\V.M_#*1L]/B?A-
M$5IL5>!!&.[+(T256*D^\!97\R)X_!=1LTZ<%80O0^2YM.>\C*P>K>?-C?4S
M^C/ZO5>YL,J2(LT2%%?9/%?%Q]B#7G8U$G5VMGIDMLNGE'/_39L@]9$'?7*R
M\B5]CPT+RY3TP]= UMJK!Z=5J],)'=>A$C[&LEJ"V9][)V%>)\3M::G6=:.F
M L1$$F_H5PHY[[W:ITP8O]W-C3I_1I5WB>1!F,%%^I&IROSWH2O(LEPLR#BD
MW*;0,WO7]IG_V-GGP_Y?\FV,[(F@"O5+\'&_'8&KY7;!RQ7#%2$5[T!XL&Z1
MJPL"D6^*^6XHI&N7U3;9/Y6S+CGW@;BQ?>!,5H+,QJC(MN2ZB#M8H[_(E>U4
MLKN<<=L%GY,7IKD7[MQ4[M$CF5V7L[#:$,XA>4]B0WPE,OMS2M.CH]*[]694
M2_[OU.'&#*MYI(KBEW]_7-(_/4+(]4%O?ZMP]D??-SG,<G?\K=X-OGB>[O?*
M8*30WI4P>4[RXM::NIK(Y5 _DFO'>ON%>EJ$O&?TI3.6_--8;)!VDN[49R[E
M"VM8;\N6\&^^=B?D0MU9PW@PH!?A9)V=[/.:L!-=Y- B=BQH?DJA(WCE=,T>
M,GPSJU>QDWUZY\ER 'B( KJYSC0ON>,]CD9+[_6979N/>O(_G4+WC2)]D.2,
M!8'/>=CKAD4)5?@6^AJJ8SY58D&)?F !<!$'&&=TMJ)L@D[3\N0@.;C("CP_
MI] 1CI+8Q'@8HA>K&*DW5L$F1,WO#E)P@FY"QY6AIF/0SH^)NWVJJ;"O3O)[
M5)XP2"#&FAQY_4["?&8Z%@31Q9U3A^/A?E4V4QZQ/+%M6G@ <\6)P(+&E6ED
M=C$>0*=5G95+6C8[(APG>*5S)V(-?2"+!;DK02%CN+-B:G;[5)*#G!WI"GP-
M-3 ]50#J3.A:%KAHK69^40^UF-6M-!]EC;KF()Z_(KBVMQ^%V4_%]%1_8\N6
MEAU2*#UX!8X@KX%S?,T1CE)"83Q@AWH9.2 BTSOW,2J[.#KNO!J (7A%=FT/
M!0C*>J6T$[ZJ5I".SEYE@YKI 7A& #Q,.T"+0A\ /:V[BB8D!:<@ CRK9VV+
M4L6",!ZS@.1,,-P*D+:* ZA$J=OMWK2<B06QH *@0R58T.8NQ\&V]$%N!K1S
M9'RW3SD5ML(T&CSX (!! 8;#B?=0L8 5 L5)@*=LH>,J\B'= (ZZGQC0. 9,
M?R]X?L,*M9C9)5F4Z*#V#H>3'6J^2+>YQX=3D \HF $4//BJX'//U_S;O^4?
MZ(5^S=^-L[-I&7((,7%H/QB-D3LL@\=FX$-9R@O,KM*[!CO<6%"$>\-K>ZHV
M.U;"CR]@ 23I%YEP9?V=,0.V<K7\7;GR6!XK@ 7W&'6(I3 3VKD,8%'B5EPQ
M^0T+M-B>8^_@$,M@;\W\#@X+I8QNO_OG@T"<1QU1)DI 20[6  7^&VL6]ZNJ
M'-0[%"6TM7IJ=Z<?4 XNQ%6GQ&'-1#2F'5<J+!#8#R4UQ7#P'B81LY^",G\
M2%O @M:RDL1I^Z$? 9.A@,7CPRZ):"Q(X=!D"S/HY@$8L 3"[*H!!%ET;V&
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MK9^8BYVLR#]E-ER)9%)@#%YGM]431=K4NG.)P@O+"!C]CA;WA,8!TT)&]"W
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M*6Z8*3\+2M,3/E":<7.C5V'8#9CI8$I%2[@^>.V0>2ISQL'T20E:T$(R*]O
MPJ5PS?+MM/JP5*N@2W.5X$3EAS:(:2:\D)KX*SWHG'Y,-00&VV$OV; *AX:U
M#$\:(AO42_IX+#M?%FD\'?L4\XTL<$?"S.1N+<,;X:U<$OT&E[K'_BEIV21W
MQS7I%:V(10@3TQRU>Y1<4L;N4-R#WVL_X]K&4"HHF [?/CP,C"WI\Y9]@[PF
M4]L_73KX-JWJXF#OGLFH1$XM\D6@)Z/#2;_S*R4 D18*DAA?(V/BM.!%G?P9
ML92H"PI"HGW6)8D7EVGHA+2U$%<>O<G?$-ZXN@BNW$E9;>;-X%V"(J\.5*96
M3>X6QGT[#$7*TNS+1UH^9].2.P=TC6K+5232P@)>I'<T\M/)>T2T+K4RPJN@
MU$B@ZB"M<IS2&Y  ]27T)VNZ)P4K#'35KB6M.\B4:\,QSO.C/M4W8JLC3?>5
M>*-VH4XP,D6Y-IXL6'S9X3IF*O$B;)86]]R-%0T%PW.6/IY1:>B@(TL8")U>
MN[:A4U06V*M1XA!@U1ER6F= 7=NWP8HRC-S>^&79!S>AX$F]+N' B')-%(V@
M"R.X?P&MR;%R$%7G^Z1Z[R-DW%U&-'1.U?/NP(>/'POALV$QG8XFI8KTV3+N
M:J[N'4VQ=^,/*'S"9;X4'15<GQVL+7OEY3#=)B@A0UWS-C*O@ICV^>V9<L$,
MGD )7I<CK]:XY=GRTIC=[<H.I+Y^'Q?:AB<QHYI(,17B;=;^;!PP7\I3"KYH
MC(3/R/9MI)0%BISRB;TZ%A$XL*D=\+0_.*KY?5A:9\WR0O*<U*R&^Y. S(89
M_6"C:9'!<U9:DHRLSO:NV:_5D%6L6 #@77IIJ#XTXJ9 K6)35?+X2'X6L8,>
M)??M9Q=GQ(F=EPR%?7:K\USN*+ZN)YYZI_OLDXC(DHH9S>F]1*=L>=M,RF^,
MO"3O9V-C/AVPK/LEQUD,@&(\A"B*;LH+"L39UI07'1Y$PXO+MR%+!6@"YFF>
M4BO+/5'++?Y7IKK&YM$HJ<]+NAB2P9(5&ZJQ)6>>R<?OQ ?&_&2FW1T,!:,#
MW'A?\Y0JR; %R2GHH3\7O;B04BZ0P(+8;5I;C_=(3[60*)D:,^69H\_,6!_N
MR-O8'CW8/I<SSI.(6"";]N)1G*1;'GE/X-09]9[W+$,E,TIKX973B6F2\RT*
M/AB/4M1'=ZL5?1HM/R_&5X*<AU]3=*RMX((CJ-G+L5\0Y<\W=N+MMSQ:=+DC
M(\R$"<J='>XJM/-:L&Z73<9,LPJ-)AK6&3*VMO5=4P2?-A_D"RL; =T!-$NJ
M650C0M&!>D^/;/469/T%'Q=MGKI+76[XA6',+?Z.@<-2IRYB>-,[T<3DH4O*
M\'4^-MDPZZ([NTTBJS-SC)_-32/FP>7""TG#O;+F[#3_+^58NA*[%RZ8QZ-X
MP]ZGF9^C^9VIP!K_Q!>^A^=/M6T$EH,$5G-OY/?=Q@(N0:JB"\\6EKO.E+P)
M%=Q_^&DO+TY,H[@D9()OZT,3&'1N6,=&!3</_ MB($#5^M3VN$*NTY.H(*#H
MYS=^GH%D!RD$@@N'7KU/>A69,O9MH2QZY&XX._7&BJJVDQV$!&X5=F)_0R=&
MDMXR@B#(G68FZT6D4TB&%YWG]3R)*SX@8R^&7=*+Q5ZG;QWR'&*\4M$YB<.=
MCJ(#YC9KU^(I''[<S,1TX#?>(4 .HRZO@#4(%L!_V.ZHV;U:O8':B]A*^05M
MSV&583!QF[<F V3PDP18M %;& &WASZ5_/S_+&F:O#:TJ "V, ANCSCDP %-
M?PO$\6V'X?CJXOD68 %XM)CBQ"= "S J9D(M?6!C-0[WM'8CME(Q;3\0<3WU
M]B@/.&_LIA!> #6=Q *Z<Q.C6/>4D[  R7!OC=KWAWR'YM O=5O!+#KE1975
M06TV1*U)@>$I2?0@Q:.P3&AW:F(4[U/A;)#H1^4NN10Y\_T]F6-BC ;49)EQ
M>XEU3A8G!,,(7L8DD!&FI1^Z #?&-8!1%2>#//2[#*5X&63"<6*;+ .WEWCG
MY(^",W'2O(=%,;3_ K][##<';B_PSLGN":7AJK'':-1&_I!Q6S*\!%CHQ(O:
MCL$UL:D?MM!EW!Y3E+A5>&ANC <'PHY>9T'Q/!F_5L6@41THM3UUC)9V>1JZ
M8^/64GH)M% 0B-K"4S?VXSJPW;@]]#%P#FKKX7Y,_V8P8.]&!JY6-5SC'BY#
MM^=XYQ2'-3#:^Z2C<,SC_7?]42E' ?C]^4@8KA,9LKZCUD:!<3R.:GEQ34A4
M$DP["LB&=D=.XC H\1CJWK_%<+]EEL>XRJV.\7R"S@)^+ 6C-N.V4HXKH5A;
M@O(?]L;+ZQE_%<U (SM1:M 'R[#M&>$YQ:_]/Z5($0HO@7UT,L83IF(^#T 7
MFFW:8PJST 7KC(/L> YQ\GK0KS0%/SB83VY/_<*!\#O".Y!A.=QFO3>!2/>Z
MYJ,7F8NRJFI8P"^8PQH>H*,FT9V(XO##+U6<8 S9D3[&\P9.W"G& =A"O4U[
MJ(DZRGB,42<%O;(A\S U#XB4W;5!(7 -P9"M&1_C>M DMF.FZPIE44,3054*
MN.Y^X:&-4XAS, XP4K84>D"($VY/$!AUU'#0Q+A@[,Z_1&*.!=2+X;>\)6W:
M(S!DX\88GVV,QC&G;S^0,O-PU$XXZFY<T^K%<J$]DM"?C6?# D0/>V/D]6"(
M$ O&'=+$+?R>OH,.%O#!$PN(XC71QDD-S.W%..VG<(270J?H!H&+], Y>2S@
M[$0Q%G!G"0O@,&HNV()5%/P&BW80BL>213.[=Q\19.#:=A[6CIDZ>A*Z75![
M12 J[[?D8*1,:>(!(1BENLJ!!7 >!NS& KOJ=DQ[+/0Q9'D6&)\^C$8B(MC"
M>.="XE;:[W'@-(,X>2WT\)DVL8#]3B9$5RF.[3!>JGJ\5)+%TOCNC%48PN$]
M_8G'BF86G3PB>(H;+2B@44=-7D\"\)+=B+4PP9 %VV!\BC$:DT@90=C!F6XL
MP!-^C-5P,$"*[U&V/.AWD %T4I!N@GY@;<KM<=^"7,_CMR& U$5-G-:0/#*K
M)3]^C .A#>Y?"G/#EOJ*;K:_$0UT05\[6#@BX %NQ'Z7$*K[H6[DL#=47I\1
M\7HE<8<8?^   IRB' (N7K'[6?D7J%X27G<D6"RA]=SYT![^&0P*ISQ6+AB?
M&,;]3D;M'-P3?;B;S8CK%Q.X5@OZVLC&T<EU7#W *8HAZ"+5,:^#6N,YJ /G
MB@8PWFNQ);GL-[#C-*75N-ZK#CV<#\T9P#7CYO<6\RWFA2)!3I,'I\>@D_B$
MI/DXC>/!U[^\BQ=-LO2XD]TY<9UGB)/'!2\/(G %MD.$;XS9]TI)\U3P"L(0
M^!6?'-40]R@,6XZV\6E5?\@I68#7MH;_--GZPUQE]<,^#EYFK>86#,C%=!R^
MV'1U*L"]5P%JHZ-*3FPAU,-?$YYI/\Y BU5'^1I^R8P?.D6SME-PX2N$[13?
M22Q@PEK)>6HK>X!^(5E\S,@M(#E/:1OXJ1$1\R)&"51=K3)TRA98;7BF%@NX
M2KMQ,#V0\C,]IG9/_0NV7MOGBYZ1FX)\(GYJ*8.+?^0:D#>%2$DX]@T(BS)4
M^-@J >*FD#%1I10\'T@A>X>]_]]OP/V[RC^1+/-/)VDEP]6@V7+DU8G?#SQZ
MX"J+D=)F_#7+;./_.,DL+^K,&!8P- OK*E_YO:.7!M _Y+WQYMR?%/\)TA<#
M.L3K79INW54L(,P;?^H'!/8YH.G!<'EISRNF0EL9NH]W+DH5?^/E!<'G3MOL
M^'.;:Q3QOYPO,AMT_JGY%)*$BQ:RR,+=/SQBA/>Z^0\Y8?3_:_DKL?'?*W\E
M-OY/+7^-U7^-U?_;RE]C]5]C]?_&\M=8_==8_;^M_#56_S56_]N*J8%KBG1)
M?Y]21?^WD-TN2DH@7Q[1:%1Q4<)4*Q'-+8?56\:"YD*Q_K5NT!F=^#)]0_^@
M$P-VL56J:O%IR?H87[M]Z_)%K]NZ$:ZO97UUE&X8WB7O9SQMU88*<<L49\^Y
M43K5(=;TX$MO,/[000RN'VW=;0ZSL( /L56.!=K#'<7HTT0*[S.&#?:J.FTN
M0MBS@[D+IJ@:+UWM[O31D_Y00%>#!80OD1[91: "NV+G,Y,/)K<(4^FJ&1KE
M"%C3'/8G;B/JW@E'>>2-2-VP*QV-G:YC1?H?>*EUUX]H-+-O4!/:];/GQ=-.
M:?D\-4VT"-2/BU:=%P^G7*B[I7S3H&9K],.<*<H]WCHN'Q);;]-7\*C26*?+
M;*"T\Y94Z:%6E@=%ZA6B.FF?"'CE&O/41-R'E:S,I2(PS7;5C:BWC UI]E &
M O"'$=T/+'/O3H9Z?4W*W ;)YDB=&G61 (/[<W?U[U455LA_LXL*NR"5P]4>
MJ!L"6+9HE3R_'#$J[3)U.-_45!V?[<&6WSTM627 2SBA$/QJ]FZAEVN&46)Q
M5$K>'BI"8=OY27[\="V1=DUX'WB >YV'6<2UMT@J2S"4;/'@).?RR NAP$G'
M=KM8!/!%C^$2].)]X0>Y,01?KNZW=CIA ;0I\J:]*7:1D#=DJP9:46R9763@
MZ8_JGO#P-8RVF#%2M^X\;IH+;\$< J?T+[M&R)3#A]1C5'VX=$R5P>V@!R.N
M1/4;%F1"8>&RF;G@UUHJ.IYBT1/#0HW9=QC]'DN"DM=A?'T&:PRO3: 667IY
MG9%+XB3[AJ1G4OI+]4D8^L?-J51'[YP]/2MR18*SL8X*Z;]?'V-K5M7V$.*8
ME#=K_2S!H@Q9_QE]?C7C:L<5PLV<',5P"+?Z0]G)&$[1CF[R17?O=Y1I+EFC
M#8]YA.ZWS%D>:&FCN29/0WO:3+  KT1$-H:ZU]()!H!<-*YG";I[EG#9PA=9
M.J7$*-=GR=#>+],M.<A<T20IEUW7N5\H,"E.7I/O+FY\29Q6((?.FZGHJ<DS
M@@2HPE+OX#WMN^<_MC)7Y O+(*@"XA2*W@^3WFP, M/;<A8%4[(-D#_4>*"A
M)&7VG+O6G6QL7.HID9(=1PO-[I-%#A(QK8\#R1!+GI2*8&4BIM8S%06T2);2
MJ)I^'J=S+\CNKKYI7GWO$_:>P8+VFS[*F[J?B(\CAC7Z]MJ]JVG*ZC:/%BC#
M+6I#P?V"BO0W2"4QRV*NL)J%DYE+"3P(3+%P1/IRV1 _U%FHK>!F[]KD-&]H
MP7S_]8A#R4]K<E&MQ-(4$IQ/6R;.%!?WAN2DY(P:CDS%=#PZ<> CR_4@IF0%
M>;HR=8I^:-[=[>I)^4]T@YXT>U$.GH,JDW?W.?>3"<,,E./IAQK!!#JPT=B!
M5@;G>BD1"7[.,(1_&*7?IO=T_;G'KO ;\_)$EUMWLX-YO>K!FM!/<9B->*C>
MUWV]<Y_:ED!/+:HLE@_N[:E^Z2GQI>U_(SNGPQ\5UY_B-0,E7HIA *V76IRJ
M;&ZQMC#J.AA2*==_+1]N]M94-('$KLSX/%K"RK1-W+Z;DZ!*GH7+82TAJLU3
MPJW$^)4>+& M+5Q)5.A1]?NRL1,^G3;4,MJ![FEV"LOB*R;#+%%,P:EASY.#
MPCVT)7@;2<\U..RY":X(QHE\U9FOV6]R]]L/]K1C].?*9Z 5D;/PORNU(QZX
MRH34GGJ["BH>59@-C95FX@(/Y=U_%*F1UF]?%,.K7E!24U[G\Z3TW>-75?P[
M@A(.=52(*)A?]+28;IJKZ=7L-B8K6+RC)K\J>/QK%'XRU@CZV]A1GWZ_)?_[
MK-B5Z7+,_'*?3NCT.*=1'M+KE$Q<@[A<SXY8UBI#D7*L[W0Z[!_TEQ.K,9<!
M!XM>4]Y^)+\OV*U.'?U&5HFNMM0]I$49<ZU,O=%Z4AIG*KR(GL2XRJ,"Y\UR
M)<LUEG7.2X3$82[I0U%3K/B8U;^"4U:</$*7R<7HA='7R[" [7HP/C[V.6X8
M&A&Q3?&E5W9P>9\T4V75<1(1/HH%=)\#\LG^Q-2^!6+4SQF33)(N[(/6*]I@
M >+7T4V,/S$-.LF]K ML#_PNM"C]9$K^*Z:#@.IN56W#[ZM7@]8K_0+7Z%/$
MR1?0S^8L"D7*KV$!"R\2W^(W#!-^R,].PILWL [,5%E#QLNB62A_LE#_P<)^
M/CPT7W,=N'I #[N,SY:0/GI,"48JY,$6)G!MX(*4U%5J5V !Q8O.:.4"S*5J
M&]0^3LQ$1-0HM+L&]C9?[0W\8,YH!M.5-+HIVHU4Y,81&N,KT;?" B2W,(\J
M116,#?/&H,-?O2=?#6(!/P$1F$LK.&XQVQ2ML=***Z75H8?"I*.;PHY*SO0\
M77*FK\9J-JYR>/!UFN&(C"U^<".0,S<)RJ$P[61]EJ2FK*8'N_41)WC]$,8K
M#=W$BKXA!-M>XYWG#$V/A1KEC26N?@':-*["IOA*\2<:H'SRN*Z.*D ?*J("
M9R DO 5:N-;7".-0L("I6[_!B?^!0\+"6S#T V<-."50\BM*7@;ZH!,5.-TI
MT+M[<-1R%.6/Z^=R](VRQ.T5X7EVX)00'ED7QF>@Q)1VE&0,^P9<S<6SP54E
M_ .$YU/[@P_N<:V=/\("3F !IE,>WJPX*_-<4^(Q#(Q4ML0?F+#YHDT,88>:
M:6\@20]9B48WQ0I^0G!=[O04UTG%WH\JU.45#V5@T$_086JCR5?X<^LN>%"$
M-Z[3+U<#43MQVQ3U-)"40UFR203CG@Q5^;0+#)&@B]/,U,EC'=KKQGC=0#?9
M:OC'[(4PP[YI[TE2%1\.3T+K/1[_Y+3"B]I)W*;X%*M@/*(3@@4\@YI,B7ES
M;> :""S"'Y[  HY;>!2#/@"C K^1",7L11\S$[J,8[8(1'SD@BUT0?&R?\83
MW,81&'G)F6'Z&EW0A$?!+U8Q>^Y4:"Y.7M1V(E[K/N8>XVLGP-5^X+Q^@='>
M+R[L]32Q2-?K)(^&5[I-J&B$!#GH&2,^KD*/L>/5-%KX&T&ZP$^5<]2Z;>V*
MVO/NO&@N1<8?7 LM?^#1* !+^21PCP#ZZ $6$'6TNF.#U"D#;L\!\<_3!)^'
M(A*?O/AV>JSQR-L$7(NQ@,*;T':<E+)H+@]2U-9W?JO A78<OS@X#;#43N+X
MD3[\]IUA(E*7DG%[S@X5")PR_0KMCFJ9Y^Q48N%=,P#CGM=75]XYJ(<$)X92
M*0"-,L#W,J7F]ZN:_CX(U'RZ&D. J?\,Y3P<7DI$%.$K.HX>WX%["Q(Y0[]H
MOU.5W2OCQ.L:%]46K#8!-WP2\31@///Q8Q-7-4[$"G236Q0YK+30$ L 8#Y_
MYP7[>[P8OXH<BR6,H33\+DPH4M?Y>RNV.=@P@TTN:()#PM/H@HVG^&0POS!0
M_;5NH\<@QI&O^7@=>? -AN^(R9\L@%./?W3$E\R40WV*203I*MW?"@\.G99Y
MO^9KP7\8SMFQF'&4]VH#2=!J:Y@XT6U6N/DDPO/NZU19"8I0P;+<_*3(60;_
M.B^MQ[?5I';/E.^ *8TA_!SOB-\L1%F#YRW*2=^/CQ2A4CJ;;-=B!,]YOEN-
M^KDX4B\)?C2J4W+YS@RPL?9S^L^/ JOM=O&L;+5<GKLB"O&NS0J=@JCPI=^$
MEU.# V=)GWX_'3Q2X<G65=#R)U?G6L[_S<[R]S4;(V[-1OK;8\@IOWHI]4\A
MDC0QU__D@NW_;F$X#7";Q*UK+\8SU^=9$3&6C-W4U)Q]HTQBZ\X:E">P0<#C
M=^.5^Y>>U;"Z+^CW3DN&#(7IDZXYTZ4E#L/WJ[Q>/KKNR*2#D!5<\;E##7A4
M%LH%T3.V,(X!;].E;:36=<]WTR'9"]:%JZ[G7'],W48CER:G9GN&1*K@.:SD
MS-LO-]/4(_K68^&;/*'0%$^%OMT\H1'=J^^B>$Z9@^DBWFO%-#*>7:9IC!9=
M#_HL2&23"!'IIN<$:8DC\L8%T%7G>(PA2DYZGKL2U(X4,^7W@"URS]^'$;]K
ML0;I&K^<X @<7;69RE):I'5Y.?ET2-#ED]'%_B&CRDT96(G1V%/3!PL/F,,.
M--0#N%!S1;#NNZ98@//,P/N]*N^.31C8(X&L_@5KAMXN\-*H^7ZL4>>E[=4A
MUI1GI-OYT&DJG]1- 96))3A*-+YP_/("O2CQ$! R4T!E9LN=D#.%XF'@*U$\
M*;;>DJ>POR3#Z8H%Q+?;E<JJXE8R_K?T=3?+?&:XQ90&!"/$A4_-.?/:I!D@
M878P?<1:QO4V+JMG$G2:KESB2C-@ZF'S?5%+9ZW!1L1L#MTA#6QF3?3@</K"
MLT>E"7*/I.M =S6][?H'^U<7%&.'JF&+/(^I;CO.H2W5-UFJD8K3/.]RZJNM
M\@O),SZT"0H'69,&B3NE+$:OU0W>T)UO4<I-U3;<9+UCY5 ?D<L74_GLRK5/
M"[9TCRIM?!/H^KG#%[0'KX59CWN^83&X2+ZI*B/?$FO\" L(^2R6.>Z59K.-
M)A[-5'ZWV=6D8N67K#%3=RG/T_9EE\#+J':J*/*;:S%T P642S$P1,E.')+[
MJ:L4T^R]ZQ<D(+ K7 7KS/!TW-I\MGYQM3#).HC47#6&/WE2UJ8R%MK1IH^"
MWEV/08QJ^ZWEZS>Y\ 1*4W^1)AQ)1S;Z P.VDJR:-)Y[N69?]%0=>.3#+$D-
M0\D 9\:7H8R=T&EC_PTN/<\5,=_#-P$N8(78=AOMTJ%Y$"T[YX9-#Z_GU80;
M2)='FYXQ'^\57 ZI_)3/J;OIL9Q(^K1W]Y*Z:DFLP(,Q2MJ<$4]FXC>N1NWL
M*:9VEY[GWI0]6=,PO=!0R;-^60_^X&EDQ79*L+U^;&\;1Q?_</6!&"9)^MOK
MY9B=4#D$%?KE ?C(EO'+T)7-<HR4J,V1)Q:@L%9#=JIL@@0^%2L4<N_%&2WJ
MJ[-#+)NOP37] IT25MQI\=$SUV52OSV*3#Q4@TXPDZ)Y#YTPLFXIX56GPPBN
MZR<18$YR^E8A?:9;K5-#>,_++.;>L1$)"FVO/J*GD:!IHU<H^O3,]^L:A7N1
M=9_5LBCTI*PPR]%@VC?%N.I150L[EI28EW1K(N)/*AA]SW=_6S/4WK@RRACE
M'EU-V_'!N(4FVKG<EOR"_(A%-^;\TE"LMP^4?BWWXRV#<$H0AUP3A$@A7J.D
M-EB_E 5S70-Y^QKW7J5URV7NQA>A5KN3R'J-@/K];J83GL6#%?3@.X.>%-/#
M3FN7Q@R&#4VZ7SR5D!<AF$@:$H22(;=.P2T=*W/74IF[PAU-1?8Z.<+VVNQW
MY8'7'D3=+MNK[2SP5:UR%30,:%^+0G<^6()M&6P 5R+P9DC2U!HE/8%T6=\'
MQNN<@=MYP/MUX*!][6#(S3*^BDN18F#F6KW8:*8VJZ>H*TUZ+V)V*WM=4YI&
M,,%9KZV$I12_.OO.7SF_O00O0,HVZI55W<#TP[4^?:"UG2LV!#UTK=:L[JV1
M<' QL6#IK"]HHV&_GEC_44U!J'0XQ:!37YJJ)4%(Z?Q7'9U0H%H%BCGX=K-K
M6XMR*6%#-Z&!65F$N7N<S0"OI!MX7Y[Z6LU"_4A:4W2>4&G>HFC:8!I3JXEY
MX]4]P>4$^LV&E:J885JYNE):19O8DSFHV&%XY%7X^#H6<.]^FLLLC&IL&PL@
M@":A30;A"W,0J>%J6*?1E!%D)I%@^;+%161HPWH6] P1D\B%TVJAT[*!#X+T
MNJ?>Z:V25$<+LX'S(<)K)K3647F+&NO+MQV?YJH:)/I:>RJZ\_"4+C[RN?[9
MGVTL/F4SOZ@HTLWP'?L8;ID7]K=?]>CV7[R]\5KL\J<J_$(O6S0_><B!0OWE
MT#,.>O[%SU-M8<I$XU^ F\L91IH*!</-1(4;ZA]J:Y8E#W#$!BT/_F@655<2
MC84 (OWQWL'^X9%P-38%*Y$^",DYO)/RL>=\*E_Z&WBLM%P2"5.:@'^JF0(D
M0UWIV@L!_T@XS7<O>]!92/I[2(D_/N6I?]AW!RD3I6.W91+\7[6+<!IU)8%
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M;V\+.<0.)K]8/:V[,\H9]S(C=D0XFNSE> #G3EH<N*2R(L0M;\;-A%KV8?M
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M73O>OU-?;ARE%3CDDEO#Q527;IEKTNM88\&5Q0N/[CGO4L<Y &ML9->Y:YG
MJQ2>4D%W"J&N5PMV;<9LOGA27&%^X%$1KO9(#?YXIM*A1F;&4(I#N3K\#$"
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M1PJ?^ HY@"%]='%N:HAN"DJNMY*M':@>:C12[WBG\=P['F8&1C^JQ%>7/4C
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M":7W\9"OB[F+YOB(%%K%";*_<;4JCZJ*C)JZ^9@B.E0G4:WA$/:>.N[1#'#
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MC47*N2I#M?2*R:_Q@YV^IF->3\1#^U?0^F7^#?+T 317+[3TFNW!+^]"& @
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MZW/Y"T*EF<5SF'JI4&)+OEE4TK3 R'KANV&IN1/3\(2@H33?MC \I90G:XD
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MSB]=5?<Q']#+>CUCF\(M@R$'+ARNJN]IQ[?P5),:-?VX%BMI<[C[33_ZU"4
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MZ??<%;6-\]M*VL@[K#H;^R\_W2_6V&S7^68SFF2N0Z%+H=.#P_2,=,KRT9>
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MG#"5+](O8H8:20_A<CE*\<U1KA?]$G&CMK*2.ZB]1!6^YJ*Q;K^Y/.8^@K5
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M9TG;Q>7GAMWWR]+(P6Z43R;)Z>,RQ]82E"USGGU[5G_7+3_>V%+P;'+OH=Q
MV-;D>3\ELB\:;(]D(ZBW8,'TI3JNO%AVB_65!6](TJ @1!^25E;VK3HZ3.!B
MJWLEZD/E!70&4S]][>+DO 7,]'TD]]K2'5@J$(N*U_J4[Z%[6;7*R;C!U,KZ
MSO10)*.J O_%/=U!TYBM;4JZNEBRA=I);KHUWK6!&9I6[5N\54N.ZR#:BF]
MNU>QCZU"VA#"K<YF\^V!LJ,3<O&4B2)]B^@R>5''Y:NQL\2#E(L*7Z$5ZJ,-
M40[VM@'B&D2;^Q\< R;@?G0;Q^Z2I*7^M^-7HL@)/R_1ZJJ=0;(2&$P]R"8A
MD\O'K1;KD@2_^,7::P<+[]].]_\9^9AUOXN.OCE^(MK%4S7>$[P I;*1;Z6(
M>Y[0&V*J:TY+*N:Z4"#OF-6+= :J,#H&DK3IT7NY2X!'7;EQ4.XZ]13N2;9.
MJE+13%"VS^*,7^4][=T22$*W?^JE6+(1&U1IA3FZ3>9TL'E/C6QX5K9(G;+1
M,UP"W"\!EN1;X!-9"Q.4I<+0$:L 02U_P@;QD1.I4]T*O$#H\=;BG5'T<X/^
MY$[&;DEV#Z^]?LL%"0&"*?V&58#3,\JB(IP%NT!HCOQQ<H"]0]B-F)H8?_8J
M"UV-PFMXI<5@-11T/E(#*KFK'+G4YQPK%4\2J[Z4T!R?-52SI3O8\-":NJVN
MQCC%V(VUQWSLV0VW$HF:AN@6!I)=#A\9=X'Z^(H7Z@5DTP$;HMC%8\R .-0[
MMCZ.:9+(SRZ:F\8SJM(_(I)@CO<25)"":5G<ZN6O@;[4K3.86(T$'U@%+S $
M;Q^^WHKI$^+#Z>_R3H/_\M''ZK&28*G92P#^H0E*AI_HN.0BE7Y3=_;V*IMC
MQ'"D9K.!7!EG7>*Q-=]D2HNB%*<6FQP7O4JIA%'=HID85K/O,X*@HSB7@"])
M!Q :Y61M%// ,U@JXPQ@]RUX?*>0L\0V";'P8(]WF]4[+%AIP.7B?HN^GF&A
MX-RK!TLZ2CJ:H&T4D9B3Y"A:O1DMCHQ*$.>[&3_41)!L<6MMD4ZXP)BM'HY,
M#X"+@9CEXN-];_41V9J@<)I%4SNK:@89/14[7[5 V<8&R\/IF">W1G0VR4RF
MR;4?4U5R->9JU@M6N\F'HFA>[$&.0TIMG&8,9U\HQ$L.K8D>DX^A#%7W(%$E
M+OS7Q*9/(2N*C&5WTK)K5.1_^%$/V_D->&;+,]6[7Y??+Y(0>C[H\HE04">/
MS/S5.UV-2E&[7>/W^S#SVC307A:TU7J!^PR[ ?75AWUWZ2>R%I58;AT.3)(1
M^,G)?MWO-=@@NW!HHO)%XA2K;&O7A2%V7]"1_??V!=JT0-=CX!TCX?.V#5OH
MK'9"#RC\7JP*;]=KE_9P*;<=LTM M&9!:\II+"CF\%MVIHARP55;;[[^"9/P
M1RZ !J6-X)^IDG^7A?ZO/*#_EH7^ZU_P<OC_A84>--M\89%9!9'4.:6)[R]R
MB/>6KQ9,@I?/+9H%@"B5^B*M>FD]T*(MILNX7HU_8V@8K?IG';BPQ)V/\J:/
MU(B>H<7J61L9YWC"QD)+GF:$L9O]!IO]H_RGP6;98Y'%1=[9G(ECJSR><8\J
MQ/Q_4 \C99>.):D;JBL^M/,[E+'?:2<WL4SNFTT\_5QDV;F.FD5'AK%C5U'E
MA#A?SK0-A6-H=J@R?P2%8RNX%6HIQMOL?B.B_KG";8:8'-;]BO>?7X<55Q[;
M_=38P37[=?L:<V!CF;4XO/9MX\F+ *GXAPFLN2P-Y16V0-<;\@C%ZY< 44UW
MVV^G;0L/*4ZZ(_Q<K@F0D^D^-;INFB8"V"S]V;ZL+@A['>L)\;8K28'PYDHE
M6%T?)N\M"8=$A_6%&%\[SSA'_TQ9I2RJ=J6AI+$=K4"F57EJ0?GD7YP'Z]3>
MMRJ6;_5:FO"=23PVA"LP.]$%$)(<%4<1/4<L\]R<(JTR^A"+*R&1Q^(R:_G*
MB[\V8:U8JLE@>AI3M'"KA$M(QMK#+-H-H#U!Y,IC/-%W_J@Z2 ZSH7 [WV:$
M1@?BQI+QF6/@6>!R#*/T<.I;<L#0X;&O_]E8(RC#HO\@Z]$PN3'=\ZX%(!=-
M%1-T)^MM>@>U/G?1(]]8T+/HBY$/.,_N#1CMAOCHVG\U7D_8^E4Y:?$DP0="
MV0<VW[AOC:_X>.A6(2^! H"?4[MMN% _XTO4_HA51*E1$[)$1_\:#C*;&6;&
M]4(W8>=9)P%;"G%?\)=P+5V1^<;[DQ[^RN4Z@=2WDQ[@1%3<X0L;%TU+8]KO
M/:K )/L,]R\GN>%E6A]RJAO-%"Q,0OA:W$25RT6JY9RVYB"MQJ*!\R.+E9&<
MU+V9'";]- =IW5/>"*6-19O)LZ0A[3=#MAI SA+(\-D?G\*FX\%;Z0Z)M;O_
MJ*7^3Q=]"F/67UNP)/94U5MIUV^$M>_$;:I? II,L*92Z47)N<'DUFG[Y]J(
MP;(I-[",71@LQ^;,K\C.CH,KL^H]K;U,C%;C/!?6_9^433^&5T[<GF"<[K,J
MJZ\)A_7FLP6NP+/7]UO)IY?4ZO+UR:,Y\#35K#', ZZ&<1"S/&GQ'^89M$FD
M]J^\;'IMV(4T1P^+:.R/(P\%)VL\@ZERB\7EL[-#N?*(MCCMWL8P^QF% <&1
MG!H":\7WFF>$ UK2**K3MWD(ADF).84?$,X-T>,C$S[C!7%*50AXQ"ZWH^'.
M<9U%="+,@VO<93VU8X=L;&4V]\/-CD=2;U9,S[SQ:"_2&JQ3S+09Y!>DCJ @
M9>UFHXU1M_SF4ITG:P%< -T?GV8>>B7W'.>ZUYN,6J3=.[,'49O:E:$=?51Y
M>D3Y;"$C+BN#K:BZD F2&"X_(VW6.M/Y]1VSBG"="L\LX1=$G3F6WOB;SG9A
M^37QR3/PI*F'U6J4[6G/))[0:'XW/"H58N5*(2VUC,4SD/&ZO_9/(D(<2(BG
M<\VYG;],/R,WS+4U>]2E+R8PE(EU^?(*?L*C"^+JKDY/;UV)_@6-I^NOJ6LV
M(1.?K+?_3&^[@F,K',__DY/ZKQEP O]3'(JLE!IY#]_16;.U1C OG%$^ZW1K
MY2_>"HU3%.S71$'[ W]= @8M,:Y#HP)S6OMH4;5+ %%+P%%Q0L,H 9KRC"'%
M;!JIS9",5<:5(O_0CO$;*_K?Q8HN"T+%?-JVM30]AU=%W%L_"!M!1B"%WG,[
M;(:^MI!)RXIB-U,?+((KRU741(A#^B6BBUY)SXG=@LEY3ZXORL20E=D!NY)0
MGCZ[I] 8@NFDI)F1\\;Y/J[][IYO>Y"LN4!K,UT3]8J2C0E(=N#"N=;@ V6+
M*B,E1LK9_;C^11#6(@VV=24HH%JZ4V3Q(/9!,,ZCV$M LYM!%(SHL THR% +
MKUH/RVL >W4CZR-.0;/=>S:K*1Z6JE$,.,!"-L_*R24MMXVWI7CDDHGSO:HG
MS36NV^5N)%-E'-%NM+L.Q"(":P; 8%L7WP?KWW"]G?1B'G8N': WN69_) A6
M7E<H*1EY.IEP36BG_1O]QV5+P9$)PZ[6;EW75=26Z:8D?8VOFDWB\<A9:I)T
M**.37D#Z/'E,P4;,)@4U>50<H:.>HM. 1%TC6RE!5]*.*S>>H8WF:5&N29/@
M]CAAJ^X^+/FG@5:-D<Y#\X@7K0ASX1B](Y&CO*CDD\G=>Z!TX+[(SZR-,\(3
M=[5P0V_+\(N7A-YWJ@HD[^[M1!9XN UJUE>$K1P#4W=H+4([=T&XG^?!("$_
M.[MB]\B<;5+['_GJ'J1-,ZN]E?4-@4)V=]L%[WJ_3OH^>&9X"4B?N[_A[+!F
MH(XJ.=!O&JO@-8]>Z#<H*Y3.1 7NZO0KPJL2 .HKJ:JX=YX2N53.D)0V#'\9
MBA@E,7I>*QUZO$/51URD90]8GX7$KK#7COGT&0LO-_$</<HV/B3S9KD$W-'R
M'1=QKT3SK"8@4X'-9TP4P3TF\)[W]'+7?C HK;N"F+N;9Q@1D[*!G+ $OA7Y
MNVW('TRCSS#7$<E*X4!]+E+AU"Q=W>;K[2Q)I3#4\_:7->>*:2L;:K=TJN(\
MU7S9TLJ<0+LHSEM*O]3W*Q>.Q/N\:[LU%[3+S@=M%H3Z56">O2X5:33##^H0
MW+:9W^#/-BRMI@+8S'+J79^BI%X&G\M?ESOW:;"MC7(8:Z>/OY\\UZTBN,ZB
MO+G^PI*=MLQ.':497EZRCF*GUO+I+5=#)>EY/-I-H>5FW&#_C&0)/IRDXU.J
MA5<HV*5DU'5(OKGQ5M9+LC)C8G/"/('"HH4[8DM8G'9(-#AH"\YNZ.W9D\S9
M]7%B3-P%HY5I88]DV?^5E.AR:E:?OEC::I.DG1Y<9YHC&6^;L'/<8]3&4[=:
M;[DN"KH$A+25\35;\B_,+RJ^,6N0,C6.\?ZB/[OA=G) <?!*)>3:(E6_0++K
MG#=!^#A71DT=G)>VQK"[5.\L1IUL:Z@.8TAT".Y>K6[QB'NA*11H-ISIOS W
M(VXWMT1^^P>:/7_$;(#>4(72VF%*I?+$\?LR1=1109Z'4K/6X)>RSZOJ.'91
M6C["PFW.VL5H(E.WD7V:VK'E]Z\48N>3-[R');3K9H]. @\C*Y5FHT]I!=]E
M&_>Z+T#HQS/@MYV^/HPLI3R5W/TU,A. FYAETIZU0<UQUX:T.2B!7(S6RWSD
MHO'=X;G>SGM=BM?*"<1,#98]"I2;P$%Q*K/LF:+QFMJ:>#FRJ>Y&,OL3)HRT
MD#=\'WU'>7XG%:8/M9VM+U3Z-=U]WN,$L.E%@N#QH\'9(R[U;#.SMC\(@FXH
MIHX)%V.X;UK_LN&;;N=L"CV-O7L)J&4182%7QI"W)2Z)$WGZ[/'M[B?9YHKT
M*W%- K^;!"T?<%LM0VC0=PQU$%OV=9#YG!IXE$["B-R';^<M9C>&,(_>#-9Y
MU_0*?G+)>VE3_PU<-BS.D+.19\,4ZY$V]%KDD6\AKG/$8'L@AQ0\8R@5%NLQ
M]]1G^T.7JF=^#3PQ?>$Q9PDZSX^9.+!.*G-C0M1&=Z04Z+'J_'*1(QA1^VE8
M0T#V/!_ H+1"\:."9X9_;V;V1>%D!$_O^WY$C<<O>>HO3($ <X3=9F5,*IQ.
MEDR#\K_ A+NVDB0063_;LNV9$Z% _@._F7'G3%/\,4R_>S'Z;NA#PIBI[UF6
M'W%P4%ZZ)CDH4UMQ16@A0>RVVX]/QQ<S/".1C,WL69L&"1E<A$''F@^?5TW&
M1.B4QBI"@V;YE&(U5BJ-39I&Q7=6-GS9E9#JW[ML]:FT/?"=)VIR$/S'>]<[
ME^4>6^G(<.'NM5SWLZL'ZXPVW1]0R:5:YI/U_H",B;CNK"4U?ZN.)UEN9%G4
MVO8BN9NR/=MKJ-+#Z6A0P]!H:CI9N+I[HW*&_-QN0:F+6,)A2E=E@=W*M@Z<
M)5"H>)OGKL\W"BDA'YWIW8"YZJ'#[JKLIT5AWPM-G6@$P-I["QM>K6E?[/!I
M+'X\JY[NLYD:= 370CWOGY!!:^W3<D3FQQ:'ZPSSNZ%W8Q;<(DF!GR!XQ41J
M%2:,;<8/!AEEO4DL:?UY>?-;4D:!>1ZJ^G"^7&NO\/63.X(='>\JB=L*U^DI
M@U7"W)(T'5T=!+OY"._3QZ>.<E_4VG]V-^J==$O_VH&Z/D..@C@_:J;T'8S\
M*>>5=D0<4)[,C=(1HB"Z+EYBMUW]@^DN3;:7KG(F2M"7?F:E3T)]H@LT^6J_
M[9Z;<_^B+G\T07;\_)N!F]T*1??D5\A_KHHO(K'VAG)J"=ST^8"B9&SU\F[N
M+'< 6L*>4,.(O9?2G"ARD8X7G)$V:%@]>F@8+D4LF4[&YW?17$PEF%:UV>NB
MYG%_A)O8<-U>3&SRPX!*Y4T]%^&"^_1TPY =1G"OFV&NF13'FZ>-N?FN% *C
MT%^:PPT3&$OV>5_FD=WVI-9A1*)5S"T=$>.+&IW>D0)[*-07;)H!&PM5ZG9X
M/G]'>(/=1'&OR]H+?K%7Q>M;]/PC(XVC?O!/7;>344WKB:&$;T85YN_E[GBT
M:^H+)BF7Z\Y^B=]EF<;@4;U!2/G#4>8L-D;D^,33--XZ(P6P<>F]CU/RI+ 6
M-U.$VM/S;V)'>:[1^*DX3=2%:E/BVTXKP-HN9)A?\#P1UM1Y/CBH,0)+Z^_6
M@!@\P.49%( -JO870F^\-&%:F&@X\^DJ4Y9,.\.M9-96NEG%4O.>LA?LH:U:
MM* BK^=$S9%;*1E .YQ.)V/>0)S4V8%GDV555VGZHP!#.##Z8F^XZ O>0R?%
MS7X!-L4\93CB=!,#]9CXKMQP">!>]VV[(%/7)_MG<B(=DT!Y57M+/9D<B<XD
MEP!?;?J@&H9;N1!J!R^:J[@:6(%U$9@G!M?,'E&7_S&]+&+4;"8'Q':0?;YF
M,2!+WN/V+U 5?^$__W!US:5.HTDDD1?T->G1GQ 5R0)_'BS94&4P\K?]@:V<
M&YG/IR$@!Q;\5Q 5?X&\R*"ZPFG&/AX._D8=,4Q@YULE86-M\ K>3/4YP6TX
M09;_#8X>QW:;8R#QVL#:A--SP $QE^\FHOMI<9&VT'=QHU4Z:C*0<*.7K/W?
MYS<ZLV%H#D6._0[,_-NSKO\E@9EL[ 7ORRMB/7'((LRWJ:3B97-F6_,,PD-P
MWC-%IRJE240"#/YEL.;?"Y_6%3N$P$*/R6QQUO*3_#(A>9.WMXW*+:LI"UP
MZD8]QNR\X(GLY.-7-R.4F=$76P$O$3[6]KX9$[-3AIU459#\TH<^/F/9<3:8
M]*CF6,?9,\2JIJRZBG&?RLOUKM7MA\KD[::Z>9XA?WA/^4*B<!CL4-!9Y-Y+
MH0?MZBG:&T)#U\/:D))5/A*9RGX/23]B2!V3!N')V_=C5"(\0VCH/U-]92\(
MK16[IZZG@WG(ATH#,78 Y&X?\*VQN\6Z*RF7H)^>P<=8L]RTGO<XX&F 8RX!
M[PNTALP_K(EJN7]XR&:> .2.^9EQ@0?A<CW4%?:1AMI_F3*>65\G[Y$P)?X
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MT%O DHA *^4:GI"W(/CZ@3]O&YY 037;J*%HO, FA1YY&.$S%"T/^Z'/-3K
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M@WX^& 2D5;@8P UY&//0*('-J4 = AQA[M<,^T -T-Y[WAT5K,KZ$CIVIQ%
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MYC6RNO7 0\(LKLOZ5>$I7BY?9F*#E;(J3['TB>\967'=\M%6]RXC]/RL*IY
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M+UYIFSH1B KP$IH<. P,PI]O]X6OS,>P>D'NEXTF) )0#L"ANC@01$SIWO0
M2C#@/*E_]LZE+8BPHD0F_MUU@&&"\!6*GIG 1(I_=CV0"@\/:-N7K!KC65RK
MH)[<S"$"C*:B XM/>E]E\48[=6."FT&$@K*^3$/$_8:"W?CMRV&XX7(?]"Y0
M,JAY=D=CM)0;.)?/4W!Z(!K3DH-6X@."!NB.?[.^?Q4,NI171,1XW\;: /P
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MXM:[%R79O@6@7>D,W)#=-N JI/6 3XPGQ/$(_<,^KN4?]G&Y?^CC?LT/7V2
MXNK77NE7B@,-D/G'^K;NE_H6Z,Z >N[7.O)7BEON;M8P^*?L"Q;]>J._[7T-
MUG72ZWK?N%E,Q$H?JC&+N=[YX^.T$^R+++EMI?$*7-MCLNZ :4NPIUT=%?>C
MI_W)7LIKC5)J8C#0.1[X)T$$*" Z^D?4_[D"?]Y(+S?OOP3DNDYDW0F#]<U[
MUCK6+%C'FH#3'_]T.G(=6;#?B>@U6_BQ(M @TZ]QQ4M<EZ(!KL[\IYL.KT1
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M96W__)K*GVS%)MXF$SR%2\XH0 >ZP8SP60^@<<K M5::S.\BSH@_-!D]-JV
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MUM  %Q4:'7,J67;C68]VNA1!/'!C6$\O)BQ-D,SJC1:]6Y*-WR^<""J]:K*
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M,G7U'S<9LN7TOL"#'#W3A'(Z%&_-LR<]^YO3\_\6X;XT*.CI$1"UZJE,Z(-
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M&1?C'78A(S3Q4G\Z"7O<JS_<?/3O')*:<*EXT C?XA/$(@+;?:MOCANUBY,
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M$R;A>(69$J.==N=J 255$UF;P+$)^_M(16W<B2X7];A%/[.TT49' Y70$*)
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MYG=W'T6DW[8DV[SL&71]U CVVHE^KIS%C*PT&3ZJT3MPC[B%%T/3TMH0]4M
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M%+2BDL8/"Q^7@W?/H:,# F@_HK7D!9\;/TUEE&NV93H"1<M)RY^JM0N3+1Y
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M" <J3P$QA"?FU!()YS0>]%V!S(.1GAB@W</&9@D"JL5J(+Y*7$-1GPT/^KY
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M>C?/DN45E-YH%E'Z1.4/ >V>6=+I;ZCW/."$6!6M&"QR<_<S+'%/PB+87F'
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MO\AEJ=+PG(14ROC K^CZ@0VQ6#XW4W 67%H>$H=QRWL>"YZ NM5J ]R@G1$
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M78BKJGE/(?&>":IYC_[(#>Q\-VM?D] DC0B1+L,FG=&W@[>Q7*L Q.3SHQL
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M\[)(H;"*3KVDPM?Y#1&D0P%5EPZ@Q\X)WTJZ%V(5XP=#]W346!0UO1:=>7M
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M[ZDRF_V1P[2W;@^ E-J.%/FW'B@=</QS.$29UOW)7<C-.1%J_[?=F5VUCCU
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M^9FF8""![4)EDMN,BQSAP ,=>;P'I!PQ\<NK7J$"4G+Z:-';[#]/R0"S/[(
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M0&Y ;D!N0&Y ;D!N0&Y ;D!N0&Y ;D!N0&Y ;D!N0&Y ;D!N0&Y ;D!N0&Y
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ME8-B2LE'$>6B)'4XUCN4BX913+% F1!!5N##N\0(T>=6<KS_SM=;_H<CQG?
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MM2\G,9B*6@$MT ;14D? U[9\[;9;T"X91F:Q:!;3)[C_Q+436G673B\RW?)
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M^?CEFE9"OB*^)JMX9G_XX[[X1BQ"'AD;!:8M]V7\5MDPYT&;$,7?UP.27S4
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M9 I\ @>[ZB_[(8Y_$,!Q)Z)-1,#.S<Q=(F#H79FF@A_WQ"O269B.EO$OLHD
MS_&O<Q7)^+<N%WV(@ CW<2) 41T,^<M[T2L.RT1 ).Q+%VZT<*5F#9=F2WB<
M2)T[T?L\U7MHN];G71418!AE4>[_WLG>%_(@7<D2$DO_]#93D@D:9[NK4KY8
M@E9"#^E_!Z&W2>?^B(&B-8F J1426P14GM!$$@$AL80Y,&FU+]9!3; ((B!_
M8AQ_2(K03()-Q\A?YGG_E_.4L!4TI&// =>\2:68'&C'E@AXC]EGP-+@I6<:
M5R!@/#T4>P1:F-TD N211,!\)JE@&R1=BP!M"CM*3X?VQ^)30$N00(7 %T3
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M"DP?V"NQ!W( GYQ:-P/N.^P5Q=)#"X>)@/55Z!XYW/>7N^[![/3"JD8\'ZB
M3+0B=J]1BZ*5B[&JK9AD_',;(L!S;!/ -:BFI@"X25_VY+3F_YX?7+QB%%XW
M 4_7Y9W+LRUJNHF +WK[Y@ZP'>:AQIE4(L 2/@DPXOD43$$:=_?[#\G5"*O9
M ] ?Y+E$P'@=] B0]5_MYZ "/4#S_^.AI37TY)QP!&CT%_3M-1Z1C=7]\L$
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M ?Y#]$E!QX%+W"YW'Q' BUJ2RPF6C<229$_(&PC727:==P/- */)H.AAII_
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ME[0"&TTS[+4/T#ZV)66Q1=V]12IPK]%_ = 5WB_/1Y6&-O1KXENJ=S)V8\6
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MH')/,+UU;$L0I[(CY!'CP5VEG;: YPFO"$RW[NA_7+L]$'@]XQWB3K:D=K)
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MUFX/SY;K3"YZWTWT[>H;&EKK,$8))R/UGL=(1!(!BJ*:N#"DDX8:QOUF^<9
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MQZ'V*@>*"DNW!R:L?YQ@X26<&@^/41@&M/Y%=!8Y*A;VUBO2&6ZI^M:1EA<
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MWEIG*(L$W?B-J==,FSC@\G[%ZPM0)"X=<IQ.-M2<744\$D?:U2Z"'P%_C4Q
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MGYZ8P;#<QA LIYWYA0ZN[T)H1F'X!Q[P?:;>1S@K \F$&)H^G\J%8FSW&_&
M!YK-$4DQ(?I;-M*K0;Z5)\,:"68F.-8#T2;6=IN2Z)S["OY&\PLKL3",/8+
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M.D@&.WI7@J%M#<"3)LQNX+^DK73Y'TE;N?ZWM)6?.5"7\(6H/<,W7-8[)WC
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MOP.'-(R1Z&8)[H.*"N@?G^V3W&#'8&8S.Y<'6Q&5LZ]M8UJ=[#6%-2R1#R@
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MGF9_1W0[)27Z+0M=%]NQP8DX:>@8T;G)XSZMT9&+[QSD<Q*]VVJ>M] 7.HR
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MR"?Z]"<<[!(Z2&@K4A,1!=N=.*RK^GT,4MM:9JW J1.DV-N9CSFXP/NKM&2
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MK_EW4AZ(9SG WF@D<_R>%!>HW-P8#@Z5#4KT=G<]XN1-"XD'/?F$C+**P!@
MX)JC NB+Z<G:.';OT)'"GIN^.$A6+<3YMR2XD0'22>72O@(M(B"R9/N7[K)K
M:58"W-.-"C_?H=3:P_MV)F'QP\@(U$G17 HWAI_!G-H<F9!.0]?7+@K\&+W
M"@-VK<UCOIWQXH69[@]?ZTZ=02RI(I<;FC(.8$EO%#E0F_AT,7]1#@!.#(%/
M!"Y]I'PF35'O,)&EZFVU2)L'(H1+Q] ZL7_XL\[8WH&:+4HG,H"O,J&0AC"X
M[S&&'_"U&]TG&^&S\SW3=!_:B:ESY]M"*:X;,KCD+P3R@SM\Z\24"GUFNI[7
MAER&KW#('8<O:%15[=G+.*4P! '>W>@J>=;=XUPP8L*^ML'G^0XOM,DM)%FO
MD4A?%B/;+M>?!)^0B9"'@A(M#E\DFV"^]_V\9/%,[PT9@NLBXNX)DKJ'*JTL
M-:DT9\%D18Q[QL;B,^T O08(^K^IDMS_[O:OB/WF^A\ ?_1G?\#?MZ0'&/RW
M#V_>_@4/3SR 81:*_/^+-0#SP$TV-EAC!@"X[R+3N2Q\^X!VHQ(+&:V%T UO
M82V'&-N3J[3!DW))$P8^+#2V](7."Q'[YT-8!<W7Q_8_K_/XM[$U(3Z4I<Z%
MMSBX$"QL(4S#SUBG79Y%4SQG?D?J*,*B123"2J/;8"Y@A^$G4=H%K&D/EB!'
MM/?3DW*"7?2]7FU<6W.!#RI80LN9%+1)WR@QX19B\3<NM=+7M.\?P<86DF'[
M=_CPUL-BWP(57Z'LX]W)?N8N19D@0#\57CM;QU)F2^J97,?@+6A4BO3&>5SJ
M!22MWT/JLU51(-R^]#;<L\A(GFI)S9&<CQFWFNQ=.@9GZ2#%@[DC2-1K0:3F
MN0O2QG-=!</[E?YX)9B;AYO<&%)H99.HHS Z,*'T)/M=I5,<:&@?N)[>A@H_
M.&$-;G%"\'33D7E6U@D'G/J22%")>G=&O9\W1/-3&\O$E-"=\F%%H =_D1 N
MV6M*[UI2F3Q@:6G\NGGA(!>XTHZN>:DK"#?<./R,6()%?=YLQTWI"R^3^1 D
MGETL(&L<.S&CG\#7Q!=#$1$PF(T+)/,9;:-!)/>#T6YT6UMGWB/(O]C9<W':
MO4OE!3U]$\>4HM5GE*XTO[@W0#G&,(\\NQ9'\IQ'P3/:@C>I*?/(W!X==JM7
M?>UT-WM!0?2*X;IPWA\?0QX0K6C")Z:1F9F LDF/]H#5:('K62&">$YWQ/>
M$#KQZ8H#V>2,3=,G0MD,7T2\JXI>8SORQSW>&Q@LN.&\39!@A4?#VJ-:B'-W
MJ69&$S>IEY;V+BL+ [<C#[_IY1'R]924D+Y4'YIGC?/0A9[L74TZCUJC;F<H
MGU,B'<I]1IIX.@TO:TO;\:VKTR*%-4%Y*G*+OGSR1&7A%#+=(PX_+-Z=LJ:6
MEOAT2Y$@Z+M7'J#"162+^X;69(LB>1C33&VYB7BK#.CKYO&D*$L<\5=_@% @
M9A16I17B'M!+@'W#43UU>*-=OO@[QE:XRF;V_7K&'#D?#?/;(DI+J0[X8Q%
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MXMK?75JI4M+1I RO!\11G!S[82CCTB?@PKW95RF1G[.1?5T;UXK3N4VU]?<
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MI@=I,@LDL?&ME:N!L>% A*X&)WN6^G0HM_4L^*#F #I%"5>7LQ'/GVLU8I"
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M=O6:_G#62"\"\B OH W(MZ"7B=,&K^#T1.<][X5'T+(":Z.D^S8.S#4-Y(X
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MK HSM0>:FK'VN:T!&BEV<1NK>BLF?)E&[/1#0P0_(M-C'#F>$?A[?/+6 *V
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MS8:@67%:(647Y5*V\@D2?G<[YG=57WT.)OPDH[!^5]R1+\B6Z.]2T147(0U
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M(-43_?>_4ZA 3PBH#TP@5:*A0!F(@X!([K!;'O0]W(6#B_%0+B4$K85PP$M
MF6,)R C0KZQ-%GXKK9@+A(<6PQE [E.#2P3EL' !?.HW:]H@RK<@ Q4T!HP!
M%X8!BR:1KK=-HHFY#CZ0/B>:K6[< ()/=E\< NH2L)J$"P!)Y*::DK7!^?8H
MKZ"IO^]>B(>G_A]%*.!6%NJ_2RN ,H?;N6 $4'^%334*@;=O.]B! @T/0 :&
MG!CQR2P(:)Q,M@0C6PBWXQ_W(ED]+?F+X"Z DDC ]Z\"0@P#@((RM>TONRO*
MT,-6SQV<?^<_F!0&J,!;BS'F@VW^@L?3]^>1\F#S'/G;TR < OH<9F> \D'?
M3AZC"+XMA>^()K10/OU2!AKZP*(D =_P<0>X0-B,_D/66P7JXDG@PO==X7,=
M+&H^3+\F(-R!<&/6#7V-6^.K]$UZL*<:J+QS;#XM(9.G> ,N#(\/(V8U].V'
MW6+$S_D7".?^TT+X$T*I#U(&CP"#1?RWL@F>_N\&E9KF[1 " R0$%";A>@ !
M>0,&RPP@)/\CLQ/()[O53:J%A-#QJ*#V_K.CZG^$MD8J7,6#M]:12X&#\?!*
M;@3!_[[_P<N?@(!(.?[,_Q]02P,$%     @ )X1;6-ONB-NOC0  9=0  !(
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M8760>T_WBLCEX>>O]ZTZ*L]%LRTBN1/?E&,\IUAGR7>9;4UC+EGUP<N*UG,
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M6MG#_YB@I;RP[DU_SJE _T"0((OGDN"X17HE.4*D*X37B;:?D3SN"AH&R!^
MBVAYZ7F9N@#\,XDL?)Z<".#O[?%;7L$7DR(#DCDU+0TA=(>/OH<+Q?N5Z#;2
M;US;+3>!:'?VJ,I?-88=?ECQSLXB%9PX;='NR"2O49D2I9DJ/>1BQTZOLK#P
M7IMM60C(]VH-@C>:.'C+FG1)=:76P'E,WJYA"($_\6!,Z*(]C6YL%4S(R%43
M69NNVEOJ^&M#X]GZU',[!DR%&> (W*&R97J>OQQ 8G]1!3:WT]%T9OV='LH=
M*'.Q#-W\FMH65GK %0O1;J4";TM'G"N8@C[<,ADA0<\G!'-LUWV2;J;N,C\+
M<&]Z_UL'\X_%\@Q-@+"&;A_N#!8AI:3=FD,FTC[?K _6&# 4&R,S5[JA(4TL
M84LOJGZ6?E)?NH_[G7IOD1-^$!I^ZN4ZA[SH6GO@4^+.WGS9N7S3WERC:0-.
MTQEWT+*$OGI_D H<NNU$PSX(WM-CRZ]>I'*)*G<&\Z\X$';#_#',P)VF8I4S
M3@]G>]XR8B4M'9U59'4)13H#\AR$WP5?"D49I S 2YX%Z3;1&X3?JQYWS!/D
M*F1N40+<0*1GOYLU5GC]'J]RQ5BH2X _QIQ-DB2F9V_7>N,DDF1:,O=9LH3+
M]I>QR6,KNLBXUQX/\WZ,$>7[Y8WQ7(_)HO=*6Z6YDO3[_)/1PQ[GN*E F:65
M-Y&KI&2>05W)G/UO83AX7_W&:9=?&A2[EWNT@^F9*>"3K?%61JG\77UW&:I<
MS&AWY)DE5[.+6"+)*SZJ<]>=BUTIFKX+EBW*H-54O7[V&N&B/#MN3.XX=<UJ
MZI*Z?VVPK#]5D3OIFJYPVJ*'F^3(03<?6B@R3.A)M'U196]<F\U=4%25,K72
M(R:8E47"H!79W8HU(2HKK%ZIJ=6!F%4MQQ'KZFWRX]58'FR&>=\+8VW;^-;D
M]JD"*Z/)'A(;+#7O N[-1U9MSG9L#-"2_O+:%38["FZ6Q0T1X1'IHZV/\AU:
M,&I*D&=^OA;-/O $41'*Q\=JF*5A]Q98S_ 2K8-_R6$A%JRCZDOUF^G=,P.%
MR="(+M'L& _,!\?T&QE3-"P2OZM#)T$![)NM<X$6L<P",..@?7/07@10!S?2
MN^;P!WU<[).X*'4*\R;)S%I$&A/+84>;/R,YN'ZJMIX 3E\9)IE&6BI':G[7
MK*S@\ZGVX*ZZ?K5\CE#:3)!:")-KETC#=FG"S0=<EJAE0 5&R.<FDQ:!# ,Y
M(6H,\4+3W@8V*VPH@"HD#@6 *]&E<VR/'(L<#_R@Y_,],KK*DS6),F+FSBM!
MU>KO@FW["#X?Q,5WH52@#8T=..Z5N3-[M2"+UL=P&J*?),)!7UGLCY=(=[S]
M8-W#E(:FQH^G FQT+*Q^/Y0MF6XTR+!G(:D0$"US>5X].3OEH,5&GPBV9-K&
M(NQN/$'&'(+N>()'P7-L OE*O\E5='@G:DKP:M(?P+0#R8F;(?1!_>B:8Z<-
M7T8E3V'#T+-E^>G61F0"$E:TXSX^L^,^=6& L^KYB?>GBH"?+58J0K#+CZ-C
M-N5[2\C!Q@,6(65#RSTSFN@2A;*=M[LT ^R=/#_#<4C7]+FJ:],O-!VHHG?[
M\(MRH]GE"R,BI+!I,0-EQE<SWA?,(,7!DY9H;V7E;\C$[<OR#M<,$-N\0!P;
M[1AT= T6/&9VN4ATCVTZ J^LD9+41?B*NN7A7P=)8/WJ<38=:H!/:2K#5/U
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MZ D^+*_18U"+4:MH0^0MN4:S^L<-;_$6X)7)WMU1N]1"2#^GY]JSF.D^[I(
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M4 *\/B'=LN[U-;I3!>"Y]YZ4=ZI]-Y'@".&<H2<N;OU0&UUE(U& ]^$TB^@
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MYKF?#-<]4.YM29K.\B,ZON[*=?X;? 'B=_E=?I?_I5*"GT[K_GI0U0L_U6Y
M[+UM600+GL^M35"%0+,!0X!-2</^G4VW:@=%B;*LO3:=0 J8RD?*5:=Y/[%W
MG'?K@\QK$D1>.\:[3_'&_)15,'!&84:VN38<-![72_2(6$;OU42C@<J0_+$7
M^NZ]&\_J%!G(=<-NZ>PJ3J&L/4"3")6*#*+>I+V*;+%/FFJQWQV 3#I36>>7
MW]KOOE^]8R0/_V)06TUM])'D<^M##W-5=Y]:/-"G'G!B+N"I!N<,("*JR0L
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M^AGOH %E'BA<X/.[ O\[CXO" 1R M/(?LWOM#X)+!K='*41>]RLVT.,WFJ"
M]$.5.%13+BH>NKR C*,S04VA@<W5(@9L\&HZRY6/XA4KYO#?\C($MNU259FT
MU,I&S)?BB9%TZ$/R9,*764^IW!@1?-$UKY!JR[%+8ZFI'NEC/<&9H5^L4+H@
M9B8G$_68QT@MRUITH=U+H9)F@6A^889Y8"*1/*R6MV)0\CW&E+LGH7J;)^%Q
MVOT)IJ]5U7W=(KAONL"-V]:""\O.IGI&1IO:U9X2JVF&C<CP'![Q&[TB:ONJ
MW](>P&O\3HIM%96B5&(7H9E="O,MMUNX=U->U_6=NX#O()B>'=B(TAU3OWW
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ML/:OPWBR\6[@)[^*LJW:OD]:-I)1GB><RUH"F&$1^<& (Z47_&":!EZ\<([
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MKJ_TVA*SF='N#QQT..^G#.%6[$B*C51*V'$\6,;_4987TO].7V;=(PV609L
M?NXU8;@1:2,PB+N32,YG16W;#]O]( ZH8 RJ?O630 .PSTF3/]$ 90/8[MP\
M4)$M82>ZMLQ-=>4%X@,N9J]Z5*<E9FT-_#0Y:XN>/E U3O5KNFHEL;RP'WFT
MG^1A,(LC2\;@1+6XR(J$6,>DMFO"@9'>O-Z=#?UYF;5O&<?"/6B ^BC93&NR
MB3(8\#=)'](Z#>SN0@.W,5H$K536*S$V1V.K#[FOW8U[4'[SX.2TN'1K9-X(
MJ6+X0(TOHSI-=LY_Z'!Q<6.TRJNQ&^FEB%I":1XE!@D8 [I;O)W+AH^LD]%
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M$X!  Z4"T7[21S&U?L(B)_LZP]XB(]KM/);JLT8&TEAIM@TC3[$^"5TR8\"
M56\ACM/ 9:_-RGXFU5'GX$\>2JD_OYX^RXANL6/!Q3PIL?8A7M! :!<AJO?V
M5G?4SW,W+F5 [P47V,L<I#$SR;8]N0)+*L62B^$2\]D%RLG4RQ>J QK.!GX
M0Y"'[5Z(ZZE>6:+]DCWQC)(+FX=6&'=LZ[47^I00QMNBJMB[',DHXOT0[_1S
MW&;?9K8Q3\YXBG"D2#DB6^=K'6H\6-?W^XX88]5-WAM^#A+@BY-YB!%V38 Q
MT3:%^G>NRF3C^VI4WM7,MYVZ5.8E"'G/EO)BW-Q<V+4](U(HHIJV)Z9]*IY[
MK9J<WY&BAY9L:\_?/0#[[]GM,>L7EG]7XJ7EF7X6/%B(*="8!QE"Z*](-'W,
M$]^R\#(=Y%?A$S8'4KL=142,QR;-"A%LBF.VSF$OS:H#G[U7M*?%PHB96J5_
M!&E@LP"'<R"?C2IS+KYMJP@0_WR3*29\(UT/F/NOWJ'][Q#,@28^ H3<=\_M
M.] '9<9*(QMQ*S<@]ND5^N1CCR\K7V*>+S=6PX#SG>>C7 \0UA9N]K;WVR#3
MHTKB/&7KK((;_I.Y+I-)\<V1#="EPF.L!&L?[LH:-TG]1WD.KL12&Y%I)]LG
M@<N#Y#KN8.7@,U4%(Q&S.ZSO3#>PT(",%#T$^ZHIL=!;9I1+-Z.A$691'3'<
M[)XEQ!P8;D*FO("2 A-"=P[0P*;++K5D(5%5CMZV5NM;(9[0V]RMK2?%E?^P
M,[K^I\C_UZO9\I5N)$P4>@6-NB(_QIC\\_>QD^T+YRS3#%>>',Z_>_-?>;.?
M@9Q?K!&_\P4F_V#^/(FC'5V/)K@C6_(MZHGVR,DWY).#*.1]%*W@4!#%I]I8
M7(FHQ^ [5ZR8@8B[68;?1W<2U9_;+N/@Z_P8F$4#)!BC_MW+UM/%0E+#BT/\
M8DJ\LT"T'&GZ/OT&7"#W/^\$S?^I\F!1&8.JB'JKUABTS6'9:8==&2Q()V,K
MW-WH:$1[H!53[&ZL-,[X=<QVOXQC1('S]5>']>=.:0X.3IV )P=9)Y6WX5+
M\VUQZ7PN[7"L.NGCS84@^\TTYA&D#*9"_FR(\_)3'=M8OLU>#U*,4EFR/L1E
MQ_Z2,8&B%Z#^9J]"]FN&R<(!D 1LLY:G\S?:G6D&;23K-$/"S$[G1*.^T>(U
M;ER'=$C_!1IHZ0%W^4E,P [*)3=0 =.)*!P%%+_'&?B8?*SY@%<%G@%RR6I@
M&ZQ# QG5N6C /Q8:0>\S>(5=Q84DB$-:8LY9EN,=[4$W.0JABZ;I*_+I3FA
MVE81#6 R_UH4>Z;'UM9PF7Z!;V6,H&)!#/]>[O_B<@7(^D\ZJ[[VND3(ND;F
M77?PUQK;L(-!7$3"T0LA\D2A2;L#OV_KKGU<RAZ[W1N&%LE"2-0<=.'T5TG'
MGFP#XC^:-TYW4&B@!C&\WH\&P#7&9U?-URCTL*,H0?OSJWHTT+Q[;=\7Z.#N
MY!4:^+4T7#ZK8:4_&06U:]Z_O#;.9N'HT@4-0&>NC1O>+!<^,D<#Z3/EEZB%
M%?G_1N6-J2\,6@;(-M>!9OAXK@@!3S.RT"4?LY-4KOX/&.QV:N_V(]' 7[F)
MYC_U71)7GON^XAA2UVNI,]*RG".4*H[&M-NP5L!:!6Z8E[W<*-\.;Q6=G;K7
M$"LHR"V\->!UH1UI#!&*111W&C&._&BNY+?NK)6EHP*_,]D$LT]$O6TPI.N.
M1$HOL_E([FT_+,VR")Z3$?49ZL8ZQ,#-!;R"R%*S=Z;-FRTYG6=J-Y3#<0E"
MAM\?@B8J+0$F)MQ<1Z-;)MG;]9-!IM_T%?K'HR5VU\0^24;$(":M#2S"QS8O
MJF.6/_AWEJ2;-W3#I>]V@^5:D4J J\N =1-AQ02+_B6$>;3*\CSR8G(-FDT4
M+A'A_*QWF^KI(SEINDX.P%$+]6@,"1:=0C3-:=Z:(2^VR^^)NX(C<8\OM"7@
M>4LL!_'%G?<:[)V#=)6E:?0:Y9;G:6KI\=_%ZJ2\BNF2)EL&DXGSD/OG%.L8
M?D_RKF%#!72_85IJ,F.)YDF3V,3\7K*76_E>@>3E&=V[LEA"517*EPY>4<_6
MU'-52"-([-3[ 1<&6\E*G\J+2?#I#PEL!MNX(55<Z=/1'?D9E=+KEGG]O]JO
M!,#Y=[U_B)Y]%:J3O=^/C?SB0K'[//2FY/:X:RW$%XY\&.PG"L:J4]+R=@N[
M@!W?%:*S[A=G>QBF_MX_I?M*UK5M%WXF"UB=SQ][S)_$G]:@-K-W[:^&I:B;
MW!KIW1K-?$K10#WKI3X:<%;%*4_=ET_=US6VAN[!)"?0P!PI1O&&U_"&UX3V
M],)E5E15\]\9"]+CS&20UAADWL_V;"UE%0T\LO]@*B(!(03<H* I-& Q(.;1
M?8ZWRP8[P$6Z#Z(!PZA#LNGKSHA,7PVV;BNXSB:"Y<9%<S,E!=O&P?)&/]G:
MPY5T2G>)MT;<0VG;P\J2"Q:!W>6T#)G3UKD-\,[@[$5#=;TA._&-FK?(W)N6
M4Q>!6^>.4C1":>Q#_)?#9F[%TS)OE,5KHBT$RLK*_(<#V0@"B*3)ECP9@BO9
MT@,O0MX)\"M4W>HH/PTETA,D>.SG T_W'DM \32.-.%*];#A_UBW%F8>?/11
MA&E3&"D+>/8ARJ6BU%"#/D;]=D=1K+U\Z<^FRD&32))<2^.;L2@O%]&O[]:M
M@\'"KAMVOL&-\JT4?//N3'*U=<S?3PMKT_+#,1&1EC=0Q6403UJUOB)C&0AM
M1!6U5M?*YB-K0N4^C<_Z?30?-JIMEC5$U",;)N.\]8QWFZD04"DJUCNYT5RJ
M(&.D"Z$Y9)[9EF+QC30F0[71X/W*1R!AL'M4>]3U^.*D G<+.=$?__)I?->.
M4U\X4JA'>$=+WV@D3M?P;ODB=1A!F.V"R(J$9,IDE/>C(:60#L7-C]*VHF/,
M)2+TUABU%MLZOF30UI:==)JJ.;7W_%J6VQ&;;^Y I<8P?KJD".P^K K,P4<0
M964_F!4:P.$;W=(36%D .94BM>&"E2V\3_9B:JIWL]$ G1YP2LU:DDYBM.WI
MZN_BECTMZ^)%25#1NZ1.=1[*'!DHL8F1F,9^@$KW.65K-!JA25GIA>!8O[S=
M>U,$-]IZ(SWDPF?O:_&"=7UDJ(5/O@);GXN+"%9'.[LK8<N%J\!6$P8\+7/9
MATECK+RT-*.J,KH;%$M)/ETGTB,!&\)UD75(NP4?7WCGK&2L,U:Z&##0,_,J
M2(=<UK C)2Z-+3ULV3A<($SAQ!"_[71D2[6"8$2Q_CE1 PYN?@8_Q@[OTQBY
MD:>M:ACF)D,8&L>-)LH3I=,K2@VP;3+;H&41X$*;S7'%T?%@8*>#%])U"\LF
MPMHY'^+[X>>SE)/E+\?E%) F,H0%I'06DC 1X=K1:68:]"32TX1YQ3]6!8$'
M',-^+66/69$0'*&ST#S(X;&,_=3.G-Z YTER1.O[B,^0(;S!NYXBT.9DCN->
M[25$A?$YT4@)WS<LVF4_,4^V'@$5&/VCBI%2@<RE=\LCS(]*!=J7<DSF- 0U
M:&F)01/U4!*D3/7!61"[@+_ED:)OT4N_ZEEBWC<^7Z3H<LG6BE>N.0/$;<+"
M^*!$T<1Y2?/GC!?!%57(HJ-15@F5#,%B^)$4*9? ')?*&,=/SOW,X+U5?P+.
M!;Y8!V[)JDPCCO+M:B5X&UOQ94YP]]/ [ZZ^'0\7B3:<B+!=TF[#@YM7Z)2M
MBWT$YP?;X16W^+>[='V"B?AVQHA2AG"]9#T$4^&*QA,N$>K*(]Y@.N2GK_C&
M'-5 YKLY)CZ34?_PBXD%/Z2/V[+"B2*'>1<;6R-X/;I+^;MI8$I<N,F$G]@V
M6Q]TR=0]L4,HD:DUC3;RM'<J>I*"HP8Z9&?<%Z<W3X\(1C$>#)0Z)SQ>T!Y5
M"Z\NC\WQ<_"B-;T3F4V*,:]FY$71X4&QY A7&N/F6"&'":O213SXB=$S();F
MB:GV _DLOHE*:=GKFVWLSZ=#G7@6)N!7/8-U&U6 IP#9FN="1ZF3]$%7D(_'
M*W.NDP>\_!@,MR@H6^92.VY[GA6<&(>B'@R7LW.Z@ CNE\6YM\B9Q?%QKTB
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M,\<8<XSZJVI4U:S)USTATY EP%,9"6D)  P,#. =] 6 +/,VB;M;F ( <G(
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M"0G'+SJ:2YL$SME/1*P>)'0A@$]<7UU@)^.4$#Y]!KHJ4#A=JPFGYUMY%BC
M;>UORN.QL*G&6/K)Y.;PD9"+@VN-2".TGN9EFH812U7R0 "25L3AO9J2!T.V
MF4<#SJEHHX>;QZH)3ZC)WI[^3)&Z1KK:) _'?5%+"$;!5LVTW:P8RX0 =-(.
M44X4"K?T!PC!@U:(Y@,P[P9(/-_B$5=R[\_4G'4^#Z&B^-P5T$+!/1*5VO
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M78< X!N *Z2XE50@ZZHJNQ<H/YH%ZHZ[;X&#^5R]/1:G+[PP$)T^2+TZPTT
M3W\EW*(S7%'IO@R@L)F.YS0M>O\[MO]#J/_=1;LWTZP<WO.=<I8?7>&"JR?S
MGZG5'@I6PPNO7"!=G)<;NCG6$B7IW7#*[]TSZSZ.D94-B-CH!3$F>T2]6WV
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M:_N:N)N0M_>NLZ8!:(7]WF;=J58GWI7OG2,Q89<CNSQ?8>F,3RI.X$M-(Y&
MMYBPB:&Z:+GZ::Y\RU%?BKL)SW#)IR7FFV1]5;\<[=B>O';*'C>R:($ ^GC(
M WANN>J?(-TAUF;'=^ZI5XH%ID[#? PB&P?G;GZ.P,Q#S'^G6CDG5$!D?8#<
MRNQ;*%/G ;<1_A4"J']M[^C8,-\^(S&#P@C@P^JY)O+\&;"-ZBM1$8&-Y5;9
MN8]OSVU0UP(Z3+2;1G1:Y[U#YS-XSF1--N)&%E>/H8:'M&6IL1(S(%;6=+2O
MK9S] XQ#RWF3!OD)@"RSK9D[.]OSL[#8.C$;&-L9FC ;V=FPN!O8L[ QL[(
M!('N]@9&5B;.%(8F9A:V0K2']<VT%!;&0K3J7'*L<O9B)N864IZ.)LJ>\BI&
MGE9&?,:T0&%T%$%W?G<;>QL39P,*=QMK6R=^=R'*/[CS0]N_AEDHA04=C4WY
ME5Y+_#4#VA.B_$L6-S<W9C<.9CM',Q8V/CX^%E9V%G9V)N@,)B</6V<#=R9;
M)ZJ_&+PV<3)RM+!WMK"SI?C5-S"T<W$6HG1QL3#F-S4PY3(T-N9B,C3@,&9B
M8S,V8#(PYF!C,N;@,.;A8N-E-V4SI/PMH(W]/^#_I2F@>- Y_&*.)@;.=HXJ
M=G;6PO_6;RT$6?[CLK_YF+R&?H1_?162B96-B9U5Y?=7(?]IT9]S!%G^@[)_
MC4#M!VW]P]I0TU/\;Z!'D$>01Y!'D$>01Y!'D$>01Y!'D$>01Y!'D$>01Y!'
MD$>01Y!'D$>01Y!'D$>01Y!'D$>01Y!'D$>01Y!'D$>01Y!'D$>01Y!'D$>0
M1Y!'D$>01Y!'D$>01Y!'D$>0_V?T]R\V3&R-A6C=:('"?SSU& X6]M<;2O#0
M-P+RK^<'(Z @(2$BHZ&@H:&BH**B8V _1<? PD!%?8KW%.L9#BXN+AHF/@$>
M#@$V#B[.'T\]AH.N@4=X@H#P! <=%1WG?YK^>.HQ3 ZL'QP,Y>-3C_]_\-3C
M=0A@F:MQ[P0"6'RM" $\R3Z\W(  FL(M(8 V;F#]#2C-$[A,3#Y_S[#>F%6?
M-G>LP<#BX,P.7<79^'"W>#F2^?!,=O%P  +P(1J' #Y:@]S.,A^PRNX71R,M
MF-<=ET!1A*"C1#T(P-?N=FODGQ% ?P! 09&G'PZW)2OB[==;( #*?Y?W<M^'
MA]<F4#$MO.ZOFP\S)>]>Q#<O)CW<<.7_9GE'973;G$TVJML>#W?WJ0_*8O3R
M]A2T*!%Y)<<":N:Y/[-2_HO?E43W)4A&**L^B!GI&BO^G^0D_X?TD[E_,B0_
M"H\\>/CB)>V&H8-Y0L7RMY3 WY*#%?YD^*?M7EY$'Y#4D*])Z/^6D1/T6VRM
MM#^Y_66-?9HY/GO@C[#FWQ*:_RUUY5_<?IMB1K;FMWT70+\$' 6UV7C\R;7Y
M%U>SHSS,@(/#XL3)'D T)\8)5C0,-1IFRX/JK'^Z-K&J8G:]L)?PX(D><8L"
M6W?7<)!)X1F4^6\>4(-6I_UA4*\'+*]ZU.RJIC#\*"*I-3CX  INR3*3NQV&
M70$FKEA;$XTY" #C"=7<A]'*$K_.M\5'%[9Z6EL.)H**[;5-FF@S7S*)V'<9
M&+BRTV3O>B& ?^D/^M7#2PT?9>$8RU+#&B*S9:&;.'/Y%BF_1%@IF7J5(2>R
M(%>PK@%72U&>Q;3R?V1)S /?ORRIXB5MXZ3W7^U/T!_[0T0^]\?^,.O@:_P/
MIT[=9OYRD2 X.Z",4%%]9 S"?^5.0[_=R7?D$I\9R??_&R^UVP8A<Z48=J'6
M6TE]Y$'KL]N<:T?5P=VA5+<?]?1^?]JM9:D<UX5K9?+5.5M3@NYR>!7X+^)N
MZT"87&]FZ^(FJVJ6T9;&G2K>\60+QJ":CP">3/PM5%9SD%O32Z?$N1H%YOPC
M<: L2.N_BO?:&]5K8;*%SHSVPLIBSNL<*_>-WE/*]U*SR6=4E2P6%%].MK03
MQ/7%=YS2_B43ZYDK4>W=K^!]\,**AP:CP^NDA.DS $;N3+'F'5]S4Y!B'#$W
M76[WQKQMV]=X>YW/4K31B$B<UQMT*GWI6:NXEYXLC<E3_]IUWK.KPXU'O/Q#
M):<F?B6H3UA8(\[E_1L;HC=Q2?[O[C/PW\Q<8K]] @$"$![Y'V^UV'](2/C_
M[R4DNS]USSYBL"1CFT"S/I4T0Y[G3 #Z13KY:R[^"CYUW<+%DG9]N$[T&M7Q
MPR<S4FML)-5W\$\9/)D&YANQ3C4W6# #VPO<+:UFY'[ZEJRYU0%#!(66%[$T
MM>;UQ%#I^,)Q?JRB*/3CD)"#/9'NF,A1BMXE[9GEV)@\:#.L#L''UQVS"]1X
M:%*_D-8@J1KKH05[?F2OL#*-T%PD!GUZ2$J*;%%5*3C,$.9Y\EGQ"]#KQ;J/
M*P1 -0N]I%BY&TPD"@13!\M/1MD8H^3.Q>8=--%?>2*IAO;7PYLYLX7YUI0\
M4[UEF9%^6T0N,.@% 5164SW<Y*<NKR?H?F+[LAQJ_&P[NOUZ4GC2S/$':V'S
M^8F0*RATAD@$)VI&]\T)B0T6_>I<]*N[<$G,+G1F\61T[JT&T!Z=,@0 J_2J
MA#3PU:0#-OSK,A(TWQH(X&>X4%7#%,=3DI> >H#[^> D!# <M"Q9F5!R@8?-
MH/)P.K%ZU6ZQB9 DR\8\W\[!LH5,/IGEOXI0%%9T\Z:-:7J>.,A.H;[UGJ%'
M55;GR7.?U=Z7:,8DF^/IY/E<).S(-I35<Q\/6@'^J2FO]#<J&HMN8^^#_;TD
MC\U*Y[R-1PQJHW''#J;%)AHJE"1+J<E'<Z&*8%\+ZU:.?V?M40D08RGKPQSC
M6F77J6"=]YG+OU9Y*G"V!3PCBBH.T>D*ZQ05J[>*66PB*-E6F'TSL,:KS42^
M" $ +F*ORI8A@/($XU-#[]4>\V:/:]5/OL_=K50"-X"5C.R,Q@U.'8KOJ4B[
M@0'NUC'$N\3VCJUK\)$)'T@]S6Z(G/?7NQG0KD4\W\/FTT[9(BDH0KGWZ@ #
MHK_7@::B&A$NPE<9^/ &3_AFB[>D-9\-QRY%=CCIR:W8R*H>594P!?3)R"Q'
MBU,_P3FSK>R9WE'7(LNK5G/\:OO\\_*'I=/AFTC+"U)5FR8J=^$I53]69J;3
M)BZ2_"7^>W[RJ6*K B47*I?:H=B:M:N:L8+:O"$YMU#!V8=GVO\JE%H?GLK]
M&76Q[?OD3N?"ORXT#/\<=UR-JYOQT) N_*>03F:Q^Y6\_2)0K[&^-@F.^[VG
M^8JQV&!WG%$Q%/3TV<F(;D$%N/9(E6ZY=K&N6@AXBP9RC;]%]O2-G;IF.^TD
M>^,;NSJGV#GX8PU8&I2[+7GQ].R>H>3$Z"RS)W(T]'M3+<?GAS:RM&SR:;&Q
ML^)FZ&#D"Z ,<_MN#!_FWO/M&\7[CT) F=V[K_<OH8LR]H3_ER]0 AE$BN@&
MQ9!GD[WV=NC$-[Q9ZTW$;&W&NHI7X)EQC:'IS*-^@DIIVZV;_HGV*!=:W" *
M2I=8E.1I6C#1),8AJD=1D=,]+R7\P$L1(>"O5[;2B*DUU;R,GR0:L6*%6Q9L
M,S/\^;,,KZ/4;5!J;O5HVK*0X-68[/>CA\H,/9_4Q0%9.3T$$VW?K, '/$)2
M7W_2W9&+MQOKY0]-DET*G\I"8HJRB?55K7H9=*?8Z\?ZBL-.4I"60,%W<MG=
M^19UZC/66=2,3=[2R=B8:"WGB+7[RJW5_,SI0N%KPJISZ-^E6M']NPGA_<>=
M2SSJ:T8J0(%U)%H1T74KH4E9P9/KZ<ABR=5]R9L1F+F-]G&>+X(=,N=T%< ^
MT=<\'FKD)FZGK.S-#8.(TD*>:EP6773B=E/ZNZ=":&0N(?GTL0P0 +ITW@R+
MKE?.@YO4\KXW0IZ^1;7G1SPE:1/+^IR:%N1,"A<A>:DE)\VRK4M7_(Q#A2BF
M@UCO[S2A_1'BNX%O103/*/RGQJ?JW(&*-3573BNSA+1NE=5^Y"_(ER/9L>T!
M:S$+#8<_PD60*(R$0/I3YV#SJ4*_?)0*&K-[*C1C"P=$\F?Q&Q4JVPMS=3M%
M:0L>5?E%V]M%$$#'IEIEC"+#>D$GH52ZSEH>H4WMCBRW.VD ^U#[#0Z[+JGE
MP4*7QPL+JL0=$1)'B6ZZREG_#UT<R9$."M^/#OQM; TG[0RJ)[Z4IA+^.*7U
M/OF19=+N0BS20M6,.WT%E/4!ME^4OBDJ:C)0L6N(BC?\Y--F@W0_<X^/JVB"
M'2&<U5A40)W8V'  _@Y,*N74)QXN;,=YV8#+R.$8*OU38&:T_C)):V&3-NO*
M=?%6],$+O5O.@2 \Y#.U0TU]7K<H"MKEC%7ZR!TQ=V6AEH8V9<*!B8:R&P#;
M*[5]H:KHL&)?U(*RJKZZ-A'83,)>R+Y:!EA3&PHZ1Q@^KR<5?];//5I4[_.*
M;W57/\WH&+MS9=ZR='VC*LFB[)[XLP$$4'JB87(ELS R%BHC=W!YUW%,VPX!
MP%NP+6Q/>A:G.Q7/?._>E,5FRAJU15ERJ'VUF=]-\JQ3]IAXV2ZHX1GF=+JN
MI8WLD^\'QN'6Z_"PG<C7Y?X15\7Q'8D@?Y;FBDH!(5LG-^<NC2*BB>XO>ZU?
M\8!TI)Z^E;ZK.B,5:7"+6WTK3QHD+SX0S<Y*6QZ#\TDU.-+DV\,B4BRTF.JS
M+Y/9NHRPLY;YPQ<7Y+AFP55:V^5;_2P$=\^/(C^J&7"EA>30H33/4@7B5<WU
MM3"K.%-C:ITH?BN1R]QRB 1[\70,$8#:1(KZJXBR^V>4Q8FN!=8T+A$(!3"
MGSS5,,#%.84Y,S\A )/M*E\1_;-069\881C]A/(AG4G<;'FE2^?J%<]:.6\?
M(C:7V:342Q!*=9H^%4_G(HHS!(!VI2\Q;L,E/D'3F"BU("4QK6Z*B$]%BP3D
M =RH2Y=X/SOJ;+Y82,N9V^DKM% S/)_9DI@\X"ZT@0>(M+O=6[B$:\O7'R$%
M.==D0P"RY8FF<4)!R(3?^</(A(!$>W?2Q\S='0-%YM]WY##"!;&2M'^LO#.*
M4G6C O"PQT0-G11_JG.+[SL1++@J&J&WD='BT[VF8["P<6Z,5RT[_30<3XO"
M-A8&2H, =%E^I]?Y(:$\:/HK8=Y<8#2.$/N5D+^ ## 51NL@ &CV$X1FQWKR
MJ1>.?R3%S-_Y^D9QK7M;O'TW&IH9L>Z'O9R+9U?D_6[BLK_)6L D#MJP+Q #
MZ=P09VJ,=3#D3WZ2/9SK?A/E/;L HY(:O1U=-K<^9^CCU3A@:W7<REI"6\(:
M(M^$K<Q5I#'U^)H8:ZD2X.EJRS.R7W*ML>6-NJS+?OCZZ'B<,XEP77*<ZHM0
MD>5@(:** $RT&,G:Z8]B*X6R"!#*+M'6&.>UBX:9WSS^'I:'ZU'5:LUK=0OJ
M -W^)YO%'AFDHB?P*H$W*S2Z_; RO8@'!$MD]P_^HPFY"SH63H1%MJ;E7\/P
MJS]W=?H62)(RV!4QE.QF"((*5"_7^Y/LQ"$ .SZNT\:T%;E\=U,FV39/DYX1
M&YMSPDHGG$(;RZ=U7S]G['=+W+9*DB2CJ;NL8,*+>S!ZNH17AE=F\:_/)1E7
M8J)9,HW'86$0O'^".K=$QJ$CZ#F9C3JXG:\G,472W^:&*)_)- 0,Q[*J"\.6
M9?3,7G.4:9-TL&]-"(+YNAES8#GY F]ZH]"O<]S!(;'"HZAR07]]>,OF3)L8
M\YDW_R0C18!)0VRT16(;@P'S3]="#QE-W%+/$J&K_83<[>-=9??56]&V-LEP
ML:Y= UA^WF1F$60,*<'3(;XAK8&&"187=+"+CY-362A=HJD/N&6(EG#)ZU@^
M36N<!;7A)G9M?:S7-'HYV!CIN33M9TS@:/;*,].H%K5U>1N>G$8PLW%LO T_
M%4COZ"+6!>R^^,;F1=?D8"N>EVEY101?A@'EP<R2K8 _#_QG 0""^K%K4+:%
MEEWP/M&L9 @L1:B4MCO3P$R8WVR$X(2 \'$,$FU(NXWHAK19U,$!Z0$BK1.5
MJ>+4!M]F=8G,]F&#<\SVU$5(XL<^-_POZHKC6AN\\<^_?U)Y=P2P/AXP+VR3
MKLX]&_0P<'"FE5:^C+9H9G#<+5$W.[&K784 IHUN&WG/LQ]:(0"SL^+:S' )
M!1)5M;IJ"^[7T3H_@($X<R#AV-6)CM'V[M2B+^H)%T,D*R6T1DD/K7!7T%N+
MTJ!OX.N<ADBF^V!G]:GUH2W+W#MJM:-C%S,G6Z?(!+C5(T*N5@6^%A7OTJ*$
MD/Y56ELCEEMXD-M9E@W6LS@]AH+RQ*&WH?U5L:9ZMVS=XZXY.WC'7%EIK$H"
M4Q+LY1'8V5H*F66J;!-\Q!_ZBC]%.Q9^D(76)PQ:4V\U#%"IC9/M?:QD>N)V
M2/<)Q;;U;-431CI$<3R2\FV<30F\.WNQPL]W'*$Z_J<8U1=S=;UW-'O^1ZWS
M1V&E"_I5P+SQ_:*C0"A DM+DE^,\E_#64;*DT@._D\GDO(1 IY,8/V3\/I&&
M$,AZ.TU67WZMWKBKKFC!KSOQDYP12S#W 39KRN^.8RQ-X]B\/H;EXI5M,&U<
MC/V3M"MB6)\ -U&=+[7UJ4R6@U7T+B8%?M_/S;YY\UW1T"^*.0 _69_=0@ T
M*?O&@CGV;#6\0I@Y#"/45_3EW.2=,^XH;LQ;4:6@PR(U>&&RA@]]V?V?-@N?
M=SDZ>APJ@TQVTDXA (?=RP&/[ZIK!PG9M*&*8T_C>SC45I<*%9J%F<?DCRLB
MZ=3MFM&'MM_H^]D.G%[U#L2Z$T?JWWF%M(TGKDI%\-1/V%)AL[Y^JYLP?8'"
M+GV#$M>U<*E4[K<SJUP3MV"L2?69P^!+F+]RGW[MR$!$2/,D)P2 PD6\9*$*
MRX*O\11CN9[JJ.O.ES-WR>M-D?&Q7C)A#5L@M8^C-C!;\:%O KCUW %:(B<"
MOY\#;Y!U0(NF:4RV6R56X=O!$$"/8L8BO)C-4$C%I(F.+<7:K<^#<$8A3TLM
M,8JW:@Z[?U3-25-[8LE]? %H6'3UX9;SE\IG3Z$W5$T#S%KSP_0UZQ  &_DU
M/3.H+8R)./W8-A4W0FKG"2GOO"Q42@E5)+M0SDYKHQTA3,$)EKU&Y0<_?/++
MGYFW+"H0P+> [OL+\W7P/%)%%_1V3/)!)C3_2&UUG6D%S++.IT+K6+(D#Y3Q
M&6JMST\0O4J2<DAU>YKEY=]SQP#\I_7_I*)WY6V&[ALS'5$(H$5QW9?_2@P8
MM&_G@BJGMJAZ0IJXPHM(Q-6#T-WO*%S3*79DI\.=N#:C KX-W1J<L!UE.>D]
M0)H*.6?9$RA4\PKO,FUEC@!.P@J;"'\[86BKE#4]T@]/ZIGK,7,L;_-J\.8W
MF\L'/'!M&>127YMZE(?+E*:@1&_8J0Q9QXBH1KTG?.M^HPSZP[GE\D)6<.W%
M& "J00YA(4G0&KXTK]9T9-? X31? GO7Z!\5?EK<7Q>X3[<H@WL[-VN#G%?>
MY$L9]8B!0MTA#-G2T]?!*]G]O8O6.#ZEZASWV3OC( O,0W5\MG.VMGHFC*1]
MO\@JE U01=!EWL,H^4+FUY*"\IS;=YG[?K5I^\_O=X"_SFQ@_F\<K/Q^;)J;
MTS(\8ZFN5L;M)HFV]PD$L%#NG,ER#;>L2UF9*7V>CH]9ZB?-1UP_]>P^"]@H
M>?'YX5R](FZ*;T%3O)H6P6W-)=HJGF.FTX:F VSWA(F$<2WCV11<]7FG* O@
M4&?HUW3R&;';"9(%TY'6EPSBFJ36_!.=%1QBZ!UEXJRP&JN.N"U\Q$&@AT:1
MB\&?79BX_1  U&J*?X!Q3R'X*]IDUX[YU!-NAIF57$, PK%B741R&_G+O&M^
MRTJ35E?[S#)F+\.(X5-;TPR]#KLKC4&61E<%%_$K^9S-0MSB+E;\!)N5*7#B
M[&G+!MJ*'4.H6BG&M5^T7 _J,EN&'-](&,1-M1G0]/!U9MW][-7QYHYO9T-7
M:I59F&6O_)X' 6@_IZ!V/ZS]I..4O#K3J-X1W6E5K->.@<>[1@_80MX!"AZK
M>S_+V4KL2O')M^#&M"F<"=3 VSFQJ@@.6>*THL(5]2"!^9"F=1I\WGE*F)W$
M_JS'Z-1,J/MZ5S=AZ*D!A[6,\[NE_'EAJQ>'=KJX%>= UJ/% "=FDL 7J5:Z
M,G(E+GJ]\RX'T#+Q#Z=ZX2UBVVBJ"@%X46;)&?+Q::H&E950<ADH+UO<#<VL
M2F!?Z0YF[J>NXC1;_V''2*@=LQ\F+'R*+<XEK;*<FVV@7'QQA[H=.*M.=*AM
MCR1>>:A*J])^H_V6UPQUBOQ\IGK8]OEZ4#LISRP"N?4_;X9X][F:\V_?_NT)
MPN]N"OGMJE"$IQD2_O#I6RF09\2?@UX?=#?;9;4%[H&Z5@O8*[Q[%+X+QD4R
M4;N]*,>+^X)8IYB;6MP/[+65(Q! ><;)*+"29C$1Z9"G8%\Q323:TPU,IQ+V
M(IMJH)_]IB:$.86)V$IOTDTHMH&##+P,PK!@8^_,ZW9NMC+3K[T(8&87$LTX
M+QK ;^?G"=X<3*/9>SJ[\W1FZ"(8*U%JG49U"IF[2F05*6^CAN5*FZBF8<(.
M=UD;+&J>:R'ZU-!]]J5R3 0OWZ"$Y>NK,@\K3D=-30T-A'K\44G;[PBIJM":
MV-'53Z&WAF3*K"JS]K3YIT<1%0V2Z;G65M*D^B%X=,^-".1O[?WZ>V=VGY.=
M@UT>S9<AQYWEV _W2R@%*G=!Z]3G)(FV,<M"P,Z^ER,F-=567M/[V;?&H13N
M:]2,_I;%R#..N7RKJ0Q#T(T.)HJ(1U_1:K!O'!AW"WS;S,_/9C([R!8G^-32
MH^GE8L%*&X,N15*Z!Y4F@S_CMR-MKVHXVG4"<K:5Z$*)G@H[QG).I>A<YKGB
M6[=FK[,]EQN3N \E.\H6549O \^C%<HY1[NV&>BCZP-;U 4\C<]W6\%VB-M:
MJDWIV4QW['HZ\]N7/$JB!_58HE6#A/+RN!$^XQ>;0V!O*\1LL%;O\'8J.9US
M=;2>&$Z_&]T0'$O$'2"3=Y#?7^DJW8$V@G9J;Y13M__S[!O_=_X6(H1O/:U7
M_?A>1.?+T;QX?7)G8FO)5J<#WKG9 8-XBF^T^_<J%C&V+XE>\S<L=V9/M(NC
ML>1KMVQ]0MQ@H=#=9!I1<>LAQ.US3P=7"*F=S*!N'8+3[:)WN!%T/?U;J=*[
MES5'[L1-*KUX1IVOSR  CL&0464^*7T"0_#&8;O#9XT()-S-)L9C^,3B7/2
MIO'H$Y\,W@?5M_+V2 8:ZF )SKDIN7N,?N%GN$%?=@R%R8(?2/4*2T <]4?[
M*8OAAS(=6@P(O*:DVC.-,9)'XCGAIFFULUVB>6MI8)YE4,#^F0_EO,P*[QBC
MCX]5SD1EH1>71]:[;VAH-^H;;-GW8-K0+J!;QE;4L4>@@5*V.C+!B45_9JB[
M(JC.<Y(;G+7-[_>U)#T"#]AQ-7M]463WU/N-AF:;%)7^9,.JSE4"6OVEE,YM
M\D/LYLKZ^_6U7-2O([GZ*U]"R5X>A2V0-T1ORL:NT'MB.)V?DTW$YUY%N=1.
M3JX^52#H>PT,)4M;5CTC#ZFZ5)?-VL'&I%?^_B2A:9=\F7;X>,C6"K.+R$I[
M ?6KM#16-:(\\HUZ>$ __;(5(S--M=PN! "XT>(JP75SKA;"W'_2TG8\"YMR
M,7)V4<P@?DQ[D9)8CRO]93\*_YMM EE7R1^I07T?QT1&43FKPFQ&N;TK2V6I
MPDSNHE5R%L$)",WZ?UX )=E*)C3'?$H5+X;$?E\1C&[':_UWBB)7(KX9' E_
M$[.QX!85NN3?/!LP]!VJ4T@AG>BC$]@@.0V3: 3RJ9\40 !XQ6]2T4L)NQ/<
M"6[?%P$3BILO0)6SR^Z+! O@%U('H^QIH\_UOC0'X6YY-S1.RUTFW0&7(W+;
M?6G'O!6X.M12W[E[]+^'H5P+[_-SK&R^P"7\<>]#+RO'W*>0:&$#-JB*6ZZ6
M.?ZF%E5WUX$A)UEL*9VY=5E]V*\VW# 0\U[4[[]Q\MY137?+OW 4%46*- $1
M@@2D@W2D1>"AB8#TWJ1);])+5 2D1KK20B_2>P?I(&#HO?=.0@TDA#?Z/.?<
M\[OWGO6N]_UC+U+V[)GYS,QG9K-6OG,P59]$NRB-C?B,3"OAT"92NY5PK\PT
MQ?T(Y7K+6G8Z'^O;']JV>]OHFR828.FSVQ[/] VDRZ5NWAVF0% XW]9&))2[
MX6Z"BVICF*_9W^8*Y0A 3UQ!3E^/ZSU@?A/GMPBDW9\F<IT]-Z'Q$E*EV-KX
M222W^C+6RT6P?@TA=[>W=S-7GD$[.#R])C%G9D;1C6NW@UK&Y7E_BQCL&)56
MU<**](A?FJ5H'"]1;B*>U?S.'^/_\:.=]L@.[:ZNHRF$C^:+ G0GV^*1/N4^
MNRO'GC::X%)3O>L6\ZVHZ$33\.;W_?3O?2?2%E778=WU#F[M/K>+][ LC67"
M.F?1WR;DXV<=NX N]V:*@W9N/R*E,9I.AIB9' R?46+WK5'"G1U=28:)X?83
MO1552L<A.@"2;[K.'2D6%BX&&KQ1PA:1.:9\I,[W@5)I%WFFCFJ)'',%9\P2
MMWFF='(7[.*')9G]2Y7&>:H=&-&R'WN R!."JNP"SN_$DF81OFOT&U]VR?Q>
M(_0:$8-[#7Y0[A&K >4.TQ+-U/I;CR,N22=@[#LV_8)(A\6,<?]0_]M^R\@.
M.2Q\DLM*HZ/PASPZ,OH:$"5*TMX2.GHKB3[$L:$9X\1I5WW Y%"XQ]>9)D+#
MPD(C/@G%#FO;K;6)/"Y"XO;C17ZX!@Q+Y]@(=*FHSLH=EFP<OG=7K4;Q*'YU
M^?R7O,1/LD_7@%5<#L$UC#T1[6C/]XO8U ,C_*%]IXWQYJL\[+AUZ(C-!7VP
MD7P2>=CVTS]=LW)H\I^V"4-K#0[X+&I9OW2B8MG(K&_]/9)QY B:;["$G'_K
MA-@#]57W81I1F$E9!+1M@0YI'+1J9-=9:5N0AW)3I3I(DH+^BI8[^GDK3,J>
M!P^TJ^$GC> )$8#?0?%WI=&TC#..-"D<=2>(KMG0S5G2VM@_O6$850^*7]O(
M,7NZ#!_%WCLCAS\3*"^]H;YCM)\[67U%;(XVO1R^*O.WTU@E^6"&(.GL+R78
MYO+,KU*\ ^>54>9HLIVZ\0+. GA3[^_6T7 8-/%TXIV#O(*>(FGRKAX#253=
MW!T[-K,=V:J)GKR0'E.DYO;8I_C<DMCAZBW;W^Z :TB*7U<C8*$\594%LUX0
MK;I1Z43A:+V70_MT*HBZU5W-*B.P!I)NN'I$ -VLOFL&>?J3*OX,<:_]HTMO
MSA[[VR1AW0BN'&[WMX??1\?FL%.25;^/G47%(]8#Z% \;8_B?[34CKMW-MHE
MBW4>80+),]\_>/_CR]7Q3)WO/%A]U+[HD'N/NYCS\(:=76B&190S;TR$'#5A
M5%K61*C9)I65V[++U"M+0?78X5K*C5&;V0-A",YDX"S^1+G5B+N=^^B, ]\9
MY=@+(2LE3S6W&,#1D62 PG9:9LZD.+C$R^R-@[7<V+OX1$F]ENH8P-1NY _K
M:T")A(TOS<R9J&3YIPVU39T _TB3_<!=^;.VTZ+90T)4H-+(ZMCA.XF7H\I?
M;B8F/HQAXB21?ASA=IJ)[I!D&!7(/Q4;)-&H&K4@4#_R521[B)]!K(/_G'JS
M+FOJE1+Y)X^JT<:*<:=9_T&>?YV*!MY'A:N/F&A4#KDK-0MPD'O?3H'>Q3ND
M6_9 _O)>:5#%]V*'=YH08EQ6?,.3@Y*E#"",U"^#W)B"7*?Q\^@D=E9#"EC,
MTVK ^-*/#Q2GL_>+DVV8SRMY_I4<\6BGUG7%LT6?_NG*$;6@&M'6?S27:.RW
MG/C7+B2"@)QB=":X3[)P,I-LN*V2LX?R(&)=C_]C+^S?G[YLJ'Q^0^J-SXVQ
M29:SX5WC<(1U!Q@19Y?F%]Y Z[:8:P?O67F(3\)^F+N01\Q/JH0OK95;(Z&Z
MU!U>L.VF[,^>$+4B\9&\Q^]C0 K6?;YO*55H09&N.#-R_<V&P M5%LFTT^FW
MEZ_TM9,BJ__ZY%>XK5DMH0Y7BFCZY"BAN*/L)]J?QHTJ>M<"0A@:V^B0&FN!
M&D5FX7A;B6'J"N+!$M0EBV,Z:5[PI1T]N7.AR(B3M[WX"%"QY^4FE(&@C9)J
M/DK9^;R5'%0!<^@,]I5V[A7-0RL=2'!T=8UFA$S>F8G9<S>S>_-F-*[("UO@
M#EGN^\:#_XT N<G:C5]W<KZM2-] )^.X=/+\RFY8W"%O>O>AG:?MM@!?Y,_=
MWN? -5/T&/T-E/4RS[TM,"+1*T\_V."A?8>5*YGPECFX"V2-XKT(.S^* NF&
MJ:2^FYMTF+Z\0R6N:=YG9'12/NVG/)Z)\EWBXI>MKHKL.K%DBI]$9R@)HSNC
MH1FE9-@I"3Y(ST*SCU,$C*3EB0QW<G$;5W&*NF-MC*59"N%- M>\4OS:@(Y!
M<7>SY4&=SAGM;TO2Y_!WA8X.XX8'<344!P'9P3V&A(230^L!([ #=HV8N-39
M+0^+TXE'Q&E/X^*2'7[.>(Z?# U@I\7<TB3>8J= 'YW]Q<86&!$;X9ESQMLU
M"T]@:DBB[(_D3@]3_$)SYRA'V#P3WF1''\NE[XNL1>0V+Q$9J$X0PW*V+VN^
MFROXP5%Q<+PNIM#&?M:.Y]2F)$@')A<3M5/ON?.,KZ8;$S6J=KE5VI-:&\T*
MK?]4;Z4]AG^%2)JVS^&=A,H&AY!%O9?]FAD>:S_'<H"Z6&!O/I7".':>+GWD
M,'*V:[,(:.4&DH\XO!^Q/_MK[QU-OJ;UU$X4Z#Y'_J"8]YX][@[F.WQ5>:C=
M)(58U1D]#5<64ZQM1A*.VM3,A(=SR'M$6KZ88F^LH\'S]"E=!H<$@)#9/LNC
M A?KL?*?^UQ(8I]\*3-M47^?=YZJH %M\-&X;%::Z>$;>$:<6',6*M=WA?;>
MW1+^N]ILSM-NCQ7[@?.,:95?[PB[_B(*M'%CT%VEX>.([X V*3PN&4WC8'F-
MV&C.7M2?-GF;%!FY/WUS86%E1&'M:\P=4H5^MQZZ01;IS"TC<4>"S(JD7933
MN6!]'JZ.<8&0K(XO\?(U0@RX*!:]G0F.B8D!V>WJ/<$1.><='^BOBH#90PUV
M;NY!NG?KTE7>VU63[]PA.#2AN&HUS)OUWT([-7/+V?7?7^C1^7/@#*C5=AU7
MZNHR HED=U=THN%/U!3%->N."ONVGA9TV94O"!;WVS">TEFL<M%[=[FFX;>(
MUG;N>@285VNP2&8' 0<F-99T#XKV>9XVZ=36_!!)YAB-\0^^*YBXI'IW=CN-
MJ6'<WCW<2'W!*/WN7>9GTSVWHMI;J&B^_11PT6172K[0GS5.\@"#!W@3M5@5
M%^!R-9)5R9VOMT6YFEQJ-N(VH5)09"D7<C)R7FLZNP\DYDL0VS4S7#%R4M S
MY]"KN!IS8_,44]B%,5LA?P</[KV<[!GN&NM\'2G23(K@CK!1[CM01^*'Y=;'
M_SH>=*F]["Q27+"I]4P.W2@_9)KS%MP:R<Y,"!'86)/W+A"SW@2U^$OLS@G,
MVYP>WK71J4CI9ZX[OK>C:ZF(<3&1F'?\LJ>B%X4_B;D&B)Y_WH,L Q&G4;"4
M9"]*VE%/[2LW0^]JD2,-J 'VH2C"8<$HXJ[[TY'3% X2;HUU(3'D%PCOY<3T
MA&JQRZ.@'Z*?E--B B\?-9[!?:[(GZ@G$+$,7:F&,.\_@R9GB9;^;X3;$AX-
MT^HG_B=BTR+B?_C9I-9WN+>K'R\3E>%L@>@)[K$AA%^88^PFL/AR((1R&KZN
M_"Y3WN5D!.8O,Y8@/Z8EY+HR9J0Y<2DB4_7.M#G6BP<;$0>1,2Z6M:2\L@\P
M,%B^!M2N7U0ZJ0ZYUS7I"66X%3P9[74H PEM]HEI!A[EO_:)TGWOU4<!1^D]
M F.>DGG9?-KV2];L'7[#67:+VY<\.NJ.XHXK_[@C,,A\<)F.?M4X7"]6]4.U
M2*+MG$/'NY[5/=67D;T1JT^O,C(*;&J2NB)J/+\4#U8U\0F# MOPQ1_(2>$S
M8(/C<PVV&OR$/#*E;N&1%L4(?")<(QI0[#';NLUUEN.0.]L\N-[I,<0MK,S_
M22T&T"=.G*Y1S),^QC6R,F-1%RQ5SQS:P>'[480Q.K'9"?3KM'#QEI\<\ITH
MT47,KEIY@FZGN0^HX@A9<W?^_%X/FAYSJ?DLF[?()5_S-:66SXTH7L/3Q ]5
M$L*=9+O.ND4^GX+"E9H_$_9LL&<OZS5&[]BESR_6_OY?E@1;*T@_1I]UH5,T
M-\,A:_N<JM9A??9%L"*0IOU#;)<52J/KTBE28+%F>T1,MM&N*#K.79P^A(;N
M^6-Z6RZ[SDM"T4\^#W,\';EYI#LYU]=^,OT, E%WF$;YG!RP.Q%[F;Q$I!;.
M;FM_G& CWJ#]%@J**E+LJ55IR7U?I2FHGTQ7MSN9?@UX7F0D"M<SLEW9.'_]
MH4CE-&R$.IA@S=[J#?^7]#6+CSZFA%JJC[P&Q9F=\&@A5>*#$8T488*W;AZ)
MX-M&=J0\LL>RM30AV.V2/+Z!%@9O#B2XWM1U[%;\T0_@\Z(1>:R6S^Y:X?!V
M,-6WXQ(26G5>/K8?-%A)R7R/W966X>-=!N046IN[N=@&>%^<QV%]NDK;I6+6
M8&:FX(WBK:6 &U&J.?H(X[SOMDF/5 MGN'(6SHS*@[7<\8,)?CR#U^%'+%G?
MG/Q<-2MAHEC_\;++G9KR%<S:<K[N0_2'W>TPVRLIWXK7:;W=X6CP2FL09RDH
M865B/H=?KJ_2^9V'1L<==3YB/HG=0-1Z=D<V2G+B%UDWK6Q-E,0FB^U%&/]A
M']:HL 7E1#3?&@(>R10:%B^:F,B=,OC*^(-6"'"7-C ZS;E#?)(2+3T +OOF
M!DV[C1G(N]3L?Q?FHZD6-2D""ZZ] [RQ"SGYY>XT#&E/1%M<CO/<$$Y<XB%K
MI,=CN<!J!9T=^D1H\C!-FN]6&.OL'V(6,_]4K>)5A?=&O4D->N2J<:&NGN9D
MKFP/Q[^!C<>RKG(HGV&CEZ) $C5N#U_5O=(BNQG(IP N(Y0Y7)(Q4%9G%#OH
MR,U\? WPK;2W>.:6XI?]>+PT_%%P9;X?$<*X&:E.;88*<^^N*FM,&N0\V*CJ
MX#^,,+?]"&X M#_VFP;SV01P3HI+/L5V(N\4IXM/'3.-..54VP!^X5&8*JPA
MM00E#%Y/5M]JG:B.5#5NB13/;AAWLJB/UW@^0S.UY.I%N=?M$BFIT=>Y)HBD
M@4TRK&3.&6$GHJN;:<Y3]D!714W.-2WJ7@E.1'>&7BV_\(56IM\6=E;%1Y#,
M"FXF*7E5REZE-KW[?=,7M.'*;JU4YL>2W:,K25KJ1P\_O 8DFQF:$C\#/K9J
MT6Y"/BTO,.KQ]B^UG3PO"]+E+CG,B=&]>?11F"N.P,><6GS$%LLTT:0H3K;;
MPCCA)SVQ]O5.<;[2.T:N2=/H*#X1D8WB<8/92VL*$6M2&HWS6$4IX7%7"(_=
MJ>0F4A#6&0Z=T6AW1;UT4,)2CK19G^GNJ0AD69?1-/UH?>+G.-N8<FMVIGZ:
MJ7D<2X4Q2EP6J"1RP&AN2W1'_5B@9>B0E#))OMTTV.C[D+%%$MJUP%@S GM9
MA31NM<QJJ)!,MONN2E=8:.W,BS\;F";W?%-"629[-PD: AP8%G20EX)9)V[:
MZ+@:*%:"UA8^D8D\)H?:!DRP[41DM4_%WW>3GW_9;Z#R"WL-\(!G70/>+N[W
M@S^UWB'O=,H7JCXS^LNPYOLO1\B$#/19ZV"* WINI4KRQC7 VL\500?OD/!!
M[WF**O^TO30:3?N+MMSMP?8/XDX?*KALZ==3'O+=I.,7,XNA@I&07L(GCXHQ
MM8Q<G0_9FJ/FEMVBZFB^#^T(/]QOF#G:Z)8NIDF:L H]>\:^&\^P'%<1/4=&
MHM_QS>U8?V="HD&/V6FO.J@A4K=O4'"X9J:V;PHMMG0-Z'2@75'=)R]=:*/E
M*@Z.YH(%<3ET!IB&,5!0WVIE^;K;W'WP;$J<K:B4PFL%?!?#A;P=?Q@BR64+
M]_<'5#:A@BB+RF:-LAZJ?Q)QCJ#8?,OJ\B&R!\S8X<O<*,M$UN<@8"'N.EL?
MN6(V'!_"$-7Y&/&\L"$OO$EV!1!>[)5G/&D>D1A&IZ&1M ZR=[\Q%;$JOMKL
M\*A/MI#>R)$RMFND\&5>/26EU:GV)-)ZJI6<$2G<28*'@G7Y)'G!?ERFA9X]
MYWE'9"S%'9)//4<A5+^EQ!ZC4_#$NT_ 3[UR LOB!>R29$8^0)J\SQV1[+LJ
MS+!5OT@2/ )]2.:?/DJ/:5;4>MX'6DVUZPI@0#+Q&MC1LTU6AU-;D'59Y]NZ
MJ=ZRKY^1%GMP%V[<$:9LUR5Z#0A-#Y[50TK6%^E*[W)JBP;G""#D^K_DJ,WE
M,[P36168USQ_7N#\BQM64959;S'CGY#DO3#OKJ^+O@9T3P[;@,G$!3TS;!8I
MJXD8)T;FJ] F^/[136+B8FXU+WZE?[QWJU>J6^C+S23D/E5G CT7R@ MM:,O
ME.R6HV=DJ&_8E3?/6#24E]95RUYY>ZL'L$2,T1F82!- "B6;<@I< ZB\ E^-
M>@/-*L:M@Q=38M'5_DUIZ02%EB4[^D9%9Y<>Y04VT8;I82MB8O6,!I^ZA92J
M(G?[EBZ'V;\KZU%^7#:4H]'<*/"8<]CL9V:!2!"!:X1+V"2G_.TH#(E[9M.J
M6M^>EX*G#P)R<^VORBZ'SSIV=1??GF?MTY\T?[T8A-4 ]7]OIL6]]\]:@%H]
MWH#/XH9]>\GJR#.HC^20CW62Q->+U#\;+TO/WHX.^X$I0@Y?SO8=PE^B$(8/
M&4B:?'0F(;<=D^"*42)3)2 \O#$>U.1FDYF>V?:PJC7'54\ODF)NBUVI)*\,
M%=ZM-GN/X-F;5O:(DQX?) FMG[0+)ZR)<U%?V;?KAKT!R?'C*__=+HQL4757
M1VKGVF3W9-=8MV^K!6:$PES*I "BC^SJC%AL8DE:.\1H"'PZ\-@<R3<V/'A:
M=I MGC(1E]]E(,VBE5:(2.SF,S(T?JM1LV4A(T[@PX%W?&-/"G\G-Q<Y'^$Y
MX3K[<\!,[#/-$CGFA<?S-GBU\S7@WI.$U6XBY_JC_>)L*XD6>U8@_*ADMDO'
M(#[(6W#YU*_M94+4Y$5:/$',F>*I?,+;AJJPD9E7$%^\K[.C@1$KC; 0^F?A
M;5BQ(??".)OB(B=0DJ9*#I[;A]V(R>A!G_Y5967Y^QNK0 2I$?X,?R"F\!*/
MR%LM3^U@!/+ATH,XL\?T@MU^_-M.RS.$3T>^G7Y.XN<JVGV6IP<CEF-OCDO4
MIBC5'*E_E@:OB98(I?E8CTDR>J%?)OZ0Y*@9K>YG<^3>?\?ZU^MY4-/W+\_B
M7^"#V7[8O]OR2;K(569Y#94.UQ,:(>*S2ZR*6B.M&OA>TK]SEYA8U1 F$X(*
ME!WSXRF@)5*?4!(KY7[>E,BPS"3%2']OIXC$\,CUMN>^1W07)R$O6=Y^(9O(
MON-W;N'67Z+[]7M)\:->C>W&>(E22.+DK)I(&R8JY_D=M6EE&[<-@4CG[P-T
MYX5/[C#T1+B7S,I-O$L^I'N;QBIZ%NZ44QI$%'L_4HXBU3%A1"%"CFRV;4Z$
MZ38H@^F#"=M5UF,+J)-*,[3U)&N?[@[D$ILW=0T($N1X]S17Y7L>I7;?,5=U
M5>K,HN_^FK_>]P4O-^.1E?&E\7?^VB<VHII"#0[8&D[3R$SU2B5&SO+Z&,FP
MG$1&.<MY+7'9%0=:-50.4I]6PER)UVY&<EYT:T&6KJD"R'Q&0_,QBZZXXXOK
M7?C+"]]]O#P5']*Y,PSZ-7>P'/5Q[_GY+YN&Q"VWT5XM"?]"'SUO@_B2UGD#
M@]+^'4B0,<>H./]R*[&^B5V20_QIY$+MQ@<(*6^E_NW(6@[S#5./,A$FEZ0\
M7$+Z&-*3(?QSS@KRNESH"PK:%VV;HFBX&)*&\-@3&)XLIF8O/5R*CI$?'-(S
M'LR!Y\O8.)\]7"<SR Z-<.&_&K?"(S# WX7:)LL@N1:#3Q5*]QXQUWT6A8HN
M/!\ES*&F7M.6N]"]6G*!=<<D3Y?NOBB,:<^V%1D[3[TB/V\TRCG$XI=AM,.,
M6'Y(DHS:#Q]6^4O:=3X:KJM.'DB3+AE:F?%.D/A.L0SC:OX,T(G%,04.=>45
MGL\^DV&<7/9.)0S*DN-I"O9[]LM5M3I.30N&K&&ZYV_NF[IOZP)MSJ]X=<?"
MXDJ@;APY!O>#- NK!SWF&^9K)\>FT6:G6?LA$^4MPX?R,Q*[8"N?N3\,\W9+
MDC7Y10N5<P_%R&V.4"D0?JF,8>F,Q!9:OME2AX1@Z-U&R;=4%?UHY[2!?3]%
MY'WU27OC^0&/H>B?'5\,2M5]=4"(6MU'GA$\63S5V9%Z4B*_1N%;RCIVD3\B
M)ED*PXM9-$+4*QUBV]'QK7#]8[NU$^; -"H22GJG@8L!^#W*$+4L6EVT6G9(
M-SUYHO*Q-MO4G6"982:Z>V>G9X+'DZ&.CB?H;0>>-W:^7W_1/#;?DL^_U+H&
MA, >%I^RC@A"&/?EZ*>ADNO^\M<  \&MVH;@T-7[%E#MZN"M_/:!'OOP$Y?>
M2ZM6 DU>&BX;]4ZIH\7+VFB$8 ':TC)+/K#?8S"%GKTI\7;C1C/8& 6V=$'/
MDVL<03'HA2/P'3S!4/QVQ=4XH:Q"@ZX'XN'NW-> #R(WFW]Z[3%E#<*=6JX!
M+FM-$G:S<3THR/(DDB>,ZW4!FKF2\YPKZB;>%S 9KW'&*I>B^8*P)=2D6*UZ
M7&#Q[K95A](G^8>>_.0)7R[+#^P^(>5#+_AZN^9#CU;I#"])'"$$*YK?-W2S
M5YK',R4>"<R+Y,L:O_JX@>@K^(O__;?H5BW@8"L[;#]D,NE'3726MK<"7Z]K
M)X0G_3&)*;M3E>_D?ATA0?MKS04T[/MZG&1>,.Y5,MA>LLJ_[')"^.^P^M /
MG'K_:21$RZ=%.*%A7(>1^.J6EKC2<58:(DE9]_A[51\,10I$LY4JH6@*V5%6
M=VO-G;Z1K)2V7B@;F]VGTU@:>)4'-AV[*_EC$XKYS*&T?*="6ZGYB<4]\2)N
M+F$ARE0I0E@8;EZ_D45ZT,5__'U&VL>/'^(&0:AF$6?7HSN0 K 9I:OEBW'P
M?125QD25BZ=X^>R7O4;]5Z8D/RXGXDL[O \UJULRG$0#/P[#ZP(^-O6$ACV[
M[*8*<+O?E:25&"' $<F-G'Z2#!3_RU'][G.:U>/])*=/ E_%01D=N1W.D_=I
MF'J7=9B.G+/>2Z:MG1:?HIS$%(9+,AQ'6/O9X3'X);QJ'8BK Z:W*^-<%M'>
M[(D,T:@WT.*>2H'++F(58W]BW^XD<U2>8M0(QZA-C7OT62-KO)QKA&9@E-3N
M&,'0$,7;!L'(<,/DA-H@<[X:/"%\B-.O&A#*W)V/*NJ22O60LQ-Z=>=S (V1
MX1W>Q1?+*L33QX';(XD3J],Q2%U'8QT)0J5]'H6Q:@X'N8V?,[YH>V\=,@;.
ME#53=$!JH1):%E^.THHG6%BCX.UANCO=2W@TYKLJ2DNG!VN\<GH-T(>@DDP,
M0\S$5<BM7_>-D75HA[YIJ:EM"M45[7$.VZ'V;#O\Z'U>R)$OETY8<ML(QR%:
M_C_0AL_!)S@61PI,HHR\@0M-00&50.S3WTY333@GL\7?20\?#ME@Q0[)K;J.
M9B/P9)VY%C6K%.$*,VMW,.5)E<!V=%_E^H(T2D3,B@4?>Y%WFG]F[HXHUW%C
MA[PM/0_R*NW95^/F,HV@MVB@[G%Y[(>M@/UL5NJF)YT0!W/E!\6L#O9=,/V:
M,X_]\NQY::HDJUVT[<R1_NS+I[7E$1T;;+W>]P8BP.10%-$[C?Q"1=WO?#GZ
M15HLOK:#0.*-R67ASRPL])8C<F \:O"O.B=<_NZ=PE!Q?C1EZE.^NX.S_A4]
M%ZRE_+\S7!#D"U2+?3FVT]\$6XJY(OJ=[":XU87[$OCVO*B>)&-3$#N-':>$
MG@6=9E9K1B,K$YM^&IME#8#7M%O/%+#[P&D9=)6O+NQM664%GW@'5I;>[!K
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M4]01<U==!,0R)/G,C^<:$!1IGC=H(RXTTYTT(E@Y5\"K4)(NKAKUPB'?$Z#
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M7Y;FWLZ'8AFI[*5=MF<3:(-[1&>L@#(A'7Q$359C2LC<][#G;@,'P!,$S4S
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M?;B#$GS34R_,EIKOE3[YXV#I3UL*+\>F2X0,"T\4'JM;FDLTG2YZ*09<%4E
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MV]\*]0XF@' <Z*Q@<=-O[,2[O,4[[$!Q 5FR NP>*OS,XPSUI<)<[0S]1E
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MV[VF1";M=KBE75*[":S#-) G"U G!=<K\( -CC(/?1D"+IK7LI>MD:]/=B"
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MGCKV7+F%C:8)Q[I1Y *Q>J#VI":TE>)5@IL27UUQJ%S-G]YN\'(  T%MM%D
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M*[%5K52*]S=3^9Q\_0.<)%/CPG.3LFSTGO+GA'M< 1A_O16MZY6!9^*4)*X
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M#,LU"Z5H"VEI+G0^<'MYF67[O"4I-R_BD8S)CJU?.H3/\%LN?AY,AWO@%88
MIQ[\9F,-4B++6C*$I@%5@*8=QLQ>]L]$,,D;ES9_3QM=O0+,U)YLA*-((JNN
M +?\0I^X2%DVD0ON'1U8+NH5F(>IG&6OJ&]UAO:A0$9P)87*R,,M_20I1XXD
MV?@B.+63AF%.2?+:PO\U?4J#K]*[LSKN"D_;"#((U_T;O".QFM3_)ZBW]?"?
M$)[W/Y$[ =G(?R-\RO_&\W[\&P#4_3?<5_!O?/!_+DA(@J3"?8)P'>.'ZJ\
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M?5(^O >*8KL"'!<[R83QQ7Y.>S 17:NJ^0X94./)Y/?J24YE B28F @O[V_
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M EQ6*+OY]!67#TV82E__!U!+ P04    "  GA%M8V0>Q=QV9   [TP  $@
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MQ2.WO"%AC,C:L9$_/;"] P+Y[H"^?=C.=8 [V>4&UVV@T32&QNBT_\[LW!V
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M"]FF-R*S>MZA\6@B0$J3_K#<&7^XO$]GF<9YGMB&(+C6-_6]W/.3<Z^BP#L
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MC$&>Q "9GZU.VV/;YK"(0F1?!'R820,\98_(,O2"Z8=V]6Z:3'35^F;DIZB
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M(*R_62<AP8A[<7(M6FFX.Y?VY?O^7'WN^>Q0UY#/H,,CCAA4^9.MVX.'-!R
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MJ.RD# 8B?8V%:)AG8-+D\;!JPQ66B"?;NS3I#>N&X74U]<95I^&@GD>7]9'
MR=JBJVK[W"T^.K3[54W3M&.!CQ(3+)^/-Z[^B-J..^@UP'&%:3O<;N48*L<V
M=>U<9&-*/7GD+DO6T]R6\;C&VI(@?G%EZ6<!?[BV1]X+)F.D4*G!9N1E;"2
M9!+HN!5 [?20A;=QGOZJDR918F:H@Z%PHV1_QID3/CAFYG^TQ/A=G9TX=!2#
M^4P&MWK/G\#N&@/%T[G8]\.VP,3$J@\E(ATUSQE)<1LGQ<VC5CHA0<#VE-#<
M[CM3]@W%?99*\(7+/YR'"L0^^5WU0!/>(L\PO[+K;3_2>J%_GO;V=2MM]62Y
M+:P^CP2N,$!'M;<JTMJ$KD(XXA=^S3L0NV5&KN:VL4Z+,BEI9$YL)M)N/EAZ
M3CR4^/(7B*/4'L!H3*K_47B?P"PUT5P;[4Q0.I3JDL#O%1YME/OTXN:B_6V,
MP-+A#C\]?NL=4)<=71S+*DPSF/C,-@=I451IM2HVU<9FF\DX.SO<<\L,^SZ]
M$?PJ!50AKAW0]B)EH!#\]-9.*J=S*2,GL"K'*IL,=P*J9+VAM>@RII/&<TC*
MP$(V8EOPO-Q0XY-8\?$3Z_P(3F5I\W= 2?=U9_WAYC%49=*=A>3:&-G00V0O
M=FPP:?_+<@*F)H(V\DFWVDJ@E_X<X>?U5J*[%+/SM>(W1N_0G/SY_36+*_?D
M'\<+EJ"_Y"8>#FZ];%IBVX26"SEU)Z0U*# _0MF^:4''P)>(#HFZO;<.&T+=
MATDL$$0K8B#Q]DBNQP;9H>\3U?;SY0CM/V"66/Q1EJ=8 D-?H9-)?^3M-A=4
M)N>B/75A::<Z4Y6\^:UI\+>JV,ZOHM@/YT'2'ELUB=X^*Y08IQ[)<)(/\L'R
M&+S@%VV@$6&3*<L?];:J#XVX>R4\$YR_ -6#=N;LL]5MLE:7,>E0_VG.FN;@
M5ZWC(@6A>_!/H9XJ3IT@!H/*=5)2%=O]_4$4.,2MG0'M<:4X6^&W5 #F2G5V
MW);QF6/=<'G0'2]%KL#,]VQ:C@LR!@_::Z:&90N$46]OZ+:VUB0N2ALOB1 1
MZSZ@]OVI^JSVJ<ZWWY6ZLER&2>>V+/C](; $Q EIBH9U+1'P8EL+=E/KF%1K
MM=9]M-*W/#>-[$I!]E.:VSD7OZ,;!6@I+X$_QWUZS0TAU\YR.>M6T#=XD<<"
MY=G3;GMN?>DJ,Q^T2R\$)-\P\FTY-WW2^_E>Z.-VT]\_U*/HD4KM]H_3B[=J
M.';W03SW_X2W,"^[*9AN3:1(*O,S?)FD:9"63D9_^HLV7@#ZA.$&A @+N78U
MEX]T6R/->'SPTJ>"1]%:H'Q'J#PP<Q(QJ_["!9OG!]O (Q?%!MD[H+.*9-%*
MZG&MJ^WC=OGSMC*Q K[^\$-$0V.:RELEUA#VN&&EK2"J"9 DQ_O(X]ULLB_7
MENL__$X[LQ@K$./N3[>F6]\4+1OVI+@(F[RH-:*&]*UE*.AQ1 ?67>KG0E\B
M,RL09#%22@8@+::Z6ZH9.P:=$X-.XN^T/39'N!BC:GA)P9'GD??,B@1\9:Z+
M5D76=E:CN7K(#TQ99NKR9_#.C7.)M&K5V!-UQ%82PUBKK31B\FL?2.TW?#[C
M(].]9VX'BW&Q?+S7STM-UD!+:$?EH/,Y[?HFA4"9T_N]G)70W(PW(02#UNSU
M_J7-_2+50(1U^]KVT*_$' 7"AQ?<[H"PRW?10D;[3@.<*.Y^7E<&^?C/7]D,
ME#9Q]?X* 6)M]_EXM$U &K5M:OQ\B?N4?RFYDT=:=3^1-F%(-OM&)1.<H+?[
M_]49QW]BQG= !$R+?-$8U F_P9UZRQ]]LFPCE3J_'H<-!.3KMDB.^JT;/QW&
M"O F/-&*7",2=:1!;[R<>S151T9E[='L-IN%C$.G&3Z<Y EU&G;+^9!L<KZ%
M_X142EP&L!0_Y.1<"[TF\R] Z_H<JO;,-= ;3IF>L8FE:H>1%@S%[VT_8D!+
MR]GG7R<7<?4G9._>2J;V+%)8+Q9]7EP[I/;VG5O<: (%R(U^B,__>&S>0!P5
M;-P>?$\0?_AW>_MW1QDZ_ Z2$:X"[WO*?SIECX'_-5QCIEF$C0?^\HWX >T&
MEV5?.^89"YW)M>Y:L=%")R+<K;WZ94L&/&V,G[@L0"R58/Q;].\]!=JTT2:$
MK-9Y.%J9+/Q:$C=$:LEF2F76.VS)S'YV@%YH6V(@@3 ZH,!I7TF<U2V+\=IY
M@P4?G00_JPK-JQ9KKO^>XHFY?S L3A>K<@*Z>.AEY1&\_709OV^9<;P-!W4<
M(<>-YNGU>^1(-F^P^V#UQ:7?5V>9HT.91\2YJA%2U2PMK/9$&:,@HG:43T=:
M4;0YLN(\ZOSQC(Q\A5)I/VF.<#?E;O$N*O6%R^>P ?N8H5C);#*QAIE63<NK
MUY"X*^'N6>^4*O%07I*?0C861!HNS(K=HR=?U_A.*MGH]CWTS<U1>^[W/!TM
M=J \_K$911;)D<9@\GA_SRP6M^%#@Z8('$3 /-OY]D._%:&X<P%\#,-6S)\6
M%D>WEDY; >-[.-FSN/3ZI-6U[^>DB[GVX.E[<>R-9*J=O2MQ<-%G*#G35E48
M5*D,8G/Q)KGNAZ&1IMP)T7!JPI>FB$BIDNC0DWG<>TDZ G@W!$!]N:+X88<\
M.E.IJBC2$+?ZN7,=8]]<1BF"1RE//2I_0^:9WQD\Z*@"LDA0 CT"Y!"&\WOE
MT"Y7Y2,>Z!;AUD*BKYGH:>MCX+#>M<+&^'F!^^D'7#778],UY%QG7I>>YR;:
ML5N.QJ?D74AJ:'87SKL.(8VM_NUZSP=0V"*IG)V#I)%C5WUJOS^%*(DU[_%O
M,FK0_!+?7Q;\ND^8G[X(!HB/-VPI?HM@C*+Q^G6MF1^C%XIMFS.F%U5"BLN+
MDUZ-UB,K2EMX;?H)"08[^M0K_=?E(ULU"]"K4Z]1?@7ND%N1"?T>#\&5GT?U
MM5ZQDXM]9/AEE#5,90&8S$*V MWMWX^C1+(PT5E=GFGG6;YFE0=Z?K[P1.6,
MNF+,DC<GSM(<5HVCDN;-+6.4UU@&HG%X!VWDK:UA!LC; L;2YMDF7W<BP^]?
M&@.QJ_B[!@,(BZ_R9+3Q.._S0D]"0QSGY"TK.JK'E D=NOCSN^%ST5](Z^:0
MTD:#O/KP.R!WD.'1.W;'-(.:T>._K"$"W54H&@17;YFO/AC%P5.T7[,X?[^B
M#BY2RJPJ[&).5!ES94*EVSZQRSYGU#N.E6-!SR%2LLS@=\"#7O@2W^.U=Z'G
M]N9:31E''V/IB+(C%Q!$Q+&8)>8B@<^A>"/"*DC]N&N*#0&6?6_.N- S!G_R
M-;ZMNM3+BAXR!SVJ:+P8/F-Q=@E2(8F! P5&)+J[:D\>Y]KU)@_2G!7EYNNP
MTS4K7M-3#=L:%N*K:WGP7NRQ"G<>RZ->^<ZU!S#YD#8*=$&.K?Z%Z:.95M+O
M-M2I])]'.!I2$GLLPEQK>#OD?G-Q 1B9.*"D<Z>FYF;D2$I.V;W@M'Y@2Y/)
M.7N4DP;B*5MYK?!"X$'X-L>K;Q]>Q93BN>J[.RXL8FU,%._-Z3^TDNJ+\<R%
M1*Z]G>&OXK<(F7O6*B 9?Z0WT/D)8(S^%@18RY.Z:UK"H^EO^J.A+S)%6ZHU
M-=V?G*E/+C($!2D_MV#XM<WJ5$!LZ;+#Q26Z=,_P8/T]CB&9M"C.95NJU9R/
MB:_++J"=)TU8U;P$6-6B?5E$U_I3?O1CZP<TR!_+* .Q#&L$3_IP>+[@Y_G8
M\UQ<3,U&[(CPL9$@.:79:^J&8 VT:[X5TLHH+'0TB;8Z]?5TZ!Y[ K"LIXWY
MJOPUG!M:T9(;/Y3-(H0&]XL_NQ9&JL <$0+42AL$9[^#CM_,','8\^IPCPP6
M/GD-UCW= MJY?M(20SOF8)HHAJX[@.S:'N5CT#3QN*YQ,F\2K--6WVB]-9VF
M%@G*59PW6%#'?^;4^UVMUS6%!?O:2[Q3! WRSF2LFRST>K@#"M;.].H1<)G*
M2#FTBVK?)A3FQS/UUKO?7=HPUB!IIXA()L75KJF>\3UVS42A275'OL2M5Y$*
MM*=44H(#H\X*# G7;U',20@^HA<H\1!>$=L1/X+V6H[Z6<V?\C:Q\L*_3FL:
MM'CC2>FP ^(5QN@VY&BOG5"B5=U@"G15WVQ]0YK'UQ*3Q7Z^D-&#HGCC<D$0
MK]P+ZP9>2C4P5W3Q8+]I&Q[*,T;&%BYKV4>^V_PI*_1GJHZ1U5R2"4-+0W3_
MCS2UW),)I8>4CAR9(*Q,L_L5<0/61I)%7Q-!+HUVFV/+Y*H*;12M.9--*O4@
MB,SE/LIBUK)G\9O^^&, 4TA6[_ A#3A,'34:9@^/<*@;A(% 4;+/J^ ? ["<
M&6,V^_349A+:M(>>2]@%D##X,Z-3^]IPFF8LD-%2CJ$P^\?;V[,'5^\^M<12
M$(D(R# ;E3J^8N1(I.+%.'K!S(@62U3U(<U9=\1$:_*[+?SZU(R<EK/_6?AV
MOO?C,Z7-8H9;\"KULJ1)NV@[$1J$P,U:7P+C[_/ NPL7]ERL\]XT-&44M1"1
M1^(^^RO9C,/>\M$FXP,\U@!2FG5PSR&HRY^PC1JT[T=K )4N]4U7;9B>T]9K
MI)#*XEM<?HQMUU$L9V;W/IFNUZT!S"*Z'=;ON>@9.'NJAK0_[(7=3#<W1A2I
MO3-9Q#Y)=_W,&2GX_$+!@U=QT!)I"6I ZR.[NS7=WSM>"Y1:SS4D$K ,)?#-
MIY)G?.78B>E4+:%RU41KE"V@!1"K\1=BCW=Z%T,+/#\,'7\7::Q7BW_I\?'!
MD/HB0[2Y[!,LE5/$5E\)PD1< 1D:A]M48KSG?" \Z ^U.SRT_S@0Y5JN6Y,0
M#L=TH^,@MAR3<49A^#U:N!9M3-+RY7HSY<>^M.<=$SS$27TAJ.3\0T\!<'^4
M'/S^X[-U_3>%4 &4:A!4/0\2UKVA-EW9#F>&C9^9R&NWIBQR64FJYR:;Q>^D
MZ!;@JI#AB:H(!$HMSD.\O6 ,=&=9:,VD/OI!DSW,)*(^Y!+2,"B8OL2W)2A%
MVK4^0/2X3=26)N7VZ8R,*%S"O9T,XN!E7WG,-2,W(ML3O[E,9/69GY%UG<9M
M^3G6=,%.OY=[5!Q7IQ&C')N@E2 Z%*%QJ#"?V_GD,>UX>,$*#PXTB$H?BR\I
M4%$^U%0<V9:^(4"*=M$D-"'KH9D3C[>A#_FYYUKDFW][\X*'@G=)W>+5P%<N
MW-:B'E.\"1&6"/U,AFDHJ BMH3%Y+5!D=3Z%3CDZ6K9Y%BB0]NA$@._=!D?,
M_@C7J 3A$ZR%-F:H6U8??<-G>U$^0B8V 4JKJC+KN6=@V:ZZ\&[?FA5B?ZF^
MH<W?\(!1#%EP-QE+5H01R6HM\S<[D3O@D"@=1$?O*'SH]&);4'Z%04FHGB83
MD)2LPD%_+=]?Y;[)D,%#:)"(L1!"AO@4B?@>CJ[21' *T\ 6,!_0L2=2"V&;
M=04(S6/?,*P[XB^@R3H7Q</LY#>F7L%B%QAH!6 *_*IEC$E'F@#$,MA/R":3
M".U?O.^9DGK+W]*,.IP-<[2;RVI[YQ.J-BO\6(4&X'Y8-O:.:J6J;P\J[8L
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MU4P6:8;"[==)DR2*Y\9-0!J?ENF9F(BH%T="39NS'W_+[?:M:=CIK=0'H8K
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M\SDE.>UK4Q-W>:P:(QKJK]I^)'*H /QVF8+\;#-Q*188>0O6Y.-&-=<\4S+
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M6\"5Z,X+];\,V3G.#"P^"!JXFSK[J+GB61Z5^C=&UW<?U5LL02Z,J+;U$#+
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M\2!/()$7UD&9":,'X)D"1')3L>D&L].DE\R^MD)9G.&P:^5AD/USAY4PN]I
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MCT]\/GRM*:_,C75%DB7C?D+L1B#@1!'XX^/%@V UV*RY28\ME:X[];O*@(0
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M1"3K39D5-4[<8D\J<<-%:8A7&?:D0!+[1$%F22JHL\8'0(.5[RFIK#T0D.>
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M&'54V$QBQ 0KZ_,D"("KE(/EIO2N=X&GI\EHSA+?U1,8G%/S$D8+ D]\A=&
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M7C.S=K_\MV'K"D/F),-&%EF2TD2&F:Z K;E,1/DL HAOR?O;*7VA7-3\S[_
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ME!@$R1/%LE*2&*84BXI2+WI+=]>5%GQ?#S^E/!Y&YP<)XT,^NN.#)8)#5J*
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MU?#'?X[;496/9^_HQA"PG7%'SV#F[@W[<Q_L(=A:$Q\K<1G4O.=N\,4=M]-
MNL6EG'G/XG2] -$=H2=6O'![>\#_D$$>=.4NBB,W&*<9;SNJ.^,/S5L,'9Y^
MA(=A4BD'!?/HN #6T,G7+KPXHVX+$UZD!F/NP?^Z+2N\A2MSRD/?='D!L/YI
MW6TN51!<DN"U)I*;0)!]DNQM2+H$*S/1LTS4.L5B+ ,I!5YN6I6)B<Z1K%0R
M5M% =7F>B7[L[.HW@]J-GH#E7DUF^WWW]YU73XHV.#P*\03D3:@.@)_^_(2(
MT[QV.#X@L1Z1Z8@GO["GLN1/I61/E>(SUC?;W[WR/M<AP'^-AZD0]&G!*1?%
M1#^K)S90&-0MHM,A<.D.X_X7IUM6%%U^"KH13H9.Z[+\.JC!V@:#K3.:)O59
M<$B7NQ(!Y[:*G7W0(2] O?]L9SC;=L5=9BA[7NE[6DR85(U_(N;#1!5HKB=X
MO>]@>)</F+Y.S;K<U ?3M!TW"-/TGJWB<Q<8#[P(3LG-3;O93)WQ-FYGB=-#
MT%3;UC5PRJ"%P$G"W"VN[/0,Z"2L.^4%-,]#T*,OMOSN+(GD <JX%8>Q]V++
M=P3O[8ZVWB3?C+$I'K,=9<NG2"5@O'W!?WK'X).0RGB#5>4C(])Q8/ 4/KJH
M8W8ZBE++<PP^4RLE=T0SG8B$3\27,1!1VA2=,E$9<T&.;,=CNOI1$T[T83SJ
MG/3 Z$YQ_+9[NLCJZ36<WLBG5I5/I5&]8O/MG.&>XJ_UR;Y[F4_S_7"G117\
M]@9GR7E7!8XXS@VFFVOBC$]$Q0RZDM'!\W.D=%-O8'O2C#3%%\<P&W"784B?
M8>H7 \"R)T4"I>D0P=F,TW*1 CVK079S8+_Z\/+WWUZ__[Q3O'W_\L.GCQ\^
M;7]^_:IX\8_BT^LWKS^]?O_R]1KZ":R$$B\C0_GXY.5'O*:;YD1>XG><94X>
M87YW_?7XQ*??Z7IXN88BMM@>#L>@_?Z6TLP*Z^3,/D"H4ULG=7//73S@;7,[
MKW!Q*BG])!&=R>W)??.92ARH_\X=7"C<JK;%\:BOPD\[#YK#JY-)H8NB,[PO
MVVBNT,0ICI-KBLD5^"M0>;&%0B'8Q$*X1U'QM/,^5PLL!^V#9L9T\"3KXJ-K
M1L7;MV_G6?I3H'R:7P6_ 1E>,$K^VA>Q=]X?=L[7\4@EWP--+V5RBQMQ5?ZH
MW&+TR@%\2_.K!H"A31=R3"^806TQ>>4,\ I9WDF6ZJSNY+2,-M5E-3Q;71>;
M3L_&S4KR3@8^L-C):>1!\0;C+=[&Y]=%H*WC</I3FW8*IDO.ZD_+&)J7I1)3
M;8PPFF@7')&1@D9+K2-."V.-IF6DZ;9Z[!26",JW<74H(N0-0S&_2T+" M(W
M;<VSG'A]#%2Y+-5$SD%=C83;)(DTV1#OO"="Q:BSU-Z'6\=?30'7%?Y>&<1>
MI4&-59F*_W 'AS\6G^MQ !WUW;N/&U):GI2PI5YW=_>]HK\ROM2\I,2RQ #]
M#2<N*T?*3*6(B6LG;GW;/CWLV5FO,+L4#N<?=?/'TV+VUZJJVM^?$=\+/_^5
M&[[+ZCQ\+9L]U=](G^]7L8:]KZ"L^[7][+[587S),<QYV*DF>H_V./H9S[$(
M [J%,N3,FWW]%<\![?QYJX&O]R%HK@/3RDCXF[P\/>@2MH( I,_;+]Z]+CZ\
M*5Y^>/\9'>.K=W_?>&WW7=?MVYC%JG;Y0!UP9DM>Y1LS^JJFG%OE4CTYT2NV
MBBYUE[O+)LR0LO.J]S1-\9SVS2XW3?IIF"QMAV_.XAO.XFR+,GY>V3EU3!?L
M:8W'MO[&E!]![_C&O/^.8ZZ8G&$.7,//3_B3=:+SRL6.*_8;-'W_U!XF3%':
M'=:CM(M!I@VN:3?7S1?X<U#7?^#']HJ2S)>=W3E0=LN(*>"]'2JC75+DH!JF
MRZOP?'S]\NWVN^+]A\^OBT^O?]W^].KM^U^+-Q\^_1W^).\^?/@K?M[YO/WY
M]6^+RL0SMRYV<R&2KQ-BW=M7R(*JJ@=D\Y!(Y5K+X';5"1[<&?1"_/68-M=?
MP.9!"++E%(XU&+EST09VQVBWNA?!]7'[T^?B[?<BC1XFQG^'_/?M*!T4;.M1
MB*0YF</^#W;9KI]5%OQF>O]V\IY5,?Q>"/P6*,<VE'Y_E+[]*$G=[395^\=N
M=EWZUUW0^R=X7_%F\KX-S5^+?)QOB/[^B/[%HR1ZOSL>-JFM!T<I[K8CE_,N
MIC)A LI=<(#?YR\O=O#E79@]OGS##JY%RU)MV,']L8.7CY(=A-UP[%,SK1UV
M?!<LX.7B"S=DOR'[/I,]?XQ4SW</F_H0%YGN1.A_G+]M0^[7D[O>D/N]D;MX
MC.0N=@=ISPV0Z$/J&BK?"=6_PY<6'T]>NB'^#?'WF?CE8R1^N0M[3KNMRVET
MO!NK%@M1C9N[$?R_P<-BIWMU\>KDU1M&L&$$/64$]Q)D^9T>1C^(]&%>NC_:
M,)/[C#/9!)KT&N>7!L"%V;8/C_UV2FGY&)72<G=2?Q?#HW=/:B>UNY.J>KOI
M7^,[44\G-56Q[M2G\P6<)M4-B]==U=^G,&+0E4E:*$-5_(9M<)I)X:BWV*P"
M_OXX;L*^:R=5 B<_7J@Q];UPF-NHON8A\9H>T-8JV8UZC.Q& 8]I4W.4KJA+
MLSJN\O]^FK[L_]L0^[5(I^B&V.^-V/5C)':]>]*(KNT<7N.NBN/NK(G.;KX;
MW>)<-[Q7\[5T"L/V0E.?-_,65R_K89RT2<0QP$K&@TF/K0^':?+RC0ZQ!%O9
MA,O>(UMYE.&RVNW^"VO)5M@B\2CAA\'L[ZE;_2[XRO]96$/'(O[/R3H6?>R%
M\_5XWC8" V\W;.-:]-4;MG%_;,,\1JYA=N?=*W=/.OWMMN/#PT'WMVON@FN<
MZ!<[)^T&D7OL+"SDN'CE1F[#)JYG$YNX_/MC$_8QL@F[.ZDZW^Y60]0FW%Z3
MIJP""]7ONA#N)#1WL@AL_8C,X=7B0B85\[<G3;)=U_AW./M83=NFG;"9$TUD
MPT\V_*37_.116BO6[>(^FWK03N+^XEW%_+R<OK9C"!_GK]ZP@0T;Z#4;>"3I
M?FNG[P]=-\:WPTG[-OC-]Q D=!NJEANJOC^J?I19>S8L!/*>+C8'*#3<_>?X
M3IP*)SH^AD],UH =H7 -Q7^-FZJ-59CT QOMNQ$H ^D(^WR]'6*QO,U5QI+\
MH]SPCT<8_+HYC-X1Z<.,BGR\D<#W&@J\B07N-=9_ASQX4H:"/D:%EM'=26^-
MNFEWT]<4QMVU>JY":C HN#FL[T:AG:[A:?%ZMHCB0YXLH_-GO9RU2RU^K>%0
MT=N]<7 OH<-N2EC<(\MXG(4JV0*C"/7!81JVU_006QVC..$.+Q?>O&$$&T;0
M:T;P*(O9,+X[*R:U6W\9@J3>KPYW06*/7#7<]6F8[B3>=YKB<UQ\F*T!@W9?
M3I91O,!E5-W-^.1YITV<Q A/@WTOS3#:L)8-:^DU:WF4A7.8F/.1!FD3/=9
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MV24.7M33)G[Z@Y2FC$-T_ ]N18+.H"R O&,>?8_T3N%C/*WI!Q(,\\XP%B@
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MZZ*XJ.UQ#;T38!?+X0UJTMCU\'EE>;5@BQA4<WL0#KO:@2\ZW0]VM0-?9>W
M[?%F \@@$*QQ]V>G'IB,C6&IT!H71= )8Z<63"UXE0#1SCUOT<H[32;=FIL
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M7KE9*0:*EHDFI<73I%^&X_S@;(W:JZZ5#:)\%O]<=M.ZS1QA.ER(TD<ZQ<5
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M2&3R/Q5_RSX\?FWN/$E9@/OI9J%/1+P*!_OOR;WBOO'N%9YG#X;7E1^)+]%
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M(5(PRJ0)<@3@FSUM>)?Z;G?2TD)Y YREHMP!@GV2P%'5<7H&MVWOFGX7Q/0
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M3OX^0 (\$"YHSUHW_1@\">%/O4[,W/6VU_76*@XHD4A>\PL&L/AY5G#A@P\
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MGG?D(^0T'OI;:/I'X(@0,::ZN.^2>'@>/3@\][X=AZ)'!J=?JLN,L!WP#G(
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M&Q4N>4O>&>%A(1&9!7M<(N QB](L$R 1HT@<;KR=@-L)N)Z1JW;"R\IBR6\
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M&VHL52BB(AD>.@9Y#2,T'?UKPG3"S8[)TJ2F/XY*8+T@N=.99'A<;K^4'(;
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M%=-*Z[/RFWVDR^=>2]HK$2AJI^NRXL!'WO.RQGCP*:,5ZPD5YX>RK&E[83?
MAF!"A1S7#JD :'00 O7U8.1DS05FCR^89\S*SI&N#((68+[;U2&MU]O08#4W
M>UT2C*%17HIW*/<C[Z6WK<D6J/*CW_.(J%87-XDD1-0Y[5BJ<FS8XN4E',F3
M/SP=XR41_?PA'2"R-K9)Z#']3AQY+H6*BZ$&4 HR-'+9A^[*GX&Q8H^2D^AQ
MYX3T/(K-,Q-ZFPM\3%^9"(KRK8(OM*>PR%KLTAXH]-#4>-DE4>\_1IK'OM[I
M<C_]>![[FL>^?KG][##^6ZZ@L1SVU2H?02@4_!C>L"^-4V%,$<5%R@8:P^*R
MGB[6;1_HY.-0GK+R9E'325H7%OGS2=*%.K# M+&D:1E3@>?ZSWG D,DR\>G;
MA0T* 'J,RFP8WWIRXD=$6 AG1.5&V>O1,D7P(!U6$!J8E[:K8W"^LSL4#RQE
M5 P$,[OE7J%,WG<_C;Z;U@$PTJ%,D"C7NG63'BM*;ID%)C!O<LF >SJ[+OFL
M$&T);B_0C9>@0)  : W^A%=_>#5]=G&X:W]^H:'O**SD0.5[BH<P7/?T\=./
M"B^01>E7VU>\4&3@K+C%TE>@L,NNB'N8#"L5BBA4C&P M'24($IZM_C[5^=.
MV.6;K\ZUO=@O7OWP_2N+N,[(CB5483^F9#GX"FT"#.AS_,<KWM#[X:_2XE9D
M_"K@Q4<E/?.Z[-:"GHQ%CLC61V;BE)# 7KVNE.]L+*[ :48HN<P4.4P7/UV"
M@>4::L U4_YESQTW3UC[7#8:!/W4=2EAIRX,KY1(EDMG7S@L\]DT,<X^>$!*
M1F9U"'M;>#>QF05T%,:75ZW$<E C?F1Y=6:D[J6?S&L?8!WD_-Z*)C[4XL/+
MXW%,JT/(&C][_<VC)W_@_WWE<T?A4L*&QU25JXC2DEY>\UGE\OI+[ZHEM=Y4
M*%I8V+YN&\Y-.@;[;.'DZ;2],)[F+?MR)504T)@3;_&76GW[C^^^2HH4"6O&
MA]&F+K=;8QD7[!DYS+8Y6@,AR"U18_%G)1V F$[LS8/8_3%@EZ\\=8WH"JM$
M&,EX)!UV?)OEG9;7<\+..1.O304E#;H*6;OIG>-%?"E_4XQ)U'_03_*1\^(I
MDZJS)DW%N\2O,%X0V2;YOCVYT(%=."6X? QC"&B'8=\FD5ZW#8-7D*'S:VEE
MU!P+3:O%IWO'&N_L6R\/.[P)F*FL5;G(K"GE\S%;=]JJL#-D/"BKA!)PULU0
M+^B(9Z%)^DM:&SO;)*>.$8BEUG1O_&KX^'[Z^,D?^;8D(ENQ1S^9[0I<-MV-
M1#/_5((8_)M$1O+JKR];<FMK=E3XW3W./>RCZU9GJA 56-4"MWRV^":R?3._
MI^ S+*TU?'BL@]&A+S$'O(8I7XWVGIS8Z9Z-L?EX01+3@*[#KKIJ\5HM-,M7
MHUB<?WO^CZ\?T1(6?)AS<NTRZZ.!C&AS'.W*INI7=*AST0D;X);;S .G]!;_
M,M"Q/!&!L7W%NT1IE.7M:/&W&.,PC+W%D(B')8Z4^_/!JURG; 9\D2[U\<2E
M"H8+Z/L109)B*G9;?/FW<ZD9HD7,R-BOPBH@$/\U(R%<YF<$0E7OXJ!?,PS*
M-\P<!TUT%6=MWB-MW@='I?7-^$W%/6COLAJ;B4A4W,U*<+: ,9H#%AYN-UJ:
MO[=7['O@UI[R2YUPI7;M_!HG3TJ?_<!UCK]\RH39.(WL;61TL!3X%OFPXK+8
M?K7.&W^T'?:P81$$,:.KO=F;Q4MY@)V@N48YEV[?%V>+EV[M>4):7PM_G)X*
MP1(0D+]@Y^0<C_D>H3N1D#L^5SI8XQ3BD5U<I].FCB85UK<\A2HD4W!)-K/Q
M!L3_3+%&V7'<66H]B1'Z#,RWMQ(/;5EK"<O+HV""@P$$?$=W3@D>W(C6HE":
MP('#W29_8/%YN<$C7- A32=@T+-3I5ZF;H,O>!3D81Y*E0=ZNI.Z3$TXCDHT
MP/<WFM7<Y#%2K")4<X:%Q9IG3/&VM2:=OCY\>G )?4K!B0]DLO78/+!MG)5^
MI<:!!IWE$KO\G6>;6R9RXJ^)#S^F/3Q%E&@U(='AD?BI7 N^UU'P:N(@3+S@
M.ZT'@)+V(X;%.4KXKQ<L?W '^9><["HX;)HM0_S$"58.2WT _[IUG?F8GM18
MW@[]/K9P:5W 1',5XH&;C]#?D+6)JYN"4%\.M P46#P;5^DJT1Z7"\IPBTJX
MR76QQ8V;N.;QT@(_O=B7;W@HX$ I1]GUWB[EXWTNI1LQ,3&2U).?/"RGW8,$
M!SY6T.?'Y1BEP>H=0.C&,TL>0KH2^GLC-<6L+$1W6H]YA+RXZKAU(FN=6/RD
M46(ZUU(,$W?L.-9*/9S6+?^J41%4[F?%9^MW[A'0;VYBO]LF]B=S$_N>-+%_
MSY$' _J84Q0QP;!3J/'$3$Q2XAWA="9(N%-IR$C R4WK#UA_AV(:ALZ5O<KB
M!B%H2>.6.#"'/H-0QY8XRXKUKE&:W_'*HNL\P"67.JP EIP(AOZ02?WZ>"@O
M4R]%(HJ\\EYP83D3-D=HN(2!M&,L'>])T=T@QF8XF&,:OY=F<A+B_?N/^7XZ
MJE8T UD(2KL=*PET24D -J4V_BPSQO.++G T)(&/_5,0_>>[1N5I2SW<UY&5
MNN"# F+'AIL4%(XA0TIIO&IJ9WF_QMQ<<G)*Q%YTH-/A;;HQBA@IQ.R+7#C3
MI) =-V3\+*O MH>RWJ-+<Q#9CU-.JC2[.%.[B4B/1%=I+@?]QD$:.,L#.9<M
M&A)2 =F#D;HO#$O#\!BN[=9UNXKV0P$DJS,REW5L8L@(2D#8+(IVS;YK:W;:
M:LKK-O0<FYJ_UKK5%D)[G1,U!RWA4&^P0FC&T/7H,.DKQE]6DEB4QKXE7W8B
M>T5>Z',OI,BGB8MIN=[I;6.KX3:I<^;1'ZO+YB)0].S<&+)L7.0CR$=2[A.R
MXU!?S]"D8=7%6D15M3%]1,TM@'?H6B6MEN($7_=["/,7-P3Z?LKPD[,_?O31
M;S5E^-'91[C8>W)"'YU]\M'G'W_RZ<>??_;QYY\_>?KQ[WG*T!EVW V"^(K'
MV(9#I89B,*E*<=CX^6-LH"=_?+Q84QIBG!@-0!D68G+_NXE#V/1Q.!;OK+D=
MF<62ZU&?,:L.FS."LQ$.#]QS!Y3!X6=R"LSF_+LW9P=\W+0KF:'!475[_&4'
M"3?F*B[H_=MIS0.0J2W72XK%1?$&8UBKEKLH]:'0U./HD$['LA[7XV-JMN+9
MBKT52_2 @;I]GY.O=*'L6RG\TRVONJ!B#Y<M=.+8T[9WRMG9S7*@6P>P<6FA
MNU?FZ:SLFD%LJXV&<[^ M&"VW-^GY58QDP J<J5TYFNA!N(V8I#YR:.RD\3$
M^I6./;B%!TKG%ETO,*6Q5YY8NLQ7Y[@5Z6!6>T$]LE>VO53M+4T_+H()5WH>
M$F6?^%DT"J#-^.AWEY__%#-)2I20&*=L?()$3;%DRF? 0X!#(Z\K5@05^,"T
M44<E219ZTRC1%.CH(JMJ)^<HDDW%TZB6^]QV3D?*YF2+,5=L%&!% CZ@^9QW
MQ0J=MSC5+%N&V.]3,*O6 <A55_W$Z[F7"_: RZ _).+T7+=G_,9K ,RY"HY\
MCQ5HCR%99XL77#N3RH@6P2<^YVHF[[,@,FNG/632):8+V.Y G0BP0"84M.JJ
MGK5ENUD=:#;&WV(R&2A,8=Z@TWK8:_%K@@/Y!$$B&H\H?'#E JZ\'>"F_9$^
M:H9D*6:$'\[V.-LC73)@((]5P'60F&."DNL",N+#P@1"#V\!Y&P[L^WHP<K3
M@LQ*5.Z';@PMIZ1QAU8?UP*XPB]>R)13REYQE.2G=I<CV+@*J.T&<GADA+/1
MS4:G1J>RR3 [WR ?C0OT%<Y+&RJ8S6<V'[JDEAY'1-'D?B[*1GM%O954P/HV
M3H^Y<3IE9^U\/,ZF=JQ,04M<)0*S17B[JH6:CS)/GA)S\]35+-8YFTXT'1W&
M\$QYLW7,UD&7= SBRG.=*7I8[$U? !O(3#\_&XX:3IK1CJ.VCB6EKA?KKMUA
MLFJQE$FYU"J8&>;_?)YS HF63WL5$D TXIE+/PX_=),].L/7O=>6VSQ0]M\T
M4/;I/% V#Y3])J/LC,M0I ^#;,A)T7^"ZF0+E <P9:I- JRC\A?1F;(@A]C=
M?2;FM#XI^\NAZ[2)H6,:F0>=P0;W]*3\?@R]\L,3?NIF2HZ1*S 82FF$IA;<
M[TIUH3-<,E%86AD0HS&8Y)K!!G.(_=Y#[.M)_\GS8\RAH 2;&*6P?HF;/DV*
MHAB) F] LZHBG6]#QSN[TP@YGPL"L]&=-#JA",5?[ \F3!>!M-?L4==5#5YK
M9K1\6PE%"!/_7-*Q&%*.DG-'M=<-_=MEM9O-;S:_D^:'@=YMR+Q;*>IV,GL&
M8X,SJZO2)DQG>YKM*=G32(3/$@RNNVS;0=.*/=C2+O+YZ%AW.2'WC=RD%2:,
M<:9RBD)B.E&9#78V6+KD*3.#%?-H^C'<7HGO*65Q9,&;H9'Q\C2C,J9CY+K?
MD@R0*X)'%HDIQ5THU8Z%8:R!8L2HR B2 _'5R*/H X 5&D_%\<^.VM["PS4;
M_VS\MQ@_LTX OQ6FI,%.EX74 'LMM\/!1_[4$S6#A0J]F1?'Y4.ME"^8IFR%
M1!8_*2J.HG*6[L9FT6:[GNWZ#G8MTX:+<DU^%"[2A1^M\JLHN62A?#3"MTB_
M6RV'F^.*0HA%3&T@C=Y%VBS;#GVD@)SM=K9;W"CN8=@K[U")^98XJS(DX>E3
MUJU"9)[?6B(81ZWC!!S-F1;_01 =J9O394&<6Q\6R HOXNQNV2TK$Z(1M=**
MHI9][RICB7YISSLF:2L@%^WGPMF\5^[LXQUG<RK$1KK<N5HQV] =X]\.17VF
M3%. %NMG;8)Z8G *UPA4!Y'BHP_O#]9<U4 6= ?J/'=DDWNPPU=-%&869C;E
M<W,\"?\,[0XJ /\.PB5_1:; Z=Q-OR5TY2 <D3Y;"CZ2.YY-?S9]NJ0C1MTN
M-3)@FW6<K5%1AFUT>K/$8SO^8!3"YB &@AUCRM7;?PR(-HJ@&Y6V=*C)2%T.
MZHIV6:M5&\\C&M0NFYR-?3;V&_R\N-IU6*&<1\:U94A@VUUCF%*TYW+"FU%I
M30/GL#;E>D!#E,ZY5A&0*>H4'ES)@!6JWL'S+71G,_!WMMT[V>Z()#*OHX'4
M[EJYEB@NJ+I$.JN&C^QP"O"EDB@="VL*UU+/R%G]H B?W*)1<@)M_'"1>?0.
MZO8FZ%14J6K"%9-NB1B5!H&FSSMCY^XI=HY>,_+.%G/0=9W>=[FX*A&N,S<$
MA>=]A;[H22L0GE7AJ63^?1X3$6D3-.>32-%T02962LX6YRHHJV#,*("G/&&F
M<G(-NV-^::%,.5FHW\)X6%'F;*'L['7U!I$=E EH/?/PT0UL0A<LA#=1KX?R
M%]:EFO9NJEQV:H6@,V,8^VH5%:E9YT\*1JJKVX2+EL5X5>-W-0@%DFW(B%.\
M94]>"Q@B_&N0D[UI%Q E!04W@+5(M;A54G@M[5$3/-W+R6NU\IYW>_D.^?;>
MT73')4_L8.D%AH89(.$WBDB6[IZ/ ^-D.2=O81F$H4^+A"/"?3Q=5 AB1%+9
M]^U*Y(XYM(E:JLHPN)UG'![,C,-G\XS#/./P;J.+'W+MB"C]EG3JU7%]\]6Y
MB"[2 8Q9W!.R<'R"A>9B?WDH^/QXE,X/40USRFCJ;44!\GNN_QW/<T[=W4:'
MR";.:XG$C[0?YQCOGL9X/SC;0OQ1BCSW+686E0*%G1PEXK83T5C]AD0H@:QE
ML&PN26] ;T6 .T76A2ZDM+:O>K/7I(J(9*T;+A(>@_EX.9Z$CNNTA***P"NC
M/SZLZK'R&Y#OPXCD:->I0I308#,R"0$<93)54VV';;QYTUT\+J14S4DEP"-1
MXS;%&%P$S!4618@ 6\AT29I-9?7QY2'S#7=_?QP$LJ"A6PX/W6+)%SR:2BE4
M#<BY1 ^WDCZGEU&Q!1GA6 H-::,BK<;MW[;M&K2=Z2<6+SO(U*R4 ''U[8N7
M1?[QOUDP?4B?E:?VGXHJD^[W= V40U&YQ>2[%T.UYMI0;R32O"!W>SH1?^0@
MW8.-;0[>C&KTDFYY,U6?.^:"7"@9[F&G.1ARE=[+7T:9%ZUK;+?H$TK)Y+0>
MY=@*Y=&$9I4%.&*@?"PYH]J4"4N=".(GY)#<PXU4<-*V:VN@#L>ORLA(#CN5
MEQ>DK6=78O%AT[D\I.32?MD)-3B2\!6=3,KV=6S[L68_R6%HQ:0K7$YTD_Y)
M/]SC=>&N.:=A8G%D2V(*87WR$+U1M54.[#U,(B;9F7:45%7N<$['@8KI!-M-
MP=U0_WK_^<X#.I:/]:(F7IV43$T"T93$)@W!$(OP0B*\<),38KOA!H#(0&2[
M'_X(QLVP,'9Y?SJ=E\X5_=]_1=\TE(_4HG7R8<JS=2$%-T8[50D0H.TYS(BJ
M3/""[%'+K)JD81)]8U/-%+*S*6:F.$$FCW9H"*H?T55;'. 4[NS:JA%P2XUC
MGH=@H:+7"_EV*O^N7)3'1[?ZUMGR9LN[Q0EF:I2,>N6S-2J6G!AT:8<]5SXL
M2G3)(5>O9\N;+4] UDE,4> 8"N7KZ#+[B'CF7(D#P:FD\(A+=#:OV;RFS2LQ
M0A;,N5W$\3X A !GPV<SI/U-I&.SM<W6%JV-!5+2'*K(3[#G@NUX%2\='KV)
MMZD?6 ;,ZE7;JN\MH:"<(19P%W__ZKQ8?/DWSHSE:':?EAKSZ2++;+BSX>;Q
MW[@ K#71K*@L^(X0JW+6[&.);Q,YYR]6W?H1JO 'WS_IM+%Q?4E;X3H((0%4
MA;+AZ'RFE;=#/0^+S!:K#*RH%^[VDGTTX4)D?X"%A-MC)XN*R_JJZN'O9,9T
M'X(ITI=66=?9O"/5%G*6])\U8]YE"U!&0S\3P3CC@)/,?S;-V33_UY_=G ;#
M@,>-(D$%QE:1C6SRQ(2$ R%W@EF_*.>Y<*6<F5@XP@%N[Q&@"V:\'2K>' >W
M,HI%#^],K\6?4W@KA0_8[(48O#N1E[!F.@;/TX?B'/'QG"\9LC82N1'(0$"9
M)$LS$L9@@E^8H& X6WQ-5P,4$5VW,'G"%S>MD7PH9#K7IZ-6-D?YD/57CO6+
M8.\-[@?K3S%$P1=B&$1:%4=KU<HVVH6.WQ!*F?#1,MB\H_][E) 31@K#B/DM
MS]XI@[1B.2R"WJ:!:)N0XI5^]?6+U\7/M!]F(C001&3-:-=<>;4\LJ1DDVRY
MC /CAX@O+WC=:%_O\7!X'<"4K/;'% =W>@G<=Y5G7PX=[?8>A]8HL]5[QU\P
MT'5(AF:OO-K;T UEO:'62?&6KH#^F6P1>7C^=U8WJ\MJV[N6-@]H]E5$=6@R
MP^CIS5"?&&Z_RV,6+,M._RQ[3)J);'2B?9R08.ER(MGJ=-Y/S$PL7M"E6\;N
M0L9]W>[V@AW!W3,PVSH]A>(% /1<?#U@YI1L^QF"#<F_Y(-:P:>M7_7&7*D]
M[?BE'QMIEG:+KW\L:$FO^\4%[J%A-R2FE]9H"XA%Y5#G9I(V^%_"2<C$"/T7
MGQP)D63J*5=8HAO@</K(7_\X%HN>L;OO%KO[QQF[.V-WWRUJ]/OI+6^C$N7J
ML@IH6QLKCWH.[6'C%!8 T>[RT),KXE#%=+L*507F1&I7'EC:VCI'T:VP#ROE
M$(#8/7OK9<AE5I/W?O=(GKLOWF\ *YKQOW?8VQ;=GCB_;@ 5\<E]B.;.P#N7
M6/T&UBZ@]:S")5-E/*7O5.-7" / &,PPPL2256V70 )RQ,DPS51LD[OPB8S$
M$I(;Z#^F[(0V7>1CX9)Q#KV/.4-AG[;H'HNV:A7AZ*:L(G00D0C%:1G*$'^I
M@Z\RFH51-$8XR**?BLI^X,X-NCD< 1V](1'>X743F9=$:W\, YV)[>?RT/MK
M$D5Y<AZLS+!@B[+W& S).^8FXVP_WGX25[.ZP0J4SO"87." [ ?YPK)/0[]7
M,[WA;$='=A2+F FQ*E4\.9\%;7@T'F0S1[,6]&Q*HJ.9@C"3K3^RFA)B?CCJ
M\MDP.MM"N;<8UH?78IL22L^"T+.]C5Q78M-C X&N2H41OW)]5;+ RDWP&M96
MHYR-4J(RM\+9Q&83BZ>CTBPE%\4@*FMCM;,%S19TVH)V'3HTBI4"#N"JK&KK
M2W$'\]<MZ[CVY&R!LP4R1JH6WT1_=14:H6#FZ*O4 >(U2 %ZY0*?K6:V&CWY
M-HS-:*Q A4EM]5K*'KM@%,OL:&:3<27-Q/;!@XA1JB/B<V8BU=EDU&2&9E->
MM0(,V@U+(",Q&<@GEK:<?AFAZ>^_Z?G\-/2K"[$TQTP'ZS9OYC<IT(P#PZYX
M,ZK 7+;]#KWGDQW.U %U)(M"/P1BQ=1.5;4=:? +B!H86!#Y2]]#:+SN3T_N
M(2-#?D(6 L+L)DL^=  #KS[U%YY3C"#ZCVZ^(]=G$IA=@LN"!LN&.6X G[%-
M80ZT60MVSMU1)';:9 (Y$T,J=U.),IY0*)4(T=;IR]U^#0<4+FX=9S$6KG?#
M8#-SS[U3?F%UK\KA118#IH^"_J[#/Y%! <+-A:(5PVT%+EHUFZXDDQEDL\"$
MRYT#K/J=A%]*&VG:LO(]0-Z]V<<)+-UMRUZK\UU&0S?FO+^!:>EL\=,ENM/9
M+HE2@/O6 2].3WUA#ZC',# P<-9]" (0'H1=[SJN+#.G"+@TRM9R[98+*JF6
MHOIMNDUY#54BQN'7_+[%BG/$P=O2EE^_W(?N2KQ6$\(ZJ[?0;_$U]6:*^!<0
M:>Y*2[#Y;S=@CMO1<[=-$^H1?9C$/'JN+E90%TNX=<S"C9XP>SW IXN_R-<7
M',0"DU=&&B_)0?\X]&,@[\/:KPA?HB3$0L<F[FRNP@:H4".\M&]?O.R-%2_?
MM9L%/?LE9+I1?LDWH7X%A9=+,I",%O)L\4T:H!Q )40AV9UO<N0[1GN?CRIW
ML?'AB7QML:7D@FFR8Q29^/\<K18%CZ6,'QT-25#XQT-.3,&-#]%=50TS6#H&
M;T"U&.K)H_=HVP#&K,S>!N+_NUSTILNY46<5BRQWS$(.?S*^K0/MP<TMRTG7
MT]545O9L?, OK^D!]"84U<C&D\P%#QP'0/@M_<'&'V2XP]U</HRQ\0M^PPHK
M@E&X]')R\SZL- S[ UNF^L)3)'OB*W('F09YR29%<18#&86ZVAOL$>18S07=
MY=K)JPB[9V,.%L'/(=W?U**V71IMP$TRM67\%4,O,E925+;Z6]XL1W5IS9E!
MW4ZA70+/H'(A+)IV)YSIQ UZCCZVS%D4"S<W'>F93KW8Z6OM+S&H,WTQI]DD
M2DVCGU_5H>RLZUZ>?G3CJM!W*MO &5EYTLP.:>#'QH+D_;LY;WNND0,\%=5C
MU&ECPT7K#G,NH :*!FEC-A(+W)^,<!YY>:?+_?3S>>3EGHR\_%=&=U: "D)C
M3.'5.FO/GSK=<@TFBKW#6M(D&=C-1PEUPK:XE;6VNQG++G.%&F*]SZK77/;Z
ME6=)R*-3.,;:.YJAC?F7W?>]!NY<YKFGCL4-T/\B30D+T]F_+#F_^:>63]KF
MHH4WRL+$GT>XGD:$CS0*CDH5&PGC<XI[F]W&.-/J37G!?^SI.G3<CN4-=%"A
M'[JK0&8NT^H8->_HAQ"$X_^=!D*!Y=BV\F7:/W36O@EA9W73+N ;BF-WN@&2
M,+C)?D_.(&- =UP=SHU\D6K;-E!TI,BY9054SL?R\8N1*@(:%YJ<1J*-4?A\
MRTUHPZ.\+B4P;LCD])I>+3B_Q@E63>=IC'T@#=\K[0ADAW,V OP4B U$4#9G
M(2B,*\!+A1D#@<E@(4!7A#@=KX-R/<6V;J'4>?B929O&[HAX39["3^0-\8D=
MEZ-_]][:[F.#Z/?O ;.ZY:A:,I8U4;!;E3&!P?"=V],-2:\<A AT>07PLE1?
M5BL:^4*K/IUD?9^JT&54.Z)CIQH:O(^O@V3 $YEOU3-$CRE;*I&'&9HW37O-
M/<ME';:],63$>KHH]O4CF S6:6A0EU]5.]Y#"5+3);!-H44/]].<"FO:#ETY
MI1LQQU!Y+1/044P]B"-#&6]LKES%FS_F>8N7IAL;LD*X9>^)(2Z6%8VMWT)@
MU&[HG3:]<5?D^B1M9]UC.B(P+'KT8_X4TI=6&"GGR:)'$:4%V"H.^JHFJX/>
M69U<PUDGX$$#5JJ^IQB"#G&.MNJPWVNY>$"[K:8]K7\W8^)F>Z%+;G'*H._H
MB*"D0V<Q,0,67+G;(KK!/G8%DB^*FCL=E?+A(GW"8W)8+PK_,!O@;("&_O;F
M%)SX+*OR(C-@BJ@H0PX=7Z/UXGBALB8%!)-930M:8T4^H] ;>YE&;1S<\X=4
M;@*$FXD>SOIBW!NUD(R"@[*.45S3-BF0FXUY-F:Z)%.$L'W^<VBT>19SSE5U
M50D,IL-</$C1HD$QD5P3]F"C8_.=#6HV*!@4IR1KSCXTE9GYT6=KN<5:6,M&
M*URSX,AL*5-1UP8\O0BS%# !PU%5WSKF 5P4V2DE:Z\?3_^,2C1CKX;9KF:[
M&IU7)VIY[2YT)CZ;ZG1::D?3(2_M^9K7S%T_FYG%V<R+C";A7H=SN+!?2('"
M?!N9&D":C&;G_A]WG=[*GS8)+3</:Z%;V:YD0F 5NXO" 8]J/R<JX(?O*7E9
M @B[;*^D'%XUE]7RF,\ZI[!F'7";N+(QJUB"9TSO23#>W$Y['X]^GAKDAO:4
M>N"X]9RXDT2,EM$'QTC)'QNFXGR]%\KN'G5!RH</"[*H84\QZK\S&'=4"/\>
MX!.VCI<=6]^.;^(K]/->IKX]OO950(/%FLE_@:=;A:E_^D[&&?!8WPVT"(O7
MH;N"CKU!4--%GTO%B/; MVR^-:O;@RB*7E;7A$.O=DW_L T@\N0VVC,*O^EV
MX9"X&^@), QZ;HP;,F-ADRMILI%WUZ[3+9?#C-O-YI'PW7.;N^QOZ4#:-75@
M1?\)L@/Q>DF3_;+5A^>F::*5V9;K*$1S_#7L!IM9,!;9?P[K"P%P,"!@W2;5
M %]?5K+9&%;"+R0D=H1^RZ@V/;XU3NG';,9GM"#.NSNBN*3 D##)EV6ON'0
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MOF4F!\L(9XOSNF\YY?QY1/D+ANZ3L2-'K?8V2BO@(FO$&__O)+GO3>I+M^1
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MD?_63AG?RM#8"3_EMTYX08L-3SUDH7*Q!I61Z39>+996[U699H26N=4W3\[
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M/_XBW8"B%<(9_\N3+Q;?-XN_#$U8//D,Z_#TB:P#,]"\'G8H&I*A#'1A.@?
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MS #L'[6;1[MV!:Y!*3[;8Y2*0O.Q4A97C",4(XQ)+#$&L9Q:.JMHN.)G/.B
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M1 D&;X'./[946I;O:,=)O^-E'+#!Z;>OF;"4#*-9816RUV<@,[8"T6) 87W
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M ;[V>Q5N67YYW;X<H(J^6A&@BTS4*:HDG+>JNM6P12:P$II)J2VK4EL%S)-
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MT6X>*SM;O&B[@-X*3AE070;_NS(/G[I.[2@'7XSP/PJ1H >XY?3.18L;)C$
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M$+,NH/'C$U[-TYMSH79XADE@"5_&Q_2O554M*#3OQU4#V^D.$8'QWS<Z3#9
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MH[;@2FZ8U6H@_0V]9AJLYI1;3*_L_>:L*UY-%G6WTAJF:CGB;Z$N!UHI&:K
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M7*G_HC07Z52@=LR-,K25BG0O7;JC/39%]O_SV<]6.FFA"E=T7>IB:YENR']
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MX%"^ FK]C/-C#AE9TU1SYO(+RFM#TR^2GC$4G)HT'4%C2(TP3NQ4*=GF4?8
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M":7! "LF4!WM (!:K/W=U$P;TX.9GO55[W9(/MAD"GHR3%J%',X1*T;:T+M
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MEMUYEXA>WJRBGN7-G4Y><K6&)!;I:ZJ/PZ'3B89-%"[Y4?L'G&$GO>WUE1_
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MR2\K<"%5A%:2BC96RV564\(K5*RQ1KYW179-WL[_CVT$:/.3-GOE8(+*-F3
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M8683ZS'D0#I-6 Q=N:*-#6=+4^&.%0<^CWM+$T,E$H04C4>!<HK&ZTI0Z]%
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M*BYI[=K+:M%,C(S+,K9ITO-WLFZRSAN(B&A7!?B29E" D#-3(!(IHP>1!:P
MCL'GG#(AP/]A$@+I]%_&3\VCZLSPU]A1=H 4*[*'B=0-S,=_2I*0=;;B"YBZ
M ,]9!%G#WX$E"1/4%91P5$(!>7-S*678'X'7*]XCW%]NP#XO7U&=_1ACS<_?
MFWP/* ?#)CC1:=8)%0K@])&*CT7[P0T\8+>FD\WEMN%_8:])^X[7+FM8VB#L
M[K1O^6_ZC5-9R:@]N+?KB[OA3E3@'MYBMS^TGTWW+/2_3KC5%["45JH-DD"F
M"@C5"O(F(Q@,5,J]M3-(Q/:84=LX(IHBHUXS;_#U=A-D@EEA0;9=B3^BC]26
MD"F^X/^^JIVTRM$PTU\+SB'^1E^&^9,"*J+C]%]S_KZ2*!>P&;^^=#[STK\\
MEM%Y(O>U?CTR)9D&C3[?Q/(-WEL>BH&H#<%;FVL%QXKR@;<:!3X)?QZQQ_BK
M7N:;6.H#PI&B-RH/WDX:Y?-<^_^F#<\E[(VR.7&U17.-5('E=DR\* (M D<C
M_]L/#J9O%8_;4-CNLNF7H8!2$ B6Q!]PB[Z%[CP"',W2#XS]CWY.X+#DKH5?
M5"C:^"5=P -0P_7< *T"E\7 8MF][VA9-UJ60G(S["*."_ :$@:^OUWR-:6C
MU./52=:<9"<#;YY.;8S(##BQ1)>%DJ%=+><Y[QXS]/P%!KBX<<F+#U^BX(^D
MT1BPFWSS=+*SJ?+12\O3(0*4@2Y$FX[,#=2F@2DK'!;#Z3)QMA(GD_]K&9T0
MA>QX5<9+Z:2$;EIEO<P$"PG&"UU$)H@+H]3R^Y5_MJJ^P];](W TK/$6]G#0
MN-T8A5#(SS(Y[!93J;LG@HIGNISK2 ZR(#Y*8D@U9Q81YI/.S>=^D4W.3R><
M(7Q\>DAP3C7I'G.WWPOLH=83?OA(_/; ,GF.IXH]-@D0H]NJRT/J4HB3* =#
MZD0.7;5K;\9KHO,WD%_;?3"DK\2P:^Q(]$Z#:")?R<[8@+RGP=;VH+I5K3"E
M[P@D*R=>[S*R@N"WWR4*4(K$T5@RXK^_H^BG:S6N)J*"[PC%C-\ L]()P(@T
M15C4MJ?&:)_V5,SCXY7Q_N]9_5___?%NOU-='N$1'QX>\7"$1QP)/.(S*</\
M!+ @G5#O;H#R;!C"ZA=(S4E5$VP$FIPT8ND?M EW3"&&( 15%ILFNP$OF$;M
MW-VX>W<EW^\=O^F WT>2XJ+.*9+TS08:DDIC>>*CV=[ &]J?#HHU/H"!]]0)
M^?BAJ2X-E.-E;#"&<D>H8!!>F5"<%P\4FKJT@5\O@66"RGC!I[_:1!(@RK08
M-)OUO5NB%_>%'!SYGH'&F3./3RYSMYS\&'JBGC%/)D+6)S\^B^-$X\K%V>!@
M032$;QLJOVY#Y\F& LVPD@3-3I?R@]]-XX4S]IAU_UB+1"UTR ->,K0\:9Q6
M&5*NR4EAB0HH*W02#*PYU2R38P?TSH8<*DBFBV+'E4HQ>:NICU#OIJ9L1]7Y
M7#H&147!70E[,(^4MP+[G-J=UV\<H P#3E&+%0LORQ/Z.=^05T":NY>'YI0\
MY67"[].OF/("9^LIR\&9NH$L1SP<Z<<G6@V7E3PNE>/83T(U)MTY;*W(-?.L
MP*J0#6./\3"9>VA4,;:_Z*?PYGD][]94IYJ[IK_;P"7'9A/)('NC_>D)&Q][
M_Q\"2W+B_7]XQBN%OHPK15LTVT[4(49U")T<G!*1Z=!RE-_#LC6X&OPJTH*]
M*-\DU3->%4Q)T'<@<8K\O 21Q"UFNJR8-PN])\H%03?$!UN-V_J1WH&>(NW^
M8%\W+K3C.33L"]L%?]ZD7'--)%:!(0NY9M \,1W^AW$=(8T=U[A-D%*<9"-%
M*E+QX8:^MN;EU!\R-A\T&H56<*U=AX;]IENOJ1(A,C^N42J1)F"CB%5AN( 5
M!KZ.#*E':,I_#H#VXG?!L/G)/([, %+C%Z>3Y_41X65UBHYH2'?<!U[Z+?>/
M#HP#@!\4U5P[4_^=%>TE">W^XG?5;'[9-:YM8V60JN2-Z$K[44X:NHPC@GH<
M$PM6L&:!A D&+\6;C#_C\I _[H'[B6@[W:SNB+WHXAN(+3P <8[X,1]%G#^\
M[7U(9]@__?_VD</4_.OP[1]WJZYI5>F!;SYS1>ZN#)],T.U>9G,Z=>82CAEY
M<^T68J).E4RF^GKC'  ;2KW#%#:!,D9)\ /;%'73^L'W;B4,3KNDP<E@[6'*
MOT=*$C(_,29(F]B-H", =#0/:.6I16ZBK_%X=SW\O=^!F/A=Q*:IO_>('/V]
MT\G/-+QC<JS/XTP=T[#NKK\7LD"JW$9JO,R08UC6(\8'&6N_NTO__N_DGG]O
MLJ5KM[]'ON5C<@#W3R>_T![RT@_RB%:;-ZSOXWP=T<#NL!OX9]4:^.@Q+NN/
M^0X^U,,.XBV.K1;_7A]N!)-\6##)HQ%,<B1@DK=^1+4?Q!H4A_V>Y\<15#Q_
M_.+78]JNGSX]IM%\#!;+&(\^^)V)/']?5O7OS$E;4X_ [TQ0\KO[HSL.(T)D
M^N!4&%F1"WD1AAL*LD^85N6'/ZAE:.J_P9GGEVTU/Z)WKF1WOXC$)67!GA((
MO9X\[^KY9=8P"0T_AM'Z.J)G> N[_4@1[GM^<#% TP_W*;R5S_\H\JS/V#1S
M*S\&5=N68O0!EF?ZRB]H7[F@M.WY0\WR,F'^VK\C[0UX^<_O_Q]%?4^>$YB#
MZ9&)A=T/=ZI<[%E#"O+"N'Q V_[S5\;;]];^'K6-7[BYCP?'Q70,BXDEJT,5
MY?Q;%#+NBPA:7S3ZXLQJ5-=XCX,:?J'S58C6*(4(.DS_)UE:?D-WKM6U569K
M1EL0.7Y-"[G8<L]7V4%,V]_%L(&2HC4/ ATG<I>\09Z2U#!*H>H-;;%:3UF!
MDY<O*D)I\0Z[#X=*TJ)R?&4EW4UEKZ$G+$,0J4]]UI9H; -A]@3]9OG'!=[>
M60_T?4X]>M[$GE/O_"?!"/7Y^Q\E/RJ) 0,*#UG-0GF;+&=M& AX+.3EH=JX
MZVX2X1Y"?);28 8G)/H&+@/.IF%Q1D'/+/R-BVH38->KNKHFV%C:4X8[B" 0
M@8U9;()X'@=&:+Q-OWH+X10>C99P,X6&;<"NK!=189EU1B3?W/Q(503_2(;A
M=ZB%@<0QZ,>,SY-XJ#P)5>@@FK*#T1L05J&&06ZG [\*-%9B(S##FEA)@K^L
MO,@B1"$<)Z$USV\FS09Z Q' IUV:>YX'S9W.GPD5/7MW8ZCGW L.1:R?_$TN
M;^,W'IY^^QGZ#6)+VICI6-%T^$V8=OZ97]#7W,]>"RI.('A"0$UHUVY-K:>$
M;FBK0.0MQW6_QKJZ['L:WN !*C4'#,+;58U_2']07+C7 94G'_\MKTR_!'\%
M ,#OW1RH6L&.G'\SU5Y^_)Q:&R9,Q-W[YL4]YHKB)R9MJ#4PAM)"JQT77YZ?
MG=$3[-Q'%1B2QYJ^XR-)GSV&PE"2TCHS)L/G ;J%=X-% 8VDURP#+02Z6"RQ
MB5Y<B7 &A'[_H.K>C^YP09X;?O=Y ]8YV(1\AR>-#83N.0,.J-OXZ_M(D(A>
ME'>.+\0'3";^M>:6WMO'D'QA"4!54RW'9K1 0\"58^(&^/X]E^5[+JO"#P_8
M_AT#MPQT"5G891;5P,A;,@K3_X=&V^ +@A?7:KV&WGRFC5\EFJ^%?AC,W>C0
MTR!^>"UKB1)Q.8A#@-1^^<,39@;:=+4W(I?H#WCC4\GD>+5PI<=,'G_^[;W[
M#'=F(OJ@1&"_./7/6LM3XP1@)V/6$TR8$21IZ<_I_.8$M""O0N2A8P(@'4]M
MAXH;N]=SMVE5)8GHNLHVJ!#2Y@;X;H%7'P9!Z@:[P\#(>0"WXHKXLUWY6/G[
MC"I_WXR5OS^U\O=&"_>=GSI?KR9-/?]?7_A_7)P].G_TX.SA-[_?/_W/9O4%
M83F'/]!IPB,^//MF\_H[>8T/SL[\?_AWKX\Z+M(_8Y%^.R[23[T\WR^\/OR=
MT@#UE5L<QR'R:7M,6+_UY.'IY/]](3/T_QW1R-XB4?KIPJX^ZX<;-ZT/NFD]
M/!LWK<]MTWKT>VST;H!>[W#&_QUDVTW>_+X\FMUL/7ET:E0E D3H^S!J9"P>
MR\@GU?*8=IE(=_)$<^X8[HNH9_XL\-D=T\ __YH5?_4V#(QIVFZ1&IXN&<I$
M2@>=]X5('?HK_$?9_0-; ;5)5D6^0.XJEF2@Q!B).#0+6%:MS86ZHG'7P*0,
M4EA*Q7O?"&-1AG"E0J3?OP:J/RBK5?5U5B].BJJ"CJH9H<FKJO0J.@V71#5,
M_-["M4^UH$R9;,%V?T4*84P32K <8:=HC>A!M]Y(L2EPW,8;$^UW'0I:0B5>
M01Z>>O&GR3V9^K_D^X-@LJ[^XX3UAQOD0XT+BU$SX6V^QBV(#I: 133Q5[B_
M*F@OEZZV%*9,"PVD .EOS_.-=LRVD+\],)=@-.(1\!W!1:-E,UO#X^LWC#TB
MD54D-0_0G.(EW&0Q_[OJU'3G6>V6G?1X\E0<N'HC:=]A*VJKR8JLR*]>C!/\
M]C*K2.>OZ6O$@Z %0B-1SNJXO;?CK[AGXE'<W#O#IY/GW-T+L <QR#+7,(\>
MF U2"5%(&*5X_5W_Z1<>(5/%W'Z4R_\LEW\9+__>6$/?G\,:O7>/K%C+Z^(5
MQ08'"N(J:Z";<R2;#6W;!VIW%UJ67&@!X<"7_?]'P8"^^D4,</ZO0Z'-F\43
MB)4NOAO\[ O\[ OYRL_Y'UV^ ",4<?5(E?^%<H-_L5.-2Q<[=>H3B_GYV<D_
M)B@PF<K2#T^&.OGOO4V=__,@Z'QV171U[GH,]XX!:B =T%E0 _->A70;9GFU
M(49I?[\NZJ.A\,V8(E9;\@NBK*ZX KS)-SX**ED"F\JZ<!A^G(0)1,#17E=@
MM*)0!-SS<]H5*1;4*OI5YYU /F-*C>RUOW"1K[,9\U[4SM[<?GFRJ5J00'+$
MXD?C_[FF^NFZ\G_H"MK_+_,9J9VH^Z/?EB>__/RS?]8R*+#5S,P=W%U+W#X*
M._C'+[]>/*;HH*ZIB,K56_R1U,YI?V5TI@]JUOEK1]K?I:/9+%SWRJWSS/R6
M?NIO3C^<=VW\BI&;TD^VZ\UE-2NRQK^(\#W<^_'//\M4X9OKK9^<?-'[SB_R
MG=+-"^??:M5X8YB<]T?\S^>_^+^M.T0E_D=ASO$U'UD6++%%LT+Q"9.,\RO@
M,"[.%6%C*<J?M-T:85Q:.J:X;RY*!_ZK:]=F%+#XIX/14PA;B D-O?EH%_3J
MUU59S8N*):[:?%8MMAQ,S8IJ_JH17(7_PM:OK)R!,4Q70L9P#B:K35L)%]O+
M'T_.P6LVOZPKOR (FK!L3XB1MFM.2$Z"=E(*J/#]^4__^OOW*.A?.V]M]/86
M?N5D/B2<3S9=X0='7G^9S^K*[V&LJ??\1SP5Q>]@DZJ@#@3"$='*XB M*"JE
M:D+@ VWS)C"J&=HZ4+]!90S4*S3E]/!%-J-*?<6J&SY<<) MRN; L>$',K^6
M;857+]8_?N=OK-J!NM;?CPK$QT*PO2=T9Z7^3%CLKNAHR_J+PALS:;*"IUE^
MT0J#,M/<;H-#%-I^X5'3O]*O^01 ['C @QJ;\?ZBQZT6%$S,BPT84 %K>R,J
M"<%B:,WHQ58E8\ACY'=*H!$"A= C<>!V[>)SS)PK16( 8-#PD!@6Q8(D28!3
M_,1E?DQ$9EMY \T)*2($AHYE-/Q7+L[.'IQ.?C3!9K,/*89;4=B) 07=NXP$
MM((.PI<79]^>WO?NN"@T6/SR_/ZWI_?T3U/P)O*F46S36^\/77=OR%/ M[Q_
M^JU>_G3"30@[HX]-""6U!3!BCZ0WT07 %_KV["*./<@Z:BQ:5N4)P+ESOU&O
M'(?H %^=<(8"^I]ED[$HY ;A-KT0D8*?*]Q6E ']:^_RYA*&(I>\>?0T@"EC
MA D4>^4M59,X_EA=MR>$ V89P(IRW_1?$<O'K^CAV=GI@S!AGU;WP*<5D]_^
MV/C2N),7D+6A=_B;35G=QO7?.[WW&0;-0&%*YB\OEP5+L/A]WHHG#LO\)%HN
M<,=] #I!Z?P:)YXQ#;?F%'9H)U*JVJMWD"5'VE90N5K4^97^_+?3E]ZON04R
M:U*-%LD<V3]J9(@0__J5.:%]J8G^9@+ L'Z- P#BC":F/(S-^PEO(R&$#I>0
M?-8Z>P6,H \%'9)8^9S2?>2N.N9'GR'EBB9'B3TD.<$MCT38N6DCYYH/T);4
M-N GUGNH$+!H4Y7N8360JN3AP,S95BN'O2\<SD/+U%1&*HE(=%74O$_ZMUZM
M?105L[6<);BJ"D2A',(:2*]T2(9.B9(V$O6"TR3AR3<M(>9(NX\U$KL!_\B#
MH?F3O' 85NQEX%V70P;:1WQ83SD[L)@V4!\3/#1#<\FW%^TE,-G7H?TC8<P+
MI@W65.Q5D0U+"(4%1AYS20!7(\M4[\DD21PSM:'FI7=GYGX\,<$PS7R@Q:-I
M=[H[$.'R1YK$&@Z!Q%Y_16*:OT\K%8><F;,O@Y^0II+CK$0XCNH8WEYS=("L
MN ]WY4]752&*;2VIN2'UGF:XK8'Z]^/OV5Y3"/6"4EX9>]E7=&$7$O+T-7_+
MITV=$:WTM0_C7<E@YWE=#9D"=O2U/[%M76 T9%M% TV&-@&>W+#.:1:B_9MW
M0[V,36A-(O)IO 6V]F/<KC__#2CU>==.&#=1"8)#A>^:$X+<E2MG];+U)*X!
M?[H9455(+ 4'/H>\@KQZHP<0S[MU" [2>I9T8.!\&YL:F-,Y32SY-]7Y2V_A
MEX_'G$9@S8<%UIR/P)HC =9\DBZPG]8PR988:R22WN1>2$H6&HUR*-[GO;*F
MJ>8Y#N3TL[]*B,I19=!UY&P/W7$I00@]*O+G.QGN[X).,BMK(_7&VK%^D"><
MDT-V,^Z\(:W$*HZ]E/EW?4>J7^E/#?>/417<_\'&L92HU^.$#RLI6OZ.0]FX
M<_CO^.M"]AP9?Q]8E)<:FB-[T_J=P'&Q6BC?27_&KSV1G"3_7T 5 H&WT>DV
M4VE;:H\QIOAL4@![Z\11F>H3*M =G5/[X(F9%YPA_@@O9P1@W"8UI(=;FR,_
MG.L7,%8,N_7K0<07Y1]_SEL[FVEG"H2&@6B]R%TR*IR*"%)BLE5QI@CNGO%.
M<>_TS\[UG9W=AD<9ZQ.W2I-C!E A:*J"SM0^]LI1'E'@4JA%[=_/M4<Z6]5.
M4&/82/ZQK:ZSR3]H%YT\J4ZGDY_;Q2F79/\ALDOXWM-ROFVIEY?;5;69E_^,
M:DI\/V45)GW1A7+G[<H0=U@1_6DY>>DV+4],J)#@= '0#'4EFSJD%AWDY<<W
MF[PPL;#P^NRO'^LOILE/U"JOJ[I8^('N,J#LFA4M" ,T2(_6^6T>3+)JPGDX
M_#33WN.\Q&^4)S$^S^GDM]"LC5RGYHQNF@;Y7'29J*#C ]^&<!F[C\S1F5]_
M+>D#ZAU^*W-FF>3L+]8/^QZY-A&O3&V:@7O$Z=JQ&#VO3D@?O>*YW?!R@Q_P
MG^P=BF0&>D/ _$EY#G3\YCW)F ;$$PEAPGG"_LTT@<$.5;",4#Z4-0^W%(V'
MZZZ)@23/3T"&NMIF!:D-9EN&B<R*(/0>P:H@96 &! (?YTXX<-AT?.R+&H$(
M7BUS26)*Y53@M7MFT"V74"<$4"*^K RJ]R>#L DISV5P<#O)T?[A1].;2$V>
MOCP]"2FDM!;1I&NQ_UH>//A+H#2+>5K)7?6_?+__Y=/)#QG^S2"D@==.I$=\
M1 $O!39'5_9.0XPZR3G[70P\NRF'"W#$^JPTRY9-_E/EO3L0J,-?>^"3*$2F
M*=^NZ:^NR0KJU9%%*?Z\YZ;VF__YV=E?#!O'[B/"27+-B-E,:I=D!=WK$U2,
MYE57MO7;SI52/-UJOIX:*A=38!=71B#JC5\$=&,J-(>E1D0PYX^2XGY.!+2+
MR?GTOK_* [\["[,-'74MK2:$1RFF6!&HOC7NFXE+Z-KW8E&:=9=4"NK+\XN'
MIP_#?<5_,M5.(KH:GT'F*$)O. ;SQ^$U33-(-HF5;U7ZC9@Z <+FJ+X)81[Q
M!#=+YO/3+_A+2RQS=P.0?X-#!EJ /OBC-QOW/S-/ >34BP2PI>=E12@TVHO^
M)Z,GH&_]HZI=%C9ONO9.T +SO3@[?]"SVLF7%P].SX*5J FK]<*K(U)%CJH1
M$AT:.A,F1YC$COD]BO@5M;[^Y5.#(W$P8W1+%EZ?.2F3&K-3<_,&[$\9HB'-
M0E\;;@:QQ#T"YODJ?,AD.TKVY-?RMU_SMN=W$/QBSW!IO3TZC6N9UD-\8G]5
M/U.A^2VL5=HBPOJ6]J(K L>1,^P!7O":^L$<O5!FUZ&.'G&($#HEO+R K#B#
M9BS$[]'>VAC6 IAB4<B7WM#6@*_1ZJ":C[X,[V4,<BDOPZOA>AW-T(9$C:NN
MP<E*'E9"J?8RKQ<3$;*CZ:$'_L0R:Y\6L=V;Y'!,<?K[N!N.29WCW%U>[F(5
M8X+'QPMK9D-;5O,.^)@R1>HD\0Z[#D+,[$,H!&BF2$J:.R"*:7!>$G"EGGA[
MH>)P#H<C),8/_O5X7($IY<GKIU<-6WKTE[3,VK.DP8JJ=ZQU^QULYH3ZO9N_
M$AR2T,H[UA5'*#?[2.9V__31@XN'%P\?/KHX/[_WS=F]^-AY22,_P=,?>%RJ
M 7YS<?$P% '-I/(]Z%S0N^K'64W!OH,1BPQIS._U0,D[YTS;%>K,L89#IGPE
MRIZYVKQ2ND984%6OLE*.T S+?_+B&9@BT8998N4,W/N[:+Q488UUUM&([Y81
M"[KJ1$TU6'4_>U(A;;X/D!\2$M:H&Q\KU_@;L\(3QLS;K_\9-_(H\'L?V#L,
M9K36T5I!1)65'34\<4D#$J9-<V(,<6J! (PA9NA X,(]":F'T;A&X[+&95(,
M;#3^UWX7KDJGI_M&=GA3\#.[_6WL:$3@?0 $WL6(P/LS$'BC.[Q3[I!.[5W!
M/<;D$2'U@6PL)>2D^C?NG:.QT$!CBMN'9X3>T< K]%?%:(O^/%K-:#7D8H;*
M] 9-:[JMN!DJ? (P;HY*3 *YW6=9=ZFA_RG%8J4@'4C[ /]QN),,U7-9HZB?
MH7B4U;'__73RQ'_Q1.$67.]M8IUPM@40H':BRJ9E.,I :;_<WC'(G?D>G ,3
M>/?>-(/RRNTDU70(4G[BM +*ZA-'2B:)4@GRV-0V) T^15!NBE""C+#U'4#M
M)#H2[KSQ5\+@R[HJBO[QDZ19,%XQ8&)L03N35<$@,&.^X QAAY99.EM<^5"^
MJH\2/_[Y%TGVUC.B\3$HR5$NMMCI/UM7"U><3KZONY4M67A+I@3;!&T53=*R
M8&_"$$X"4:$H0_VDD%SK+]?VDDA70"4(0HJZR%U]P\6GI@(CO:#<4J$-T31Q
M_-A='5:):0;I+;6]["\--,VRA,M#\"%2TZF5DVP"<,G-,Z[UH5V]-F[B2^Z?
M+:ZP,^PI*"W25\-U_3B^FYQ4KZ ?'"R>FMM#BB(9#\G5H3VU<(!=LC:==IVD
M/Y:OHRU\TA35-544*!E1U?R0Y&L(O>#M_@X#99ZV$U"D:A,^@ JLU><$OQ?Z
M@[B;/MATZ.5QTJ/=M!%W(6P(P.'!NOR@@]EKT7,:;:1INX7&NKWEL;]^R1:G
M YH:&&'D+'VW._3%!;/)%67BN5<JH>J4,BK)_S&$CH#^:"V#>4]EU0EM[EAM
M'<\*'V?!;\!WS $7ULN8>A@-@P::RD^+B8AS0Y:*:9Q'<QG-9==<>BQ$0%J,
MEC):BEI*Z!V@4Q;C59E-E:FJ."2GV,LM1K,9S4;-AC@'6)_<!_0A0\G'122+
M)OZ%K1C=+1O6:#ZC^:CY, LT;4B6OBI;TOEM797$_BR,&YQ1U",BV1G$FUG&
M-O)[K%PY'ZMUHXT9&[,I/CU71=L:+66T%+441SFV;,[=QN*%T-U;.%-%V2'U
M&<N\HQ&)$7%2DRNX<Y=ON NX3/<H(?882[A"1*%;_U17V$QY4;BAG*"O*(N
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MZVR!MGD"ZC=O(Q+^:>T@^YM)Z"@Q>1RR")/G=556E.Q&O]JGH$WP^2^0'Y&
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M#HTA'8-F['AK![;9W.C>%4>1>BO+=2[BMDV/)VU3[K1W;+3:+ZJQ-H"5CN.
M4UUL&I4Y6: %_.;/KSJO5D]\J\C-R99F4PQ_DHPQ\%U[Z<K]0R#H!T307P?!
MV[\4470WXMDDGE.%521N(FXJFYL^)5:98*6K]XG+<&V+:F*D2X?VC<TRO/S:
MB>!)UO(^T0X8WR,_#L$ "G<DOC,BK%FA99#0FF^U!;8R22B">N*:+;EF[>%S
MXAKB&N*:K1*SB66(98AEBBNW]E +L<QJZY%J5"U?T \;!][H:%6]6^(=_^!4
M-;9YGRHP6EOM=ZF=?'TVFWB:>'I-=9:^VNT12]=GKXFEB:7758)4]7ZMV]A6
MCZ7/]F0R[6Z5.;G6P%S]9M3GZ</XY)$/@VH\'%G67D"-AW97U=IG7^?APM"9
M) 9)C(-)#*.G=G6J(T42@R0&28Q-)8;9HHJWY-\AB4$28R-Z.?^N'-2OC?JU
M7::"9S0-Y$';C_&X^@57&5Z\$-4@E\KV;)M;-%+X2(*0!#DW"7+0QFPD04B"
MD 0Y;PERT!Y+)$#(YU09 7(BK].9RHV#=5JJD,PXWYX'QRE[^'<NO$16M$$=
MP\A7AFYL13&+N"RZ_*^8!< 8^$WZJ\WA:E$P%.MICK@2.6/QUW"NI&>A:&>A
M9#J,-1["-W$ -Q4KBA9'E-^9E6<^_LHI!6J:(9IDG]-"NJN)9I\"S?M03?$8
MYQ:+(2_%5ZVKZ'+'75=LX5^YQX.D:.:-#9<GY<0?^3Y[=_#Q+]W>\Y<)&Y1"
M#=/=?2CL+IO9W5WJGXK_&FD55)VJH-:T"JJI-WO]E>4QFV9KUZJ=G:;9,[7\
M9_?JGS2&_<=@=(S"&+3VKH/8>0"]SF9U6"]VXA==I8[*F^Q;WD37J+X)5: E
M=J(*M ?B)M'XH"$U?ZI&2TQ%3%4.4QF2J71B*BKQ3"6>JT985$.02CP3[!/7
M4(EGXAKBFI-SS=HCP,0UQ#7$-508G5B&6(8*HQ/+$,L0RE2,BHAEB&4(92K3
M?J.8I"B>N$L-@F+.GWA(\:G:BJS'JI0HN/7'8QY8CJA3X+*(VU26X$RJ!%/A
M[ZVY03=576_7>=/ID-YDY@5_NH6[!X'S)S5D7M@(>> ,B>>)YPO>96#Y3IWW
MO'HL3RA.''W*@[5MXN?Z;#3Q,_'SNJYY:K_$"CW$TN=<.H-VM\*<W#9JW55K
M[VH6M=[W"^-J NKM@5KM=FK-X-63Y(33Y[R[567D5K^\+DV5%=VG[)M'P4=\
MSC=1.NKNK__)QI-W-Q1X)#E;Q]W=1V%JJ;I&\<:::TP7'&^LWO97E=7[:J_$
M@I^TU839M+LG8N1.OTM;79NM)D8^Y]W=Q\FA&AUBY)KKWL3(Q,@EMGNMH[.R
MUMM.3$U,O<0U5E[;=]IHPN8SW]W*LG&=M[GZ?9,ICHC/^<Z#T/<\[BJ6'T:%
MKC04421Y6\/=W><TDZ'V^A1GJ+GF1!'%"FU_55E=UU53J[5^=6%[3:!]SKN[
M!R=W5*-#YYOJL]7$R.>\N_M!<IN2 ^JN?1,G$R?K&@45:[OOQ-7$U8O/'ZN:
MN;8! VTUP3/M;K49N5?K8\9T/K$><<6[R+?^: Q8R+&@\1ACB2QR?._L./&4
M<G9] >ASEL1;E;^NIZS6.VI/*^\\^29UL,^98BJLF54E;$DBY=Q%BJ9J)3IH
M2*14@1Y("2&)<3B#4>WKY85826!4@1Q(8)# .&!.1J_$Y"H2&)4U6DA@D, H
M16"4EW5=46E!0642'B0\#N/04+4>N4A)VR"!00)C,X%17AI+1:5%]0_?[A(3
MKW[0^Z<?,5<)N>LZWH.J/'"/!_ !'JIE-MSDA%' (N>1T^G:BY'<Q^^%< $B
MO--1^\;9BW%2^B@N3K+EZ"T03=5HG[U#JGJRA=02$AU5()5]*HBT5:/$VFLD
M.JI #R0Z2'0<1>OH=,B-?0$6S26+#G)CEYG(>_::!D7-27J0XG'H[%Y-+Z_L
M2D4%">D=ERTY2.\HT5(Y^[A+:>%S^)<-7"Y^S291/,G=:K9-\Y<5Q[D[\&>)
M,UL>8LG?OO)UF_)196:<[*7!\7^+";V$^7_T R4:<67*6:!PF*FMO.<6'P]X
MH)BZJAB:8:J*'\-56Z<(*(YG!5P<I!],E=>FV>PJ,#BW<)A^2\XN8<(PF4 !
M"^0751D&_EA,?A(X\"$N05/Y"7^GX\8O8-?@\8H3*G;,81&NYVC%=AXS65TH
M?0#48O1^>6<[X<1ET^NARY_G:>6?<1@YPVDZ-G%-(XQ8$+T35-& !1B'UUB)
M ):<OZ"??(9(FMU?2D@/V6E]6\UNV]"[O4ZK;YC=5M=HY_-V/!QZ0TQ_Q7R1
M#WN&T<D8L;"J\B6ZILT_]5CSFZ6?&R\G#W^H**]UO:FE9 U?8<V(,0\L!S;B
MWZ)PA,(L8 LG<N#YPX3= OX8C[GG#"3_/,.%+I#: "C.?PC8.&QF9 9+D?R7
MR(W([76K:6;4%G"712!=(S^["(4N?.Y%*OP"U#:6)!AQ:^3!@!^FJC**X85P
M30A2W8(;D )=_@"R/'U>*L";"E$A4>%"H==KMHI";S+3C"-$XK/<V 9-0?%\
MKV&Q< 0C7EQ81Q44F-*>N'\I98\XLRT_]B+\)HPG$S^(%*8\!/X3O@N(&D#<
M&HDGVOR1N_X$Q&P$F/_ O$P>PY>P.A,6R+]1*.=26W%9[%FC36A?;*;M!-S"
MYUS#7L1C;Y;\)\S&52A8"HY<YC0I%?Y<2".@BX&5\8P;!_=?9P;'\X9VA6[L
MKH[FYMWQ26VN.V>ZZJ,LFW?"'KA,U&VP(0SSFKE/;!J^>_5V?GO2M1=FUJ*%
MWV=]2[7;UBWFVKW<W$N0+NC"@EUK;9Q]J&H?\?PD-VW@N_8V1"8OQ5==.V"]
M.-;2E?J$%,_#2/D@L4\(B4\>B 5>8>/PP+PX;QPN,@V==.$2I0'$;M'H,YK]
M%">$Y=4W5QE>Z;UH;N6VES2\Q V@%,!@I=@&('KQ\@)NX.5L+$U:UX>E8P\!
MYP(-8&"XO0,>/7'NB2MO 9"8)S__+P""V.6 8K"P "9/+ 0%*A OAH<!#-WQ
M2207 A;!:)[.FE6(.%=[+C(*<00OS[DD]':N30OR-#K:<OIT<H^&H(D7%#H"
M(05OS]X)^D6B7^>O98\\  13!LQEG@7J%%B,J!WQ?\7.(W-A;O*.<"14&]3-
M?<0PH#]XRB,\%DFX8!_NL_%G*\Z_B4YP5XDP?Y-(<E7Q>$0<LYIC\ KIZY/M
M]*YXNHA.OH@%@LZ8!75Z4*D'+D=SP/&%I)SEHI<LPPJ6A;!<@0?B3+Z#9@Z4
M AP2!V#36M,9^1XP&Y[-IOC&Y?RP@OA[^VZBXMA_?@6<'KM1>.\/[WV8MQA[
M> \COS<TO7?_&.*_W>,RRC(*^.R E+&=2.+<+9L@&RD_4E? ]FMX(CXXO/P
M*?WH\*?+%18W(3+@ OGPQ)41LP5HJ2N@2R+64OR2(@9M]M<=#8RS%(6;RITC
M8#%&'+5 SY+0#'_FW 4#> 0$1=TM%RA#4,_@!@'L**$F@6]Q;H=20.$#)O$
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MU0 NU0H!"[P4%[V1/@^N;.:OA-5*;'77S2DM75S0/KAKH]V.&\#"D!>L<?(
M'=F>3=46X "; ^BX8;HSBZD/]!:@BE?BP^_2=GRE7'WU(Z[HK3>I\@/O$-E<
MDFF$8HFP'T;P@01@8=H"M-UX7BQ,*(Q$59$,+A!>/\9"!?Z8Z)(_"JKP/AMT
M\'%?,"LOLJS8(["S<">M-$'6&9IH@X3Q<.A8#I> (RRKS+X1T6"7><)&P%<4
M32>II4OM&=&/"Y,M-;C@T5+_?Y));U8D33>IL4L'UP N*4:[9_ X->/0Z^8$
M-N!1 $AC@5V,*:?+E>X0O1,6WI==F\3=92)';B@5;)@9FS%-W_,?>8!!=7F_
MT'.D<2T 4!B"L$QCX<@6R!G&XXE4+,1&C=D4#=3'9*["1QA@0#Q;&,N/ 2[C
MD"?FLERZ//TD],%(07T$: XO%ZZ^R)TF*UHAF4J1_\-&_GL4^3]JY+\6H:(]
MO9B9>NA.U208X8/4$6(\XA(!["!&-Q=H"[:0<VCAI&(U"D#Q$RX4%)#XD)>N
M%Y&SB<]T4@=.?E?F#!&B%5[B^5$F4A-W580:I#2T0@4,*W@4HHW(<++P+[3Z
MI@)%P$22=\VX8&:<4VF64V8A^G8,P%28'ZC-3R..\* FOWN)-3I-G6=X&ZQD
MXIZ2*#B4:E4NP0L>1@%[TK6$,#'&4/H09N8'Q5RPZTK*\OD$F.X%93!VC$ZG
M:^BZV=/,<TY@C$16/XB").,P95DU86,UR3N4RID(Z E%;TX,+.6I=]MGRA*=
MG2F=)>[TE+02\1P*KU7(^1_I9_X <4&FK>:!A@EJTTAK65S]X_N;5,2G\?4T
M+EZ\,8[ &A*.^&+VK8 \'T>'#@P,D0"FC(I7R[B,D.52I7\2\7O,'5?&?I"!
MV3(%G4B?2#\E?4'F&,L*\?B@@U;[&&@<Z5Q%<A&'780M.^2)&A5:_B0+/:&/
MU76YU(B $8 .,:H&5O[0=QU_GK 3Y[30R/) F%>(PR5:S2 +B(JPXIC]P87J
MD]([7I/$)M5%#FX9#!8X(1/'Q:]#QTT^\M%+'(D_Y-12'N=X!L.2?^&P(C$J
M>+.TSA?/5YQ[)4@AOA)\!9OP!\<X*R9#R)1!TD*(9#82Q;.2$;8(A1I**1:C
M79P(J<26Q#_AJ3':;7$@4S\FT@)TTD2'3)4 ^ <M!<GNY6VA$R5''7.KM!&"
M&LUG+R1R)7)=1JY(/;F"/ D<*Z56T'S'@S@(TZB_B.1+ )=*;"$DF*JN/GXH
M7#23$0O&S/(YO-X?.Q:H!AZ'X1 M$BW.T"+(RTR+%4*-B:P2B<:9Y,2B!\X@
M%IIB45I*^EWL?G/@R8[,8DL_3)7/<)$IF 92;"YS+*2**@::G,?,3Y,#I1<]
M@5QQ1"P-*.P11^\'\[<6CIZ+>QLO;A<*\"?/FD:<F(28I,@DH4P\1+$KM(K,
M3)*$]ICXUQVO*),',5P!HACI,>&._+<BGP@T2,^M.Z3=$O45?;D@"X-XDD8Z
M_N#3.6=M(3%537Q>X?PEJ*AB#K0#\A;U4:(OHJ]9%0#&DU)9DAJ&10<P&#<2
M"<Z>73B6($TD%H8^P">F=]@<YI*&!>>,))'%*I\U:\_GQTY%X@2S'SGB]U1Q
MQC#5)#4F3QO/<DU$=L4L?>=#(](FTDY(FP^'F*B$T2U,2Q((G<.LE>B;B=>I
M$&8&_(4OB(Z(CE[]!66-QY/Z+)B5(/,0<B5/X#/^$DY#W+\DC7L8,#"88I2!
MO.C,SU-LI86/'G]A=,F[13(_6$!8YB7)SQ6G]9<5R;JD#)<T8<_S,P!)+$=,
M79ZM;(,VK%CAY(XH20-$K!+QB40)3P[#)3'(]%-A >..HWK>5'X'W'&E9H7G
M>U1AUSYB3HG<+-#DL\?#90,@<AF$G'^+6DB?Q.Q,>8XO.UPG" W#CX$?/X 6
MAQ,:%$X:H-<GFA;/\]E\$*4D!1\D)0HSVDS/F(G)9<?\O/D38BP(F/>0IH%^
M>$;WNSQ)!RM5/&"QZ-B4#*HFCBH\-8$W+DWGS#(S_2 -3Q7.@.&=R\^7Y2?*
MLK,88[&B(B4']UAL-@X:*<&)9-YIRIXB"1.GX*9'@RN4<'D4/D80J@0G8XX5
M9H4)U>U%)G)Z"$:HDD.@-5GQ"F\/DA2RF5,_R\Z6INEK4@U(LG@%%\_<'J0L
M*86\H*'D8(4[<XA<#'0(HPGE^221(R;/_P/;S!W1*)2DDP<Q-CIL,7]T4)2F
M7:1NL#CRT]*\N#^8<@9B&B]O &3Z,>"M\\SM=W+Y^UH3\#2Y7K#O).37H2P,
MEFD:(AHK'_UJOK/LHQ,Z4A6_3N]_MZ!EK'B;V6KV>J"?R&S5!1?HS=ZJ;U=\
MUV\:AJ'E/ZNN7?D=C> "1["B93*>$'K9,5E6N%XL!S=MH[RXK/;B!.S>T2IF
MKQ#MFQS@N1*6OA^'(!C#-^N*C:^MPY^.]X!+LCC?O\PJ_+# ^,V?7QFO5D]\
MJP+T)UN:70Z++5LYT71[-RK9I/Y\%9;K /T<B&TNG&T^8QP?LU%_'01O_Z(K
M_P"CBKB(N(BX:!LNTM&L,P4+(0.%Q$'$0<1!VW"0B1S4)@XB#B(.VHV#OOCR
MS)'4Y-H*L=&FE+7"9R/\SR^=-A8LP=#:V#^S2><X6)Y3')G?HP/<MZR HBM;
M2H@T3:P-PA7QB/6Q#YQ.H]7L]/K%'R"W=7&!3K,+%TW\4#C#KT4)$.>1K]G\
M*WVM'XG:PV[1N._D]+ILGF4V?ZW&-N_3(5KM:>4U:SSGMIW5V&KB:.+H=1RM
M]SMUWG/B:.)HXNABN2Z-^+D^&TW\3/R\;M-[AF[4>M>)IXFGB:<OG:>W]XVF
M"6T7[1M-NT$)SVC1,8I)R#)/O4+>T2N#_*)ERO/UP:=:\/Z.^[]5Z*V>4&"4
M9ZUM$FL[9VJI!BV0M"!I<3AW;8ND!4D+DA8D+3:2%N7%:DE:5($62%J0M*B-
M4XI$1A4(@D0&B0P2&=7W=9]/'O"!)0Y)W:V8R&@:R$6V'V-QCA/*W>.'"3=9
MB&J0RWXIN4;O.+13+Q%,\H/D!\F/#>2'H6LD/TA^D/P@^;&#_.CHI'V0]"#I
M0=*C>@XDDB D04B"D 2Y4 F2.J'A7RRU.]\0H$K5_Z. >2'6(+X6_0BOM&:G
M^^;=!F0QMXEA/ $2GMN159N0O;CA V4ZPFFNB!&^F,+6;0,*-2*JVS+@DZ?<
MQ \P#:Q#K8L*Y2&L)%:>5\Q.8PP7CD1=<B],"KMCE>H\&5UTUBY4ZL!JTW]G
M;C1B8U7Y<M-49EY@E/,"G-8__. /5?GZ#_&&+VR:U-&&QZ_OA2&VR78"V4L8
M:T3'8V^V'<8$RV-[#X58E",7,0WCP)\+=Y][-@B19]P6K'.=R9/G#87&/NT.
M]BL-M!\A=?HS,BA=]5$6_YJP!RY#6PTVA&%>,_>)3<.DW'%Q>]*U%S)TT<+O
ML[Z'CW45WKUV+S<7Z@O(F"3X=A*\4!9^Y-@V][:7Z=47Z)EP-;J)<,UE*9OI
M^+=$G/[$GEB.YXSC<7)KUMZ"#?Q'#MJ0Z%^1-C[ %A;B7!"W12L+T:.#,]EA
MGLNF(=8(R$LVTH"O7-'",^)*Q)YYN*Q;S :$;A"AEZ2J&/505?[&O)@%TUR5
M$(#'L8=1Y"O1DP]D'@>-*6<!T*C7L)#Z7-&7XF5EL>P G5 A_A9[/-<A9IZ+
MW5[@V<L?N^2I-ZZ+_7%X]G)LW\$LRX^]*.D"Q$+LG%,\XB<94/PJFM;Q2-Z7
ML!L."5OU /%$4U6!3?%D@^;LO:K"(M$HC]HPY6V88/7B #?4]<,P:6)JQ>-8
M'F=4//X@?RFT31%]B/)6?:"UINV/\)>););"G]->68(XN&QA--_?10=:6-;X
MY0E': O1;"4C$BT*@9@<T0[N=5\SFBUL/.3"*YO*WU'D@B1Q)D*$8I^8M*U0
MUG00^W_AC(6J[<"CD$J2J0NRBP2%14*[]F"CE!![1 $-XC1"\9*T]1.^ &>]
MM$V2:)G(8738:U:VEG*3YDZ((V$4R+7-VBDM&FL@:?\&^0'>%+M1H5L2MC0K
M %?*+]B5*L96CS"Z8KO')]FGD<OVX\P)^?(V5;@ HO]6UK+J1:,JT9_9%YVA
M95^FL-@C;>(CJ8G>0,4^5;"&/WW9T0=MFRC;*#F>1;-)AB@:"<E^/;,#PV'@
MT%1I$SW!0H<C9R*;NG'9&%.TPHQ\ZX^1[X)>G*SU $#;<6,@K+S1$#:M#I,5
M@ &%',A%]LC&54O!73852E8K705@T"&\$;@@Z5.4-\-DLHLAOD!X>K(V7/S9
MD5V'$Q6A.$B0O\.%2X.[F[<86]X'+&WE*9=-3;=><+[H^ 6T"?, UGYD;BSD
M=C*ZI'MHL9^QFJY^T@@-A@K$.1;*BQW$#\5>R/#10R!X2_8K"[$9DUQ9L3 X
M"M258 .&[!&&CJ^&=\;9G%&TQU[Z^9H5F*6#8B^UIQ'W!)_@%B?3'_"T4Y7H
M%26ZGF(SZ+$#) 0?QI9H8B:[EZ,L*39&+S(X7)0L2;$+N=P&/@1Y$A56(E_8
MY!$S?2OGUB^37J*GJJ"N)UP!26%+'I(U3J]B2[05 -H[#8 6*_Z6,/.;J ';
MU/@B]^);TMY/^1[XL/_C4CK%=>JH:0@O%,)CYD>;T2%9TJ<QZPLHVP+>^D]<
M]BN^E;TS5>7SYUN!.#_?RV_5I*M@AFH6,HLJ]1-L\8ALDK1Z#,.89WBLA&!U
M\4(CQ%SPHF@4W8X?8#@/HA.D&!UPOR7:.L(]\00?_+K;;FJI\J&*GO'P\,!)
MGBO[((ZQ8#23A"&95,S@YN<7=4$?R,2IA^N$EZ2DTU2^)8Z\3D$WRJ23O>2F
M[X$CVS.F5XIQHI<1"#Y= KF"BQX@U:%L&3R@Z>(BB):=SP[V_P-T>VT4%F.^
M_=VET?ITB;7$8!&?%E-[2M*GI6A#TS8D::235?1KSI)B-CTG%*A?1%\Q?'25
MA*!5HT8NYZ*P,5J#H3*(08T236)#\?1$'(CP5O==F*VG,/#B,-6D)!B[Z(%A
MH2_UB!22L8$C*%W9ZCL1#BL8BS[DS,ZZG2?K!&\')084D^^ KS%">>1GZG%A
M*]5T%U+54C!:SF'AB+M#&,]#HOF+'4IZ1J)Z]!&&H-PUS)N['\K5C^)E7_VF
M8IIFPVBW.AW]3:K(#[C%@":PU2/VJ+3$?&6?3#0KXHF?:'\.FB#XBD00MU+C
MZ]L\L<P,G2'+\T<F;T^4C$F BX'?"649B;)@+:0MY0O&2G(#*EZ/+)BNMOC$
M>PVUJ_?5;JM5(.N94<Y(+?.%U%HCJUI&4U\KJ\Y&79&7XJO6=0.\11/_(YKX
M^ZB/!Q]F.4UW:PDO/V=:Z3K(96$\'J/C#UDD<]%<5T?_KV?OVPZ\33=7]CS5
M]9W[I6K-3FME8]US>W&_:;:[Q0)KU.?U!(<%+ZQ]D:Y1_Z*YI1/]BI0/'D9+
MBOH7M3#:(FOL(L41M9VFKFNGDEIHXY&$(K GKMF2:]96.2.N(:XAKIGC&IVX
M9C]M^.P+^>QQ*N<KCZ2?[BH.15SH#7JJ'QVTR ;3-%D' Q#HPQ=I)W0&CMJ
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MJ+092DA)2'DN6T9(N>V1-G+CUA4IV]V.WD:D[.JF#DC9.IHA>C?A%DQ:=C$
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M]*9.YFZ=X#9-MC(UK:UULW1G0S]>LM5=/ @=VV&!PP52(A:E92@ =[="223
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MBYFC>*X?;D7SS&KU:#B,33ZTB8DT%3+-389V,AW'N7JZ')%>!-8O"G.6X_/
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MZW5N1N-E;P4R=6_IL-PN+Q<8>P^6^SQ3F79&)]Z:!9J?.2TG;"87I]'VF)$
M,F"YW5TN,/8>+'=U__"!:J]91[]IHCR[XXTO?H]RO%RAOCCW/;\KWE1A[%-T
M9YGI<#Y HS1@^&('5YK0W<B"#]FM+O+E;7LP'-VQ \]N3]VVSC]TCLQ/D(7_
MZ'_-9!S^5(ZOEA-2I03JIU^IQM)P3I"E)"&NK$'.B8249%Q8(912^KOFV&M^
MLX]E<NCK7R.33&K,D(V)(DZ)0U:3B#!50ENLF4[LNVIH3_,+3VOTV=JSET42
M#X:A_'5X(88'D]=V/"ZS?/[;#J;QNVHZ[,^>\LNOOQR_R0HPTR'?)=\N1-\_
MM8/Z+]^A_*_90:^_?-?_.GDYG)ZB,&I&CI8KOOLK-:+'#/^//U]>\5]WF>';
M$^6=X'. ,X"S5> ,8V<PEJ(@688S9ATR- A$N<4J"D,C9E?AS!BO99 :X1!)
MAK,8D5:$HB \]R8Y1;1Y3CA3O,>$W',T6SUX! ;S(Z3J^*+A6G_X)=:3JRV;
MNX$[>Z9>]LQX:-](%LEAEBSB-JL)+EG(6D4)))1/^3^GG%5M&,F-]'W*PO?V
M0O;:LHE5MHDQV,0[S-8 6EVF;ON@Q9/VA$L4-7:(8T60P98@8D5T009N16C#
M%%XC:'%,>IR#Z0NQXLV:OHM>PYT#&5 AH$(>H4)8)$)[')!-W"!NM$;6!H,P
MP2IR8C7'M V[]\U<W@Z:$H=YP4-+.D3VM!9[KD%VFJL!L[I,W=8Q2QC)//88
M&2VRV4ML26UE)!(Q$N:HMNYZ0FL5LW>=F*5[PNP[9D' =S,5$N7(]ZRUZV@X
M;S-7SIKWJF&<= YM0)> +GF$+DDF,1E51))(CKAT CD=-'*&<LV"DXY<"Z$\
MQOZMA^'KRTL2^/%< %=3)4UK"/2_<3R:-6\G]-6>ZY&=YFC JRY3MWV\4L99
M2C5*T47$/8[(LH#S'THEI4403CS%]FT?KZZ9OJS'U;YGJ2#@NQ'3=S&4[HXY
M;[,S-YT#GN=4*_<?FM\)&5V1_H]J&= EU20TPSSYB$Q0HF0CLQ6-I40Q4LN]
MULI=5TVKA)+G0CV?V'TP#$=%H-<1I&$]:MCZ--5#&B9T65*V0PX *0$I-UVW
M$2G+>.=1)-(BKI1!AFN""+8\F^/.X,#;"&!O#BE)SY UAK,[@Y1K#WFO8N9O
MOQW_:30I$S#!9(=(T*Y2MW4E$HT.W$N'B/(E<ATILLPPI%/D-C&3_W]-B:QB
M;J]#70B->UKM>]7?3O,SH%67J=M^<(![SKCPB&?K%G%CL_F*A4'*I0QD+''"
MGA2W7B=:<6UZ2N\[6JT]9-U-T_7=J,SI@=-VH UVE[JM:X/@O'.4"<2DD8C[
ME"U2$3PR,G%L>911IC9LUR)\:SIL9WJ:FCU7"3O-U !97:9N^^ZV5!XG)Q'U
MWB >>4+&,X($=5XRAZ,@I@T#=GV0)7I<[CMB0?QUQ3J*T5DL@]";>>G_GO;/
M"F-" 3'HA5VC[AH"&PYG*'?(,ZP05QAGLS0F)!2CRB62),;M5#W,1/##P XG
M!\-PN)#"][&U,RE[KAQVFK$!MKI,W368LXP3S63VP$/,YFPQ3?/_$,X64%">
M"!%E.R4(:X<MBO<<MR RNY)@?"P[A$8)3>LXJRGH'&R 4@"E\ BE0$)PTOK2
M4+,<AN/9H,VVJ$=68BZY#H+35II!'&658"?]X>=WT=:QD<.C]$L=F^1=:Q5I
M7*L]5PP[S=V 75VF;OL&K=/<.5/\<)T-6FX"TD0H%(UWC ?F%79M&+2;P2[,
M(%(+D=I5C-I83\9]/XFS@1B=PPW0"J 5'J$5'(TZ1*V13M@7A+?(.I+_23 3
M/KFDVFEO=B%VI5_\^]'0MUJ!1@F8LCO,U@!:7:;N&GH\*$^\)<@DGDU90B2R
M*GHD@[74$A)5;.5XV)I!BZSS1-A.L#4$9E>2BN:4(ISR:E\7P''CO3QN'*V,
M7'N#O \<\2 =<HPQ%!B/5&H7*?>MA'4O3A>WKDRXA$8,';>C !D!&3==O.53
M"0-(1 (/B)LHD,ZV<[:TE0K84ZQ].T'C-2*CQFN,#70&&2&<_(3&"V"*KUGA
MT!>T2%883=T@/J?*V?R4TH=LQ':P2^O:QW#C+)88!<P4XDYZ9#@)B+'($A>*
M8M?**;B9XFEKV :A/:W76')W)T/LEM(!= 1T!'1<$1TET\HZ+Y&SW"&>K,A(
MYS&B1M(DDZ=)MQ(%;Q4=N5$]RM;8*J)#Z+AZ=/PFYGJHG;XS)GGSM-]G^^%&
M@W![AXFW!S^^???VT]O#X^K@_9OJ^-/1Z__Z^]&[-X<?C_]4'?Z_7]Y^^N=]
M_+<OBBCO>_GD+]_1[_9MZ;#<+B\7&'L/EKMZ$&LO-.:M [#F?4,'?>OZ@_ZD
M'^N7P$V &[#<#B\7&'L/E@MC=#:B0 ^\SWLXJ:LS^ZT,@H)8YVX7Z&X^CKD=
M9&X]1JD#Q89Y@31V#G$O.7*<2J2"QU1Q(H55K61PY@+X829_[;:W-3TCR9Y7
MZNXT6P-Z 7JM@E[,ZJ"HILA1E=$+IU30*R$?G7'1$^K%M=95*V58UHE>O,<$
M-("!0>J;B"-=&J0^MX6A"6('5,J>&0SM]_/FVD1B Z):9ZT@<;9I@Q ($VL]
M48HZ1]J=HKX675)R]W3/=<E.,S; 5I>IV_Y!6XRS^4M=?D'%$%=&(4N\0C)1
MRZS ,E#=[C#U-F K];_&@/XWCD>%TIH2^FK/,0O"P)L* X^G\<YIZDLIUL[!
M#R@74"Z/4"[8<$FR!D&*$H&XT#);ND$B')W$1FEBGF83+T57BE2^NY"\Q:#?
MI5^U-1#=]+38]T%H.\WF &)=IF[K(*9BXIY2@PS!!F4#UR)KE4")&,I9(AG%
M;$LAXHV!&.4]NO>S9R%DO-'2P[/1N)&J4:K&RVW'%_;RM\Y!$2@:4#2/"<40
M:B(/!F6;-UO+1A.D1;:!C69.*<8<=:']UN,+Y?*MW3ARZ=^[[[W/=IJ] ;RZ
M3-W6P8MZHJ*P&"7>6+P,(VNT0X%F'/-:IZ!C^[W'UP1>G/$]ARX()S^7;>SM
M6;\TG!D4_NX<[FQ/1P5H<+8G#<Y4I(&(:!"WQB&NM$6.68$,MY)JP1)/XNF%
M&3-!_C"3XZ/T>B;%C9)JRZ)>8UE&9WJ< 3@". (X/F+<&;.!Z*"1"S9EA%0!
MZ>@S3 9O+ F<"/JD&9B; L<UAAHZ@XW0__$)_1^AN@/T#^B?]D\/DLB%ROI'
M8BY*<M4AS51"5-M$9!#YOU9&QR^E4-L-%0G=PV9CS<YV6/L ,@(R C(^'!D]
MQX035XXB<HNXXB5L(32BB1FN0^#67NN,NTI ?6W(2$T/2[#+H0GDFNSR=Z/A
M9Y3%_12:6D'OGSVF])XM%QA[#Y8+I9F;F91]8QUFKQK$NCZ/>,UST^#308'3
M#E&W_4B5,,HG+Q%),2$NF44F$I7]'1T8CM(8]:0T\CT%3JW/S!)*[WF-TT[S
M-Z!7EZG;?I[7NN0QT4AX4B)#&8X<#QY)H;%)0E'#K]66MUB>V3IZ*6SV'+V@
M0G,S%9K+Y9A@&4.V [(=:RG2M)$KJRVR.&K$HW;(!".1<4R%P!D/IH7N64MU
M1^^R(%^N2VJK3'-C<P%W..4!\ CP"/#XB&2PB#1B'I$A+,-CB4!HRS527EO!
M"5/"LJ>7:6X$'AG X_.'O[M<J3FX*2\,2@B4$"BA)W;S8CBP1 (*#"O$&<N6
MM_(>J40YETHJITS+M9KM1[WU&J/>G=$_@(R C(",CS#/J=.8&X8831AQ'3QR
MD0M$DTH*,ZVQOI8;?&*M9OL1=0KG2[<@ZMYIRQSL<= ZH'7:TCK)$>Q--L53
MQ!%QIQ.R)DA$N E8Z\@<::4BI?WVDT+WI%YCBYW.J!N 1(!$@,2'0Z),T=&8
M&%*"),2Y=,CQ F_,$,&UT(:T?6BJO=-22BN Q#7&QG?WM-3E/4-U]*C_%9WT
M0XC#ES_]&J)SR9N I%(E.\05<H9J1!2F+"5J$C97-_[:382GW.<[(9,41SP6
M,<C"@"(EVE(IB)&AS;J:T>EI?W(:RTCE,D.C?-(??HY#GV6J^O[]:!(K(G\X
MYX ;_]K? Q)P% :6V]WE F/OP7+AV/-*BO-X,O*_G8P&V9JK_U3%?T_[DV]P
MZAF  Y;;Y>4"8^_!<N'4\T8TZ(=Q3'$\CF5;LB[M57]8$&.ML2E%N"I3[Q!S
M)?0N*$>F',82DE',DL:4N#;"]>?+:RR%#W9\-#Z>V$D,_VT'T_@ACH]/[/A*
MW\W\8[D^7U4?I8/3.,[T?U.&MH[K^=7SH!9>#FK=%].Z95) -"4.%Y ,B2#N
MG$4N\(AH](PQ48X!7&OYMDJ,;GOV ;_ F-P0VKLEUM<2%\YPYLR.JR]EP;UJ
M(UP>2+0&6XRXCQQQ%1321"D4=<"2.,.\OA:!?3J7-\2I#Z:3D]$X0T^X1-6Z
M^7"98&_?_[02ZUJ/N9>:(N6B1SSE=S1>"A2QY,0JK+Q0[;-NZXLCN)>I7?Y[
M)J:<O71ESY?TZC_<^,_S#Y?_W C+&L%U)J5 Q%A1\J@:&9DD(IYKEEC0W+?2
M@_(FJAY-)_7$#D-_^'E-/.NE5$3$;#(DF062J;(Z09%@2=)D.8_L20.^-[6Z
M9^;5T<52*CNIWD0?3UT<5XST*HHI:X+85W]+(:<+;0=VB+KM6P.8N2@I0RX6
M6P]KC"SAV3C(YB[QSBB5KDV%>CJT-@;>:GG9U/^:H?)_XWA4B*PIH:_VO,_
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M%-+6. $R<>*3X4CATOU.&H4LB=D)P-X['DQBI)7>'I<4W,$7VQ\4B/@T>MT
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M^^C:2":!8[(SX@)GM5:0KE^&><F#_(*A^FS[PZH(V/!+G+,\9*$Z+"^[;#J
ME;@WI 8Q[BYM08SWAM0@QMVE+8CQWI :Q!AB-BLGDSVQ24:/+!<1<<L"LM(S
M9!VU0JA((J-78S:11V*,Y4@1F;_#*$<Z\8"BU5)XZK%2^&K,YFAR$L<E%#..
M)W%8][_$MT,_.HT7ON[?1X/0'W[^6_9XWXWJ^FAX'/UTW)_T8WTP[M?YH^7*
MX?=Q<I0^V:\MQ6JXV>\X#< ?T'8;:0M6S-Z0&L08K)A5K1B-58@V8*2%SA:)
M<Q8YD1SB.M!H@I$!AS8R3V#%;+6(P*FG%23JOV,]R0Q9C5+U\?@7R"YU6#Y
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M4>DYXCY?KIW6R%&OG/4R6N^NAL;?Q\ELI,J[JUWO5P][4]XS=(UQ;\!'P$?
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MU^I/6\TKK='!V//&=MM]HG9+VS0WK%J=3<?^Q-8Q<V.(X^KP^,,'R YV6%1
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MIZ5'G&WBO_-^<9#YZ+#$ #@"J7> U"#&W:4MB/'>D!K$&.H05JU#\%)93&-
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MZ&/698;9"G8 N "X +C8!8;9"G8 N "X +C8!8;9"G8 N "X +C8!8;9"G8
MN-AYN( >8;?&W6FR.#(7D21-F]30%" KI$0,@1NKJ+X6=Q?$J,@]+_U7,>).
ME-:JBB*L@[).IR ,NQIW?Q\GLZ9@[ZX.?6ZAL1?AIL>87E]T?3MQ&/JF B #
M('<,D(41CEG,$/6X.1$BD='8H')2)*.K8I+8-A*A ,A;!<APNG %"?K1#NS0
MQ[G7]2;Z>.KBN&*D5U%,*:1,.UQ, ,4TM^L0$K5,&F<MD*)%W!N&+,D_*>UI
M++\CP5S5(2HFA@6AB ?I$%=&(DV31U)Y8CB7W$=RK9BF.19X-)W4$SLL!\Z?
M>&A0ZAXAI,>TV.]"&;#.@;;[B%N4&B*]P<A+KQ'7(B&M!46$4!^$-T3+:PW+
M5\*M4NA7>F3$<7WX[VE_\JVE*C\%N 6XM0NT?9BG\@< L$=6,6OB<0P$!<%Y
M=L2-1I8YAAPC)$3,B(WZ*H!9$Y45$2,2O4'<T QZ_Y^]=V]N&TGR1?^_GP+1
ML1/;'<'2H!Y 576?LQ$:VSVC>]RVK^6>.?O71#TM3%.DAB!E:S_]S2H )$A*
MLBR1$A]U]DQ;HD  59GYRZQ\%D(C;8K<RZ(L2W)[.X=M !@>X!(/B-CBT3T!
M60*R!&1'[>,4%.?>48,\=1@Q+"220@%6$I)3KGE)V!I,VI+*G'F.!--PII4<
M[#P,^(I93B3UA2F%VB1,/G"D3%X>$E*FB%*"S 29NPB9& O,I "\LQHL2U[D
M2&/'$%$R]XR3W(NUL)#@WI=*260ER^$X[<"HQ-8C@B7G3$BA]=H(U.U#9BGI
M(&=Y@LT$FP=(Y,.#S2T#F_%<%ER!+>A=\-\)#D=F;@&NM-5..I*+M:$54AI1
MVE*@W ;[D3B'!,<$3MV&&>DUQW=T0-S&D9F5?,!8*NW=X=+>C0G((^/7#S,K
MEGOEVFKBS#0;@UB$,O5!-G+AM^P_7N*\5E@FK5=(V-"J5/D221O*](7CEN>Y
MI8ZNRFB.B2JM+^"\1L!@ ?L$R5(5J'!Y:85RA.GE_M7W5>:_;W?AS=<K-ZK=
M=^2K?"--!2P1=J?D;H7*C0QU9,U<NZ*4JW# Z)CT_]W8PL  L&5>(IXK@5@1
MXG>YE(@4F)16E@1TQYK+W$A".%R>*ZX0PQP#ML!_<.E"9T)*'38/P98F?^%U
M1-H.8I[:]Y@,& W_2XV/T[DFT?;HX$P0FN><*.1*C0.<%4CE"GY5G'+J68'=
MUN LFDKWH-D3#*4$9@G,$FV/#<R<P:1PRB*OG0C%80*)4!Q6VG"$\YYKMY9'
MFG.AB]PZ5&@& &AU@:2)83MO-6&4]N)T+P-F!!<#6=Q][$MLGR MT385WR=2
M)S%.M$UBG$B=Q'AW:;O7!PR18U]R)A$KPO@[Q3B2K"P0HZIDKB2F\&O!WXT&
MEK9XP#CR&K;=+FC>QXBPFJ+IA4/P,G^X16"X?M'(L,^=* B1" L+PLB41J+@
M&'G@?^R\$-JO9?)2;[5QHD0RMR#T1"D0^H(B90N9Y]I@;N6#!?AT^NG"_1:W
M9%M!XD$N[D[R?<88<0H1'S!<)BOA;I"Q!<9%63!D1>X1 RV/E#84>2M+1[TK
ME&%K+5&T<T30 FP#"_:$@_^(PF $'^8&2\J5*1\>(KX%9=ZYZ1-#Q63 L1SP
M>Q)0$N>GLT^B;7)A)%(G,3Y@VNZU<4*)+X03!(6D<S@!%1HI#L8))XSSTN8L
M7T_XX(70UBF*J! 8,2DQTEQ[Y"S5F&-'L"R><@):M4V>D-Q.!I@>>6Y[0K9$
MVUVD;3)0CH;428P/E[9)C(^&U$F,TSGCT74RA2#,68=*:FSCT)1>6.1H*1G5
MBA6N7$LLI\0R;!PJ>&CN3QU'VG."C,MS+ K'C//IG+$KW+_;-;0[V@(Z<BS2
MJG86F/\R!,I4E)H4-#M\B=EG6R"9?4=#ZB3&ATO;),9'0^HDQNGT]NCV;9PS
MHC5'LC0:,2T8$EY@1!6CQ%'KC;5/B1)U78Y.[;]F]?027J7^-#ZUM@KOH(8?
M5&7/1J_45355PYC2$BWF5SV#^:/[]ZRJ8:'G;G)=&=><_#XZ,_X\BG>)A\ -
M'?=H/I!%*BI.4)AHNW.T31;-T9 ZB?'ATC:)\=&0.HEQ.I@\OOT:94XS'P;$
MP2%#28DD'# 0S7&)A:34R+6^TM\35DH'D[T3E]VNW-O1.-3O(UCR$%[09I]5
M-<J"@(VN7<OR*0IUP/*RSZ9#LA*/AM1)C ^7MDF,CX;428P/E[9)C(^&U$F,
MD\_FT<%D+[0F6B"7^Q(QHRB2Q#-4%#QG-B<V=VO!9$Q888SDR-B0/LR%0BK'
M'CF&O=->Y,SQ59_-^^F%FP17S,1=N%%=7;NSD1E?NL59]V_CH:U&G_\*)]ZW
MX[I^/SIW9C:III6K3R=5#7_JIQ&_"YG#G]37S35F(:EW0D+ 1-N=HVTR9(Z&
MU$F,DR'S6$-&*\RT+S0JA)&(X5PB ?]%!>%:$8F%$FO=XQX3?$J&S*Y+2:I]
M>FSM4W8UFY@+53O@1>LFV9OS#Q]2N.F 124IE+L5"B=6:^HHPIKDB)78(>6U
M!ZU"M5.^+)7'3^D4N#1,]JYF@6\NKX;C&^?B11]:Z?PP5*/ZB0T#*1MPR8];
M4213.=%V%VF;3KQ'0^HDQH=+VR3&1T/J),:'2]LDQD=#ZB3&ATO;),9'0^HD
MQH=+VR3&J?YFV[&0SNF:?:FF%Q=--*].P9!#EY4$BXG4>T#J),:'2]LDQD=#
MZB3&*37AT9-2=9X[C$N$M>.("5HBK0J'C"Y*PXPEUNLGSPGJK.!_](S@-_75
MU882U23.4_9! J]$VUVC;;)!CH;428P/E[9)C(^&U$F,TU'BL4>)@G)5D%(B
M. LH.$K('$FB*;)A/A Q0G*U-@_]NT<!I:/$CD5Y4L7+#__U 2[PH<[%9E_4
M9*)&T\RH^F+HZCIS7]W$5&GBST%+35(+=ZL%(JPE95Z$2=0:,2\(TLQ35#!.
MJ<K+@EGWE.*7J!9  G^- OB/1O[>M%)WWE:S/*G 111\@.F1M]],5FVB[2[2
M-AU.CX;428P/E[9)C(^&U$F,#Y>V28R/AM1)C ^7MDF,CX;428P/E[9)C%.%
MR[9C'W]W];0:?<[&/OMX_GN*<ARP?*0HQ]U1#B=+1628I.Q%B%APAT2I+2H+
M92U6I7'";[W%UT>0Q4EEIL[&RTZ_J(G]ZV1</S4 (@<X)RG\L:]F0,*UPZ5M
M,O&.AM1)C ^7MDF,CX;428P/E[9)C(^&U$F,#Y>V28R/AM1)C ^7MDF,4^G'
M]DL_QL8Y6V=^,KZ<%WN$:$@=QZ",KX*OM$YQD0,6G!07N2<N8O+"D$(B1:E"
MC#*.5,$*Y#V3\#$V3N9;CXO$/[YO)+&K#+%/C(F4)1GD+$5%]M8Z2*AVN+1-
MEM_1D#J)<3).'EV:R@K#B(8#C2\,8IQ0)"@S""NJ1.Z,*.Q:TL;W-#_[AG'R
M=S6<N6_;)H_O9E ,,!')0DG0EFB[:[1-%LK1D#J)\>'2-HGQT9 ZB7$Z:#QZ
M +3EA%&2PRE!"\0TG#$DDQ8I7I;68>LH+Y[2&BT=-%Z<_5/QT".DY9V;9L-Q
MG<)CCY4,#<SB)O-7/2FNIED]'E8VZ^BQ#[+S2%)_>_$[83CLD(UXSXXU<)33
M0V:8G6"'!!<)+A)<[ /#[ 0[)+A(<)'@8A\89B?8(<%%@HL$%_O ,#O!#@DN
M]AXNMNL8?P!>K%#FCAW\L=N\9W2[>TM*)W2!:"X58IXK)'*GD6,TYY)B1O7:
M<$.?EYI9)I'D.46,E0II)4J4$UOH0@F,L5YUN[]ST[.1&5^ZMZN]5NYUJ=>P
MZ_#3-WSK))<#6FYQ+,ENXO R,]Q%]Y\2("= 3H"\+X"L-6.86XT\LQPQ)3C2
MEEO$2T9Q+JA78FT6R&/BH F0=PJ04V7A(R3H+VJH1L:UIZ[7SKA+[289Q8.,
MY(2FD.E&I(N<D"!>=CS30W=\>N[VY>^&IMNR+L(YP2H<#IK*1"$*)$4A4<FD
M5 R7FI1DK3*1>EWZ B-,X1C!X!R!)"OA<" ]$UAX3,5Z96(L+7P_F]93-0KS
M"I\ZC8H-!"D')=UB[>&]3'(,SID$B2\/B0\S./XC8>,6JK:U8-PH@KQP@(W*
M,"2P,LB6G&/L':#=9K QY"2&,:YN4K_Y]ZR:WFPH(7&+R8@)&Q,V)FP\7FRT
MG#*A1(XHEA0QCLLPSY0C97/)-958EG3-A^$]4THYI(QTB&%I 4\E0[[07!6F
M*(FUSX:->,"*<D#YLWDP$D8FC$P8>4P8F6ME!"]S5'@P'<&4)$B2TB%L2T6U
MD;GV:QAIK%6,&(=TX0O$:.C_8[!#E!M!#3:RY/39,)+@9$$F=$SH>)SHN-<Q
M-B<%931T7%,N!QPM*!)$,$1+7#"&A=2<KV(O(8#8U FD<;!/K==($Z60YH4A
M1BG+R%K2PU.P]V&!-IF3 <N/T$Q]_MR'A,@)D7<9D;<="_*8$/@?(IC!F=[K
M @FG'9*\R#GQU O,5C'3T9*6(J=(.4\0(U@C)<!>S0DOA,H%%?[Y[-6B8 ,L
MR^.#RL<7:L._"MX^_O@ ?L8$?G_DBR\$Y]%61GR=>Q]_QT9\NG"9,F9\"4^^
M"8,:1^,I?%%-X&-@?[CL\T0-LRLUF8:NQ=,+5[O Z3'A1$V=S7PU4B-3P47U
M%#ZXA/O6)[<9-L^SH*Q'U$ [6UW/J3=T7Y&M)BXR_\_P/K/+T2^VJJ^&ZN;G
M\-=?KI0-,=A><DW5/*K-1\'PZ[]F];3R-]TSXQ>1&UD0@J_AY>'[/\_EX>L#
M\7!?^>=7]'*DYDOR"X2.!+^8YQ!=J<^NR0]"RL,._:R&7]1-_<L/?U[EC([L
M$7]NH_E32+M]NZCW[&^RT<,!L=O0;2[Q::S[I2&0!HVY"7XZ_^]WKT__;_;A
M;Z<??SM]]>;W3V>O3M^>#[*S=Z^>!&@;?LU5A'L ?<JG@TLTA?K _\\%W/_3
MJ/KBGWXX_E+O!B5?O7]W_O[MV>O33V]>9^>?X)_?WNP0!=]].L_>_YJ].CW_
M6_;KV_?_.-^A=WL$=[V0]#]LG<VEX<X_5U-XK+G;&W,V OMF/*O5R-8_'>TV
MK#) -(/G]G2SBJ"9?E:SZ;@S_,.+!>4(ZPJ7(S"HQC,PC:JOSO[2/$7F)_F?
MNNMA<4-U5;N?:P>F)>!(MS_Q>-?<^H?5G.#KJJYT-81CT<_=]V_+]HU/*_%)
MSLL_M;K^E@OP22GE?7^_YV_RA-Q_[Z-][CVIW.+>-E>WL?=#\[N_6:_3&5*W
M"+'8J@QOP8OU/0ZZ32UNVPXZX(7PE__] \Y_N'^=WU6&\V)D?XSJOFOK_MNI
M29V]&5DX:O>S_!_')P^I'=F%'=P0=R4X2G#T!#@B"8U6=NXAI44)>8X2$)+4
MW"<U)$E-DIHD-=\I-3A)S3:LW*Y^>H-6[MWUTR)L_TM64#^8X1;^V.S7C^]_
MR]Y_>//Q]-/9N[]FIZ\^G?W][-/9F_.?-VH0;W5K7@2F'IH/LKFE/U>?E+3>
M UUOXNVTWD-=;^+MHUCOH_V<#S3VXC*JD0WI3C'4^)B6.OW88;Q)_Z[Y+SMD
M,=XWC^3',)#DIZR*_:.VGF*]/Q;B]V:,OOQAX3E2J'<C/?J[4@E:$MR5)'%_
MR4KSY<T752O,/3<.8:X58CDND"JP0=YHQ?.BI!+C332&^S 9P^OL95>XW96G
MEVC"N1]J^\ (G8!SYX"3:>KST%$3@%,@5I8**6,,*DICG34%\Z5<J[0N5<F)
MI4B4E"+F5(Z4%@I9[H50AGDCU[I1; \X,0/@I,\^/7 7Y"D!9P+./07.K0.;
M-X(6VF!$<0G676X V KXR1LC >5$@8E8!;;2$4%H(9 N/0!;6>1(NSS,6LUI
MKJ30ALM- -O]AB ;2++%2KR7X/(]"5FM>3$.WF%Q:D.Q6JS1R*;C;.+@3Z8:
MNFS43E8-GX:?0P%'=C497U<AS_#'60W_K48_+3[2-_]+3_[<4K3_W_&5FZAI
MJ!P,G'Q=32M7IR#9,3D?C\W9>I3K3;R=UGNHZTV\?13K?<X@&=E$D(SLI<WY
MVL$EIE+A6)/B8P=^CDM.BON<%)1Q:HG!B#%K$>/"(\$H1M(IYXRF'.NU7FO?
M$[:J1_;KSWUY.QW9CVX8JO,7)[]-M07>XCR)Q.M[HT03?8\4RY@@12Z<1Z5E
M C&L"@1WDXCGA(8IFK*0Q5,B2<^)990F+$M8ENA[K%BFN0PM<#4B%BO )1\&
M_Y88"6RP<Q@S1M?FUWQ/\.@YL8P=/98].I:4SO7?(TH_GAHS<8'!?LK4Y1A6
M^S^1MT-;R&IT[=HX4SKR'[BX[;5JV?N$+D^=+$I7(LZQ1LR6!*F\L$@H7'JF
MA,_U6BOBQV3"SH7]M"?J[_WKJC8 I=,:--J'B;NL9I?UV4+X-^5K8 .1'YA>
M2RE?"5$3HNXBHEH"UKO&*'<%H*/E'@G/)5CW#'.)X3B0K]46/"9%]D41E0ZH
M.# ';@+4!*B'"*A;!SSGN<5$"T0$$6 .*HIDGFNDF2RX ^A2I=Y$ZNRV >]A
M]0,E8X>%>RGQ84<=)._&(Q3S:!<IL4.G:I>YKU=N5*=BX4.7LZ1V[E,[A'B5
M2^\1T=%FIA*)0BI$*+.TT%[P\NG)$""#003?=Q+X-@C@FT;^-F1*<RJ/7:$D
M^SG1]XB!3'+C"BD1]24&("O!2"J=0M0:PPIL>6[72L^^.Q/B&8",A?:*"<@2
MD"7Z'B>0&>X(_#^*C!<6L2*<YSGF2''#K&/"<NJ?G ;Q'$"&#RQ6E'(@=OV(
M'P9C3EP];?N 93^V9_SM#UU.A_RD4G97I0C)2LLT1:65(4M8ETAH9Q&67N2V
M8+C4:YEUWWW(_Z J>S;Z/P <9ZT8GBY^_.B  #6HA4?IECBP#/V/FXP##PB"
MR2_'KEJ2C9SH>[R AHVF'H[TJ#2"(P88AA18S0A3[1C8R,:*M7RK[S[L;Q'0
MUG.K!OC04JMVCN<3IATV?5-&U3>:#I9<6X ^JDN&&"DUD@"6 )R6LI!K157^
M9+_"AC'S@5U<27%8T/F$)*J45? L+H=7%VKT&9Y=C3*OJDEVK88S%VHNK)M4
MUVI:7;ML6*EF+G+R/NR5]!V98MN^]T$++ZB@*&>L1,R )E&L*!&8W 5VJL32
MNDT41[R>B]Y?534*S2'?CQ:?O7./K.U+SH=DJ"?Z[@^>[;VA+I5PDN2A'3@'
MO'3<()%;@B2F2MNR9%JO&>J/*7W8$EZN^S8$/RS 3#4."3D3<NX@<I:.RIR4
M''&G#&*""R09$\A:; I#R\)PLXD:BN="3BH.+*GU.1T;*9?B,8)U/AV;/Y!6
MH=6X&5^&](G4,W+_!.W(--?VG>>T=*Q0 @DBP28OC$'*2(6P+;#%>5%BO3:Q
MYS$^C/,+-7%_"=+WJB=\FU(G^4 6*;LXF>")OD<+9!*#I42\0X9JAI@"4!($
M*U0HK"GGU%FVYHQ]C'-AJT"&RT&.#\PTWCE&3T!VV/3=<R!3UCBI#9S;?4[@
MW&X84G!B1]93XKQUCA1V$V?][0(9'5!\8-[1U EA1X_V[Z<7;I+.\0<N3$EK
MW%LEG,N<$8E17H8SN98$-  1R&A>EI053.$G54)T6B/*6EMD=Q:+D9Y47)=R
M$)+UF^B;<&Q1 "&]]LISQ T#Z]?G)9)@V:*BI(;#<5T59"W2]9AC?,*Q/>?S
MA&.'3=^4$7 O3@8#C>"<@NU6>L0$8)YP2B#KG8'_RRFV:^VM'N,EV#!.KCL*
M#@LF7R(/X#9F>K0'X>"=!;T"A]XL\;IVTSI3(SLO;DASQ=-\VK3>0UMOXNVT
MWD-=;^+MHUCO<P:5Z":"2G0O[<0/$W>E*MMUTVZ,PW$X#;768@HX[=7)[,@<
M'%MW0/C<2:D<0Z'6%3'*&9+"E*B4V.)"*(OSM32%QP2<SD9F$GHXOG;-OV>C
M5C)?.^\F$V=;?\3IR$9?Q6D4SHV/=>#E83DJ=DX<]D/Y)OKN)MSMO3_7&E40
M;PI$C,T1TX(BP7*%X&-)M/+8B+7FN(^)>VT;3N_O9S.0/(T%2X"ZCX1.@+I?
M@"J<P:PH!"(T!,BH%D@;KI'S4N4<<Y;G:V,3'A,@>U% Q0,J#VS>V)Y4TAZQ
M9^35>#A4>CQIQK%?J1NEA^[/$V=<=1U^'&0C-TW>D;V2NB/3;EO7/MKA7'!N
M$6'"((8%0ZH4 GE7,NNTSQ5?F_+[W8W)UU7/DFA^G$ODIK1-/N!Y\H,DLSW1
M=U>!;>_-]J(T2I&B1-@+AQAA'$G*-.*$R. %*9RD3VZ O@7@?)@;F0X83_9Z
M0M)])/21(>G6D8X+2W)<ELA[!N8>LW &I48A57CE".>4ZK6&!=_=MGS+)F(J
M>TCI&2_CA#@U!C9Q6G?^A^1O.'"Y2LKDW@:1S$M,=(FH*0EBDH4AP:I 6BEK
MO+>EP6H[V1B=('YHY'!#KH9B4.(#*PW9.99/]O%ATS=Y&NX?1^P]%1*L;F%#
M3]V":22U]\@289S@*C=\(]W(-PB9#W,RX $]M!YBR<F00/00073K("<YT4K3
M E$I%6(BC%O7GB%:^,(5QI58;*29V'/9A62 RZ.W"U.>P[.X&+H$GFSBKMUH
MEEP,ARY7297<VRF<Z,*Y4B-F08LP(4"5"#":C26L+*WVN5Y+J-N,B^$5W#.\
MRS^JZ<6K60W[X29ONQF$R7&]']R?#.7#IN^>HYO) :@<LT@0"Q"G<P9(A152
M2I1:.EX4Q1JZ;<8;D-#M +@_H=MATS?Y4N]%3S#DB*="(,.<0ZR0&$F2<^2(
M]=*R4A*OM^-FV!!Z/M"S2@>8TL."TCT9R7[$?HA38R8S=VLGBEZSLN2=>+38
M:6 _-YF_:EAG5H^'E<TZ>AVT#OSV\G=#2VZ_I44I.1.$(Y.#^<R4,DA0P8)&
MLH7!KF";Z:%^J[,\B/C;A3AWY8+ONQZ%O;]MJIR##42YQ1D=]_!5HPAR>MB"
ME0X/"5H3M#9MW7'!"@+@R+ /;=V51<(+@SSGBDLJE9%KT+JQ9(OGAU8Y8&2+
M8<J$K E9$[(F9(W(FDN?6T60MV'NI5<826%+Q$O-I6.>X7PMC6UC&1[/CZQD
MP,LM)K<=#K*F))%G<<Z\<],LS$;(?IR%R?+5Z*?L:C*^KBS\HF_Z+>:!4Z^3
MIR8IO2-0>GL?SY" ],+G#G%:&L1(CI&&HPAB5#%<*&<<+S;A"0+T> 7@\:%%
MC+_<_ X@<C::Z\_3.6AL/)11YH,R/\(S2DHE3[B=</M <=MY(35U#"E: &X;
M2I @JD"XE%1IQCBC&ZGI>4'<IG10\B+A=L+MA-L)MY\)5[DW!(Q9CZ0Q8 5S
M1Y'RVB$B'!.%98+8M>[4CW$R;0-7[W<GR0&F1V@%/V-?D]NX[Z%.IF^XCW;(
M/Q2?]J79#ST>VKN[IYZ>_RW[]>W[?YQGOWY\_UMV]N[O;\X_G;W[:W;ZZM/9
MW\\^G;TY3X,'[U_HX6KFM-X#76_B[;3>0UUOXNVC6.]S1A3Q)B**>"\CBA]F
M$W.A0I[WV(=8(IQ]IC<QY]O]>U9=7<)5*8*X5R46.Y<6M>?>"&=+4E"ED552
M(V:81LHIB:PTIG"<:*WE)J)S']1-D+;ZT_C4@.A-W(=6&C\,U6AZ.K)O.H%,
M99K[P?C[H6@3?8\4V#3WM@0\0]06'C&M/9*V$ CG"N<EMUIL9@A@ K9#8_P$
M;(=-WQ3WO[][A]:*44618V ,,EQ( $&I$/'"8BL8$>5&VMQM&SC7P_TD=?)\
MB7+S8_8_3,;&.5MG?C*^S&I@VNB)2,Z'_12X(U-E6U<U%BO/B\(AK@N,6*$)
M$BZT.G%,@.IP-"_65,VCG ^M&/X*4G@.0OC>_Z;,135RDYMDH.\?UR<#_;#I
MN^>H)LL2>\LD$GGH$UTZ!V:Q(*@T3%*+24GIVOR01WD>MHEJZ]E=9(N)LHGM
M$ZP=/'WW'-9H;O*B+$H$",41 VLK3/O(D<DY9R5WE NS$;] ,M9V.QDUI2(\
M.16AOAA/IC$/83@>?4: &9=9-;IV]32ZQ));X,!E;J\US=Y[N MBN,U%@3QQ
M!C%%)6BEDJ&"2LQRH3CAV\EY. ]B_PF$_6PAZQLRSVG!!F5>'I8R2W5J"4$3
M@NX@@A(A>:F=1H5F!6)&4B2YL:CTI<!66$]*MI7DBBTB*)/%@+*$H E!]Y'0
M"4'W"T%S)9EV2B#A"0F=/!62!DQ2(6@I+5B6.%]KXKF1+(LM(BB1;,#3N-24
M9/'R21;!M0*,.IO$ O>YRR5Y6E(_B]3/8L.=_A4KG< .U% X"Q0Z1T+J$I6%
MR(O@*:;E6J+U)I(X3D?VMT;";][[TVM5#<-LW%_'D_#'<V=:V=_4Z8"3 <%'
MV"MHYPS+ SXX)$A-D-H,4"RU!$!$E!<,(+4LD1;>(Y-[I8B@N" ;Z?#_LI!*
M<S&0VQP!EB U06J"U 2I,=58YH*Y'$S,,@Q-(9(AH4J#<(ZQ)"+7A5U+RMM$
M]LKS0BHIZ$ >8T?+W4Y[(9MPSI"]=,[,>_KW._DO^OLWKIC4TS]INZ3M-CI]
ML624*(ZDE@5B'E.D+1:(%H9[)H7E)=UBS_VS3JHWWF,48SXH\S2T)IT9$HH>
M.XKN?0R8%P1+3D)IO5>(62Z1+*1"PEI)2V>$TQMQ\VP#I1_885^4 RS$\<%U
MRKM)N)UP^T!Q&VO-I2\)TI02Q#@ND':$@W6M"P5VM\=JFQW\GP&W63X0_ @]
M\R^1[)-Z^M_;T__7LW>G[UZEGOZI-W1:[P&O-_%V6N^AKC?Q]E&L-Q72OT"Z
M=U77,S4R+J1XF_'EY3@\8FS^R*H1''&&P_&7##ZZFNEA9;+_I2=_;@FX_M^Q
M]VX"IZIZD(U<ZLRW7U4:.Q<>V?, HK:EMD+GB.84(V;+'.FBE$@IKKCG/*=:
MK[HXL"2L*+Q#0A04L=![6Q'ED29$JY+@W)?JOG29LU:4W_M749#/@QQO*C$&
M%P-9I Y6R;><Z'NTH%902PU7#GDM!6(FS+967B-#<F8=-ZZ@:UD1 '7,<<]0
MF4N&F) 2288-PMS ]PU6MJ O!6JXQ -9)E!+H);H>[2@5I:"8T\T8IJ%.2<%
M!X/+4R2HUQHKCWF)UY((I"\TQ6#=D="AE%&&9!&:^AE 04Q-H9E^*5 3>$ .
MK8_1,TZ(3KZ$[?@2U!1-+QR"5_O#31_F2$A^A&.0U*2=[FT490DVS'N4$POF
MLRLETDR$M >OK2ESEMNU5GM@7Q=*V!)15I2@DTAP(6",0&&5HG0LET&CO8QV
M8F2 Z8%U.-DYGD\6]V'3=\\Q35CN3$$ELM@#II4&+"Y9&J2Q!KM,"H'Q6O,[
ME9?,.[B\P,XB1HP*Z5\>>2D++53NK'@QWRB6 Y::^R=,2_0]7DRS3BJ16X)\
M:6EP<VJD*( 4,T;GN;)&\;7F_M(+*TJ"$>9@UK&<2R1\KI&4KB@,HUP+]U*8
M5H"9AH\=TE)"PK,X$4Z'P[%149C&/M0Y-RZ%Z7C%B0#L[BRPMW63;'KALK.1
MN9FZ[/Q"35S6C0?(3C]/G$NS 8] /)-&NE\CF5(S[!&U6(;YW:"1C!?("H)S
MEL,'=$TC8<LH!FV%<DY+T$B8@&5N'&(J]Y(5S%GU7!HI#9I)%G:B;\*S1=&8
M$873<.2GTN6(<<>0M@5!N=#::U804ZS%Z;PK"P ^C');<,! ZY'$H= ,LY):
M8G,PVA.>'2B_)SP[;/KN.9XQ4LJ2Y@I9RPAB@B@D#&9(4"-*RW.2%VX5SQRG
MDDF>HT*Z$-FQ)1)2E:A@H:!6R,+C>WM4;C5#E T$VV*G@OW@^91W\,(N ^LF
MU37\Y=IEPTKI:EA-;[*),Z%@.CD/DG)*RNDARLGE6'DK)6*.A;0#(I"6W('A
M;*PO."_%>F<=[P5CA5'(>Z:;GFD""X:49X)R,, )N[<G?3*V]YC?D[%]V/3=
M<SSC#NO":HUR1T5P! BDE,B1*CPS)"<,F[64 TQ-KF&[$5:Y1XQ:"WCF.#)&
M85M0GCO-$IX=*+\G/#ML^NXYGAGLB',$(U-0%?!,(BUP;,Z>VP)^XH582S>P
MDN8*\,P:#3:=##UMG2H1*SDKG#=6>O-BZ08\52RD9(-GJ5AHYCF&I@9QEMUP
MK$;IL'_@LI64R;W-SCVCHA *&9IS,'2Y0=ICBVPP@(D-#7/7>A4\:@!=.TKU
MU_&DKU=>NZMQ74W?C]Z"*";[>#]8/MG'ATW?U,'V_N0J[[FWI 1;6GC$1*C(
MLKE'1>$)_) [2=?*LAXU8&YKD+D>O\L'4AZ8%9ZZB"?\/$3\W#J^Y8XI*[@
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MO3@P+.S/,#0D5C&9+C<]SD&OFSG5[<R6\3?%'$Z+BPDHL90K1/><79_2'N\
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MAB*U,)&CB9;,.T#VAELVLEFO]+N!=W*?X?<JMN781:;-)2,N+R7*N:-@"Y?
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M^[U]+SN]6G4%SYDF] OX5(4(R7Q"XZ;XB.XN'ZV[QOO,$@JIHB<_F\:=Z8V
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M?:([!CXGW]G?N@6$C0.$<O"WKS_^[:_PSXXIW3>+!3'.GS:G1:82N7&%*FS
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M-F353(B*"6042<6[N$4Z%8R/D:5[P1[!1\E6Z2E!K2+)8[Q OCW^3^22CK*
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M /I, #78<"%Y0$&$"&"8#F\D(4@''RSSE6.6[R,W]M  ^B*YL 5 "X 6 "T
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M@'J3^1P''V"2&:"',%.X%_!__&&4?QJW5)P)""Z8<TI+BO?RR(KHGEY-PKH
M/]ZD-Q I0Y6!*3>SX?1BE9= +'I04J9I.5KHNQVDK\WU>)8UJ-FTY<A',32L
MT7PEX8\;T,?&?JXN=*^[2J@Z&-;7=7H4D$T:YH/K## #FP=B!)#9F=$T[^'@
M9MQDK:N92^XM&E.K!:S-=PS/2Q.NTVIE:&G"<)B1[2KCT<@-9VG_/M7P=;K2
M)D@%S642EI?; .,,F8C H+I=0.IUTAL23;EQ,UVLQU+*)'VSHZ]C*@.KN@ P
M:_B<)_VWOX*-M,#'8?B,6CT)%OD-#&QV/7KKZ^9F:&[?I%_?WB3%%T3I,L2_
M;M_91<7#G_\[:Z9 5=W+\XT(5OZM'7].LX#[WRP.H3X_TA!]V&S:K8DLS_Y>
M?MU_1,?;<TK6S.=D#;<F\U^O%L=D-^9#: ^^D(FP2F_,\).Y;=Y^]9<UTNCV
M/5O+VS;].7M[HN9WZU[XRRYF>OPK%SK#W',Q5QF$]8$''A&M4M:B( S$/_4H
MA<E02H1V9*/]R/Y5AO?I\WMXP]^'8_?G5X, &L)-,B,FL_#54\V*YW#S\>R*
MU@P>#X?C3UD)R#9D,[N&P<)SFT>HV-]D]7D\:T#X--^^Z8DX>+4LVCD(YSNU
MF2EE9M-Q%Q"1QI/@"X:?]P]D'NA"\(K/P;]M7Z?Q)?ZZNQXV:FANFO"F"3=F
M HI2MPPY"*1]]%?;(A,^UDUMZR'H V^Z9^R(-&C?RLDE9=77"9)W7T0NE=0/
M7?/0[_A2$?K<AY2!]&,@#^0OJGO3%Q\?([/)Z\\]@U![@I[M:E\/#EE.:X*/
M/C%[:MKX89?CL?+T4\L6=CST.U?K76?L_=5._O*W[\#@>SII/#U7^K3(YS3X
M8_4-__$=W&XG]7]<@)K6H 94\E@8:"\,],>H\\YE#DINR$<E>Q<6*BQ46&@;
M"WWS<W9N?UNXJ'!1X:)'<U'*"LO\DU/#"O,<K/KVGI,M[I:].4J*T^-(+S_2
M!S>>Y+"0-[ X83*L1^'QIWCG&MWW96C5CRRO%Q579<I]FG(O9':/U^<,2>(,
MIURXH)!$F7+A@D(21S2[2D?O)T;M?C>^O@X3E_));LQ-F.RY6L4KL,>V/+9O
M[<6.4XFD']"S]XAUIGRE-7-(6680=\HC8Z-$VE26:QLB)_)N^)E*54$QM@A[
M _=0J9!EE4-4A2H8XHW;4B?T3L#9G7"T[L@UG;;^W33UOBKJ [U?B$J6[IFG
M3_HOKHB= !D4*-QGQ;IH2!!6 GK$B+@, BG&'8J*<BVT"];J%X#"94K&?T[&
M3;,\"4SGZ'_/^0GOS>=]X2,_<+^1@HT%&PLVGA VGG4/XI/>] ("!00.JB#Q
MBCDI.4/"L IQKL!JE!5&DNLH*\.L<.P0"M)2.5I7E?9H(RI\X!+I)P.!I0W[
M"WLD)S<I=B0,['CD]]T3J3@D^\MH1;:LRA;/*5.J(LA:)5,:K$&:88=<Q;WQ
M1-@*\XTTV("CD)(A2HE&W&N&-*$6::>#5E%$KVA/_)!<7I *%Q%S^I1?M.Q"
M!H< 0.6U)9QB5*6F&5PR $!E!<*$*/B?R*UY"0!\4>^CH 413Y\5"B(6,B@^
MQ_/<],+[A0P.H0U5RF)#0*DA1E:@V42';! &59(JS)G4U,5#:$,'=C6"&0A
M5Y2>9W@:2^SC$QGMC]\'[R>Y5/9M\3*>#9,5L;(J5J03GG/"$7$A-9A4%IE
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M%,D?E\+\J-8 !=(+I!=(WU?"3@R5=$(AR]-1>G "&:(,\D9&K'4@\/TA(/C
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MJ8EVC<D>A='F]8)J$*J-?Y$$-OJ<1< $HA(KQ'5N>^D3,%*.H^.>$-FM=GY
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MI]F#XHD+3L6>BCT]JYK_U+'GX?M,/ >!J1KQHC3B@?M&/'&!J3D)!X7^UX$
M/QE/\XO )9?AHH0#%O,Q_.US#]"ZJ/8$MP;5NNO'+*HKK/,V$82Y<(CG=M!:
M>8<T?&PDTT*)3E6?.Y=M6"GCSRM=;-OO'G<%3 Y9K>]3T:O_4UK1ZXCH)12W
M3%B-F XQ%YTAR.7%%FZ"3H(&(1@YN(C#(Z 7'S+UP OX3P:]ZOZXXQ#?V>>\
M!&:+MF3:.X\3NRA?5.+[DO2I6HP=OJLH<UPDY(F4B$>GD,8ZHB"#U992QTBG
M'OM]4F9__7P^F5W$^$>K=5OK]<?>Z#&$5ZJFHZ)7G=(7@%[")L:H0-H;0"*&
MP5O'0B 6G7<B$<+Q4;JD/19ZB:'AE??6@.\1>>_Y?)9BTX <V<D@Q5J1]P6I
M4#46.[6"".:6V@1VPF'$)3'(14N0\S)P85CRX2@%S5::]_N6XKV-1^>Y0RYP
MM105N>J4/G_DPC@DPIA D1"!N$DDHY!&)-=@D!*^2AWDN@_-?23D8J(ZZ#6V
M>T2."X\1F\5L&FLP]X4I4+43.SMYI;/&)HZTPT!SN6/(!>\1E2K2:$*@ZFC)
M"_^YUKFR_G<LVX"',!35.%2XJE/Z_.%*1:>==0)1:CCB/EKPQ37@3Q2&8B\Y
ML>)8V0H/ E>THE4-UQY'0VH9WUJK\@$*V;R@6I64*DX8\\@[F2U#2,@8:Y%.
M0I,0@_(I'JV,;[?LP'&#)%KK6J^R,N6*CQ4?CX6/B0N;O'6("6413T(@XX-
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M<D+Y$!$A "<<FTS*P77S6BE!2>![RM9(*JU4.@'PY%(W 8R+!@E$>5$Q^,
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M\65F $=/#NQ#=N 3@$+E1DZ;$FH[9=,\S,IVA;--,>^KM=#@&NWT#G9JC+<
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MQ[VZT1+':R3A5CRR+L9N5:F1W&AO$>;)@F=((]@.@I$GGA,94L"BV^)2,1V
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M+MI22?N&M+,G' ?A0&2!RR0DK!*(2V,1N(,&<8Y-E#%([3LJQZU4FG*,F"?
M@KP!E=.)(1(X4U:YW+S]I'&0FP.V9BCZU6*W&P7(27?/**A1<@B??RRC!J$?
M$Y'?^\4L<^;<4F68F_/"M],VO64CC3"5B_%\HRA] V 91"X^*)#0&4RE"0#
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M)14$(=I&H%I]6(A^1*DE:M2KU;^5V/9TG3EAQZ)5'#A$=L8L2\#,,4&,8!>
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MG_,V\,DDAG]_.YNG.*X^T!% X^;\[.<.*W?*4'^:=OYQ_"B"B6:!@!\5%7
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MW<0D;UK<8'RHS/6[*TZT.M8W&8@!_$O&%:*1@0Q029&ATJ/ ..;,<.-XI\\
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MC]/340"E_=1OSI'4]>QLC)?47Z_97S$0VT3CC]-8X%EQ.[PH3FU=C">C\WZ
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M IV$N&6>Z"CES<".?>@1$@@?AB+CB=)?B-(G);3"G"!#.,4*Z5IKHF+B3I>
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M946-(%1'"=;+:Z(Y1?Y<;\N4C UA?:LVE&7EJ"/6"4LX@Q6'U8J3B@E6ALJ
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MZDE'MZ8S#\'@ *-TE,FGK9]M):&.&1ZDY;8BMQ)VP,VB5C^J@:P]]7-A+V<
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M6\W?T"OL;D*?L-HM7-9,VS/QP>%^H_L+-59Q0P7-5W<^\KF=J5:HKRLV/_N
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M'!0Z*A7HJ1?MTHIKF0Z*TRD\J:Z2.@GG7UWY:U!>,DUU"*Z'Y)B%>>FD_QQ
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MH['*?/""ZC;^&'+3 I6"VX7+<FZP+2/D*%5V@H%$=,]/DOH0HN^QQ1V03?Z
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M:OH1T"UPLBM\N1;JRG-R&SXK7#=49>WMGV*0F)FW<<VH2L\- B%WS[XC$G/
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M>HU&3I&@8E.] LG:B$BU)EVF;F-7&"?-L=XME>S?6C<M'D U!>W-P#@U?"/
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M"8+!M\Q7A3Y;B\Q1YX'C;Q.A-J]_A76L:S'5 $U[1U8X**2]L_TC39#!,CC
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M##!.P)3&W NSFEW81(M&89$@AUY\3H[]YRA6HXJ62\TG:AFR.E,92DX.0QT
M'7+:J^V1O:B8B'>Y:0+/:JFA._+02<BU&)Y'$3-8O^ EA$%&S_LO<93MU.K,
M;A5GYI/=0>&AJ&*-$3F=:X/K=:68Q>,YBE-X?#/!OPD(N+:HF< N=@[GT2!5
M9-4$$*T&P[4.(F\_]/UL3\]("J[;L-C4Y0U&Y34,[M@HO3ZD[<EZ41@))R-V
M=#7KIM7EYX 8K-2<S $V)\</4#M2=H(?:*D^C\VC<;/H%6Z3=!>SZ8)/DK:
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M#78+0:7K+/3 $/JXNX)X"*YL$8FXQPH"A,,X;P)E.U0.NHAY,Q.+ OKY%,(
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M)/Q)?@TR <S0\V4*SNHC$67VI@>6*Z47/(A1'+/).L0BFEJ4$S!9=FPJ<7H
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M?];19LD2+AI>"!3\166I2PY<!J*EQ B1-QI388 "8R3?\-XKZ4,4*I!C8^\
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M17)F32]C3\J],+LH4&%Y.P@:0J(EQ)HZ7J;EQ?RU85XGWZ2DS:L@>GW(=KN
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M$ "^QM>A"WH[?(9#3'KC.\'R-21=WOB[&W_KLW/Z=$VXN(W2 : H!^<][X1
MR7-8-T#@]GE'T%/>$Q2)KI"5+/J"'.@,))(@O9GV3K S8GP#B)'B^'J\>7BV
MB0Z@H@<H[P(J^H!H)Q#KQ6]PH,JQOEK7U>0.<NX&>UD ?CSD%/#\( .#2>$B
M</G&$/8A\_LY=:-V6.S:I1.#S)L(&%(:+#_8SXQU CPHY&[([A2B(PS\4.H*
M5!*=*;!9.0K!]!!>5L>O[.K&!W'981"O#@=Q:7,0Q?Z\P.S?ZS#7"W*%PT@'
MS?R@^E8T\3O0M!7:QSS1F3&,]>EXKKH#T*R'4<XL4Y%3%8N)# P%M@)[5A*A
M@^G_R0?Q'<>D+@4NA1X[K].D/K()DH\,!IG@+UP0@(0E!#[G/_ .+<J!8S!D
MHE,+I(PO@Y[].XQF2:)DR,K5W&W3NWC7@N]2PU*>F8P":!,B&](]\ ;0#CN\
M8#:T!2IRMM&RHE'J(/&;&(K2G4-YW D>,XJ6=?EP=V?#.C4\4WRS[2TQFEU=
M+V=EFYMC )^_2.1UF,.+'$'<7"!0\OS!<6)%*XMJKC XI8N6D&C*!D#@Q*/1
M(X.:B<BY(@<Q0+)IBIC#.5&*R#;M0UL+(WR-"@8*8A0^;_[]KW'GEF>!O6S-
M1;-+<1_)*EH^I8X??HDB+Z'HT#3;4S(V@*L. :!H=B&YQAA\(@C'\!&Q1)(W
MNY&0H#%=-NK)3B/.\#/,[A<</<?.;D-.RF!4Z(!,R$S(G"X&2O>(1,V,']@H
M#[9Y=M&T7YK(IT=DB+-/0KK/\\-J\9?GKAEG)Y\*@=\1+4R>\U G8^+0YPQ]
M*AYIYC+J3L%7Z3GN@7U^1^ZUK0WVZE'.:739<OV8,*!67>#M]P+=_!%X!,I'
MQ5;),UH&:J='AA$$0:W\'+A)5SB:''>F2SKZVRADD$,LY0<]HP_58;=1^G><
MUB>NGTK0S/M51J!:4)TB6-#0'J>HZ-,"G6XAH.O?<E!+<1^ Y\QIEO2/(C,A
MBG'@<"@I%L\5&4H%?ZCHY\D3)7\+\I*A$>W%/BQ^TVOR$(D;I0:HNH %U$M'
MJSG($M,#5)?'4F2OI&,1T;$PZK)RCY]]>%6&*3QZQGFJ%+0F?4'IZGR-6XHA
M#J@,5D;\AC3U[@:O7B,M,C/UJ/-SZM2UFY"'(-,C8BHWFI60V1$G2^-#C8C+
M>KDJ@6QS5CX;$XSA6HQ"4&DMUQ53WDAM5D$;?"-J;)T&=%C%Z7#J>:1,PO^Y
M\4/\_;CSC5-:B \(:*+5)I[.OU,K-S4'G@66FNQ-EV_D^,6ABY?K:8/:\H:*
M5!A%Z)=1N(9)AZ%BA>.B)_"*#4;SW3 Q*W%C?\<@X$)\G>+A>83XO/+9E"BC
M7^@*IL0-S9TVYJIQBHQ!:_S=8S!Y8$\X:!&A-=MF]#%S01T)AX>5,\*%Z]>W
M$FW$B4^.VZ.?OP,1/^?(8^2.D"%)G]QQU@PA+(JDU.!1R'Q+"*7!YJI2AFON
M00/TCH,+=;)N$SXQ#]EN%U UDA, T,%5$+U>AS2W+?4 &VDBE:A3$ H$])'4
M@ F02YI%0\J: >=S.:O&V 0A<C:0!:)0O6XY:<C$.4*T<B=>!')*$'1# 5O+
MB4-,'XFC7J+5$] <KHL.-E37$S^ZYY]_FCE[%F_QA"KG5ALGY)K<7!,\*O1*
M0P('[I8J=57&#LW3.^3]74P< #7[H3^,!I:P+6D8\ (]YD-E-A/TS(=,CAMO
M&K0B7-S4N-5[!;.>*=V"!UNX&ERDQ6 T^4A/+NH9&HY.;M(+0^C_AG@N6WZ+
M3<"1(3@B+&-_-Z$_//A&??5#B,,;)6=P&M-KM\?VMQ2 :*C3RJ<3/U1%@HNA
M2L.ZMZ#(%I33/CKFREOD0;)#%\E;CH\K]<-7MK3G#$Y_WOG/S/6=2  %_BYW
MLA\;)B(1+X'LYF$&!N,+IF&T='=EVZT3TX3P+8R;BG@#+Y*$OVC!V^,NQ@"=
M)EP$F(FK<-@>.]VY_8RVNT!2RPO$VUY(/A3<Q"9[C!M/B&YZJ&KCD,F*X>V)
M:$K9U43H'\QX\98-.V-3'%7L6,9R&&GB0U8GJYDQI$'6Q%/Y9F5.UT7,,]7G
MY3X]1S-/I4R)];Q,>/)2A>1?R9U-MK,X1JY#5XMKC" KSE.(XW.G5:WJXH2?
M H<<  -F'&%T,2(OKYP;$X\=D9;I*HJQZR3C_/@%D2/J>5V**F2,C]RGE^K%
M<F^A4;%/7,^:$S.6/44+$S5 !CG%V28*(<?HQ?"DLN,3A<"+[F+"W*FV!DAO
M.A53HW2!8_^%YD#3!D)8D)1E0D-HA#KYD6=48FIR:9!>UITB)_3$0QR(6+F:
M/6%-,SUL#40+DD(G9(7-Q(#C!D=&W%*YX8&/"(.YJK$P%LV658^_E0&IFB?J
M8F8FY?9QMXZC,.66N@30^ER'IIUG5[ P1>1I(D9N!]X>VO$&*3:?*T*",+OV
M<R/-&O)BO$"STVZ"R4>!+WW!O6@(Y2T!DB,7>G)+7)$5Y+B9+RL%'G<GI250
M7@&[,J YF_QI]WN2^EMHGLD. 9$W'W 0, D'W(YOR']#*2YX[(4@VD-)WB"Y
M'&B+""#XJ=(N8(V:"NZ>?!#$V9\S7S2$>$N(-@4@B+RQ(E3ZN'DO/6R&S?ZT
M,.#I:H._.O$_<'H7 ^Z$!@/H:7J2;O#)EE(EC%&R9A0SNM@)?C.<'*+LV^.H
M'#UV'9(E@Y-T&09[Y@Q18"8->32V!/[YO#D4D?8$-K"$J00/QFF/V6G9SU^,
MY1!!T0R"=@2 M(2'->7#V #7\JDC:)\TS/!L/>1R^>HT2;+M3@#4?<7I)O*B
M('K>:P38&NC)*26JDWI)+8I2/PW"<Y42)<&K+'3] -]BLLS(6PI#8HM5!)[R
MY "%U$[>V?Z1\"4!_9ZZJ?_"XMLU8/T>9!:+18\ 0(0F-8%OX3.D*X2SEW8*
M?9O!8/OA[V2$X+QCDZ,"SV$4@]H!S#N#2&\0ZP[Z%CKT._B9QD"(3L':_?91
M#&1AJBOZ9G!APJ%7&/5'#@H]TJW WY7/;G(F^,D#>:,YWC+\R8E]\*FX)X?J
M)SUWU0+1%A!K@MS32#2"[HVH;Z=A5CX@&(-)SN"+8#">D,$B=)HK;^\QC:.A
M*OLT&ZS)8X'3PHLD)XH8U6/AIB86W#1+$B+!-@JEE&*G&;E58U T#L<A(!0/
MLH@55(^(H9))B'%53GKG&./J'B?8B=T-$<\N\ L.HAT<&-S!:G \%:-)A2F)
MJO#;.BJ>#A)-%XQY!>FC8JB2=KJ6I:E5]M/,52FLN7D1&O)&@XN8X82/=QQ]
M(E(%QQRW@#VN@9.RX13D)?+R@IBE25-<T)?[/5D!888+:]?C+@I7/#6N=LTX
M;TTVA&8[ .C@#5K0BT\\ /G1SQB7[)W0#A(-F=>)3\QW^7H8,.MF (?'/F5-
MX3SIZ75)C?'P<+EZ,!D"(PZUY5H2&;5$+>7')5E(LC1\=-R599#39[(9((%W
M82ZG]J.C8TL=M^1+,^=*$C^X@JTC2.IW JD0LB=R/@B?F34Y,FAR9 .(O?SH
M8FGE0KKI?O;3S7E&^K+%L1X)1IR//.4>:P:]DG:0:,B&8#,M[W47!+^,I@3*
MH'??=>CN4WP>Q>3I3R43+48W1I4LXYSLM)*+)BX"85BAO9?(F;$7:N*B;",R
MSLIHTQ"+XEZNN0KEQ?$#T!E>1?$7 &BU9P\ZQ%A >=_( 1TCVKM_EU%5Z:>(
M9 N^GY UE0R)N-.F'I6OV %3 ;.X[C*J''#!JPO'(^/Q"\*(4EX@09NF5C*V
MF_1S6(K@GPN;PJ9-KC_LO\ "'>=0GKL#% 2-^9-KXZ7.Z \O2$X5#"L^!7NA
MAD2#2NY!#I)JS?;_\?&[CQ\_?D([A_O!+A"IMOC(_I]JZ3Y)?U<4X<A)T049
M%GI*?_\):G_^GBOWRM]^7L Y!0O<?\'!_O]"?_K]XD^?_[#XP_>?:?D__&GQ
MZ=.GQ?=_^D&T$F4I]6&CMNJ!S<Q]9FJ-*#S)*(-RF3RTBCQHZ& QV_?*>0,3
MI#"+^RRE P_.J6!80T_9;0B/);AVAEKZ1"^$"1YPK*$CJ-P3<I+DP3IUF-=Y
MAU#>HP6X)+D&#A_+(UD?T?22#X@C"$^N)6+A4@D1A>"L5.=YD+XJ? _X@3WV
M52LZ@7@O%G5),61$!SE71M&;_.8R"OAA=P3K4F<T8#L83")"&[XEV\E)-FR3
MC3.),D8XP=SYA].<'!%Y/#<_,FY"JJ836'Z4[/S[7@=2T3@=ADR#(BT)G)GB
M,2<_]:0_1J3LE%NIRQ$%SV+Y3S.)/2?FO:QTZS4 DZ/+1TXHCMNA./E 0EPW
M<^YO)6VER>@OS>%]1L/V- 7ES;G+I61KO-];/R /78@CVIE9W'7Z_CPVO6(Y
M'OSDJK-TE("1JF;SX^:\;-_[*D\K/7*9?F-Z+J^R./13\%H.O2O_#3Z-@PK/
M"5+Q5) TID'3QX^\_2PQQ4(6.8;C<LU3PR>/NQTLQ:V?GJY)+T6!TX0_KIWG
M<4;:PR!63A\T_Z^\"RB#/J  .H$<Z$6.-8F<!*)Q>$<.S;D3A[8:'RNA,Q',
M+]=(-(UHVX@VCFCK.8PJ.DU0T0&H9,)9P=(0E33MSAO%RE4O$.0Z(7K":(,#
M[AR$J^MO2F]S_I:^(F]X)_@[=N++T!L#^\.?YHP> H( XSYI))Y.-DJJ+ N\
M-%O^-%A#55F!Z</7D#^V'N8J$",G5>29(^%$>A;UG:N)=1.PMTXSST^C>$3F
M6$YA\GRQ(WI:4CT:Z*Y807)>Z97S=H9#O/;3A(4/'Z8N'OH,E'-7@\E"M+(0
M,=,UV9R/FO%RYFX7QY!6!Z6$]5V4^),B+9GA3SHQ!LVN:>S=(MIV-"9R*5+V
M"!B0YXJ']_J,!>KWR*.B#:Q()9KAYX^??OST>1R4B!JH$ 'YDT_F<A]/PF?9
MA?R17,/?&6<,0F0>L)O%S!(G>74]. &^QPR$_0LYZD9L-!J'4[2R*/S>3M91
M? (M@7Z*M86@,4-;<5KNRQ8"SMTS(98@(@D O %.Y$ ."./88)0XX)(3HZV3
M0L=H'@.G-&"T1)+W^\A'23K+!B\4 R(KBW6^?*-Q/?2^9U?AN&CPRS=4$.27
MZ]3S22YTUM (DQ\(!5P4,&/-&]5I>2<6/9\8QN<0#':?NUSZ6W*1+-?@&.F'
M#"'3?]Z,#0BL@XFE(;;4"S.EC<)9 F=,6C2-8FA[:B2GR0<COVJJ ,"2*RH;
MA.4:2<TAVMZQ\U^"9:B?=&,\%PZLW'6,*Q;X*V)X5(7PI>/TT+><XN2"@B9.
MY$D"A![Z>@0\GL2 8DD7#])]W30EQCQ<&H+[1Z;L;8[N-YC!5SN+#0 -,J>F
M.%0H-H1J(2$=S )X?4$ W1VYNV-V@X-0()0O^A59HGF4-\^>U[0#0OJAXH1E
M!= TXU3KCY<W11XN00%## /" 02-:<-NX7V$E^MEKNT8N 08(;@E"U)&/63'
M<U*Z6')VSK+$#W$R^4R4DC.2-QK@,/+'ZW)]^%XLGG=ZLFS"6Y@B*DK/Y0[O
MR-_(F#2DL70"[N',%0G@"TXSVT9Q>@(/ )-!/Z:&0Q).]*R3B<48^CQ0Y#IF
M\*8%JO&21^L3R7'D4Y&E3^#)C3V6\9H?WS1N"B*4X,7 08\%3 "@!$S[4)Q^
M)/@AHL[Y+0!;4T2:0ZP])!H$7,TC'P#UB?&-(T-=?U-&AU@8R*TP.#:9?":\
M!1?8RUQZ?XKQ&::B.]PMU'Y>DX/&*7MX)U*Y/%T#= _^@OXA+^]@L:?8OIMX
M6\UD8,7F4Z6PD5WFS_:E5#>E4'K$^X6*CA5;U(!R;R[C6=K+E(+O=EALTSIM
MRPF>!0*5CHR]A[M22NV<(UTER,L;FGA+3<2EV")RXNJ"NU**YND?*)-R6G*V
MJF5W<JNNR*53OY_'A>.U>ET9\HR;ADF[R;BFY:VL''M09:##PELN-:'G/,3O
M6)%*H]*?5B [$) TE@15'S^-."24*1,)7:G"=)2^.:=B-)ONB'X?IJ UTWEZ
M)W$O>*8 =7TG6+Z&I#<;?T?=\!UNGN<>\B,E#>%R_Y2WAB+1' O@8 ="X9(_
MK>@Q+?/B>.!,%ZV@O!E4M",%81PQSW4!%MUGVX#S6;;-J+:=!I7#%1?C#;E\
M<G@.<()1:]&*+"&WH#I8.6\C411$=U!$@]Q=N4/"$_';P(0'UPS&AF^8T^7Y
M]:*;1K%H<\%#OTBS4X]4CLFRPNXF]/^9C1,?)&R:W2Z.'&X]S(D;$R1T\24O
M\3;F9@O2QU/K4D2^Y'J<AYH&P$/>G06#-DP PH=U:4$3%$5K1/;C&M/ T,E?
M>W8'M?I@XIG6GX$LLZ.*H +,DRK_UH=$$:-D8K$9\DZYWNX</X9>+N,+/]E%
M"9%<UC=1^'P#L>D,+4L/\G'1%#@/B\: ;6CNA+;'@<5LIG@P,2(EO$-I6&J&
MP@BTD$(H$0)'??S.2#A]#FM5DLQ*82[YK@ /%G.H^^8'1%X-RQIY]9FZD5-I
M=?+4@0KS'L/4O<>$0=^EN95),7JL?8F'AUVH;9PBM14XTXLV6>2\.$QIN[^-
MT2@)=H0H]XB]?W@4PS#W:W998(=>AV10R+IUQP!TZKQLI;XM4-Z[:8W%LQO7
MTA'#L[Q&\L 4Z2<,#1%#JA!RI!9,_IS:Q @DXSHME*F"BB&(F7&=+FE2S?;\
M"GLX=H*S*/1TP/PP:HB2.Q8&@B/N^\$>%3P\ <7)]FEN/W#BD!QO$(!.SUF-
M8CN/:A8M@-S"KJ,CXTD<1Q4^;+S!>"P2D7U=!N!\&GKWS(V[4$F.CD(KR%.E
MF? 3=_(6IHXUT\L?G\$27X0NXH0E9>Y1L57.DUC0GAQ>CKS&J>1SMI>,M33/
M\XAP5-GNRW)&FXE*U<R-RI1-"<X!\9U\>1YCSQ\,']H=&A]^8&W-"O-^P C4
M!M)\P2&[J7F,!G(I5>0Z<;R/7LA".%)N:Y2[HR;=%*P,QP"/RN@L&MRCF,[I
M6^XN))!:C*3<T\M42;,H4[4&-J]ILNI0V]7,V8X($2[#(HO!U+$@N?,P7\$3
MO_^G9+U5,<J#/W)?<M'0T7)<$O-\(N6E4EA'96:-05_=@$)?RK4A$+XOLK%V
MCQMREV*\0 6X%VVK!(6=1H"/>N?XWJ*$Q)F'AIDSAPC&KZ)8#I$C$CF$T2Y#
M@,8?&B?)2=-$>M^60GU^AW@#@#D$31PCFZ7@!ZZ=!@@EB&P,CHVG6AG1)%=R
M(G-5FMH<9/TK3C>1=T5^CN*Q]T\I8Z];PK%W1<;> K1_2UM&:]:TD73VTXX&
MWZQB%*Y*>8M_+N4M+C#N68N(-WG\@U!Z]U:0_//H'KH+IF579#F]B_%5%GK8
M$QC? M3;(]M='S(\SPB[7"/2(&(M%O#G>9O@N6(.X'SJ,>!+?FZ\5X04(7.-
M]<3()9$\[YA!=PM=S)1-G((C(3A.[CA!;EC2:+J_"R ,+?3R>(.1DR/H+A"E
M3#764BS#Y/-4( O^% 49.1?B_14Y  ??(QQ6,">&&+79=[]D 37+0QU$Q8WO
MPKJ^PN"'PO+(:$$KX701$$;WAC+4:&9,GBK!S]J LVHS#.D*/H\UTW7PWD>_
MT)9,NDQ.R7C)+3G;;F&[1>LZOA\FQYL=%UI?CJ2'^&1 ;+X?D+"C#OZA+@"T
M#OX!U<$_'(3?TQAUZ!PBM^C48>KVAU,HW4:#/AP@/"#1*6I*^*V/8DG^:EI/
MDPX$D=1WCN\]D+T!$$XWD>L$*^=M+&X5)8H2H$HE,(CJ#@ =<^+#1AL[09F3
MAYP32A*MCH>3@\//"D=R/GJ?X9,1GD#]0!8]#MU2@NB1#P"I#<I>J942WH99
M%WD6G@"9>5C*J%'&.A'V49 ["AZJ5E3'2-"&WK"H42[\DX9%F7'RMS^8)2%7
M >:UX,GS(NZ^S</R_@U&IPQWLC3+/SLG7#?.L"?9 \]U''J,*I+(+M"YR>-/
M%UN5<]"&.9J%RIB&HZ2/JF1N>)0ZQT*<]&J?!-;:S! I=0[!8$A*,^%;-WX(
M^5NI6]J5XU(G@L/@Q"L!M3U\!4 SH'MA#2'1TJ(^U]J$TVZ*[Q*H2!X@M17X
M*U$<1Z^PPEUG1UI/]^ Y1QL]>L8EA[/>LV[('U+V"=?@,C_G[JI<X4VAV(WJ
M>RE[5D''%+X!D1%)D11\J8:??((*=\FZ?'.##.(FT;FS\U.>[4L4DEV[3L&K
MV$@.M)&,EF7LG%]0K9@.:()8 A=.G>L4;P>;&6OBF2CA!;Q&N;7^/"#/=7J0
M\>E<O4;L2^' \@L]_6A'I@>[TSH.)7ME93#86!AE[Q!@?[G^ZK@;TGZ\E\WE
M^G(ND#LK;Z%L-C]25MM2*1"&L2D6#XU\!R;  O2,OO@A+4R1A/$,KZ,8#P<R
MZP9A)H' T3Z@HA,T,2,Y"&@_3$";61FM<C[H$N]F@#,V4>"1/L!Z3_<CM>",
M")G6-(W]IRRE)NXT(A=R;,8/1C]G%< M3O4_Z"Y.]Y.[+.6Q@4P-#E:90A/$
MH_N\97@/"Q7>M*3 ;00)GMB?-.9O[#T-?6 Q#0MN!& VG*(C2/0$O(SSOM!2
M<F]$5*7!&\WJ^)5 #?)!%&-XJAK#I3R&I_;&L/#+&@7RR#VQIH9R'-O;JO.8
M#0V!@*@5>HMSKK;0K0[*D7ES!8EHZ9BY[J@,FOYJ=3?8RT"HK%Y%MU&*A8/R
M,J8I5)/1B1YX>S#5Y6N*M8F@T47A%QW%+'=K8L$1S=C8E.YN:8!D-W" +L,Q
M(/E!?--51I/>@9[:"=WI-80X2:*X',X&Z77)[N!!$B/"UZ*X)GP-J+,A8/2/
MC\-Z#_* ZCA3SIUKB+N:A,R'"0D&OYZJ":@7J)*7X @9+*M)9\%E<2"=.\GF
M*HA>'[+=+J ]<(+">2?1XAU<.HE(>P@:7""Y2<EAR.X!/>EXE)V&%=S+@T16
M SFDMT8L 8=ZOK$OXZIRS]QK6!<OAWG'&=JI0.K/.9O\2<R"L^NCP/<B^EK+
M7NT;!EZ$?AO?M 8&1>'ESX6FKWY(A6S:,LK#QB$@+SX<P&F]6+_Z[L;!P5><
M_NL9Q^/A"#D]Q D:RDVC@8G@R/M_F$'',!]2=A#PBP>G%0#9\T?'<A8$D:!H
MX#J@TW(>O>*0ND%O=TZXO_G_V7O7Y<AQ+$WP56"V:]N99A[5&5$SL]L]OURW
M*$TIY&K)E6DU^:.-<L(E3M%);Y(NA=?3+\[!A0 )^HT$"(\LF^E*A40>X -
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M-'#WV5W@"%?7PIXF;U$P0(GSY2%"XRU\<^P#PX:O^I.?<8/P0A-*8N>D98,
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MZ3AB!GP7U;97(N*YUAO6#\%0QN!:BQ3U): [N%:3T.(]6/Y16[O4+WR"&G.
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M]8<W2)9H!N]+TG%P-J=0*9+7U_*W;WE1).40=<ZY0/+;GXB4Z8D+9@@@Z0^
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MOD@W,8UOBGP%MJY-)8H?-'U %UN[@!Z!<;I K>R%)Q:L@,;#V"[M@^):P2V
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MG!3G#$9?<&,BVL4&/:WF;Y1G44ORYU.K/Q_+)!Y5:,<2V?.2"5I5/!R//WS
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M?:D=LZK7L%$7-0V,Y6:!@ @@TO:Y?\[<WN"1@\91#;Z[&&+.-%!3#?(1DO2
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MWVF?LV@%8=VL\U@DC%T;P930+RM?$XJ^12+%2I?CF:#Z-XXJ0PXF:9;1P<4
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MZTVEW(+M45!C)8JVK7UY9-HWI5X,RO(..%VOBSP2D4_UA= 7J?(0F$QJY=W
MG/.%@4$$8@QN5U ?B(>/];JN*XE$%^DMYG1 0/H\C8RJ3:W>XV.R\:E[^H"&
MP;&/'-ZY23JK$HQ@2MXU]]7U]T6ZB6D,#+[:MMP^#.YZ5A/1F]?]6;(#G,>W
M<3*TSTPO)3K&'C(C+'/?N-TTQVTVVKAQ@C2F&M)2,D,/8C'F(A7?F6.NNP'Z
M+]4_WF]%Z.W%'#I$_PWWHF<0+5+JVOQ0]O2L6WWGI4?GN4:TK7[\2\*N1L7B
M;7L'6:H]3D@-G9*)>MG]]%?_1.(#XNNHW-0"Z?2S>HB2^#;[:Y+%DH-@6O_X
MR* 5993VJF.:9Y^PY&4B.0Y\<0:[P]?8QZ$-"*K^.VNEAAGI_RA$2V[W>"=@
MQ6>((&\S M*)XJN8ZO^0+7@G6^RD\!V0<;'!6CPQ:8O/$/)^3DV9*X-0Z1E#
MM427'#_%GCA9W)6G_I5]HV=4&IQW]T>H"]YOX$T:LT<FJT@6,#*<+7F3@7OV
M'9OXPPV1=0]K5T[_U<_H["HS=$\_\$_#EQ:9*)BL#?Z$'R+@P:&:*_U22[P"
MFI(/69>+L\F?)\3N>E#[*#1++T6?KE?K--]2^DB1KD(+JA5QMJ<F.0BYGPHN
M6 _7G<@8WK,#9QBT1(CR0C\408&0B!=YZ3X9?'B(>LK&(9/H24TR0U;[L1ZV
M@G(]L1\.@L'@GE1 >&RM)R+$2W:]A_^#4_X]2N%\K]44^ -3VLU?:$^R?2_=
M@%O]*BG7.;L]8O5?=,^6"YYS1./>25;0*%NB8(?0VL8Z]%*=XH_ %]OXI?F&
MZB^1'1;UBKFCM^XSJ3O]1YZ 9G3*Y?3I+VPFV/^2Z_]XOOUU>G=]/W\BT_LK
M\GC]-'^\O9Q?7^'?_Y__Z__[\OG+_Z1L7)DNMZ51\<]QU$-3CA[)%Q65\L_Q
M- ZV<7<'3R>F)>ZQI]^A(Y;33^HB5\=G2TA(23)^$5VRP_ F*<JJYH*#+"7@
M6V&_%-0\,=.[XTWOK$Y1N8E]257= Q)!%\@2FD/F"-X)4D8\6(K_09!#(1D-
M],2Q4=CW0$DC*A^@V9)H+1-LFF SI&Z<IX/.EN(/L@-$].#'&A_C#CC<*CI@
MD*;%PAB6J%C(CK,?]_1=//&OD)-.U]4G/LWB=;C"\M($4[;]53F,WNHV5K.0
M6_Z(X_:O(W6U#E$J2TI-35RQ)DDC\=6&WM/OU?R#IN_T&]O"WTH=65]900R$
M9L4#8L[[/(OJW\S93R7;TN&XXGYR&_XC18P*6Z^B@5U#%JQ'NLZ+JKEJNYX+
M8MY.MLDJ3_:T+#<K;H:%.RAH-K_FP T%RQ:H'VQS[:'9<(;W93_.EZ,#U54B
MK*3KWD0IG$%?.H?;;S>"&/Y6'MQMAF;34B7$F8SLMK$[5D80P,&7SNX):G8$
MCSOD$LQ>TN25:Z$6M >]."I$3MC)?I$LV%(KF&;3/E*ZG@FAXU%9SI:R%GKQ
M"%\3]Q-8 '0^.RX0=G8I/LBO-'\MHO4;C#2$,1DH=CTX_ER<? A-LVR#=/H%
MZ&B"5XEMAK>9)!_D?AZ=[^(KS&%KBOUW(8!AQ]#)^4=N1F.VQ\;^7!#[JU)#
M-!_&-S83&W90S)A^M]@4X/1#%I/G+'\I:?$.LW";K3=5@V90Y@[9MF,7[00Q
M@*<O?/@?\,@KG^KG015,B_P@!JR;:\MDT;'>K Y\-PB@<D^[HOR_H&[1=93$
M4A&3U=:R&,- N%)F@WV:I" &H;828R#!,T3I/#X]=U^>=[X0!"2UE>'>5&+<
M\^=N0#L>'_WF?YU58)+9,(5X<9/F4>O*WWI@='VM<6VS'+E=#X6Q>)!QG';:
MQ*PK:,\[00!3;A7.*+)3&>AZ-@@@G6&VSR5=;M*[9&F=I ->"P*>N!?S[#9N
MZ?@MJ=XN-V7%YJ3@>6=,98 SA/U_L!;LN%X?(V9\A7T:QVBVC%)V<$:;M%(Y
M 0WKWOZGQP<CKT<\/A /2WF_Z+B&[WTCB 6JLL^G:9I_P,;7-%Q=OH'N>YM-
M5T##:5N=Q\H8_2"^72P+X12:5A4MN7?U)HU>FR=R]Y-!S!X0.G"*Y%>:+;8/
M%&VMEVF4K$J^_JP>H[UO!?"]@;MCN<EBN'\\K]G.EU7B$&;W4YJ\V[ZX_>^,
M#^Q0=QUZ@_]&HV+^D;>0GB)D?.BS)=L5X'ZLL[.WL%F?&ET1GB<5>.)OV:?R
MGL2;*(7S%^-=P='QEJSG.=?>KW(P@3=5Y"-?'W^NGM=+[?,IY_D%?:35ILAH
M_+P&JY"*&Y@M5;AX:RY/DC+Z7!]21A'*'M;U$^V3?JJ<((X6NY=*1EEUV!)V
MO!' DEZ\- NS=9B0.Y\,8F9JCBG=JTTQ^N$ >Z_)/&4U@@[9P/CS?I=D#(I9
MJ>4Z1=?_?5[-\ZLB^FB?L >\%,1JZ% "F"ZTX*D1MAG>^U(0T.IUB+>GBRUZ
M-G%Y[5ZVK<>#@&/AX  &&7XG*MM'R#'O!0&PP<O?\!YTSML!KP4!3]OZ+%-B
MO6CM?",(4")8 +^8.TFQ9,-B?3 ("/QLNNS>[8P'QC^/T)N$"O$-;5]_C+\&
M,;Y2>V<?).N2=7$T'@FBV]K'Q_26)ZV2(L\+W_/!6M\9W7+%+XG3."YH66*,
MS*S XGW9PEA*^YX-8H9:(7+H3K4?$;8G@P#1D;&->[U*V+:J*X>\& ;$X6B3
MNXV2@S?R0PS=5^XO$ P5#4<K_O&*?==*N7 QL$=V(8AA!Z0%?8/*TK*@X#VM
M9LL.]]J.QT??\>=%!&OZ:;MZR=/F%F_\,8B1;^W4;" /VM'9<^.K9E#SJQ0L
M!O,<_@6?!H:II^R=7.1.MI2V ]\+8H:TRGJ=\5T[;P)'"0@"\EV>O8*M&6Z:
MWZ)*]/%1*MHE&&"95I2L(336XG/I(R>( ?!%H80IQ6Y.HUX]"6(21!2A-7IP
MQ^WU@->"@"=W=-P++Z-UPB8 "BF*_IL=;V>#[SHD3A09Q+"P<XUK%.!UWP76
M^F (1R+6DB]@L)?+9$%5J%57_LR>%\:'9$L^LZ<W'?#X^' @P"BI<*/,XCJN
M0Y;%M4W0KN>#^&K@A*WW^IVFX\9C072?)]%H5]+.HU!_*(BN'QI:@NK-6T'M
MAN]CA00!78O4$X<-GR)P;!?O- ;KYJ8"]TM9;J*&Q>UD(>-O('4:&"BP4IME
M/ZV2S4K3:;G'25NP<W;X4J2-:)NQ^\L,8DUH81NH:UA,!3NH"0Y]>?PUP&XJ
M\[=\4[))8*?"_(--UI;]3LOC12V\*^GNN-?'A5NMB_^\_YL!@?]J_%EHQ$MU
M1CIV/#>ZL<IP.5RR'V?%//\P5*H=CXT__KML\FSONMED,5Y<FP'=$)A_E11T
M4<GHQ=:4#2<ZB'UQ9_%VI!QCVSJ$[HN#8'\4RGX900"W9M?OT?3VO3/^PK^S
MA#M]8Y>>U6:%='KY.\U8UW^+K-O146^',8NL6S=I_O&T6:]3M#M%J5;%9F=X
MW*'O!@$4;DB6DL-=EZFNZL1CP^C,]]J):/];08![VKR4]+\VK%_7[U:[RLX'
M0X0P9XTU63WV/!H&C)Z^4G:Y6]*DPNI:&9AL1?7Z+O>I43;8A?.V5X>"F)(Z
M+Y#7&1*7ZAV7KETO! 'I/L^>=Q#::7\>7S&0[.M/M'AG2\*^'H$QY#4#RSRJ
MKF+MW>=LAVKGA/26&,0<MG,>6<_>\CA/\U<>/:8QS=EF^2@!04"^93>4598L
MDP7V^^LF FV6[K!_['XC"%!H01:6.'0SW?(0>'%)@XAXIN[-BH>HJ)(H%?_6
M:"4[S=)]A 8Q-.TR#KO<5]U/C[^)B:T&=QFQE7231]F?#&)&#*?OKLFP/CAZ
M7MTEW.=IL6:K?@MY;S;>-]LSXR\@46;E6Y+2LLHS636C'0C4]6 0R^>A$/YT
M/%/9YC,K,"Q8&*$L";G'O1D$2$4<*'(5C/CM7=_,02^.OQ1W5H@ZS09I>S>(
MN52T$0LT!?*D</ ;I;3^U1,8T<"W\+R.V0S>KE;L?X&[\YI!L4_U$'+'7PFF
MS^4)*&*8;I6=YK+9]WH0ZZ'O;9B'B/&+,*9RSG/X53=-L?/[>;\>!3$I'5[^
M'1%MN]\( M2WJ/@[K2">I(YIY?19-D#=3P<!YLYBGN^RSG4]&RR0FP*-B8OM
M;"F_KTQ^:1"K>S#*O8*"&()C,_)Y183"2-!7IH<Y7;QE"4-] "F EX:#&&(S
MJ$S$>6^O.DH2=#\]OH:@YDSY'MLW%LLS0<Q"I^^F(Z%DU_/CSX0XVQ[R@I/=
M"*,T'H"M*=GU<!!S<YM!Y6<87![$)*GZ[#9 ^[/CSPEG(IKGF!-;PJ[$KN[/
MZ]9T=#P7Q$RXUS^GKZ\%%KIF$\<V\C)9.,LT/+DS04P%OQ:JP+YY]!U"5TPR
M]6EU0V.F_*9@;-A4>;$U'K8-Z@!BQ__4Q,D"D1,I+4MYB>&&A]8'M_/I(.;Z
M8E,R#1)8%%<O@L!,!=)7[*<RB46=176[L<WM"6*"@*^9ROA"PT2"5FSK@=:V
M0T2,;KM^6M L*I+\.2O9WI0L$QK;2=\Z'PQBYB#:8K;4MN2N>Z#UP4#B2R\I
MY.&DX%W\_E=J?%F=#P4Q^M8X0%5X19D.+J,TI?'%5NKCXL%=M#RGB@QB6$!E
M!U]/-P66^400G3[%ACR-\W5EQD\.(&[\XUTS):,=&5, U*]NDB48EKGS(8-
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M7RAO+==U-RT$,6BWJW64%%AQI& 'YSHOV2>_O,N!<.>=QMR=?$"\T"ER@AB
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MO:_]5A#@FF0SMUFC?KO=>KKGI2"@01#4;"DLO-??*R@"P/IVEY16C6O'XT'
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M#!S"BGV]@L##UT]UY*JS1-M+5ELK%D+QC^#1'G&K2DG>EQA)]) 9RJMC7"L
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MTBS$#X5!\7P8H1O]%411\<2(65IW=K05J0^B>14O2(2*<W N5D3( T.WQ;%
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MHIB&G^ 5^#DD+CYWW_TH#T!0U!!I^*R4.BP2(THWE0;+7J*SREG2OT)0!/)
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MH+8S;90NI[.!I/+:W7><C2<%SS#$![^::_EK^A/?:*TXUB3;L(F![$[TF]K
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M,B7IBOF4XQ1$"OK>6>!:M4>Z$A&I/Z@YA5T_?2P;W%6G2A])5-Q'RPMPHYY
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M7GLI")H-\.[(8J#C4S8#A^D7?A8^S[X/<R]*R7]!\SX?#I;<\/8 1/B1M$1
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MFZY.#CAB)INZ%^[MF((D YVALW_(OY!HLZ6RZ]4[_71S%'1;"A!5Y)F\#!*
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ME<66LMU_'3DBQV4EFN'T),@_2TH3=^]U^U'%.?!&8]J^U+,J'N\_"&[*L=Q
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MNRB2TY'-P ;&_/ONOKS:P]-"*B\=OS^32/1(-D%<"3X<\N"-P">KN3_6@1U
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M<W"PF4]GTZ>SZ=/9Y(EJY.CMN_0#^?0^?7J?O.(##F06;TPB@^2CQS1(*!J
MY(ZUWAX2UAD+_N$XP^B6O!7',U'9,$2CG4G0_0W)3 R\D6:WG6=%9\OT7\?M
M0E^O9Q+$=SDDYT&B71B6NY)5N;DE^XR$$2,&X.^+]5.64FY8'+B:]4E+S048
M*AO]MJ'W"B*H=?17X-DQR6^"?<2J-H=<+4P^%MTAW)(\S"+&7(X(Y%AU3E_/
MV;6!F[M8WV2$,J3[((SBB NA<C@J !Z!<V=2<Y1RVJ4!9*E@B^*6-9T+7Y-\
M3V_!.J(70L3+Q&,-,ZOFAQ8)OTZ,8-!Y$<?O_3A&&G?<>3DIR'M\1 Z^/>NV
MOE+);E?NA!OK?W]^C(G>D?8[)**4TK(O'&[XVBY)M@,96GQG!R.<(;#/A:7(
MXPXUC#A "15*7DA8@MYTM<D(8QEB1"IFH'H;OP;?X1Y?IUF6?D3)AHJ5])OB
M,.&=%"[A#-"_4U8.B@F4]I72#V>@LTT_9=&.;43J@1F.0L+F)$(O9R"23<_F
MS>[+]W4)5X+[T3 4&YYX)=W(W@C,#.[)3%NSQ:33GB@_G(QUA=ZT_$C5>M-Q
MT'FE_NHI%TO]O>\-(^AHUE7+JL*QAO=T'V5Y<46Y_XI9.]/IPN#$%=R)'Y6+
M ?R)W29^E$>E>50L$MBW2";1F6KX8 9FZ"Q(PBV17BW%#--: T=0OHL).!6_
MI90,;K/@@ZL[Z,P["R[I%(F!1SD'E9;SD!0D(SGK]=$Q(T]0<D0K(!%EN]MC
M1JW5$\GH6U($&SU'CG0!)$!>!WF4OU"9*5@MDJZ<^+,6B)+IAB]4S1 7ZX9Z
M;K9!MB$C@Y5T++(+%%*\Y93TJ_\'5L_<R]](,>D6299!0F4W098=HF33]+#1
MH*S!%%0G=Y^1?Y8D"0]4NZBC")(FG@!DIRF^*O5:5E^FAD<MDOA0D<VQ2<PM
MZ^*D>J>4*YQ]_Q F 7SH=9\F3T%61$&\R.[+.(:'?K$^BBGS@--?'LGM^QH4
M3"[FG*?&!--\O'T"034G^XK2Z5^[J-S!1U$21OL@KN[]HBRHDI^L*"-X2)C8
M_P\2<(4G(^OB@97J,FFRL@!L9V$LT"ZW](X%ZX(O%9M8UB*D?1&#_KN$1#I@
M!7S11'.JQ1W?)2O*I>C34OWN,IVP9>E<.Q(?E6?:7[TG4H%O-!2#YL_9LVB4
M:02VMX6NSD5;;\ 9M/7:PWT3Y-N;])TDP4@8G#35S8Y_":)W,JS#.6,!:Z:^
MV\K8VE4_Y?8^W@2'C:&J7=05_D$R$5P?WDAO4W84P:[]#J*<P%+,$?22@' 3
M;J&VOZ4XYA,S=K3S"R0!Q0P%I\>08D:37EH6CP6+,K1X8_MQC9[@0]:BQR1"
MO&_1HQ4 >FR*/8[*1 VW]((H0S@;%B+!#VKH%6_,."2T 7@0EHD:2.41CP(Y
MVY>ABP#4,*JSQU0A1^T-'CJ]/8=;%H71PJQRIWN.@PER,E<=$\9F>HX7<3!8
M%R6C@$C44&M)?.*@2;'.Y$U&O9Z,=QH*/)'JM(A!%,/9Q0/OIG@"N8P(YH%^
M"8=O+'ERBA;--TAX@D0>':'!XB60I#K8MWLM^7*=)]#+>-)\\.T2@:E*%Z9,
M=VIC#68L&#>X=&)./89;9G+HQX1["N1D=5P<C>XY!K04\ZEQ[Y[C9(*BKA<G
MC[GC@^F'X%Q/@"GX37()51K"1>&!>R\F9#M@[L-A^E+PS!R8X;=_*;KY)!>%
MB<EV76$VB@VT_!NR"S)P_& &V2PE3$G8P=POQS2G'-L",4-ODR9D^4V8V_28
M9 T"MS]F\ W*4>+$,<_; )W\8LK2SSQOP3.;7PPSU6S@X<\H\<"C$8U$-RM6
M"ESQ!+/2YJS@!9?YQGPZGA6DX=+M=5+TK* !ERYG,!?0"K9PZ3LFLPFMH N7
M*F N'=$*LC *R;H9C580@DMHGI@P:04CN$1E>3JF%03@E)%':9U6?!$(I=]!
M*JD5L!$*MSR=B)O#:@4AN 37.2FR5M""4)!5Y-Y:00,N"56:O>MK?YR'A(XE
MR^ [R2WTQQ'D<7=^=(3I;OHV=YSAG/+.;_#ZU_#'.,L<IWNH; Z2HJK],>ZW
M*BVE.ASEUW;=E]IM2?.J++:, TDH0S 8T>:ER!<.=U>$BNXG+Z+P!O3K[" M
MP<X?:YR;U:\'859^RL:A]UM%LN*JG!JSW)5E+C-H3_]2!]D_TA^)*0G4C^\U
M2>C.1=4S].8B(G^(CIET?]L)R("8>(\Q=!<W# B&IX'*J52:>R948RG)"\G>
MHY \/+](V91J%J+SF?58N#^7'COZ?V46Y:LH!%E;>BZJ688?DFNRB9)EREQ^
M5$E8?J3+;5KF0;*B>UA^4*YZ>(F^BY^42?/=TY36<R(:[; [1EQ6_5_C./T(
MDI JHVM"W[P5T'V>D^)F"S%S#XFT*NWD91 !_)70V[U*XW0340V64E>>E[NJ
MH:TVM+(U'-8W[1]!OM@3<+XGF\<TS[MR6MY(EB+!<\9*/H#=XXBGP]Y?SGA%
M7^U]'*,L*@&<QUU/60[/T=(_*C-K;\//)"=!%FYU3U2QBNV#;'ZHVL.\TU.M
MX>S(7I.,A.DFB?[%=EL_>'FUK6%TG># IJV!#=3VS7\B5"@NJ@=B8 &>!KC6
MBMC0L-P&Q2]I&:\>=OL@+.[6:T*%SW< @U-[\\3%\'"HQRAX P<0/21QQP+5
M+#S@T#^:S^2DJS/3NS*D2M=#Z^L:^P0\*50@*=/ ]1QTW5HC [@G,,N*,TP%
MVH^Z',K$":ECJ^_*Y'L/,$.OX<Q5F8IZ0:I\$[[G&!!XLSH<3NTG\!0%6FQ^
MHG<!-2JTV+_:UR#G"Q=63LX<.OQX,F8Q37ZNMK9[ 34^9EX:?0JYZ,LR%0T7
M4NI*6ZX:R)V8@38L3BF=6Y[C0B583?.;>8J,22*6T,>&N<B-317K*&E@QH"I
MXY_NH_2TRLN)6)$Z,CTM=S());,<GI[6_+"%F(%+U-/R%_J&VI/<JI[6QCB-
M=E0^5T^+8IQ ,DH'KJ?U,2;1R41'KZ\5,4S@1,\C[&MM#!,84CJ+?:V!<1KK
M'3J3?2V!<?(#-/)!^YH\=Y/N=E'!TJ4I#[A)$Y \2!)&YTRF.VYBN(?1P72#
MD'2F&8Z=$O^D,/-.-<59;,55EH'6VIS]-WK2QT^@WD\>,+-7+@WJGKJ*\0.)
MZ8;22MP!M2$*X4*.RG3SSD5KIMGCR;.B<S3T7\=CZ=4 _$+231;LMQ%5@CC9
M-/*QY]UR%=O2W00WJ4$^UEW.)%U[L>X0L2PKE3O6,$%_B=,W>H[)ZA5<VRMV
MROP;J!SN#*G/9!/E1:V"U!7ICEB[/NBA>^HJ2,'M_"G-]IFZRH\%KON<I_L@
MRL#F22HA\"M5(ZG\M%HDS] :(J.O.JMB^YJD;SG)WN%M?TCV9?$,5;V@!@<#
ME9(M,QC'09Y+\6/MYPSS*_K@/Y-U614/A.HB3?4=,<]233&\PQ>246'K^N>G
M,@NW@99LH)IB>(>O>ZJ6)$6#!MZ.AD/<7X,N:4FXN'B\,Q#N_EE"01SFK7A(
MWDE>B E6;X[Q#(UW$J=[5NDVS:E<G><IM&(CJU^B8GM#%P#1:9E%5"_F$<ND
M^<Z.H;E<B[<XVC!N)< ]9Z"S35^7.=4M\YQJ=6]1PC;3ZG04V4D>K4CUJ#6V
MDH, JCDK^1FP/D&];VW<2D4;=5"2.@ACIO+=P8^>WHL:3<I^H4I]N"V>+]9"
M,6- +T9#T^C4B][BJ[68<:&9 R+3U[L8F'S!4.-&T;M198-IV8;4NH : UK4
M,=/PT*6;R=JM)UB31<>>'VT7$W)NVRK0WEREGNTY(F=:E8Y=:55:OJ?XF2U!
MCXP*J!&@Q=Z5MH<N1[)W,S&'/%N3*"6XQXP/)"Q<T_3D*29G\ZAIAB[,L>;&
M[YU"_<6,"\.4(K,78@ZTM\:*)XOKF+%DB5AFV6D1!'&-;-(,282L=C^Q'EUY
M1(GB+BEW[>XIVYP;CC4KX.,I2U=ER(PJ=<(LWY$I'^O,@%\;2J7.GOZ8J4=/
M>718QH'5 +[V90!23N-H!6_F=1!#&L[+EA N370VQKW9_)L+NVIO[Q]^__L_
MME<W+W=54.!O([H9@9V;R51UC0+>1055%FXV_3\0CMZ#F%GLVA:/3#+KZAL?
M)-IL"R;7*%F9"X@[,;) ]D4:_KI-8[K[O!+^>$C@C?(28LE!7X4A),?E],5B
M)HQFI#]P5K3,?Y'I>QR%] X"'7^C:H%_T'5CNSL C(%]3),-])5Z3(.D.4U/
M >6"Q\>#/_#IL1QZ'<L=;(UJNL669%10VF=D"Q+&>]U2!1+0KMZ#*(83OD^S
M%\J;7T GKIC;ZG_+2GW]1HK%>AE\]PE)PG=I[%VE>CZ)WGM4_C-^ .<\0[V;
MX26H6@<J>($\@%3\ C5,N6-4\@DP[<?GF!T+:7RM[L;AU'Y!K;B.'M*J'LL!
M]3Y-V-B^I.\!A$K=YI;LTSQB9LWNP*.Y#3N$>I+]+<GH^PCID1**]0!:,7=E
M$E+U-8?3> ":DK]6KV2PCXH@KE@K&,^J<4]I5EE;_8%7C_D\974:)X?_> "D
MDO_TU=*NZ18[:'J,1R ,#%F/!_"*60__[?  )+TK^ SYQ E9W0590@\R[ZBE
MMV0=A9%7,"MO).O0'#5IXU0QZ[PLPS/^-_SP:EO^LI*L^AHI YRG<'H MOBV
M/F4IY4G%X2D.F,,*"']?VTA\@E#3AM16"'BB1/V0U/)#1Z;W"6;EY7W94D%(
MI&3_"3^ .G:2GL2W6'<E0I] E8CR/9GA&<!8K%_S*OAG+HAG*MC (]!A.8;>
M&'<M3_6\>EP0].8Z="#K&59'/F7%-(?-'#5!P+1I,2\3X]WYK1"Y0/DWF3_8
M,?>1LAV7-0E$#ECN=H7#,="S<O?\L>ZVSO4'\W?.&XH!YVI,.^4:YCVU(I9C
M_)=LUGOJ>F9[ $F'VMR1E+,KASN_PCW%1GJ#NR.=;5O#&<@%0CW/G> \\H?Q
M9>3A,(<=^K@^+NZN^6,=;EWFMQ) ()GB[A[PW5-\VN>.-<T3%8XD#EN4SW!7
MI(3G(N(BEC<2B3RL)06C8^/RFZB8Y!#S:H>&X#24$UW> K7;0G0KE#-=2M8Z
MC@F1K*PQU^&)R1P1@J.23'%W1AH^!OX!J2>Z,[EQ/0E\HQMOJ.GG6FKUYSS6
MLO%(GI&195_C%1G.&6?^#')[T*3^M!_FBW4-$W3=P>&,J=LKWM,/(0<O"\*"
MI?>6>9'N2';W/8S+%3T#0#K]WZICH!CX5D-"5CFL4V=HW1.25YH]X'4<??Y;
MK/ZIENZ.5A5^=,0,S/D3A-]BH18/N#AX(3'];/.%)'0PE"ZZ6NVBI$Z ?2=M
M!7Y_P*9Z5]H__T$K^U&/TFY;#AZ5_^[WO\<**RGD),Z]"9RSQ NB%A4W+7HH
M_7:*'@P/]6<O )Y(OXW84@UMZ-DWF%5T+$&*5X!JODP<HA\'SJ)F3%.(F.EU
MZA/^P^03/I=-8K8 -C)23%_)I0XL%QA%:K!TEGO]9GPS15I-9Z3[;0^?1]&F
MVW'NU'--D9.OL.M-=@:<DO$-X!&/=P;"2";F;GPXRAW&>;+#$,N],2[]!C(Q
M5>1&D,QQ2"0BP5- +8+A;KUZ4V^K8I*?%BU!' H2\Q9G=\,XFYZBT.<&7JFZ
M$T$5!1%!T\T@AI:;?TUC$!>_!%$"Z%@DG5BB+,KI5[<E5&"LNKB."DU,5ZG.
M%L6APM,XH$,XX_/ATF265DA-S&9M_)RG##K(M_=Q^H&%)5-TLA+96?H>4?BO
M#Z]4%WU(6A7C"IKY"NLNT&GKJ/"1/5.8!VD3_1@/*J+U/^B,Y#?*IO^N-'JJ
MVF^AJB2T/Z[:(0L>-VW$>X5: 6"5U*BFJ+H(]S*]"BG&,R+TM7MHW^?AY3Y*
M@B34N6FMK>4ASTLH7\C$O5'^H ]NG5E,IZZ#3!^2L"HDS>XH"_LY1E-[9D-&
MRX>XU]4KU)[(ASKW#2+W%^NO0;B-$I(=N$S(@R(\)S*@FC'?IUD7-W6@\B*!
M1!4>-M &%IPF^4!0&V'[W4%LS[^"*KX'VL6S7#1*)$\9V47E+N?E0'OB^D'+
MGKA$ZT\]&L,RDC3=WA-2,R<>,7$(Q,5+( D=F0BR$^C4?H3>T./ZQQ_PT:;<
MZ6M0@"WAL%B+<_$N T=S;\J"@9???2=9&.6=Z$ /J@B=<&FJ4.>_1<FJ\5]<
M'?\$YWV64SAY15F\HPQ-D>:8L74TQ1T_^\:O^>'ADZ*)CI=MD)%KRDE78+VD
MO#2H,K)J'/S[#T 1C8L,7A=^',]__ B4,!9AZUR=VSJ/C9NST^+H/R\91XR7
MCA&D*@O^YTM]6\0T,ZA2<M25O3;KSD8'+RBNTV"H08[7MJ93:$60,G<4\GD5
MZ+&&54['S]AWJKN RR#*UAG&!:(SP&FYL?-;=#AUR\ZX"6QD+]%F]<B>MX [
MLI_@L>-?"_T%L)VD1.?6.TG> BBBP 4^1A%?4\PSG(6K=@+V]JDW!P7:I:XF
M)?)ELYWS![GC2,H9I%.=UD28XP+B@CIS,>>GJO!!Z#%\HYG[9N]CQY>@OG['
MP889GMS"/V9VTO$X$#O%/*_%^'17PP$^W_*N1V*C>8:I3=,T/B8[O8D(JI@)
M#=S< U#/<U@>A6^DYL(A&.P\;8-C7N;N7SS>8>K,/-,P%[Z9BQF^_1.,N6,.
MH#\9T9&-++.:IS.<AP@DA755$T#Y*HC G6HOU3_@*<NBS$@ #2).\S(C3 C,
M7\"<G5$1Z;ZDPA+Y&B71KMRQ[QJY_)7^;M:7'?-;J+D7(TE:@+*7A CJ&C90
MW);< @6Z<_]!@FSYD?H45CT'+8QKZTZ\6E-1;H@8#R)?ST$OW^B%77Z0^)U\
MI5QS.SOV[$QEK"=B9%C;6G<Z>@!;:CX)SF85PZ+8O'LYELIFK8/^Z,8W[J0S
M'"V'[3GOO.14!6V*WSZ1C.EUH-*516TVI$I>%$*5@2@NBV.A7)C7C$?UH/=2
M8UO;S3+M^!#J;CH,,D&@N+?)XK^P+9+5U3LET@WY5N[>J "VKD^/'5>^*(N\
M"!)P<?+ %RPQFEOC[T=##Y/MX::W96W9K*NBR*(W>FT8M1WM(S5;N,HR<"6+
M>\0CB[&8<X=D2>H:J^  5P<8=UN=2;\#8*:N@@U<$2N: JQ@#;>6B!/9BM@6
M<=K"V,27@36B"?(8E$\7?(Q*6M&I&*_5ZO9+YI^L,A7X7G.&8P@&_3LF=2Q&
MU^6M3O?_>7HX]6<C 3. U/0Z#91J$H:><"?2GRANP\SRR-GU?1!EK%//5ZH_
ME]7;E+^$6[(J(>:H_3JG?U<Q;4%<^:<HE!TC>3U]=56T4U#Q]LY6CQMLL2!/
MF^*%9/O!U*N3T@28WW68._ERD2!-N<:J(NH1M[BS)V\2@F@.M6N//]9Q@V#]
M(Q"/=YI'H,D$N"#IS[^$UD/^O.B-=U@<0(?JN1YN\Y:\%9WR@97D!?%.>0&F
M GXI%_D:1P&/2;+'NH40#'9-UFE&!,UD,&=[ND0<6./&B/,CT\\&WKIWJ[L:
M^FX)<Y$Q?-ZF+H,58%U6,0<+FFM[AYH!,S"*FO[::% CON]:T NG(Q<X^@U.
MVU"ZND5B)>,>+0HZHU&)(A,ZO_:-PVS:0T)1!(ESGKV',Z$^)@4T <'MX-EO
MGD?@LU']N4/X_X3TS;_0!L?C:RB#X3C,>6<7S@T2>!1%X]WF?PAN 1<&R03D
M;U\=22YXS3I&J>,#J#T%U2LXJ5%X&X!<S[JAGT8AN+SS#C/QRX@\%?YFXMUN
M'Z<'0NK$],[H(2+\$ QF(Z*>",522)XSF*"KG)_RP6PL5&_C:/80"],K5IXO
M-UX;;DXJO'JNX5!K*0?J;5,YW!G2-5@(%^'J>:[I2,@,9 0DFN16WI'<:;',
M(YZ$7.Z!"AUU>F3K6JBS]".(%7C*HB2,]D&\>(NC#=M5E7[VF"8;<*B B0.5
M@ ,0#3-%^^$ ;P55#XJL9&V @BP[0'F?'62*>B;+R$$9@]X]L^,A/U-Q_5!W
M/VJ/^R$1YDOY@1L1&52O0V.R!@,D8""HZIRL #.0P.ZE1&>5'&19A7A1HF(&
MKTG0D +#7ET<2](-&[//T#X!T(?VE![A&$F@^_WITCM."*MC[H^;73C]3*%0
M'*"&@4_=(0[#G-27;A3M))GB$.,G20>"(SIE3=,JI.ZKSU$G-:?Z<7B*G.HY
M2SD#7/6"<T%43/+H%*L'V= YLL50<'RYRLT;Z?S,M!XLSE#D!H(J/W,9?.^Z
M/IY)2'E>%$=U.CNKF@N&G/LTZTRH4MXAEP Z[)84]X=[0J4.(+AZ$%2!7J:"
M^:CL"E6MZK8]<KUWJ, 4)25]ONL"!FG"]QYP9_?Q>%74V&FQU1OLF0)N'U^L
M;3-DK]!['7?(QC,=U3ZBZ(<W5%:)_&LZ9Q\W5'BC_+*DPR@S]K,GFWTDW;"*
M_0])4^>0#JK"0B ^O0(VCM./7GB4'QVY[..N\@^T9<QS] %$TU$R=%?I+X ,
MR(GO\03HIZV,&BWB9W<V/H1+HD9$]UF=#7IG$=3 \M_)V6!SET.-@$EOX&R\
M3/D5U.@:/WNS<3):RA^5&33@-*FL+9TC1:78CDA-4"AD-,['ZB@B(#3 /58H
MI#.8T7Z=9A]!MO(>![H'+I'V9Q1]00&Z_O%#L?<T)#ET0B/T-R$[^I:\DS@5
MEK_Q&A%U4Z;!L)M@'Q55\A85VK+B==_&/4.(G6>^80-8X%-#'QE^F!%.N!O-
M!]7+YYD)X 2XV5/>:_W0;=Q!2>*:)&1-97M^9P^@DA/, =XC"^Y.]L["AUD
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M"[3*82@/]CI*"P@"3N-T4R6, #]]?!J82!6C4()6=Z!@\21UAXE1,()H $J
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M7W@,X"2"E0@K.UYX,J*-CB;JGVG6M#-YI(L?[)I?P[N:2Y*UYI3EYH9[\';
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M<^9V=PH_8&G& Q=GA&I!*[Q&L>84%PB-,<VT_GB4MN<9VCF>H2UKF>Y*;.Z
M BY#@@X$MA=2.+<!'*, )4R1P7/8?B@$T$O(/"(S3YT]/FJY4]^%3EB,"+N<
M1158O'0NB8=\CPQ@QS8;4$>5M;K#C6U;.6R]"_(3)!1U50"I!TZTJ#9P>9D)
MTU_-2>-"(O4Z@<!% N?6P ^IF01;^GN2Y1$+&*SB+A9V@J\VN;575+6ET:O9
MG:)OM'IV"&MT/'J5+E?#P].+;]&@[3G,-C)HFPTN.V;6/FJZ<HLK:KZ^]W7
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M7N849VPPF_>1M3ZR]I)2[+BO:]A(BL6B.QADZL_W>9&$XJOW:2I . 2R+*(
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M4<[+#-:(,P>ZWY>Z&!YF B/%OC>.J',P=[V%!P[B,H_N8>+7DY;GM>]!$AT
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MWV],=:K<19,HCUNPIG<)O"(/Y@5Z&L$H1*L7I[!$H/ ?8/KBJS=/06%REY\
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M(VJKJ9(UZHGW2+@BMYFZ21K ;S*L^U%[TVZW, 7I:NJK\,P(*MV)$LPT*TH
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M@BP>C;J<#KZ.T<$V(]0:OFO."'&,L(%&9>15<%\'UP^V\S83)#F!8/9& P6
M,;L3A8$DIILE%[3TC!P24X0+Z,4*(/\)7G7"CC5]R;7,R]^ON+O+Y!T*OPV%
MF['+<9@LI*ID)5E7C(AMDJBM$@S&I<7,W\>6\N6-5\[3Q#0'Y"@/F#5WL \;
MH]*$<';:O?GD4.(XS+(MRJ#?Z$_>Z'6ER2THR2-4;\:FM90/2+VQF#B*^(;P
MW;>_1LPCXHNODCG2%FN\TRH)K^Y)57!I&GNH[1N&Z+E%BP9J,R!T_5[="<TD
MN9^:3R+4_;4401U_(+_.HXSK#B*WBZ5Q1PU9=VYX.PPW5MH^R5JO2QH[5PO&
M989(((!MN2)9ME);$+'>ZO/Y?$E16Z]ZC8)#9*JZ=55?IWYXO,R2^/LNP;C/
MR^OT"3.;QN>)TQZLR*Z9^.+T4:O-444N<S$S!&$B;^<S>Y#9CDN1+5I_WSTB
M]#NG'+W=W)-RY(EM9M3(<"P?'"E28!8ABGDN<Y[*.%1=!IO=NY<(_YQH76B0
MMGP65=H;GJ'F)"JFC:H9XWIOG\E7R!,B$8-/Z.I%G6UQ]6-&GU3&XQOM:Z6
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M9S)WAG"'K?R $.X3;^]RL&D[!PV4M8BL>YCNWH\\8$OK3)$O(YUF%[(>':7
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M.IISO,1KFS52C:H;)FAT1Q=6LWE5S6D&)2@I#,KV@ MAM@ZB@:L.O=_GS!V
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M41"!<BARK8(HYPE::^E.]%D+$E*L0@_.NJ@>GW1ZZAH -VM?-0^M8UTEW]D
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MGVA5V0?COCZY.O'T]53_V<X00VQ_%;9A #D$?=0_S<9 $/]*]L622('J_:V
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M45D;B@- VEED)+<R'Z 1A9G"Q !3VI;01RB>T-.,AM(JK8IX.N"I::EYCKI
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ME (5=D^?)>2S4N-:D+1SIE&.&7_+2CI;&5KU]:LKMBJV>MG$?Z=#JD_ 0=*
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M.#W[O2LN/@Z&@P]GP\'ZU-,NTC#XF*M(9@&15VVOG)9%"=+/+$NG*H>V\)V
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M-/P(S+VE_5&9PQG-H:,Q*C:Y64?#W4$(N(*5B;IBDE[+*YDA\P\*IVN<V2Q
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M8U6)ID0Y)61X;SMR?)KT9&X]+BK)2ZT3XBJ@MX=< C!<4GPYI# C9<WM<4G
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M]/6-'DYO/*EY?%)SL(6DYC05QV4C6LL$6[[7=M>U:O2UXCE54,(MI7/PP2I
M [-:IR56KXVQ!*U!5$ 5-S!X&EU3C0GT:\[&9<*V )+9B$BUY2=;T>7A3DV6
M#<N+42Y9N].L]U8\ZQ#]^MF&7,7^\.+DZ-- O%Q.\'T2R6,<O^>41/*+.V^?
M1/)X221WHF<'ZR?B*PXM?NIXF(VBX!>#X>>3T_[%R=FI^/WDXJ,XZG\]'XBS
MH7C_A_CM[-/7TXO^\ \Q')R?_,J/O1-G%Q\'0S$\^?7CQ;GHGQZ+]X/3P8>3
MB_/[\,?]GTTJ\,:5S=5X7O:VTK;BA&2C/>*(8(+JT'EKSD->Q%XU<>12(^TO
M@EE7%I.%*!,[2UU*AX#D;-A):T9>'?/<U(NMX'[J'LDJ%%Q'@=L VJHVE_6?
M=LG$;>U#73<XIQ&[U$\24-G$>PS^/@]B#.*R+7.8SFW@OLY>&SB+LC E6A&&
M$2;;Z7*@#,X8BYE:5Z=U?U8/+F80Y.@J(+V.PE3"CH5UQT G6C9C/JO5D:W5
M?Z5(-.BAM<JW@U]4B[5!&"IX$Q;V,@NFB(N49>C5M*US[[:NN%.=7$<?.9CN
MC2S+."!'Z2R%SN8=W#$;/E8[@+#U6"+-8N)S,-<=YGL]8?!.<G<0D%.H8%!%
M5S\3*MSM6NTT':#4MK?;45;MC&:\?J.*4VSB@X&KP8 ^-F>,1926HV(1_:96
M <%U3E%-^_KDG-  =LK)CG KTYC$D7E%<98</L%.NUM3<&9N%>[V!!Q+!Q]D
M>%FU"6)+12PO73VZ=+6-YF17N@*9ZC>+]#>4.6RM_:'.15Q.Y#Z(-_971-<=
M$O9?9YUR&47((J6JT NS^IP:L,(JY]"HFV;TXU)7D_W>)GEMM7!E9:M:*'!=
MQEHF9YIX^#IC^ME8WJH/Y(-8XZ'GC)XS/@5G/-Q"SLC48LBJ$I*/]2L"E$$U
MP<",A=PH6W[! A-3)%V;B(WMJ:3D(F3 M8HRDY5*9["3D5!I]0]TO#0I&8H:
M-<0KQXFZH-02250,K#G+@A!QH!VG;Z/D :XK4K1FIA/B$E>:Y%_ ^."PN3B:
M\#*O!.=XZ-G6]$\=X\S!W7H;\T8?Q#"8TB]HWPMVF9:4><>'O=^U?[[H6@;X
MLK=?8X@@)3)F93N^:0ORI0$W-7R)@^1ARZYT$0G#SXA/UJI$JEK3)G/,88L5
MC\-]U)LW[]J-TPP:M[9IC @*+F]A8\)- 9\;4$ 7L!I:K"=LD;AM-#[ J,W3
MX%+X7=!\#X 9&;<?N4CU=\_1U6.<]:_\XOWXXAT//IR<GJ#_ZSY>KL>^;$_#
M?+\R:,QBFN%BH'HS;;FH5?ZDG%'%MFA;J0T&<A__X7-)3_0B_'I%^%=/XSI<
MA9U\PYT*[],@B];O2R#T*0;PI!$AV3JF.+4T:SJ>?-SCG2C4RQ=O;HAPV%]M
M@,/AFU\\E7*HU"M<(*133V*$?P9TBAQOFT*GNMIX6I4(;!2B;-@5VC+_WHJ=
MH(.I<9,T <V9TUFLIQLTS/:"M+9%DP*M(N/J)C5X/%:Q<FL35\4<ZV^\$XBF
MAP@P*L_UD DP+U)A84LHH?$_$&,9I]P&&^/A;W@KDK@8^"6%Q%.&#BP ZOT9
MCB,45RK5J",=+MM$A8>G*19=+D! 546).>\1JO\@E]K%H*[&65!&E6N^&EBW
MAH4#D\RE%7>[%L8P2)RYD$5H1/O$9;TF,LBTQ:DJI@7/A#(B\Y-C/F=;$#4'
M4G+0J.:,ZVS;MO6WG)Y:ZS^FXS%ESX-<CM!A'=B,L(.EE4&B3^0ED%"$Y>E2
M/OJXC'&UX2QB*3'>(]A&2M;D(3SV.8DZ,$J8,TX>0WMI KQNK9@P;EFORJ1C
M35EM4$(&9&WI,,C$Q*$>,"0Z=!T&G\$/<'*"$=52Z_E2"CX*_M'9P9O6D&T?
M!;^64@I/)\INK@SW>X,%A#$Q'R#=KE?:U";&VIB)*8I):%?B<&_7A4&U4"_0
M%#)$XEI,^[LB3>)Y U'.^1WX7L*UP6SY9'36A[H6#N+<:20;! T@D#2-0LRV
M=AI!S^4-R#BTHX$@Z6HL"-9@K%"V!^Z$M307PQV6\Y0:'AP,Q0R,O2O%0Z$*
MGHVJZ8UAZS6&/8D_^SDHF4T7X:8HG$3'&/*9%0."+\2:P4BP,G@B" TZ%?]D
MX5XR&3/@>O54WK7R>\)%D=/,*@*58X!<]_G;!UG;G@<%]'A6FUCXXH$.6K@>
MH%^7:*L F82"+2EF@00)4-7+V2W5$_8/47.&A_=?T!]\O^#7,E-4>'I@<.2H
M!/I8[+\Y?,'I+5,NH+T=>0FU:7RAI5H_W>Q@)@@"PFC:>9T@1 ,K_;&U=/&G
M+L-BV7UIF$0RB4$PN/=LO)(<:#Q6XX($9G2-BYV7>W^W>PS]C@B']RJEEV;I
M-:,(.\TZ.0:85)66A<6A=H=2!3:/YN)*946IPUFF,KO$*2'L5AH[Z(2F)+Q#
M\!>AK@NW-'KWAN@8+1QK9&LLJX9<B.R"*4?+:+!'BHD-_RI5KHQ=;/F2ZK*^
M2M<P@><)P =#B-*LV[!0%5SRHVZK:SET.A0I),#IO'VMG2$1GVSPSIO99A7K
M-,L4T&DXEP1BK:YPF&.5!$E(B^LT:F*B'26$;*BP9UAC LXH*6KX2 P,-\:^
MZ;#F$S7C]"B]6&TSWL'WMH)(G.O@[(VA#Q0^)R,^)Y&.:$88:;[0P25N"IPC
MQ)XRQ]>]I/IJ.P>J4=P:_YZ5&6Q:[@0H-J[(8BN-B$2JL&UN;%(25"M>K4F
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MJ:/ZAP[X+[TW*];NUWK*3PRD%&4X9U,Q14PH&)?.0ZA*QQ\MK=RT8^-W,8-
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M(HR79G\65/0(A_:QA#F;0_:)X#T;SW\&YAN$$SC&!3S2[.Y+A@<;&'7[R^=
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M0*-+QBU"8R5^8D$H(D6YZH74=1F_M,AA..UM)>.Z["H_*-O;4B*TVL8^X[V
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MOIQUS7U;.]F$@XA1OQXQJ"E>ZY(F-)IL-'E?]AKM59F].FBO-'E')<N<4QI
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MKH^QQO%T:<IE^;R=^EQ;:V6GSQ=A>+L4.X>NVVLJ)8H]$\4N@/GDE/H^O?5
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M<]NV$G[OKT";26O/B++D2YI0;F;<Q)GQG.EETCR<5Y!8BC@& 18 =>FO[RY
M2K(LQXJ=G"B)/&/+)!>+Q>ZWBP\@=%[Z2KW\CIV7P 5^LG,OO8*7E_]-3H;]
MX?E1O$2!HU;B/#-BSIR?*_CEAXK;L=0IXXTWW\NJ-M9S[4<U%T+J<<J>U[/1
M#T&MD).N4?LT\:9.!_TSJ4>5U$D)<ESZ=(B7F9DE3OY#&C)C!=@$[Z">\[I3
M41CM2032X:#VHVA&5#@*SPI>235/W\D*'/L=INRMJ;CN!#/CO:E0UL/,)US)
ML4XM=4^=4/NNG]PH8],G@_ SFI;20^)JGD-:6TBFEM>QNVDT/C-*C-9L>Z\Y
M:,M4"E^FA?1)CI*@R8;+62DSZ5D, 6EX>7Y4XR]Z,7AS"T<\NZ_ONUV1HQ5@
M=\07KR[?OKMZ<_7JXMW5'[__U7EC!PQC*Y'9,B;#XX<'14'Q8'@^;J!7/?:;
MS$L.BEWTV6_@_QF#[;$<K)?%G/F2^_0Q<?E$80B^DUJ@6'K:/SLY>;K>W<?)
MEL\7F&&?7;&23X!9F$B8@L!@2,<NM&ZX8F^!ZC$SFKTQMF+#0?(?9@KVUUP+
M/F-_EMQ6:%'C9<Z5Z[$KG?='7WH<O\P,.^ZS7[G#\&&LJCF[UF:J0(RA%^-I
M8R"%067:>$8-N=2,ZSEKM+<-H+G<0X7:*,*<57AE)6*@X#G>LLQ4.)UX$^5N
M"6C(P3ENYR12\6O ?E=T.KPGT!CL4E$)I3Y(()<V;RH4T]@<+<&9FJ&+\I*Y
MAOXLVT_!0JN$!E!)IY!-X 3/IM*7.$!70QX,)+TUFF8$#G."S03+YJMNV$/T
MLT#TY#T0!59(C2 @/"V#WD-\HC@^MBO/I2ZP&'$O48_4N6H$ZD1@K42XAZ"4
M5LT9VN\(T@1UI9:8;>'BUKI&8X4DQ3V2:!0*(% -HBETYX(].7<E*Y29N@[%
M%L;2>8N\E7&Z&>U&*WLK8'2=,;>LW>/QL^#QM,_>W0C>CT]FQX/ABY%K(=?2
M$ZHQIB@D7AZXPQ#:*\8M!! A*&2F@(+- )&;*>E*:D%B%998*K-T+:3+E7$-
MMB,3K%$13;4U.0B\[=@!@D< HC$BY'*&C$F/@5U@77O;*)08GO!D>'8 T8KA
MF8A7\5(2Y=81Q:2?4?%; 7<$&]FRUA%T'5$AMZL=%3<Z*K C&N<ZY%&"*,0N
M,K@6> 2R#L8WD?WSZ8NOCM0=\$/V&AP:@?$-\^C]X.O1%)_SQFW?A.;:#!!(
M;4]Q]C:-1058\B;2A4**4J"#'J+YRQ*\6L8M*!Z0V4[?2W3UVA)/#R668[3%
M&24%]\'0S$DAN94T !E)1IA8-&EJ'$W\(9==8 FA[!H':)#',D^-:HXID3>*
MTVR!PPI&+ D$MHAT9)5%X7\9D" &#=N#V,4"_FTB/UM'_M9%\58";%].M\X#
MS)V)% 1O[HSF-&]PAZE![)<PSZWH\(<9(7DFE?1S8AF;NJ5L#% -*(R)=$-T
MA3V'Z6G6#JAN;(U9X (KRG-C13 @\.@Q:"0["I,!GT!-648BN$:(@,=LE#7.
M$*,][E9QEQ^RRPE732A+%!0H"N27<H+N=!MXXI)J;%%GX^5F[AAPA@VQ1KK(
M4#/3^+M-V&8FX MI(/I=W+^B8EE'[$/J0'0%VC,BY?OJN",H%5@=8_QOXXAV
M EH:&)YL1NL'%$6:[$V>-Y;@LC*S;E);&8?,$VC7&)6Y'#7]W>#,C+H/[FI3
M(/*Q8*V)M[;C&@W"/@9M<82MK&C98;2KY&Y!1*C4A4P!$>: X)*V/L^9DM>@
MVDV--?G>X[VTJ^GQ#:S^SAZS^@L[IJ)+I=ZR_%$U7@7SLA(2&C^ C-PBPDOS
M.+)A;ZQ;$(!P W56E?0>X'VS36:08Y" D&AAT'* F,?B[FCRP$\BY5VJPM^-
MQ &$K&QT'K9 #O?+O!U!,"WS+A32/#1#(D!I+4ZK^EP"PJGE#8OEUA3X-1&!
M2/L"%0B$-6SM=AM<'P32=F44=T(V%$PNL*&#1;V\&] MS\4V"$JDH[U(1QQR
M$==4Z'ST4QA-.U=MW O<U5KZ;6(3%V(7R"@*B\6IATB!4%,1:V'SO@5E+\[&
M4D^,F@!-R9J/VW<0MBW#4-7*S &?3DL3"R^_ 7F$Z,>A+/T=!,_7-NN^QLBG
M[ UDMJ%W1<<_]]CQX/CTB_+\@\^'/-[M]\9\RU'ZL/>PH4#1*9Q1>V*&S* #
M-#@&$D\4G^/2$C7/0(QB+Z>#_N!I)X]#4;QVD+JX'P'QW [V9KNN:"\D%ONT
MDVZ%4$IT4E'W\_[@V5-RUY$7=X@,[WG^8M!_<7I#!O^QZT9UQX8HS!G/K\?6
M-%HD;62*\+,Y,E,<>)+AY'>=AK\)W=@PH)O'E09T0&E"[!(7+BTT\$EWY"D)
MQX@ZN8UG:G;Q$--=T/MUGMXX?[0A6(]PSR=VQ@,S=ILT?(0G%B?:HL']LQJ-
MHTWQK\%'1^YHPUFA38[;Y_+_.Y<_$GZ_ I3N/=%Y8I^K^US=;83N/;$X"%U*
M*-CE#/*&W@NQ/^*^YCYA]PF[2S#=>V*QC?9G?.'.U>VL/7Q?VN(GK=D_Q9;&
M<VQZSX@_U6;-CT^&SP;K)P]6OA94*)@E\<V&-)JV&)I*CX1TM>+SE)XN0+%<
M/-W^\M#_&D=O?KJ.0\,$M/@\WRIZB(.':P[^Z17JRJS\J>>X=HD#*XOMO;S\
MTE!IERDXAEC1$UY@M4VYFO*Y"S7]_(B^X/7RN_.C\-6P?P%02P,$%     @
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M^IS NUC"?)(0,*8F"XZN'!R)J!N@6> O 5DQ,/3:3X3(.273\TJ=FPFL,!G
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M8(@T3F#GI8H?1@YJ[\XZ0F?TF*T/]DAYGU7W53:8$42C\UR:XP%YOZ_AV4D
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MUM.*[\6[YX.R37ON[S^X_QYLZ'O#^=.';4-3=O+7&M'G=V]$;^74[I@XN5J
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M-S$W-3 V.%\S+FIP9U!+ 0(4 Q0    ( ">$6UC9![%W'9D  #O3   2
M          "  9@V!0!I;6<R,#<Q-S4P-CA?-"YJ<&=02P$"% ,4    "  G
MA%M8YV+;K#"B P!O/2L $0              @ 'ESP4 <VYD>"TR,#(S,3(S
M,2YH=&U02P$"% ,4    "  GA%M8 )]U*6>\ 0 CKQD $0
M@ %$<@D <VYD>"TR,#(S,3(S,2YX<V102P$"% ,4    "  GA%M88S&]'RJ*
M  "&3 4 $               @ ':+@L <VYD>"UE>#$P7S$V+FAT;5!+ 0(4
M Q0    ( ">$6U@LOM??*@@  'MM   0              "  3*Y"P!S;F1X
M+65X,3!?,C N:'1M4$L! A0#%     @ )X1;6%ERG8R#60  HZ,# !
M         ( !BL$+ '-N9'@M97@Q,%\R,BYH=&U02P$"% ,4    "  GA%M8
M:9-9*"H(  !T;0  $               @ $[&PP <VYD>"UE>#$P7S(S+FAT
M;5!+ 0(4 Q0    ( ">$6UBQV45V$0@  $QL   0              "  9,C
M# !S;F1X+65X,3!?,C4N:'1M4$L! A0#%     @ )X1;6/1#K-,'"   -6P
M !               ( !TBL, '-N9'@M97@Q,%\R-RYH=&U02P$"% ,4
M"  GA%M8.-_F?QP(  !K;   $               @ $'- P <VYD>"UE>#$P
M7S,P+FAT;5!+ 0(4 Q0    ( ">$6UA4T$5&%@<   0Y   0
M  "  5$\# !S;F1X+65X,3!?,S$N:'1M4$L! A0#%     @ )X1;6!H]]-,S
M P  D!    \              ( !E4,, '-N9'@M97@R,U\Q+FAT;5!+ 0(4
M Q0    ( ">$6UBR+0Y.#P@  "$V   /              "  ?5&# !S;F1X
M+65X,S%?,2YH=&U02P$"% ,4    "  GA%M8)1L+JOH'   2-@  #P
M        @ $Q3PP <VYD>"UE>#,Q7S(N:'1M4$L! A0#%     @ )X1;6"<L
M-4E[!@  QS4   \              ( !6%<, '-N9'@M97@S,E\Q+FAT;5!+
M 0(4 Q0    ( ">$6UCV3O2%\!$  .!S   .              "  0!># !S
M;F1X+65X-%\S+FAT;5!+ 0(4 Q0    ( ">$6UAKR\-.Q1D  %/)   -
M          "  1QP# !S;F1X+65X.3<N:'1M4$L%!@     5 !4 &04   R*
$#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>sndx-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sndx="http://www.syndax.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sndx-20231231.xsd" xlink:type="simple"/>
    <context id="C_9f8d8621-1769-4079-8f0b-99e55c437b8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:AtTheMarketStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_baf118b0-3cb5-42c6-83f0-5fe1ec439d64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">sndx:SeriesB1PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-04-30</instant>
        </period>
    </context>
    <context id="C_6e282358-b6f3-4650-be0c-94030a98bc79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ddd4ae65-26c4-4c11-8b88-b2c7bac6eacb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4373a863-e88a-4778-ad8a-e38be55f38f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sndx:CowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_af3f7b3f-463f-4a43-9924-f3224ae76c2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0733728d-ca28-4bce-89bd-0ce117dade3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_2fde2bde-fcd6-4136-938c-690acb7faf69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">sndx:HerculesCapitalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sndx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-23</startDate>
            <endDate>2022-09-23</endDate>
        </period>
    </context>
    <context id="C_e9760b9c-06c7-4dcd-b0bf-ccb9fd1298a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fd52ffb1-9775-4773-a4a5-24f8f2743b17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_626a678f-9c61-4d24-8cc1-62a2dcd3abf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-12</instant>
        </period>
    </context>
    <context id="C_a5804989-e5d4-4066-86ae-9576d589c5cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_707b5fb4-b3b3-44e7-845a-f9f779873732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_220ba3e8-b19e-4dfb-b2aa-b75c2caad42b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_29366536-a819-434b-97a9-ff39b709d103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-12-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="C_38a4d3d9-61d6-470e-85bb-48eeea883916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:EquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_43d48b69-d64f-4673-aae8-70b5559a6dd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b2cdaf15-a3dd-4128-b806-5785e9adeb08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sndx:CowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_f8419044-984d-4ea5-bd39-f4268be140ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="C_75ddf898-7154-4fbc-bbc2-0484c10d01f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2023-04-12</instant>
        </period>
    </context>
    <context id="C_bc34cf4d-0ad9-4ca8-abcc-8a189f682e20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-03-31</instant>
        </period>
    </context>
    <context id="C_76ed7aa3-1ed8-4f3a-a48f-60eaa77cb270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-17</startDate>
            <endDate>2021-08-17</endDate>
        </period>
    </context>
    <context id="C_02ca18d5-fa6f-4bfb-a876-c093b9ca6330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_9c35cea5-4932-446f-bd97-79a9161a45c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_66e29f85-4ac7-49ec-9bd3-2f763f1d6dfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_3c1506a9-4d8e-4770-b740-d3e5f9ee156e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_92d9f658-4420-4f6b-8599-bdb04a896f5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_07dde341-6b8e-4d35-a0a4-24bc46311598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7a26f97c-58f3-47db-91e7-cf5136111b06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sndx:FederalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4bd80ba5-9483-4290-bd6b-8b3b7622307a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sndx:GlobalAndUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_d380c115-0599-4d7d-9e27-c31a2dc98460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6644a9fe-b908-416a-b736-f657bd63cd2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_610a039f-ddb5-49bf-b2aa-26efc9285ba9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c9f5b310-329a-4434-9537-4ce7c13c5b4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bbef3127-bb0c-4874-825e-07108d441436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa3bed87-c1df-42e6-8758-39e220363797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_88e95505-429a-46a9-b560-ae0bf5e61908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_85e6672e-416a-4bb1-ba66-37049365978f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_192455fe-8853-44c4-a2af-b22ba6210f6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_89ee900b-0daa-4278-b35c-28e5ea1dacc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_50387594-1a28-42ed-ac94-8000e7132fac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cef59505-ba7f-4bd7-ba0f-7111fc336f1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndTwentyTwoPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae0f6773-2219-4d93-912b-9c9e98f6fd82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7005891b-8702-43ec-a77e-2e47fc88621f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7214ed50-0829-4c9b-97ed-3efc7a00a846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_e51750f9-2ca2-48a3-9d96-269b2ec8e4b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9f09442a-717e-4f09-b5dc-359eda68d688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2024-02-19</instant>
        </period>
    </context>
    <context id="C_4e02600c-bd29-4c11-ab55-d1e0405d802e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-08</instant>
        </period>
    </context>
    <context id="C_84340f1a-f771-4068-83fa-b64ee4e714f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_665c9384-a612-4a95-ba6a-78cf2d4a9797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndTwentyTwoPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ff8445ca-ff4b-4f13-8184-af4837d5724f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_758bdea3-3881-4991-b7bf-ed3b171e2195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bda1e555-b0cf-4f5d-88a3-0159c9f3b0d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_2e0f6494-687d-4fd7-836a-90f591faf296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5d906a55-0f18-4eb6-ae44-5a99a86227fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="C_6d113b0b-ab5a-4247-a874-32521d39ece2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sndx:NonRefundableCashPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0422204c-ea29-458e-977a-fbc28c65fb5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a6fd8f00-bdcc-47d9-a213-80afd3cac541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fb680055-68ee-453c-b640-6693cd2778c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_c711bf57-6128-4aae-b770-abe66d25ee43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b2f341e1-b250-4994-9c50-93dfdd23e649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_5197e4c4-abe0-4b59-8b72-08d7ab8fd593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_faebc9a2-2fb9-4f9c-a490-ab75ff58a5e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7ff0eef-d6fb-487a-ac3a-bd8883e7c5ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteCollaborationAgreementAndSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_12411cb5-5f6c-4911-b870-4a0f20b18078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_c271aab5-a01e-42fd-86b6-0377aa3b4a22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7ef30512-4d6b-4796-82fc-67c194464ce1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1d4310ad-0736-4012-b9ce-4a0f9454edae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ac9227a8-0a7a-4171-9671-16e3b7033e1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_24de1833-922d-42e7-b50e-b99703d2a57a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="C_361a189b-bde2-4ebc-a732-bb3aba4d7e9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5b6fd47e-9446-44a8-8162-95fdb9778785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dbf91643-4660-41e0-b476-3872edbb72d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sndx:MichaelMetzgerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d63904f7-84ba-4976-8198-140293f5c68a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_012a6df5-8424-40f8-96a5-5e06d8ae24bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_26c0fc6f-728e-49e8-824f-78d32eaa25c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9bfce7e8-ef98-48b8-86a7-775779587ee8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6950da94-09bf-4054-a1fa-0feb68fcf8c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aff4aaae-ac9e-419d-8194-f5b7a5c562dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f5a2c5e6-ee95-4e95-ac72-df05f5b19d1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_7704e7f4-6094-4899-941c-17cce4c1ad53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9897c974-eaaf-4ce1-84bb-983cacae668c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_98367a91-be3e-42b9-a2a7-0457ff239e69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a8268fa6-6e38-4789-b18f-986f4e625037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6f419700-e28e-40c1-b23d-a0b900e72318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f4d0fa56-19c4-4e1e-be2c-7d22cb6fdd00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_65978307-b055-4116-8a9e-5b4d03aedbd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_8240772c-7e9d-4f0c-9469-d94e57373408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_113325fa-4d36-4203-99b1-36c13868211f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_916862c9-8345-48c9-8135-c267e4176f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-26</startDate>
            <endDate>2023-05-26</endDate>
        </period>
    </context>
    <context id="C_c5bfe040-8225-40e0-ac2c-1d2335fa468e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6e76b045-86c3-442e-89f0-3831e63a85a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_10d30f98-e352-4e95-8d0c-6ec352eb4220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c1bbc6b4-e3a0-44a7-bf52-605ed66340b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandTwentyThreeInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-06</instant>
        </period>
    </context>
    <context id="C_29309db1-308b-4019-86e8-51c14a636d14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sndx:BriggsWMorrisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_41f595f4-58d1-4879-8f5e-6bf3c89f425e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aea89429-70c4-454c-97d0-6401610eb508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">sndx:HerculesCapitalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sndx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9415a8d6-3456-4c2f-b211-310686e40961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:AtTheMarketStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_72227cf4-0a6a-4050-89fc-fc52e7d77a79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sndx:GlobalAndUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_1245cc97-cdcd-478a-a01f-e41febf804e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_65848bf9-3945-493c-98fa-73d365aadae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_fe987b96-157e-484d-ab17-c2d98a5f8ce5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_49c6449d-685a-4b8d-9ad2-69b9cf9fce2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f94caae1-f892-4d89-8e4b-773c52c2f2b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_074a6418-7106-47c6-9070-807b4c2674f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a02bc65a-614e-4743-902b-962e339de54c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_99c2e544-076a-4909-9149-b0b33903b58f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2da8d5ee-6ea1-4242-a4dc-afb090386702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c7c24763-4fb0-48dc-a5f9-391a27f7a6e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-03-01</startDate>
            <endDate>2007-03-31</endDate>
        </period>
    </context>
    <context id="C_22fc27d0-840a-44e9-bbda-98d42fe3a807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_02ad79b9-c653-4f87-a48e-92ebf9946d11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2b797780-f333-41ad-9804-9f77932b06b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="C_382491e5-93f3-4c43-b99a-07ae7ae81dd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_87ff6aa9-d940-48eb-b1df-219774898bb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_abcfbe51-431c-4e69-83e7-98632aac4ec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_007add38-cb78-4807-8ceb-0a17db3708dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a5fddb73-bec6-44ab-935b-04ba4ac070ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_6fb90d48-7668-4c0f-a774-c90206135131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f06b4d49-9703-446a-ba86-02d5b5a8111b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_13c0b160-1a0f-43dd-81e7-cca1d5370eb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e3636803-aef2-421b-a81e-02758a0838f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e1753470-c399-4d8b-ad2e-484c414ecc39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6da63ab9-2ebc-46a8-b7da-7c40838fae15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sndx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9e7a5e0-1ec9-492f-858b-bc50f9566629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a6b0a3dc-0d13-4e49-af3e-9c0ec95c0551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sndx:BeginToExpireInTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_14164814-000e-4a3d-8ee4-dd58a37f263b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_22b82249-a476-47d0-8dbf-74f15062836e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sndx:FederalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2e5821c0-1935-43a7-b0ba-c858e0c7d907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e7394970-59e6-4cd6-89a6-54b79f895f1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6a968746-243d-4b7c-af53-3e25f8258536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f9cd7896-122a-468d-9a8b-9879b929f973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4d513726-c3ac-4260-a084-166bd284aeba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteCollaborationAgreementAndSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6cacdbd9-72ea-4585-80a2-d53f1908716b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_97645584-c333-40ca-801b-2613f368a789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8c652789-8302-4cea-ba90-91fe2cce9a9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_29ad8473-2e34-453e-8357-0aecf445558f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cdda42ce-b5f5-4335-9c1e-37c83c1c9673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_784acd93-e389-42e6-b562-fe5fa32789cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_6a664e17-cf9e-4ee2-bfdc-d015d6af8887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ac62b3c-c563-4a8e-956a-51511134c433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fe65bbb1-0d57-4bdf-9127-31463d2d09a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_03d34840-d717-4c96-9735-0033d3f99ef2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_078b50de-5b41-4db5-9cf7-84fdb243368a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_03aeaecd-5be7-490b-86d3-d29870f2e796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_0ac7d980-2b3e-46ff-96cc-410f348499f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3afde7f0-2827-4e68-8635-4702b62c6d21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sndx:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndNineteenPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_96174531-bfea-4e9f-8dc3-133a02db014e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4f9cd118-679a-40a6-847e-91450d6633ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0d97a76a-d900-4c17-babb-1f3067aebaca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_444b653e-7ff0-4aea-832b-063c09c055b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteCollaborationAgreementAndSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d5b70f38-d948-41d2-b18c-a03562f8c1ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4711878e-a968-48f8-9c3d-730171fe4f23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandAndSevenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_7641cc13-8c39-40ae-b57f-0758cc213d32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7b7db385-57f7-42af-835a-310ebe8bfb57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_91017a34-0c67-4d46-b4ae-37fe8f976968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c738d44a-3667-401f-876a-5549892bf0b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndTwentyTwoPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f48e2289-7c74-4e8f-bb83-8c460905d6be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_9a61dd5c-53ff-496f-8daa-f66e8960c075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_4a678240-3c1b-4c9f-88f3-1d437a7bd663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sndx:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandTwentyThreePerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_722e2254-0e1d-493b-95a1-3d802704cc35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:TwoThousandAndNineteenPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0134674c-550a-4425-b294-4c3c79a415b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fee34826-8d9f-4166-a555-2a64fedf432a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="C_a064fef4-51ed-42ca-be0f-f995b8a0ed8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:AtTheMarketStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b85eec17-a5e7-48d2-bfca-2ef6ffdae4ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sndx:BeginToExpireInTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4be5e2a-ca86-4e3c-b7a9-c1323e17fe48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0d5d3e07-b0b8-4bc6-b16b-19628d2c4e5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="C_160ba5f0-0235-4944-95c1-f31751bf8c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3cbcc0e4-7e7b-486d-b6a3-470613e2d7a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sndx:IndefiniteCarryforwardPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2b24797a-527f-4f5d-beb7-f6e788fb41fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e4ddcb8-8500-42e0-9874-81661d600b3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sndx:NonRefundableCashPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_92922bd5-099d-4ec5-8e83-d7fd9dbf0f21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1fc4e017-06d9-47f7-8d2d-9de747aea836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_b690c391-1b7b-4548-a001-dbef6009526c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sndx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f35290a2-0231-4805-aa9a-709a7b059991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="C_7ea6052a-2eb2-4c2d-8093-dc9a96bc2333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7ef8960c-7219-442c-81b3-4e10b484489f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="C_c3fb6f51-13eb-4e43-9466-09f4818f1386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a245d0cf-1677-4b8f-a3f8-dfbf1b2276ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8a5e0f58-65f4-485e-beb0-bd6d07cb0472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_868dfba4-86a0-4c35-b789-a2dee2096244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e4e199a4-716e-4324-8f4d-ea865c2c0770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5e8b74ff-4a3e-4c5e-9f04-3c68740d89c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_56f021a8-a8b1-4814-8e60-e30e3153a6ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandTwentyThreeInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7c5c1097-e2eb-4741-8da2-1908684c710b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_51f40d68-fa17-4b98-aa7c-a40331129e97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="C_6ed50075-e059-4c68-a550-a38411e61645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sndx:MichaelMetzgerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_61e6f7c1-9801-49e0-ac76-fee878967704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_40e59aaf-8789-463b-945c-25dc7a6c94bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:VitaePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:AllerganLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_7b2fc26e-e3b0-4306-aa00-2175018e0133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_844de8bc-e6f9-4600-bf14-e5765bd7475d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DirectPlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d925cfd-9465-4602-88c6-bc4641cd2271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a9a02a8b-944c-450f-9447-629ff2beb166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_297b9be3-9752-4119-bccd-c1340527438c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3fdbce86-90d7-42aa-9453-ad5900bc17d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_34717b5e-c295-4ed1-ac0e-58d0e54bae5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3a9ae94c-95c4-4bc4-9ea1-a708c250d19f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sndx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="C_f2aa831f-6fca-40f4-af27-257fe1eaf973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_bf403011-6a3c-4874-b13f-c83dceca4aaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sndx:BriggsWMorrisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_92736a1f-42c0-4d1d-a622-0b95ffb0a33b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="C_6963fa61-8ec6-4bd0-aa49-52db5ff91e9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_56286884-2fcc-4f47-8d67-14db89877f0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9d930a60-dcb4-4913-bea6-46745efcd9fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:IncyteSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_00ddaa2a-3337-45b1-b374-1c84e826418c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_d21a99f4-ccca-4ef1-962f-a9239148a2f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sndx:FollowOnPublicOfferingOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b1cf4bfa-5db9-4119-8b19-8336fe8db925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_beb1fbb6-8eaa-4bd9-a278-f0c3ba62c037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6ff18d23-59d3-47d1-9c4b-5af2583db483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6fa3ac50-99f5-4a54-9d47-385cab5f80e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f584b500-1b67-48fb-b034-847318b00b67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_4d702b7c-2eb0-4b1b-9fdd-4c94f41fbc74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Employee">
        <measure>sndx:Employee</measure>
    </unit>
    <unit id="U_Segment">
        <measure>sndx:Segment</measure>
    </unit>
    <unit id="U_Claim">
        <measure>sndx:Claim</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_026657be-4472-43be-b934-35ed42b29885">false</dei:AmendmentFlag>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_91017a34-0c67-4d46-b4ae-37fe8f976968"
      id="F_6e6cbe80-054b-43e0-8d6f-dba3d9ad3d9f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_cf5e2c01-f3bc-4a4a-aee2-65795177679e">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      id="F_5615f5e0-c1bf-4350-9f87-98c7130e89d5">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <dei:EntityCentralIndexKey
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_49217c6b-d1c6-4a8c-980b-beb8c95d7595">0001395937</dei:EntityCentralIndexKey>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      id="F_6f2174af-1087-4534-a1d4-8c84dd8719fd">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_91017a34-0c67-4d46-b4ae-37fe8f976968"
      id="F_d12f5813-8d4e-42e6-a1b5-dd3b99859a2c">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_bdf0f075-bc1e-404e-af00-b70e479f0d98">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      id="F_debbfc9d-6778-4f47-b928-17023ff29f09"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      id="F_5c24cdeb-9f74-4eee-842e-e218a265196d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_bfa9a871-0b75-4568-9859-df85dcd68379">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      id="F_6061cd85-0c54-4a24-9e24-640882b2bfe9">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      id="F_0835679e-b7bf-456b-81ca-3e9b85f608a3">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a6fd8f00-bdcc-47d9-a213-80afd3cac541"
      id="F_0e6f7b74-b212-412d-a290-cfa9eb6e858f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_297b9be3-9752-4119-bccd-c1340527438c"
      id="F_91e0244e-9f65-4985-ba1b-f7857d8ad080">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_8b3a0436-44d2-4836-b16d-ee6d78894c69">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_d934129f-b075-48f8-a595-48228ba9323d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_a3c2867e-5630-4c6d-b01d-22f6e542fd3d">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_e90f3a73-aacf-4d72-8432-4b6bbd06c4f8">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_5bad62e7-9f35-4f89-8bdf-a4323fddad98">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_01e10b44-e28a-4b25-a3e2-d3ab6ccfe346">001-37708</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_64f710e4-ea15-46a3-a652-37398051e76e">Syndax Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_86cc9d3d-6932-4421-bad5-a5c01331f2e6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_43baf5a9-bec8-4f14-b407-047b272a8d67">32-0162505</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_fbf571bb-09a3-4eeb-a23d-3f35895f8a7a">35 Gatehouse Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_c8f17822-6481-476b-a69f-b86ebec6e3f2">Building D</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_ba3798ca-9140-4e45-a96c-b4dc1a8420ff">Floor 3</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_59378add-33ef-4d96-a589-0c79b8b61f31">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_a3cdca37-3d20-4a53-b22e-041abc28efd3">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_9ecaff22-906c-4a9d-a4b2-d5963127bdba">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_e56ec8b3-967d-4c40-b017-cb0668df2a1b">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_6b588813-2009-4241-9040-a18f35669865">419-1400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_0a523d5d-2dcd-4e85-9401-4066bfa0a852">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_b57e0524-82a0-4bba-89dd-9a387945343a">SNDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_8906f365-c385-4844-b80b-18f36251bbfb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_225bf403-4485-4e49-a23e-24b850d278bc">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_000237c4-e982-44a0-b3d9-6e01986c0aca">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_85de03f4-be89-49d9-8855-f132bc635185">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_76729c6e-93e5-4827-9514-9d231251cb0f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_29f7ccdd-7c89-4fe0-a67b-5b7a9eae63a5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_0d4e2d7a-b1ff-435b-96f9-c6f3710cd06a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_bc0e2e9c-ae8c-4f4e-af0c-ac86f6b2eeb7">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_bb52c361-2496-4fbc-85fa-4a18b9a1bf9c">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_79d98125-a15e-402f-bfa8-e2b53eefbe96">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_e37841e8-820f-4593-bc57-3a7b2c49cdb7">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_9a61dd5c-53ff-496f-8daa-f66e8960c075"
      decimals="-3"
      id="F_9246c324-cb77-428c-a7b2-fb9ce75fbce0"
      unitRef="U_USD">1452441662000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9f09442a-717e-4f09-b5dc-359eda68d688"
      decimals="0"
      id="F_e3468b80-b0d1-4a2c-a080-ad7dfa7d3574"
      unitRef="U_shares">84965486</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_522906f3-a228-49d7-a8be-6dfce787cb24">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.4%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_20788387-7aca-4d03-a09a-a73898705d0e">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_2d22defd-29e4-48f8-babb-36dd7f47bbcc">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_68b57250-91e1-4882-af6a-5f043de27a37">New York, New York</dei:AuditorLocation>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_bbef3127-bb0c-4874-825e-07108d441436"
      id="F_e07c93a4-3386-43c9-ad5b-bb785d13f31f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Change in Control Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 27, 2024, several of our named executive officers entered into amendments to their employment agreements providing, in part, for increases in their change in control benefits. For Mr. Metzger, in the event of an involuntary termination without cause or resignation for good reason within three (3) months prior to, or within twelve (12) months following, a change in control, he will receive (i) an amount equal to 24 months of base salary, payable in a lump sum, (ii) an amount equal to 24 months of the target annual incentive award, payable in a lump sum, and (iii) continuation of health benefits for 24 months. For Drs. Gallagher and Madigan and Messrs. Albrecht and Goldan, in the event of an involuntary termination without cause or resignation for good reason within three (3) months prior to, or within twelve (12) months following, a change in control, each will receive (i) an amount equal to 18 months of base salary, payable in a lump sum, (ii) an amount equal to 18 months of the target annual incentive award, payable in a lump sum, and (iii) continuation of health benefits for 18 months.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Trading Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During our last fiscal quarter, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or a &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as defined in Regulation S-K Item 408 for the purchase or sale of our securities, except as set forth below:&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:16.76%;"&gt;&lt;/td&gt;
      &lt;td style="width:14.88%;"&gt;&lt;/td&gt;
      &lt;td style="width:14.76%;"&gt;&lt;/td&gt;
      &lt;td style="width:13.58%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:15.58%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:22.44%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Name and Title&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Type of Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Adoption Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Duration or End Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Number of Securities to be Sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Michael Metzger&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Chief Executive Officer and Director&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rule 10b5-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;trading arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;01/05/2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12/22/2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales of shares intended to satisfy the affirmative defense of Rule 10b5&#x2013;1(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Briggs W. Morrison&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;M.D. - Director&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rule 10b5-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;trading arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;02/09/2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12/06/2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;466,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales of shares intended to satisfy the affirmative&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:16.76%;"&gt;&lt;/td&gt;
      &lt;td style="width:14.88%;"&gt;&lt;/td&gt;
      &lt;td style="width:14.76%;"&gt;&lt;/td&gt;
      &lt;td style="width:13.58%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:15.58%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:22.44%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;defense of Rule 10b5&#x2013;1(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"&gt;Termination&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"&gt; of Rule 10b5-1 trading arrangement, each of which the reporting person terminated prior to the sale of all plan securities.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_bbef3127-bb0c-4874-825e-07108d441436"
      id="F_1c00081c-deb4-4401-9876-0a78674e9af7">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_bbef3127-bb0c-4874-825e-07108d441436"
      id="F_3f715556-20d6-4b67-beec-e15a39e06583">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_bbef3127-bb0c-4874-825e-07108d441436"
      id="F_24c0f399-bfba-46be-a421-080dfeed1540">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_bbef3127-bb0c-4874-825e-07108d441436"
      id="F_e804158a-a5f6-48a8-8906-69634e2818bf">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName
      contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6"
      id="F_019950da-7c9e-4648-93df-baef4c55a740">Michael Metzger</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6"
      id="F_be72bccc-3c4e-47b0-b1b1-834994aefc81">Chief Executive Officer and Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6"
      id="F_b8284168-3f13-4768-8d1a-4f6d9ed68283">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6"
      id="F_42f41713-7dec-4dd8-8d64-6791652a1511">01/05/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrTerminationDate
      contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6"
      id="F_c3360dfa-27fe-4447-a74c-63e3d28f0078">12/22/2023</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_6ed50075-e059-4c68-a550-a38411e61645"
      decimals="0"
      id="F_4f2f9700-4e1d-4c92-9424-0beb6649895a"
      unitRef="U_shares">100000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName
      contextRef="C_29309db1-308b-4019-86e8-51c14a636d14"
      id="F_37e11f1a-0751-4158-b47f-05f24953c364">Briggs W. Morrison</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_29309db1-308b-4019-86e8-51c14a636d14"
      id="F_2066d97d-612e-430c-95c1-8f92d450ae3a">M.D. - Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_29309db1-308b-4019-86e8-51c14a636d14"
      id="F_6937d70a-a198-4693-b219-f050ccd3a68f">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_29309db1-308b-4019-86e8-51c14a636d14"
      id="F_61ce5d82-2fc2-471d-8f25-dc0d1c95d9fe">02/09/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrTerminationDate
      contextRef="C_29309db1-308b-4019-86e8-51c14a636d14"
      id="F_78d37cf1-d9ac-4057-a403-c5a56376cccc">12/06/2023</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_bf403011-6a3c-4874-b13f-c83dceca4aaf"
      decimals="0"
      id="F_55a6884f-7ae3-4155-95c6-5e9d88608453"
      unitRef="U_shares">466167</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_dbf91643-4660-41e0-b476-3872edbb72d6"
      id="F_a5af59a3-600d-4bce-b90a-3156d43b6359">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_29309db1-308b-4019-86e8-51c14a636d14"
      id="F_98b6abb6-35d3-4cdb-9c67-b01ba925a536">true</ecd:Rule10b51ArrTrmntdFlag>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_28069441-a21f-47a9-bb5f-76345a557778"
      unitRef="U_USD">295394000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_00b90065-47af-43ab-92d5-24a07e592e03"
      unitRef="U_USD">74356000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_25fb03fa-4a68-463d-9275-57cf57cb7ba7"
      unitRef="U_USD">275304000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_24f8c146-e80b-4071-90a1-1a5ebd6d4a5d"
      unitRef="U_USD">401446000</us-gaap:ShortTermInvestments>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_3e158c0d-af49-4988-aad9-0107e41a8402"
      unitRef="U_USD">6885000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_5963c0c0-985b-41a1-a2f2-5ee13b28ab78"
      unitRef="U_USD">8595000</us-gaap:DepositsAssetsCurrent>
    <sndx:CollaborationReceivable
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_f9f36e7e-6164-46b5-b8d8-b92483db6b1d"
      unitRef="U_USD">0</sndx:CollaborationReceivable>
    <sndx:CollaborationReceivable
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_f79ba228-febe-4c0e-a3d0-a377f785d5b5"
      unitRef="U_USD">3474000</sndx:CollaborationReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_58304fce-9d75-4078-b066-ee2a4c887bb5"
      unitRef="U_USD">3293000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_2e23ef2c-e16a-4779-9481-10a4fb7b90d4"
      unitRef="U_USD">1915000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_e98d4c6b-17c4-46e2-a393-8fe4af39f394"
      unitRef="U_USD">580876000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_54c4345c-4b90-49ae-8059-7bfe983f4135"
      unitRef="U_USD">489786000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_dbcbb235-3696-4cf3-a5dc-96f40a4e6e6f"
      unitRef="U_USD">29829000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_e67c0fb6-2cc9-4e4f-9c31-52bc63b0e519"
      unitRef="U_USD">5469000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_54b09fbb-c307-4700-a8ef-57327bf1f600"
      unitRef="U_USD">8000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_e6341836-36de-4eee-8888-0bacd7c155e6"
      unitRef="U_USD">20000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_1ddb6acb-9264-4407-838c-a604648d5422"
      unitRef="U_USD">1487000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_eb84bb9b-c38e-449d-8157-e9cb34d3c70b"
      unitRef="U_USD">1039000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_b2e8de88-8f0c-42ea-ab18-81035cfbf702"
      unitRef="U_USD">217000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_f77c1ca1-9f4e-4116-a7ec-6daa2a11e7e4"
      unitRef="U_USD">115000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_ea6e48c9-ccd4-4d6b-b333-d34e268be24c"
      unitRef="U_USD">463000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_5cf35cf6-1d4d-49e5-842e-6d77d0c208cb"
      unitRef="U_USD">807000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_949ba060-d037-4b6c-941d-33e3f45720bf"
      unitRef="U_USD">612880000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_6387abc6-ba4b-4fa5-a8c0-2962f6fc2f84"
      unitRef="U_USD">497236000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_8d2093c5-80bb-4c64-b426-7dc0274165a7"
      unitRef="U_USD">9961000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_3a8d7282-b27b-40ff-b42f-ceb9bec12c50"
      unitRef="U_USD">4350000</us-gaap:AccountsPayableCurrent>
    <sndx:CollaborationPayableCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_d489e1ad-2881-460b-ad55-01aac1772bb1"
      unitRef="U_USD">7232000</sndx:CollaborationPayableCurrent>
    <sndx:CollaborationPayableCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_f002822b-fa73-4797-a1c7-6f2a3a506d28"
      unitRef="U_USD">0</sndx:CollaborationPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_094616d2-7215-4586-aed6-0eb6097819b1"
      unitRef="U_USD">39856000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_7ef4c229-9109-4c9a-aa75-f19243f1819a"
      unitRef="U_USD">24276000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_f129e4d9-21b5-4981-85f2-983b7733b2bd"
      unitRef="U_USD">1035000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_2c17e5a0-f4e1-4230-a98b-d2981c88fd8e"
      unitRef="U_USD">434000</us-gaap:OperatingLeaseLiabilityCurrent>
    <sndx:CurrentPortionOfCapitalLease
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_7e2d15e9-4a9b-478a-b3a5-94a62853f4f5"
      unitRef="U_USD">12000</sndx:CurrentPortionOfCapitalLease>
    <sndx:CurrentPortionOfCapitalLease
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_13ad18d8-bdaf-4a7d-8ecb-4dc9a1d41526"
      unitRef="U_USD">5000</sndx:CurrentPortionOfCapitalLease>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_81e457d8-6045-4c9b-837f-28af16d516d0"
      unitRef="U_USD">58096000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_c40141bf-ce4a-474a-b358-2f3948dd4aaf"
      unitRef="U_USD">29065000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_8597cfc6-1fef-463a-9e17-de8d30e69975"
      unitRef="U_USD">578000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_1abfc018-5c11-42f2-b4dc-65809f57294d"
      unitRef="U_USD">709000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <sndx:CapitalLeaseLessCurrentPortion
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_7ae47a8a-a0e8-4e8b-9d96-9b37dd434d91"
      unitRef="U_USD">10000</sndx:CapitalLeaseLessCurrentPortion>
    <sndx:CapitalLeaseLessCurrentPortion
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_c5e2e04e-9138-4fef-8a48-7c8a541375a3"
      unitRef="U_USD">13000</sndx:CapitalLeaseLessCurrentPortion>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_030d3f1d-d307-4333-a7cc-7f2446767b79"
      unitRef="U_USD">588000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_c2b80493-32f0-48dc-be45-2f7f70388085"
      unitRef="U_USD">722000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_fb10c907-fe0e-4b8f-a9d6-149d088e3b15"
      unitRef="U_USD">58684000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_6feb2ef3-751f-446b-b41e-03915485891f"
      unitRef="U_USD">29787000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="3"
      id="F_71476097-3bf2-4524-9c11-563203f8021b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="3"
      id="F_2e95891d-6df1-4bba-bd4e-2ec333547a80"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_d1ea90a0-4ce4-47d7-8177-e8d061b93c8f"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="INF"
      id="F_ac04c682-7bec-4f1e-9c65-e0641a707c57"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_9548f1e5-19a5-4b88-96f6-1c483f3d84c0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="INF"
      id="F_c66715ed-cf64-4378-9652-53f62fa44e38"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_d03be623-bef1-4080-a140-4f801cb977fe"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_58c3ff3b-07b7-4796-a85e-fca42f80424c"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="4"
      id="F_0702abbf-b28a-4d6d-b818-b71b7a45f915"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="4"
      id="F_e447e163-1331-4efa-a1d6-9bfb2623ffcf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_795b1daf-e38a-45c3-a14e-30a56444c9ba"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="INF"
      id="F_1b72a559-cbdc-4f84-9f22-37652a0a9087"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_d23002fa-2f3d-4336-977c-54044fe19591"
      unitRef="U_shares">84826632</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="INF"
      id="F_2c3df322-03f9-4390-984b-2931cea6a7f1"
      unitRef="U_shares">68111385</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_e1ea7712-e063-4e01-84c5-ec71836a1a87"
      unitRef="U_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_e704bbc4-fa74-4a5a-a60c-8cbba7d009c0"
      unitRef="U_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_be718fcc-15d9-4337-b9ce-b951142d8be2"
      unitRef="U_USD">1456370000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_4f6addff-7b68-4a59-8053-2cf6a2406f2e"
      unitRef="U_USD">1161288000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_88c4955c-5313-4a94-95b7-b7c24ba55500"
      unitRef="U_USD">218000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_741ce834-a449-4294-acd0-56e3b7c50514"
      unitRef="U_USD">-806000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_8cbd17c5-a54d-4664-ba16-f9d7845b009b"
      unitRef="U_USD">-902400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_79ac0ec5-14f4-4aed-a2b8-6bb9d857a871"
      unitRef="U_USD">-693040000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_bf5bb96b-b0c0-4c90-b7c3-283138c66af6"
      unitRef="U_USD">554196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_a0520343-b26c-4699-be81-a4be00e95c32"
      unitRef="U_USD">467449000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_db1e2032-f3bb-48c1-8068-4b72a874c1c7"
      unitRef="U_USD">612880000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_506c1302-954f-4fe5-b3fc-2131c27dc349"
      unitRef="U_USD">497236000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_acce096e-c2e4-43ba-a75f-5d7bfdad8376"
      unitRef="U_USD">0</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_f4e764d0-8228-45a7-a091-fce3ae4c94ef"
      unitRef="U_USD">0</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_4a4306d7-646b-4cc9-bb87-d09127ee0141"
      unitRef="U_USD">139709000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_f330f219-0e47-4bbe-8271-1c4e2906bcf9"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_2f4ec015-f60a-494a-a33b-76f17adbdbf2"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_de7f2d15-3dbe-4fa0-b2b9-72bc83c3727d"
      unitRef="U_USD">139709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_42ea97a5-4c7c-464b-b9c9-d1a7a52da32b"
      unitRef="U_USD">163032000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_7d6f1777-d7f6-46a0-a7e1-7e8208902161"
      unitRef="U_USD">118499000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_66638b3c-ddc2-48a9-9419-fa04005a2424"
      unitRef="U_USD">88248000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_7de400a5-25c2-420e-8bd4-c82b58bc8d24"
      unitRef="U_USD">66922000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_4f7ba0c9-f86f-42a6-afd4-d52c04bf7454"
      unitRef="U_USD">33258000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_f1ed76ef-3ac9-45d5-a64a-1497ec990c50"
      unitRef="U_USD">25241000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_75a89285-c568-4094-85e5-98cf67a42de3"
      unitRef="U_USD">229954000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_155514d0-da62-4249-ae5c-d060dcd53daa"
      unitRef="U_USD">151757000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_e702e52f-b7f8-4d25-9cc1-17a6ad4f21f6"
      unitRef="U_USD">113489000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_6ecf43ec-5579-4073-940e-c03e17a4c510"
      unitRef="U_USD">-229954000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_d9807462-de57-4567-9164-93df866f32c8"
      unitRef="U_USD">-151757000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_eaaffe3f-1a57-4a7c-890d-1d3653d6b834"
      unitRef="U_USD">26220000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_8bf9b137-2b30-4f1f-9ae3-804c469e108b"
      unitRef="U_USD">208000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_68f155df-8951-4d08-862a-ff6dd6dd6a32"
      unitRef="U_USD">3137000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_f18396a2-b3bc-4a35-849d-d9e2410d7db8"
      unitRef="U_USD">1899000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_aded91ae-870d-4aca-8b4f-1d2b344ac1cb"
      unitRef="U_USD">21163000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_e777cf11-7ac1-4f64-89c9-d30500a66709"
      unitRef="U_USD">5872000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_9eb2d92a-6f19-4414-ae8c-ec4aa4250a7b"
      unitRef="U_USD">403000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_dbfcf8f8-02de-43a2-8c9a-18dd49684db7"
      unitRef="U_USD">-361000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_6e0e47bf-89ff-4330-95b2-f6cfa64ff251"
      unitRef="U_USD">-316000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_f945d485-f726-4f22-9272-c96370e565bd"
      unitRef="U_USD">202000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_70dcff03-2280-4065-ba94-1f53cd5cc47d"
      unitRef="U_USD">20594000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_d1c0dda5-af55-4af7-be64-14bd6e077abb"
      unitRef="U_USD">2419000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_c9464f28-b9c2-4591-9249-94b720788d91"
      unitRef="U_USD">-1294000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_80159323-cc32-4889-b57f-6da82ef4faff"
      unitRef="U_USD">-209360000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_12c56e80-f629-4aa0-8196-1b425b568dd4"
      unitRef="U_USD">-149338000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_a86d3ef6-6f15-43da-89c5-81a602e281a7"
      unitRef="U_USD">24926000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_6f41cf94-7051-4697-a1e6-10ccb4d9f31b"
      unitRef="U_USD">-209360000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_6446bcfc-ce2f-4d5f-bf2e-6ea331850722"
      unitRef="U_USD">-149338000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_c83899d9-5066-4677-82e0-b907f78bf2a1"
      unitRef="U_USD">24926000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="2"
      id="F_49afbd28-6957-4879-98cc-0800b0cfdde6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="2"
      id="F_08b7c7b2-a7fa-4c84-b06f-92719a047d14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="2"
      id="F_8f7640a1-e33a-42fb-bef8-ce366d3d363e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="2"
      id="F_b0fe79a5-ea67-4996-9915-15617795302e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="2"
      id="F_3bc82022-de7c-4ada-8657-849522875fda"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="2"
      id="F_ccfdbe41-2014-42d7-953b-a0f0e351ec6f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="INF"
      id="F_db7e8ef8-48b6-498f-98c4-19cae260d793"
      unitRef="U_shares">70370519</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="INF"
      id="F_3660de7a-d97b-47f1-8db2-12ddd76e8221"
      unitRef="U_shares">60760906</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="INF"
      id="F_bbd56fb3-37d9-4ab3-a061-5ddbb3572c43"
      unitRef="U_shares">52064809</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="INF"
      id="F_0c89380e-81ea-4e5e-b81a-21695811fae0"
      unitRef="U_shares">70370519</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="INF"
      id="F_e0c94f22-1662-4619-b3da-006eece70f33"
      unitRef="U_shares">60760906</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="INF"
      id="F_b9c61176-1167-42c2-8f31-d02547441ba2"
      unitRef="U_shares">53622904</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_06ca38fa-0de2-4afd-90cb-2cc86e44501e"
      unitRef="U_USD">-209360000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_9ee261cf-4a0c-4eb7-8909-3e7cee2d3256"
      unitRef="U_USD">-149338000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_38ea2548-1e2b-4ed2-befb-74ac1a09d8a7"
      unitRef="U_USD">24926000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_0b5b456d-64a5-46a7-8e17-5a8708da2e88"
      unitRef="U_USD">1024000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_5eaf4923-8991-4510-b4f0-9124b64d3a80"
      unitRef="U_USD">-851000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_8f565952-a6e4-423d-8f14-2d539d2600fd"
      unitRef="U_USD">49000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_219bf695-df22-453d-9b02-1dbdbbe2b882"
      unitRef="U_USD">-208336000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_b69e8f8c-9a97-4ff2-ab9b-3cb1eb334761"
      unitRef="U_USD">-150189000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_c2b613e8-ad22-4668-974f-e6ed4193fc31"
      unitRef="U_USD">-24975000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_02ad79b9-c653-4f87-a48e-92ebf9946d11"
      decimals="0"
      id="F_bc2e6ca0-6125-4254-a1ad-a4068ac89f06"
      unitRef="U_shares">47881223</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_02ad79b9-c653-4f87-a48e-92ebf9946d11"
      decimals="-3"
      id="F_0af9143e-6f27-4bb7-b315-e1f7994db98f"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5ac62b3c-c563-4a8e-956a-51511134c433"
      decimals="-3"
      id="F_02d5bfd3-ffa9-49ae-b1eb-8808304462f4"
      unitRef="U_USD">820815000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_99c2e544-076a-4909-9149-b0b33903b58f"
      decimals="-3"
      id="F_8633ffd1-43eb-4ec5-a0a2-db33e428efd4"
      unitRef="U_USD">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_29ad8473-2e34-453e-8357-0aecf445558f"
      decimals="-3"
      id="F_64bec66b-28c6-492c-ae03-c861f7187353"
      unitRef="U_USD">-568628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_07dde341-6b8e-4d35-a0a4-24bc46311598"
      decimals="-3"
      id="F_b922e013-fb82-4ea8-9f38-298323cbb1c4"
      unitRef="U_USD">252188000</us-gaap:StockholdersEquity>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_e8da1f2a-7d2f-4985-b770-774b3acc473a"
      unitRef="U_USD">159000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses>
    <sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet
      contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc"
      decimals="0"
      id="F_272736e9-fb1a-45e9-a2f6-8165253dbb59"
      unitRef="U_shares">277629</sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet
      contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244"
      decimals="-3"
      id="F_bbcc8fdf-2ea2-4235-ba4e-510fac671895"
      unitRef="U_USD">5131000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_e9e6d35e-5119-4896-8fdc-3c1d9ea55e78"
      unitRef="U_USD">5131000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet>
    <sndx:StockIssuedDuringPeriodValueOfferingExpenses
      contextRef="C_844de8bc-e6f9-4600-bf14-e5765bd7475d"
      decimals="-3"
      id="F_f54c011b-9426-477e-8c93-b0b28f63766d"
      unitRef="U_USD">5332000</sndx:StockIssuedDuringPeriodValueOfferingExpenses>
    <sndx:StockIssuedDuringPeriodSharesDirectOffering
      contextRef="C_50387594-1a28-42ed-ac94-8000e7132fac"
      decimals="0"
      id="F_4d58a3f2-ade9-4f41-ade3-eab841e1f095"
      unitRef="U_shares">3802144</sndx:StockIssuedDuringPeriodSharesDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_50387594-1a28-42ed-ac94-8000e7132fac"
      decimals="-3"
      id="F_07e0490b-37d1-4d4c-9b85-b4c5d2efbde2"
      unitRef="U_USD">1000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_2b24797a-527f-4f5d-beb7-f6e788fb41fa"
      decimals="-3"
      id="F_80000b97-acd8-4e39-ba3c-ee4b97474d72"
      unitRef="U_USD">81205000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_844de8bc-e6f9-4600-bf14-e5765bd7475d"
      decimals="-3"
      id="F_1345371e-8728-4140-8d78-99176fb45e5e"
      unitRef="U_USD">81206000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc"
      decimals="0"
      id="F_d8d39fb5-f112-44e0-aeff-9bc0e904edfe"
      unitRef="U_shares">26878</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <sndx:PreFundedWarrantExerciseShares
      contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc"
      decimals="0"
      id="F_9b99582b-eaef-40a0-a336-0a13c3bfd59f"
      unitRef="U_shares">725784</sndx:PreFundedWarrantExerciseShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc"
      decimals="0"
      id="F_9913a288-63e2-440c-8d3f-db7a195323ec"
      unitRef="U_shares">1421523</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244"
      decimals="-3"
      id="F_3bb4776f-b42c-4909-8018-dc8fdfdf8597"
      unitRef="U_USD">24848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_e78d8118-010f-4b9a-8ef7-5a43905806c9"
      unitRef="U_USD">24848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244"
      decimals="-3"
      id="F_d550b12d-c3ca-45b6-b5c8-ccff206468f5"
      unitRef="U_USD">13317000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_512d34d6-570c-4b60-897c-f0b99e3c4ceb"
      unitRef="U_USD">13317000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e4e199a4-716e-4324-8f4d-ea865c2c0770"
      decimals="-3"
      id="F_dc1af6ec-a45e-4a3d-a6c3-ab2a557e1e32"
      unitRef="U_USD">49000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_807dead0-858e-4bba-b5fb-48d2e9d96d0d"
      unitRef="U_USD">49000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc"
      decimals="0"
      id="F_5d24bbb9-c376-4f62-9ef4-8daf1ac0850f"
      unitRef="U_shares">5500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <sndx:EmployeeWithholdingsEspp
      contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244"
      decimals="-3"
      id="F_86d1814b-fc0e-4a43-8966-15801b6a0734"
      unitRef="U_USD">367000</sndx:EmployeeWithholdingsEspp>
    <sndx:EmployeeWithholdingsEspp
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_023b757c-8b0f-4c93-a017-4bba380b4727"
      unitRef="U_USD">367000</sndx:EmployeeWithholdingsEspp>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_be6037f3-9813-4534-80b2-c77aa4bd8cbc"
      decimals="0"
      id="F_fa40bc6c-75b6-4bb8-b948-1ee22613cfcc"
      unitRef="U_shares">842424</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_868dfba4-86a0-4c35-b789-a2dee2096244"
      decimals="-3"
      id="F_654541f4-a773-4e76-bde0-8652cb69cc1f"
      unitRef="U_USD">6336000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_642d9f58-ec8f-47fe-b386-2a3a9a6bcdf6"
      unitRef="U_USD">6336000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_ddd4ae65-26c4-4c11-8b88-b2c7bac6eacb"
      decimals="-3"
      id="F_13d9d170-a67d-4613-9811-f8855234fd99"
      unitRef="U_USD">24926000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_f2d47245-f3e2-4f5f-8205-a18009e28259"
      unitRef="U_USD">24926000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4f9cd118-679a-40a6-847e-91450d6633ea"
      decimals="0"
      id="F_e211daba-ce1b-4841-8358-2cebe2c075a2"
      unitRef="U_shares">54983105</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4f9cd118-679a-40a6-847e-91450d6633ea"
      decimals="-3"
      id="F_95d5e218-46f7-4c15-8e96-4fff29fd078d"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5e8b74ff-4a3e-4c5e-9f04-3c68740d89c7"
      decimals="-3"
      id="F_f03740fa-a11b-4356-a886-ea3ded60e721"
      unitRef="U_USD">952019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8d925cfd-9465-4602-88c6-bc4641cd2271"
      decimals="-3"
      id="F_882656ce-8d52-411a-bd90-4932af13ba12"
      unitRef="U_USD">45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_43d48b69-d64f-4673-aae8-70b5559a6dd7"
      decimals="-3"
      id="F_be29b2bf-821f-4455-98e1-d749ebc4d5cd"
      unitRef="U_USD">-543702000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166"
      decimals="-3"
      id="F_1065d4b9-1ab2-4f9f-a5bf-1369a0784d81"
      unitRef="U_USD">408368000</us-gaap:StockholdersEquity>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
      contextRef="C_d21a99f4-ccca-4ef1-962f-a9239148a2f8"
      decimals="-3"
      id="F_6ebe7847-6e63-4586-8bd8-e9eb6b9484a1"
      unitRef="U_USD">600000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses>
    <sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet
      contextRef="C_97645584-c333-40ca-801b-2613f368a789"
      decimals="0"
      id="F_976a7ada-ef58-405e-abf4-b5a5dba8fe76"
      unitRef="U_shares">1111111</sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet
      contextRef="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf"
      decimals="-3"
      id="F_bbfd4efa-c2d3-4815-8db9-8e4d4e77bcf2"
      unitRef="U_USD">19425000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_1daefd5d-b94c-41c4-be33-139b172f0b6b"
      unitRef="U_USD">19425000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet>
    <sndx:StockIssuedDuringPeriodValueOfferingExpenses
      contextRef="C_a5804989-e5d4-4066-86ae-9576d589c5cb"
      decimals="-3"
      id="F_ac99ea7f-5dae-423a-9857-705b3c010c26"
      unitRef="U_USD">10535000</sndx:StockIssuedDuringPeriodValueOfferingExpenses>
    <sndx:StockIssuedDuringPeriodSharesDirectOffering
      contextRef="C_0422204c-ea29-458e-977a-fbc28c65fb5d"
      decimals="0"
      id="F_bc13e855-d5c8-4ea0-86f5-c3203ea625b4"
      unitRef="U_shares">7840909</sndx:StockIssuedDuringPeriodSharesDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_0422204c-ea29-458e-977a-fbc28c65fb5d"
      decimals="-3"
      id="F_47e8c531-8364-4ba1-be2c-c90ef9c5e786"
      unitRef="U_USD">1000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_88e95505-429a-46a9-b560-ae0bf5e61908"
      decimals="-3"
      id="F_79e2fc2f-83d7-46cb-aca8-2dfdbf39bfb9"
      unitRef="U_USD">161965000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_a5804989-e5d4-4066-86ae-9576d589c5cb"
      decimals="-3"
      id="F_a7046870-353c-4222-9f65-c587de891c62"
      unitRef="U_USD">161966000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_97645584-c333-40ca-801b-2613f368a789"
      decimals="0"
      id="F_41d869ef-2fee-4915-b379-1bf2e08800b2"
      unitRef="U_shares">28999</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <sndx:PreFundedWarrantExerciseShares
      contextRef="C_97645584-c333-40ca-801b-2613f368a789"
      decimals="0"
      id="F_4707e89a-7680-40cd-a69c-0aa0638f0b85"
      unitRef="U_shares">2832151</sndx:PreFundedWarrantExerciseShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf"
      decimals="-3"
      id="F_c67a02ed-f97d-446d-b3a0-aa543e25fe36"
      unitRef="U_USD">16019000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_1d94dad8-c42b-45ad-b6b3-aa6d2d100527"
      unitRef="U_USD">16019000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_97645584-c333-40ca-801b-2613f368a789"
      decimals="0"
      id="F_a43e8318-7271-441f-b87b-d03ce5e78a5b"
      unitRef="U_shares">38749</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_b1cf4bfa-5db9-4119-8b19-8336fe8db925"
      decimals="-3"
      id="F_5dfa556d-5a63-4ad9-a7a7-abed1815978f"
      unitRef="U_USD">-851000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_a0040670-0216-4848-84d5-3c1bdbb2404b"
      unitRef="U_USD">-851000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <sndx:EmployeeWithholdingsEspp
      contextRef="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf"
      decimals="-3"
      id="F_fd6de439-63c3-4a49-a27c-d1fd795f48e2"
      unitRef="U_USD">401000</sndx:EmployeeWithholdingsEspp>
    <sndx:EmployeeWithholdingsEspp
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_f74e9d4a-e8ec-4d3d-bd4c-28c7ec3e33ad"
      unitRef="U_USD">401000</sndx:EmployeeWithholdingsEspp>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_97645584-c333-40ca-801b-2613f368a789"
      decimals="0"
      id="F_6459eb36-43b7-4f53-95e2-82b2879ba6af"
      unitRef="U_shares">1276361</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_db5b9e81-2bb2-427b-9060-529ca5cf6dbf"
      decimals="-3"
      id="F_dbb4effe-a639-4ac5-af42-3b70b537fb61"
      unitRef="U_USD">11459000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_bdb9f1dc-18ed-4b30-a795-6fc08e4c844e"
      unitRef="U_USD">11459000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_5197e4c4-abe0-4b59-8b72-08d7ab8fd593"
      decimals="-3"
      id="F_2fa0e3be-61b9-41d3-95e7-75edd49a728e"
      unitRef="U_USD">-149338000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_595b3a03-2c07-4f56-9809-64597ab7361a"
      unitRef="U_USD">-149338000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_7ef30512-4d6b-4796-82fc-67c194464ce1"
      decimals="0"
      id="F_1e86f800-afea-4c93-a1ea-78c2eafea1d9"
      unitRef="U_shares">68111385</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7ef30512-4d6b-4796-82fc-67c194464ce1"
      decimals="-3"
      id="F_22916c90-c6c8-485f-8852-112cd5c9186b"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a9e7a5e0-1ec9-492f-858b-bc50f9566629"
      decimals="-3"
      id="F_b81c0ed1-d544-4e98-a3b3-b311de031ae8"
      unitRef="U_USD">1161288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d63904f7-84ba-4976-8198-140293f5c68a"
      decimals="-3"
      id="F_8310fe3c-f3e1-4189-98a8-a22037b76248"
      unitRef="U_USD">-806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_87ff6aa9-d940-48eb-b1df-219774898bb5"
      decimals="-3"
      id="F_11814988-1db4-4750-b1e4-2a90f4720f8a"
      unitRef="U_USD">-693040000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_cf7957ac-ffeb-4787-a37d-48bdbe9e2082"
      unitRef="U_USD">467449000</us-gaap:StockholdersEquity>
    <sndx:StockIssuedDuringPeriodValueOfferingExpenses
      contextRef="C_012a6df5-8424-40f8-96a5-5e06d8ae24bd"
      decimals="-3"
      id="F_85d49dfa-8d36-4af6-9ded-48e7d700d3e3"
      unitRef="U_USD">14044000</sndx:StockIssuedDuringPeriodValueOfferingExpenses>
    <sndx:StockIssuedDuringPeriodSharesDirectOffering
      contextRef="C_ac9227a8-0a7a-4171-9671-16e3b7033e1c"
      decimals="0"
      id="F_4cf7d606-70a8-4596-8099-25126d962bac"
      unitRef="U_shares">12432431</sndx:StockIssuedDuringPeriodSharesDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_ac9227a8-0a7a-4171-9671-16e3b7033e1c"
      decimals="-3"
      id="F_8230072a-e6b1-4595-a0aa-ea7373f451ec"
      unitRef="U_USD">1000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_078b50de-5b41-4db5-9cf7-84fdb243368a"
      decimals="-3"
      id="F_ec125ead-fbe8-41d8-85e7-6d6d8aff7be9"
      unitRef="U_USD">215954000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <sndx:StockIssuedDuringPeriodValueDirectOffering
      contextRef="C_012a6df5-8424-40f8-96a5-5e06d8ae24bd"
      decimals="-3"
      id="F_801f6749-45b7-4a47-9465-43a64e62c5f2"
      unitRef="U_USD">215955000</sndx:StockIssuedDuringPeriodValueDirectOffering>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
      contextRef="C_3fdbce86-90d7-42aa-9453-ad5900bc17d9"
      decimals="-3"
      id="F_f0e85229-18d4-44ab-8571-f9551ef88bf8"
      unitRef="U_USD">1086000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses>
    <sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet
      contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6"
      decimals="0"
      id="F_d5115654-d80f-46d8-abc3-fd96e3fe5ac4"
      unitRef="U_shares">2719744</sndx:StockIssuedDuringPeriodSharesAtTheMarketOfferingNet>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet
      contextRef="C_758bdea3-3881-4991-b7bf-ed3b171e2195"
      decimals="-3"
      id="F_32f58e82-7189-445b-a7c3-724776d040ec"
      unitRef="U_USD">42139000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet>
    <sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_45824ede-63cd-4ed5-9f8d-e36943ba45e6"
      unitRef="U_USD">42139000</sndx:StockIssuedDuringPeriodValueAtTheMarketOfferingNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_758bdea3-3881-4991-b7bf-ed3b171e2195"
      decimals="-3"
      id="F_17742bb7-96cb-4b84-8f81-3a432e3dfcdd"
      unitRef="U_USD">30951000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_4c34eb4f-a1e1-4a99-9ed3-301618933c9a"
      unitRef="U_USD">30951000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_1245cc97-cdcd-478a-a01f-e41febf804e7"
      decimals="-3"
      id="F_1f8bb2b8-e0f6-4ca3-92f4-55704d02d0ed"
      unitRef="U_USD">1024000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_ba14bf5b-58c9-4109-8410-527ba2918a88"
      unitRef="U_USD">1024000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6"
      decimals="0"
      id="F_72dbb3e3-1b20-461e-afbf-843beaf66af1"
      unitRef="U_shares">34797</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <sndx:EmployeeWithholdingsEspp
      contextRef="C_758bdea3-3881-4991-b7bf-ed3b171e2195"
      decimals="-3"
      id="F_fb00e116-1be7-4836-ba5e-cb56c4cd2dfb"
      unitRef="U_USD">910000</sndx:EmployeeWithholdingsEspp>
    <sndx:EmployeeWithholdingsEspp
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_537a5269-7bfa-4890-92b3-d4ede2c897a4"
      unitRef="U_USD">910000</sndx:EmployeeWithholdingsEspp>
    <sndx:PreFundedWarrantExerciseShares
      contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6"
      decimals="0"
      id="F_28dd2605-718b-4f82-b4f3-54733a0654de"
      unitRef="U_shares">857131</sndx:PreFundedWarrantExerciseShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6"
      decimals="0"
      id="F_e96a29b7-9f85-4e7e-86bd-65add1a6ce8f"
      unitRef="U_shares">9102</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_cbee2835-96d5-4ed5-85c1-e280c1937ac6"
      decimals="0"
      id="F_ec05c259-a33a-4347-a545-ff492591ce90"
      unitRef="U_shares">662042</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_758bdea3-3881-4991-b7bf-ed3b171e2195"
      decimals="-3"
      id="F_245c42bd-cf5c-4723-834c-1a3a80ec85df"
      unitRef="U_USD">5128000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_7d724320-edb8-4b4c-949d-a766de1de375"
      unitRef="U_USD">5128000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_f06b4d49-9703-446a-ba86-02d5b5a8111b"
      decimals="-3"
      id="F_fd26e8b5-309a-4f7a-80eb-e430793143bb"
      unitRef="U_USD">-209360000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_bb4417db-f4d7-4a87-bd7d-76431083fa8e"
      unitRef="U_USD">-209360000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_c3fb6f51-13eb-4e43-9466-09f4818f1386"
      decimals="0"
      id="F_1021a8b5-a33a-4885-9859-6499a416b262"
      unitRef="U_shares">84826632</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c3fb6f51-13eb-4e43-9466-09f4818f1386"
      decimals="-3"
      id="F_eb847ca2-f8ea-4ac4-81ac-d67711fef482"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aff4aaae-ac9e-419d-8194-f5b7a5c562dd"
      decimals="-3"
      id="F_d7348a80-3193-4716-b4f7-ad097b391963"
      unitRef="U_USD">1456370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cdda42ce-b5f5-4335-9c1e-37c83c1c9673"
      decimals="-3"
      id="F_0bac8760-5fc4-47c2-926e-1d6a3bc90bf3"
      unitRef="U_USD">218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_220ba3e8-b19e-4dfb-b2aa-b75c2caad42b"
      decimals="-3"
      id="F_e9834359-aae0-4353-8284-361544189b77"
      unitRef="U_USD">-902400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_1f122f12-2143-4fb5-8ebe-975072f3f814"
      unitRef="U_USD">554196000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_da17f7ce-17ba-4015-a51c-fcba70563911"
      unitRef="U_USD">-209360000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_4b3f07db-17b8-466a-accc-56cdedc54f69"
      unitRef="U_USD">-149338000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_fc835bc1-3169-40ca-a569-fcc966a85128"
      unitRef="U_USD">24926000</us-gaap:ProfitLoss>
    <sndx:DepreciationAndRelatedAdjustment
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_3473d2c1-44dd-478f-8431-9eaeecb371b7"
      unitRef="U_USD">12000</sndx:DepreciationAndRelatedAdjustment>
    <sndx:DepreciationAndRelatedAdjustment
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_482508ef-6d48-41a5-ace9-70236e8b9595"
      unitRef="U_USD">33000</sndx:DepreciationAndRelatedAdjustment>
    <sndx:DepreciationAndRelatedAdjustment
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_b794359b-2d1a-4efa-8061-81c1ee114432"
      unitRef="U_USD">43000</sndx:DepreciationAndRelatedAdjustment>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_f3e956e6-771b-4d62-a05d-8a16f4a8f0b4"
      unitRef="U_USD">14803000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_fd298bb1-0e59-4d7f-8f79-be41791e1101"
      unitRef="U_USD">3382000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_ef7d12b8-2828-43a3-900b-b4957efc9a6b"
      unitRef="U_USD">-644000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sndx:NoncashOperatingLeaseExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_22fa09ff-2b33-4e39-859a-234d35bf8767"
      unitRef="U_USD">739000</sndx:NoncashOperatingLeaseExpense>
    <sndx:NoncashOperatingLeaseExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_297ce599-3f61-4e6d-b6ea-3dcc451d70d8"
      unitRef="U_USD">421000</sndx:NoncashOperatingLeaseExpense>
    <sndx:NoncashOperatingLeaseExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_c7e22223-cf8d-450c-9717-a7c4de48d73f"
      unitRef="U_USD">413000</sndx:NoncashOperatingLeaseExpense>
    <sndx:PaidInKindInterestAndInterestReversal
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_8946d4b3-6d98-41b6-8bed-19f80d5416b2"
      unitRef="U_USD">0</sndx:PaidInKindInterestAndInterestReversal>
    <sndx:PaidInKindInterestAndInterestReversal
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_1cb3fd70-6c87-40d5-ae22-13be4e48cd84"
      unitRef="U_USD">1103000</sndx:PaidInKindInterestAndInterestReversal>
    <sndx:PaidInKindInterestAndInterestReversal
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_4b67bd33-3b64-426b-9e4e-aed3498bb3a0"
      unitRef="U_USD">-225000</sndx:PaidInKindInterestAndInterestReversal>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_8b8f8383-0446-4cf3-a456-c4f51ea619de"
      unitRef="U_USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_9a8e920c-5676-4e7c-80d2-913abd664bb0"
      unitRef="U_USD">187000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_6e390267-7eac-4878-9448-dd1c5c365c7c"
      unitRef="U_USD">389000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_436e45a8-8296-45cc-ac9a-1d51d10561b9"
      unitRef="U_USD">30951000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_91bac2fe-c3b4-4ae7-821a-5a1b3773ed4e"
      unitRef="U_USD">16019000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_adce9bc8-bf02-46c4-a030-df32efdee25d"
      unitRef="U_USD">13317000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_20904291-06b9-4b92-be28-cb7663454a12"
      unitRef="U_USD">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_19fbfaf7-7c42-4f06-9235-563c76a6a52c"
      unitRef="U_USD">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_01852103-576f-48a0-8ea8-dfecece031d7"
      unitRef="U_USD">1000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_f0e99ae4-f51e-4374-98c6-691d158ad10d"
      unitRef="U_USD">-676000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_dca52fc5-2cd0-4b83-840a-ca592baf1c8f"
      unitRef="U_USD">2972000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_8ec14558-236f-43b8-bc7b-ef9a07174008"
      unitRef="U_USD">1394000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sndx:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_be10877d-248c-4184-a688-fe64debf0a71"
      unitRef="U_USD">10706000</sndx:IncreaseDecreaseInCollaborationReceivable>
    <sndx:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_56caa256-1f8e-4247-934b-7229af1c5e93"
      unitRef="U_USD">-3474000</sndx:IncreaseDecreaseInCollaborationReceivable>
    <sndx:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_78d20166-ff49-44dd-b3ca-a5fae27733be"
      unitRef="U_USD">0</sndx:IncreaseDecreaseInCollaborationReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_64f912b6-3c62-494d-b6a5-baadcffd6c1a"
      unitRef="U_USD">5611000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_cff389dd-8dac-454b-9bff-d28ce87a0c70"
      unitRef="U_USD">-1319000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_972bab35-399a-4817-abf4-35f5e5ce618d"
      unitRef="U_USD">2161000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_42b5ee6b-4d17-4887-a84b-cd2466dbf0b8"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_c0d41e4d-82db-4b04-bf1a-aa86b9e75558"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_e4c2f388-c4ee-4591-9207-e2df9d4692fb"
      unitRef="U_USD">-13133000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_f6974827-c0ed-4aac-8384-940d5c1e5412"
      unitRef="U_USD">14867000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_115452e7-41f2-4fad-8f8c-f77a7939ac92"
      unitRef="U_USD">9421000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_109f0da2-fdb4-4fa1-98d6-76b79e4f4100"
      unitRef="U_USD">2769000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_9fff8f0e-736c-4201-b72d-43a415aece75"
      unitRef="U_USD">-160601000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_ef89b3e4-a35c-4c32-82a5-1693ab447430"
      unitRef="U_USD">-133675000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_7fc2bf7f-9ccd-47e3-afbe-28e485d482df"
      unitRef="U_USD">29131000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_ed6253ab-da9b-4c4b-aea9-d9cc5e72bbb9"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_b7fd64c4-3d5f-4bbf-9d58-10a1067db88f"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_cbba43a3-e44b-4159-ab9a-2f8d1d84286d"
      unitRef="U_USD">129000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_d1af755e-7b51-45b2-8e07-ee48940e305d"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_9661fd49-809a-46ee-b682-6c493d12633a"
      unitRef="U_USD">225000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_30c05656-6337-4001-8da0-c077467e378c"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_52c7d085-f2ec-4a39-be64-5391408a7279"
      unitRef="U_USD">354606000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_28976beb-5b45-4c93-97cd-6f681d8df264"
      unitRef="U_USD">495346000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_0a94bea8-8f22-41fa-9c85-88369df72102"
      unitRef="U_USD">294719000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_fa46e81e-9445-45b0-89b6-65805f0fc36f"
      unitRef="U_USD">472215000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_c06b9bf7-3754-4566-b8ff-c0faa2831522"
      unitRef="U_USD">308933000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_d9084e02-c6f2-4294-8a6c-10119280b5da"
      unitRef="U_USD">253975000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_f66432a7-9b95-4f13-bd18-35c7f498d763"
      unitRef="U_USD">117609000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_7521972a-2ffa-4d79-959a-8dd936ec8eb2"
      unitRef="U_USD">-186188000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_1bb79f62-b332-4715-be27-35b5a432f1af"
      unitRef="U_USD">-40873000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_192455fe-8853-44c4-a2af-b22ba6210f6a"
      decimals="-3"
      id="F_bd6bd8b0-3031-4d60-b569-aa7a7f7703bb"
      unitRef="U_USD">215955000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7704e7f4-6094-4899-941c-17cce4c1ad53"
      decimals="-3"
      id="F_53d3c7ae-fb98-4ce4-aafb-c204de7ce533"
      unitRef="U_USD">161965000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c9f5b310-329a-4434-9537-4ce7c13c5b4b"
      decimals="-3"
      id="F_66871f2b-4b4f-4b57-b2f3-83fbb1af1761"
      unitRef="U_USD">81206000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9415a8d6-3456-4c2f-b211-310686e40961"
      decimals="-3"
      id="F_2d21c4ff-02d4-4e69-b48c-94fbdc6040d9"
      unitRef="U_USD">42139000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a064fef4-51ed-42ca-be0f-f995b8a0ed8a"
      decimals="-3"
      id="F_8d7ec539-d1f4-46cd-b96c-b1bbac988114"
      unitRef="U_USD">19425000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9f8d8621-1769-4079-8f0b-99e55c437b8e"
      decimals="-3"
      id="F_de9a80d2-f6d3-489b-a3ca-4ccb00adca7c"
      unitRef="U_USD">5131000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1d4310ad-0736-4012-b9ce-4a0f9454edae"
      decimals="-3"
      id="F_dec6b41f-3d19-4bbb-acf8-d8210404bb3c"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_fe65bbb1-0d57-4bdf-9127-31463d2d09a8"
      decimals="-3"
      id="F_1c85eb0f-39e0-47e4-bd52-08bbfb452c51"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e7394970-59e6-4cd6-89a6-54b79f895f1d"
      decimals="-3"
      id="F_4269630a-dd42-482a-8c14-83c86d70205e"
      unitRef="U_USD">24848000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ff8445ca-ff4b-4f13-8184-af4837d5724f"
      decimals="-3"
      id="F_e01afd99-4e44-4e28-b97e-31cdf57768b2"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_13c0b160-1a0f-43dd-81e7-cca1d5370eb4"
      decimals="-3"
      id="F_7e1b5dbb-0e38-4bd8-aa80-a5f4c20241c4"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9d930a60-dcb4-4913-bea6-46745efcd9fc"
      decimals="-3"
      id="F_c1e2ee21-c53a-4bd9-b812-c6f0d5812758"
      unitRef="U_USD">576000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForProceedsFromDepositOnLoan
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_ff43858a-c307-437c-bf1d-d3c0b2d6a67b"
      unitRef="U_USD">0</us-gaap:PaymentsForProceedsFromDepositOnLoan>
    <us-gaap:PaymentsForProceedsFromDepositOnLoan
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_dff7fd26-dc8f-488c-9d0f-55f29d00e939"
      unitRef="U_USD">20996000</us-gaap:PaymentsForProceedsFromDepositOnLoan>
    <us-gaap:PaymentsForProceedsFromDepositOnLoan
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_0e4ad878-55a0-4208-9a71-1ad8b28938be"
      unitRef="U_USD">0</us-gaap:PaymentsForProceedsFromDepositOnLoan>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_0900e17d-c283-4ea5-81a2-916515cc827c"
      unitRef="U_USD">910000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_972230b3-d7df-4c16-a68e-eda2446b5974"
      unitRef="U_USD">401000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_7e85e71c-9ddb-41cf-bab2-b475492b4527"
      unitRef="U_USD">367000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_c88c490f-e673-4285-9d27-e5b76bd5932c"
      unitRef="U_USD">5128000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_100c5d75-c85c-48f2-916b-8e561f17f14c"
      unitRef="U_USD">11459000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_4edad0d8-f0c2-47e3-91ef-ab9f1d34fa08"
      unitRef="U_USD">6336000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_5ab157d9-a722-4f94-8bb5-4f9f473afb1b"
      unitRef="U_USD">264132000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_a85c2143-28d2-4565-a631-d24cd9c45046"
      unitRef="U_USD">172254000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_a38a25eb-163c-4612-81a8-659fcf9345aa"
      unitRef="U_USD">118464000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_2c3334a8-68a0-4eea-8ef1-7afe8a225312"
      unitRef="U_USD">221140000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_152382fd-bafb-4e5d-a793-94e8afbbc55d"
      unitRef="U_USD">-147609000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_c15c371f-c617-4b23-8f1c-c7f8128d3511"
      unitRef="U_USD">106722000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_08e1667c-80d6-4206-b534-fe06c8b7625e"
      unitRef="U_USD">74471000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166"
      decimals="-3"
      id="F_e0887133-caff-4385-a62d-01e2d022ff62"
      unitRef="U_USD">222080000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_07dde341-6b8e-4d35-a0a4-24bc46311598"
      decimals="-3"
      id="F_2e47f811-449b-4f63-a766-359d3dee193a"
      unitRef="U_USD">115358000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_a3fb8f1c-c8d5-4202-8d98-9e59fbc6d981"
      unitRef="U_USD">295611000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_b034d1b9-26a1-4ade-b810-b406adea315b"
      unitRef="U_USD">74471000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166"
      decimals="-3"
      id="F_d66fe369-db97-409a-a6c8-e6fa8565e9c6"
      unitRef="U_USD">222080000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_cae6e758-3b5e-4a83-8de9-bb32d8d0c5ce"
      unitRef="U_USD">295394000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_33b0495b-bae9-42ba-822c-af257edce7e1"
      unitRef="U_USD">74356000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166"
      decimals="-3"
      id="F_a7791ab0-4b69-4fa7-a701-aeebd815194c"
      unitRef="U_USD">221965000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_16577908-adb9-478a-a981-b4fc55340bb0"
      unitRef="U_USD">217000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_0f23c04d-3ca9-4d25-a06e-7175381ad3e1"
      unitRef="U_USD">115000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166"
      decimals="-3"
      id="F_86417aea-9f37-4814-a3e6-a6a78149fa80"
      unitRef="U_USD">115000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_7703d346-60df-435f-99c6-b55aa6197a4e"
      unitRef="U_USD">295611000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_9f688a25-49b7-4e7e-8e47-8feff69844ed"
      unitRef="U_USD">74471000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166"
      decimals="-3"
      id="F_6be7a242-e00f-4b93-a61a-1d3ee994037c"
      unitRef="U_USD">222080000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_6c22bc0b-6b50-4e24-b305-90456bc49bbf">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Nature of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Syndax Pharmaceuticals, Inc. (&#x201c;the Company&#x201d; or &#x201c;Syndax&#x201d;) is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's two lead product candidates are revumenib and axatilimab. The Company is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, (&#x201c;KMT2Ar&#x201d;), also known as mixed lineage leukemia rearranged, (&#x201c;MLLr&#x201d;), acute leukemias including acute lymphoblastic leukemia, (&#x201c;ALL&#x201d;), and acute myeloid leukemia, or AML, and nucleophosmin 1, also known as NPM1, mutant AML. The Company is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The Company is developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor, (&#x201c;CSF-1R&#x201d;), in chronic graft-versus-host disease, (&#x201c;cGVHD&#x201d;), as well as idiopathic pulmonary fibrosis, (&#x201c;IPF&#x201d;). The Company plans to continue to leverage the technical and business expertise of its management team and scientific collaborators to license, acquire and develop additional therapeutics to expand its pipeline.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company&#x2019;s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it will be several years before any of its product candidates is approved, if ever, and the Company begins to generate revenue from sales of such product candidates. Accordingly, management expects to incur substantial losses on the ongoing development of its product candidates and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s management believes that the cash, cash equivalents and short-term investments balances as of December 31, 2023, should enable the Company to maintain its planned operations for at least 12 months from the issuance date of these financial statements. The Company&#x2019;s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds were not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and selling, general and administrative activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to challenges and risks specific to its business and ability to execute on the strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of the Company&#x2019;s late-stage product candidate; delays or problems in the supply of the Company&#x2019;s products, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing the Company&#x2019;s intellectual property rights; complying with applicable regulatory requirements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_a48757d7-732f-475a-93d5-69226bf88e03">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has prepared the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). &lt;/span&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_0eeaa7a6-0ff7-4d63-81cb-50312f315a10">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents include all highly liquid investments maturing within 90 days or less from the date of purchase. Cash equivalents include money market funds, corporate debt securities, U.S. government agency notes, and overnight deposits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; All investments in marketable securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses excluded from earnings and reported net of tax in accumulated other comprehensive income, which is a component of stockholders&#x2019; equity. Unrealized losses that are determined to be other-than-temporary, based on current and expected market conditions, are recognized in earnings. Declines in fair value determined to be credit related are charged to earnings. The cost of marketable securities sold is determined by the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents, restricted cash, and short and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company&#x2019;s cash, cash equivalents, and short and long-term investments were deposited in accounts at two financial institutions, and at times, such deposits may exceed federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#x2019;s available-for-sale investments primarily consist of government money market funds, corporate debt securities, commercial paper, credit card asset-backed securities and overnight deposits and potentially subject the Company to concentrations of credit risk.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0e6f7b74-b212-412d-a290-cfa9eb6e858f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). Assets under capital leases are amortized over the shorter of their useful lives or lease term using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value. To date, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such impairments have been recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. The Company recognize revenue following the five &#x2013; step model prescribed under FASB Accounting Standards Codification (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ASC 606), Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: (i) identify contract(s) with customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: Revenue from non-refundable, up-front fees allocated to the licenses related to the Company's intellectual property, are recognized as the license is transferred to the customer and the customer is able to use and benefit from the license. This generally takes place over the related know-how transfer period, or if applicable, over the term of transfer of future updates to the intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Development Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: The Company evaluates whether milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license fees and earnings in the period of adjustment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commercial Milestone Payments and Royalties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: For arrangements that include sales-based royalties, including milestone payments based on the level of commercial sales, and the license is deemed to be the predominant item to which the royalties or commercial milestones relate, the Company will recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date no commercial milestone payments or royalties have been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;When no performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability. Upfront payment contract liabilities resulting from the Company&#x2019;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For additional information on our collaboration and license arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Note 4, Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to these consolidated financial statements. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses include payroll and personnel expenses, consulting costs, external contract research and development expenses, and allocated overhead, including rent, equipment depreciation, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. The Company expenses upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In instances where the Company enters into cost-sharing arrangements, all research and development costs reimbursed by the collaborators are accounted for as reductions to research and development expense. During the years ended December 31, 2023 and 2022, the Company has incurred external costs related to Incyte cost-sharing collaboration. During the year ended December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company incurred &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; external costs related to cost-sharing collaborations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Clinical Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Clinical study and trial costs are a component of research and development expenses. The Company expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific contract tasks using data such as patient enrollment, clinical site activations, or other information provided to us by our vendors. Depending on the progression of the contract and timing of invoicing and payment the research and development expense can be an accrued expense or a prepaid expense. Prepaid clinical study and trial costs are included in short-term deposits on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#x2019;s financial statement carrying amounts and the tax bases of assets and liabilities and for loss and credit carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is provided to reduce the net deferred tax assets to the amount that will more likely than not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. The Company has standard indemnification arrangements under office leases (as described in Note 5, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to these consolidated financial statements) that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the Company&#x2019;s lease. Through December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had not experienced any losses related to these indemnification obligations and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; related reserves were established.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for all stock option awards granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value of the stock option grants and is recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(Loss) Earnings Per Share&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Syndax by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_099713ed-c4b2-4dad-ac78-ec8ab6eb21d1">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_f716aeee-3947-4697-a207-9bf5a52e651b">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents include all highly liquid investments maturing within 90 days or less from the date of purchase. Cash equivalents include money market funds, corporate debt securities, U.S. government agency notes, and overnight deposits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_a898836d-b42e-4d91-8073-991a37725d49">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_492cec17-f51e-474d-88ab-f62816a189f2">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; All investments in marketable securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses excluded from earnings and reported net of tax in accumulated other comprehensive income, which is a component of stockholders&#x2019; equity. Unrealized losses that are determined to be other-than-temporary, based on current and expected market conditions, are recognized in earnings. Declines in fair value determined to be credit related are charged to earnings. The cost of marketable securities sold is determined by the specific identification method.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_cc676cd9-783e-4446-b93f-18c31f610309">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="INF"
      id="F_2ffafec2-4da9-47fb-abf5-fb783d0ead24"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_8d10f854-076b-4993-842f-82a61ae35d2e">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents, restricted cash, and short and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company&#x2019;s cash, cash equivalents, and short and long-term investments were deposited in accounts at two financial institutions, and at times, such deposits may exceed federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#x2019;s available-for-sale investments primarily consist of government money market funds, corporate debt securities, commercial paper, credit card asset-backed securities and overnight deposits and potentially subject the Company to concentrations of credit risk.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_7d24d114-6e8c-451d-92e6-d04e99469eff">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0e6f7b74-b212-412d-a290-cfa9eb6e858f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). Assets under capital leases are amortized over the shorter of their useful lives or lease term using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d5b70f38-d948-41d2-b18c-a03562f8c1ad"
      id="F_fb1798ad-d15a-477b-ae87-aa1ecd110033">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_310c46c4-060c-4985-9921-39a09c1c3c97">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value. To date, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such impairments have been recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="0"
      id="F_73573a35-28e0-4f93-bff3-8fe7490389bd"
      unitRef="U_USD">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_4c1a82fc-d310-46bd-89db-4290893229b2">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. The Company recognize revenue following the five &#x2013; step model prescribed under FASB Accounting Standards Codification (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ASC 606), Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: (i) identify contract(s) with customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: Revenue from non-refundable, up-front fees allocated to the licenses related to the Company's intellectual property, are recognized as the license is transferred to the customer and the customer is able to use and benefit from the license. This generally takes place over the related know-how transfer period, or if applicable, over the term of transfer of future updates to the intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Development Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: The Company evaluates whether milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license fees and earnings in the period of adjustment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commercial Milestone Payments and Royalties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: For arrangements that include sales-based royalties, including milestone payments based on the level of commercial sales, and the license is deemed to be the predominant item to which the royalties or commercial milestones relate, the Company will recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date no commercial milestone payments or royalties have been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;When no performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability. Upfront payment contract liabilities resulting from the Company&#x2019;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For additional information on our collaboration and license arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Note 4, Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to these consolidated financial statements. &lt;/span&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_28ca995c-a577-45f7-ab1c-114bf8993e9b">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses include payroll and personnel expenses, consulting costs, external contract research and development expenses, and allocated overhead, including rent, equipment depreciation, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. The Company expenses upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In instances where the Company enters into cost-sharing arrangements, all research and development costs reimbursed by the collaborators are accounted for as reductions to research and development expense. During the years ended December 31, 2023 and 2022, the Company has incurred external costs related to Incyte cost-sharing collaboration. During the year ended December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company incurred &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; external costs related to cost-sharing collaborations.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <sndx:CostsRelatedToCostSharingCollaborations
      contextRef="C_8240772c-7e9d-4f0c-9469-d94e57373408"
      decimals="-6"
      id="F_baa6705c-7f69-4984-ae0c-ac2c0325ad39"
      unitRef="U_USD">0</sndx:CostsRelatedToCostSharingCollaborations>
    <sndx:ClinicalTrialCostPolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_49f211de-582d-489f-aa17-2616fde6a8bd">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Clinical Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Clinical study and trial costs are a component of research and development expenses. The Company expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific contract tasks using data such as patient enrollment, clinical site activations, or other information provided to us by our vendors. Depending on the progression of the contract and timing of invoicing and payment the research and development expense can be an accrued expense or a prepaid expense. Prepaid clinical study and trial costs are included in short-term deposits on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</sndx:ClinicalTrialCostPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_58eb5c03-abc7-4493-9c35-c3ef4b36d732">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#x2019;s financial statement carrying amounts and the tax bases of assets and liabilities and for loss and credit carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is provided to reduce the net deferred tax assets to the amount that will more likely than not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <sndx:PercentageOfIncomeTaxContingencyRealized
      contextRef="C_297b9be3-9752-4119-bccd-c1340527438c"
      decimals="2"
      id="F_cfed8db2-112b-4230-b708-91b95d86b382"
      unitRef="U_pure">0.50</sndx:PercentageOfIncomeTaxContingencyRealized>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_7d803ae9-7cf7-49de-839f-a97ecaca6159">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. The Company has standard indemnification arrangements under office leases (as described in Note 5, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to these consolidated financial statements) that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the Company&#x2019;s lease. Through December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had not experienced any losses related to these indemnification obligations and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; related reserves were established.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="C_6644a9fe-b908-416a-b736-f657bd63cd2b"
      decimals="INF"
      id="F_c7991757-719c-4155-b524-efd38d5cd55e"
      unitRef="U_Claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <sndx:IndemnificationObligationsClaimsReserves
      contextRef="C_22fc27d0-840a-44e9-bbda-98d42fe3a807"
      decimals="-3"
      id="F_0942e069-07e3-4965-bc5e-6e30311ff2e6"
      unitRef="U_USD">0</sndx:IndemnificationObligationsClaimsReserves>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_5b66291a-6448-4951-8d60-fe1e92cf8829">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for all stock option awards granted to employees and non-employees using a fair value method. Stock-based compensation is measured at the grant date fair value of the stock option grants and is recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_77736f33-020f-4a6f-aeda-5567e788ea55">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(Loss) Earnings Per Share&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Syndax by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_8cb2372d-40bb-4d80-948c-ab3b914f1151">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <sndx:CollaborativeResearchAndLicenseAgreementsTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_1ed644b8-ad26-4414-a34f-64b482bd9308">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Collaborative Research and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Incyte Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2021, the Company entered into license and collaboration agreement (the "Incyte License and Collaboration Agreement") with Incyte Corporation ("Incyte") covering the worldwide development and commercialization of axatilimab. Also, in September 2021 the Company entered into a share purchase agreement with Incyte, ("Incyte Share Purchase Agreement" and together with Incyte License and Collaboration Agreement, the Incyte Agreements"). Under the terms of the Incyte Agreements, Incyte will receive exclusive commercialization rights outside of the United States, subject to its royalty payment obligations set forth below. In the United States, Incyte and the Company will co-commercialize axatilimab, with the Company having the right to co-promote axatilimab with Incyte, subject to the Company&#x2019;s exercise of its co-promotion option. Incyte will be responsible for leading all aspects of commercialization of axatilimab in the United States. The Company and Incyte will share equally the profits and losses from co-commercialization efforts in the United States. The Company and Incyte have agreed to co-develop axatilimab and to share development costs associated with global and U.S. &#x2013; specific clinical trials, with Incyte responsible for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of such costs and the Company responsible for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of such costs. Each company will be responsible for funding any of its own independent development activities. Incyte is responsible for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of future development costs for trials that are specific to ex-U.S. countries. All development costs related to the collaboration with Incyte will be subject to a joint development plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Incyte Agreements, in December 2021, Incyte paid the Company a non-refundable cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,421,523&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock with an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.62&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. Additionally, under the terms of the Incyte Agreements, the Company is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;220.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in future contingent development and regulatory milestones and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;230.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in commercialization milestones as well as tiered royalties ranging in the mid-teens percentage on net sales of the licensed product comprising axatilimab in Europe and Japan and low double digit percentage in the rest of the world outside of the United States. The Company's right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of licensed patent rights covering the licensed product in that particular country, (b) a specified period of time after the first post - marketing authorization sale of a licensed product in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Incyte Agreement and the Incyte Share Purchase Agreement were executed on the same date and negotiated simultaneously. Management therefore concluded that the Incyte Agreements are to be combined for accounting purposes and therefore allocated the total consideration to the units of account identified. The common stock issued to Incyte was recorded at fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Pursuant to the Letter Agreement, Incyte is permitted to terminate the Incyte Agreement, under circumstances under which the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million would be returned to Incyte and a cash settlement on the sale of the Company's common stock would be made to make the parties whole (the &#x201c;Letter Agreement&#x201d;). In connection with the closing of this transaction in December 2021, the Company determined that the cash settlement feature of the Letter Agreement represented an embedded derivative requiring bifurcation and separate accounting recognition at fair value. The Letter Agreement terminated in March 2022. Accordingly, the Company initially allocated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the total consideration received to the derivative liability. As of December 31, 2022, the fair value of the derivative is zero.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluated the terms of the Incyte Agreement and determined it is within the scope of Accounting Standard Update &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2018-18, Collaborative Arrangements (Topic 808)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and has elements that are within the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 606&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 808&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company identified the following promises in the Incyte Agreements that were evaluated under the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 606&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: (i) delivery of a license for axatilimab to develop, commercialize, and conduct medical affairs and (ii) services to be performed in accordance with the development plan. The Company also evaluated whether certain options outlined within the Incyte Agreements represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Incyte and therefore are not considered separate performance obligations within the Incyte Agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed the above promises and determined that the license for axatilimab represents the only performance obligation within the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 606&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The license for axatilimab is considered functional&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;intellectual property and distinct from other promises under the contract as Incyte can benefit from the license on its own or together with other readily available resources. The services performed by the Company to obtain regulatory approval of axatilimab are not complex or specialized, could be performed by another qualified third party, are not expected to significantly modify or customize the license given that axatilimab is late-stage intellectual property that has completed its Phase 1/2 trial and is currently enrolling in a global pivotal Phase 2 trial, and the services are expected to be performed over a short period of time. Therefore, the license represents a separate performance obligation within a contract with a customer under the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 606&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; at contract inception.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers the collaborative research and development activities and manufacturing activities to be separate units of account within the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 808&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and are not deliverables under &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 606&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company and Incyte are both active participants in the activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities in the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 606&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company identified contract promises for the license of intellectual property and know-how rights for axatilimab. The Company determined that the license was capable of being distinct from the ongoing collaboration activities. After the allocation to the common stock and derivative liability, the total transaction price to be allocated to the Incyte Agreement is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company estimated the standalone selling price of the license to be the entire $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, based on an application of the income approach by measuring the fair value of the discounted cash flows from commercialization. Significant assumptions included in the valuation included judgments relating to the probability of achieving both regulatory and commercial milestones, forecasted future cash flows and the election of the discount rate. As the Company concluded the license was distinct, revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recognized upon transfer of the license to Incyte in the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential preclinical, development, and regulatory variable consideration milestone payment under this agreement is zero, as achievement of those milestones is uncertain and highly susceptible to factors outside the Company&#x2019;s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based royalties, including milestones based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate. The company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Company considers the collaborative research and development activities and manufacturing activities to be separate units of account within the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 808&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and are not deliverables under &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Topic 606&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company and Incyte are both active participants in the activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities in the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company has recorded &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as a collaboration receivable due from Incyte related to the Company's development and pre-commercialization costs under the Incyte Agreements and has recorded approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as a collaboration payable due to Incyte for development and pre-commercialization costs incurred by Incyte as of December 31, 2023. Both expenses and cost offset are recorded as part of research and development and selling, general and administrative expense.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</sndx:CollaborativeResearchAndLicenseAgreementsTextBlock>
    <sndx:DevelopmentCostsAssociatedWithClinicalTrials
      contextRef="C_72227cf4-0a6a-4050-89fc-fc52e7d77a79"
      decimals="2"
      id="F_5967dca2-fb0a-4527-8938-4e053d2ec6ac"
      unitRef="U_pure">0.55</sndx:DevelopmentCostsAssociatedWithClinicalTrials>
    <sndx:DevelopmentCostsAssociatedWithClinicalTrials
      contextRef="C_4bd80ba5-9483-4290-bd6b-8b3b7622307a"
      decimals="2"
      id="F_bd92d8fb-35fa-4fc0-b914-191fb82bd9b3"
      unitRef="U_pure">0.45</sndx:DevelopmentCostsAssociatedWithClinicalTrials>
    <sndx:DevelopmentCostsAssociatedWithClinicalTrials
      contextRef="C_784acd93-e389-42e6-b562-fe5fa32789cf"
      decimals="INF"
      id="F_1b69bf6b-75ca-42f1-825d-901cb8614408"
      unitRef="U_pure">1</sndx:DevelopmentCostsAssociatedWithClinicalTrials>
    <sndx:UpfrontPayments
      contextRef="C_8e4ddcb8-8500-42e0-9874-81661d600b3a"
      decimals="-5"
      id="F_9e8c5491-18b9-4976-95f8-e209b901ab00"
      unitRef="U_USD">117000000</sndx:UpfrontPayments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b"
      decimals="0"
      id="F_d5827f76-17e7-4c07-9a36-e0db1a0e1bba"
      unitRef="U_shares">1421523</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b"
      decimals="-5"
      id="F_bfc91ade-8af5-4d40-ba91-d57da8c64c1b"
      unitRef="U_USD">35000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0ac7d980-2b3e-46ff-96cc-410f348499f9"
      decimals="2"
      id="F_42cc179d-c6d3-4dd4-a40d-125fc85e28c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.62</us-gaap:SharesIssuedPricePerShare>
    <sndx:PotentialMilestonePaymentsUponAchievementOfMilestone
      contextRef="C_abcfbe51-431c-4e69-83e7-98632aac4ec0"
      decimals="-5"
      id="F_7e7051a2-0b8b-43b4-9a85-a7cceb3e3e4f"
      unitRef="U_USD">220000000</sndx:PotentialMilestonePaymentsUponAchievementOfMilestone>
    <sndx:CommercializationMilestonesAndTieredRoyalties
      contextRef="C_abcfbe51-431c-4e69-83e7-98632aac4ec0"
      decimals="-5"
      id="F_d1172761-e452-4a49-ae64-f3c930e46c92"
      unitRef="U_USD">230000000</sndx:CommercializationMilestonesAndTieredRoyalties>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b"
      decimals="-5"
      id="F_64754950-a238-4c0d-b217-2cbbd8e55773"
      unitRef="U_USD">24800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sndx:UpfrontPaymentsToBeReturnedUponTerminationOfAgreement
      contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b"
      decimals="-6"
      id="F_1ae48f44-e627-46b1-8932-48526fb9caaa"
      unitRef="U_USD">117000000</sndx:UpfrontPaymentsToBeReturnedUponTerminationOfAgreement>
    <sndx:CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability
      contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b"
      decimals="-5"
      id="F_95299003-9e3a-4f71-a6a7-08ade6e120bb"
      unitRef="U_USD">600000</sndx:CollaborationAndLicenseAgreementAllocatedConsiderationReceivedToDerivativeLiability>
    <sndx:CollaborationAndLicenseAgreementConsiderationTransactionPrice
      contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b"
      decimals="-5"
      id="F_47ca9c3b-cda2-498a-af6b-7e29a288aee8"
      unitRef="U_USD">126600000</sndx:CollaborationAndLicenseAgreementConsiderationTransactionPrice>
    <sndx:EstimatedStandaloneSellingPriceOfLicenseAgreement
      contextRef="C_56286884-2fcc-4f47-8d67-14db89877f0b"
      decimals="-5"
      id="F_81bbf944-2b61-4322-b65b-49b42ee321d7"
      unitRef="U_USD">126600000</sndx:EstimatedStandaloneSellingPriceOfLicenseAgreement>
    <sndx:RevenueRecognizedUponTransferOfLicenseAgreement
      contextRef="C_007add38-cb78-4807-8ceb-0a17db3708dd"
      decimals="-5"
      id="F_e61f006b-f9c0-4153-9dd7-98bb6885ba41"
      unitRef="U_USD">126600000</sndx:RevenueRecognizedUponTransferOfLicenseAgreement>
    <sndx:CollaborationReceivable
      contextRef="C_6fa3ac50-99f5-4a54-9d47-385cab5f80e9"
      decimals="-5"
      id="F_3e586a21-aa17-4261-b6e5-248b8c686992"
      unitRef="U_USD">2200000</sndx:CollaborationReceivable>
    <sndx:CollaborationExpenseDueToCounterparty
      contextRef="C_6fa3ac50-99f5-4a54-9d47-385cab5f80e9"
      decimals="-5"
      id="F_b8163d2c-7611-453f-9bc6-36edd30ab4ad"
      unitRef="U_USD">9500000</sndx:CollaborationExpenseDueToCounterparty>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_3a52eaa7-bd0f-4682-83dd-9110a77d9e33">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for leases in accordance with &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ASC 842, Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and determines whether an arrangement is a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. For leases that do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The ROU asset also includes any lease&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company identified three existing long-term building leases under ASC 842 that are classified as operating leases. In September 2016, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,207&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office space in Waltham, MA, with a lease commencement date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 1, 2017&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 17, 2021, the Company signed a 36-month extension to the lease for the Waltham, MA office with aggregate payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, with a lease commencement date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2015, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-month operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,039&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of space in New York, NY, which commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2016&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In February 2021, the Company signed an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-month extension to the lease for the New York office, which commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In August 2022, the Company signed a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-month extension to the lease for the New York office, with aggregate payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;689,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with a lease commencement date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-month operating lease f&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,217&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; sq&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;uare feet of space in New York, NY, with aggregate payments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;with a lease commencement date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The remaining lease terms as of December 31, 2023, for the facility in Waltham, MA and the two facilities in New York, NY, were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the consolidated balance sheet includes a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating lease ROU asset and a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ROU liability. The Company used a weighted average discount rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to calculate its lease obligations, and an increase or decrease in the rate does not have a significant impact on the ROU asset or ROU liability. The ROU asset is amortized on a straight-line basis over the remainder of the lease term. For the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the Company recorded approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;743,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in operating lease expense and made approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;924,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in lease payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments under the Company&#x2019;s operating leases, were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.99%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.401%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:39.208000000000006%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.401%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments under the Company&#x2019;s capital leases as of December 31, 2023 and 2022, were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,864&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,441&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="C_f35290a2-0231-4805-aa9a-709a7b059991"
      id="F_0f706b3a-8041-4adb-af97-d82a8154496a">P5Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_f35290a2-0231-4805-aa9a-709a7b059991"
      decimals="0"
      id="F_b0cd7ae3-0289-4543-8e4b-e1607e2911aa"
      unitRef="U_sqft">12207</us-gaap:AreaOfRealEstateProperty>
    <sndx:LeaseCommencementDate
      contextRef="C_02ca18d5-fa6f-4bfb-a876-c093b9ca6330"
      id="F_058311a0-2f9f-4fe4-8b84-c8f2cabbe0ac">2017-03-01</sndx:LeaseCommencementDate>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0d97a76a-d900-4c17-babb-1f3067aebaca"
      id="F_bba6e7b7-7b09-4e14-bb43-4ba494122d66">On August 17, 2021, the Company signed a 36-month extension to the lease for the Waltham, MA office with aggregate payments of $1.6 million, with a lease commencement date of March 1, 2022.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeasePayments
      contextRef="C_76ed7aa3-1ed8-4f3a-a48f-60eaa77cb270"
      decimals="-5"
      id="F_4550e691-4cca-4d79-be1b-06a3aaef2b21"
      unitRef="U_USD">1600000</us-gaap:OperatingLeasePayments>
    <sndx:LeaseCommencementDate
      contextRef="C_76ed7aa3-1ed8-4f3a-a48f-60eaa77cb270"
      id="F_db83ca62-25c9-4943-bc25-af017dcb7cd1">2022-03-01</sndx:LeaseCommencementDate>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="C_1fc4e017-06d9-47f7-8d2d-9de747aea836"
      id="F_169339ce-0987-456f-af6d-b0b42b0f45aa">P62M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_1fc4e017-06d9-47f7-8d2d-9de747aea836"
      decimals="0"
      id="F_c1fb3016-8ce2-4a92-a6b5-c89ef72c4be3"
      unitRef="U_sqft">4039</us-gaap:AreaOfRealEstateProperty>
    <sndx:LeaseCommencementDate
      contextRef="C_66e29f85-4ac7-49ec-9bd3-2f763f1d6dfa"
      id="F_6fe6a37d-f975-4f4c-b7b8-ef28d5a6ca0b">2016-01-01</sndx:LeaseCommencementDate>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="C_12411cb5-5f6c-4911-b870-4a0f20b18078"
      id="F_973e6232-a3ce-4a72-a59a-935f0f8d9ada">P18M</us-gaap:LessorOperatingLeaseTermOfContract>
    <sndx:LeaseCommencementDate
      contextRef="C_00ddaa2a-3337-45b1-b374-1c84e826418c"
      id="F_b8c03bf9-9516-4040-9649-c258224ebf45">2021-03-01</sndx:LeaseCommencementDate>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="C_51f40d68-fa17-4b98-aa7c-a40331129e97"
      id="F_04baecb4-11a2-4bce-bda7-209045294230">P36Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeasePayments
      contextRef="C_84340f1a-f771-4068-83fa-b64ee4e714f5"
      decimals="0"
      id="F_08357b12-e32f-456c-8872-7805133f1204"
      unitRef="U_USD">689000</us-gaap:OperatingLeasePayments>
    <sndx:LeaseCommencementDate
      contextRef="C_84340f1a-f771-4068-83fa-b64ee4e714f5"
      id="F_b51ad27d-8e6d-472a-a6b6-a163e60b0e4a">2022-09-01</sndx:LeaseCommencementDate>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="C_03aeaecd-5be7-490b-86d3-d29870f2e796"
      id="F_5be2adda-67b0-45dd-a04d-944b011f3725">P27M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_03aeaecd-5be7-490b-86d3-d29870f2e796"
      decimals="0"
      id="F_66ec374b-74b7-45fa-a83a-9adafb4ae3dd"
      unitRef="U_sqft">12217</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0733728d-ca28-4bce-89bd-0ce117dade3e"
      decimals="-5"
      id="F_3c63786c-0f17-4c45-b7be-89111541a91c"
      unitRef="U_USD">1600000</us-gaap:OperatingLeasePayments>
    <sndx:LeaseCommencementDate
      contextRef="C_0733728d-ca28-4bce-89bd-0ce117dade3e"
      id="F_7ba0fc96-6566-4ee2-b437-508c00e14702">2023-06-01</sndx:LeaseCommencementDate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_fd52ffb1-9775-4773-a4a5-24f8f2743b17"
      id="F_d85560df-1301-4730-89be-3923efd503fc">P14M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_2e5821c0-1935-43a7-b0ba-c858e0c7d907"
      id="F_b900ea8d-f559-4e66-948a-ce24a2c098c5">P20Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-5"
      id="F_163d61d0-f806-4774-a86f-4196f486f93e"
      unitRef="U_USD">1500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-5"
      id="F_e0a51645-da5c-4f64-90d7-153cf0ef963b"
      unitRef="U_USD">1600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="2"
      id="F_34c63128-4911-41d0-bb99-b8437cebc1b9"
      unitRef="U_pure">0.14</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="0"
      id="F_b28d3a06-84e9-4926-a7c5-4c9dc8849faa"
      unitRef="U_USD">743000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="0"
      id="F_bde2f449-ee41-469f-adc7-0b992784fe4e"
      unitRef="U_USD">924000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_db40cab2-8f0f-4307-8d36-f7754aecaf51">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments under the Company&#x2019;s operating leases, were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.99%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.401%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:39.208000000000006%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.401%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_aa2564fe-2590-4e7d-ad55-fc2a8e41f3e6"
      unitRef="U_USD">1196000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_4e65ebc7-2092-4905-a7e8-1c8a635d34ba"
      unitRef="U_USD">606000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <sndx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_67f90d6d-b5d4-4d3c-a8de-d2973660f59c"
      unitRef="U_USD">0</sndx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_1c740c0a-e152-4ec0-9099-8cfe40bf9107"
      unitRef="U_USD">1802000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_5d66d4e9-f706-4ace-b609-0e18e06fa730"
      unitRef="U_USD">189000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_eb519ed3-d7ef-41d2-b896-35a7ab9c6480"
      unitRef="U_USD">1613000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_1f80c76a-baa8-43c1-b6e7-850cacb9bcc3"
      unitRef="U_USD">25864000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_7f6330d5-cf8b-47bf-8a2d-4be174e66858"
      unitRef="U_USD">22441000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_8aa2d22f-8f38-4164-902f-55b2d0bf1461">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. (Loss) Earnings per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted (loss) earnings per share are calculated as follows (in 000s):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.352%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.022%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;209,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;209,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Effective of Dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non - vested restricted stock units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Shares used in calculating diluted (loss) earnings per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in 000s):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For additional information related to the Company's common stock see &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Note 12, Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_54982a5c-8abb-44c5-a912-edc372c4f540">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted (loss) earnings per share are calculated as follows (in 000s):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.352%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.022%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;209,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;209,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Effective of Dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non - vested restricted stock units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Shares used in calculating diluted (loss) earnings per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_62f8e7f0-3245-42ef-88d0-f60346e9d7a0"
      unitRef="U_USD">-209360000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_6bd5eecf-812a-4fff-b5fc-169bc0c64781"
      unitRef="U_USD">-149338000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_428161a0-9c6f-4278-8e75-5780a019275c"
      unitRef="U_USD">24926000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_9b7a9da7-6e80-43a8-9f1f-c663d11d0ecb"
      unitRef="U_USD">-209360000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_c02cc855-a6c2-46e0-bc86-e372e648c98d"
      unitRef="U_USD">-149338000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_5da5e785-974f-4d6f-b21c-c79075818870"
      unitRef="U_USD">24926000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_88bf2ad6-4eeb-4b96-be88-0da49eddcee0"
      unitRef="U_shares">70371000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_dd8eff4a-c3ae-4509-88c5-d2c33080e195"
      unitRef="U_shares">60761000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_bf675e7c-8326-4d94-9cbb-cba7f7a7214b"
      unitRef="U_shares">52065000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_6ff18d23-59d3-47d1-9c4b-5af2583db483"
      decimals="INF"
      id="F_7e37a5ab-205c-499a-98d2-822a9236ea38"
      unitRef="U_shares">1429000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_6963fa61-8ec6-4bd0-aa49-52db5ff91e9b"
      decimals="INF"
      id="F_6d53564f-d952-44d0-b2cb-0ebc9e0f7b57"
      unitRef="U_shares">118000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_26c0fc6f-728e-49e8-824f-78d32eaa25c6"
      decimals="INF"
      id="F_b6a47c1c-5d45-499a-bb82-b49a0f901d32"
      unitRef="U_shares">11000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="INF"
      id="F_6c1d644c-864c-4c16-8dad-fbca8bd58374"
      unitRef="U_shares">1558000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_2f94308c-e7cb-45d0-a143-abab2043ca23"
      unitRef="U_shares">70371000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_b1a00ea0-510d-4579-9b07-6727eecdc346"
      unitRef="U_shares">60761000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_6e3914fb-841a-414f-8062-b3fdd1c9f4fb"
      unitRef="U_shares">53623000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_389f4f48-50ab-4774-a918-d7a245fde56a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in 000s):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For additional information related to the Company's common stock see &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Note 12, Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5b6fd47e-9446-44a8-8162-95fdb9778785"
      decimals="0"
      id="F_4c34434f-23e2-497e-a496-859d8630983b"
      unitRef="U_shares">10685</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_382491e5-93f3-4c43-b99a-07ae7ae81dd4"
      decimals="0"
      id="F_6bea7473-c4d0-41ef-be1e-06412cb2033f"
      unitRef="U_shares">7982</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2e0f6494-687d-4fd7-836a-90f591faf296"
      decimals="0"
      id="F_f85de70b-d673-4dad-92bb-f9daada57d54"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a02bc65a-614e-4743-902b-962e339de54c"
      decimals="0"
      id="F_2862681f-9304-4f9f-aa67-cee39c2f602a"
      unitRef="U_shares">309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f4d0fa56-19c4-4e1e-be2c-7d22cb6fdd00"
      decimals="0"
      id="F_d84f05c2-b07b-4110-9920-7d5b0eb92b27"
      unitRef="U_shares">131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8a5e0f58-65f4-485e-beb0-bd6d07cb0472"
      decimals="0"
      id="F_558a13d4-054c-471d-96cd-526e8c3961b7"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e4be5e2a-ca86-4e3c-b7a9-c1323e17fe48"
      decimals="0"
      id="F_1bba4765-724c-47ff-a617-6098aef5dc0c"
      unitRef="U_shares">35</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7b7db385-57f7-42af-835a-310ebe8bfb57"
      decimals="0"
      id="F_5edfe43b-c2a5-4cab-a52a-dc18cb96f4d8"
      unitRef="U_shares">17</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_113325fa-4d36-4203-99b1-36c13868211f"
      decimals="0"
      id="F_58251fda-0823-42a7-8e64-f307effe1954"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <sndx:SignificantAgreementsDisclosureTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_f37d0864-f2d6-4fcf-86c9-e774e463cf1d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Significant Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Vitae Pharmaceuticals, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2017, the Company entered into a license agreement (the &#x201c;Allergan License Agreement&#x201d;) with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan (&#x201c;Allergan&#x201d;), under which Allergan granted the Company an exclusive, sublicensable, worldwide license to a portfolio of preclinical, orally available, small molecule inhibitors of the interaction of menin with Mixed Lineage Leukemia (&#x201c;MLL&#x201d;) protein (the &#x201c;Menin Assets&#x201d;). The Company made a nonrefundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Allergan in the fourth quarter of 2017. Additionally, subject to the achievement of certain milestone events, the Company may be required to pay Allergan up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in one-time development and regulatory milestone payments over the term of the Allergan License Agreement. In the event that the Company or any of its affiliates or sublicensees commercializes the Menin Assets, the Company will also be obligated to pay Allergan low single to low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in potential one-time, sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, the Company may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with Allergan. The Company is solely responsible for the development and commercialization of the Menin Assets. Each party may terminate the Allergan License Agreement for the other party&#x2019;s uncured material breach or insolvency; and the Company may terminate the Allergan License Agreement at will at any time upon advance written notice to Allergan. Allergan may terminate the Allergan License Agreement if the Company or any of its affiliates or sublicensees institutes a legal challenge to the validity, enforceability, or patentability of the licensed patent rights. Unless terminated earlier in accordance with its terms, the Allergan License Agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years from the date of the first commercial sale of the product in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of the date of the Allergan License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility. As the processes or activities that were acquired along with the license do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset acquisition. As a result, in 2017, the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded as research and development expense in the consolidated statements of operations. Since the inception of the agreement, the Company achieved certain development and regulatory milestones resulting in $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in expense, which included $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million paid in the first quarter of 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;UCB Biopharma Sprl&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2016, the Company entered into a license agreement (the &#x201c;UCB License Agreement&#x201d;) with UCB Biopharma Sprl (&#x201c;UCB&#x201d;), under which UCB granted to the Company a worldwide, sublicensable, exclusive license to UCB6352, which the Company refers to as axatilimab, an Investigational New Drug Application-ready anti-CSF-1R monoclonal antibody. The Company made a nonrefundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to UCB in the third quarter of 2016. Additionally, subject to the achievement of certain milestone events, the Company may be required to pay UCB up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;119.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in one-time development and regulatory milestone payments over the term of the UCB License Agreement. In the event that the Company or any of its affiliates or sublicensees commercializes axatilimab, the Company will also be obligated to pay UCB low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in potential one-time, sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, the Company may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with UCB. The Company will be solely responsible for the development and commercialization of axatilimab, except that UCB is performing a limited set of transitional chemistry, manufacturing and control tasks related to axatilimab. Each party may terminate the UCB License Agreement for the other party&#x2019;s uncured material breach or insolvency; and the Company may terminate the UCB License Agreement at will at any time upon advance written notice to UCB. UCB may terminate the UCB License Agreement if the Company or any of its affiliates or sublicensees institutes a legal challenge to the validity, enforceability, or patentability of the licensed patent rights. Unless terminated earlier in accordance with its terms, the UCB License Agreement will continue on a country-by-country and product-by-product basis until the later of: (i) the expiration of all of the licensed patent rights in such country; (ii) the expiration of all regulatory exclusivity applicable to the product in such country; and (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years from the date of the first commercial sale of the product in such country.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of the date of the UCB License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility. As the processes or activities that were acquired along with the license do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset acquisition. As a result, in 2016, the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded as research and development expense in the consolidated statements of operations. Since the start of the license agreement, the Company achieved certain development and regulatory milestones and has recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as research and development expense. Additionally, in connection with its most recent amendment of the UCB License Agreement, in the second quarter of 2022 the Company paid UCB $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is recognized as a milestone expense. In the fourth quarter of 2023, UCB achieved a development and regulatory milestone resulting in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million expense, which has been recorded in accrued expenses as of December 31, 2023. The Company paid the amount to UCB in the first quarter of 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;     &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Bayer Pharma AG (formerly known as Bayer Schering Pharma AG)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2007, the Company entered into a license agreement (the &#x201c;Bayer Agreement&#x201d;) with Bayer Schering Pharma AG (&#x201c;Bayer&#x201d;) for a worldwide, exclusive license to develop and commercialize entinostat and any other products containing the same active ingredient. Under the terms of the Bayer Agreement, the Company paid a nonrefundable up-front license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and is responsible for the development and marketing of entinostat. The Company recorded the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million license fee as research and development expense during the year ended December 31, 2007, as it had no alternative future use. The Company will pay Bayer royalties on a sliding scale based on net sales, if any, and make future milestone payments to Bayer of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the event that certain specified development and regulatory goals and sales levels are achieved.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</sndx:SignificantAgreementsDisclosureTextBlock>
    <sndx:UpfrontPayments
      contextRef="C_65848bf9-3945-493c-98fa-73d365aadae6"
      decimals="-5"
      id="F_678fc3cb-f58a-4b32-9373-6e0a9028bbfd"
      unitRef="U_USD">5000000</sndx:UpfrontPayments>
    <sndx:PotentialMilestonePaymentsUponAchievementOfMilestone
      contextRef="C_40e59aaf-8789-463b-945c-25dc7a6c94bd"
      decimals="-5"
      id="F_eaf7c472-0872-41d2-967a-beebba1e86da"
      unitRef="U_USD">99000000</sndx:PotentialMilestonePaymentsUponAchievementOfMilestone>
    <sndx:AggregatePotentialMilestonePayable
      contextRef="C_40e59aaf-8789-463b-945c-25dc7a6c94bd"
      decimals="INF"
      id="F_6ddbe3b4-dbbc-411b-ae81-62e2549e7ecf"
      unitRef="U_USD">70000000</sndx:AggregatePotentialMilestonePayable>
    <sndx:LicenseAgreementsExpirationPeriod
      contextRef="C_65978307-b055-4116-8a9e-5b4d03aedbd6"
      id="F_2ea2e841-0852-41fc-b5dc-a382993c7410">P10Y</sndx:LicenseAgreementsExpirationPeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bda1e555-b0cf-4f5d-88a3-0159c9f3b0d3"
      decimals="-5"
      id="F_2144a0cc-d997-4b82-883d-40ad7361f4ca"
      unitRef="U_USD">5000000</us-gaap:ResearchAndDevelopmentExpense>
    <sndx:DevelopmentAndRegulaotryMilestonesExpenses
      contextRef="C_b2f341e1-b250-4994-9c50-93dfdd23e649"
      decimals="-5"
      id="F_29e2afe3-8ee6-43a1-9f25-daeac85f5ff4"
      unitRef="U_USD">8000000</sndx:DevelopmentAndRegulaotryMilestonesExpenses>
    <sndx:MilestoneExpensesPaid
      contextRef="C_b2f341e1-b250-4994-9c50-93dfdd23e649"
      decimals="-5"
      id="F_5ad94e4b-0365-42bf-addc-01da3c351ce2"
      unitRef="U_USD">2000000</sndx:MilestoneExpensesPaid>
    <sndx:UpfrontPayments
      contextRef="C_9897c974-eaaf-4ce1-84bb-983cacae668c"
      decimals="-5"
      id="F_1012e9c0-b8b2-49b8-ade0-3f99c2be30d8"
      unitRef="U_USD">5000000</sndx:UpfrontPayments>
    <sndx:PotentialMilestonePaymentsUponAchievementOfMilestone
      contextRef="C_24de1833-922d-42e7-b50e-b99703d2a57a"
      decimals="-5"
      id="F_62f6cc45-26de-4d7e-842d-d85cdaa50337"
      unitRef="U_USD">119500000</sndx:PotentialMilestonePaymentsUponAchievementOfMilestone>
    <sndx:AggregatePotentialMilestonePayable
      contextRef="C_24de1833-922d-42e7-b50e-b99703d2a57a"
      decimals="-5"
      id="F_3f1a063b-704f-4ab5-8af1-b0b5e9b47369"
      unitRef="U_USD">250000000</sndx:AggregatePotentialMilestonePayable>
    <sndx:LicenseAgreementsExpirationPeriod
      contextRef="C_0d5d3e07-b0b8-4bc6-b16b-19628d2c4e5d"
      id="F_440ed2b1-1cb4-4643-83de-94c6966f29b5">P10Y</sndx:LicenseAgreementsExpirationPeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4d702b7c-2eb0-4b1b-9fdd-4c94f41fbc74"
      decimals="-5"
      id="F_17a78484-5643-4ffc-aeb5-253bec967052"
      unitRef="U_USD">5000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f48e2289-7c74-4e8f-bb83-8c460905d6be"
      decimals="-5"
      id="F_e53fad42-cc96-4229-89db-30d950e0df18"
      unitRef="U_USD">6000000</us-gaap:ResearchAndDevelopmentExpense>
    <sndx:MilestonePaymentDue
      contextRef="C_f5a2c5e6-ee95-4e95-ac72-df05f5b19d1a"
      decimals="-5"
      id="F_c1703637-19c4-44ed-aa6d-462a67911da3"
      unitRef="U_USD">5800000</sndx:MilestonePaymentDue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fe987b96-157e-484d-ab17-c2d98a5f8ce5"
      decimals="-5"
      id="F_c69c5671-c4d9-466d-8d20-84098e8a9c25"
      unitRef="U_USD">10000000</us-gaap:ResearchAndDevelopmentExpense>
    <sndx:UpfrontLicenseFeesPaid
      contextRef="C_c7c24763-4fb0-48dc-a5f9-391a27f7a6e7"
      decimals="-5"
      id="F_115b0353-100f-43fc-90c5-1e268658a504"
      unitRef="U_USD">2000000</sndx:UpfrontLicenseFeesPaid>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_29366536-a819-434b-97a9-ff39b709d103"
      decimals="-5"
      id="F_6581a953-6309-4d95-9b70-9892313064e4"
      unitRef="U_USD">2000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ContractualObligation
      contextRef="C_bc34cf4d-0ad9-4ca8-abcc-8a189f682e20"
      decimals="-5"
      id="F_f7d5aa38-95ce-4d14-b3be-01817a334453"
      unitRef="U_USD">150000000</us-gaap:ContractualObligation>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_fa27265f-dc3e-41c6-854b-fcf4b3c1693a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Property and Equipment, net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_9ed08bed-99b0-4eb4-a6d7-b56d3028c929">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_34717b5e-c295-4ed1-ac0e-58d0e54bae5b"
      decimals="-3"
      id="F_599b71b6-432b-48c6-8a14-babba9caef17"
      unitRef="U_USD">84000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_03d34840-d717-4c96-9735-0033d3f99ef2"
      decimals="-3"
      id="F_c0e22e03-2506-47e0-b16c-bd4bcb09a5c5"
      unitRef="U_USD">84000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_faebc9a2-2fb9-4f9c-a490-ab75ff58a5e6"
      decimals="-3"
      id="F_a9bcda3b-bfd4-4a41-9001-738f2bbeb710"
      unitRef="U_USD">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e51750f9-2ca2-48a3-9d96-269b2ec8e4b2"
      decimals="-3"
      id="F_8a072e33-48fa-4de2-ba95-85abf67ffd22"
      unitRef="U_USD">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e1753470-c399-4d8b-ad2e-484c414ecc39"
      decimals="-3"
      id="F_f7bad042-6d59-4aa4-9f01-dad4531c0502"
      unitRef="U_USD">134000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c271aab5-a01e-42fd-86b6-0377aa3b4a22"
      decimals="-3"
      id="F_ac5f6cc0-f42d-4e5a-89b0-260e51f1a086"
      unitRef="U_USD">134000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6da63ab9-2ebc-46a8-b7da-7c40838fae15"
      decimals="-3"
      id="F_5b554c07-a9b4-4635-b77d-02f92ea8c5c7"
      unitRef="U_USD">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b690c391-1b7b-4548-a001-dbef6009526c"
      decimals="-3"
      id="F_e6f1a65a-983d-4a7f-9c25-8049cac7abef"
      unitRef="U_USD">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_8bc3ff39-355b-445b-b01b-4f57656b2b38"
      unitRef="U_USD">419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_e4c26f3f-43d6-475a-8905-6ef452918c46"
      unitRef="U_USD">419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_64720435-e68a-4fa7-bebb-358c96132ac2"
      unitRef="U_USD">411000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_c1256aea-e07d-4b37-a1a5-646d2a6458fd"
      unitRef="U_USD">399000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_0804304a-9d45-4235-83cb-3777ac9e3263"
      unitRef="U_USD">8000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_a2e26346-f9e7-4243-a5ef-d31a60bf09ee"
      unitRef="U_USD">20000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_8bde99d8-6c54-4f9a-a76a-7812d2d14ffc"
      unitRef="U_USD">12000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_bc18e627-7231-4512-a8b1-5c806f779151"
      unitRef="U_USD">33000000</us-gaap:Depreciation>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_243192c7-4902-4cbd-8f9a-917903fe1b6d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of cash and cash equivalents, restricted cash, accounts payable, and accrued expenses approximated their estimated fair values due to the short-term nature of these financial instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Quoted prices (unadjusted) in active markets that are accessible at the market date for identical unrestricted assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below presents information about the Company&#x2019;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques the Company utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.411%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;275,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;275,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;305,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;401,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;401,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;421,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There have been no material impairments of our assets measured and carried at fair value during the years ended December 31, 2023, and 2022. In addition, there have been no changes in valuation techniques during the years ended December 31, 2023, and 2022. The fair value of Level 1 instruments classified as cash equivalents are valued using quoted market prices in active markets. The fair value of Level 2 instruments classified as cash equivalents and short and long-term investments was determined other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and fair value is determined using models or other valuation methodologies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The short-term and long-term investments are classified as available-for-sale securities. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the remaining contractual maturities of the available-for-sale securities were 1 to 15 months, and the balance in the Company&#x2019;s accumulated other comprehensive income was comprised solely of activity related to the Company&#x2019;s available-for-sale securities. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; realized gains or losses recognized on the sale or maturity of available-for-sale securities during the three years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. As a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the same periods. The Company has a limited number of available-for-sale securities in insignificant loss positions as of December 31, 2023, which the Company does not intend to sell and has concluded will not be required to sell before recovery of the amortized cost for the investment at maturity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The following table summarizes the available-for-sale securities (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.812%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.812%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.812%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.812%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;US Treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;304,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;305,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;321,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;321,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;US Treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;421,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_b4989e8d-0cc5-4ac3-850b-1716ec22094b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below presents information about the Company&#x2019;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques the Company utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.411%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;275,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;275,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;305,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;401,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;401,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;421,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6cacdbd9-72ea-4585-80a2-d53f1908716b"
      decimals="-3"
      id="F_1b9ffb74-7af5-4361-be13-ae91be703765"
      unitRef="U_USD">295394000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e9760b9c-06c7-4dcd-b0bf-ccb9fd1298a2"
      decimals="-3"
      id="F_6894b061-8af8-46cc-8cca-df53433348c0"
      unitRef="U_USD">295394000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_6cacdbd9-72ea-4585-80a2-d53f1908716b"
      decimals="-3"
      id="F_7bfa1b97-d63b-4baf-afb2-dbfb0e32ef99"
      unitRef="U_USD">275304000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_41f595f4-58d1-4879-8f5e-6bf3c89f425e"
      decimals="-3"
      id="F_4b766162-2e18-4db7-8bcd-962bd54ca3ab"
      unitRef="U_USD">275304000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_6cacdbd9-72ea-4585-80a2-d53f1908716b"
      decimals="-3"
      id="F_5fb874ea-e5fc-4076-bf3d-f7b01677a7ff"
      unitRef="U_USD">29829000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_41f595f4-58d1-4879-8f5e-6bf3c89f425e"
      decimals="-3"
      id="F_e0415f48-1d3f-4f0f-a384-b60ff96d9c90"
      unitRef="U_USD">29829000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6cacdbd9-72ea-4585-80a2-d53f1908716b"
      decimals="-3"
      id="F_849322c9-e7ba-4aa0-bf71-85c97623843b"
      unitRef="U_USD">600527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e9760b9c-06c7-4dcd-b0bf-ccb9fd1298a2"
      decimals="-3"
      id="F_a0a4674e-e6ef-4576-b711-9edeb3d5c3b4"
      unitRef="U_USD">295394000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_41f595f4-58d1-4879-8f5e-6bf3c89f425e"
      decimals="-3"
      id="F_7ad5879e-e383-4aff-a79a-2177d4617bf5"
      unitRef="U_USD">305133000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8"
      decimals="-3"
      id="F_371a226b-88f7-4305-94ef-e3fa64390e7b"
      unitRef="U_USD">74356000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7c5c1097-e2eb-4741-8da2-1908684c710b"
      decimals="-3"
      id="F_2cea8f4a-0956-44c5-96c0-dfcc44b71780"
      unitRef="U_USD">59496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7b2fc26e-e3b0-4306-aa00-2175018e0133"
      decimals="-3"
      id="F_d4cbda32-9d39-4575-b7a6-e5f867147e4c"
      unitRef="U_USD">14860000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8"
      decimals="-3"
      id="F_d1c8db72-2ccf-49c7-81dc-e382e4d544e9"
      unitRef="U_USD">401446000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_7b2fc26e-e3b0-4306-aa00-2175018e0133"
      decimals="-3"
      id="F_ca48a024-2cbe-4bb0-8cff-2cf8dd0722cc"
      unitRef="U_USD">401446000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8"
      decimals="-3"
      id="F_9391da86-5e39-4e20-8ca0-005903cbc3cd"
      unitRef="U_USD">5469000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_7b2fc26e-e3b0-4306-aa00-2175018e0133"
      decimals="-3"
      id="F_8e201247-f78d-40b1-97f3-9ea710c6a0e8"
      unitRef="U_USD">5469000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6b961ad6-93db-4222-9ee9-50b77b90a7c8"
      decimals="-3"
      id="F_4283c7a1-e700-4c56-a217-94f19f6c8ecb"
      unitRef="U_USD">481271000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7c5c1097-e2eb-4741-8da2-1908684c710b"
      decimals="-3"
      id="F_bec41c78-0091-495e-9fae-a4e2b02c0b62"
      unitRef="U_USD">59496000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7b2fc26e-e3b0-4306-aa00-2175018e0133"
      decimals="-3"
      id="F_1e8f6dbd-596f-4a47-84fb-4aa7b71b9756"
      unitRef="U_USD">421775000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_4d1a97b6-76e2-4148-99f0-9e6a414aa118"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_6bde4e4f-258d-4613-bf2d-aa7b22169c10">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The following table summarizes the available-for-sale securities (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.812%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.812%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.812%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.812%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;US Treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;304,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;305,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;321,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;321,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;US Treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;421,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_89ee900b-0daa-4278-b35c-28e5ea1dacc8"
      decimals="-3"
      id="F_38d5993c-8b3a-4c8d-abf7-9a5b49bef417"
      unitRef="U_USD">160657000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_89ee900b-0daa-4278-b35c-28e5ea1dacc8"
      decimals="-3"
      id="F_1fa1e6b7-deff-47e6-834c-f824969cebb9"
      unitRef="U_USD">149000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_89ee900b-0daa-4278-b35c-28e5ea1dacc8"
      decimals="-3"
      id="F_453c7743-6a35-448c-8750-749f75a3b6c3"
      unitRef="U_USD">160806000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ae0f6773-2219-4d93-912b-9c9e98f6fd82"
      decimals="-3"
      id="F_d4238851-bb87-461a-930c-c54dad16b504"
      unitRef="U_USD">47150000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ae0f6773-2219-4d93-912b-9c9e98f6fd82"
      decimals="-3"
      id="F_8d9b1420-5dbd-473a-98b6-0118181f4ba4"
      unitRef="U_USD">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ae0f6773-2219-4d93-912b-9c9e98f6fd82"
      decimals="-3"
      id="F_58b0a119-1a75-4dfc-be6a-5728043792cf"
      unitRef="U_USD">47212000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6a664e17-cf9e-4ee2-bfdc-d015d6af8887"
      decimals="-3"
      id="F_7c6d4414-1ce0-438b-ae21-08dcb45fdcde"
      unitRef="U_USD">68111000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6a664e17-cf9e-4ee2-bfdc-d015d6af8887"
      decimals="-3"
      id="F_ded489b1-6273-45fb-ba32-e8458db90bfa"
      unitRef="U_USD">46000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6a664e17-cf9e-4ee2-bfdc-d015d6af8887"
      decimals="-3"
      id="F_b72378d1-faaa-418f-8413-ae3fdbf8c02b"
      unitRef="U_USD">68157000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7a26f97c-58f3-47db-91e7-cf5136111b06"
      decimals="-3"
      id="F_d9e0448b-2cc3-4021-877c-09ed7675c1a4"
      unitRef="U_USD">28998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7a26f97c-58f3-47db-91e7-cf5136111b06"
      decimals="-3"
      id="F_4be363d9-a3a1-4921-bb03-4a10944b7209"
      unitRef="U_USD">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7a26f97c-58f3-47db-91e7-cf5136111b06"
      decimals="-3"
      id="F_8fe57c68-b473-4ec6-a18a-da7f099e1b47"
      unitRef="U_USD">28958000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_fcb23742-94fd-42ab-845b-a87bf8e3c2f0"
      unitRef="U_USD">304916000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_14e211ec-5486-4c82-a549-3fbf71b8f8d6"
      unitRef="U_USD">257000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_0a9f03ac-b19c-4bc4-a39d-bc82e4ecc608"
      unitRef="U_USD">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_8400a493-29f3-4d1a-a0c4-d3e1f559fca6"
      unitRef="U_USD">305133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7641cc13-8c39-40ae-b57f-0758cc213d32"
      decimals="-3"
      id="F_2649570e-b602-4868-8f5b-1e3df22085cd"
      unitRef="U_USD">321630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7641cc13-8c39-40ae-b57f-0758cc213d32"
      decimals="-3"
      id="F_444ded94-a177-43f3-9bda-b4f1b06d6537"
      unitRef="U_USD">205000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7641cc13-8c39-40ae-b57f-0758cc213d32"
      decimals="-3"
      id="F_c6d1aba6-50b9-4fb4-847a-d90b6fed8948"
      unitRef="U_USD">321425000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6fb90d48-7668-4c0f-a774-c90206135131"
      decimals="-3"
      id="F_56facb17-8bca-4518-a3ca-8a1141209389"
      unitRef="U_USD">64759000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6fb90d48-7668-4c0f-a774-c90206135131"
      decimals="-3"
      id="F_cc0739aa-bc05-4639-b51c-de3061872c4d"
      unitRef="U_USD">566000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6fb90d48-7668-4c0f-a774-c90206135131"
      decimals="-3"
      id="F_cfe0a75f-d8f6-4d34-9d8d-0384db45f793"
      unitRef="U_USD">64193000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_22b82249-a476-47d0-8dbf-74f15062836e"
      decimals="-3"
      id="F_458f8b33-6fe9-4c43-9f8f-19a4745fb2b3"
      unitRef="U_USD">36192000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_22b82249-a476-47d0-8dbf-74f15062836e"
      decimals="-3"
      id="F_ab72566a-45db-4549-87f3-adf8e770c206"
      unitRef="U_USD">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_22b82249-a476-47d0-8dbf-74f15062836e"
      decimals="-3"
      id="F_aff022a2-0d7b-4365-84c8-d5c6484a4f58"
      unitRef="U_USD">36157000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_bfb3a611-03ea-4a22-8583-2c88fbaf9981"
      unitRef="U_USD">422581000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_a4cfb426-d219-44bb-a585-330a74671e8f"
      unitRef="U_USD">806000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_86b124e7-ac8d-4873-93d6-0adada4391a9"
      unitRef="U_USD">421775000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_92a4b7df-b2c2-4643-bb39-71b777ec5754">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.482000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.283000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest receivable on investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid subscriptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid state and local taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid rent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_f1ce3233-e15a-4a1d-b22a-bdaf7567acc5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.482000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.283000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest receivable on investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid subscriptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid state and local taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid rent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_e64fef7c-d6e8-4402-bbb2-e6a1fe63255a"
      unitRef="U_USD">807000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_bbacad30-7882-4fd8-8101-f30c89a5c8f4"
      unitRef="U_USD">692000</us-gaap:PrepaidInsurance>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_1e07234e-b13f-49c5-aa02-ec58436aedae"
      unitRef="U_USD">1227000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_c71cc3ea-3f0b-448a-9f5c-734f74baeb6c"
      unitRef="U_USD">583000</us-gaap:InterestReceivableCurrent>
    <sndx:PrepaidSubscriptions
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_7645569d-5f84-4b4a-b453-900fdf0f795a"
      unitRef="U_USD">769000</sndx:PrepaidSubscriptions>
    <sndx:PrepaidSubscriptions
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_9f09227d-b22e-4184-82ed-9bf7c38af2c3"
      unitRef="U_USD">446000</sndx:PrepaidSubscriptions>
    <sndx:PrepaidStateAndLocalTaxes
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_f175158c-d7f2-465f-a597-529212941606"
      unitRef="U_USD">264000</sndx:PrepaidStateAndLocalTaxes>
    <sndx:PrepaidStateAndLocalTaxes
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_60a3500f-1381-4bf2-855d-2faf320f8ae7"
      unitRef="U_USD">3000</sndx:PrepaidStateAndLocalTaxes>
    <us-gaap:PrepaidRent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_ec843635-2607-480f-acfb-a40eb4c11658"
      unitRef="U_USD">163000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_9f6ba834-7ad8-4086-8733-19ebe1e2fedd"
      unitRef="U_USD">74000</us-gaap:PrepaidRent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_6a1557bf-4cf7-46af-aa96-899ef49166d7"
      unitRef="U_USD">63000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_d8ab0b1c-296c-4f1f-a1eb-c1e6e65f1a2f"
      unitRef="U_USD">117000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_bd7c2d0d-7fa4-4bef-a965-27f3bc1adbb7"
      unitRef="U_USD">3293000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_ef7e62e5-3500-49e7-8f32-d5b2571692ad"
      unitRef="U_USD">1915000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_dfb36a51-7667-4d5e-9b31-1c044ccdc02f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.652%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.604%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical study and trial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation and related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued milestone costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expense and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_202b47f6-7d85-438c-960b-c390b7c6310d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.652%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.604%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical study and trial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation and related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued milestone costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expense and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <sndx:AccruedClinicalCostsCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_15abcaf1-045b-42c2-87cb-8abc96385753"
      unitRef="U_USD">16346000</sndx:AccruedClinicalCostsCurrent>
    <sndx:AccruedClinicalCostsCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_574a35a8-38de-4651-b1ce-49d8f52d5531"
      unitRef="U_USD">14375000</sndx:AccruedClinicalCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_1723b45f-c166-4eb7-808e-d6da8a22b31c"
      unitRef="U_USD">11172000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_15af3325-8c92-4302-8055-3ebcb5f11404"
      unitRef="U_USD">5945000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_9104a2af-43b0-4619-bea1-bc6d4593fcd8"
      unitRef="U_USD">1450000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_00df1335-e115-49f1-a818-1e65f66133f8"
      unitRef="U_USD">1352000</us-gaap:AccruedProfessionalFeesCurrent>
    <sndx:AccruedMilestoneCosts
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_e6ba9af4-8b0f-44b3-bdcc-267e2e9dd273"
      unitRef="U_USD">10000000</sndx:AccruedMilestoneCosts>
    <sndx:AccruedMilestoneCosts
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_7eb8bab5-2294-4cea-bc8b-ae5920c641a5"
      unitRef="U_USD">2000000</sndx:AccruedMilestoneCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_2274133c-cb61-42df-99aa-8f581ded7cfe"
      unitRef="U_USD">888000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_f45afcab-357a-4f55-9cd5-8460912801cb"
      unitRef="U_USD">604000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_905ae9fb-7c65-48b4-96b0-4cd877945c5a"
      unitRef="U_USD">39856000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_c139be2a-67f6-4cbe-b09b-a1b1826ee0fa"
      unitRef="U_USD">24276000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <sndx:CommonStockDisclosureTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_3282fc02-7897-4496-b92b-3f5b10534ec6">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is authorized to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The holders of each share of common stock are entitled to one vote per share held and are entitled to receive dividends, if and when declared by the Board, and to share ratably in the Company&#x2019;s assets available for distribution to stockholders, in the event of liquidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2021, the Company entered into a sales agreement with Cowen and Company, LLC, or TD Cowen, under which the Company could, from time to time, issue and sell shares of its common stock having aggregate sales proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in a series of one or more at-the-market, or ATM, equity offerings, or the 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ATM &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Program. On May 26, 2023, the Company terminated the 2021 ATM Program. Prior to termination the Company sold shares under the 2021 ATM Program for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the Company entered into a new sales agreement with TD Cowen under which the Company could, from time to time, issue and sell shares of its common stock having aggregate sales proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, in a series of one or more ATM equity offerings, or the 2023 ATM Program. TD Cowen is not required to sell any specific share amounts but acts as the Company&#x2019;s sales agent, using commercially reasonable efforts consistent with its normal trading and sales practices. Pursuant to the new sales agreement, shares will be sold pursuant to the previous shelf registration statement on Form S-3ASR (Registration No. 333-254661), which became automatically effective upon filing on March 24, 2021. The Company&#x2019;s common stock will be sold at prevailing market prices at the time of the sale, and as a result, prices may vary. In the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;2,719,744&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; common shares of common stock under the 2023 ATM Program, with net proceeds of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,802,144&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,142,856&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The offering price for the securities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for each Pre-Funded Warrant,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;with net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On January 24, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants were exercised for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,998&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, under a cashless exercise. On April 12, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;273,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants were exercised for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272,996&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, under a cashless exercise. On May 9, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;498,142&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants were exercised for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;498,137&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, under a cashless exercise. As of  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;285,714&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants were considered issued and outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2021, in connection with the Incyte License and Collaboration Agreement and Share Purchase Agreement, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,421,523&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, with net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company recorded the equity issuance at a fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million based on the market price of the stock on the date of issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2022, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,840,909&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The offering price for the securities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, with gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, offset by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of issuance cost.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,432,431&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The offering price for the securities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, with gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;230.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, offset by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of issuance cost.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has reserved for future issuance the following shares of common stock pursuant to the following outstanding securities or equity plans:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock issuable under pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;285,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;At-the-market program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,280,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs and Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,204,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,403,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2015 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,732,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,906,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</sndx:CommonStockDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4e02600c-bd29-4c11-ab55-d1e0405d802e"
      decimals="INF"
      id="F_eb550c53-acbb-46af-b41d-0db65025dffe"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b2cdaf15-a3dd-4128-b806-5785e9adeb08"
      decimals="-5"
      id="F_6f61aa55-7dbd-4101-89e0-a4336304d57e"
      unitRef="U_USD">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_916862c9-8345-48c9-8135-c267e4176f68"
      decimals="-5"
      id="F_cb4dc982-e9c7-416b-85e3-4acd98e7b49d"
      unitRef="U_USD">25000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_4373a863-e88a-4778-ad8a-e38be55f38f0"
      decimals="-5"
      id="F_68162a2e-a73c-4648-a68c-eecf88131af1"
      unitRef="U_USD">200000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6f419700-e28e-40c1-b23d-a0b900e72318"
      decimals="INF"
      id="F_be04d0db-109f-444d-90d0-6ae03b9c07ce"
      unitRef="U_shares">2719744</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6f419700-e28e-40c1-b23d-a0b900e72318"
      decimals="-5"
      id="F_82664c87-c71c-4736-83f4-48bc8047498e"
      unitRef="U_USD">42100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_af3f7b3f-463f-4a43-9924-f3224ae76c2a"
      decimals="INF"
      id="F_800fead2-989a-413d-b153-3c17ff6e3931"
      unitRef="U_shares">3802144</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_10d30f98-e352-4e95-8d0c-6ec352eb4220"
      decimals="INF"
      id="F_32dcaf15-d97c-449e-a6ae-a267cf938e1b"
      unitRef="U_shares">1142856</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sndx:OfferingPricePerShare
      contextRef="C_c5bfe040-8225-40e0-ac2c-1d2335fa468e"
      decimals="INF"
      id="F_9286ee5b-8951-453e-80e9-b63f50f7cebe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.5</sndx:OfferingPricePerShare>
    <sndx:OfferingPricePerShare
      contextRef="C_92922bd5-099d-4ec5-8e83-d7fd9dbf0f21"
      decimals="INF"
      id="F_39884d9d-c9a4-4897-9b42-37bb15426965"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.4999</sndx:OfferingPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_af3f7b3f-463f-4a43-9924-f3224ae76c2a"
      decimals="-5"
      id="F_eba0d67c-cdc1-483f-bcdc-3ba9c02ea630"
      unitRef="U_USD">81200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2b797780-f333-41ad-9804-9f77932b06b7"
      decimals="INF"
      id="F_e712cec0-15f3-4abf-b5da-9cdcb947a6cb"
      unitRef="U_shares">86000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sndx:NumberOfPreFundedWarrantsExercisedForCommonStock
      contextRef="C_f8419044-984d-4ea5-bd39-f4268be140ef"
      decimals="0"
      id="F_4fcc14b8-8470-47a9-9297-9180a21bd785"
      unitRef="U_shares">85998</sndx:NumberOfPreFundedWarrantsExercisedForCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_626a678f-9c61-4d24-8cc1-62a2dcd3abf0"
      decimals="0"
      id="F_b7b57cde-11bf-409e-8052-c877521d4cfe"
      unitRef="U_shares">273000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sndx:NumberOfPreFundedWarrantsExercisedForCommonStock
      contextRef="C_75ddf898-7154-4fbc-bbc2-0484c10d01f1"
      decimals="0"
      id="F_a4e154bc-a8a1-4a71-a7b0-48c249546f2b"
      unitRef="U_shares">272996</sndx:NumberOfPreFundedWarrantsExercisedForCommonStock>
    <sndx:NumberOfPreFundedWarrantsExercisedForCommonStock
      contextRef="C_3a9ae94c-95c4-4bc4-9ea1-a708c250d19f"
      decimals="0"
      id="F_83f88cf5-09aa-42f1-9f3e-c310928e9ce4"
      unitRef="U_shares">498142</sndx:NumberOfPreFundedWarrantsExercisedForCommonStock>
    <sndx:NumberOfPreFundedWarrantsExercisedForCommonStock
      contextRef="C_fee34826-8d9f-4166-a555-2a64fedf432a"
      decimals="0"
      id="F_5869c23b-604b-4e8f-8c83-e83b7a96dbaa"
      unitRef="U_shares">498137</sndx:NumberOfPreFundedWarrantsExercisedForCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_96174531-bfea-4e9f-8dc3-133a02db014e"
      decimals="0"
      id="F_9b02a6b8-b4ed-4ea5-b14d-6297e7ccff9b"
      unitRef="U_shares">285714</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_444b653e-7ff0-4aea-832b-063c09c055b5"
      decimals="INF"
      id="F_1930ba17-47a6-4869-acad-62ff49f7c17f"
      unitRef="U_shares">1421523</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_444b653e-7ff0-4aea-832b-063c09c055b5"
      decimals="-5"
      id="F_200c7844-aeca-4804-91ba-c6eae57ded4c"
      unitRef="U_USD">35000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_444b653e-7ff0-4aea-832b-063c09c055b5"
      decimals="-5"
      id="F_b902eb2c-b566-4260-9ca2-f6bb645fc24a"
      unitRef="U_USD">24800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_14164814-000e-4a3d-8ee4-dd58a37f263b"
      decimals="INF"
      id="F_152bd809-0f43-4a4b-b630-962ea5b04d09"
      unitRef="U_shares">7840909</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sndx:OfferingPricePerShare
      contextRef="C_14164814-000e-4a3d-8ee4-dd58a37f263b"
      decimals="2"
      id="F_973df9f6-b5a1-4180-ace8-94e0370a61d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22</sndx:OfferingPricePerShare>
    <sndx:GrossProceedsFromOffering
      contextRef="C_14164814-000e-4a3d-8ee4-dd58a37f263b"
      decimals="-5"
      id="F_439f4643-466b-4668-aabe-f2bfa3fb6626"
      unitRef="U_USD">172500000</sndx:GrossProceedsFromOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4d513726-c3ac-4260-a084-166bd284aeba"
      decimals="-5"
      id="F_0acc4633-799c-4da8-b5e8-90b419ea8673"
      unitRef="U_USD">10500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6a968746-243d-4b7c-af53-3e25f8258536"
      decimals="INF"
      id="F_bf74b330-d600-4425-a146-75227b029689"
      unitRef="U_shares">12432431</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sndx:OfferingPricePerShare
      contextRef="C_6a968746-243d-4b7c-af53-3e25f8258536"
      decimals="2"
      id="F_347a47d6-6b6f-4de8-93dc-c67b014e4c9b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.5</sndx:OfferingPricePerShare>
    <sndx:GrossProceedsFromOffering
      contextRef="C_6a968746-243d-4b7c-af53-3e25f8258536"
      decimals="-5"
      id="F_c43d0af2-c4fb-4ff7-8431-43e71ea2648d"
      unitRef="U_USD">230000000</sndx:GrossProceedsFromOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a7ff0eef-d6fb-487a-ac3a-bd8883e7c5ec"
      decimals="-5"
      id="F_17643c59-5f48-44fa-b4c1-e3a7c407d9e0"
      unitRef="U_USD">14000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_537a0c8c-87ac-4881-940a-540f411b0f07">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has reserved for future issuance the following shares of common stock pursuant to the following outstanding securities or equity plans:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock issuable under pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;285,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;At-the-market program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,280,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs and Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,204,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,403,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2015 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,732,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,906,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_96174531-bfea-4e9f-8dc3-133a02db014e"
      decimals="INF"
      id="F_9674502d-7f2f-4571-93ab-1f5a326fa2aa"
      unitRef="U_shares">285714</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8c652789-8302-4cea-ba90-91fe2cce9a9e"
      decimals="INF"
      id="F_6a1a0950-9677-4c54-b568-4ab44a25f97e"
      unitRef="U_shares">7280256</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c711bf57-6128-4aae-b770-abe66d25ee43"
      decimals="INF"
      id="F_c1e0f3a6-90f1-452d-9189-73b8224c8eb5"
      unitRef="U_shares">11204294</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_38a4d3d9-61d6-470e-85bb-48eeea883916"
      decimals="0"
      id="F_36bca15f-bdea-4c6f-94f6-b87915abe583"
      unitRef="U_shares">3403382</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7ea6052a-2eb2-4c2d-8093-dc9a96bc2333"
      decimals="0"
      id="F_986f8575-e054-4c5b-abb3-4d3db7b75701"
      unitRef="U_shares">1732614</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_2e9c94f7-2d34-4ee3-ae86-105029dbc4c8"
      unitRef="U_shares">23906260</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_0850ad17-12b2-45fb-9e63-a6dcb8d1945d">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2015, the Company&#x2019;s board of directors adopted its 2015 Omnibus Incentive Plan (&#x201c;2015 Plan&#x201d;), which was subsequently approved by its stockholders and became effective upon the closing of the IPO on March 8, 2016. The 2015 Plan replaced the 2007 Stock Plan (&#x201c;2007 Plan&#x201d;) and allows for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, dividend equivalent rights, performance awards, annual incentive awards, and other equity-based awards to the Company&#x2019;s executives and other employees, non-employee members of the board of directors, and consultants of the Company. Any options or awards outstanding under the Company&#x2019;s 2007 Plan remain outstanding and continue to govern the terms of any equity grants that remain outstanding under the 2007 Plan. Any shares of common stock related to awards outstanding under the 2007 Plan that thereafter terminate by expiration, forfeiture, cancellation or otherwise without the issuance of such shares will be added to, and included in, the 2015 Plan reserve amount. The Company initially reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock for the issuance of awards under the 2015 Plan. The 2015 Plan provides that the number of shares reserved and available for issuance under the 2015 Plan will automatically increase each January 1, beginning on January 1, 2017, by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company&#x2019;s board of directors. On January 1, 2024, the shares available for issuance under the 2015 was increased to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,393,065&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2023, the Company's board of directors adopted its 2023 Inducement Plan (the &#x201c;2023 Inducement Plan&#x201d;), which became effective March 1, 2023. The 2023 Inducement Plan allows for the granting of nonqualified stock options, restricted stock units, and other awards under the 2023 Inducement Plan to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, an inducement material to such persons entering into employment with the Company. The Company initially reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,900,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock for the issuance of awards under the 2023 Inducement Plan. On December 6, 2023, the Company's board of directors increased the reserve by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,191,732&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for issuance under the 2015 Plan and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211,650&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for issuance under the 2023 Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees and related to the Employee Stock Purchase Plan in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.540000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.540000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.540000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of unrecognized compensation cost related to employee and non-employee unvested stock options and RSUs granted under the 2015 Plan and the 2023 Inducement Plan, which is expected to be recognized over a weighted-average remaining service period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. Stock compensation costs have not been capitalized by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the straight-line method to the extent achievement of the performance condition is probable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2019, the Company granted to certain employees &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;583,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options that contain performance-based vesting criteria (&#x201c;2019 Performance Awards&#x201d;), primarily related to the achievement of certain clinical and regulatory development milestones related to product candidates. In the fourth quarter of 2020, one performance milestone, for the 2019 Performance Awards, was achieved. The Company recorded approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of stock compensation related to the achievement of the performance milestone for years ended December 31, 2022. As of December 31, 2022, all other performance milestones were not achieved, and the associated awards have been cancelled.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2022, the Company granted to certain employees &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; performance-based stock options (&#x201c;2022 Performance Awards&#x201d;), primarily related to the achievement of certain regulatory development milestones related to product candidates. Recognition of stock-based compensation expense associated with these performance-based stock options commences when the performance condition is considered probable of achievement, using management&#x2019;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the first quarter of 2022, management estimated one of the milestones, for the 2022 Performance Awards, was probable of achievement. The Company recorded approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;258,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;479,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of stock compensation expense for these awards for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options outstanding were unvested, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options had been cancelled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the first quarter of 2023, the Company granted to certain employees &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,550&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; performance-based RSUs, primarily related to the achievement of certain regulatory development milestones related to product candidates. Recognition of stock-based compensation expense associated with these performance-based RSUs commences when the performance condition is considered probable of achievement, using management&#x2019;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2021, in connection with the retirement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; employees, the Company entered into severance and consulting agreements. Under these agreements the Company extended the vesting term for an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,728&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unvested options, which would not have otherwise vested and extended the exercise period of the vested options post termination of the consulting agreement. The Company accounted for the change as a modification of an equity award under ASC 718. As a result of the modifications, the Company recognized approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of incremental stock compensation expense in 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model with the weighted-average assumptions noted in the table below. Expected volatility for the Company&#x2019;s common stock was determined based on an average of the historical volatility of the Company's public stock price. The Company estimated the expected term of its employee stock options using the &#x201c;simplified&#x201d; method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The contractual life of the option was used for the estimated life of the non-employee grants. The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The risk-free interest rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. The Company accounts for forfeitures when they occur. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The grant date fair values of options issued to employees and non-employees were estimated using the Black-Scholes option-pricing model with the following assumptions: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.03&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of employee and non-employee option activity under the Company&#x2019;s equity award plans is presented below (in thousands, except share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,981,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,800,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;662,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled, forfeited or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,684,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,468,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options vested, or expected to&lt;br/&gt;&#160;&#160;&#160;vest&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,684,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value of options granted during the years ended December 31, 2023, 2022 and 2021, was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. The fair value is being expensed over the vesting period of the options (usually &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_91e0244e-9f65-4985-ba1b-f7857d8ad080;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) on a straight-line basis as the services are being provided.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;662,042&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options exercised for the year ended December 31, 2023, resulting in total proceeds of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million options exercised for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, resulting in total proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;842,424&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options exercised for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, resulting in total proceeds of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The intrinsic value of options exercised during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. In accordance with the Company&#x2019;s policy, the shares were issued from a pool of shares reserved for issuance under the 2015 Plan and 2023 Inducement Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs awarded to Board of Directors or employees vest on either i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one &#x2013; year anniversary date of the related grant or ii) 25% on each anniversary for 4 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes our RSU activity:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.609%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.177%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.697%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.999%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;224,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested&#x2014;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;519,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs granted in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 and 2022 had a weighted average grant date fair value of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.94&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. The fair values of RSUs vested in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 and 2022 totaled &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;705,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2015, the Company&#x2019;s Board adopted the ESPP, which was subsequently approved by the Company&#x2019;s stockholders and became effective in 2016. The ESPP authorized the initial issuance of up to a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to the Company&#x2019;s employees. The number of shares of common stock available under the ESPP will automatically increase on January 1st of each year, continuing until the expiration of the ESPP, in an amount equal to the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, or (b) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares. On January 1, 2024, the shares of common stock reserved for issuance under the ESPP was increased to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,982,614&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Under the terms of the ESPP, eligible employees can elect to acquire shares of the Company&#x2019;s common stock through periodic payroll deductions during a series of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; offering periods. Purchases under the ESPP are affected on the last business day of each offering period at a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% discount to the lower of closing price on that day or the closing price on the first day of the offering period. The Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,797&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares during &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The ESPP is considered a compensatory plan with the related compensation cost expensed over the six-month offering period. For the years ended December 31, 2023, 2022 and 2021 the Company recorded stock-based compensation expense related to the ESPP of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee Benefit Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a Section 401(k) defined contribution savings plan for its employees. The plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis, subject to legal limitations. Company contributions to the plan may be made at the discretion of the Board. For the years ended December 31, 2023, 2022 and 2021, the Company made &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;712,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;444,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; contributions to the plan, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_2da8d5ee-6ea1-4242-a4dc-afb090386702"
      decimals="INF"
      id="F_cf8c2842-5526-472a-9efe-cf58674f01be"
      unitRef="U_shares">1750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant
      contextRef="C_6e76b045-86c3-442e-89f0-3831e63a85a7"
      decimals="2"
      id="F_464be5cf-0936-4748-94a9-bd363bbb20c2"
      unitRef="U_pure">0.04</sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentageInNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f2aa831f-6fca-40f4-af27-257fe1eaf973"
      decimals="0"
      id="F_928cd6b1-6e39-4960-b8e7-a49198fa67d5"
      unitRef="U_shares">3393065</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_56f021a8-a8b1-4814-8e60-e30e3153a6ee"
      decimals="INF"
      id="F_c3362ddd-9497-4610-b411-5246ac336f0d"
      unitRef="U_shares">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_c1bbc6b4-e3a0-44a7-bf52-605ed66340b7"
      decimals="0"
      id="F_e50e54b6-be8a-47d7-a307-de5c2302a947"
      unitRef="U_shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2da8d5ee-6ea1-4242-a4dc-afb090386702"
      decimals="0"
      id="F_f56874f4-d65b-4eef-b5fb-5555690800b0"
      unitRef="U_shares">2191732</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_56f021a8-a8b1-4814-8e60-e30e3153a6ee"
      decimals="INF"
      id="F_db9a5996-686b-4b25-8d4f-1392aff1c194"
      unitRef="U_shares">1211650</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_f1217fca-2358-4577-bc4e-900fb455b16b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees and related to the Employee Stock Purchase Plan in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.540000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.540000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.540000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_85e6672e-416a-4bb1-ba66-37049365978f"
      decimals="-3"
      id="F_a859b2fd-3a82-48cd-92d8-db9ae121d888"
      unitRef="U_USD">14147000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a245d0cf-1677-4b8f-a3f8-dfbf1b2276ba"
      decimals="-3"
      id="F_7574b0d5-6fef-4ba5-bd23-a4d94b16fdec"
      unitRef="U_USD">6016000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_610a039f-ddb5-49bf-b2aa-26efc9285ba9"
      decimals="-3"
      id="F_4027ec0c-5a2f-485e-ad5d-1e7b12227028"
      unitRef="U_USD">4398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_61e6f7c1-9801-49e0-ac76-fee878967704"
      decimals="-3"
      id="F_1bda3627-10fc-4c0b-a76d-974251d0c281"
      unitRef="U_USD">16804000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_49c6449d-685a-4b8d-9ad2-69b9cf9fce2a"
      decimals="-3"
      id="F_033630bc-3748-425b-93be-5d8f39f08472"
      unitRef="U_USD">10003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fa3bed87-c1df-42e6-8758-39e220363797"
      decimals="-3"
      id="F_daa4349d-a50a-46a8-b074-d9116910c82b"
      unitRef="U_USD">8919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_1da9cb34-1be2-4247-9ba2-8c8016ccf013"
      unitRef="U_USD">30951000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_9f7080ab-0720-4bb6-9c7a-df79056534c3"
      unitRef="U_USD">16019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_30877b7e-8fe9-428b-9ce5-4522e9732af7"
      unitRef="U_USD">13317000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_361a189b-bde2-4ebc-a732-bb3aba4d7e9c"
      decimals="-5"
      id="F_d9dfc764-40e8-4a4a-80fc-4a7ec35c4299"
      unitRef="U_USD">74800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_3c1506a9-4d8e-4770-b740-d3e5f9ee156e"
      id="F_625d4d64-098e-4ebf-a621-e26e1d05e266">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_3afde7f0-2827-4e68-8635-4702b62c6d21"
      decimals="INF"
      id="F_dec1abcf-5069-4830-b6dc-0da17f83f4dd"
      unitRef="U_shares">583000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions
      contextRef="C_722e2254-0e1d-493b-95a1-3d802704cc35"
      decimals="0"
      id="F_576b6f8e-8620-44a8-9cf2-8b6614b4d615"
      unitRef="U_USD">128000</sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_665c9384-a612-4a95-ba6a-78cf2d4a9797"
      decimals="INF"
      id="F_f74cf854-acd0-43ce-9e79-595e256cf67c"
      unitRef="U_shares">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions
      contextRef="C_c738d44a-3667-401f-876a-5549892bf0b8"
      decimals="0"
      id="F_406498ca-04fa-4e2e-ac10-c1c416dfd057"
      unitRef="U_USD">258000</sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions>
    <sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions
      contextRef="C_665c9384-a612-4a95-ba6a-78cf2d4a9797"
      decimals="0"
      id="F_f45dcb3c-bc4b-4930-aa3d-c4e55ab3e08b"
      unitRef="U_USD">479000</sndx:EmployeeServiceShareBasedCompensationRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_cef59505-ba7f-4bd7-ba0f-7111fc336f1d"
      decimals="INF"
      id="F_03fd3fa4-606e-4165-a987-f4b48971d567"
      unitRef="U_shares">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_c738d44a-3667-401f-876a-5549892bf0b8"
      decimals="INF"
      id="F_0050d25e-0ecf-4b7d-a7df-2cb5a0c16668"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_4a678240-3c1b-4c9f-88f3-1d437a7bd663"
      decimals="0"
      id="F_44e2c4bf-5a75-469a-8219-4409e6ed68c8"
      unitRef="U_shares">129550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <sndx:NumberOfEmployeesRetirement
      contextRef="C_4711878e-a968-48f8-9c3d-730171fe4f23"
      decimals="INF"
      id="F_6d5a3625-581b-469d-8265-ff547faee518"
      unitRef="U_Employee">2</sndx:NumberOfEmployeesRetirement>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_4711878e-a968-48f8-9c3d-730171fe4f23"
      decimals="INF"
      id="F_fcc628b6-874b-4dbd-96d9-d2f657d83838"
      unitRef="U_shares">34728</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4711878e-a968-48f8-9c3d-730171fe4f23"
      decimals="-5"
      id="F_04f871e6-f84c-4e44-a3f7-52fbf830426d"
      unitRef="U_USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_a3be5e38-5bfa-4601-9b74-424b0d6918ad">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The grant date fair values of options issued to employees and non-employees were estimated using the Black-Scholes option-pricing model with the following assumptions: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.03&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_fe8216da-ec01-40f4-8a62-ab8b7771b7c1">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      id="F_1542e676-0ae8-4ef1-ab32-df29fa0cea60">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      id="F_7887c418-db09-4e03-89fd-6b10b501074f">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="4"
      id="F_1b6a9ba2-4ec9-4de4-a1b3-3500bfd5e1ba"
      unitRef="U_pure">0.7513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="4"
      id="F_5c4a2212-3582-43d4-92fe-5b8931b8f5e3"
      unitRef="U_pure">0.7787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="4"
      id="F_795b483b-f74d-4884-82b4-7f4572f92631"
      unitRef="U_pure">0.8584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="4"
      id="F_43d0943c-3d2b-4241-a3a4-54b00fb21f5a"
      unitRef="U_pure">0.0365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="4"
      id="F_27e00844-0614-4ef3-9c1d-e66a6ff5d99d"
      unitRef="U_pure">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="4"
      id="F_879cdf7f-6940-4dc4-bc6c-9bac924e77c5"
      unitRef="U_pure">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="4"
      id="F_aadeb771-1047-47f5-b696-6cf4d79ee087"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="4"
      id="F_a3bb8ecb-f8ce-49ed-bc0a-59ace066086c"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="4"
      id="F_4b3e904a-6e7b-439a-a1bb-5372c85014cf"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_9c3ccd8a-7bf5-40b6-b7d7-081e8c9a9fb1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of employee and non-employee option activity under the Company&#x2019;s equity award plans is presented below (in thousands, except share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,981,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,800,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;662,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled, forfeited or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,684,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,468,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options vested, or expected to&lt;br/&gt;&#160;&#160;&#160;vest&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,684,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="INF"
      id="F_215e0556-3761-49d8-b1a8-4bfa3b07fbb0"
      unitRef="U_shares">7981677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="2"
      id="F_1a9500c5-1c6a-4e96-9a4d-3e37f19eca98"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      id="F_c17eb7eb-deec-44b8-959b-185bdf169792">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_15f2208b-4e94-44a5-884e-98d0505a4eaa"
      unitRef="U_USD">88016000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="INF"
      id="F_dd2eb33b-51ce-4f46-96f4-283044f6fc5b"
      unitRef="U_shares">3800691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="2"
      id="F_607923be-60fd-4e52-b34e-647a7bef80c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="0"
      id="F_4cad8591-5a45-4844-8e79-447831136c82"
      unitRef="U_shares">662042</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="2"
      id="F_ba000a6b-c793-49cc-b878-f061a2554e05"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="INF"
      id="F_889be445-c19d-48bc-8d80-c738f335d2de"
      unitRef="U_shares">435468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="2"
      id="F_0da951bd-2f6f-4408-beeb-f02e39ffe601"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_7ec8e33a-4ea6-4be6-8d39-1e191108efbe"
      unitRef="U_shares">10684858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="2"
      id="F_5c700937-9e48-4fcb-931c-e21f81ce0d13"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_549862ca-e9c2-4e58-a65c-5044fffb922b">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_c29b0e7e-9b60-4625-a0b9-5f997bf61ad8"
      unitRef="U_USD">55091000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_56881dbb-601f-4d12-9d32-612a47fc74cb"
      unitRef="U_shares">5468638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="2"
      id="F_3701ce03-ed7a-41ac-b435-f89090256522"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_51a9ca4a-bde9-4d4b-81c7-1ddafe54f08e">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_6cfbed41-3ac9-4998-97d5-da96efbb24ab"
      unitRef="U_USD">43160000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_3a86d813-b7d9-46d5-978a-90c62c89b5ad"
      unitRef="U_shares">10684858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="2"
      id="F_812714d5-5279-46fb-ba5d-6c23014db586"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_5d1573ab-b8ee-442e-90d8-9388674e5052">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_496328d1-af00-47e8-9270-514636b722b8"
      unitRef="U_USD">55091000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="2"
      id="F_8182edeb-964d-4968-b7f9-bf4d01cefa33"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="2"
      id="F_3a805712-fe20-4cf9-a363-7e9fff7edbbf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="2"
      id="F_2902b789-e522-49ee-ac40-062fe82e528c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0134674c-550a-4425-b294-4c3c79a415b3"
      id="F_40ca8732-8745-499f-b2bf-5563c1a2bb88">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="INF"
      id="F_62acfa11-7f3b-43b0-9fdc-fcfb25bf8675"
      unitRef="U_shares">662042</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-5"
      id="F_bc316470-a16f-48cd-b7ea-81012e028993"
      unitRef="U_USD">5100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-5"
      id="F_9aafce0d-8b11-41c0-a451-b39d3c55f1d6"
      unitRef="U_shares">1300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-5"
      id="F_f7220bf1-d4ed-447e-8398-3e011172dc3b"
      unitRef="U_USD">11500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="0"
      id="F_d9420b50-8e78-4819-bee6-d737480a4c84"
      unitRef="U_shares">842424</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-5"
      id="F_013fdedf-1d0d-444f-99e3-0bcf7ee55918"
      unitRef="U_USD">6300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-5"
      id="F_3bcf71c7-6602-43ff-9f17-b6f6c098fba1"
      unitRef="U_USD">9500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-5"
      id="F_58e5cfed-a2af-4833-8cd8-f7d5118aeb50"
      unitRef="U_USD">17000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-5"
      id="F_f0b3ea74-44ed-4a3f-8e01-310bd650785c"
      unitRef="U_USD">10100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      id="F_8fc2d0f0-6d97-4cad-aacb-9682cf12a0fc">one &#x2013; year anniversary date of the related grant or ii) 25% on each anniversary for 4 years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_484aa305-e0f9-4afa-a816-d5feded3e458">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes our RSU activity:&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.609%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.177%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.697%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.999%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;224,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested&#x2014;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;519,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs granted in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 and 2022 had a weighted average grant date fair value of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.94&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. The fair values of RSUs vested in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 and 2022 totaled &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;705,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_707b5fb4-b3b3-44e7-845a-f9f779873732"
      decimals="INF"
      id="F_a685c568-babc-4bd0-9a03-2c6cf9d362d0"
      unitRef="U_shares">224788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_707b5fb4-b3b3-44e7-845a-f9f779873732"
      decimals="2"
      id="F_ae125faf-4fb8-402f-a60c-db4b03632ec3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      decimals="INF"
      id="F_571d65c8-f8f1-445f-8ee1-7e17ce2ffbfc"
      unitRef="U_shares">308550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      decimals="2"
      id="F_4c71cf37-0a72-4642-a37b-7ae4969c410b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      decimals="INF"
      id="F_4aa78e38-7d83-4c38-8111-fe67192c14c5"
      unitRef="U_shares">9102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      decimals="2"
      id="F_0daec735-3730-404d-a4e0-7a8c46416b64"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      decimals="INF"
      id="F_10183d18-7e70-4b1d-8782-131bb0f9518b"
      unitRef="U_shares">4800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      decimals="2"
      id="F_30c173cc-940e-48e8-99f7-ec54d9417b58"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f94caae1-f892-4d89-8e4b-773c52c2f2b9"
      decimals="INF"
      id="F_9bc01169-8804-4032-b5d5-edf27b956a1e"
      unitRef="U_shares">519436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f94caae1-f892-4d89-8e4b-773c52c2f2b9"
      decimals="2"
      id="F_a89518c1-4d5c-4283-b726-c437ab30898e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      decimals="2"
      id="F_3b906284-6131-41ce-ac8a-d18db056ec52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.94</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_f9cd7896-122a-468d-9a8b-9879b929f973"
      decimals="2"
      id="F_9e604f75-0071-4eaa-9ed0-aed1558f07a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.79</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_92d9f658-4420-4f6b-8599-bdb04a896f5e"
      decimals="0"
      id="F_5a0f3cd6-ee77-4cb9-8bf2-4c25bd4d5474"
      unitRef="U_USD">126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_f9cd7896-122a-468d-9a8b-9879b929f973"
      decimals="0"
      id="F_c965d754-a51a-4ed6-a582-e6ba23fa21a2"
      unitRef="U_USD">705000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_7ef8960c-7219-442c-81b3-4e10b484489f"
      decimals="INF"
      id="F_5fb2add6-8e08-40f0-aebe-ee7f46d65ceb"
      unitRef="U_shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <sndx:ExpirationOfTheEspp
      contextRef="C_5d906a55-0f18-4eb6-ae44-5a99a86227fd"
      decimals="2"
      id="F_cdf07de0-487c-49a1-8bb4-cc538f73c4b5"
      unitRef="U_pure">0.01</sndx:ExpirationOfTheEspp>
    <sndx:ExpirationOfTheEsppShares
      contextRef="C_92736a1f-42c0-4d1d-a622-0b95ffb0a33b"
      decimals="INF"
      id="F_a1238dbb-f24f-4834-bbd6-837380bb5311"
      unitRef="U_shares">250000</sndx:ExpirationOfTheEsppShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f584b500-1b67-48fb-b034-847318b00b67"
      decimals="INF"
      id="F_e1c89e27-d7b8-4eaf-aed4-7b807c907ccd"
      unitRef="U_shares">1982614</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod
      contextRef="C_fb680055-68ee-453c-b640-6693cd2778c7"
      id="F_32460169-8e76-4a4c-9c51-7a444ba5446b">P6M</sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionsOfferingPeriod>
    <sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate
      contextRef="C_7214ed50-0829-4c9b-97ed-3efc7a00a846"
      decimals="2"
      id="F_b5a1ee02-04bc-45f4-8772-671114bbdc5e"
      unitRef="U_pure">0.15</sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodDiscountRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a8268fa6-6e38-4789-b18f-986f4e625037"
      decimals="0"
      id="F_16c59131-b7fe-4478-9604-18a6b4f20a65"
      unitRef="U_shares">34797</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_160ba5f0-0235-4944-95c1-f31751bf8c30"
      decimals="0"
      id="F_ed3c4347-2e3e-4262-926c-d34043949b4c"
      unitRef="U_shares">28999</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a8268fa6-6e38-4789-b18f-986f4e625037"
      decimals="0"
      id="F_d45ad10c-3d83-4733-84ab-0390103d1be0"
      unitRef="U_USD">308000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_160ba5f0-0235-4944-95c1-f31751bf8c30"
      decimals="0"
      id="F_eda64f49-ddfb-4296-a573-f9dd43cc16d1"
      unitRef="U_USD">166000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_98367a91-be3e-42b9-a2a7-0457ff239e69"
      decimals="0"
      id="F_865bace4-83f4-4e4b-8eb9-97c325e73255"
      unitRef="U_USD">175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-5"
      id="F_c3c97055-fe34-48a0-83e9-0f2fed5417c8"
      unitRef="U_USD">1300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="0"
      id="F_1a21dd4e-95e2-42e1-a4fd-611ecb57cc8d"
      unitRef="U_USD">712000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="0"
      id="F_eb9fdafa-385e-4e8f-baa8-cc51284d1e72"
      unitRef="U_USD">444000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_1a2c13fc-6647-4001-a38d-ab8c04ca9013">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. Loan Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2020, the Company entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;). In December 2021, the Company entered into Amendment No. 1 to the Company&#x2019;s Loan Agreement (the &#x201c;First Amendment&#x201d; and the Loan Agreement, as amended, the &#x201c;Amended Loan Agreement&#x201d;) with several banks and financial institutions or entities from time-to-time party thereto (collectively, the &#x201c;Lender&#x201d;) and Hercules, in its capacity as administrative agent for itself and the Lender.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 23, 2022, the Company made a prepayment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to satisfy in full all of the Company's principal and interest obligations and related fees under the Amended Loan Agreement. The payoff amount paid by the Company in connection with the termination of the Amended Loan Agreement was pursuant to a payoff letter with Hercules and included payment of (a) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as an end-of term fee and (b) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as a pre-payment fee. Hercules released all security interests held on the assets of the Company and its subsidiaries. The Amended Loan Agreement was fully terminated as of September 23, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2022, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which included $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of pre-payment fee, of interest expense related to the initial advance pursuant to the Amended Loan Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:PaymentsForProceedsFromDepositOnLoan
      contextRef="C_2fde2bde-fcd6-4136-938c-690acb7faf69"
      decimals="-5"
      id="F_feea0dbb-4e10-4f0e-a0aa-dffdd41b73b1"
      unitRef="U_USD">21500000</us-gaap:PaymentsForProceedsFromDepositOnLoan>
    <sndx:PaymentForEndOfTermFees
      contextRef="C_2fde2bde-fcd6-4136-938c-690acb7faf69"
      decimals="-5"
      id="F_d89bea67-8fe8-4db0-9225-288739f95335"
      unitRef="U_USD">1000000</sndx:PaymentForEndOfTermFees>
    <us-gaap:PaymentsForFees
      contextRef="C_2fde2bde-fcd6-4136-938c-690acb7faf69"
      decimals="-5"
      id="F_af33855c-0dc5-4ca4-adaa-515f0cf64842"
      unitRef="U_USD">400000</us-gaap:PaymentsForFees>
    <us-gaap:InterestExpenseDebt
      contextRef="C_aea89429-70c4-454c-97d0-6401610eb508"
      decimals="-5"
      id="F_f57fe242-db14-4f47-af67-f0e821296db5"
      unitRef="U_USD">2100000</us-gaap:InterestExpenseDebt>
    <sndx:PrepaymentFee
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-5"
      id="F_e05b7fae-9b6a-4ab9-9c23-aacfbc5351a0"
      unitRef="U_USD">400000</sndx:PrepaymentFee>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_8691bee3-033d-4062-bad0-0cd6e6edb43c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized current state income expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the year ending December 31, 2023 as a result of investment income earned in Syndax Securities Corporation. The Company recognized no income taxes in the years ended December 31, 2022 and 2021, due to the utilization of tax attributes to offset current year federal and state taxable income, immaterial investment income earned at Syndax Securities Corporation, the historical losses incurred and the need for a full valuation allowance on deferred tax assets. The Company&#x2019;s current year profit and historical losses before income tax for the periods presented was generated entirely in the United States.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the provision for income taxes computed at the statutory federal income tax rate to the provision for income taxes as reflected in the financial statements is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.493%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.382%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.382%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.382%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General business credit carryovers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Return to provision true up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components of the Company&#x2019;s deferred tax are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized start-up and other costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized research expenses, and capitalized start-up costs. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized start-up costs, partially offset by a decrease to other deferred tax assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;136.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in federal and state Net Operating Losses (&#x201c;NOLs&#x201d;), respectively, which may be available to offset future taxable income. The Company has generated federal NOLs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and state NOLs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million which have indefinite carryforward period. The remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of federal NOLs and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million the Company&#x2019;s state NOLs will begin to expire at various dates starting in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had federal and state research credits of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, which began to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Realization of future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. Under the Internal Revenue Code provisions, certain substantial changes in the Company&#x2019;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards which could be used annually to offset future taxable income. The Company last completed an analysis from January 1, 2021 through December 31, 2022 and determined that no ownership changes had occurred in that period. Prior analyses determined that on March 30, 2007, August 21, 2015 and May 4, 2020, ownership changes had occurred. The Company may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, its ability to use its pre- change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Coronavirus Aid, Relief and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted in the United States on March 27, 2020. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides extensive tax changes in response to the COVID-19 pandemic, the provisions did not have a significant impact on the Company&#x2019;s financial results. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) eliminates the option to deduct research and development expenditures currently and requires taxpayers to amortize them, over five years for domestically incurred expenditures and over fifteen years for foreign incurred expenditures, pursuant to IRC Section 174. As of December 31, 2023, the Company has recorded a deferred tax asset of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the Capitalized IRC Section 174 expenditures, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million relate to expenses required to be capitalized under the TCJA.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, and 2022, the Company had uncertain tax positions of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to research and development credits, which reduce the deferred tax assets with a corresponding decrease to the valuation allowance. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; interest or penalties were recorded for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. The Company expects none of the unrecognized tax benefits to decrease within the next 12 months related to expired statutes or settlement with the taxing authorities. Due to the Company&#x2019;s valuation allowance as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the Company&#x2019;s unrecognized tax benefits, if recognized, would affect the effective tax rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.493%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.922000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.922000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.922000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefit--beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decreases related to prior period positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefit--end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company files tax returns in the U.S. and various states. All tax years since inception (October 11, 2005) remain open to examination by major tax jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service or state tax authorities if they have or will be used in a future period. The Company is currently not under examination by the Internal Revenue Service or any other jurisdictions for any tax years.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_7005891b-8702-43ec-a77e-2e47fc88621f"
      decimals="-5"
      id="F_ff4619b1-29f6-4e4c-8975-65c5b65d917b"
      unitRef="U_USD">300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_b2a0db1f-d380-4b79-88d5-a0a03f0106ca">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the provision for income taxes computed at the statutory federal income tax rate to the provision for income taxes as reflected in the financial statements is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.493%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.382%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.382%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.382%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General business credit carryovers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Return to provision true up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="3"
      id="F_71c08e5b-7643-4a82-8cbe-292f9a860075"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="3"
      id="F_f04bc3fe-08a5-470d-a184-47ba4480eec4"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="3"
      id="F_c88f626e-8e28-46f1-b270-d5aa7ec09e4a"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="3"
      id="F_a94af9c9-46c2-4fb5-b2da-13a8aee4ec86"
      unitRef="U_pure">0.132</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="3"
      id="F_b1750047-2b3e-4a47-9858-67bbf486a557"
      unitRef="U_pure">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="3"
      id="F_2705a8af-366e-4f31-82af-7376f0d04f1f"
      unitRef="U_pure">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="3"
      id="F_1b20c533-e8c8-4a4c-a7bd-a4e22b624ec5"
      unitRef="U_pure">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="3"
      id="F_e929cebe-9e03-4be9-8027-4ade0e26acdd"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="3"
      id="F_9de9888e-6f2b-486a-9d1a-9c9799ec56ff"
      unitRef="U_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="3"
      id="F_276e0edd-28c3-4100-8084-12e64f8e81ad"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="3"
      id="F_b1cb7768-2955-4e96-9caa-5e9427063451"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="3"
      id="F_2fe32d91-f20f-4f58-8a0b-ab14742e2a9b"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="3"
      id="F_4c9498ff-90c4-4b8d-8b0a-38112f4f6971"
      unitRef="U_pure">-0.349</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="3"
      id="F_182c4ec4-16e3-41c9-81be-371d453c06c7"
      unitRef="U_pure">-0.241</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="3"
      id="F_8e8438c7-11c0-4e1a-b67f-583e71fff821"
      unitRef="U_pure">-0.192</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <sndx:ReturnToProvisionTrueUp
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="3"
      id="F_c6dc73a8-127b-47c8-8237-8299a4f22931"
      unitRef="U_pure">0</sndx:ReturnToProvisionTrueUp>
    <sndx:ReturnToProvisionTrueUp
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="3"
      id="F_ebb0a301-548f-4bef-b6c2-a06fe3efd9bb"
      unitRef="U_pure">-0.002</sndx:ReturnToProvisionTrueUp>
    <sndx:ReturnToProvisionTrueUp
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="3"
      id="F_2a7af693-8575-4ee6-8def-f3549630bf56"
      unitRef="U_pure">0</sndx:ReturnToProvisionTrueUp>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="3"
      id="F_941369b3-e419-4cb8-9dae-949460544bfc"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="3"
      id="F_d23be24b-9c4b-4a3c-9b2f-494d74a26509"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="3"
      id="F_fbda3bac-ef9e-47d0-ab31-8207d8fe1b76"
      unitRef="U_pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="3"
      id="F_0de6057e-68cc-4cd0-811c-f2399016e86a"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="3"
      id="F_be46b5df-835c-44e1-b181-5ed56e5a982a"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="3"
      id="F_37ff3ce0-7c58-41a6-9d0b-94880eb9c277"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_64bdb8b0-ad73-4e85-86ed-67a344f798c8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components of the Company&#x2019;s deferred tax are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized start-up and other costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_641f97bf-04c3-4870-ae14-059549032d66"
      unitRef="U_USD">32664000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_7533a460-356e-41a5-b13e-9ca87dc4ff18"
      unitRef="U_USD">23650000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_45d1e50c-1733-4da7-a2e9-e0b29d1e4dea"
      unitRef="U_USD">11765000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_7321e03c-9ed7-4957-8a5b-cf77b01ebf3f"
      unitRef="U_USD">8124000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <sndx:DeferredTaxAssetsCapitalizedStartUpAndOtherCosts
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_1a561eb8-cf2e-4f42-ad65-6b8d537f9e4a"
      unitRef="U_USD">68859000</sndx:DeferredTaxAssetsCapitalizedStartUpAndOtherCosts>
    <sndx:DeferredTaxAssetsCapitalizedStartUpAndOtherCosts
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_434110e4-2db9-4665-8411-f2a539f0a139"
      unitRef="U_USD">45374000</sndx:DeferredTaxAssetsCapitalizedStartUpAndOtherCosts>
    <sndx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_aed8fb07-a5d3-4688-8d58-8b6260eedd60"
      unitRef="U_USD">79562000</sndx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <sndx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_ef6395c8-9175-4125-ac80-7864d844d452"
      unitRef="U_USD">48917000</sndx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_2f6e8528-bb0d-4dc5-bc5f-07e8f78aabfe"
      unitRef="U_USD">10276000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_43490b31-f355-4e92-96ed-5fd0a975e5c8"
      unitRef="U_USD">5004000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_6555631c-e06d-4923-b05d-395006578f89"
      unitRef="U_USD">2795000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_af708051-b5ed-4a03-98cb-2bbb8e0f1862"
      unitRef="U_USD">1985000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_1dcb2e0b-7457-4789-b6c7-fc593f52b4fa"
      unitRef="U_USD">36000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_c4267aa8-e0d5-4418-a0cf-753156f37988"
      unitRef="U_USD">27000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_003ec259-6cfe-4fb5-891b-d157173e8979"
      unitRef="U_USD">205957000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_79e370c4-9240-4aa2-9267-14f794d06e27"
      unitRef="U_USD">133081000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_78401e72-9298-462d-bc6f-b1b757e01ce2"
      unitRef="U_USD">205957000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_39ffbaae-6fc0-401e-a311-2f81ffda37e3"
      unitRef="U_USD">133081000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_ee605dbd-56d3-46ea-9078-f2ac3766ab1c"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_b82de64d-fe55-4f6a-97fa-bcb0da06ee37"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceMethodologiesAndAssumptions
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_205edd71-4c80-4b4c-b189-bdb5d0fae92b">The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased by $72.9 million in 2023 due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized research expenses, and capitalized start-up costs. The valuation allowance increased by $35.9 million in 2022 due to the increase in deferred tax assets, primarily driven by the generation of net operating losses and capitalized start-up costs, partially offset by a decrease to other deferred tax assets.</us-gaap:ValuationAllowanceMethodologiesAndAssumptions>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-5"
      id="F_218aa801-0d92-4a01-be2a-b519fb3956a6"
      unitRef="U_USD">72900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-5"
      id="F_0603aea5-cb40-437e-a9e1-0771dca2de58"
      unitRef="U_USD">35900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-5"
      id="F_bfb03fc6-f485-4732-853e-6796c33bbdf0"
      unitRef="U_USD">136400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-5"
      id="F_83dc8c75-65d1-4368-85cc-e45c79d2c92f"
      unitRef="U_USD">63500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_3cbcc0e4-7e7b-486d-b6a3-470613e2d7a2"
      decimals="-5"
      id="F_716f9b8f-d9a9-4577-a890-d3d01f8840c1"
      unitRef="U_USD">114300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_3cbcc0e4-7e7b-486d-b6a3-470613e2d7a2"
      decimals="-5"
      id="F_6576f5c5-8cc8-4d45-8de8-b4740f7940c8"
      unitRef="U_USD">900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_b85eec17-a5e7-48d2-bfca-2ef6ffdae4ef"
      decimals="-5"
      id="F_9f8692fb-6d0d-47d0-b538-3f995bb80ba8"
      unitRef="U_USD">22100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_a6b0a3dc-0d13-4e49-af3e-9c0ec95c0551"
      decimals="-5"
      id="F_ce63756e-94b3-4071-8dff-9cfce8d88556"
      unitRef="U_USD">62600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <sndx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod
      contextRef="C_074a6418-7106-47c6-9070-807b4c2674f4"
      id="F_5ffe6952-c04c-4d20-9c9b-257e955a971c">2026</sndx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod>
    <sndx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod
      contextRef="C_7005891b-8702-43ec-a77e-2e47fc88621f"
      id="F_94aa6462-4c13-4a90-88d0-bf668b3e9d6d">2026</sndx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_6950da94-09bf-4054-a1fa-0feb68fcf8c9"
      decimals="-5"
      id="F_1274320f-b56e-432b-a917-3ecb47181d6d"
      unitRef="U_USD">8900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_beb1fbb6-8eaa-4bd9-a278-f0c3ba62c037"
      decimals="-5"
      id="F_53ce5fe7-7085-4036-85d6-59469d951106"
      unitRef="U_USD">3800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sndx:DeferredTaxAssetsResearchCreditsExpirationPeriod
      contextRef="C_074a6418-7106-47c6-9070-807b4c2674f4"
      id="F_ce79edc1-78a6-483d-912c-8cdd31b52a0d">2024</sndx:DeferredTaxAssetsResearchCreditsExpirationPeriod>
    <sndx:DeferredTaxAssetsResearchCreditsExpirationPeriod
      contextRef="C_7005891b-8702-43ec-a77e-2e47fc88621f"
      id="F_8b250376-83d5-42ea-9d0e-b67d8e3438b4">2024</sndx:DeferredTaxAssetsResearchCreditsExpirationPeriod>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-5"
      id="F_841b91d5-f7d7-41e0-802f-0d3670842c82"
      unitRef="U_USD">79600000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-5"
      id="F_84241a0b-f50c-4cf5-875d-a846a2e61ed7"
      unitRef="U_USD">53700000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-5"
      id="F_dd7ff8c3-c7f4-4c68-add0-6aca99c7ca30"
      unitRef="U_USD">100000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_9bfce7e8-ef98-48b8-86a7-775779587ee8"
      decimals="-3"
      id="F_422f9681-d186-4fc7-9305-6d92026d6481"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_9c35cea5-4932-446f-bd97-79a9161a45c0"
      decimals="-3"
      id="F_adb9fcf9-fb9c-4515-a88e-d37418b90ccc"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_d380c115-0599-4d7d-9e27-c31a2dc98460"
      decimals="-3"
      id="F_8da92fdc-1912-4726-8309-a871f4675c10"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_e4fb1705-53bf-469d-bf86-3504aa18a5d8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.493%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.922000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.922000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.922000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefit--beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decreases related to prior period positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefit--end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_51cf7587-dec9-4001-b888-7ef4b8102128"
      unitRef="U_USD">143000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166"
      decimals="-3"
      id="F_549fad41-aa81-4685-9426-bd2390f612ee"
      unitRef="U_USD">163000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_07dde341-6b8e-4d35-a0a4-24bc46311598"
      decimals="-3"
      id="F_3e712020-7c48-405f-ae92-b363f28b2203"
      unitRef="U_USD">163000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_18e71f7a-0462-4ba0-9b5b-c81c2e378313"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_dda32b9e-ee9e-47b8-8161-009c2c9441b2"
      unitRef="U_USD">20000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_43f2687a-ddbc-4523-a2c1-6afe8ea7a8ba"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="-3"
      id="F_eeec11d2-7d4a-4ff6-ba5c-05a6fef35b40"
      unitRef="U_USD">143000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="-3"
      id="F_ffbefd9a-5f49-400f-98b2-e0895202a729"
      unitRef="U_USD">143000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a9a02a8b-944c-450f-9447-629ff2beb166"
      decimals="-3"
      id="F_128fe104-2281-48be-9f4e-fda9e65493c2"
      unitRef="U_USD">163000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_6dbd4d83-49ed-4ea9-b41b-67718f967b4d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;16. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Incyte &#x2013; In September 2021, the Company entered into the Incyte Agreement and Incyte Stock Purchase Agreement. Under the terms of the Incyte Agreement, Incyte will receive exclusive commercialization rights of axatilimab outside of the United States.  In the United States, Incyte and the Company will co-commercialize axatilimab, with the Company having the right to co-promote the product with Incyte. In exchange for these rights, Incyte agreed to pay a non-refundable cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and in addition a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million equity investment. In certain cases, the Company is required to assist Incyte and is responsible for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of development costs associated with global and U.S. specific clinical trials.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Eddingpharm&#x2014;In April 2013, the Company entered into a License and Development Agreement (the &#x201c;Eddingpharm License Agreement&#x201d;) and a Series B-1 purchase agreement (the &#x201c;Eddingpharm Purchase Agreement&#x201d;) with Eddingpharm International Company Limited (&#x201c;Eddingpharm&#x201d;). Under the terms of the Eddingpharm License Agreement, Eddingpharm, in exchange for rights to develop and commercialize entinostat in China and certain other Asian countries, purchased $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of Series B-1 and agreed to make certain contingent milestone and royalty payments based on revenue targets. In certain cases, the Company is required to assist Eddingpharm, and Eddingpharm is required to reimburse the Company for any out-of-pocket expenses incurred in providing this assistance, including reimbursement for person-hours above a certain cap.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, the Company may be subject to various claims and proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; contingent liabilities recorded as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, or 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sndx:UpfrontPayments
      contextRef="C_6d113b0b-ab5a-4247-a874-32521d39ece2"
      decimals="INF"
      id="F_c8063095-08e6-43c8-8407-70ca1ff9adda"
      unitRef="U_USD">117000000</sndx:UpfrontPayments>
    <sndx:UpfrontPayments
      contextRef="C_a5fddb73-bec6-44ab-935b-04ba4ac070ab"
      decimals="INF"
      id="F_1b9158d4-36af-4fb4-808b-0257ecb64ed8"
      unitRef="U_USD">35000000</sndx:UpfrontPayments>
    <sndx:DevelopmentCostsAssociatedWithClinicalTrials
      contextRef="C_4bd80ba5-9483-4290-bd6b-8b3b7622307a"
      decimals="INF"
      id="F_aa61cf58-4aa3-4869-a1b2-8d278048da4f"
      unitRef="U_pure">0.45</sndx:DevelopmentCostsAssociatedWithClinicalTrials>
    <us-gaap:PurchaseObligation
      contextRef="C_baf118b0-3cb5-42c6-83f0-5fe1ec439d64"
      decimals="-5"
      id="F_c74f5586-a7c2-4088-8888-670861285aa7"
      unitRef="U_USD">5000000</us-gaap:PurchaseObligation>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_e3636803-aef2-421b-a81e-02758a0838f3"
      decimals="INF"
      id="F_473230ea-372c-422d-8892-e2efcd8045cf"
      unitRef="U_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_99c86d68-0de1-42ee-8712-d5c4c9fb7189"
      decimals="INF"
      id="F_064abf4c-015d-4ff9-96c6-3aa1f0af30b8"
      unitRef="U_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_22aa7756-f492-4244-b911-00d62f65616e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;17. Supplemental Cash Flow Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.913%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.2170000000000005%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.2170000000000005%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.2170000000000005%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Supplemental Disclosures of Cash Flow Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Supplemental Disclosures of Non-Cash Investing and Financing&lt;br/&gt;&#160;&#160;&#160;Activities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Issuance costs included in accounts payable and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      id="F_98428a58-509a-4ac0-a9dd-40721560f322">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.913%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.2170000000000005%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.2170000000000005%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.2170000000000005%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Supplemental Disclosures of Cash Flow Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Supplemental Disclosures of Non-Cash Investing and Financing&lt;br/&gt;&#160;&#160;&#160;Activities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Issuance costs included in accounts payable and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_256eb23f-2755-42dc-9d52-978c2f8a3513"
      unitRef="U_USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_da34bf4b-2d84-4281-ae5d-483dced76aa2"
      unitRef="U_USD">2059000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_affe8a4e-638a-4397-b0be-fbeadd623876"
      unitRef="U_USD">1997000</us-gaap:InterestPaidNet>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_a32d41ce-57b9-43e7-bf72-ce00185e4cef"
      decimals="-3"
      id="F_58f09d77-4026-4035-8a9b-03e4e3efbe8a"
      unitRef="U_USD">250000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_c6a672d3-8633-4ea0-ab8a-d7f88ac4fc9d"
      decimals="-3"
      id="F_3ddbd58a-fd68-465d-ba04-f2a519a4b4ec"
      unitRef="U_USD">131000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_6e282358-b6f3-4650-be0c-94030a98bc79"
      decimals="-3"
      id="F_3ee4e662-988a-4be0-aef4-100286726594"
      unitRef="U_USD">134000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_37e11f1a-0751-4158-b47f-05f24953c364"
          xlink:label="F_37e11f1a-0751-4158-b47f-05f24953c364"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_019950da-7c9e-4648-93df-baef4c55a740"
          xlink:label="F_019950da-7c9e-4648-93df-baef4c55a740"
          xlink:type="locator"/>
        <link:footnote id="FNT_aaa0a647-4c49-431e-a394-238030f55c8b" xlink:label="FNT_aaa0a647-4c49-431e-a394-238030f55c8b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:11pt;font-family:Times New Roman;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination</xhtml:span></xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of Rule 10b5-1 trading arrangement, each of which the reporting person terminated prior to the sale of all plan securities.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_37e11f1a-0751-4158-b47f-05f24953c364"
          xlink:to="FNT_aaa0a647-4c49-431e-a394-238030f55c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_019950da-7c9e-4648-93df-baef4c55a740"
          xlink:to="FNT_aaa0a647-4c49-431e-a394-238030f55c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_4c71cf37-0a72-4642-a37b-7ae4969c410b"
          xlink:label="F_4c71cf37-0a72-4642-a37b-7ae4969c410b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_571d65c8-f8f1-445f-8ee1-7e17ce2ffbfc"
          xlink:label="F_571d65c8-f8f1-445f-8ee1-7e17ce2ffbfc"
          xlink:type="locator"/>
        <link:footnote id="FNT_82b8419b-1637-433c-bec5-9d6f6e1629e5" xlink:label="FNT_82b8419b-1637-433c-bec5-9d6f6e1629e5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs granted in </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 had a weighted average grant date fair value of </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.94</xhtml:span><xhtml:span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.79</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair values of RSUs vested in </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and 2022 totaled </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126,000</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">705,000</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4c71cf37-0a72-4642-a37b-7ae4969c410b"
          xlink:to="FNT_82b8419b-1637-433c-bec5-9d6f6e1629e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_571d65c8-f8f1-445f-8ee1-7e17ce2ffbfc"
          xlink:to="FNT_82b8419b-1637-433c-bec5-9d6f6e1629e5"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
